<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005067.pub5" GROUP_ID="SKIN" ID="106203061613533394" MERGED_FROM="" MODIFIED="2017-11-22 09:52:20 +0000" MODIFIED_BY="Laura Prescott" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;First version of the protocol (after lead editor review).&lt;br&gt;Sent for the peer review process (25th of june of 2003).&lt;br&gt;Include two tables in word (no able to pass to RevMan).&lt;br&gt;Re-sent with some style changes from the copyedited version of the mucocutaneous protocol ( 21th of August of 2003).&lt;br&gt;Sent to Tina in RevMan for Peer review (12/12/03)&lt;/p&gt;&lt;p&gt;Ready (adapted from the changes of the MCL protocol) for peer reviewing. Sent to MB and TL (14/4/04)&lt;/p&gt;&lt;p&gt;UG made changes from the MB comments. Sent (26-4-04) to MB and TL.&lt;/p&gt;&lt;p&gt;28apr04 - TL did minor edits, mainly style and spell check&lt;/p&gt;&lt;p&gt;Errors:&lt;br&gt;No errors detected.&lt;/p&gt;&lt;p&gt;Warnings:&lt;br&gt;Empty field(s) for reference 'Klaus 1999': PG&lt;br&gt;No link in the text to reference 'Hollis 1999'.&lt;/p&gt;&lt;p&gt;29/4/04 I have made minor amendments in red. Finola&lt;/p&gt;&lt;p&gt;removed red - ready for peer rev (TL)&lt;/p&gt;&lt;p&gt;21may04 - with refs edited by KC&lt;/p&gt;&lt;p&gt;30june04 - checked by TL and ready to go back to Urba for revision&lt;br&gt;UG, 14-10-04 protocol send to Tina for publication with responses to peers comments&lt;/p&gt;&lt;p&gt;1nov04 - started edits from HW and TL, sent to Fin&lt;/p&gt;&lt;p&gt;Minor amendments to the search section FD 1/11/04&lt;/p&gt;&lt;p&gt;2nov04 - almost finished edits -just need advice from Jo re sensitivity/subgroup analysis&lt;/p&gt;&lt;p&gt;3nov04 - finished edits to analysis section, did spell check, no errors or warnings - ready for Laura and Urba&lt;/p&gt;&lt;p&gt;21may07- authors modified: Neil Hepburn, Carmen Chica and William R Faber are no more reviewers. Mariona Pinart is a new author of this review.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: Interventions for Old World solitary or limited cutaneous leishmaniasis #85&lt;/p&gt;&lt;p&gt;22May07 I have pasted in the search strategies and have made comments to Mariona in red italics. Finola&lt;br&gt;Old title: Interventions for solitary or limited cutaneous leishmaniasis #85&lt;br&gt;Old title: Interventions for Old World cutaneous leishmaniasis&lt;br&gt;From 21 June 07 to 2 July 07: I've sent e-mails aking for the randomisation method employed to: Dr. Fagihi, Moosavi, Akhyani, Sharique, Kirtak, Syda, El-Darouti, Sadeghinia and Makram. Only 2 authors replied (Dr. G. Fagihi and Dr. Z. Moosavi). The Moosavi's paper was pseudorandomised while the one of Fagihi was properly randomised (flip coin method).&lt;br&gt;27Aug07: I've sent 2 emails to Dr. R Salmanpour and A.Khamesipour to have more information about the randomisation method and the follow-up.&lt;/p&gt;&lt;p&gt;3Sept07 -I have updated the search strategies due to the new title. All in red -remove the red when you have approved it. Queries to Mariona in red italics. Finola&lt;br&gt;7Sept07- I've sent an email to Dr. Saxena (for J Dogra 1986) to have more information about the randomisation method.&lt;br&gt;10Sept07- I've sent an email to Dr. Gita faghihi to clarify the primary outcomes as the reviewers (MP and LR) extracted different figures from the article (Asilian 2004B)&lt;br&gt;26Sept07- I've sent an email to Dr. MA Dabbagh to clarify whether this clinical trial was randomised or not (Mapar 2001).&lt;br&gt;2Oct07- I've found one RCT trough Google (word search: triclhloroacetic acid treatment AND leishmania). This RCT belongst to the Egyptian Dermatology Online Journal)&lt;br&gt;16Oct07: Dr. A Khamesipour extracted the data from the Gholami original paper as it is written in persian language.&lt;/p&gt;&lt;p&gt;9 Jan 08 DAH minor edits to style, format, language etc, and spell check&lt;br&gt;22Jan 08 DAH proof read texr, refs need to be looked at later&lt;/p&gt;&lt;p&gt;28Apr08 I have made amends to the search section and put strategies into the Appendices. A few questions to Mariona. Finola&lt;/p&gt;&lt;p&gt;August 08 -I have added the April search dates into the text.Finola&lt;/p&gt;" NOTES_MODIFIED="2017-11-20 09:47:55 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="#85" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2017-11-22 09:52:14 +0000" MODIFIED_BY="Laura Prescott">
<TITLE MODIFIED="2017-06-14 12:28:01 +0100" MODIFIED_BY="[Empty name]">Interventions for Old World cutaneous leishmaniasis</TITLE>
<CONTACT MODIFIED="2017-11-22 09:52:14 +0000" MODIFIED_BY="Laura Prescott"><PERSON ID="z1504131145345024920315694334049" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julio</FIRST_NAME><LAST_NAME>Heras-Mosteiro</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>juliolhm@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Preventive Medicine and Public Health &amp; Immunology and Microbiology</DEPARTMENT><ORGANISATION>Rey Juan Carlos University</ORGANISATION><ADDRESS_1>Avda. Atenas s/n</ADDRESS_1><ADDRESS_2>Alcorcón</ADDRESS_2><CITY>Madrid</CITY><ZIP>28922</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>003414888928</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-11-22 09:52:14 +0000" MODIFIED_BY="Laura Prescott"><PERSON ID="z1504131145345024920315694334049" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julio</FIRST_NAME><LAST_NAME>Heras-Mosteiro</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>juliolhm@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Preventive Medicine and Public Health &amp; Immunology and Microbiology</DEPARTMENT><ORGANISATION>Rey Juan Carlos University</ORGANISATION><ADDRESS_1>Avda. Atenas s/n</ADDRESS_1><ADDRESS_2>Alcorcón</ADDRESS_2><CITY>Madrid</CITY><ZIP>28922</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>003414888928</PHONE_1></ADDRESS></PERSON><PERSON ID="z1407231219325999415383586780781" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Begoña</FIRST_NAME><LAST_NAME>Monge-Maillo</LAST_NAME><EMAIL_1>begomongem@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Tropical Medicine &amp; Clinical Parasitology, Infectious Diseases Department</DEPARTMENT><ORGANISATION>Ramón y Cajal University Hospital</ORGANISATION><ADDRESS_1>Carretera de Colmenar Viejo km. 9,100</ADDRESS_1><CITY>Madrid</CITY><ZIP>28034</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 91 3368108</PHONE_1></ADDRESS></PERSON><PERSON ID="FCAE293482E26AA2010C81A6332E42D8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mariona</FIRST_NAME><LAST_NAME>Pinart</LAST_NAME><SUFFIX>BSc, PhD</SUFFIX><EMAIL_1>mariona.pinart@gmail.com</EMAIL_1><MOBILE_PHONE>+49 16099271377</MOBILE_PHONE><ADDRESS><ORGANISATION>c/o Cochrane Skin Group, The University of Nottingham, Nottingham, UK</ORGANISATION><CITY>Nottingham</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1504131152230471574516565383950" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Patricia</FIRST_NAME><LAST_NAME>Lopez Pereira</LAST_NAME><POSITION>Resident Medical Intern</POSITION><EMAIL_1>patulp77@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Preventive Medicine and Public Health</DEPARTMENT><ORGANISATION>Ramón y Cajal University Hospital</ORGANISATION><ADDRESS_1>Ctra. de Colmenar Viejo, km. 9,100</ADDRESS_1><CITY>Madrid</CITY><ZIP>28034</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>913368372</PHONE_1></ADDRESS></PERSON><PERSON ID="14522" ROLE="AUTHOR"><FIRST_NAME>Ludovic</FIRST_NAME><LAST_NAME>Reveiz</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><EMAIL_1>mmreveiz@hotmail.com</EMAIL_1><EMAIL_2>reveizl@paho.org</EMAIL_2><ADDRESS><DEPARTMENT>Free time independent Cochrane reviewer</DEPARTMENT><ORGANISATION/><CITY>Potomac</CITY><REGION>MD</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="z1504131148568839104121293814395" ROLE="AUTHOR"><FIRST_NAME>Emely</FIRST_NAME><LAST_NAME>Garcia-Carrasco</LAST_NAME><POSITION>Mph and Scientific Researcher</POSITION><EMAIL_1>mlycarrasco@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Infectious Diseases Department</DEPARTMENT><ORGANISATION>National Referral Centre for Tropical Diseases</ORGANISATION><ADDRESS_1>Ctra Colmenar, Km 9,100.</ADDRESS_1><CITY>Madrid</CITY><ZIP>28034</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 91 33 69 137</PHONE_1></ADDRESS></PERSON><PERSON ID="z1407231349246516044793790332904" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Pedro</FIRST_NAME><LAST_NAME>Campuzano Cuadrado</LAST_NAME><POSITION>Research fellow</POSITION><EMAIL_1>pedro.campuzano@urjc.es</EMAIL_1><ADDRESS><DEPARTMENT>Department of Preventive Medicine and Public Health &amp; Immunology and Microbiology</DEPARTMENT><ORGANISATION>Rey Juan Carlos University</ORGANISATION><ADDRESS_1>Avda. Atenas s/n</ADDRESS_1><ADDRESS_2>Alcorcón</ADDRESS_2><CITY>Madrid</CITY><ZIP>28922</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34914889048</PHONE_1><FAX_1>+34914888955</FAX_1></ADDRESS></PERSON><PERSON ID="8F32682882E26AA200B56EFEFD8F6DC9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ana</FIRST_NAME><LAST_NAME>Royuela</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>aroyuela@idiphim.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Biostatistics</DEPARTMENT><ORGANISATION>Biomedical Sciences Research Institute,Hospital Universitario Puerta de Hierro-Majadahonda</ORGANISATION><CITY>Majadahonda</CITY><ZIP>28222</ZIP><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="z1407231225205029839493798338216" ROLE="AUTHOR"><FIRST_NAME>Irene</FIRST_NAME><LAST_NAME>Mendez Roman</LAST_NAME><POSITION>Consumer</POSITION><EMAIL_1>ireneicab@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>c/o Cochrane Skin Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>A103, King's Meadow Campus</ADDRESS_1><ADDRESS_2>Lenton Lane</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2NR</ZIP><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="z1407231336574244895976137663761" ROLE="AUTHOR"><FIRST_NAME>Rogelio</FIRST_NAME><LAST_NAME>López-Vélez</LAST_NAME><POSITION>Head</POSITION><EMAIL_1>Rogelio.lopezvelez@salud.madrid.org</EMAIL_1><ADDRESS><DEPARTMENT>Tropical Medicine &amp; Clinical Parasitology, Infectious Diseases Department</DEPARTMENT><ORGANISATION>Ramón y Cajal University Hospital</ORGANISATION><ADDRESS_1>Carretera de Colmenar, 9100</ADDRESS_1><CITY>Madrid</CITY><ZIP>28034</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34913368108</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-11-17 18:22:24 +0000" MODIFIED_BY="Laura Prescott" NOTES="&lt;p&gt;Minor update: 5/22/07&lt;/p&gt;" NOTES_MODIFIED="2017-11-17 18:22:24 +0000" NOTES_MODIFIED_BY="Laura Prescott">
<UP_TO_DATE>
<DATE DAY="17" MONTH="11" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="11" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="10" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-11-20 09:47:55 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-11-20 09:47:55 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="11" YEAR="2017"/>
<DESCRIPTION>
<P>Ludovic Reveiz was added as an author.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-11-20 09:47:37 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="11" YEAR="2017"/>
<DESCRIPTION>
<P>The new citation incorporates Ludovic Reveiz on the author byline.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-11-20 09:39:38 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-20 09:39:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="11" YEAR="2017"/>
<DESCRIPTION>
<P>The corresponding author is now Julio Heras-Mosteiro. Of the authors from the first review, only Mariona Pinart and Ludovic Reitez have participated in this update. There are seven new authors: Begoña Monge-Maillo, Patricia Lopez-Pereira, Emely Garcia-Carrasco, Pedro Campuzano Cuadrado, Rogelio López-Vélez, Irene Mendez Roman, and Ana Royuela. We have not searched CINAHL for this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-11-20 09:39:35 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="11" YEAR="2017"/>
<DESCRIPTION>
<P>The incorporation of GRADE into this updated review means that compared with the previous version of the review, we are now less certain of the evidence on which we base our conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-07-24 14:24:11 +0100" MODIFIED_BY="Laura E Prescott">
<DATE DAY="17" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>The lead author's contact details have been edited.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-17 12:07:20 +0100" MODIFIED_BY="Laura  Prescott">
<DATE DAY="18" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-06-21 09:22:09 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-10-23 06:32:15 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-10-23 06:32:15 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Madrid. Hospital Universitario Ramón y Cajal. Carretera de Colmenar Km 3.1 Madrid 28034</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Methodology support</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2017-06-21 09:22:09 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-08-04 08:39:33 +0100" MODIFIED_BY="[Empty name]">
<NAME>Office of Control of Neglected Tropical Diseases (WHO/CDS/NTD/IDM), Communicable Disease Cluster, World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-06-21 09:22:09 +0100" MODIFIED_BY="[Empty name]">
<NAME>The National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The NIHR, UK, is the largest single funder of the Cochrane Skin Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-11-20 09:45:28 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-11-15 16:29:52 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-06-16 12:13:14 +0100" MODIFIED_BY="[Empty name]">Treatments for Old World cutaneous leishmaniasis</TITLE>
<SUMMARY_BODY MODIFIED="2017-11-15 16:29:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Old World cutaneus leishmaniasis (OWCL) is an infection caused by the <I>Leishmania </I>parasite, which is passed onto humans by the bite of sandflies. It is a serious skin disease associated with a broad range of signs, symptoms, and degrees of severity. We wanted to assess the competence and safety of all available treatments for OWCL.</P>
<P>
<B>Review question</B>
</P>
<P>We assessed participants with a healthy immune response who had OWCL diagnosed by laboratory methods. Treatments had to be given alone or in combination with another treatment, and they were compared against no treatment, placebo (an inactive substance) only, or another active treatment. Some of the main outcomes we were interested in included the percentage of wounds cured after the end of treatment, the number of participants completely cured after the end of treatment, speed of healing, side-effects of treatment, and clearance of parasites (i.e. infection).</P>
<P>
<B>Study characteristics</B>
</P>
<P>We reviewed 89 clinical trials, which included 10,583 people, in total, with OWCL. We included participants of both sexes and all ages (mean 24.5 years); most participants were over 18 years of age. Most studies were carried out in single centres in different countries, mainly in the Far or Middle East, and lasted between two to six months. We included a variety of treatments, such as antimonials, antifungals, and antibiotics, which were administered either directly onto the skin or into a wound, taken by mouth, or physically applied (e.g. laser treatment, heat therapy, etc.). Most of the included studies assessed OWCL caused by two species of parasites known as <I>Leishmania major </I>(<I>L. major</I>) and<I> Leishmania tropica </I>(<I>L. tropica</I>).</P>
<P>
<B>Key results </B>
</P>
<P>The evidence is current to November 2016.</P>
<P>Two of the most important treatments that we assessed in this review were itraconazole, an antifungal drug taken by mouth, and paromomycin, an antibiotic applied as an ointment. Trials compared both to a placebo tablet or inactive cream (vehicle).</P>
<P>Participants received 200 mg itraconazole for six to eight weeks or paromomycin ointment at a concentration of 15% plus 10% urea, twice daily for 14 days.</P>
<P>When assessed on average 2.5 months after treatment, more participants were completely cured and cleared of the infection-causing parasites with itraconazole than placebo, but they also had more side effects (mild stomach pain, sickness, and abnormal liver function, as well as headaches and dizziness).</P>
<P>When paromomycin ointment was compared with placebo, there was no difference in the number of completely cured participants or the number who were found to be cleared of parasites when assessed on average 2.5 months after treatment, but those in the paromomycin treatment group had more contained skin reactions (such as swelling, blistering, pain, redness, or itch).</P>
<P>However, as the certainty of the evidence for these outcomes for these particular comparisons was very low, we are not sure of the accuracy of these results.</P>
<P>Neither of our key treatment comparisons assessed the percentage of wounds cured after the end of treatment and speed of healing (i.e. time taken to be cured).</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The overall certainty of the evidence for the different outcomes in the two main comparisons was very low. Important reasons for this were that studies were not blinded, or had a small sample size, making the results less precise. Some of the evidence only focused on young people, and the results greatly varied between each study.</P>
<P>We need more research to fill in the following research gaps: 1) trials of OWCL caused by other types of infection such as <I>L. infantum, L. aethiopica</I>,<I> or L. donovani</I>; 2) involving specific subgroups of people such as children; 3) assessing effectiveness and safety of different anti-<I>Leishmania</I> drugs compared with placebo in self-healing forms of leishmaniasis or with traditional first-choice antimonial treatment in complicated form (defined as more than four lesions over 4 cm in size, located close to an opening or small joints, for which previous treatment has failed); and 4) assessing areas such as wound healing and patient-reported outcomes, such as quality of life. In addition, few studies assessed relevant issues such as drug resistance. International collaboration is required to improve the quality and standardisation of future trials in order to develop a better evidence-based approach.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-11-09 13:53:46 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-10-19 09:31:01 +0100" MODIFIED_BY="[Empty name]">
<P>Cutaneous leishmaniasis, caused by a parasitic infection, is considered one of the most serious skin diseases in many low- and middle-income countries. Old World cutaneous leishmaniasis (OWCL) is caused by species found in Africa, Asia, the Middle East, the Mediterranean, and India. The most commonly prescribed treatments are antimonials, but other drugs have been used with varying success. As OWCL tends to heal spontaneously, it is necessary to justify the use of systemic and topical treatments. This is an update of a Cochrane Review first published in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-10-19 10:47:00 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of therapeutic interventions for the localised form of Old World cutaneous leishmaniasis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-10-23 10:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>We updated our searches of the following databases to November 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of included studies for further references to relevant randomised controlled trials (RCTs). We wrote to national programme managers, general co-ordinators, directors, clinicians, WHO-EMRO regional officers of endemic countries, pharmaceutical companies, tropical medicine centres, and authors of relevant papers for further information about relevant unpublished and ongoing trials. We undertook a separate search for adverse effects of interventions for Old World cutaneous leishmaniasis in September 2015 using MEDLINE.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-11-09 13:49:31 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials of either single or combination treatments in immunocompetent people with OWCL confirmed by smear, histology, culture, or polymerase chain reaction. The comparators were either no treatment, placebo/vehicle, and/or another active compound.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-10-23 10:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trials for inclusion and risk of bias and extracted data. We only synthesised data when we were able to identify at least two studies investigating similar treatments and reporting data amenable to pooling. We also recorded data about adverse effects from the corresponding search.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-11-09 13:51:42 +0000" MODIFIED_BY="[Empty name]">
<P>We included 89 studies (of which 40 were new to this update) in 10,583 people with OWCL. The studies included were conducted mainly in the Far or Middle East at regional hospitals, local healthcare clinics, and skin disease research centres. Women accounted for 41.5% of the participants (range: 23% to 80%). The overall mean age of participants was 25 years (range 12 to 56). Most studies lasted between two to six months, with the longest lasting two years; average duration was four months. Most studies were at unclear or high risk for most bias domains. A lack of blinding and reporting bias were present in almost 40% of studies. Two trials were at low risk of bias for all domains. Trials reported the causative species poorly.</P>
<P>Here we provide results for the two main comparisons identified: itraconazole (200 mg for six to eight weeks) versus placebo; and paromomycin ointment (15% plus 10% urea, twice daily for 14 days) versus vehicle.</P>
<P>In the comparison of oral itraconazole versus placebo, at 2.5 months' follow up, 85/125 participants in the itraconazole group achieved complete cure compared to 54/119 in the placebo group (RR 3.70, 95% CI 0.35 to 38.99; 3 studies; 244 participants). In one study, microbiological or histopathological cure of skin lesions only occurred in the itraconazole group after a mean follow-up of 2.5 months (RR 17.00, 95% CI 0.47 to 612.21; 20 participants). However, although the analyses favour oral itraconazole for these outcomes, we cannot be confident in the results due to the very low certainty evidence. More side effects of mild abdominal pain and nausea (RR 2.36, 95% CI 0.74 to 7.47; 3 studies; 204 participants) and mild abnormal liver function (RR 3.08, 95% CI 0.53 to 17.98; 3 studies; 84 participants) occurred in the itraconazole group (as well as reports of headaches and dizziness), compared with the placebo group, but again we rated the certainty of evidence as very low so are unsure of the results.</P>
<P>When comparing paromomycin with vehicle, there was no difference in the number of participants who achieved complete cure (RR of 1.00, 95% CI 0.86, 1.17; 383 participants, 2 studies) and microbiological or histopathological cure of skin lesions after a mean follow-up of 2.5 months (RR 1.03, CI 0.88 to 1.20; 383 participants, 2 studies), but the paromomycin group had more skin/local reactions (such as inflammation, vesiculation, pain, redness, or itch) (RR 1.42, 95% CI 0.67 to 3.01; 4 studies; 713 participants). For all of these outcomes, the certainty of evidence was very low, meaning we are unsure about these results.</P>
<P>Trial authors did not report the percentage of lesions cured after the end of treatment or speed of healing for either of these key comparisons.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-11-09 13:53:46 +0000" MODIFIED_BY="[Empty name]">
<P>There was very low-certainty evidence to support the effectiveness of itraconazole and paromomycin ointment for OWCL in terms of cure (i.e. microbiological or histopathological cure and percentage of participants completely cured). Both of these interventions incited more adverse effects, which were mild in nature, than their comparisons, but we could draw no conclusions regarding safety due to the very low certainty of the evidence for this outcome.</P>
<P>We downgraded the key outcomes in these two comparisons due to high risk of bias, inconsistency between the results, and imprecision. There is a need for large, well-designed international studies that evaluate long-term effects of current therapies and enable a reliable conclusion about treatments. Future trials should specify the species of leishmaniasis; trials on types caused by <I>Leishmania infantum, L aethiopica</I>, and<I> L donovani </I>are lacking. Research into the effects of treating women of childbearing age, children, people with comorbid conditions, and those who are immunocompromised would also be helpful.</P>
<P>It was difficult to evaluate the overall efficacy of any of the numerous treatments due to the variable treatment regimens examined and because RCTs evaluated different <I>Leishmania</I> species and took place in different geographical areas. Some outcomes we looked for but did not find were degree of functional and aesthetic impairment, change in ability to detect <I>Leishmania</I>, quality of life, and emergence of resistance. There were only limited data on prevention of scarring.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-11-15 16:49:55 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-11-15 16:15:00 +0000" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for a glossary of terms used.</P>
<CONDITION MODIFIED="2017-11-15 15:53:38 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Definition</HEADING>
<P>
<LINK REF="REF-Desjeux-1996" TYPE="REFERENCE">Desjeux 1996</LINK> describes leishmaniasis as "a group of diseases caused by infection with protozoan parasites of the genus <I>Leishmania</I>", transmitted by bites from sandflies infected with the parasite. Leishmaniasis has two main clinical forms of presentation (cutaneous and visceral), which are associated with a broad range of signs, symptoms, and degrees of severity (<LINK REF="REF-Herwaldt-1999" TYPE="REFERENCE">Herwaldt 1999</LINK>; <LINK REF="REF-Reithinger-2007" TYPE="REFERENCE">Reithinger 2007</LINK>). Depending on its geographical distribution, cutaneous leishmaniasis (CL) is classified as New World cutaneous leishmaniasis (NWCL) or Old World cutaneous leishmaniasis (OWCL). The latter commonly &#8211; though not exclusively &#8211; presents as chronic, painless ulcers or nodules. Treatment of cutaneous leishmaniasis is complex and should depend on the <I>Leishmania </I>species involved, the area of acquisition of the infection, and the clinical form (<LINK REF="REF-Monge_x002d_Maillo-2013" TYPE="REFERENCE">Monge-Maillo 2013</LINK>). Management may vary from local or systemic treatment to no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epidemiology and impact</HEADING>
<P>In many tropical and subtropical low- and middle-income countries (LMICs), protozoan parasites are amongst the most common infectious agents and have serious consequences for socioeconomic development (<LINK REF="REF-Alvar-2006" TYPE="REFERENCE">Alvar 2006</LINK>; <LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). The World Health Organization (WHO) considers leishmaniasis to be one of the most serious parasitic diseases, and the World Health Assembly has advocated for prioritising their control (<LINK REF="REF-WHO-2007" TYPE="REFERENCE">WHO 2007</LINK>).</P>
<P>An estimated 700,000 to 1.2 million new CL cases occur each year (<LINK REF="REF-Alvar-2012" TYPE="REFERENCE">Alvar 2012</LINK>). CL is widely distributed, with 70% to 75% of the global incidence located mainly in 10 countries: Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica, and Peru (<LINK REF="REF-Alvar-2012" TYPE="REFERENCE">Alvar 2012</LINK>). Global incidence of OWCL is estimated at more than 900,000 cases per year, distributed from the Mediterranean basin across the Near East to Northwest India, with a few foci in Central China as well as a thin band across West Africa and in the Horn of Africa (<LINK REF="REF-Alvar-2012" TYPE="REFERENCE">Alvar 2012</LINK>; <LINK REF="REF-Pigott-2014" TYPE="REFERENCE">Pigott 2014</LINK>). OWCL is also increasingly present in immigrants, military personnel, humanitarian aid workers, tourists, and travellers from endemic areas (<LINK REF="REF-Reithinger-2007" TYPE="REFERENCE">Reithinger 2007</LINK>).</P>
<P>Immunosuppression is also a factor that can increase the prevalence of CL, altering its clinical presentation and treatment response (<LINK REF="REF-van-Griensven-2014" TYPE="REFERENCE">van Griensven 2014</LINK>). This factor is most closely associated with HIV, but recent years have seen a worldwide increase in other immunosuppressive conditions, mainly because of better medical care for chronic illnesses and the use of immunosuppressive drugs like tumour necrosis factor (TNF) inhibitors (<LINK REF="REF-van-Griensven-2014" TYPE="REFERENCE">van Griensven 2014</LINK>). In any case, the reported leishmaniasis case figures seem to be only a fraction of the true burden, and the disease appears to be underestimated and on the rise in several countries (<LINK REF="REF-Alvar-2012" TYPE="REFERENCE">Alvar 2012</LINK>). Leishmaniasis, as with many other neglected tropical diseases (NTDs), occurs mostly in LMICs, affecting rural and remote locations that may escape official data sources (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Aetiology and transmission</HEADING>
<P>Five <I>Leishmania </I>species cause OWCL: <I>L major, L tropica, L infantum, L donovani</I>, and<I> L aethiopica </I>(<LINK REF="REF-Pace-2014" TYPE="REFERENCE">Pace 2014</LINK>)<I>. </I>Most cases are due to <I>L major</I>, with around 500,000 cases per year; <I>L tropica,</I> with 400,000 cases per year; followed by <I>L aethiopica,</I> with 50,000 cases per year (<LINK REF="REF-den-Boer-2011" TYPE="REFERENCE">den Boer 2011</LINK>). Transmission of leishmaniasis is through a complex life cycle involving sandflies belonging to the <I>Phlebotomus </I>species (<LINK REF="REF-Pace-2014" TYPE="REFERENCE">Pace 2014</LINK>). Non-vector transmission (e.g. by accidental laboratory infection, blood transfusion, or organ transplantation) is possible but rare (<LINK REF="REF-Cardo-2006" TYPE="REFERENCE">Cardo 2006</LINK>). Transmission of leishmaniasis can be either anthroponotic or zoonotic (<LINK REF="REF-Pace-2014" TYPE="REFERENCE">Pace 2014</LINK>).</P>
<P>Zoonotic cutaneous leishmaniasis (ZCL), occurring mostly in rural areas, is where the parasite is transmitted from a range of animals to humans (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). It is geographically distributed in the Middle East, North-western China, and North Africa, where it may be caused by <I>L major</I>, and in the Mediterranean basin where it is mostly caused by <I>L infantum </I>(<LINK REF="REF-Pace-2014" TYPE="REFERENCE">Pace 2014</LINK>). The Old World ZCL often heals spontaneously after two to four months, although in some cases it may persist for as long as five years (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
<P>Anthroponotic cutaneous leishmaniasis (ACL) is transmitted from person to person, mainly in urban areas; it is geographically distributed in the Middle East, the Indian subcontinent, and western Asia (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). ACL is mostly caused by <I>L tropica </I>and also by <I>L donovani,</I> which may cause post-kala-azar dermal leishmaniasis (PKDL) in Asia (India, Nepal, and Bangladesh) and in East Africa (Ethiopia, Kenya, and Sudan) (<LINK REF="REF-Alvar-2012" TYPE="REFERENCE">Alvar 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical manifestations</HEADING>
<P>CL can affect the skin and mucous membranes and has been categorised into five different clinical forms: localised, recidivans, diffuse, mucosal, and PKDL.</P>
<SUBSECTION>
<HEADING LEVEL="4">Localised leishmaniasis</HEADING>
<P>In the localised form, the parasite is confined to the skin (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). After an incubation period of 1 to 12 weeks, a papule or bump develops at the site of the insect bite, and the papule grows and turns into an ulcer (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). A typical lesion of the localised form of CL is a painless papule or ulcer covered with an adherent crust of dried exudate and located on exposed parts of the body such as the face, arms, or legs (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>; <LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). CL due to <I>L infantum</I> usually causes single lesions. By contrast, <I>L tropi</I>ca frequently causes multiple lesions, as does <I>L major</I>, in this case often severely inflamed and ulcerated lesions that heal slowly and cause large disfiguring or disabling scars. Other variations exist as well: some people may have as many as 200 simple skin lesions, with some growing but not ulcerating (sporotrichoid), while certain <I>Leishmania </I>species also infect the lymphatic system, producing lesions along the lymphatic channels (nodular lymphangitis) (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). Secondary bacterial infection is common, causing pain and serious disability (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014</LINK>). Most lesions heal spontaneously over months or years, leaving permanent scarring with skin thinning. Scarring of leishmaniasis typically displays a depigmented centre and a pigmented border (<LINK REF="REF-Reithinger-2007" TYPE="REFERENCE">Reithinger 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Leishmaniasis recidivans</HEADING>
<P>This form appears in around five per cent of people with CL by <I>L tropica </I>and is characterised by microsatellite and confluent lesions that relapse and finally ulcerate on the border of previous scars (<LINK REF="REF-Sharifi-2010" TYPE="REFERENCE">Sharifi 2010</LINK>; <LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Diffuse leishmaniasis</HEADING>
<P>This form affects only the skin but with generalised skin lesions; it is seen mainly in Africa and transmitted by <I>L aethiopica</I> (<LINK REF="REF-Alrajhi-2003" TYPE="REFERENCE">Alrajhi 2003</LINK>)<I>. </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mucosal leishmaniasis</HEADING>
<P>In mucosal leishmaniasis, the parasite may spread to the mucous membranes, especially those of the nose, mouth, and throat, causing extensive damage and disfiguration. It mainly occurs in South America, but it can also be caused by species from Old World countries including <I>L tropica</I>, <I>L major, </I>and <I>L infantum </I>(<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Post-kala-azar dermal leishmaniasis</HEADING>
<P>PKDL is a form of diffuse cutaneous leishmaniasis and a sequel of visceral leishmaniasis (VL) that may appear in affected individuals up to 20 years after being partially treated or untreated or even in those who supposedly received adequate treatment (<LINK REF="REF-Rathi-2005" TYPE="REFERENCE">Rathi 2005</LINK>). PKDL is mostly seen in areas where <I>L donovani </I>is endemic, such as in Asia (India, Nepal, and Bangladesh) and East Africa (Ethiopia, Kenya, and Sudan) (<LINK REF="REF-Alvar-2012" TYPE="REFERENCE">Alvar 2012</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diagnosis</HEADING>
<P>Clinically diagnosed OWCL should be confirmed using the traditional diagnostic techniques of smear, parasite culture, and histological analysis of skin by aspiration, scrapings, or biopsies (<LINK REF="REF-Saab-2015" TYPE="REFERENCE">Saab 2015</LINK>). Circulating antibodies in the bloodstream are generally low or undetectable in cases of OWCL (<LINK REF="REF-Masmoudi-2013" TYPE="REFERENCE">Masmoudi 2013</LINK>). Modern molecular diagnostic techniques, mainly the polymerase chain reaction test (PCR), appear to be the most sensitive single diagnostic test for species identification in skin samples (<LINK REF="REF-Faber-2003" TYPE="REFERENCE">Faber 2003</LINK>; <LINK REF="REF-Schallig-2002" TYPE="REFERENCE">Schallig 2002</LINK>). Identification of the <I>Leishmania </I>species involved is essential for selecting the most appropriate treatment.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2017-11-15 16:15:00 +0000" MODIFIED_BY="[Empty name]">
<P>Issues of treatment in CL are difficult to deal with because there are many factors that can influence the efficacy of drugs: the size, the number, and the appearance of the lesions; the duration of the disease prior to treatment; the frequency and time to self-healing; the frequency of relapse and re-infection; the frequency and severity of either mucosal or diffuse involvement; immunosuppression; co-infections; prior anti-<I>Leishmania </I>treatment; and the knowledge of resistance to anti-<I>Leishmania</I> drugs (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). Laboratory studies have described acquired resistance to anti-<I>Leishmania</I> drugs for decades, but only recently has clinical resistance been described. Monitoring resistance is currently controversial due to an inadequate correlation between clinical and in vitro resistance and a need for knowledge about the biochemical and molecular mechanisms of resistance (<LINK REF="REF-Croft-2006" TYPE="REFERENCE">Croft 2006</LINK>).</P>
<P>The location of the lesion (e.g. face or joints) and the patient's sex and age often determine the choice of treatment (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). Other factors are intrinsic and related to the different <I>Leishmania </I>species (<LINK REF="STD-Safi-2012" TYPE="STUDY">Safi 2012</LINK>). An effective treatment in one geographical area for a given organism may not work in a different geographical area or for a different organism in the same location. In these cases, efficacy depends not only on the <I>Leishmania </I>species but also on the response of the person to the parasite and factors such as immunity, variable clinical response to treatments, drug toxicity, drug resistance, HIV co-infection and adherence (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014</LINK>).</P>
<P>Different authors have described many treatments for OWCL (<LINK REF="REF-Modabber-2007" TYPE="REFERENCE">Modabber 2007</LINK>; <LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>; <LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>), of which we summarise the most relevant in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>
<I>. </I>Nonetheless, several authors have pointed out the lack of properly controlled clinical trials (<LINK REF="REF-Hepburn-2001" TYPE="REFERENCE">Hepburn 2001</LINK>, <LINK REF="REF-Herwaldt-1999" TYPE="REFERENCE">Herwaldt 1999</LINK>; <LINK REF="REF-Moskowitz-1999" TYPE="REFERENCE">Moskowitz 1999</LINK>; <LINK REF="REF-Monge_x002d_Maillo-2013" TYPE="REFERENCE">Monge-Maillo 2013</LINK>). Another disadvantage and paradox is the lack of availability of most of these drugs in rural and poorer areas where leishmanias appears most frequently (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). Systemic treatments are generally given to those with CL who present with big (&#8805; 5 cm), multiple (&gt; 5), or disseminated lesions; in those who have simple lesions involving cosmetically sensitive areas or joints, with mucosal reaction, or with the presence of nodular lymphangitis or lymphadenopathies; or for whom local therapy has failed (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014</LINK>). For people with immunosuppression, there is controversy. Some experts consider that acquired or induced immunosuppression is a risk factor for developing mucosal leishmaniasis, so they recommend systemic treatment. Meanwhile, other experts have considered different treatment for the same type of people (<LINK REF="REF-Blum-2012" TYPE="REFERENCE">Blum 2012</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Systemic and intralesional antimonials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Meglumine antimoniate and sodium stibogluconate</HEADING>
<P>The current mainstays of systemic treatment for OWCL are the pentavalent antimony (Sb<SUP>v+</SUP>) compounds sodium stibogluconate (SSG) (Pentostam, Stibanate) and meglumine antimoniate (MA) (Glucantime) (<LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK>; <LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>); they often constitute the control condition in trials of new treatments. The recommended dosage is 20 mgSb<SUP>v+</SUP>/kg/d intramuscularly (IM) or intravenously (IV) for 20 to 30 days (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>); oral administration is not an option. SSG and MA can also be administered intralesionally (IL) with the recommended dosage of 1 mL to 5 mL per session every 3 to 7 days. Up to 10 sessions are needed depending on the clinical response, but most people require less than five sessions.</P>
<P>Despite the widespread use of SSG and MA, there are concerns about their cost, toxicity, and the development of drug resistance. Parenteral antimonial drugs are associated with severe adverse and often dose-dependent effects, including nausea, vomiting, diarrhoea, skin eruptions, dizziness, cardiac arrhythmia, hypotension, arthralgia, myalgia, abdominal discomfort, headache, reversible elevation of hepatocellular enzymes, occasional anaemia, and thrombocytopaenia (<LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>; <LINK REF="STD-Ejaz-2014" TYPE="STUDY">Ejaz 2014</LINK>; <LINK REF="STD-Esfandiarpour-2002" TYPE="STUDY">Esfandiarpour 2002</LINK>; <LINK REF="STD-Farajzadeh-2015" TYPE="STUDY">Farajzadeh 2015</LINK>; <LINK REF="STD-Mohebali-2007" TYPE="STUDY">Mohebali 2007</LINK>; <LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>). Pain at the site of the injection is greater in intralesional administration than in the intravenous/intramuscular route (<LINK REF="STD-Iraji-2005" TYPE="STUDY">Iraji 2005</LINK>; <LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>; <LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK>). Whilst there is no general consensus on optimum treatment, there are active lines of research to identify alternatives to systemic antimonials (<LINK REF="STD-Jowkar-2012" TYPE="STUDY">Jowkar 2012</LINK>). <LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK> has investigated combination therapies with allopurinol, and <LINK REF="STD-Sadeghian-2006a" TYPE="STUDY">Sadeghian 2006a</LINK> with pentoxifylline, as treatments that may help to reduce drug resistance by increasing the efficacy of the antimonials, reducing their doses, or both.</P>
<P>Infiltration of skin lesions (injecting a substance directly into the infected lesion) can be very painful. Adverse effects of IL treatments are burning at the site of injection, itching, inflammation, and vasovagal shock due to severe pain (<LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>; <LINK REF="STD-Mapar-2010" TYPE="STUDY">Mapar 2010</LINK>). A safe and efficient therapeutic method for IL injection is the use of a Dermojet device (<LINK REF="REF-Bogenrieder-2003" TYPE="REFERENCE">Bogenrieder 2003</LINK>). Preventing blood-borne transmission of other infectious diseases in LMICs entails reducing the use of injections, implementing blood safety practices, and providing sterile injection equipment in healthcare centres (<LINK REF="REF-Kermode-2004" TYPE="REFERENCE">Kermode 2004</LINK>; <LINK REF="REF-Simonsen-1999" TYPE="REFERENCE">Simonsen 1999</LINK>). Several studies provide evidence for the efficacy of intralesional pentavalent antimonials for OWCL, mainly in Asia and the Mediterranean basin (<LINK REF="STD-Alkhawajah-1997" TYPE="STUDY">Alkhawajah 1997</LINK>; <LINK REF="REF-Uzun-2004" TYPE="REFERENCE">Uzun 2004</LINK>). Moreover, local administration reduces the systemic toxicity of antimonials; people may receive anywhere from a few injections or &#8211; for those with multiple or complicated lesions &#8211; daily injections for up to 40 days (<LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>). (Complicated CL is defined as more than 4 lesions over 4 cm in size, which are periorificial or located close to small joints, for which previous treatment has failed. Clinically important lymphatic dissemination is present, as well as underlying immunosuppressive conditions, and "there is significant comorbidity for which systemic treatments could be contraindicated in a benefit&#8211;risk assessment (e.g. unbalanced diabetes, malnutrition)" (<LINK REF="REF-Gradoni-2017" TYPE="REFERENCE">Gradoni 2017</LINK>).)</P>
<P>Self-limiting lesions are normally amenable to weekly or alternate day IL injections of SSG or MA (<LINK REF="STD-Alkhawajah-1997" TYPE="STUDY">Alkhawajah 1997</LINK>; <LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>). According to some authors, deficient infiltration of the lesions is one of the most common and important causes of treatment failure with IL antimonials (<LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK>). There are also other studies that have evaluated the association of intralesional pentavalent antimonials as a way to increase the efficacy (<LINK REF="STD-Asilian-2003" TYPE="STUDY">Asilian 2003</LINK>; <LINK REF="REF-Munir-2008" TYPE="REFERENCE">Munir 2008</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Non-antimonial systemic treatments</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Oral antifungal</HEADING>
<P>Oral azole antifungal drugs (fluconazole, ketoconazole, itraconazole) are potential therapeutic agents in CL. The first reports of oral ketoconazole for the treatment of CL in both the New and the Old World came out in the early 1980s (<LINK REF="REF-Urcayo-1982" TYPE="REFERENCE">Urcayo 1982</LINK>; <LINK REF="REF-Weinrauch-1983a" TYPE="REFERENCE">Weinrauch 1983a</LINK>; <LINK REF="REF-Weinrauch-1983b" TYPE="REFERENCE">Weinrauch 1983b</LINK>). However, reports of liver toxicity and low cure rates for certain species led to ketoconazole being withdrawn from the market, making it necessary to search for other azoles (<LINK REF="STD-Alrajhi-2002" TYPE="STUDY">Alrajhi 2002</LINK>). In the mid- to late 1980s, another azole called itraconazole was touted as a treatment for CL (<LINK REF="REF-Borelli-1987" TYPE="REFERENCE">Borelli 1987</LINK>; <LINK REF="REF-Cauwenberg-1986" TYPE="REFERENCE">Cauwenberg 1986</LINK>), with different cure rates depending on the species involved (<LINK REF="STD-Momeni-1996" TYPE="STUDY">Momeni 1996</LINK>; <LINK REF="STD-Nassiri_x002d_Kashani-2005" TYPE="STUDY">Nassiri-Kashani 2005</LINK>). Fluconazole, another antifungal azole, has also been used as an alternative therapy for CL, with good cure rates at different doses (<LINK REF="STD-Alrajhi-2002" TYPE="STUDY">Alrajhi 2002</LINK>; <LINK REF="STD-Emad-2011" TYPE="STUDY">Emad 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral dapsone</HEADING>
<P>Some studies have proposed the antibiotic/antileprotic drug dapsone as an inexpensive oral alternative to the treatment currently used for CL (<LINK REF="STD-Dogra-1986" TYPE="STUDY">Dogra 1986</LINK>; <LINK REF="STD-Dogra-1991" TYPE="STUDY">Dogra 1991</LINK>), although the main side effect of dapsone is blood cell destruction and anaemia (<LINK REF="STD-Dogra-1991" TYPE="STUDY">Dogra 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral allopurinol</HEADING>
<P>Allopurinol (a medicine used to treat gout) alters protein synthesis and inhibits the growth of <I>Leishmania </I>in vitro (<LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>); different authors have assessed its use as a potential therapeutic agent for the treatment of both CL and VL, mainly in combination with pentavalent antimonials (<LINK REF="REF-Chunge-1985" TYPE="REFERENCE">Chunge 1985</LINK>; <LINK REF="REF-Jha-1983" TYPE="REFERENCE">Jha 1983</LINK>; <LINK REF="REF-Kager-1981" TYPE="REFERENCE">Kager 1981</LINK>; <LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral antibiotics</HEADING>
<P>Researchers have also reported several other oral antibiotics like metronidazole and cotrimoxazole as possibly promising anti-<I>Leishmania</I> agents in the treatment of VL (<LINK REF="REF-Rodriguez_x002d_Cuartero-1990" TYPE="REFERENCE">Rodriguez-Cuartero 1990</LINK>), while others have looked into the efficacy of a short-term course of antibiotic rifampicin for CL (<LINK REF="REF-Bygbjerg-1980" TYPE="REFERENCE">Bygbjerg 1980</LINK>). Oral azithromycin is another antibiotic that is effective in vitro and in mice (<LINK REF="REF-Minodier-2007" TYPE="REFERENCE">Minodier 2007</LINK>), but research has not established it as superior to antimonials for OWCL in humans (<LINK REF="STD-Layegh-2007" TYPE="STUDY">Layegh 2007</LINK>), even when combined with allopurinol (<LINK REF="STD-Dastgheib-2012" TYPE="STUDY">Dastgheib 2012</LINK>). Thus, azithromycin needs further investigation for human leishmaniasis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral pentoxifylline</HEADING>
<P>Oral pentoxifylline, used in people with vascular diseases, also has anti-<I>Leishmania </I>effects (<LINK REF="REF-Lessa-2001" TYPE="REFERENCE">Lessa 2001</LINK>), decreasing the inflammatory reaction and the resulting tissue damage (<LINK REF="STD-Sadeghian-2006a" TYPE="STUDY">Sadeghian 2006a</LINK>). Pentoxifylline has a good safety profile, although nausea, arthralgias, dizziness, abdominal pain, and diarrhoea can occur (<LINK REF="REF-Lessa-2001" TYPE="REFERENCE">Lessa 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral miltefosine</HEADING>
<P>Oral miltefosine, which was originally developed as an anticancer drug, is active against the <I>Leishmania </I>membrane (<LINK REF="REF-Croft-2006" TYPE="REFERENCE">Croft 2006</LINK>). Miltefosine was included in the WHO essential medicines list as an anti-leishmaniasis medicine in March 2011 (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>), and in March 2014, the US Food and Drug Administration (FDA) approved oral miltefosine for visceral, cutaneous, and mucosal leishmaniasis (<LINK REF="REF-FDA-2014" TYPE="REFERENCE">FDA 2014</LINK>). Miltefosine seems active against most <I>Leishmania </I>species, but with variable efficacy depending on geographical regions, even for the same species (<LINK REF="REF-Monge_x002d_Maillo-2015" TYPE="REFERENCE">Monge-Maillo 2015</LINK>; <LINK REF="REF-Soto-2004" TYPE="REFERENCE">Soto 2004</LINK>; <LINK REF="REF-Stojkovic-2007" TYPE="REFERENCE">Stojkovic 2007</LINK>). Limited experience with miltefosine for OWCL shows efficacy, mostly against <I>L major </I>(<LINK REF="REF-Dorlo-2011" TYPE="REFERENCE">Dorlo 2011</LINK>; <LINK REF="STD-Mohebali-2007" TYPE="STUDY">Mohebali 2007</LINK>; <LINK REF="REF-Stojkovic-2007" TYPE="REFERENCE">Stojkovic 2007</LINK>). The most commonly reported adverse drug reactions associated with miltefosine are transient gastrointestinal discomfort, nausea, vomiting, abdominal pain, and mild elevation of liver enzymes and serum creatinine (<LINK REF="STD-Mohebali-2007" TYPE="STUDY">Mohebali 2007</LINK>). Women of childbearing age require contraception beyond the end of treatment because this drug is contraindicated during pregnancy (<LINK REF="REF-Sindermann-2006" TYPE="REFERENCE">Sindermann 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral zinc sulphate</HEADING>
<P>Early studies on oral zinc sulphate reported promising results for the treatment of CL (<LINK REF="REF-Sharquie-1996" TYPE="REFERENCE">Sharquie 1996</LINK>; <LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>; <LINK REF="STD-Sharquie-2001" TYPE="STUDY">Sharquie 2001</LINK>), although more recent studies have not reported good cure rates (<LINK REF="STD-Yazdanpanah-2011" TYPE="STUDY">Yazdanpanah 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral artesunate</HEADING>
<P>Artemisinin is effective against promastigotes in vitro, and artemisinin and artemether are leishmanicidal for amastigotes in infected murine macrophages (<LINK REF="REF-Adam-2008" TYPE="REFERENCE">Adam 2008</LINK>; <LINK REF="REF-Keiser-J-2007" TYPE="REFERENCE">Keiser J 2007</LINK>). However, an RCT performed in Sudan did not show that artesunate combined with sulphamethoxypyrazine/pyrimethamine was better than placebo for OWCL (<LINK REF="STD-Adam-2009" TYPE="STUDY">Adam 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other oral drugs</HEADING>
<P>
<LINK REF="REF-Jiang-2002" TYPE="REFERENCE">Jiang 2002</LINK> was the first to describe using omeprazole, a common treatment for peptic ulcer diseases, as a potential antiparasitic drug for the growth of <I>L donovani </I>in a laboratory setting, and <LINK REF="STD-Nilforoushzadeh-2008" TYPE="STUDY">Nilforoushzadeh 2008</LINK> concluded it was a good alternative to antimonials when these have to be given in a lower dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parenteral liposomal amphotericin B</HEADING>
<P>Amphotericin B, an antifungal drug used since 1960 (<LINK REF="REF-Sampaio-1960" TYPE="REFERENCE">Sampaio 1960</LINK>), is commonly used for treating American mucocutaneous leishmaniasis, HIV co-infection, and visceral leishmaniasis (VL) in areas where <I>Leishmania </I>is resistant to antimonial and pentamidine drugs (<LINK REF="REF-Karamian-2007" TYPE="REFERENCE">Karamian 2007</LINK>; <LINK REF="REF-Laguna-1999" TYPE="REFERENCE">Laguna 1999</LINK>; <LINK REF="REF-Musa-2005" TYPE="REFERENCE">Musa 2005</LINK>; <LINK REF="REF-Sampaio-1997" TYPE="REFERENCE">Sampaio 1997</LINK>; <LINK REF="REF-Sundar-2007a" TYPE="REFERENCE">Sundar 2007a</LINK>; <LINK REF="REF-Thakur-1996" TYPE="REFERENCE">Thakur 1996</LINK>). There has been little experience with this drug for OWCL due to pentavalent antimonials' dominance as the most commonly systemic regimens until now. However, the toxicity of pentavalent antimonials has prompted an increase in the administration of amphotericin B (mostly the lipid formulations), with promising results mainly with <I>L major</I> and <I>L tropica</I> (<LINK REF="REF-Solomon-2011" TYPE="REFERENCE">Solomon 2011</LINK>; <LINK REF="REF-Wortmann-2010" TYPE="REFERENCE">Wortmann 2010</LINK>). <LINK REF="REF-Zanger-2011" TYPE="REFERENCE">Zanger 2011</LINK> also reported a case of OWCL due to <I>L aethiopica</I> in a immunosuppressed person with response to liposomal amphotericin B.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Non-antimonial topical or intralesional therapies</HEADING>
<P>Mild disease caused by <I>L major </I>is often self-healing (<LINK REF="STD-Alkhawajah-1997" TYPE="STUDY">Alkhawajah 1997</LINK>; <LINK REF="STD-Nilforoushzadeh-2006" TYPE="STUDY">Nilforoushzadeh 2006</LINK>). OWCL can be managed with local care alone and may not require other specific therapies when it is a simple CL (<LINK REF="STD-Shazad-2005" TYPE="STUDY">Shazad 2005</LINK>), defined as CL: not caused by <I>Leishmania </I>species with common mucosal dissemination; not a diffuse, recurrent or post-kala-azar CL; with no lymphatic nodes affected; with small lesions; with fewer than five lesions; with lesions that are not localised in joints or aesthetic areas; or in people who are not immunocompromised (<LINK REF="STD-Nilforoushzadeh-2006" TYPE="STUDY">Nilforoushzadeh 2006</LINK>). Topical and local therapies are attractive options that are appropriate for early self-limiting lesions, offering reduced systemic toxicity and possibilities for outpatient treatment (<LINK REF="STD-Iraji-2004" TYPE="STUDY">Iraji 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Topical antifungals</HEADING>
<P>Early research on topical antifungals was based on clotrimazole, miconazole, and ketoconazole. The only RCT performed was in Saudi Arabia; investigators compared clotrimazole and miconazole and concluded that clotrimazole was more effective (<LINK REF="STD-Larbi-1995" TYPE="STUDY">Larbi 1995</LINK>). Topical ketoconazole was tested in Afghanistan, but it did not significantly change the course of the lesions (<LINK REF="REF-Storer-2005" TYPE="REFERENCE">Storer 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical paromomycin (aminosidine)</HEADING>
<P>Topical formulations often offer easier administration, fewer adverse effects, and sometimes cost-effectiveness, although there may be difficulties in getting enough of the active drug absorbed through the skin (<LINK REF="STD-Jowkar-2012" TYPE="STUDY">Jowkar 2012</LINK>). Paromomycin is an antibiotic in the aminoglycoside family, originally identified as an anti-<I>Leishmania </I>drug in the 1960s. Parenteral formulations have been used for VL (<LINK REF="REF-Sundar-2007b" TYPE="REFERENCE">Sundar 2007b</LINK>), and topical preparations for CL since 1987 (<LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>). The literature uses the names paromomycin, aminosidine, monomycin, and neomycin E interchangeably, although the active principle is the same (<LINK REF="REF-Bryceson-1994" TYPE="REFERENCE">Bryceson 1994</LINK>). Two main topical preparations are available for CL: 15% paromomycin sulphate dissolved in a soft white paraffin base, either with 12% methyl benzethonium chloride (MBCL) or with 10% urea (<LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK>; <LINK REF="STD-Shazad-2005" TYPE="STUDY">Shazad 2005</LINK>). Paromomycin ointment combined with MBCL has been shown to be more efficacious than with urea (<LINK REF="STD-Iraji-2005" TYPE="STUDY">Iraji 2005</LINK>). The original paromomycin formulation is no longer used because of its toxicity, and newer penetration-enhancing formulations have been subjected to clinical evaluation (<LINK REF="REF-Davis-2003" TYPE="REFERENCE">Davis 2003</LINK>). More recently, studies have also evaluated new combinations of paromomycin plus gentamycin (<LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>). Of the topical preparations, paromomycin ointment is commonly the first-line treatment in uncomplicated CL (<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>). Adverse effects encountered were redness, pruritus, burning, oedema, local pain, inflammation, contact dermatitis, urticaria, or lymphadenitis with pain (<LINK REF="STD-Ben-Salah-2013" TYPE="STUDY">Ben Salah 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intralesional zinc sulphate</HEADING>
<P>Intralesional zinc sulphate had a direct anti-<I>Leishmania </I>effect against <I>L major </I>and <I>L tropica </I>species in both an in vitro and in vivo study (<LINK REF="STD-Firooz-2005" TYPE="STUDY">Firooz 2005</LINK>; <LINK REF="REF-Najim-1998" TYPE="REFERENCE">Najim 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical imiquimod</HEADING>
<P>Topical imiquimod is an immune response modifier used for treating genital warts and premalignant skin cancer conditions, first used in combination with antimony for American CL (<LINK REF="REF-Arevalo-2007" TYPE="REFERENCE">Arevalo 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intralesional hypertonic sodium chloride</HEADING>
<P>Intralesional hypertonic sodium chloride solution (HSCS) can act by its osmotic effect to destroy the parasite as well as the surrounding tissue of the granuloma (<LINK REF="REF-Sharquie-1995" TYPE="REFERENCE">Sharquie 1995</LINK>; <LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>). It appears to be a cheap, safe, and effective local method for treating CL.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intralesional interferon-gamma (IFN-&#947;)</HEADING>
<P>Intralesional interferon (IFN-&#611;) is a lymphokine originally used for the treatment of leprosy, cancer, HIV, and chronic granulomatous disease, and it has been shown to enhance the leishmanicidal capacity of human monocytes in vitro (<LINK REF="REF-Badaro-1990" TYPE="REFERENCE">Badaro 1990</LINK>; <LINK REF="REF-Passwell-1986" TYPE="REFERENCE">Passwell 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical aminoglycoside ointment (WR279,396)</HEADING>
<P>The topical aminoglycoside ointment (WR279,396) is a hydrophilic formulation of paromomycin 15% plus a second aminoglycoside (gentamicin 0.5%) that was developed for topical administration, avoiding the potential skin irritation of other combinations performed with MBCL. Researchers in Tunisia have studied this combination of ointment (WR279,396) for <I>L</I> <I>major</I>, with better results than vehicle (<LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intralesional metronidazole</HEADING>
<P>Metronidazole was initially the first line treatment for trichomoniasis and later for amoebiasis and giardiasis. Its effectiveness for cutaneous leishmaniasis is controversial. Several case reports and a clinical trial performed in Iraq showed good cure rates for OWCL with intralesional metronidazole (<LINK REF="REF-Al_x002d_Waiz-2004" TYPE="REFERENCE">Al-Waiz 2004</LINK>). However, a more recent clinical trial performed in Iran showed that metronidazole is ineffective (<LINK REF="STD-Mapar-2010" TYPE="STUDY">Mapar 2010</LINK>). Moreover intralesional metronidazole injection was very painful.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical miltefosine</HEADING>
<P>Pre-clinical animal studies initially evaluated topical miltefosine, showing a potential benefit for NWCL and OWCL (<LINK REF="REF-Schmidt_x002d_Ott-1999" TYPE="REFERENCE">Schmidt-Ott 1999</LINK>). A trial in Syria did not demonstrate efficacy of topical miltefosine for OWCL (<LINK REF="REF-Garnier-2002" TYPE="REFERENCE">Garnier 2002</LINK>). However, a recent RCT in Iran showed that topical miltefosine was significantly more efficacious than meglumine antimoniate (<LINK REF="STD-Asilian-2014" TYPE="STUDY">Asilian 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical dapsone</HEADING>
<P>Dapsone is a synthetic sulfone employed orally for infectious diseases such as leprosy and for certain cutaneous disorders such as nodulocystic acne. However, the potential for systemic toxicity has limited its use in many cases. Topical formulations have also been developed especially for acne, thus reducing the possible systemic secondary effects (<LINK REF="REF-Stotland-2009" TYPE="REFERENCE">Stotland 2009</LINK>). For OWCL an RCT in Iran compared dapsone 5% gel mask plus intralesional meglumine antimoniate (ILMA) versus cryotherapy plus ILMA, but investigators did not find any statistically significant difference in cure rates (<LINK REF="STD-Fekri-2015" TYPE="STUDY">Fekri 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical 0.045% pharmaceutical chlorite (DAC N-055)</HEADING>
<P>DAC N-055 seems to promote tissue regeneration, which may be of benefit for cutaneous lesions due to OWCL (<LINK REF="REF-Migdal-2011" TYPE="REFERENCE">Migdal 2011</LINK>). A clinical trial in Afghanistan compared this treatment, both alone and in combination with bipolar high frequency electrocauterisation, versus intralesional antimonials (<LINK REF="STD-Stahl-2014" TYPE="STUDY">Stahl 2014</LINK>). Use of electrocauterisation is based on the fact that physical wound debridement practised with bipolar high frequency electrosurgical cauterisation (HF-EC) seems to speed up wound healing (<LINK REF="STD-Jebran-2014" TYPE="STUDY">Jebran 2014</LINK>). The results of the RCT showed that DAC N-055 alone was significantly more efficacious than ILMA (<LINK REF="STD-Stahl-2014" TYPE="STUDY">Stahl 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical Thio-Ben</HEADING>
<P>An Iranian study reported promising results in OWCL using topical thioxolone plus benzoxonium chloride, or Thio-Ben (<LINK REF="REF-Daie-Parizi-1992" TYPE="REFERENCE">Daie Parizi 1992</LINK>; <LINK REF="REF-Daie-Parizi-1996" TYPE="REFERENCE">Daie Parizi 1996</LINK>). Thioxolone, which has long been topically administered for the treatment of acne and psoriasis, is recognised as a safe drug. A later RCT from Iran compared topical Thio-Ben plus cryotherapy versus meglumine antimoniate (Glucantime) plus cryotherapy (<LINK REF="STD-Daie-Parizi-2015" TYPE="STUDY">Daie Parizi 2015</LINK>), showing that topical Thio-Ben plus cryotherapy had good efficacy for OWCL, with fewer side affects than ILMA.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Physical therapies</HEADING>
<P>People with OWCL may receive a range of physical treatments, including vaporisation, cauterisation, freezing, surgical excision, and the application of local heat.</P>
<SUBSECTION>
<HEADING LEVEL="4">Laser</HEADING>
<P>Carbon dioxide (CO&#8322;) lasers have been used to vaporise CL lesions, thereby destroying affected tissue without significant side effects in normal tissue (<LINK REF="STD-Asilian-2004b" TYPE="STUDY">Asilian 2004b</LINK>). Studies have shown that a single session is enough, with lesions healing within three to four weeks, with quite admissible cosmetic results, although the procedure is painful and requires local anaesthetic (<LINK REF="STD-Shamsi-Meymandi-2011" TYPE="STUDY">Shamsi Meymandi 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trichloroacetic acid (TCA)</HEADING>
<P>The efficacy of TCA for treating CL could be due to the destruction of infected tissue and skin regeneration (<LINK REF="STD-Nilforoushzadeh-2006" TYPE="STUDY">Nilforoushzadeh 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cryotherapy</HEADING>
<P>Cryotherapy with liquid nitrogen has been used to treat individual lesions, destroying infected tissue, but it is labour intensive (<LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>). As an effective, painless, low-cost technique with few side effects, it is an especially good option for children (<LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>; <LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK>). However, it is not suitable for multiple or complicated lesions (<LINK REF="REF-Alrajhi-2003" TYPE="REFERENCE">Alrajhi 2003</LINK>; <LINK REF="REF-Bassiouny-1982" TYPE="REFERENCE">Bassiouny 1982</LINK>; <LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>; <LINK REF="REF-Leibovici-1986" TYPE="REFERENCE">Leibovici 1986</LINK>; <LINK REF="REF-Minodier-2007" TYPE="REFERENCE">Minodier 2007</LINK>; <LINK REF="REF-Mosleh-2008" TYPE="REFERENCE">Mosleh 2008</LINK>; <LINK REF="REF-Ranawaka-2011" TYPE="REFERENCE">Ranawaka 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Thermotherapy</HEADING>
<P>Laboratory studies have reported that <I>Leishmania </I>parasites cannot multiply in macrophages when temperatures are greater than 39ºC (<LINK REF="REF-Berman-1981" TYPE="REFERENCE">Berman 1981</LINK>; <LINK REF="REF-Sacks-1983" TYPE="REFERENCE">Sacks 1983</LINK>). These findings have stimulated investigations into the efficacy of thermotherapy for CL with direct-current electrical stimulation (<LINK REF="REF-Sharquie-1998" TYPE="REFERENCE">Sharquie 1998</LINK>), ultrasound (<LINK REF="REF-Aram-1987" TYPE="REFERENCE">Aram 1987</LINK>), infrared light (<LINK REF="REF-Junaid-1986" TYPE="REFERENCE">Junaid 1986</LINK>), hot-water baths (<LINK REF="REF-Neva-1984" TYPE="REFERENCE">Neva 1984</LINK>), laser (<LINK REF="STD-Asilian-2004b" TYPE="STUDY">Asilian 2004b</LINK>; <LINK REF="REF-Babajev-1991" TYPE="REFERENCE">Babajev 1991</LINK>; <LINK REF="REF-Meawad-1997" TYPE="REFERENCE">Meawad 1997</LINK>; <LINK REF="REF-Rodriguez-1990" TYPE="REFERENCE">Rodriguez 1990</LINK>), radiofrequency waves, and ThermoMed device (<LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK>; <LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>; <LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>). The procedure is painful and may require local anaesthetic (<LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical photodynamic therapy</HEADING>
<P>Photodynamic therapy is a light-mediated technique that causes cytolysis of <I>Leishmania</I> parasites, resulting in an effective and safe therapeutic option for OWCL (<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mesotherapy</HEADING>
<P>Mesotherapy is based on the use of a specific amount of variable substance (hormones, nutrients, enzymes, pharmaceuticals, and detergents, among others) and is not an invasive technique. People have received it for treating cellulite and acne scars, reducing aging skin, and rejuvenating the hands and neck (<LINK REF="REF-Amin-2006" TYPE="REFERENCE">Amin 2006</LINK>; <LINK REF="REF-Rohrich-2003" TYPE="REFERENCE">Rohrich 2003</LINK>). One RCT performed in Iran compared mesotherapy with ILMA, finding no difference in cure rates between the two therapeutic options (<LINK REF="STD-Kashani-2010" TYPE="STUDY">Kashani 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methods for promoting healing</HEADING>
<P>Methods used in wound healing, including dressing and antiseptics, are often employed in ulcerative lesions of CL to accelerate cure, normalise epithelialisation, and reduce scarring, especially at cosmetic sites (<LINK REF="STD-Stahl-2014" TYPE="STUDY">Stahl 2014</LINK>). Compromised wound healing due to repetitive trauma, contamination, and infection are major problems encountered in people with OWCL, and it is important to improve scar formation or at least not interfere with the natural healing process (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). A recent consensus panel on recommendations for chronic and acute wound dressings reported that "hydrocolloid (polymer dressings with medium absorption properties and containing carboxymethylcellulose) and low-adherent dressings seem to be the most suitable dressings for the epithelialisation stage of chronic and acute wounds" (<LINK REF="REF-Vaneau-2007" TYPE="REFERENCE">Vaneau 2007</LINK>). The highest impact of scarring and ulcerative lesions is on the faces of young women, which exposes them to stigma and which may affect their marriage prospects (<LINK REF="REF-Weigel-2001" TYPE="REFERENCE">Weigel 2001</LINK>; <LINK REF="REF-Reithinger-2005b" TYPE="REFERENCE">Reithinger 2005b</LINK>). To assess the cosmetic impact, clinicians often use the Burn Scar Index (also known as the Vancouver Scar Scale) to document change in scar appearance (<LINK REF="REF-Baryza-1995" TYPE="REFERENCE">Baryza 1995</LINK>), which should be ideally measured six months after completion of treatment (<LINK REF="REF-Modabber-2007" TYPE="REFERENCE">Modabber 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Alternative therapies</HEADING>
<P>Increasing treatment failure with antimonial drugs has accelerated the search for alternative therapies (<LINK REF="STD-Nilforoushzadeh-2007" TYPE="STUDY">Nilforoushzadeh 2007</LINK>). Up to 80% of the world's population may depend on medicinal plants as the only source of remedies for this disease; modern drugs may be either too expensive or wholly inaccessible (<LINK REF="REF-Fatima-2005" TYPE="REFERENCE">Fatima 2005</LINK>). Practitioners of both traditional and modern medicine in Iran have long used herbal remedies and honey (<LINK REF="STD-Nilforoushzadeh-2007" TYPE="STUDY">Nilforoushzadeh 2007</LINK>; <LINK REF="STD-Zerehsaz-1999" TYPE="STUDY">Zerehsaz 1999</LINK>). Different plants with medicinal value (<I>Azadirachta indica</I>, <I>Acacia nilotica</I>, and <I>Allium</I> <I>sativa</I>), traditionally used in the west and central parts of Sudan, have proven to have active anti-<I>Leishmania </I>activity on <I>L major </I>promastigotes in vitro (<LINK REF="REF-Fatima-2005" TYPE="REFERENCE">Fatima 2005</LINK>; <LINK REF="REF-Khalid-2005" TYPE="REFERENCE">Khalid 2005</LINK>). Honey is effective for wound healing through enhancement of granulation and epithelialisation stages, enhancement of debridement, and downsizing of wound malodour (<LINK REF="REF-Moore-2001" TYPE="REFERENCE">Moore 2001</LINK>; <LINK REF="REF-Pieper-2003" TYPE="REFERENCE">Pieper 2003</LINK>). Studies have described that honey from flowers in Australia and New Zealand has antibacterial effects (<LINK REF="REF-Pieper-2003" TYPE="REFERENCE">Pieper 2003</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2017-11-09 15:04:42 +0000" MODIFIED_BY="[Empty name]">
<P>OWCL is a heterogeneous group of diseases that differ in their clinical presentation, prognosis, and response to different the therapeutic interventions. There are two main factors affecting response to treatment: the species of <I>Leishmania</I> and the clinical form of the disease.</P>
<P>The mechanisms of action of the different therapeutic options for OWCL are diverse and may act over different targets, which can result in a complementary effect when working in combination (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). There are two main types of therapeutic options: local physical therapies and local or systemic pharmacological therapies (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). Physical therapies such as HSCS, CO&#8322; lasers, TCA, cryotherapy, thermotherapy, and photodynamic therapy can destroy the parasite, the infected tissues, and the locally formed granulomas (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). Pharmacological therapies, such as pentavalent antimonials, amphotericin B and its lipid formulations, miltefosine, paromomycin, and pentamidine, seem to enter the host cells and act against amastigotes, compromising the parasite metabolism, altering the parasite membrane fluidity or damaging the parasite mitochondria, among other mechanisms of action (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>).</P>
<P>Therapeutic interventions could work in several ways: healing the forms of disease that would run a chronic course without treatment (<I>L aethiopica</I>); avoiding the progression of the disease to more complex clinical forms (mucocutaneous leishmaniasis, diffuse cutaneous leishmaniasis, leishmaniasis recidivans, etc.); speeding the healing of those forms that would naturally cure (<I>L major</I>); avoiding sequelae and disfiguring residual lesions (<I>L major, L tropica, L infantum</I>); and decreasing the human reservoir in anthroponotic forms (<I>L tropica</I>).</P>
<P>As a wide range of interventions are available, from physical or pharmacological local therapy to parenteral treatment, and response to treatment varies depending on the <I>Leishmania </I>species, knowing the optimal therapeutic approach in each situation is of great interest. This review aims to analyse the different interventions in order to provide the best treatment options for OWCL.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-10-23 10:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Controlling CL currently depends on early detection and rapid treatment (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). The mainstays of treatment have been pentavalent antimonials, but other oral and topical treatment alternatives have become available in recent years (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). Global health development policies have mainly focused on innovative research to develop effective and affordable tools to tackle neglected tropical diseases (NTDs) and provide necessary new knowledge (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). WHO is now prioritising the delivery of drugs that are currently available and using existing resources to reduce mortality, morbidity, and disability as a result of NTDs in low-income countries (<LINK REF="REF-Savioli-2006" TYPE="REFERENCE">Savioli 2006</LINK>). However, evidence for the comparative effectiveness, cost-effectiveness, and safety of different treatment strategies is needed to improve disease control.</P>
<P>This systematic review focused on addressing the effects of treatments for the localised form of CL due to <I>L tropica</I> and <I>L major</I>, which account for more than 90% of CL in the Old World (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). Since the overwhelming majority of OWCL cases heal spontaneously within 3 to 18 months (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014</LINK>), the rationale for using systemic and topical treatments needs to be well established and preferably stratified for different geographic regions and <I>Leishmania</I> species. Separate Cochrane Reviews have addressed treatments for American CL and prevention measures for all types of cutaneous and mucosal leishmaniasis (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>; <LINK REF="REF-Gonz_x00e1_lez-2015" TYPE="REFERENCE">González 2015</LINK>).</P>
<P>The protocol of this review was first entitled 'Interventions for solitary or limited cutaneous leishmaniasis'. However, we split the clinical subject into two reviews. We amended the title of the present review, first published in 2008 (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>), to 'Interventions for Old World cutaneous leishmaniasis', and we also published a separate Cochrane Review, entitled 'Interventions for American cutaneous and mucocutaneous leishmaniasis' (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). Thus, some parts of the Background and Methods sections are common to both reviews.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-10-23 10:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of therapeutic interventions for the localised form of Old World cutaneous leishmaniasis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-11-14 12:18:42 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-11-14 12:11:40 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-11-09 15:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>All immunocompetent people who had localised OWCL confirmed by parasitological diagnostic methods (i.e. tissue smears, histology, culture or PCR).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-11-09 15:06:54 +0000" MODIFIED_BY="[Empty name]">
<P>The interventions were either single therapy or combination therapy. The comparators were either no treatment, placebo/vehicle only, or another active compound.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Systemic and intralesional antimonials</HEADING>
<P>1.1 Meglumine antimoniate (Glucantime)<BR/>1.2 Sodium stibogluconate (Pentostam)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Non-antimonial systemic treatments</HEADING>
<P>2.1 Oral antifungals<BR/>2.2 Oral dapsone<BR/>2.3 Oral allopurinol<BR/>2.4 Oral antibiotics<BR/>2.5 Oral pentoxifylline<BR/>2.6 Oral miltefosine<BR/>2.7 Oral zinc sulphate<BR/>2.8 Oral artesunate</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Non-antimonial topical or intralesional therapies</HEADING>
<P>3.1 Topical antifungals<BR/>3.2 Topical paromomycin (aminosidine)<BR/>3.3 Intralesional zinc sulphate<BR/>3.4 Topical imiquimod<BR/>3.5 Intralesional hypertonic sodium chloride (HSCS)<BR/>3.6 Intralesional interferon-gamma (IFN-&#947;)<BR/>3.7 Topical aminoglycoside ointment (WR279,396)<BR/>3.8 Intralesional metronidazole<BR/>3.9 Topical miltefosine<BR/>3.10 Topical dapsone<BR/>3.11 Topical 0.045% pharmaceutical chlorite (DAC N-055)<BR/>3.12 Topical Thio-Ben</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Physical therapies</HEADING>
<P>4.1 Laser<BR/>4.2 Trichloroacetic acid<BR/>4.3 Cryotherapy<BR/>4.4 Thermotherapy<BR/>4.5. Topical photodynamic therapy<BR/>4.6. Mesotherapy</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Measures for promoting healing</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Alternative therapies</HEADING>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-11-14 12:11:40 +0000" MODIFIED_BY="[Empty name]">
<P>We did not limit the measurement of any outcomes based on length of follow-up.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-10-23 10:53:03 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Percentage of lesions cured after the end of treatment</LI>
<LI>Percentage of participants with a complete cure after the end of treatment</LI>
</OL>
<P>By cured, we meant that all inflammatory signs disappeared (either skin oedema, hardening, or both) and that complete scarring or healthy repair occurred in ulcerative lesions. We did not consider lesions to be healed if there was no re-epithelialised skin, or if inflammatory signs remained after follow-up.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-10-23 10:54:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Speed of healing (time taken to be 'cured')</LI>
<LI>Duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</LI>
<LI>Degree of functional and aesthetic impairment</LI>
<LI>Prevention of scarring</LI>
<LI>Quality of life</LI>
<LI>Adverse effects</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">Tertiary outcomes</HEADING>
<OL>
<LI>Change in ability to detect <I>Leishmania</I> by parasitological diagnostic methods (e.g. smear, PCR, or culture)</LI>
<LI>"Emergence of treatment failures (defined as a decline in the efficacy of a drug against a population of parasites previously susceptible to that compound. The definition assumes that the original susceptibility of the population is known, which is not always the case for <I>Leishmania</I>)" (<LINK REF="REF-Ponte_x002d_Sucre-2003" TYPE="REFERENCE">Ponte-Sucre 2003</LINK>)</LI>
<LI>Microbiological or histopathological cure of skin lesions</LI>
<LI>Development of cell-mediated immunity (i.e. positive leishmanin skin test)</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-11-09 15:10:48 +0000" MODIFIED_BY="[Empty name]">
<P>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-11-09 15:09:47 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, we revised all our search strategies in line with current Cochrane Skin practices. Details of the previous search strategies are available in <LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>.</P>
<P>We searched the following databases up to 17 November 2016:</P>
<UL>
<LI>Cochrane Skin Specialised Register, using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1.</LINK>
</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10) in the Cochrane Library, using the strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2.</LINK>
</LI>
<LI>MEDLINE via Ovid (from 1946), using the strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>
</LI>
<LI>Embase via Ovid (from 1974) using the strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</LI>
<LI>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Trials registers</HEADING>
<P>We searched the following trials registers in October 2015 using the term 'cutaneous leishmaniasis'.</P>
<UL>
<LI>ISRCTN registry (<A HREF="http://www.isrctn.com">www.isrctn.com</A>).</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>).</LI>
<LI>Australian New Zealand Clinical Trials Registry (<A HREF="http://www.anzctr.org.au">www.anzctr.org.au</A>).</LI>
<LI>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>).</LI>
<LI>EU Clinical Trials Register (<A HREF="https://www.clinicaltrialsregister.eu/">www.clinicaltrialsregister.eu</A>).</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-11-09 15:10:48 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">References from unpublished studies</HEADING>
<P>We checked the bibliographies of included studies and key papers identified by our searches for further references to relevant trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unpublished literature</HEADING>
<P>We wrote to national programme managers, general coordinators, directors, clinicians, regional officers from endemic countries in the WHO Eastern Mediterranean Region, pharmaceutical companies, and relevant authors for further information about unpublished and ongoing trials. We also contacted the following tropical medicine centres.</P>
<UL>
<LI>Department of Infectious Diseases and Tropical Medicine at the University of Munich, Germany.</LI>
<LI>Swiss Tropical Institute, Switzerland; Prince Leopold Institute of Tropical Medicine, Belgium.</LI>
<LI>McGill Centre for Tropical Disease, Canada.</LI>
<LI>Tulane University School of Public Health &amp; Tropical Medicine, USA.</LI>
<LI>London School of Hygiene &amp; Tropical Medicine, UK.</LI>
<LI>Tropical Medicine at the Liverpool School of Tropical Medicine, UK.</LI>
<LI>Department of Public Health and Tropical Medicine James Cook, University of North Queensland, Australia.</LI>
<LI>Institut Pasteur, France.</LI>
<LI>Bernhard Nocht Institute, Germany.</LI>
<LI>TropEdEurop, Spain.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>We searched MEDLINE (Ovid) from 1946 to 30 September 2015 for adverse or side effects of interventions for Old World cutaneous leishmaniasis using the search strategy in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-11-14 12:18:42 +0000" MODIFIED_BY="[Empty name]">
<P>Some parts of this review use text that was originally published in other Cochrane Reviews (predominantly <LINK REF="REF-van-Zuuren-2015" TYPE="REFERENCE">van Zuuren 2015</LINK>, <LINK REF="REF-Ingram-2015" TYPE="REFERENCE">Ingram 2015</LINK>, and <LINK REF="REF-Delamere-2008" TYPE="REFERENCE">Delamere 2008</LINK>; the latter was an exemplar Cochrane Review at the time the original review was written).</P>
<STUDY_SELECTION MODIFIED="2017-10-23 11:00:32 +0100" MODIFIED_BY="[Empty name]">
<P>We checked the titles and abstracts identified from the searches by at least two authors (JHM, PC, PLP, BMM, EGM). If it was unclear, then two authors obtained the full text study for independent assessment (BMM, EGM). The authors decided which trials met the inclusion criteria. The authors resolved any disagreements by discussion, with referral to a third author (AR) if necessary. We describe excluded studies and reasons for exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-11-14 12:11:32 +0000" MODIFIED_BY="[Empty name]">
<P>At least two independent authors (MP, LR, JHM, PLP) carried out data extraction using a pre-designed data extraction form. We extracted data for all outcomes for all relevant drugs, paying attention particularly to the doses and therapy frequencies. We resolved disagreements by discussion. We obtained the missing data from trial authors when possible.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-10-23 11:16:21 +0100" MODIFIED_BY="[Empty name]">
<P>The quality assessment included an evaluation of the following components for each included study, since there is some evidence that these are associated with biased estimates of treatment effect (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<UL>
<LI>The method for generating the randomisation sequence.</LI>
<LI>The method for concealing allocation &#8211; it was considered 'adequate' if personnel and participants could not have foreseen assignment.</LI>
<LI>Blinding (participants, clinicians, outcome assessors).</LI>
<LI>Loss to follow-up in each arm (split into postrandomisation exclusions and later losses if possible), and whether participants were analysed in the groups to which they were originally randomised (intention-to-treat).</LI>
</UL>
<P>In addition, the quality assessment also included the following.</P>
<UL>
<LI>Declaration of sample size calculation.</LI>
<LI>Definition of inclusion and exclusion criteria.</LI>
<LI>Reporting of <I>Leishmania</I> species involved.</LI>
<LI>Time of follow-up.</LI>
<LI>Baseline comparability of severity of infection, age, sex, and duration of complaint.</LI>
<LI>Conflict of interest.</LI>
</UL>
<P>We assessed these other risks of bias. When trials reported two or more incorrectly, we judged them to be at high risk. When trials reported only one incorrectly, we judged them to be at unclear risk. We recorded the information in 'Risk of bias' tables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and described the quality of each study based on these components.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-10-23 11:18:26 +0100" MODIFIED_BY="[Empty name]">
<P>We reported all outcome data with their associated 95% confidence interval (CI). We expressed results as risk ratios (RR) and 95% CIs for dichotomous outcomes. We presented continuous outcomes with the same scale as reported in each trial, with a mean change from baseline with its associated standard deviation (SD), or as weighted mean difference (MD) or standardised mean difference (SMD) if more than one study was available.</P>
<P>If enough information was available in the study reports, we decided to describe hazard ratios (HR) for time-to-event outcome data.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-11-14 12:18:16 +0000" MODIFIED_BY="[Empty name]">
<P>We found that most RCTs included in this review assessed participants instead of lesions as the unit of analysis. When lesions were used as unit of analysis, comparisons were performed with lesions cured over lesions at start, not taking into account the correlation of multiple lesions per participant. We only pooled together studies which reported number of participants cured (not number of lesions), due to unit of analysis issues. </P>
<P>The approach followed to 3-arm trials, was comparing the arms in pairs (A vs B, B vs C, and A vs C).</P>
<P>We only considered parallel group designs for all clinical trials. We did not consider cross-over trials in this review because they are an inappropriate design for treatments that can potentially cure an infectious disease. We did not find any particular additional important information in the specific search for adverse effects for every particular treatment. Authors described these qualitatively in the Results and Discussion sections.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-10-23 11:23:00 +0100" MODIFIED_BY="[Empty name]">
<P>For all missing data from trials that were less than 10 years old, we tried to contact the authors. Only six of the trials explicitly stated intention-to-treat (ITT) analysis. Where an ITT was not stated, we used the numbers originally randomised to the groups in order to calculate effect estimates.</P>
<P>For each study, we took all participants that were randomised into account when introducing the data in our tables. We sent emails to study authors asking for more information, and we recorded these emails and their responses. When we had no response, we assumed that missing data were treatment failures. Concerning the losses to follow-up, it was not always possible to determine the arm in which the losses occurred, making ITT analyses impossible. In that case, we introduced only available data into the tables for analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-11-13 05:35:09 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the consistency of the study results, we obtained the I² statistic, which measures the proportion of total variation across studies that is due to heterogeneity rather than chance. I² lies between 0% and 100%. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity. We analysed statistical heterogeneity using a Chi² test (on 1 degree of freedom, with a significance level of 0.05) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>)<I>.</I>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-11-14 12:18:42 +0000" MODIFIED_BY="[Empty name]">
<P>In this review, the low number of studies evaluating similar interventions and comparisons did not permit an assessment of publication bias. In future updates, if a sufficient number of trials assessing similar effects are identified for inclusion in this review, publication bias will be assessed according to the recommendations on testing for funnel plot asymmetry (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) as described in section 10.4.3.1 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If asymmetry is identified we will try to assess other possible causes and these will be explored in the discussion if appropriate</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-10-23 11:29:07 +0100" MODIFIED_BY="[Empty name]">
<P>We performed data synthesis only when we were able to identify at least two studies investigating similar treatments and reporting data amenable to pooling. Although there is inevitably a degree of heterogeneity between the studies included in a review, we entered these into a meta-analysis if clinical reasoning could explain the heterogeneity and if there was a coherent argument for combining the studies. We used the random-effects model, as this is more conservative in the presence of heterogeneity.</P>
<P>The percentage of lesions cured after the end of treatment was the primary outcome measure if available. If this were not available, we used secondary and tertiary outcomes. To estimate differences between treatments, we pooled trials that evaluated similar interventions and controls and calculated a weighted treatment effect across trials, using a random-effects model. Where it was not possible to perform a meta-analysis, we summarised the data for each trial.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-10-23 11:32:11 +0100" MODIFIED_BY="[Empty name]">
<P>In view of the limited number of included studies covering any one specific intervention, we did not conduct any of the subgroup analyses that we originally planned: <I>Leishmania</I> species, location and severity of infection, geographical setting, diagnostic techniques, type of treatment (topical, systemic, or combination), and relapse or re-infection.</P>
<P>We assessed clinical heterogeneity by examining the characteristics of the studies, the similarity between the types of participants, the interventions, the comparisons, and the outcomes as specified in the criteria for included studies.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-10-23 11:33:37 +0100" MODIFIED_BY="[Empty name]">
<P>We plan to carry out a sensitivity analysis by excluding studies at high risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>We used the GRADE approach to rate certainty of the evidence (for each outcomes) and strength of recommendations (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). For better understanding of the review, we highlighted the GRADE assessments in 'Summary of findings' tables of key comparisons and outcomes.</P>
<P>Depending on the study design, risk of bias, consistency of the results across studies, and precision of the overall estimated across studies, certainty of evidence can be high, moderate, low, or very low.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-11-15 16:49:55 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-11-15 12:23:11 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-11-15 12:13:09 +0000" MODIFIED_BY="[Empty name]">
<P>The previous version of this review identified 49 trials with 5559 randomised participants (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>).</P>
<P>The update searches of the five databases (see <LINK TAG="ELECTRONIC_SEARCHES" TYPE="SECTION">Electronic searches</LINK>) retrieved 517 records. Our searches of other resources identified six ongoing studies. We obtained no response from the institutions we contacted to try to identify further trials.</P>
<P>Once we removed duplicates, we had a total of 521 records. We excluded 452 records based on titles and abstracts and obtained the full text of the remaining 69 records. We excluded 15 studies (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) and included 40, taking the total number of included studies to 89 (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>There are eight studies awaiting assessment: (<LINK REF="STD-Farajzadeh-2016a" TYPE="STUDY">Farajzadeh 2016a</LINK>; <LINK REF="STD-Farajzadeh-2016b" TYPE="STUDY">Farajzadeh 2016b</LINK>; <LINK REF="STD-Hanif-2016" TYPE="STUDY">Hanif 2016</LINK>; <LINK REF="STD-Jaffary-2016" TYPE="STUDY">Jaffary 2016</LINK>; <LINK REF="STD-Na_x002d_Bangchang-2016" TYPE="STUDY">Na-Bangchang 2016</LINK>; <LINK REF="STD-Rajabi-2016" TYPE="STUDY">Rajabi 2016</LINK>; <LINK REF="STD-Refai-2016" TYPE="STUDY">Refai 2016</LINK>; <LINK REF="STD-Sattar-2012" TYPE="STUDY">Sattar 2012</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>). We found six ongoing trials (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
<P>Two studies were reported in two references: <LINK REF="STD-Nilforoushzadeh-2006" TYPE="STUDY">Nilforoushzadeh 2006</LINK> and <LINK REF="STD-Shanehsaz-2015" TYPE="STUDY">Shanehsaz 2015</LINK>.</P>
<P>For a further description of our screening process, see the study flow diagram <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-11-14 15:46:12 +0000" MODIFIED_BY="[Empty name]">
<P>We included 89 studies (including 40 new to this update) involving 10,583 randomised participants with Old World cutaneous leishmaniasis (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All of the studies were RCTs: 30 were placebo-controlled, and 59 had an active treatment comparator. Seventy-two took place after the year 2000; 85 were single-centre studies, and the other 4 were multicentre studies (<LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>; <LINK REF="STD-Asilian-2003" TYPE="STUDY">Asilian 2003</LINK>; <LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>; <LINK REF="STD-Ejaz-2014" TYPE="STUDY">Ejaz 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>The number of participants included in the individual studies ranged from 18 to 444; the most common sample size was 50 to 120 participants (interquartile range).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>The studies included in this review took place in different countries, mainly in the Far or Middle East. Fifty-three took place in Iran; seven in India; five in Africa (Sudan and Tunisia), four each in Saudi Arabia and Afghanistan; three each in Pakistan, Iraq, and Syria; two each in Kuwait and Sri Lanka; and one each in Yemen, Turkey, and the USA (recruiting Department of Defense healthcare beneficiaries who were likely to have been infected in Iraq or in Kuwait). Most studies took place in regional hospitals, teaching hospitals, local healthcare clinics, and skin disease research centres. A few studies were in military hospitals or army medical centres.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The studies had a mean of 41.5% of women participants, but this ranged from 23% to 80%. Four RCTs conducted by military institutions only included men (<LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>; <LINK REF="STD-Ejaz-2014" TYPE="STUDY">Ejaz 2014</LINK>; <LINK REF="STD-Mashood-2001" TYPE="STUDY">Mashood 2001</LINK>; <LINK REF="STD-Shazad-2005" TYPE="STUDY">Shazad 2005</LINK>). Mean age in the individual studies ranged from 12 years to 56 years, with an overall mean age of 24.5 years. There were three RCTs including participants exclusively under 14 years (<LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>; <LINK REF="STD-Asilian-2003" TYPE="STUDY">Asilian 2003</LINK>; <LINK REF="STD-Lynen-1992" TYPE="STUDY">Lynen 1992</LINK>). This review focused on <I>L major </I>and<I> L tropica</I> infections because of the paucity of studies involving <I>L infantum</I>,<I> L aethiopica</I>, or<I> L donovani</I>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Trials evaluated a wide range of interventions, which we categorised into six types.</P>
<OL>
<LI>Systemic and intralesional antimonials (8 studies).</LI>
<LI>Non-antimonial systemic treatments (28 studies).</LI>
<LI>Non-antimonial topical or intralesional therapies (28 studies).</LI>
<LI>Physical therapies (28 studies).</LI>
<LI>Measures for promoting healing (1 study).</LI>
<LI>Alternative therapies (5 studies).</LI>
</OL>
<P>The 89 studies covered 68 comparisons, and 59 included an active control arm. Duration of the intervention in most studies ranged between two and eight weeks (mean six weeks).</P>
<P>We describe examples of the first four categories in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section under <LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK>. The study on promotion of healing compared two topical interventions: diminazene aceturate (Berenil) versus cetrimide plus chlorhexidine (Savlon). Examples of alternative therapies were topical interventions based on substances like garlic, herbal extracts, or honey.</P>
<P>Systemic and intralesional antimonials included meglumine antimoniate (MA) and sodium stibogluconate (SSG) administered intramuscularly (IM) or intralesionally (IL). The standard dosage was 20 mg/kg/d, though some studies used higher doses such as 30 mg/kg/d or 60 mg/kg/d. The standard schedule frequency was 20 days (three weeks), but in some studies the treatment was extended until achieving cure.</P>
<P>Non-antimonial systemic treatments included oral antifungals such as ketoconazole, itraconazole, and fluconazole. Trials compared itraconazole only against placebo or no treatment, whereas the trials on ketoconazole and fluconazole compared increasing dosages. Some trials compared ketoconazole versus intramuscular or intralesional SSG and intralesional meglumine antimoniate (ILMA). This treatment category also included oral dapsone versus placebo, oral allopurinol versus intramuscular meglumine antimoniate (IMMA) or intravenous sodium stibogluconate (IVSSG), oral antibiotics alone or combined versus placebo or IMMA, oral pentoxifylline alone or combined versus IMMA, oral zinc sulphate versus IMMA and oral artesunate versus placebo.</P>
<P>Non-antimonial topical or intralesional therapies comprised topical antifungals like miconazole, ketoconazole, amphotericin B, and clotrimazole as well as topical paromomycin alone or in combination with oral ketoconazole, photodynamic therapy, intralesional zinc sulphate, hypertonic sodium chloride (HSCS), INF-&#611;, metronidazole, topical imiquimod, miltefosine, dapsone, 0.045% pharmaceutical chlorite (DAC N-055), and Thio-Ben. The vast majority were tested against ILMA or ILSSG, with some therapies also compared to placebo/vehicle (topical paromomycin) or different regimens of paromomycin (photodynamic therapy).</P>
<P>Physical therapies included ablative or fractional CO&#8322; laser, compared against each other, IMMA, or cryotherapy. Trichloroacetic acid (TCA), alone or combined with non-ablative CO&#8322; laser, was compared with ILMA. Cryotherapy, alone or combined with 15% paromomycin and/or ILMA, was compared with ILMA alone or combined. Cryotherapy was also combined with topical treatments such as 3% salicylic acid cream and 3% sodium nitrite cream and compared against cryotherapy plus 3% salicylic acid cream plus a vehicle. Thermotherapy using radiofrequency waves was compared with ILMA, ILSSG, and IMSSG. Another type of thermotherapy included electrocauterisation, tested with or without DAC N-055.</P>
<P>Measures for promoting healing included topical diminazene aceturate (Berenil) versus topical cetrimide and chlorhexidine (Savlon), and trials of alternative therapies included topical interventions alone or combined compared with ILMA (topical honey plus ILMA; topical <I>Cassia fistula </I>alone or with fruit gel plus ILMA; and topical <I>Achilles millefolium</I> cream plus ILMA) or IMMA (topical herbal extract).</P>
<P>Heterogeneity in study design, medium to high levels of data bias, missing standard deviations, and a mix of different comparators, dosing regimens, and scheduled frequency did not, in general, permit pooling of the data or allow us to make accurate and direct comparisons of a substantial number of the interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Three RCTs did not clearly report the time points when the primary outcome was assessed (<LINK REF="STD-Dandashli-2005" TYPE="STUDY">Dandashli 2005</LINK>; <LINK REF="STD-Mapar-2010" TYPE="STUDY">Mapar 2010</LINK>; <LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK>), and the remaining studies reported a time ranging from the end of treatment to six months after treatment.</P>
<OL>
<LI>
<B>Percentage of lesions cured after the end of treatment</B>. Only 18 RCTs reported the primary outcome as percentage of lesions cured at three months after the end of treatment (<LINK REF="STD-Al-Hamdi-2010" TYPE="STUDY">Al Hamdi 2010</LINK>; <LINK REF="STD-Alkhawajah-1997" TYPE="STUDY">Alkhawajah 1997</LINK>; <LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>; <LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK>; <LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>; <LINK REF="STD-Dandashli-2005" TYPE="STUDY">Dandashli 2005</LINK>; <LINK REF="STD-El_x002d_Sayed-2010" TYPE="STUDY">El-Sayed 2010</LINK>; <LINK REF="STD-Firooz-2005" TYPE="STUDY">Firooz 2005</LINK>; <LINK REF="STD-Harms-1991" TYPE="STUDY">Harms 1991</LINK>; <LINK REF="STD-Jowkar-2012" TYPE="STUDY">Jowkar 2012</LINK>; <LINK REF="STD-Khatami-2013" TYPE="STUDY">Khatami 2013</LINK>; <LINK REF="STD-Larbi-1995" TYPE="STUDY">Larbi 1995</LINK>; <LINK REF="STD-Maleki-2012" TYPE="STUDY">Maleki 2012</LINK>; <LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>; <LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>; <LINK REF="STD-Shamsi-Meymandi-2011" TYPE="STUDY">Shamsi Meymandi 2011</LINK>; <LINK REF="STD-Shanehsaz-2015" TYPE="STUDY">Shanehsaz 2015</LINK>; <LINK REF="STD-Sharquie-2001" TYPE="STUDY">Sharquie 2001</LINK>).</LI>
<LI>
<B>Percentage of participants with a complete cure after the end of treatment</B>. The rest of the studies reported the percentages in terms of participants cured.</LI>
</OL>
<P>Varying numbers of studies reported the following secondary outcome measures.</P>
<OL>
<LI>
<B>Speed of healing</B> (time taken to be 'cured') in 16 studies (<LINK REF="STD-Alrajhi-2002" TYPE="STUDY">Alrajhi 2002</LINK>; <LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>; <LINK REF="STD-Asilian-2004b" TYPE="STUDY">Asilian 2004b</LINK>; <LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>; <LINK REF="STD-Farajzadeh-2015" TYPE="STUDY">Farajzadeh 2015</LINK>; <LINK REF="STD-Jaffary-2014b" TYPE="STUDY">Jaffary 2014b</LINK>; <LINK REF="STD-Jebran-2014" TYPE="STUDY">Jebran 2014</LINK>; <LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>; <LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>; <LINK REF="STD-Nilforoushzadeh-2007" TYPE="STUDY">Nilforoushzadeh 2007</LINK>; <LINK REF="STD-Nilforoushzadeh-2013" TYPE="STUDY">Nilforoushzadeh 2013</LINK>; <LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>; <LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK>; <LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>; <LINK REF="STD-Sharquie-2001" TYPE="STUDY">Sharquie 2001</LINK>; <LINK REF="STD-Stahl-2014" TYPE="STUDY">Stahl 2014</LINK>).</LI>
<LI>
<B>Duration of remission and percentage of people with treated lesions that recur within more than 6 months </B>in nine studies (<LINK REF="STD-Al_x002d_Fouzan-1991" TYPE="STUDY">Al-Fouzan 1991</LINK>; <LINK REF="STD-Bumb-2013" TYPE="STUDY">Bumb 2013</LINK>; <LINK REF="STD-Ejaz-2014" TYPE="STUDY">Ejaz 2014</LINK>; <LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK>; <LINK REF="STD-Fekri-2015" TYPE="STUDY">Fekri 2015</LINK>; <LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>; <LINK REF="STD-Ranawaka-2010" TYPE="STUDY">Ranawaka 2010</LINK>; <LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>; <LINK REF="STD-Sadeghian-2006b" TYPE="STUDY">Sadeghian 2006b</LINK>).</LI>
<LI>
<B>Degree of functional or aesthetic impairment</B> (no studies measured this outcome).</LI>
<LI>
<B>Prevention of scarring</B> in eight studies (<LINK REF="STD-Alkhawajah-1997" TYPE="STUDY">Alkhawajah 1997</LINK>; <LINK REF="STD-Asilian-2004b" TYPE="STUDY">Asilian 2004b</LINK>; <LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>; <LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK>; <LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>; <LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>; <LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>; <LINK REF="STD-Sharquie-2001" TYPE="STUDY">Sharquie 2001</LINK>).</LI>
<LI>
<B>Quality of life</B> (no studies measured this outcome).</LI>
<LI>
<B>Adverse effects</B> in all but eight studies (<LINK REF="STD-Al-Hamdi-2010" TYPE="STUDY">Al Hamdi 2010</LINK>; <LINK REF="STD-Asilian-2014" TYPE="STUDY">Asilian 2014</LINK>; <LINK REF="STD-Farajzadeh-2015" TYPE="STUDY">Farajzadeh 2015</LINK>; <LINK REF="STD-Kochar-2006" TYPE="STUDY">Kochar 2006</LINK>; <LINK REF="STD-Nilforoushzadeh-2004" TYPE="STUDY">Nilforoushzadeh 2004</LINK>; <LINK REF="STD-Nilforoushzadeh-2008" TYPE="STUDY">Nilforoushzadeh 2008</LINK>; <LINK REF="STD-Nilforoushzadeh-2012" TYPE="STUDY">Nilforoushzadeh 2012</LINK>; <LINK REF="STD-Nilforoushzadeh-2013" TYPE="STUDY">Nilforoushzadeh 2013</LINK>).</LI>
</OL>
<P>Three studies did not report secondary outcomes (<LINK REF="STD-Jaffar-2006" TYPE="STUDY">Jaffar 2006</LINK>; <LINK REF="STD-Kochar-2006" TYPE="STUDY">Kochar 2006</LINK>; <LINK REF="STD-Nilforoushzadeh-2004" TYPE="STUDY">Nilforoushzadeh 2004</LINK>).</P>
<P>A number of studies also reported tertiary outcome measures.</P>
<OL>
<LI>
<B>Change in ability to detect <I>Leishmania</I> by parasitological diagnostic methods</B> (e.g. smear, polymerase chain reaction (PCR), or culture). Two RCTs reported results where <I>Leishmania</I> was detected by parasitological diagnostic methods (e.g. PCR or culture, positive smears) (<A HREF="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=106203061613533394&amp;versionPK1=z1606071523005637262921402807851&amp;versionPK2=z1607131000335293690867293892488#STD-Jaffary-2014A">Jaffary 2014A</A>; <A HREF="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=106203061613533394&amp;versionPK1=z1606071523005637262921402807851&amp;versionPK2=z1607131000335293690867293892488#STD-Jebran-2014">Jebran 2014</A>). No studies reported emergence of resistance.</LI>
<LI>
<B>Emergence of treatment failures</B> (defined as a decline in the efficacy of a drug against a population of parasites previously susceptible to that compound (<LINK REF="REF-Ponte_x002d_Sucre-2003" TYPE="REFERENCE">Ponte-Sucre 2003</LINK>). The definition assumes that the original susceptibility of the population is known, which is not always the case for <I>Leishmania</I>). No studies reported this outcome.</LI>
<LI>
<B>Microbiological or histopathological cure of skin lesions</B>, reported in 15 studies (<LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>; <LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>; <LINK REF="STD-Asilian-2003" TYPE="STUDY">Asilian 2003</LINK>; <LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK>; <LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>; <LINK REF="STD-Dogra-1990" TYPE="STUDY">Dogra 1990</LINK>; <LINK REF="STD-Dogra-1991" TYPE="STUDY">Dogra 1991</LINK>; <LINK REF="STD-Dogra-1996" TYPE="STUDY">Dogra 1996</LINK>; <LINK REF="STD-Harms-1991" TYPE="STUDY">Harms 1991</LINK>; <LINK REF="STD-Jebran-2014" TYPE="STUDY">Jebran 2014</LINK>; <LINK REF="STD-Kashani-2010" TYPE="STUDY">Kashani 2010</LINK>; <LINK REF="STD-Kochar-2000" TYPE="STUDY">Kochar 2000</LINK>; <LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>; <LINK REF="STD-Nilforoushzadeh-2006" TYPE="STUDY">Nilforoushzadeh 2006</LINK>; <LINK REF="STD-Shamsi-Meymandi-2011" TYPE="STUDY">Shamsi Meymandi 2011</LINK>).</LI>
<LI>
<B>Development of cell-mediated immunity</B> (i.e. positive leishmanin skin test). One study reported the percentage of participants who developed Leishman bodies three months after treatment (<LINK REF="STD-Kashani-2010" TYPE="STUDY">Kashani 2010</LINK>).</LI>
</OL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-11-15 12:23:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2016-12-30 10:49:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Decimos que no hay estudios en curso&lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:52:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; (ongoing studies)&lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:49:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;, pero ponemos que hay &lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:50:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;6 ensayos en curso,&lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:53:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;y en el apartado studies awaiting assessment pone que identificamos 7 ongoing studies fro&lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:54:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;m&lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:53:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; trials registers....&lt;/span&gt;&lt;span modified=&quot;2016-12-30 10:54:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; Est&amp;#225; muy confuso este tema&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-11-15 12:23:11 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>We excluded 15 RCTs for the reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables and below.</P>
<UL>
<LI>Participants were randomly selected but not randomly assigned to the treatment groups.</LI>
<LI>Cross-over studies.</LI>
<LI>No assessment of clinical primary outcomes.</LI>
<LI>Review and meta-analysis.</LI>
<LI>Participants included in the study were immunocompromised and chronically ill patients.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting assessment</HEADING>
<P>We identified seven studies from full-text screening (<LINK REF="STD-Farajzadeh-2016a" TYPE="STUDY">Farajzadeh 2016a</LINK>; <LINK REF="STD-Farajzadeh-2016b" TYPE="STUDY">Farajzadeh 2016b</LINK>; <LINK REF="STD-Hanif-2016" TYPE="STUDY">Hanif 2016</LINK>; <LINK REF="STD-Jaffary-2016" TYPE="STUDY">Jaffary 2016</LINK>; <LINK REF="STD-Na_x002d_Bangchang-2016" TYPE="STUDY">Na-Bangchang 2016</LINK>; <LINK REF="STD-Rajabi-2016" TYPE="STUDY">Rajabi 2016</LINK>; <LINK REF="STD-Refai-2016" TYPE="STUDY">Refai 2016</LINK>), and one by assessing an abstract (<LINK REF="STD-Sattar-2012" TYPE="STUDY">Sattar 2012</LINK>). These studies evaluated the following.</P>
<UL>
<LI>Intralesional injection of zinc sulphate versus ILMA (Glucantime)e.</LI>
<LI>IMMA plus vehicle versus IMMA plus topical terbinafine.</LI>
<LI>Intralesional versus oral chloroquine administration.</LI>
<LI>ILMA (Glucantime) plus topical trichloroacetic acid (TCA) 50% versus ILMA alone versus fractional carbon dioxide laser.</LI>
<LI>Shiunko ointment versus vehicle.</LI>
<LI>Topical liposomal form of azithromycin versus ILMA (Glucantime).</LI>
<LI>Radiofrequency-induced heat therapy versus ILMA (Glucantime).</LI>
<LI>Topical ointment prepared from the stem extract of <I>Morinda citrifolia</I>.</LI>
</UL>
<P>We will evaluate them in a future update of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified six ongoing studies (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-11-10 08:07:18 +0000" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for the 'Risk of bias' summary: review authors' judgments about each risk of bias item for each included study, and see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for the 'Risk of bias' graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.</P>
<P>Our assessment of the risk of bias in the included studies has broadly followed the criteria set in the protocol. We thought the quality of the RCTs was generally poor for the following reasons.</P>
<ALLOCATION MODIFIED="2017-11-10 08:06:37 +0000" MODIFIED_BY="[Empty name]">
<P>Forty-two (47.2%) studies clearly described an adequate method of random sequence generation, meriting a judgment of low risk of bias, whereas the risk of bias in the rest of the studies (47/89, 52.8%) was unclear (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Of the 42 studies that were at low risk for sequence generation, only 12 (13.5%) also used an adequate method of allocation concealment (<LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>; <LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>; <LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>; <LINK REF="STD-Ben-Salah-2013" TYPE="STUDY">Ben Salah 2013</LINK>; <LINK REF="STD-Farajzadeh-2015" TYPE="STUDY">Farajzadeh 2015</LINK>; <LINK REF="STD-Firooz-2005" TYPE="STUDY">Firooz 2005</LINK>; <LINK REF="STD-Firooz-2006" TYPE="STUDY">Firooz 2006</LINK>; <LINK REF="STD-Khatami-2013" TYPE="STUDY">Khatami 2013</LINK>; <LINK REF="STD-Nassiri_x002d_Kashani-2005" TYPE="STUDY">Nassiri-Kashani 2005</LINK>; <LINK REF="STD-Nilforoushzadeh-2014b" TYPE="STUDY">Nilforoushzadeh 2014b</LINK>; <LINK REF="STD-Daie-Parizi-2015" TYPE="STUDY">Daie Parizi 2015</LINK>; <LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>; see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for details). However, in most studies (77, 86.5%), the method used to conceal the allocation prior to assignment was unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-11-10 08:07:18 +0000" MODIFIED_BY="[Empty name]">
<P>Only 21 studies were at low risk of performance bias because they clearly reported blinding participants or used other methods that we judged as unlikely to add risk of bias. Thirty-three studies did not provide enough information about the blinding of the participants. Among the 35 studies that did not blind the intervention and were at high risk of bias, there were some interventions that were impossible to blind due to the different administration routes (<LINK REF="STD-Esfandiarpour-2002" TYPE="STUDY">Esfandiarpour 2002</LINK>; <LINK REF="STD-Farajzadeh-2015" TYPE="STUDY">Farajzadeh 2015</LINK>; <LINK REF="STD-Jaffary-2014b" TYPE="STUDY">Jaffary 2014b</LINK>; <LINK REF="STD-Nilforoushzadeh-2013" TYPE="STUDY">Nilforoushzadeh 2013</LINK>; <LINK REF="STD-Daie-Parizi-2015" TYPE="STUDY">Daie Parizi 2015</LINK>; <LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>; <LINK REF="STD-Salmanpour-2001" TYPE="STUDY">Salmanpour 2001</LINK>; <LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK>).</P>
<P>With regard to the blinding of the outcome assessment, most studies 62/89 (69.7%) did not provide enough information about the blinding. Authors described 20 studies as blinded, and we therefore judged them to be at low risk of bias, whereas we judged 7 studies to be at high risk. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further details on who was blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-10-24 08:48:05 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 89 included studies, we considered the risk of bias for 39 (43.8%) to be low; for 24 (27.0%), unclear; and for 26 (29.2%), high.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dropouts</HEADING>
<P>The overall number of participants lost to follow-up was 1439, or 13.6% of the total number of study participants included in the review. We have categorised the dropouts into groups according to the percentage of evaluable participants (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat analyses</HEADING>
<P>Sixty-four studies accounted for losses to follow-up, while the other 25 did not report dropouts. However, 55 out of the 64 studies did not carry out intention-to-treat (ITT) analyses, or rather they just assessed participants who completed treatment. For each study, we took all randomised participants into account when introducing the data in our tables. We assumed that missing data were treatment failures. Concerning the loss to follow-up, it was not always possible to determine the arm in which the losses occurred, complicating ITT analyses. In that case, we introduced only available data into the tables for analysis.</P>
</SUBSECTION>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-10-24 08:53:08 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 89 included studies, 53 (59.55%) reported all expected outcomes, meriting a judgment of low risk of bias. We considered 22 studies (25.72%) to be at unclear risk of bias. Fourteen studies (15.73%) failed to report, or reported only incompletely (making it impossible to enter the data into meta-analysis), results for a key outcome that would be expected to have been reported, and we therefore considered these studies to be at high risk of bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-10-24 08:55:42 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed other potential sources of bias such as sample size calculation, the reporting of <I>Leishmania</I> species and baseline comparability among intervention groups. If a study reported all three items correctly, we classified it as being at low risk of bias. If at least one of the items were not reported correctly, we classified it as being at high risk of bias, and if the study did not report enough information to assess if there were other biases present, we classified it as being at unclear risk of bias. Of the 89 included studies, we considered the risk of bias to be high in 41 (46.07%), unclear in 28 (31.46%), and low in 20 (22.47%).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-11-15 16:49:55 +0000" MODIFIED_BY="[Empty name]">
<P>Please see the 'Summary of findings' tables, where we have summarised the certainty of the body of evidence for two of the most clinically important comparisons (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). We have produced two forest plots for our primary outcome, with subgroups for each comparison (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), and we have summarised adverse effects in seven tables (see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>; <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>; <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>).</P>
<P>We describe only those outcomes with data below. If a particular primary, secondary, or tertiary outcome is missing, then this is because we did not find suitable data. Pooling of outcome data across studies to provide a summary estimate of effect was only possible for five interventions and comparisons; these investigated the effects of topical paromomycin, itraconazole, radiofrequency waves, oral dapsone, and intramuscular meglumine antimoniate (IMMA). We categorised a substantial number of the studies included in this review as being at unclear or high risk of bias (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), so readers should interpret the results with caution.</P>
<P>We have addressed our pre-specified outcomes under the following intervention headings.</P>
<OL>
<LI>Systemic and intralesional antimonials.</LI>
<LI>Non-antimonial systemic treatments.</LI>
<LI>Non-antimonial topical or intralesional therapies.</LI>
<LI>Physical therapies.</LI>
<LI>Measures for promoting healing.</LI>
<LI>Alternative therapies.</LI>
</OL>
<P>We have also referred in the text to tables where we have summarised reports of adverse effects of the different interventions.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Systemic and intralesional antimonials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Meglumine antimoniate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 Different doses of intralesional meglumine antimoniate</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Pakistan compared intralesional meglumine antimoniate (ILMA) weekly versus fortnightly, until complete cure or up to eight weeks (<LINK REF="STD-Mujtaba-1999" TYPE="STUDY">Mujtaba 1999</LINK>). Two months after treatment, 92% (102/111) of the lesions were cured in the weekly, and 85.6% (89/104) in the fortnightly group. There was no statistical difference between weekly and fortnightly administration (risk ratio (RR) 1.07, 95% confidence interval (CI) 0.98 to 1.18; N = 215; 1 study, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>Most lesions had healed at six weeks in both groups with minimal or absent scarring.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Authors did not report adverse effects in any of the participants, except transient pain at the site of the injections in both groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 Intralesional versus intramuscular meglumine antimoniate</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>One RCT from Saudi Arabia compared ILMA every other day versus IMMA 6 days a week, over a 30-day period until the lesions had blanched (<LINK REF="STD-Alkhawajah-1997" TYPE="STUDY">Alkhawajah 1997</LINK>). The authors reported a comparable cure rate: 68.6% (48/70) and 59.7% (46/77) of the of lesions in the respective groups at the end of the treatment period (RR 1.15, 95% CI 0.90 to 1.46; N = 147; 1 study, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, both groups reported pain at the site of injection, but it was greater in the ILMA group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.3 Different doses of IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Syria compared IMMA 60 mg/kg/d plus placebo versus IMMA 30 mg/kg/d plus placebo or cimetidine for three weeks (<LINK REF="STD-Shanehsaz-2015" TYPE="STUDY">Shanehsaz 2015</LINK>). Three months after treatment, 91.1% (82/90) of the lesions were cured in the IMMA 60 mg plus placebo group, 84.6% (127/150) in the IMMA 30 mg plus cimetidine group, and 78.3% (94/120) in IMMA 30 mg plus placebo group. We did not find any significant differences in cure rates between the IMMA 30 mg plus cimetidine group versus the IMMA 30 mg plus placebo group (RR 1.08, 95% CI 0.96 to 1.21; N = 270; 1 study, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) or between the IMMA 30 mg plus cimetidine group versus the IMMA 60 mg group (RR 0.93, 95% CI 0.85 to 1.02; N = 240; 1 study, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). Cure rates were significantly higher in the IMMA 60 mg group compared with the IMMA 30 mg plus placebo group (RR 1.16 95% CI 1.04 to 1.30; N = 210; 1 study, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>A pooled analysis of two trials showed that cure rates in the IMMA 60 mg group were better than in the IMMA 30 mg plus placebo group (RR 0.83, 95% CI 0.71 to 0.96; N = 148; <LINK REF="STD-Nilforoushzadeh-2008" TYPE="STUDY">Nilforoushzadeh 2008</LINK>; <LINK REF="STD-Shanehsaz-2015" TYPE="STUDY">Shanehsaz 2015</LINK>, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). We assessed the certainty of evidence as low, which means we are uncertain whether there is much difference in cure rate between these two concentrations of IMMA.</P>
<P>An RCT from Iran compared IMMA 60 mg/kg/d plus placebo versus IMMA 30 mg/kg/d plus placebo or omeprazole for three weeks (<LINK REF="STD-Nilforoushzadeh-2008" TYPE="STUDY">Nilforoushzadeh 2008</LINK>). Three months after treatment, there was complete cure in 93% (40/43) of participants in the IMMA 60 mg plus placebo group, 89% (32/36) in the IMMA 30 mg plus omeprazole group, and 80% (36/45) in the IMMA 30 mg plus placebo group. There were no significant differences in cure rates in any comparisons: IMMA 30 mg plus omeprazole versus IMMA 60 mg (RR 0.96, 95% CI 0.83 to 1.10; N = 79; 1 study, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>), IMMA 30 mg plus placebo versus IMMA 60 mg plus placebo (RR 0.86, 95% CI 0.73 to 1.02; N = 88; 1 study, <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>), or IMMA 30 mg plus omeprazole versus IMMA 30 mg plus placebo (RR 1.11, 95% CI 0.92 to 1.34; N = 81; 1 study, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, <LINK REF="STD-Shanehsaz-2015" TYPE="STUDY">Shanehsaz 2015</LINK> reported serious adverse effects in 83.3% (n = 25) participants in the IMMA 60 mg dose group and 60% (n = 18) participants in the IMMA 30 mg group; 40% (n = 12) of participants in the IMMA 60 mg dose group and 23.3% (n = 7) in the 30 mg group experienced skin hypersensitivity, while there were five and three cases, respectively, of cardiac toxicity (QT prolongation) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>). Hence, there were fewer serious adverse effects (RR 0.72, 95% CI 0.52 to 1.00; N = 60, 1 study), fewer skin reactions (RR 0.58, 95% CI 0.27 to 1.28; N = 60, 1 study), and less QT prolongation (RR 0.60, 95% CI 0.16 to 2.29; N = 60, 1 study) in the IMMA 30 mg plus placebo group, but none of the results were significant.</P>
<P>In <LINK REF="STD-Nilforoushzadeh-2008" TYPE="STUDY">Nilforoushzadeh 2008</LINK>, the authors reported one case of anaphylactic shock to meglumine antimoniate (not described).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.4 ILMA alone versus ILMA plus silver or non-silver dressing</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>One RCT from Iran compared weekly injections of ILMA for 6 weeks alone versus ILMA at the same dose plus silver or non-silver dressing (<LINK REF="STD-Khatami-2013" TYPE="STUDY">Khatami 2013</LINK>). We performed an ITT analysis considering the lesions allocated in each arm at the beginning of the study: 26 participants with 45 lesions in the ILMA-alone group, 31 participants with 60 lesions in the ILMA plus silver dressing group, and 26 participants with 53 lesions in the ILMA plus non-silver dressing group. At one month after treatment, 35.5% (16/45) of lesions were cured in the ILMA-alone group, 33.3% (20/60) in the ILMA plus silver dressing group, and 35.8% (19/53) in the ILMA plus non-silver dressing group. There were no significant differences in cure rates between groups: ILMA plus non-silver dressing versus ILMA alone (RR 1.01, 95% CI 0.59 to 1.72; N = 98, <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>); ILMA plus silver dressing versus ILMA alone (RR 0.94, 95% CI 0.55 to 1.60; N = 105, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>); or ILMA plus silver dressing versus ILMA plus non-silver dressing (RR 0.93, 95% CI 0.56 to 1.54; N = 113, <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, participants reported itching and burning in 7.5% (n = 3) of lesions in ILMA alone group, 10.9% (n = 6) of lesions in the ILMA plus silver group, and 17.7% (n = 8) lesions in the ILMA plus non-silver group; there was also oedema in 12.5% (n = 5), 7.2% (n = 4), and 6.6% (n = 3) of the lesions, respectively. One lesion in each group showed exudation, and another lesion was accompanied by dermatitis in the ILMA plus non-silver group. There were no significant differences in any adverse effects rates in any comparison (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>; <LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>; <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>; <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>; <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.5 ILMA plus gel mask versus ILMA plus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>One RCT from Iran compared ILMA (weekly injections for six weeks) plus gel mask twice a day with ILMA (weekly injections for six weeks) plus placebo (<LINK REF="STD-Mostafavi-2013" TYPE="STUDY">Mostafavi 2013</LINK>). At the end of treatment, 75% (15/20) and 65% (13/20) of participants, respectively, had complete cure. There were no significant differences in cure rates between groups (RR 1.15, 95% CI 0.77 to 1.74; N = 40; 1 study, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, none of the participants from either group suffered severe adverse effects such as local irritation or pruritus.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Sodium stibogluconate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Intralesional versus intramuscular sodium stibogluconate (SSG)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">
<I>Primary outcome: percentage of lesions cured after the end of treatment</I>
</HEADING>
<P>An RCT from Iran compared ketoconazole 200 mg three times daily for four weeks plus intralesional sodium stibogluconate (ILSSG) (100 mg/mL on days 1, 3, and 5) versus intralesional plus intramuscular sodium stibogluconate (20 mg/kg/d intralesionally on days 1, 3, and 5, and 80 mg/kg/d intramuscularly simultaneously) versus ILSSG alone (100 mg/mL on days 1, 3, and 5) (<LINK REF="STD-El_x002d_Sayed-2010" TYPE="STUDY">El-Sayed 2010</LINK>). The authors reported that two months after treatment, 92.3% (12/13), 93.3% (14/15), and 58.3% (7/12) of lesions were cured in the respective groups. There were no significant differences between intralesional plus intramuscular SSG versus ILSSG alone (RR 1.60, 95% CI 0.97 to 2.63; N = 27; 1 study, <LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Afghanistan compared ILSSG (five injections of 2 mL to 5 mL every 5 to 7 days, depending on lesion size) for up to 29 days versus intramuscular sodium stibogluconate (IMSSG) (20 mg/kg/d for 21 days) (<LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK>). Two months after treatment, 47.3% (70/148) and 18% (26/144) of participants had complete cure in the ILSSG and IMSSG groups, respectively (RR 2.62, 95% CI 1.78 to 3.86; N = 292; 1 study, <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>In <LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK>, the speed of healing took a median of 75 days in the ILSSG group and 100 days or more for the IMSSG group (the original paper reported that the time to cure was significantly shorter for participants treated with thermotherapy; P = 0.003, by the log-rank test).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, <LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK> reported that one participant experienced bradycardia and one an undefined local reaction in the ILSSG group. In the IMSSG group, one participant reported bradycardia, one tachycardia, and one palpitation. There were no significant differences in adverse effects rates between groups (RR 0.32, 95% CI 0.03 to 3.08; N = 292; 1 study, <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>). In <LINK REF="STD-El_x002d_Sayed-2010" TYPE="STUDY">El-Sayed 2010</LINK>, all participants from ILSSG group suffered pain and swelling at the intralesional site, which calmed on its own within two days. IMSSG was associated with pain at the injection site.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Non-antimonial systemic treatments</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Oral antifungals</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1 Different doses of ketoconazole</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Kuwait compared oral ketoconazole at 600 mg/d versus 800 mg/d for six weeks or until the participant was cured, whichever occurred earlier (<LINK REF="STD-Alsaleh-1995" TYPE="STUDY">Alsaleh 1995</LINK>). The authors reported that at the end of treatment, 66.7% (12/18) and 60% (9/15) of participants in the respective groups had a complete cure (RR 1.11, 95% CI 0.66 to 1.88; N = 33; 1 study <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>). Thereafter, investigators followed up participants every one to two months for a period of six months, with no change.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>None of the participants from either group relapsed during a six-month follow-up. With regard to adverse effects, one participant had nausea and vomiting in the ketoconazole 800 mg/d group. There were no significant differences in adverse effects rates between groups (RR 0.28, 95% CI 0.01 to 6.43; N = 33; 1 study, <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.2 Ketoconazole versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared oral ketoconazole 600 mg/d for 30 days versus six to eight injections of ILMA, biweekly (<LINK REF="STD-Salmanpour-2001" TYPE="STUDY">Salmanpour 2001</LINK>). The authors reported that six weeks after treatment, 89% (57/64) and 72% (23/32) of participants in the respective groups had a complete cure. There were no significant differences between groups (RR 1.24, 95% CI 0.98 to 1.56; N = 96; 1 study, <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In the ketoconazole group the most common side effect cited was nausea and abdominal pain, and liver enzymes doubled in two participants, returning to normal two weeks after the end of treatment. There were no significant differences in adverse effects rates between groups (RR 2.54, 95% CI 0.13 to 51.36; N = 96; 1 study, <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). In the ILMA group, the most common side effect was redness and swelling after the injection. None of the side effects were significant enough to discontinue treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.3 Ketoconazole plus ILSSG versus ILSSG alone versus ILSSG plus IMSSG</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">
<I>Primary outcome: percentage of lesions cured after the end of treatment</I>
</HEADING>
<P>An RCT from Iran compared oral ketoconazole plus ILSSG for four weeks versus ILSSG plus IMSSG versus ILSSG alone (<LINK REF="STD-El_x002d_Sayed-2010" TYPE="STUDY">El-Sayed 2010</LINK>). The authors reported that two months after treatment, 92.3% (12/13), 93.3% (14/15), and 58.3% (7/12) of the lesions were cured in the respective groups. There were no significant differences between comparisons of either ketoconazole plus ILSSG versus ILSSG alone (RR 1.58, 95% CI 0.96 to 2.62; N = 25; 1 study, <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>) nor between ketoconazole plus ILSSG versus ILSSG plus IMSSG (RR 0.99, 95% CI 0.80 to 1.22; N = 28; 1 study, <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, in one trial all participants complained of pain and swelling at the intralesional injection site that subsided on its own within days; no participants in the oral ketoconazole group reported adverse effects (<LINK REF="STD-El_x002d_Sayed-2010" TYPE="STUDY">El-Sayed 2010</LINK>).</P>
<P>We also found one trial comparing oral ketoconazole with topical paromomycin/MBCL (<LINK REF="STD-_x00d6_zg_x00f6_ztasi-1997" TYPE="STUDY">Özgöztasi 1997</LINK>); we assess this comparison in the topical paromomycin section (section 3.2 below).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.4 Itraconazole versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>Three RCTs compared itraconazole versus placebo and reported complete cure three months after the end of treatment as a primary outcome (<LINK REF="STD-Al_x002d_Fouzan-1991" TYPE="STUDY">Al-Fouzan 1991</LINK>; <LINK REF="STD-Dogra-1996" TYPE="STUDY">Dogra 1996</LINK>; <LINK REF="STD-Nassiri_x002d_Kashani-2005" TYPE="STUDY">Nassiri-Kashani 2005</LINK>). Although heterogeneity was high (P = 0.02; I² = 73%), the three studies obtained results favouring itraconazole, so we decided to maintain the pool of results and the meta-analysis (RR 3.70, 95% CI 0.35 to 38.99; N = 244; 3 studies, <LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>).</P>
<P>Please see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, where we assessed the certainty of evidence as very low, which means we are very uncertain about the difference in cure with itraconazole compared to placebo.</P>
<P>Two RCTs evaluated complete cure of participants at other time points. An RCT from Iran compared oral itraconazole for three weeks versus placebo (<LINK REF="STD-Momeni-1996" TYPE="STUDY">Momeni 1996</LINK>). Fifty-one days after treatment, results showed complete cure of participants in 51.4% (36/70) and 38.6% (27/70) of the participants, respectively. There were no significant differences in cure rates between groups (RR 1.33, 99% CI 0.82 to 2.18; N = 140; 1 study, <LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>). An RCT from India compared oral itraconazole for six weeks with placebo (<LINK REF="STD-Dogra-1992" TYPE="STUDY">Dogra 1992</LINK>). At the end of the treatment period, 75% (15/20) of participants in the oral itraconazole group and 0% (0/20) of the participants in the placebo groups achieved a complete cure. There were no statistically significant differences in cure rates between groups (RR 31.00, 99% CI 0.83 to 1151.33; N = 40; 1 study, <LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In <LINK REF="STD-Al_x002d_Fouzan-1991" TYPE="STUDY">Al-Fouzan 1991</LINK>, two participants from the itraconazole group reported nausea and headache during the course of treatment, and one participant had elevated liver enzymes that returned back to normal upon discontinuation of the drug. <LINK REF="STD-Dogra-1992" TYPE="STUDY">Dogra 1992</LINK> reported nausea in 12 cases (30%) between the itraconazole and dapsone groups. In the itraconazole group, two participants (10%) also had mildly abnormal liver function that reverted after completion of therapy. In <LINK REF="STD-Momeni-1996" TYPE="STUDY">Momeni 1996</LINK>, six participants in the itraconazole group and four participants in the placebo group complained of mild abdominal pain and nausea. None of the laboratory values were outside normal limits. In <LINK REF="STD-Dogra-1996" TYPE="STUDY">Dogra 1996</LINK>, one participant showed abnormal liver function and one nausea in the itraconazole group. Participants in the placebo group did not report adverse effects. In <LINK REF="STD-Nassiri_x002d_Kashani-2005" TYPE="STUDY">Nassiri-Kashani 2005</LINK>, the most common adverse effects were gastrointestinal complaints and headache &#8211; reported only in the itraconazole group during the follow-up period. Participants in the placebo group reported adverse effects only during the treatment period.</P>
<P>Participants of itraconazole group had more side effects, including mild abdominal pain and nausea (RR 2.36, 95% CI 0.74 to 7.47; 3 studies, N = 204, <LINK REF="CMP-022.02" TYPE="ANALYSIS">Analysis 22.2</LINK>) as well as mild abnormal liver function (RR 3.08, 95% CI 0.53 to 17.98; N = 84, 3 studies, <LINK REF="CMP-022.02" TYPE="ANALYSIS">Analysis 22.2</LINK>). However, the very low certainty of the evidence means we are uncertain about these results (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>In <LINK REF="STD-Dogra-1996" TYPE="STUDY">Dogra 1996</LINK>, parasitological cure was significantly higher (Fisher's exact test P = 0.048) in participants receiving itraconazole compared to placebo. Parasitological cure occurred in 80% (8/10) of itraconazole-treated participants but in none of the participants in the placebo group at six weeks follow-up (RR 17.0, 95% CI 0.47 to 612.21; N = 20; 1 study, <LINK REF="CMP-022.03" TYPE="ANALYSIS">Analysis 22.3</LINK>).</P>
<P>Please see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> where we assessed the certainty of evidence.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.5 Itraconazole versus no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from India compared oral itraconazole 200 mg/d for six weeks versus no treatment (<LINK REF="STD-Dogra-1990" TYPE="STUDY">Dogra 1990</LINK>). The authors reported complete cure of participants in 66.7% (10/15) of the treatment group but in none of the no treatment group. Low statistical power meant that these differences could have been due to chance (RR 7.88, 99% CI 0.23 to 265.70; N = 20; 1 study, <LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>Participants responding to therapy had no relapses at three-month follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, the drug was generally well tolerated, although 20% (3/15) of participants in the itraconazole group reported mild headache and dizziness. There were no significant differences in adverse effects rates between groups (RR 2.63, 95% CI 0.16 to 43.63; N = 20; 1 study, <LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>At six weeks, 66.7% (10/15) of the participants in the itraconazole group were free of parasites. Untreated participants were still parasitologically active. Low statistical power meant that these differences could have been due to chance (RR 7.88, 95% CI 0.54 to 114.56; N = 20; 1 study, <LINK REF="CMP-023.03" TYPE="ANALYSIS">Analysis 23.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.6 Fluconazole versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>One RCT from Aleppo, Syria compared fluconazole 200 mg/d for six weeks versus placebo (<LINK REF="STD-Dandashli-2005" TYPE="STUDY">Dandashli 2005</LINK>). The authors reported that at the end of treatment, 28.4% (75/264) of the lesions in the fluconazole group and 9.8% (10/102) in the placebo group had completely resolved. Cure rates were higher in the oral fluconazole group compared with placebo (RR 2.90, 95% CI 1.56 to 5.38, <LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>One RCT from Saudi Arabia compared oral fluconazole 200 mg/d versus placebo for six weeks (<LINK REF="STD-Alrajhi-2002" TYPE="STUDY">Alrajhi 2002</LINK>). Three months after treatment, 59% (63/106) participants in the oral fluconazole and 21% (22/103) in the placebo group had achieved complete cure (RR 2.78, 95% CI 1.86 to 4.16; N = 209; 1 study, <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>Only <LINK REF="STD-Alrajhi-2002" TYPE="STUDY">Alrajhi 2002</LINK> reported the speed of healing, finding that this took a median of 8.5 weeks in the fluconazole group and 11.2 weeks in the placebo group (the original paper reported that the time to cure was significantly shorter for participants treated with thermotherapy; P &lt; 0.001, by the log-rank test). Also, none of the participants with complete healing had a relapse during a mean follow-up of seven months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In both studies participants from reported mild and similar side effects, although the authors did not describe them (<LINK REF="STD-Alrajhi-2002" TYPE="STUDY">Alrajhi 2002</LINK>; <LINK REF="STD-Dandashli-2005" TYPE="STUDY">Dandashli 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.7 Different doses of fluconazole</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>One RCT from Iran compared oral fluconazole 400 mg/d versus 200 mg/d for six weeks (<LINK REF="STD-Emad-2011" TYPE="STUDY">Emad 2011</LINK>). The authors reported that at the end of treatment, 48.3% (29/60) of participants in the 200 mg group and 81% (47/58) in the 400 mg group achieved complete cure (RR 1.68, 95% CI 1.25 to 2.24; N = 118; 1 study, <LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, two participants in the 400 mg group discontinued treatment because of a rise of serum creatinine and liver enzymes. Participants in the 400 mg group reported 45 (75%) cases of cheilitis and 10 (16.6%) cases of nausea, compared to none in the 200 mg group (cheilitis: RR 94.08, 95% CI 5.93 to 1492.36; nausea: RR 21.71, 95% CI 1.30 to 362.21; N = 118; 1 study, <LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Oral dapsone</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1 Dapsone versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>Two RCTs comparing oral dapsone versus placebo reported complete cure after the end of treatment as a primary outcome (<LINK REF="STD-Dogra-1991" TYPE="STUDY">Dogra 1991</LINK>; <LINK REF="STD-Dogra-1992" TYPE="STUDY">Dogra 1992</LINK>). Although heterogeneity was high (P = 0.02; I² = 73%), both studies obtained results favouring dapsone, so we decided to maintain the pool of results and meta-analysis (RR 24.08, 95% CI 1.44 to 403.43; N = 160; 2 studies; I² = 71%, <LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>In <LINK REF="STD-Dogra-1992" TYPE="STUDY">Dogra 1992</LINK>, participants initially responding to therapy did not relapse at follow-up, while two cases with single lesions (10%) demonstrated spontaneous healing in the placebo group at three months' follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, 30% (n = 12) of participants in the dapsone group experienced nausea. In <A HREF="Interventions%20for%20Old%20World%20cutaneous%20leishmaniasis.htm#STD-Dogra-1991#STD-Dogra-1991">Dogra 1991</A>, 5% (3/60) of participants in the dapsone group developed anaemia and 15% (9/60), nausea. Nausea rates were higher in the dapsone group compared with placebo (RR 21.86, 95% CI 3.04 to 157.29; N = 160; 2 studies; I² = 0%, <LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Regarding the parasitological cure, 5% (3/60) of participants in the placebo group showed healing with negative smears one month after treatment (<LINK REF="STD-Dogra-1991" TYPE="STUDY">Dogra 1991</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Oral allopurinol</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 Allopurinol versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared oral allopurinol 15 mg/kg/d for three weeks versus IMMA 30 mg/kg/d for two weeks versus oral allopurinol 15 mg/kg/d plus IMMA 30 mg/kg/d simultaneously, using the same dosage schedule (<LINK REF="STD-Esfandiarpour-2002" TYPE="STUDY">Esfandiarpour 2002</LINK>). The authors reported that 18% (9/50) of participants receiving allopurinol alone achieved complete cure, compared to 24% (12/50) in the IMMA group and 46% (23/50) in the allopurinol plus IMMA group at the end of the treatment period. The group receiving allopurinol plus IMMA had better cure rates than those receiving allopurinol alone (RR 3.83, 95% CI 1.71 to 8.60; N = 100; 1 study, <LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>) or IMMA alone (RR 1.92, 95% CI 1.08 to 3.41; N = 100; 1 study, <LINK REF="CMP-028.01" TYPE="ANALYSIS">Analysis 28.1</LINK>). There was no difference regarding cure rates between the groups receiving allopurinol alone versus IMMA alone (RR 0.75, 95% CI 0.35 to 1.62; N = 100; 1 study, <LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>).</P>
<P>An RCT from Iran compared oral allopurinol 20 mg/kg/d plus IMMA 10 mg/kg/d versus IMMA 20 mg/kg/d alone for up to 28 days (<LINK REF="STD-Ejaz-2014" TYPE="STUDY">Ejaz 2014</LINK>). There was no data to address the primary outcome of percentage of participants with a complete cure.</P>
<P>Another RCT in an Iranian army camp compared oral allopurinol 20 mg/kg/d plus low-dose IMMA 30 mg/kg/d for 20 days versus IMMA 60 mg/kg/d for 20 days (<LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>). In this trial the authors reported that 51 days after treatment, 69% (25/36) and 72% (26/36) of participants, respectively, achieved a complete cure (RR 0.96, 95% CI 0.71 to 1.29; N = 72; 1 study, <LINK REF="CMP-030.01" TYPE="ANALYSIS">Analysis 30.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Esfandiarpour-2002" TYPE="STUDY">Esfandiarpour 2002</LINK> observed a few adverse effects in the allopurinol group: three participants experienced nausea and heartburn, and two saw a mild increase in serum glutamic-oxaloacetic transaminase and serum glutamic pyruvic transaminase levels. In <A HREF="Momeni%202002">Momeni 2002</A> participants tolerated the drugs well, and only 17% (6/36) in the combined treatment group complained of mild abdominal pain and nausea; however, 3% (1/36) of participants in the IMMA group developed skin eruption, and 11% (4/36) suffered generalised muscle pain and weakness. There was no significant difference between groups in total adverse effects (<LINK REF="CMP-030.02" TYPE="ANALYSIS">Analysis 30.2</LINK>). <LINK REF="STD-Ejaz-2014" TYPE="STUDY">Ejaz 2014</LINK> reported secondary infection in 12.1% (n = 21) of participants in the allopurinol plus IMMA group and in 12.5% (n = 19) of participants in the IMMA group, myalgia in 5.7% (n = 10) and 7.9% (n = 12), anorexia in 7.5% (n = 13) and 5.9% (n = 9), and ECG changes in 0.6% (n = 1) and 1.98% (n = 3), respectively. In the IMMA alone group one participant suffered chest pain; two, pain at the injection site; and five, abscess. There was no significant difference regarding adverse effects rates between the two groups (<LINK REF="CMP-031.01" TYPE="ANALYSIS">Analysis 31.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Only one study reported that 83.3% (30/36) of participants in the allopurinol plus IMMA group and 75% (27/36) in the IMMA alone group had parasitologically free lesions one month after the end of treatment (<LINK REF="STD-Momeni-2002" TYPE="STUDY">Momeni 2002</LINK>). There was no difference regarding cure rates between groups ((RR 1.11, 95% CI 0.88 to 1.41; participants = 72; studies = 1) <LINK REF="CMP-030.03" TYPE="ANALYSIS">Analysis 30.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Oral allopurinol versus intravenous sodium stibogluconate</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT with participants from the Pakistani army compared oral allopurinol 20 mg/kg/d versus intravenous sodium stibogluconate (IVSSG) for 15 days (<LINK REF="STD-Mashood-2001" TYPE="STUDY">Mashood 2001</LINK>). The authors reported at the end of the treatment period, 85% (17/20) of participants in the allopurinol group and 70% (14/20) in the IVSSG group achieved a complete cure. There was no significant difference regarding cure rates between groups (RR 1.21, 95% CI 0.86 to 1.71; N = 40; 1 study, <LINK REF="CMP-032.01" TYPE="ANALYSIS">Analysis 32.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Mashood-2001" TYPE="STUDY">Mashood 2001</LINK> observed adverse effects that included nausea, vomiting, anorexia, and diarrhoea in 5% (1/20) of participants in the allopurinol group and 20% (4/20) of participants in the IVSSG group. In the SSG group, 10% (2/20) of participants experienced liver abnormalities and 15% (3/20), myalgia and body aches. In the allopurinol group, 5% (1/20) had elevated liver enzymes, and 10% (2/20), macular rash, but there was no myalgia or body aches. There was no significant difference in adverse effects rates between the allopurinol group and IVSSG alone group (<LINK REF="CMP-032.02" TYPE="ANALYSIS">Analysis 32.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Oral antibiotics</HEADING>
<P>For a summary of adverse effects of oral antibiotics please see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1 Oral rifampicin versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Saudi Arabia compared oral rifampicin 10 mg/kg/d for four to six weeks versus placebo (<LINK REF="STD-Jaffar-2006" TYPE="STUDY">Jaffar 2006</LINK>). Three months after treatment, 45.7% (21/46) of participants in the oral rifampicin group and 18.8% (3/16) of the placebo group achieved complete cure. There was no difference in cure rates between oral rifampicin and placebo (RR 2.43, 95% CI 0.84 to 7.08; N = 62; 1 study, <LINK REF="CMP-033.01" TYPE="ANALYSIS">Analysis 33.1</LINK>).</P>
<P>Two RCTs from India address the primary outcome of percentage of participants with a complete cure at the end of treatment. <LINK REF="STD-Kochar-2000" TYPE="STUDY">Kochar 2000</LINK> compared 10 mg/kg/d oral rifampicin for four weeks versus placebo, reporting that 68% (17/25) and 4% (1/25) of participants, respectively, achieved complete cure by the end of the treatment period (RR 17.00, 95% CI 2.45 to 118.19; N = 50; 1 study, <LINK REF="CMP-033.01" TYPE="ANALYSIS">Analysis 33.1</LINK>). <LINK REF="STD-Kochar-2006" TYPE="STUDY">Kochar 2006</LINK> compared 10 mg/kg/d oral rifampicin plus 20 mg/d omeprazole for six weeks versus placebo, reporting that 64% (16/25) participants in the rifampicin group and 12% (3/25) in the placebo group had achieved a complete cure at the end of the treatment period (RR 5.33, 95% CI 1.77 to 16.05; N = 50; 1 study, <LINK REF="CMP-034.01" TYPE="ANALYSIS">Analysis 34.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Jaffar-2006" TYPE="STUDY">Jaffar 2006</LINK> reported that one participant had elevated liver enzymes that returned back to normal upon discontinuation of the drug. <LINK REF="STD-Kochar-2000" TYPE="STUDY">Kochar 2000</LINK> reported that the drug was very well tolerated, and there were no adverse effects during therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>
<LINK REF="STD-Kochar-2000" TYPE="STUDY">Kochar 2000</LINK> reported an absence of parasites in 8% (2/25) and 32% (8/25) of partially healed lesions in the rifampicin and placebo groups, respectively, at the end of treatment (RR 0.25, 95% CI 0.06 to 1.06; N = 50; 1 study, <LINK REF="CMP-033.02" TYPE="ANALYSIS">Analysis 33.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.2 Oral terbinafine plus cryotherapy versus IMMA plus cryotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>An RCT from Iran compared cryotherapy (liquid nitrogen via a cotton swab for 10 s to 25 s every two weeks for four weeks) plus either oral terbinafine 500 mg/d for four weeks or plus IMMA 15 mg/kg/d (<LINK REF="STD-Farajzadeh-2015" TYPE="STUDY">Farajzadeh 2015</LINK>). After three months' follow-up, the crude hazard ratio was 0.53 (95% CI 0.30 to 0.98) and after adjustment for sex, it was 0.35 (95% CI 0.19 to 0.69). A Kaplan-Meier analysis indicated that the difference in complete treatment between the groups was not significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.3 Azithromycin with or without allopurinol versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared azithromycin 500 mg for five days/month up to a maximum of four months with IMMA 60 mg/kg/d for 20 days (<LINK REF="STD-Layegh-2007" TYPE="STUDY">Layegh 2007</LINK>). After 16 weeks of follow-up, 10.3% (13/29) and 34.4% (20/58) of the lesions were cured in the respective groups (RR 0.60, 95% CI 0.18 to 2.01; N = 87; 1 study, <LINK REF="CMP-035.01" TYPE="ANALYSIS">Analysis 35.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared azithromycin 10 mg/kg/d (maximum 500 mg/d) plus allopurinol 10 mg/kg for one month versus IMMA 20 mg/kg/d for 20 days (<LINK REF="STD-Dastgheib-2012" TYPE="STUDY">Dastgheib 2012</LINK>); 38.9% (14/36) and 40% (14/35) of participants, respectively, had achieved complete cure at two months after treatment (RR 0.97, 95% CI 0.55 to 1.73; N = 71, <LINK REF="CMP-036.01" TYPE="ANALYSIS">Analysis 36.1</LINK>). There was no statistical difference in cure rates between azithromycin plus allopurinol versus IMMA in ulcerated (P = 0.40) and non-ulcerated (P = 0.37) lesions or with regard to the site of lesions (P = 0.30).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, <LINK REF="STD-Dastgheib-2012" TYPE="STUDY">Dastgheib 2012</LINK> reported that one (2.7%) participant in the azithromycin plus allopurinol group had gastrointestinal complaints and severe headache, and three (8.3%) experienced slight gastrointestinal complications (nausea, heartburn, and epigastric pain). <LINK REF="STD-Layegh-2007" TYPE="STUDY">Layegh 2007</LINK> described only nausea and vomiting in two participants (9%) in the azithromycin alone group. Only <LINK REF="STD-Dastgheib-2012" TYPE="STUDY">Dastgheib 2012</LINK> reported myalgia in two (5.7%) participants in the IMMA group. There were no significant differences in adverse effects rates between groups (<LINK REF="CMP-035.02" TYPE="ANALYSIS">Analysis 35.2</LINK>; <LINK REF="CMP-036.02" TYPE="ANALYSIS">Analysis 36.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Oral pentoxifylline</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.5.1 Oral pentoxifylline plus IMMA versus placebo plus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared oral pentoxifylline 400 mg three times daily plus IMMA 20 mg/kg/d versus IMMA 20 mg/kg/d plus placebo, for 20 days (<LINK REF="STD-Sadeghian-2006a" TYPE="STUDY">Sadeghian 2006a</LINK>). Three months after treatment, 81.3% (26/32) and 50% (16/32) of the participants in the respective groups had achieved complete cure (RR 1.63; 95% CI 1.11, 2.39, <LINK REF="CMP-037.01" TYPE="ANALYSIS">Analysis 37.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, one participant in the IMMA plus placebo group had an allergic macule-papular itchy rash. There were no significant differences in adverse effects rates between groups (RR 0.33, 95% CI 0.01 to 7.89; N = 64; 1 study, <LINK REF="CMP-037.02" TYPE="ANALYSIS">Analysis 37.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Oral miltefosine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1 Oral miltefosine versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT in Iran compared oral miltefosine 2.5 mg/kg/d for four weeks versus IMMA 20 mg/kg/d for two weeks (<LINK REF="STD-Mohebali-2007" TYPE="STUDY">Mohebali 2007</LINK>). Three months after treatment, 81.3% (26/32) and 80.6% (25/31) of participants in the respective groups had achieved complete cure (RR 1.01; 95% CI 0.79, 1.28, <LINK REF="CMP-038.01" TYPE="ANALYSIS">Analysis 38.1</LINK>).</P>
<P>An RCT from Iran compared oral miltefosine 2.5 mg/kg/d for four weeks versus IMMA 60 mg/kg/d for two weeks (<LINK REF="STD-Khatami-2012" TYPE="STUDY">Khatami 2012</LINK>). At one month after treatment, 32% (10/31) and 35.7% (15/42) of the participants in the respective groups had achieved complete cure (RR 0.90, 95% CI 0.47 to 1.73; N = 73; 1 study, <LINK REF="CMP-039.01" TYPE="ANALYSIS">Analysis 39.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Mohebali-2007" TYPE="STUDY">Mohebali 2007</LINK> did not report any relapse at six months post-treatment. With regard to adverse effects, during the first week participants from the miltefosine group suffered from nausea, vomiting, diarrhoea, abdominal pain, and cough. Participants from the IMMA group had only diarrhoea and local pain. During the second week, participants receiving miltefosine suffered from nausea, vomiting, abdominal pain, headache, itch, and fever. Participants receiving IMMA developed those adverse effects as well as local pain, chest pain, and cough. <LINK REF="STD-Khatami-2012" TYPE="STUDY">Khatami 2012</LINK> only reported that adverse effects were higher in the miltefosine arm (nine cases versus one case).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Oral zinc sulphate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1 Different doses of oral zinc sulphate</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iraq compared oral zinc sulphate at different doses: 2.5 mg/kg/d, 5 mg/kg/d, or 10 mg/kg/d, versus no treatment (<LINK REF="STD-Sharquie-2001" TYPE="STUDY">Sharquie 2001</LINK>). The authors reported that 45 days after treatment, 66.7% (26/39) in the 2.5 mg/kg/d group, 73% (27/37) in the 5 mg/kg/d group, and 79% (31/39) in the 10 mg/kg/d group had achieved complete cure. In the control group, all lesions were still active at day 45. There were no significant differences in cure rates between oral zinc sulphate 2.5 mg/kg/d versus 5 mg/kg/d (RR 0.91, 95% CI 0.68 to 1.23; N = 76; 1 study, <LINK REF="CMP-040.01" TYPE="ANALYSIS">Analysis 40.1</LINK>); 2.5 mg/kg/d versus 10 mg/kg/d (RR 0.84, 95% CI 0.64 to 1.10; N = 78; 1 study, <LINK REF="CMP-041.01" TYPE="ANALYSIS">Analysis 41.1</LINK>); or 5 mg/kg/d versus 10 mg/kg/d (RR 0.92, 95% CI 0.71 to 1.18; N = 76; 1 study, <LINK REF="CMP-042.01" TYPE="ANALYSIS">Analysis 42.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>In the zinc sulphate 2.5 mg/kg/d group, the mean time taken to cure was 30.8 days (range 21 to 45): 29.96 days (range 15 to 45) in the 10 mg/kg/d group and 28.32 days (range 15 to 45) in the 10 mg/kg/d (the original paper reported that the time to cure was not statistically significant between the different treatment groups). None of the participants recovered in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>In all treatment groups there was minimal or no scarring at the site of lesions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, one participant each in the 2.5 mg/kg/d, 5 mg/kg/d, and 10 mg/kg/d group had nausea and vomiting. Only one participant from the 5 mg/kg/d group had a leishmanid reaction, while two participants in the 2.5 mg/kg/d group and two from the 5 mg/kg/d group, plus one participant in the 10 mg/kg/d group, had oedema. There were no significant differences in adverse effects rates between groups (<LINK REF="CMP-040.02" TYPE="ANALYSIS">Analysis 40.2</LINK>; <LINK REF="CMP-041.02" TYPE="ANALYSIS">Analysis 41.2</LINK>; <LINK REF="CMP-042.02" TYPE="ANALYSIS">Analysis 42.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.2 Oral zinc sulphate versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared oral zinc sulphate (ZS) in a dose of 10 mg/kg/d for 45 days versus IMMA 20 mg/kg/d for up to 20 days (<LINK REF="STD-Yazdanpanah-2011" TYPE="STUDY">Yazdanpanah 2011</LINK>). The authors reported that 45 days after treatment, 30.2% (8/26) and 35.5% (26/74) of the respective groups achieved complete cure (RR 0.88, 95% CI 0.46 to 1.68; N = 100; 1 study, <LINK REF="CMP-043.01" TYPE="ANALYSIS">Analysis 43.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, the authors did not report any adverse effects in the oral zinc sulphate group, but six participants in the IMMA group dropped out because of adverse effects, including severe erythema and pruritus at inoculation site and severe muscular pain.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Oral artesunate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.8.1 Oral artesunate plus sulphamethoxypyridazine/pyrimethamine versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Sudan compared oral artesunate plus sulphamethoxypyrazine/pyrimethamine (400 mg artesunate plus 1000 mg/50 mg sulphamethoxypyrazine/pyrimethamine for four days, four times each two weeks) versus placebo (<LINK REF="STD-Adam-2009" TYPE="STUDY">Adam 2009</LINK>). The authors reported that 72 days after treatment, 90% (18/20) and 85.7% (18/21) of the respective groups had a complete cure (RR 1.05, 95% CI 0.84 to 1.32; N = 41; 1 study, <LINK REF="CMP-044.01" TYPE="ANALYSIS">Analysis 44.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>One participant in the placebo arm developed a mild skin rash with itching. There was no significant difference in biological tests (liver and renal function tests) in any of the participants before or after treatment.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Non-antimonial topical or intralesional therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Topical antifungals</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1 Topical 2% miconazole versus topical 1% clotrimazole</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions with a complete cure after the end of treatment</HEADING>
<P>An RCT from Saudi Arabia compared 2% miconazole cream twice a day with 1% clotrimazole cream twice a day for 30 days (<LINK REF="STD-Larbi-1995" TYPE="STUDY">Larbi 1995</LINK>). The authors reported there was no lesions healed in the miconazole group and 15% (14/89) of the lesions healed completely in the clotrimazole group at the end of treatment (RR 0.05, 95% CI 0.00 to 0.81; N = 151; 1 study, <LINK REF="CMP-045.01" TYPE="ANALYSIS">Analysis 45.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In both treatment groups, the medication was well tolerated, with no reported adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.2 Ketoconazole cream versus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical ketoconazole versus vehicle, twice daily for 21 days (<LINK REF="STD-Momeni-2003" TYPE="STUDY">Momeni 2003</LINK>). The authors reported that 51 days after treatment, 24% (11/45) and 13% (6/45) of the participants in the respective groups achieved complete cure. There were no significant differences in cure rates between topical ketoconazole and vehicle (RR 1.83, 95% CI 0.74 to 4.53; N = 90; 1 study, <LINK REF="CMP-046.01" TYPE="ANALYSIS">Analysis 46.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, the drugs were well tolerated, and only two participants (group unknown) complained of mild pruritus at the site of the lesions.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.3 Amphotericin B versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical liposomal amphotericin B (3 to 7 drops twice daily) versus ILMA (maximum 2 mL) for eight weeks (<LINK REF="STD-Layegh-2011" TYPE="STUDY">Layegh 2011</LINK>). We performed an ITT analysis considering the participants allocated in each arm at the beginning of the study. After six months of follow-up, 44% (22/50) and 48.3% (29/60) of the participants in the amphotericin B and ILMA groups, respectively, achieved complete cure (RR: 0.91, 95% CI 0.61 to 1.37; N = 110; 1 study, <LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>One (1.7%) participant in amphotericin B group presented hypersensitivity, and five (10%) mild pruritus around the lesions. Seven (11.7%) participants in the ILMA group suffered erythema and oedema at the injection site. There were no significant differences in any hypersensitivity rates (RR 3.59, 95% CI 0.15 to 86.19), mild pruritus rates (RR 13.16, 95% CI 0.75 to 232.30), or erythema and oedema rates (RR 0.08, 95% CI 0.00 to 1.36) between groups (N = 110; 1 study, <LINK REF="CMP-047.02" TYPE="ANALYSIS">Analysis 47.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Topical paromomycin (aminosidine)</HEADING>
<P>For a summary of adverse effects of topical paromomycin please see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 Paromomycin versus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared topical 15% paromomycin sulphate in 12% MBCL (PR-MBCL) versus vehicle, twice daily for 30 days (<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>). Two months after treatment, 41.2% (14/34) and 13.3% (4/30) of the lesions in the PR-MBCL and placebo groups, respectively, had completely healed (RR 3.09, 95% CI 1.14 to 8.37; N = 64; 1 study <LINK REF="CMP-048.01" TYPE="ANALYSIS">Analysis 48.1</LINK>).</P>
<P>An RCT from Iran compared topical 15% paromomycin in 10% urea (PR-U) versus vehicle, twice daily for 30 days (<LINK REF="STD-Iraji-2005" TYPE="STUDY">Iraji 2005</LINK>); 12.5% (5/40) and 17.5% (7/40) of the lesions in the respective groups had healed completely one month after treatment (RR 0.71, 95% CI 0.25 to 2.06; N = 80; 1 study, <LINK REF="CMP-049.01" TYPE="ANALYSIS">Analysis 49.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>A pooled analysis of two trials showed no significant differences in cure rates between topical PR-U and vehicle (RR 1.00; 95% CI 0.86, 1.17; <LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>; <LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>; <LINK REF="CMP-050.01" TYPE="ANALYSIS">Analysis 50.1</LINK>). Please see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> where we assessed the certainty of evidence as very low, meaning that we are uncertain whether there is much difference in cure rate between paromomycin and vehicle.</P>
<P>An RCT from Iran compared PR-U versus vehicle, twice daily for 14 days (<LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>). Two and a half months after treatment, 63.5% (80/126) and 63.2% (79/125) of those receiving PR-U and vehicle, respectively, achieved a complete cure.</P>
<P>An RCT from Tunisia compared PR-U in soft white paraffin versus vehicle, twice daily for 14 days (<LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>). Two and a half months after treatment (day 105), 60.6% (40/66) in each group achieved complete cure.</P>
<P>An RCT from Tunisia compared topical 15% paromomycin plus gentamicin 0.5% versus 15% paromomycin alone versus vehicle, daily for 20 days (<LINK REF="STD-Ben-Salah-2013" TYPE="STUDY">Ben Salah 2013</LINK>). Five and a half months after treatment (day 168), 80% (101/125), 82% (102/125) and 58% (73/125) of participants, respectively, had achieved a complete cure. Paromomycin alone (RR 1.40, 95% CI 1.18 to 1.66, <LINK REF="CMP-051.01" TYPE="ANALYSIS">Analysis 51.1</LINK>) and paromomycin plus gentamicin (RR 1.38, 95% CI 1.17 to 1.64, <LINK REF="CMP-052.01" TYPE="ANALYSIS">Analysis 52.1</LINK>) were more efficacious than vehicle. There was no significant difference between topical 15% paromomycin plus gentamicin 0.5% and 15% paromomycin alone (RR 0.99, 95% CI 0.88 to 1.12; N = 250; 1 study, <LINK REF="CMP-053.01" TYPE="ANALYSIS">Analysis 53.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>Only <LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK> reported that at the end of the study there was no significant difference in number of deep or disfiguring scars between the PR-MBCL group (8/34 lesions; 23.5%) and vehicle group (3/10; 10%) (RR 2.35; 95% CI 0.69 to 8.07; N = 64; 1 study, <LINK REF="CMP-048.02" TYPE="ANALYSIS">Analysis 48.2</LINK>). However, we have used the number of lesions originally randomised in presenting the data in this analysis, whereas in the original paper the authors assessed scarring only in lesions that were completely healed at the end of the study (which perhaps makes more sense as a denominator). Both methods of calculating the degree of scarring failed to show any significant differences.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Twelve participants between the PR-U and vehicle groups in <LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK> reported a local reaction (inflammation, vesiculation, pain and/or redness); 8 participants from the PR-U group and 11 from the vehicle group in <LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK> complained about redness, local pain, vesiculation, and inflammation; 3 participants in the PR-U group in <LINK REF="STD-Iraji-2005" TYPE="STUDY">Iraji 2005</LINK> reported mild contact dermatitis; and participants in all three groups in <LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK> reported mild and tolerable itch, burning, redness, discharge, oedema, and pain. In <LINK REF="STD-Ben-Salah-2013" TYPE="STUDY">Ben Salah 2013</LINK>, all adverse effects deemed by the investigators to be at least possibly related to a study treatment were reactions of mild or moderate severity at the application site. The paromomycin group reported a little more skin/local reaction (RR 1.42, 95% CI 0.67 to 3.01; N = 713, <LINK REF="CMP-050.02" TYPE="ANALYSIS">Analysis 50.2</LINK>); however, the very low certainty of the evidence means we are not confident about these results (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>In a pooled analysis of two studies comparing PR-U versus placebo, there was no significant difference in the number of negative parasitologic smears at a mean follow-up of 2.5 months (RR 1.03; 95% CI 0.88 to 1.20; <LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>; <LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>; <LINK REF="CMP-050.03" TYPE="ANALYSIS">Analysis 50.3</LINK>). The certainty of evidence was very low, meaning we are uncertain whether there was any difference in parasitological cure between the two groups. In another study (<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>), 64.7% (22/34) in the PR-MBCL group and 20% (6/30) in the vehicle group were parasitologically free two months after the end of treatment (RR 3.24, 95% CI 1.52 to 6.90; N = 64; 1 study, <LINK REF="CMP-048.03" TYPE="ANALYSIS">Analysis 48.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.2 PR-U versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared PR-U ointment, twice per day for a mean duration of 45 days and a maximum duration of 3 months versus ILMA weekly (<LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK>). At less than two months after treatment, the authors reported complete cure of participants in 16.6% (8/48) and 41.7% (20/48) of the PR-U and ILMA groups, respectively (RR 0.40, 95% CI 0.20 to 0.82; N = 96; 1 study, <LINK REF="CMP-054.01" TYPE="ANALYSIS">Analysis 54.1</LINK>).</P>
<P>Another RCT from Iran compared PR-U ointment twice a day for 20 days versus ILMA (dose unspecified) every other day for 20 days (<LINK REF="STD-Shazad-2005" TYPE="STUDY">Shazad 2005</LINK>). One week after the end of treatment, 66.7% (20/30) and 60% (18/30) participants of the respective groups achieved complete cure (RR 1.11, 95% CI 0.75 to 1.64; N = 60; 1 study, <LINK REF="CMP-055.01" TYPE="ANALYSIS">Analysis 55.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>
<LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK> reported a reactivation in 6.3% (3/48) of the participants in both groups at one year after complete recovery, due to lymphatic spread in the PR-U group and non-lymphatic spread in the ILMA group (RR 1.00, 95% CI 0.21 to 4.71; N = 96; 1 study, <LINK REF="CMP-054.02" TYPE="ANALYSIS">Analysis 54.2</LINK>). Scarring occurred in 4.2% (2/48) of participants in the PR-U group and for 8.3% (4/48) in the ILMA group (RR 0.50, 95% CI 0.10 to 2.60; N = 96; 1 study, <LINK REF="CMP-054.03" TYPE="ANALYSIS">Analysis 54.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, <LINK REF="STD-Shazad-2005" TYPE="STUDY">Shazad 2005</LINK> reported that 1/30 in the PR-U group and 3/30 participants in the ILMA treatment group withdrew from the study because of cutaneous reactions like erythematosus, urticaria, or lymphadenitis with pain. They were all put on systemic MA and cured thereafter. They did not observe any systemic toxic reaction attributable to the drug. There were no significant differences in adverse effects rates between groups (RR 0.33, 95% CI 0.04 to 3.03; N = 60; 1 study <LINK REF="CMP-055.02" TYPE="ANALYSIS">Analysis 55.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.3 PR-MBCL versus oral ketoconazole</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Turkey compared topical PR-MBCL twice per day for 15 days versus oral ketoconazole 600 mg/d for 30 days (<LINK REF="STD-_x00d6_zg_x00f6_ztasi-1997" TYPE="STUDY">Özgöztasi 1997</LINK>). One month after the end of treatment the authors reported complete cure of participants in 37.5% (15/40) of the paromomycin group and none in the ketoconazole group (RR 24.95, 95% CI 1.55 to 401.63; N = 72; 1 study, <LINK REF="CMP-056.01" TYPE="ANALYSIS">Analysis 56.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Irritant contact dermatitis was the most common adverse effect described in the PR-MBCL group. In contrast, the ketoconazole-treated participants reported no adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>The PR-MBCL and the ketoconazole groups showed incomplete improvement (absence of parasites on culture or smear): just 20% (8/40) and 21.9% (7/32) of participants, respectively, had achieved a microbiological cure at four weeks post-treatment (RR 0.91, 95% CI 0.37 to 2.25; N = 72; 1 study, <LINK REF="CMP-056.02" TYPE="ANALYSIS">Analysis 56.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.4 PR-MBCL versus topical photodynamic therapy (PDT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared topical PR-MBCL twice daily for 28 days versus topical PDT every week for four weeks (<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>). Two months after treatment, results showed complete cure of lesions in 41.2% (14/34) and 93.5% (29/31) of the PR-MBCL and PDT groups, respectively (RR 0.44, 95% CI 0.29 to 0.66; N = 65; 1 study, <LINK REF="CMP-057.01" TYPE="ANALYSIS">Analysis 57.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>At the end of the study, there was no statistical difference (Fisher's exact test P = 0.0558) in the number of deep or disfiguring scars between paromomycin (8/24) and PDT groups (0/31) (RR 15.54, 95% CI 0.39 to 625.57; N = 65; 1 study, <LINK REF="CMP-057.02" TYPE="ANALYSIS">Analysis 57.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Both groups experienced mild and tolerable itch, burning, redness, discharge, oedema, and pain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Two months after the end of treatment, 64.7% (22/34) of the lesions in the PR-MBCL group were parasitologically free, as were all 31 lesions in the PDT group (RR 0.65, 95% CI 0.51 to 0.84; N = 65; 1 study, <LINK REF="CMP-057.03" TYPE="ANALYSIS">Analysis 57.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.5 Different regimens of topical paromomycin</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared two tubes of 15 g of paromomycin ointment (each tube was enough for two applications per day for 14 days) for a four-week treatment versus one tube of 15 g of paromomycin ointment for two weeks plus vehicle for two additional weeks (<LINK REF="STD-Asilian-2003" TYPE="STUDY">Asilian 2003</LINK>). Two and a half months after treatment, results showed complete cure of participants in 50% (58/117) and 37% (43/116) of the four-week and two-week regimens, respectively. There was no significant difference in cure rates between the four-week and the two-week treatment (RR 1.34, 95% CI 0.99 to 1.80; N = 233; 1 study, <LINK REF="CMP-058.01" TYPE="ANALYSIS">Analysis 58.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Participants tolerated the treatment well, and investigators did not observe any adverse effect or adverse reactions to the ointment in either group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Three months (105 days) after treatment initiation, there was a small difference in parasitological cure in favour of the four-week regimen 49/117 (41%) versus 33/116 (28.4%) respectively (RR 1.47, 95% CI 1.03 to 2.11; N = 233; 1 study, <LINK REF="CMP-058.02" TYPE="ANALYSIS">Analysis 58.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Intralesional zinc sulphate</HEADING>
<P>For a summary of adverse effects of intralesional zinc sulphate please see <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 Intralesional (IL) zinc sulphate versus ILSSG versus IL hypertonic sodium chloride solution (HSCS)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iraq compared mono doses of IL 2% zinc sulphate solution versus ILSSG 100 mg/mL versus IL 7% HSCS (<LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>). Investigators left a few lesions on unimportant and unexposed parts of the body as controls. At six weeks after treatment, 94.8% (36/38), 88.5% (31/35), and 85% (34/40) of the lesions, respectively, had healed completely. There were no statistical differences between any comparison: 2% zinc sulphate solution versus ILSSG (RR 1.07, 95% CI 0.93 to 1.23; N = 73; 1 study, <LINK REF="CMP-059.01" TYPE="ANALYSIS">Analysis 59.1</LINK>); 2% zinc sulphate solution versus IL 7% HSCS (RR 1.11, 95% CI 0.96 to 1.30; N = 78; 1 study, <LINK REF="CMP-060.01" TYPE="ANALYSIS">Analysis 60.1</LINK>), or ILSSG versus IL 7% HSCS (RR 1.04, 95% CI 0.87 to 1.24; N = 75; 1 study, <LINK REF="CMP-061.01" TYPE="ANALYSIS">Analysis 61.1</LINK>). In the untreated group, nine participants with 38 lesions were followed up for six weeks, showing no decrease in the size of the lesions and no disappearance of parasites.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>
<LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK> reported that in the zinc sulphate group most lesions were cured by 30 days. In the HSCS and in the ILSSG group, lesions were cured after 30 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>In all three groups the scar was minimal or absent after healing, but all participants developed postinflammatory hyperpigmentation. In the control group, some lesions (mainly on the lower limbs) showed signs of infection.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, all participants from both groups in the <LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK> study had pain at the time of the injection.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 IL zinc sulphate versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared IL zinc sulphate up to six times weekly versus ILMA up to six times weekly (maximum 2 mL) (<LINK REF="STD-Firooz-2005" TYPE="STUDY">Firooz 2005</LINK>). At five weeks after treatment, 22.6% (12/53) and 50.9% (27/53) of the lesions in the respective groups had healed completely (RR 0.44, 95% CI 0.25 to 0.78; N = 106; 1 study, <LINK REF="CMP-062.01" TYPE="ANALYSIS">Analysis 62.1</LINK>). However, baseline characteristics were unbalanced: both mean diameter induration and mean diameter ulceration were higher in the zinc sulphate group (induration: 10.0 mm (standard deviation (SD) 11.4)), and ulceration: 2.7 mm (SD 4.6)) than in the MA group (induration: 2.4 mm (SD 8.7) and ulceration 0.6 mm (SD 3.6)). However, the authors claimed that there was no significant difference between the two groups (P &gt; 0.05; exact p value not reported).</P>
<P>An RCT from Iran compared two double bouts of IL zinc sulphate, delivered at a two-week interval, versus six weekly bouts of ILMA 60 mg/kg/d (<LINK REF="STD-Maleki-2012" TYPE="STUDY">Maleki 2012</LINK>). At eight weeks after starting treatment, 33.3% (8/24) and 80% (8/10) of participants achieved complete cure in the respective groups (RR 0.42, 95% CI 0.22 to 0.79; N = 34; 1 study, <LINK REF="CMP-063.01" TYPE="ANALYSIS">Analysis 63.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>One RCT from Iran compared IL zinc sulphate with ILMA at a maximum dose of 2 mL (<LINK REF="STD-Iraji-2004" TYPE="STUDY">Iraji 2004</LINK>). In cases with slight to mild improvement, the authors gave another injection after two weeks. The authors reported complete cure in 53% (26/49) and 38% (21/55) of participants in the respective groups at the end of the treatment period. There were no significant differences in cure rates between groups (RR 1.39, 95% CI 0.91 to 2.13; N = 104; 1 study, <LINK REF="CMP-062.02" TYPE="ANALYSIS">Analysis 62.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In <LINK REF="STD-Firooz-2005" TYPE="STUDY">Firooz 2005</LINK>, the most commonly observed adverse effect was pain, found in 25% (18/72) of participants: in 36.1% (13/36) of participants in the zinc sulphate group and 13.9% (5/36) in the ILMA group (RR 2.60, 95% CI 1.03 to 6.54, <LINK REF="CMP-062.03" TYPE="ANALYSIS">Analysis 62.3</LINK>). In the zinc sulphate group, 8.4% (3/36) of participants complained about burning at the injection site. Itching occurred in 8.4% (3/36) and in 25% (9/36), and inflammation in 19.4% (7/36) and 22.2% (8/36) of the cases in the zinc sulphate and ILMA group, respectively. There were no significant differences in other adverse effects rates between groups (<LINK REF="CMP-062.03" TYPE="ANALYSIS">Analysis 62.3</LINK>). <LINK REF="STD-Iraji-2004" TYPE="STUDY">Iraji 2004</LINK> reported pruritus, erythema, and scaling in the periphery of the injection site in three cases in the ILMA group; IL zinc sulphate was painful, and the severity caused vasovagal shock in two cases. There were no significant differences in skin reactions (RR 7.84, 95% CI 0.42 to 148.08; N = 104; 1 study, <LINK REF="CMP-062.03" TYPE="ANALYSIS">Analysis 62.3</LINK>) or severe pain rates (RR 5.60, 95% CI 0.28 to 113.87; N = 104; 1 study, <LINK REF="CMP-062.03" TYPE="ANALYSIS">Analysis 62.3</LINK>) between groups. In another study the side effects seen in both groups were pain after injection and hyperpigmentation (<LINK REF="STD-Maleki-2012" TYPE="STUDY">Maleki 2012</LINK>). All participants in the zinc sulphate group experienced burning after injection and necrosis of the lesions, and three of these participants also had inflammation and swelling. There were no significant differences in inflammation and swelling rates between groups (RR 3.08, 95% CI 0.17 to 54.71; N = 34; 1 study, <LINK REF="CMP-063.02" TYPE="ANALYSIS">Analysis 63.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Topical imiquimod</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.4.1 Imiquimod cream versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared 5% imiquimod cream three times per week for 28 days plus IMMA 20 mg/kg/d for 14 days versus vehicle plus IMMA at the same dose (<LINK REF="STD-Firooz-2006" TYPE="STUDY">Firooz 2006</LINK>). At 3.5 months after treatment, 44.1% (26/59) and 40% (24/60) of participants in the treatment and control groups, respectively, achieved complete cure (RR 1.10, 95% CI 0.72 to 1.68; N = 119; 1 study, <LINK REF="CMP-064.01" TYPE="ANALYSIS">Analysis 64.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>At four months after treatment, relapse occurred in 1/32 participants available for assessment and treated with imiquimod plus IMMA, and in 3/37 control participants (RR 0.39, 95% CI 0.04 to 3.52; N = 69; 1 study, <LINK REF="CMP-064.02" TYPE="ANALYSIS">Analysis 64.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>The only adverse effects related to topical treatment were moderate itch and a burning sensation in three imiquimod-treated participants. There were no significant differences between groups (RR 7.12, 95% CI 0.38 to 134.84; N = 119; 1 study, <LINK REF="CMP-064.03" TYPE="ANALYSIS">Analysis 64.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Intralesional hypertonic sodium chloride solution</HEADING>
<P>For details about the adverse effects of intralesional hypertonic sodium chloride solution (HSCS) please see <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.5.1 IL 7% HSCS versus ILSSG</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions with a complete cure after the end of treatment</HEADING>
<P>An RCT from Sri Lanka compared IL HSCS (0.2 mL to 4 mL per lesion and maximum 5 injections) versus ILSSG (maximum 2 mL and 5 injections) (<LINK REF="STD-Ranawaka-2010" TYPE="STUDY">Ranawaka 2010</LINK>). Average duration of treatment was 8.78 weeks and 5.11 weeks, respectively. At 18 months of follow-up, 92.2% (86/96) and 100% (136/136) lesions had healed completely in the respective groups (RR 0.87, 95% CI 0.79 to 0.96; N = 147; 1 study, <LINK REF="CMP-065.01" TYPE="ANALYSIS">Analysis 65.1</LINK>). There was no difference in treatment response between therapies with regard to the size, duration, or location (head, trunk, upper, and lower extremities) of the lesions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>In both groups the scar was minimal or absent after healing, but all participants developed postinflammatory hyperpigmentation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>There were no systemic adverse effects with ILSSG or HSCS in <LINK REF="STD-Ranawaka-2010" TYPE="STUDY">Ranawaka 2010</LINK>. Pain during injection was the only local side effect noted with both therapies. After healing, scarring was minimal, but all participants receiving both treatments had postinflammatory hyperpigmentation, which faded over six to eight months.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.2 IL 5% HSCS versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared IL HSCS (0.5 mL to 1 mL) with ILMA (0.5 mL to 1 mL) weekly for 6 to 10 weeks (<LINK REF="STD-Sadeghian-2006b" TYPE="STUDY">Sadeghian 2006b</LINK>). At the end of treatment, 25% (9/36) and 33.3% (12/36) lesions had healed in the respective groups (RR 0.75, 95% CI 0.36 to 1.56; N = 72; 1 study, <LINK REF="CMP-066.01" TYPE="ANALYSIS">Analysis 66.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In the HSCS group, there were three cases of sporotrichotic dissemination but with no allergic reactions. In the ILMA group, there were three cases of sporotrichotic dissemination, two satellite lesions, and two allergic reactions including redness, oedema, and severe itch around the lesions. There were no significant differences in sporotrichotic dissemination rates (RR 1.00, 95% CI 0.22 to 4.63; N = 72; 1 study) or allergic reactions rates (RR 0.20, 95% CI 0.01 to 4.03; N = 72; 1 study) between groups (<LINK REF="CMP-066.02" TYPE="ANALYSIS">Analysis 66.2</LINK>).</P>
<P>
<B>3.5.3 IL 7% HSCS versus IL ciprofloxacin solution</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iraq compared IL 7% HSCS (0.1 mL to 0.5 mL per lesion) with IL ciprofloxacin solution 2 mg/mL (0.1 mL to 0.5 mL per lesion) (<LINK REF="STD-Al-Hamdi-2010" TYPE="STUDY">Al Hamdi 2010</LINK>). At two months after treatment, 76.2% (16/21) and 81.5% (22/27) of the lesions had healed in the respective groups. There was no difference in cure rates between IL HSCS and IL ciprofloxacin (RR 1.07, 95% CI 0.79 to 1.44; N = 48; 1 study, <LINK REF="CMP-067.01" TYPE="ANALYSIS">Analysis 67.1</LINK>).</P>
<P>
<B>3.5.4 IL 10% HSCS versus IL 15% HSCS versus ILSSG</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Sri Lanka compared IL 10% HSCS versus IL 15% HSCS versus ILSSG (0.2 mL to 4 mL per lesion and maximum five injections) (<LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>). The authors reported that three months after treatment, 93% (268/290), 93.6% (92/98), and 96.3% (226/235) of the lesions in the respective groups had completely healed. There was no difference in cure rates between any comparison: IL 15% HSCS versus IL 10 % HSCS (RR 1.02, 95% CI 0.96 to 1.08; N = 388, <LINK REF="CMP-068.01" TYPE="ANALYSIS">Analysis 68.1</LINK>); ILSSG versus IL 10% HSCS (RR 1.04, 95% CI 1.00 to 1.08; N = 525, <LINK REF="CMP-069.01" TYPE="ANALYSIS">Analysis 69.1</LINK>); and ILSSG versus IL 15% HSCS (RR 1.02, 95% CI 0.97 to 1.08; N = 333; 1 study, <LINK REF="CMP-070.01" TYPE="ANALYSIS">Analysis 70.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>There was no difference in speed of healing between IL 15% HSCS versus IL 10% HSCS (MD &#8722;1.45, 95% CI &#8722;4.34 to 1.44 weeks; N = 388; 1 study, <LINK REF="CMP-068.03" TYPE="ANALYSIS">Analysis 68.3</LINK>). Lesions in ILSSG group cured significantly faster than in 10% HSCS group (MD &#8722;5.20, 95% CI &#8722;6.31 to &#8722;4.09 weeks; N = 525, <LINK REF="CMP-069.03" TYPE="ANALYSIS">Analysis 69.3</LINK>) and in IL 15% HSCS group (MD &#8722;6.65, 95% CI &#8722;9.41 to &#8722;3.89 weeks; N = 333, <LINK REF="CMP-070.03" TYPE="ANALYSIS">Analysis 70.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>After six months of follow-up, the authors described four cases of relapse in 10% HSCS group, four cases in 15% HSCS group and three in the ILSSG group (<LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>). There was no significant difference in this outcome in any comparisons: 15% HSCS versus 10% HSCS (RR 2.93, 95% CI 0.75 to 11.50; N = 362; 1 study, <LINK REF="CMP-068.02" TYPE="ANALYSIS">Analysis 68.2</LINK>), ILSSG versus 10% HSCS (RR 0.90 95% CI 0.20 to 3.96, <LINK REF="CMP-069.02" TYPE="ANALYSIS">Analysis 69.2</LINK>), and ILSSG versus 15% HSCS (RR 1.02, 95% CI 0.97 to 1.08, <LINK REF="CMP-070.02" TYPE="ANALYSIS">Analysis 70.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>All participants experienced pain during injections, particularly in the 15% HSCS group. All lesions presented postinflammatory hyperpigmentation, which faded over six to eight months. Ulceration and necrosis occurred in 30% (30/98) of the lesions treated with 15% HSCS and in 3.1% (9/290) of the lesions in the 10% HSCS group. There were statistically significant differences in ulceration and necrosis rates between the IL 15% HCS group and the 10% HSCS group (RR 9.86, 95% CI 4.86 to 20.04; N = 388; 1 study, <LINK REF="CMP-068.04" TYPE="ANALYSIS">Analysis 68.4</LINK>) and between the IL 15% HCS group and ILSSG group (RR 145.41, 95% CI 8.98 to 2354.65; N = 333; 1 study, <LINK REF="CMP-070.04" TYPE="ANALYSIS">Analysis 70.4</LINK>), with more events in the IL 15% HCS group.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 IL interferon-gamma (IFN-&#947;)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.6.1 IL IFN- &#947; versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions with a complete cure after the end of treatment</HEADING>
<P>An RCT from Syria compared IL IFN-&#947; versus ILMA once weekly for five weeks (<LINK REF="STD-Harms-1991" TYPE="STUDY">Harms 1991</LINK>). At one month after treatment, 3% (1/37) and 76% (29/38) of the lesions had healed completely in the respective groups. The cure rates in the IL IFN-&#947; group were significantly lower than in the ILMA group (RR 0.04, 95% CI 0.01 to 0.28; N = 76; 1 study, <LINK REF="CMP-071.01" TYPE="ANALYSIS">Analysis 71.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In the IFN-&#947; arm, pain at the injection site of was mild on 68 occasions, moderate on 47, and severe on 38. In the ILMA group it was mild on 55 occasions, moderate on 51, and severe on 40. Other adverse effects included local maculopapular erythema in the ILMA group and headache in the IFN-&#947; group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Parasitological assessment one month after the end of treatment showed 65% (24/37) and 100% (38/38) of the lesions were parasite-free in the IFN-&#947; and ILMA groups, respectively (RR 0.65, 95% CI 0.51 to 0.83; N = 75; 1 study, <LINK REF="CMP-071.02" TYPE="ANALYSIS">Analysis 71.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Topical aminoglycoside ointment (WR279,396)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.7.1 WR279,396 ointment versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Tunisia compared WR279,396 (a third generation aminoglycoside ointment) versus vehicle twice daily for 20 days (<LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>). After a six-month follow-up, 86% (43/50) and 64% (27/42) of the participants in the respective groups achieved complete cure (RR 1.34, 95% CI 1.04 to 1.72; N = 92, <LINK REF="CMP-072.01" TYPE="ANALYSIS">Analysis 72.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, 30% (n = 15) of participants from the WR279,396 and 24% (n = 10) from the vehicle groups suffered from erythema at the site of application (RR 1.26, 95% CI 0.63 to 2.50; N = 92; 1 study); 14% from both groups (n = 7 and n = 6, respectively) had mild pain within 30 minutes of application (RR 0.98, 95% CI 0.36 to 2.69; N = 92; 1 study); 28% (n = 14) and 21% (n = 9) presented mild increases and decreases in hearing acuity from baseline; 28% (n = 14) and 21% (n = 9) had changed hearing acuity (RR 1.31, 95% CI 0.63 to 2.71; N = 92; 1 study), and there were no deaths reported in either group. See <LINK REF="CMP-072.02" TYPE="ANALYSIS">Analysis 72.2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.8 Intralesional metronidazole</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.8.1 IL metronidazole versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT compared weekly intralesional metronidazole (2.5 mg to 10 mg = 0.5 mL to 2 mL for each lesion) with weekly ILMA (150 mg to 600 mg = 0.5 mL to 2 mL for each lesion) for up to eight weeks (<LINK REF="STD-Mapar-2010" TYPE="STUDY">Mapar 2010</LINK>). At the end of treatment, 16.6% (3/18) and 72.2% (13/18) of participants in the respective groups achieved complete cure (RR 0.23, 95% CI 0.08 to 0.67; N = 36, <LINK REF="CMP-073.01" TYPE="ANALYSIS">Analysis 73.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Authors did not describe any systemic or local adverse effects with metronidazole, but two participants in the ILMA group suffered local inflammatory reactions with oedema and induration that diminished in about 10 days. There were no significant differences in local inflammatory reactions rates between groups (RR 0.20, 95% CI 0.01 to 3.89; N = 36; 1 study, <LINK REF="CMP-073.02" TYPE="ANALYSIS">Analysis 73.2</LINK>). In both groups the participants reported severe pain at the site of injections, but in the ILMA group it was intolerable.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.9 Topical miltefosine</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.9.1 Topical miltefosine versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical miltefosine ointment 6% once daily versus ILMA twice a week for up to 28 days (<LINK REF="STD-Asilian-2014" TYPE="STUDY">Asilian 2014</LINK>). At one month after treatment, 81.3% (26/32) and 50.0% (16/32) of the participants in the respective groups achieved complete cure (RR 1.63, 95% CI 1.11 to 2.39; N = 64; 1 study, <LINK REF="CMP-074.01" TYPE="ANALYSIS">Analysis 74.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.10 Topical dapsone</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.10.1 Niosomal dapsone 5% gel mask plus ILMA versus cryotherapy plus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared niosomal dapsone 5% gel mask (twice a day) plus ILMA (weekly) versus cryotherapy (every two weeks) plus ILMA (weekly) for up to 16 weeks (<LINK REF="STD-Fekri-2015" TYPE="STUDY">Fekri 2015</LINK>). At 16-week follow-up, 82% (29/35) and 86% (33/38) of the lesions had healed in the respective groups (RR 0.95, 95% CI 0.79 to 1.16; N = 73; 1 study, <LINK REF="CMP-075.01" TYPE="ANALYSIS">Analysis 75.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.11 Topical 0.045% pharmaceutical chlorite (DAC N-055)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.11.1 Topical 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electrocauterisation versus ILSSG</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Afghanistan compared 0.045% pharmaceutical chlorite (DAC N-055) plus bipolar high frequency electrocauterisation for 15 minutes versus 0.045% DAC N-055 for 15 minutes alone versus ILSSG 0.6 mL for up to 75 days (<LINK REF="STD-Stahl-2014" TYPE="STUDY">Stahl 2014</LINK>). After a 75-day follow-up, the authors reported a complete cure in 100% (23/23), 87% (20/23), and 65% (15/23) of the participants in the respective groups. There was no difference between DAC N-055 plus electrocauterisation versus DAC N-055 alone (RR 1.15, 95% CI 0.96 to 1.37; N = 46; 1 study, <LINK REF="CMP-076.01" TYPE="ANALYSIS">Analysis 76.1</LINK>). DAC N-055 plus electrocauterisation was more efficacious than ILSSG (RR 1.52, 95% CI 1.12 to 2.05; N = 46; 1 study, <LINK REF="CMP-077.01" TYPE="ANALYSIS">Analysis 77.1</LINK>), and DAC N-055 alone was not more efficacious than ILSSG (RR 1.33, 95% CI 0.95 to 1.87; N = 46; 1 study, <LINK REF="CMP-078.01" TYPE="ANALYSIS">Analysis 78.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>The hazard ratio for DAC N-055 versus ILSSG was 4.4 (95% CI 2.2 to 8.7) in the per protocol analysis (P &lt; 0.001) and 3.2 (95% CI 1.6 to 6.3) in the intention-to-treat analysis (P &lt; 0.001). The lesion closed three to four times faster in the DAC N-055 group than in the ILSSG group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, four participants developed reulceration of lesions in the DAC N-055 plus electrocauterisation group, three in the DAC N-055 alone group, and seven in the ILSSG group. There were no significant differences in reulceration rates between DAC N-055 plus electrocauterisation versus DAC N-055 alone (RR 1.33, 95% CI 0.34 to 5.30; N = 46; 1 study, <LINK REF="CMP-076.02" TYPE="ANALYSIS">Analysis 76.2</LINK>). Two participants (8.7%) developed keloids and keloid scars in the DAC N-055 plus electrocauterisation group.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.12 Topical Thio-Ben</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.12.1 Topical Thio-Ben plus cryotherapy versus ILMA plus cryotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared 1 mL to 2 mL of Thio-Ben tincture daily plus cryotherapy (liquid nitrogen (&#8722;195°C) fortnightly versus ILMA weekly (dose of 0.5 mL to 2 mL per lesion) plus cryotherapy (<LINK REF="STD-Daie-Parizi-2015" TYPE="STUDY">Daie Parizi 2015</LINK>). After three months' follow-up 91% (20/22) and 92% (23/25) of the lesions had healed completely in the respective groups. There was no difference between Thio-Ben plus cryotherapy and ILMA plus cryotherapy (RR 0.99, 95% CI 0.83 to 1.18; N = 47; 1 study, <LINK REF="CMP-079.01" TYPE="ANALYSIS">Analysis 79.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>On average, lesions required the same amount of time to achieve a complete cure: 2.45 months in the Thio-Ben plus cryotherapy group and 2.41 months in the ILMA plus cryotherapy group (<LINK REF="STD-Daie-Parizi-2015" TYPE="STUDY">Daie Parizi 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>The rate of relapse was slightly, but not significantly, higher in the Thio-Ben group 20% (4/22) than in the ILMA group 13% (3/25) (RR 1.52, 95% CI 0.38 to 6.04; N = 47; 1 study, <LINK REF="CMP-079.02" TYPE="ANALYSIS">Analysis 79.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Regarding adverse effects, investigators observed itching and mild erythema in almost all cases with different degrees of severity, and oedema especially after cryotherapy in almost all lesions. Participants from the ILMA plus cryotherapy group experienced pain at the injection site in almost all cases, while three participants reported dizziness and nausea (RR 0.16, 95% CI 0.01 to 2.96; N = 47; 1 study), and one had a hypersensitive reaction (RR 0.38, 95% CI 0.02 to 8.80; N = 47; 1 study, <LINK REF="CMP-079.03" TYPE="ANALYSIS">Analysis 79.3</LINK>). There was poor adherence to treatment particularly among children.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Physical therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Laser</HEADING>
<P>See <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> for a summary of adverse effects of lasers and <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK> for a summary of adverse effects of cryotherapy.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.1.1 CO&#8322; laser versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared CO&#8322; laser applied to the lesion (30 W, continuous) versus IMMA (50 mg/kg/d) for 15 days (this treatment was repeated after 15 days of rest) (<LINK REF="STD-Asilian-2004b" TYPE="STUDY">Asilian 2004b</LINK>). At six weeks after treatment, 11% (20/183) and 12% (30/250) of the lesions had healed completely in the respective groups (RR 0.91, 95% CI 0.53 to 1.55; N = 433; 1 study, <LINK REF="CMP-080.01" TYPE="ANALYSIS">Analysis 80.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: speed of healing</HEADING>
<P>The time taken to be cured was one month for the CO&#8322; laser group and three months for the IMMA group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>In the laser group, study authors considered most scars to be 'acceptable', except in five cases (4%) in which the lesions were located on the joints or neck, and the resulting scars were raised and hypertrophic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In the laser group, 3% (4/123) of participants experienced hyperpigmentation and persistent redness (RR 12.28, 95% CI 0.67 to 226.62; N = 433; 1 study, <LINK REF="CMP-080.02" TYPE="ANALYSIS">Analysis 80.2</LINK>), and five participants had hypertrophic scarring (RR 0.16, 95% CI 0.01 to 2.96; N = 47; 1 study, <LINK REF="CMP-080.02" TYPE="ANALYSIS">Analysis 80.2</LINK>). In the IMMA group, 9% (22/250) of participants reported myalgia, sensitivity, headache, urticaria, and nausea; these were higher in the IMMA group than in the laser group (RR 0.03, 95% CI 0.00 to 0.50; N = 433; 1 study, <LINK REF="CMP-080.02" TYPE="ANALYSIS">Analysis 80.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.2 CO&#8322; laser versus cryotherapy plus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared CO&#8322; laser (30 W, continuous) applied to the lesion (repeated maximum 3 to 5 times) versus combined cryotherapy (liquid nitrogen 10 s to 25 s) biweekly plus ILMA (0.5 mL to 2 mL per lesion) weekly until complete cure or up to 12 weeks (<LINK REF="STD-Shamsi-Meymandi-2011" TYPE="STUDY">Shamsi Meymandi 2011</LINK>). At 12 weeks, 94.7% (90/95) and 77.9% (74/95) of the lesions had healed in the respective groups. CO&#8322; laser was more efficacious than cryotherapy plus ILMA (RR 1.22, 95% CI 1.08 to 1.37; N = 190; 1 study, <LINK REF="CMP-081.01" TYPE="ANALYSIS">Analysis 81.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>There was no worsening (increase in size of the lesions) or relapse after the two types of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>The authors reported adverse effects to participants (80 participants per group). In the laser group, 25% (n = 20) of participants had hyperpigmentation and trivial scarring, compared to 18.7% (n = 15) in the cryotherapy plus ILMA group (RR 1.33, 95% CI 0.73 to 2.44; N = 190; 1 study); 8.75% (n = 7) and 18.8% (n = 15), respectively, had atrophic scars (RR 0.47, 95% CI 0.20 to 1.09; N = 190; 1 study), and 5% (n = 4) in the laser group only had hypopigmentation plus trivial scarring (RR 9.00, 95% CI 0.49 to 164.88; N = 190; 1 study; <LINK REF="CMP-081.02" TYPE="ANALYSIS">Analysis 81.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.3 Ablative CO&#8322; laser versus fractional CO&#8322; laser</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared ablative CO&#8322; laser (10 ns, frequency: use of 20 kHz, and power: 25 Kw for one session) versus fractional CO&#8322; laser (energy: 25, one pulse, pass: 1, dot cycle: 6) until complete cure or up to 12 weeks (<LINK REF="STD-Nilforoushzadeh-2014a" TYPE="STUDY">Nilforoushzadeh 2014a</LINK>). At six months' follow-up, 46.7% (28/60) and 76.7% (46/60) of participants in the respective groups achieved a complete cure (RR 0.61, 95% CI 0.45 to 0.83; N = 120; 1 study, <LINK REF="CMP-082.01" TYPE="ANALYSIS">Analysis 82.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Nilforoushzadeh-2014a" TYPE="STUDY">Nilforoushzadeh 2014a</LINK> reported erythema in two participants (3.3%) in the ablative CO&#8322; laser group and four (6.7%) in the fractional CO&#8322; laser group (RR 0.50, 95% CI 0.10 to 2.63; N = 120; 1 study, <LINK REF="CMP-082.02" TYPE="ANALYSIS">Analysis 82.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Trichloroacetic acid</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.2.1 Trichloroacetic acid versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared trichloroacetic acid (TCA) 50% (wt/vol) applied fortnightly until complete re-epithelialisation or up to three times versus ILMA (0.5 mL to 2 mL per lesion) weekly until complete re-epithelialisation of the lesions or up to six weeks (<LINK REF="STD-Nilforoushzadeh-2006" TYPE="STUDY">Nilforoushzadeh 2006</LINK>). At the end of the treatment period, 65% (26/40) and 57.5% (23/40) of participants in the respective groups achieved a complete cure (RR 1.13, 95% CI 0.80 to 1.60; N = 80; 1 study, <LINK REF="CMP-083.01" TYPE="ANALYSIS">Analysis 83.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>Recurrence occurred in 12.5% (5/40) of the cases in the TCA group and 10% (4/40) in the ILMA group after three months' follow-up (RR 1.25, 95% CI 0.36 to 4.32; N = 80; 1 study, <LINK REF="CMP-083.02" TYPE="ANALYSIS">Analysis 83.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>The observed adverse effects included mild erythema and itch (two cases in the ILMA group), with no significant differences between groups (RR 0.20, 95% CI 0.01 to 4.04; N = 80; 1 study, <LINK REF="CMP-083.03" TYPE="ANALYSIS">Analysis 83.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Parasitological assessment at week 6 showed 72.5% (29/40) and 75% (30/40) of the lesions were parasite-free in the TCA and ILMA groups, respectively. Parasitologic tests were positive at week 6 in 27.5% (11/40) and 25% (10/40) of the cases in the TCA and ILMA groups, respectively. There were no significant differences in parasitologic test rates between groups ((RR 0.97, 95% CI 0.74 to 1.26; participants = 80; studies = 1 <LINK REF="CMP-083.04" TYPE="ANALYSIS">Analysis 83.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2.2 Non-ablative laser plus TCA versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared non-ablative laser (weekly for four consecutive weeks) plus TCA (applied weekly for up to two weeks) versus ILMA (twice a week up to eight weeks) alone (<LINK REF="STD-Nilforoushzadeh-2012" TYPE="STUDY">Nilforoushzadeh 2012</LINK>). At six months' follow-up, 42.1% (16/30) and 63.2% (24/30) of the participants in the respective groups achieved a complete cure (RR 0.67, 95% CI 0.46 to 0.97; N = 60, <LINK REF="CMP-084.01" TYPE="ANALYSIS">Analysis 84.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>The authors performed a subgroup analysis according to sex. In the male group, 36.3% (8/22) of the lesions treated with laser plus TCA, and 53.3% (8/15) receiving ILMA, had healed completely at six months (RR 0.68, 99% CI 0.26 to 1.77; N = 37). In females, cure rates in the respective groups were 50% (8/16) and 69.6% (16/23) (RR 0.72, 99% CI 0.34 to 1.50; N = 39; <LINK REF="CMP-084.02" TYPE="ANALYSIS">Analysis 84.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2.3 TCA plus ILMA versus factional laser plus ILMA versus ILMA alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared TCA (applied weekly for up to eight consecutive weeks until the lesion was frosted) plus ILMA versus fractional laser (fortnightly two sessions) plus ILMA versus ILMA alone twice a week until complete re-epithelialisation of the lesions or up to eight weeks (<LINK REF="STD-Nilforoushzadeh-2013" TYPE="STUDY">Nilforoushzadeh 2013</LINK>). At six months' follow-up, 90% (27/30) of the participants in the TCA plus ILMA group, 87% (20/23) in the fractional laser plus ILMA group, and 38.5% (10/26) in the ILMA alone group achieved complete cure. Cure rates were significantly higher in the TCA plus ILMA group compared with ILMA alone (RR 2.34, 95% CI 1.42 to 3.86; N = 56; 1 study, <LINK REF="CMP-085.01" TYPE="ANALYSIS">Analysis 85.1</LINK>). ILMA alone was less efficacious than fractional laser and ILMA (RR 2.26, 95% CI 1.36 to 3.77; N = 49; 1 study, <LINK REF="CMP-086.01" TYPE="ANALYSIS">Analysis 86.1</LINK>). There was no difference in complete cure rates between TCA plus ILMA versus fractional laser plus ILMA (RR 1.03, 95% CI 0.85 to 1.26; N = 53; 1 study, <LINK REF="CMP-087.01" TYPE="ANALYSIS">Analysis 87.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>Analysis of time to heal data in the <LINK REF="STD-Nilforoushzadeh-2013" TYPE="STUDY">Nilforoushzadeh 2013</LINK> study only showed significant differences in mean time to heal between TCA plus ILMA versus ILMA alone groups (MD &#8722;1.60, 95% CI &#8722;2.35 to &#8722;0.85 weeks, <LINK REF="CMP-085.02" TYPE="ANALYSIS">Analysis 85.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Nilforoushzadeh-2013" TYPE="STUDY">Nilforoushzadeh 2013</LINK> reported adverse effects in 80% (n = 72) of participants. There were five (6.9%) cases of local irritation, two (2.8%) cases of infection, one (1.4%) case of enlargement of lesion, and three (4.2%) cases of satellite lesions. The study did not describe the adverse effects by intervention.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2.4 TCA plus ILMA versus ILMA alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared TCA 50% (applied fortnightly up to frosting the lesion) plus ILMA (twice a week until complete<BR/>resolution of the lesions or up to eight weeks) versus ILMA alone (twice a week until complete resolution of the lesions or up to eight weeks) (<LINK REF="STD-Nilforoushzadeh-2014b" TYPE="STUDY">Nilforoushzadeh 2014b</LINK>). At the end of the treatment period, 85.7% (78/91) and 80% (76/95) of the participants in the respective groups achieved a complete cure (RR 1.07, 95% CI 0.94 to 1.22; N = 186; 1 study <LINK REF="CMP-088.01" TYPE="ANALYSIS">Analysis 88.1</LINK>). The authors also performed an analysis by the type of lesions (papule, nodule, plaque or ulcerative nodule), but they did not observe any difference between groups.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Cryotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1 Cryotherapy alone versus ILMA plus cryotherapy versus ILMA monotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared a combination of cryotherapy (freezing time was 10 s to 30 s with a thawing interval of 20 s) plus ILMA (after 5 to 10 min of cryotherapy) versus cryotherapy alone versus ILMA monotherapy (0.2 mL to 1.5 mL per session per week) (<LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK>). Ninety per cent (18/20), 70% (14/20), and 75% (15/20) of the participants in the respective groups had achieved a complete cure; however, authors did not report the time of this assessment. There were no statistical difference in cure rates between any comparisons: cryotherapy plus ILMA versus cryotherapy alone (RR 1.29, 95% CI 0.93 to 1.77; N = 40; 1 study, <LINK REF="CMP-089.01" TYPE="ANALYSIS">Analysis 89.1</LINK>); cryotherapy plus ILMA versus ILMA alone (RR 1.20, 95% CI 0.90 to 1.61; N = 40; 1 study, <LINK REF="CMP-090.01" TYPE="ANALYSIS">Analysis 90.1</LINK>), or cryotherapy alone versus ILMA alone (RR 0.93, 95% CI 0.64 to 1.37; N = 40; 1 study, <LINK REF="CMP-091.01" TYPE="ANALYSIS">Analysis 91.1</LINK>).</P>
<P>An RCT from Iran compared cryotherapy (liquid nitrogen (&#8722;195°C) twice to the lesion for 10 s to 15 s, with a thawing interval of 20 s) versus ILMA monotherapy (0.2 mL to 1.5 mL per lesion) weekly for up to six weeks (<LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>). At six months' follow-up, 58.3% (21/36) and 27.8% (10/36) of the cryotherapy and ILMA group, respectively, achieved a complete cure (RR 2.10, 95% CI 1.16 to 3.81; N = 72; 1 study, <LINK REF="CMP-092.01" TYPE="ANALYSIS">Analysis 92.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared cryotherapy (liquid nitrogen (&#8722;195°C) 10 s to 25 s with a thawing interval of 20 s) plus ILMA (after thawing, 0.5 mL to 2 mL per lesion) versus cryotherapy alone versus ILMA alone (0.5 mL to 2 mL per lesion) fortnightly until complete cure or for up to six weeks (<LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK>). At the end of the treatment period, 80.5% (120/149), 52.2% (120/230) and 52.5% (84/160) of the lesions in the respective groups had healed completely. Cure rates were significantly higher in the cryotherapy plus ILMA group compared with cryotherapy alone (RR 1.54, 95% CI 1.33 to 1.79; N = 379; 1 study, <LINK REF="CMP-093.01" TYPE="ANALYSIS">Analysis 93.1</LINK>) and ILMA alone (RR 1.53, 95% CI 1.30 to 1.81; N = 309; 1 study <LINK REF="CMP-094.01" TYPE="ANALYSIS">Analysis 94.1</LINK>). There were no significant differences in cure rates between ILMA alone and cryotherapy alone groups (RR 0.99, 95% CI 0.82 to 1.20; N = 390; 1 study, <LINK REF="CMP-095.01" TYPE="ANALYSIS">Analysis 95.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>Only one study reported that none of the cured lesions recurred during the six-month follow-up period (<LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK> reported mild adverse side effects, such as postinflammatory hypopigmentation: 5/100 of cases in the combined cryotherapy and ILMA group and 10/230 in the cryotherapy group. There were no significant differences in adverse effects rates between groups (<LINK REF="CMP-093.02" TYPE="ANALYSIS">Analysis 93.2</LINK>; <LINK REF="CMP-094.02" TYPE="ANALYSIS">Analysis 94.2</LINK>; <LINK REF="CMP-095.02" TYPE="ANALYSIS">Analysis 95.2</LINK>). In <LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK> there were no serious side effects in any of the treatment groups. However, 35% of the cases in the cryotherapy plus ILMA group, 60% in the cryotherapy alone group, and 20% in the ILMA alone group showed erythema and oedema of the lesions and perilesional area, but these adverse effects rates were not statistically different (<LINK REF="CMP-089.02" TYPE="ANALYSIS">Analysis 89.2</LINK>; <LINK REF="CMP-090.02" TYPE="ANALYSIS">Analysis 90.2</LINK>; <LINK REF="CMP-091.02" TYPE="ANALYSIS">Analysis 91.2</LINK>). The most common adverse effects reported by <LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK> were erythema and oedema at the treated site; these adverse reactions appeared during the initial hours after treatment. <LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK> also described blistering at the treatment site, which became evident one or two days after treatment with a good response to local treatment. Other minor adverse effects are shown in <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Only <LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK> reported that all cured lesions showed negative direct smears at the end of treatment and six weeks after treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.2 Triple combination of cryotherapy plus 15% paromomycin plus ILMA versus ILMA monotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared a combined triple therapy of cryotherapy (fortnightly for up to 3 sessions) plus 15% paromomycin plus 10% urea cream applied twice a day for 4 weeks plus ILMA (twice a day for four weeks after cryotherapy) versus ILMA monotherapy twice every week until complete healing or for a maximum of six weeks (<LINK REF="STD-Nilforoushzadeh-2004" TYPE="STUDY">Nilforoushzadeh 2004</LINK>). At six weeks after treatment, 84% (68/81) and 75% (57/76) of the participants in the respective groups had achieved complete cure. There were no significant differences in cure rates between groups (RR 1.12, 95% CI 0.95 to 1.31; N = 157; 1 study, <LINK REF="CMP-096.01" TYPE="ANALYSIS">Analysis 96.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.3 Triple combination cryotherapy plus 3% salicylic acid cream plus 3% sodium nitrite cream versus cryotherapy plus 3% salicylic acid cream plus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared cryotherapy (once a week) plus 3% salicylic acid cream (twice a day) plus 3% sodium nitrite cream (twice a day) versus cryotherapy plus 3% salicylic acid cream for up to 12 weeks (<LINK REF="STD-Jowkar-2012" TYPE="STUDY">Jowkar 2012</LINK>). At the end of the treatment period, 83.3% (30/36) and 74.1% (20/27) of the lesions in the respective groups had healed completely (RR 1.13, 95% CI 0.86 to 1.47; N = 63; 1 study, <LINK REF="CMP-097.01" TYPE="ANALYSIS">Analysis 97.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Jowkar-2012" TYPE="STUDY">Jowkar 2012</LINK> reported erythema, a burning sensation, and skin irritation in seven participants (19.4%) in the cryotherapy plus salicylic acid plus sodium nitrate group, and in one participant (3.7%) in the cryotherapy plus salicylic acid plus vehicle group. Statistically, this was not a significant difference (RR 5.25, 95% CI 0.69 to 40.17; N = 63; 1 study, <LINK REF="CMP-097.02" TYPE="ANALYSIS">Analysis 97.2</LINK>). See <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Thermotherapy</HEADING>
<P>For a summary of adverse effects of thermotherapy please see <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.4.1 Thermotherapy using radiofrequency waves versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>One RCT from Iran compared controlled localised heating using a radiofrequency heat generator (4 MHz, maximum output 90 W weekly) versus ILMA (0.1 mL to 4 mL per lesion) for four consecutive weeks (<LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>). Six months after treatment, 80.7% (67/83) and 55.3% (52/94) of the lesions in the respective groups had healed completely. Cure rates were significantly higher in the thermotherapy group compared with ILMA (RR 1.46, 95% CI 1.18 to 1.80; N = 177; 1 study, <LINK REF="CMP-098.01" TYPE="ANALYSIS">Analysis 98.1</LINK>).</P>
<P>We assessed the certainty of evidence as very low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>There were two studies assessing complete cure after the end of treatment (<LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>; <LINK REF="STD-Safi-2012" TYPE="STUDY">Safi 2012</LINK>). Heterogeneity was substantial (P = 0.08; I² = 68%), although both effects are in the same direction. The pooled analysis showed no significant difference in cure rates between thermotherapy and ILMA groups (RR 1.23, 95% CI 0.97 to 1.55; N = 499; 2 studies, <LINK REF="CMP-098.02" TYPE="ANALYSIS">Analysis 98.2</LINK>).</P>
<P>We assessed the certainty of evidence as very low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>Only the study from Iran reported not finding relapse from lesions with complete response in either group after six months of follow-up (<LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>
<LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK> reported that although all participants with complete response in both groups had scars, the size of the scars was smaller in the heat-treated group (15.9 mm before and 11.2 mm after treatment) than in the ILMA-treated group (15.0 mm before and 14.8 mm after treatment).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>In <LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>, allergic reactions such as erythema, oedema, and pruritus occurred in the ILMA group in four participants with 10 lesions, and there were also four cases of post-treatment sporotrichotic lesions and three cases of satellite lesions. There was only one case with satellite lesions after treatment in the ILMA group. <LINK REF="STD-Safi-2012" TYPE="STUDY">Safi 2012</LINK> reported mild and minimal adverse effects only in the ILMA group.</P>
<P>Participants treated with controlled localised heating reported fewer allergic reactions (RR 0.05, 95% CI 0.00 to 0.76; N = 117, 1 study, <LINK REF="CMP-098.03" TYPE="ANALYSIS">Analysis 98.3</LINK>) but with very low-certainty evidence.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4.2 Thermotherapy using radiofrequency waves versus intralesional or intravenous sodium stibogluconate (SSG)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iraq and Kuwait compared IVSSG (20 mg/kg/d) for 10 doses versus one session of thermotherapy using radiofrequency waves (50 uCTM applied for 30 s) (<LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>). Two months after treatment, 73.3% (63/86) and 59.5% (50/84) of lesions had healed completely in the respective groups. There was no difference in cure rates between groups ((RR 1.23, 95% CI 0.99 to 1.53; participants = 170; studies = 1); <LINK REF="CMP-099.01" TYPE="ANALYSIS">Analysis 99.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Afghanistan compared ILSSG (five injections every five to seven days depending on the lesion size) for up to 29 days versus IMSSG (20 mg/kg/d) daily for 21 days versus thermotherapy using radiofrequency waves (one session of &gt; 1 consecutive application at 50ºC for 30 s depending on lesion size) (<LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK>). Two months after treatment, 47.3% (70/148), 18% (26/144) and 54% (75/139) of the participants in the respective group had achieved a complete cure. Cure rates were significantly higher in the thermotherapy group compared with IMSSG (RR 2.99, 95% CI 2.04 to 4.37; N = 283; 1 study, <LINK REF="CMP-100.01" TYPE="ANALYSIS">Analysis 100.1</LINK>), but there was no difference compared with ILSSG (RR 1.14, 95% CI 0.91 to 1.43; N = 287; 1 study, <LINK REF="CMP-101.01" TYPE="ANALYSIS">Analysis 101.1</LINK>).</P>
<P>An RCT from India compared ILSSG (2 mL to 5 mL per lesion twice a week, for seven injections over 29 days versus thermotherapy using radiofrequency waves (one treatment of two or more consecutive applications at 50ºC for 30 s depending on lesion size) (<LINK REF="STD-Bumb-2013" TYPE="STUDY">Bumb 2013</LINK>). Six months after treatment, 98% and 94% of participants in the respective groups had achieved a complete cure (RR 1.04, 95% CI 0.96 to 1.13; N = 100; 1 study, <LINK REF="CMP-102.01" TYPE="ANALYSIS">Analysis 102.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>In the <LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK> study, the speed of healing took a median of 75 days for the ILSSG group, 100 days or more for the IMSSG group, and 53 days for the thermotherapy group (the original paper reported that the time to cure was significantly shorter for participants treated with thermotherapy; P = 0.003, by the log-rank test). <LINK REF="STD-Bumb-2013" TYPE="STUDY">Bumb 2013</LINK> described a median time to heal of 11 weeks (95% CI 8 to 12) in the thermotherapy group and 10 weeks (95% CI 8 to 12) in the ILSSG group. In <LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010,</LINK> time to heal was similar (P = 0.24) in both groups in the analysis using blinded reading of photographs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK> described secondary infection in 3.7% (5/148) of participants in the ILSSG group, 1.4% (2/144) in the IMSSG group, and 5.7% (8/139) in the thermotherapy group, and there were no statistical differences in either comparison: thermotherapy versus ILSSG (RR 4.14, 99% CI 0.55 to 31.03; N = 283; 1 study, <LINK REF="CMP-100.02" TYPE="ANALYSIS">Analysis 100.2</LINK>) or thermotherapy versus IMSSG (RR 1.70, 99% CI 0.41 to 7.17; N = 287; 1 study, <LINK REF="CMP-101.02" TYPE="ANALYSIS">Analysis 101.2</LINK>). The authors also reported one participant with bradycardia and one an undefined local reaction in the ILSSG group. In the IMSSG group, one participant reported bradycardia, one tachycardia, and one palpitation. In the thermotherapy group, some participants experienced superficial second degree burns. In <LINK REF="STD-Bumb-2013" TYPE="STUDY">Bumb 2013</LINK>, radiofrequency heat treatment (RFHT) was associated with less scarring and hyperpigmentation compared with ILSSG. <LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK> reported four participants (15%) in the thermotherapy group and three (11%) in the ILSSG group suffered serious adverse effects (RR 1.30, 95% CI 0.30 to 5.64; N = 170; 1 study, <LINK REF="CMP-099.02" TYPE="ANALYSIS">Analysis 99.2</LINK>). See <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4.3 Electrocauterisation plus DAC n-055 or electrocauterisation</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>An RCT from Afghanistan compared bipolar high-frequency electrocauterisation plus daily moist-wound-treatment (MWT) with polyacrylate hydrogel including 0.045% DAC N-055 versus electrocauterisation plus vehicle (<LINK REF="STD-Jebran-2014" TYPE="STUDY">Jebran 2014</LINK>). The speed of healing took a median of 43.15 days for the electrocauterisation plus DAC N-055 group and 42 days for the electrocauterisation group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>
<BR/>Six participants in each group had bacterial and fungal superinfections (8% in the electrocauterisation plus DAC n-055 group and 9% in the electrocauterisation group; RR 0.85, 95% CI 0.29 to 2.50; N = 135; 1 study, <LINK REF="CMP-103.01" TYPE="ANALYSIS">Analysis 103.1</LINK>), and two participants in electrocauterisation plus DAC n-055 group and four participants in the electrocauterisation group reported Keloïd formation (5% and 6%, respectively; RR 0.42, 95% CI 0.08 to 2.24; N = 135; 1 study, <LINK REF="CMP-103.01" TYPE="ANALYSIS">Analysis 103.1</LINK>). Other minor adverse effects are shown in <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Topical photodynamic therapy (PDT)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.5.1 Topical PDT versus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of lesions cured after the end of treatment</HEADING>
<P>An RCT from Iran compared topical PDT every week for four weeks (0% 5-aminolevulinic acid (5-ALA) hydrochloride in a water-in-oil cream) (<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>). Lesions irradiated using visible red light at 100 J/cm² per treatment session) with vehicle twice daily also for 28 days. Two months after treatment, 93.5% (29/31) of the lesions in the PDT group and 13.3% (4/30) in the vehicle groups healed completely. Cure rates were significantly higher in the PDT group compared with vehicle (RR 7.02, 95% CI 2.80 to 17.55; N = 61; 1 study, <LINK REF="CMP-104.01" TYPE="ANALYSIS">Analysis 104.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: prevention of scarring</HEADING>
<P>At the end of the study, none of the lesions had deep or disfiguring scars in the PDT group. However, 20% (3/30) of the lesions in the vehicle group had deep or disfiguring scars (RR 0.14, 95% CI 0.01 to 2.57; N = 61; 1 study, <LINK REF="CMP-104.02" TYPE="ANALYSIS">Analysis 104.2</LINK>). Both groups had mild and tolerable itch, burning, redness, discharge, oedema, and pain as adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Two months after treatment, parasitological cure rates were significantly higher in the PDT group (100%, 31/31 lesions) compared to placebo (20%, 6/30) (RR 4.69, 95% CI 2.37 to 9.31; N = 61; 1 study, <LINK REF="CMP-104.03" TYPE="ANALYSIS">Analysis 104.3</LINK>).</P>
<P>The same author also compared PDT with topical paromomycin plus methyl benzethonium chloride, which we analyse in section 3.2, 'Topical paromomycin (aminosidine)'.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.6 Mesotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.6.1 Mesotherapy versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>One RCT from Iran compared mesotherapy (0.05 mL injection of MA in each shot in the depth of 2 mm) versus ILMA (0.1 mL of MA) for up six weeks (<LINK REF="STD-Kashani-2010" TYPE="STUDY">Kashani 2010</LINK>). Three months after treatment, 83.3% (25/30) and 86.7% (26/30) of participants in the respective groups had achieved complete cure (RR 0.96, 95% CI 0.78 to 1.19; N = 60; 1 study, <LINK REF="CMP-105.01" TYPE="ANALYSIS">Analysis 105.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>The authors did not report significant improvement in ulcer, induration, erythema, or scar size between the two groups. However, the study described faster improvement in participants who received mesotherapy compared to ILMA: ulcerated lesions improved at the rate of 0.27 cm per week (SD 0.14) and 0.15 cm per week (SD 0.72), respectively, with an improvement for erythema of 0.31 cm per week (SD 0.15) and 0.22 cm per week (SD 0.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Pain severity evaluated by VAS was significantly higher in the ILMA group than in the mesotherapy group (7.67 cm versus 6.06 cm; P = 0.005). Two participants in the mesotherapy group and one in the ILMA group suffered an allergic reaction. There were no significant differences in allergic reaction rates between groups (RR 2.00, 95% CI 0.19 to 20.90; N = 60; 1 study; <LINK REF="CMP-105.02" TYPE="ANALYSIS">Analysis 105.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: development of cell-mediated immunity (i.e. positive leishmanin skin test)</HEADING>
<P>Three months after treatment, there were positive <I>Leishmania</I> antibodies in three participants in the mesotherapy group and two participants in the ILMA group. There were no significant differences in adverse effects rates between groups (RR 1.50, 95% CI 0.27 to 8.34; N = 60; 1 study) (<LINK REF="CMP-105.03" TYPE="ANALYSIS">Analysis 105.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Measures for promoting healing</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Topical diminazene aceturate (Berenil) versus topical cetrimide plus chlorhexidine (Savlon)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Sudan compared diminazene aceturate solution versus cetrimide plus chlorhexidine solution for 50 days (<LINK REF="STD-Lynen-1992" TYPE="STUDY">Lynen 1992</LINK>). At the end of the treatment period, 80% (28/35) and 57% (20/35) of participants of in the respective groups achieved a complete cure, with a statistically significant difference in between groups and in favour of the diminazene aceturate solution (RR 1.40, 95% CI 1.01 to 1.95; N = 70; 1 study, <LINK REF="CMP-106.01" TYPE="ANALYSIS">Analysis 106.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes: duration of remission and percentage of people with treated lesions that recur within six months, one year, two years, and three years</HEADING>
<P>In the diminazene aceturate group, three re-ulcerations occurred (two after 20 days and one after 25 days of cure). In the chlorhexidine group, two re-ulcerations occurred after 35 days of cure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Extreme drying of ulcers and surrounding skin occurred in participants in the diminazene aceturate solution (Berenil) group. Participants from the cetrimide plus chlorhexidine solution (Savlon) group experienced a slight burning sensation and drying of the skin at the site of treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Alternative therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">6.1 Garlic cream</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Topical garlic cream versus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared 5% garlic cream treatment versus vehicle twice a day under occlusion with sterile gauze for three hours, for three weeks (<LINK REF="STD-Gholami-2000" TYPE="STUDY">Gholami 2000</LINK>). At 40 days after treatment, 18.75% (18/96) and 20% (15/75) of the participants in the respective groups had achieved a complete cure. There were no significant differences in cure rates between groups (RR 0.94, 95% CI 0.51 to 1.73; N = 171; 1 study, <LINK REF="CMP-107.01" TYPE="ANALYSIS">Analysis 107.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2 Herbal extract</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.2.1 Topical herbal extract versus IMMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical herbal extract Z-HE, covered with a dressing for five consecutive days plus placebo injection (0.5 mL saline) versus IMMA (15 mg/kg/d to 20 mg/kg/d) plus vehicle (petrolatum and charcoal powder) for 20 consecutive days (<LINK REF="STD-Zerehsaz-1999" TYPE="STUDY">Zerehsaz 1999</LINK>). Six weeks after treatment, 74.4% (64/86) and 27.1% (23/85) of participants in the respective groups had achieved complete cure. There was a statistically significant difference in cure rates between topical herbal extract Z-HE compared with IMMA (RR 2.75, 95% CI 1.90 to 3.98; N = 171; 1 study, <LINK REF="CMP-108.01" TYPE="ANALYSIS">Analysis 108.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Participants in the IMMA reported urticaria and generalised itch.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3 Honey</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.3.1 Topical honey plus ILMA versus ILMA monotherapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical honey soaked gauze twice a day plus ILMA (weekly) versus ILMA (weekly) for four weeks (<LINK REF="STD-Nilforoushzadeh-2007" TYPE="STUDY">Nilforoushzadeh 2007</LINK>). Results showed that two and a half to three months after treatment, 46% (23/50) and 64% (32/50) of the participants in the respective groups had achieved a complete cure, but with no significant difference between them (RR 0.72, 95% CI 0.50 to 1.04; N = 100; 1 study, <LINK REF="CMP-109.01" TYPE="ANALYSIS">Analysis 109.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>The mean time taken to be cured after omitting dropouts was 7.04 weeks and 6.3 weeks in the honey plus ILMA and the ILMA groups, respectively.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.4 <I>Cassia fistula</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.4.1 Topical <I>Cassia fistula</I> fruit gel plus ILMA versus ILMA plus vehicle</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical <I>Cassia fistula</I> fruit gel plus ILMA (0.5 mL to 2 mL) twice a week versus ILMA (0.5 mL to 2 mL) twice a week plus vehicle (<LINK REF="STD-Jaffary-2010" TYPE="STUDY">Jaffary 2010</LINK>). Results showed that three months after treatment, compete healing occurred in 67.1% and 41.4% of the participants in the respective groups. There was a statistically significant difference in cure rates in favour of <I>Cassia fistula</I> fruit gel as an adjuvant to ILMA compared with ILMA monotherapy (RR 1.62, 95% CI 1.17 to 2.24; N = 140; 1 study, <LINK REF="CMP-110.01" TYPE="ANALYSIS">Analysis 110.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Nine (12.9%) participants in each group suffered from adverse effects such as itching and erythema (RR 1.00, 95% CI 0.42 to 2.37; N = 140; 1 study, <LINK REF="CMP-110.02" TYPE="ANALYSIS">Analysis 110.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4.2 Topical concentrated boiled <I>Cassia fistula </I>versus topical <I>Cassia fistula</I> hydroalcoholic versus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical concentrated boiled <I>Cassia fistula</I> versus topical <I>Cassia fistula</I> hydroalcoholic versus ILMA (0.5 mL to 2 mL), twice a week for four weeks (<LINK REF="STD-Jaffary-2014b" TYPE="STUDY">Jaffary 2014b</LINK>). Results showed that four months after treatment, 40% (22/55), 36% (20/55), and 65% (36/55) of the participants in the respective groups had achieved complete cure. Efficacy of ILMA was higher than concentrated boiled extract (RR 0.61, 95% CI 0.42 to 0.89; N = 110; 1 study, <LINK REF="CMP-111.01" TYPE="ANALYSIS">Analysis 111.1</LINK>) and hydroalcoholic extract of <I>Cassia fistula</I> (RR 0.56, 95% CI 0.37 to 0.83; N = 110; 1 study, <LINK REF="CMP-112.01" TYPE="ANALYSIS">Analysis 112.1</LINK>), but there was no significant difference between application of concentrated boiled extract and hydroalcoholic extract of <I>Cassia fistula</I> (RR 1.10, 95% CI 0.68 to 1.77; N = 110; 1 study, <LINK REF="CMP-113.01" TYPE="ANALYSIS">Analysis 113.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: speed of healing (time taken to be 'cured')</HEADING>
<P>Participants receiving ILMA healed more quickly than those treated with concentrated boiled extract of C<I>assia fistula</I> (MD &#8722;1.80 weeks, 95% CI &#8722;3.49 to &#8722;0.11; N = 110; 1 study, <LINK REF="CMP-111.02" TYPE="ANALYSIS">Analysis 111.2</LINK>), but there was no difference between concentrated boiled extract of <I>Cassia fistula</I> and hydroalcoholic extract (MD &#8722;0.30 weeks, 95% CI &#8722;1.70 to 1.10; N = 110; 1 study, <LINK REF="CMP-113.02" TYPE="ANALYSIS">Analysis 113.2</LINK>). There was also no difference between hydroalcoholic extract of <I>Cassia fistula </I>and ILMA (MD &#8722;1.50 weeks, 95% CI &#8722;3.20 to 0.20; N = 110; 1 study, <LINK REF="CMP-112.02" TYPE="ANALYSIS">Analysis 112.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Three (5.5%) participants in the concentrated boiled extract group and two (3.6%) in the other groups withdrew from the study due to an allergic reaction to the medications. There was no significant difference among these three groups in this regard: boiled extract of <I>Cassia fistula </I>versus ILMA (RR 1.50, 95% CI 0.26 to 8.63; N = 110; 1 study, <LINK REF="CMP-111.03" TYPE="ANALYSIS">Analysis 111.3</LINK>), hydroalcoholic extract of <I>Cassia fistula </I>versus ILMA (RR 1.00, 95% CI 0.15 to 6.85; N = 110; 1 study, <LINK REF="CMP-112.03" TYPE="ANALYSIS">Analysis 112.3</LINK>), or boiled extract of <I>Cassia fistula </I>versus hydroalcoholic extract of <I>Cassia fistula </I>(RR 1.50, 95% CI 0.26 to 8.63; N = 110; 1 study, <LINK REF="CMP-113.03" TYPE="ANALYSIS">Analysis 113.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.5<I> Achilles millefolium</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.5.1 Topical<I> Achilles millefolium</I> cream plus ILMA versus vehicle plus ILMA</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: percentage of participants with a complete cure after the end of treatment</HEADING>
<P>An RCT from Iran compared topical gel of 5% <I>Achilles millefolium</I> (twice daily) plus ILMA (weekly injections at 20 mg/kg/d) versus ILMA (weekly injections of 20 mg/kg/d) plus vehicle (twice daily) for four weeks (<LINK REF="STD-Jaffary-2014a" TYPE="STUDY">Jaffary 2014a</LINK>). Two months after treatment, 53% (16/30) and 40% (12/30) of the participants in the respective groups had achieved a complete cure. There was no difference in cure rates between <I>Achilles millefolium</I> as an adjuvant to ILMA compared with ILMA monotherapy (RR 1.33, 95% CI 0.77 to 2.31; N = 60; 1 study, <LINK REF="CMP-114.01" TYPE="ANALYSIS">Analysis 114.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse effects</HEADING>
<P>Eight (26.6%) participants in the <I>Achilles millefolium</I> group reported mild or moderate severe itching and redness, and one experienced severe itching and increasing wound discharge. In the control group, two participants reported mild itching (6.6%) and one, severe itching (3.3%). There were no significant differences in itching rates between groups (RR 3.00, 95% CI 0.90 to 10.01; N = 60; 1 study, <LINK REF="CMP-114.02" TYPE="ANALYSIS">Analysis 114.2</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Tertiary outcomes: microbiological or histopathological cure of skin lesions</HEADING>
<P>Six weeks after treatment, 33% of the participants in the <I>Achilles millefolium</I> group and 40% in the control group had parasitological cure (RR 0.83, 95% CI 0.43 to 1.63; N = 60; 1 study, <LINK REF="CMP-114.03" TYPE="ANALYSIS">Analysis 114.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Results from the MEDLINE search for adverse effects</HEADING>
<P>We performed a MEDLINE search for adverse or side effects combined with therapeutic terms. However, we could only find general papers reporting known adverse effects derived from the evaluated drugs that are already mentioned in the Background under the <LINK TAG="INTERVENTION" TYPE="SECTION">Description of the intervention</LINK> section.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-11-14 12:40:43 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-11-10 12:07:58 +0000" MODIFIED_BY="[Empty name]">
<P>The randomised controlled trials (RCTs) included in this review assessed a broad range of treatments and many different clinical questions. Yet together, there were few opportunities to describe and pool useful data. We have some concerns regarding the precision of data reported in several studies. Furthermore, because most RCTs were at high risk of bias, it was difficult to conclude whether one treatment was more beneficial than the comparator much of the time. Many interventions ruled ineffective in an essentially inconclusive study could still prove to have some benefit if evaluated with greater statistical power. Nonetheless, this review accurately documents the existing RCT evidence on the usefulness of treatments, and that relevant information can be extracted for practice and future research.</P>
<P>We found 89 RCTs that covered more than 20 different interventions, broadly categorised into six main groups: antimonial drugs, non-antimonial systemic treatments, non-antimonial topical and intralesional treatments, physical therapies, methods for promoting healing, and alternative therapies. Given that sample size per se is not a source of potential bias but a source of potential imprecision that may lead to bias, care has to be exercised in not concluding that the evaluation of the efficacy of interventions of small-sized RCTs was untrustworthy.</P>
<P>It was difficult to evaluate the efficacy of any of the multiple treatments due to the variable treatment regimens examined and because the studies evaluated different <I>Leishmania</I> species and took place in different geographical areas. Moreover, most of the studies compared different regimens, and only a few RCTs compared treatments with sham therapies.</P>
<P>We created 'Summary of findings' tables for two comparisons (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>); however, where measured, we rated all of the key outcomes included as very low-certainty evidence, so we are not confident that the results found are conclusive.</P>
<UL>
<LI>A pooled analysis of three RCTs comparing itraconazole versus placebo favoured itraconazole with very low certainty of evidence, in terms of the following outcomes.</LI>
<UL>
<LI>Percentage of participants with complete cure (N = 244).</LI>
<LI>Adverse effects (mild abdominal pain and nausea (N = 204) and mild abnormal liver function (N = 84).</LI>
<LI>Microbiological or histopathological cure of skin lesions (N = 20, only in one RCT).</LI>
</UL>
<LI>A pooled analysis of two RCTs comparing paromomycin ointment plus 10% urea versus vehicle showed no difference in cure rate between interventions with a very low certainty of evidence, in terms the following outcomes.</LI>
<UL>
<LI>Percentage of participants with complete cure (N = 383).</LI>
<LI>Microbiological or histopathological cure of skin lesions (N = 383).</LI>
</UL>
</UL>
<UL>
<LI>However, the paromomycin group had more skin/local reactions, as assessed in four studies (N = 713).</LI>
</UL>
<P>Neither of the key comparisons offer data on the percentage of lesions cured after the end of treatment and speed of healing (i.e. time taken to be cured).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-10 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>Not all of the trials assessed the primary, secondary, and tertiary outcomes that we hoped to evaluate in this review. Our two main comparisons did not report our primary outcome of the percentage of lesions cured, and the comparisons that did measure this outcome (along with percentage of participants cured) lacked data on long-term effects. Assessing the two primary outcomes, we established that dealing with participants rather than with numbers of lesions proved to be a better cure criteria: lesions cured did not provide a realistic reflection of the number of participants that achieved complete cure or rather, whether all their lesions had healed. In addition, from a clinical perspective, it may be more relevant to know whether a person is completely or partially cured irrespective of the number of lesions fully healed by the tested drug. In fact, only 18 RCTs reported the primary outcome as percentage of lesions cured; the rest reported the percentages in terms of participants cured.</P>
<P>The main secondary outcome reported in our studies was the description of adverse effects, which is key when deciding a specific therapeutic option. Several RCTs also reported other secondary outcomes, but none reported the degree of functional and aesthetic impairment or quality of life. Only two tertiary outcomes were reported ('Microbiological or histopathological cure of skin lesions' in 15 trials and 'Development of cell-mediated immunity (i.e. positive leishmanin skin test)' in just one trial.</P>
<P>Many of the included studies did not specify the infecting species of leishmaniasis or made assumptions regarding the disease-causing species. We did not find any RCTs related to <I>L aethiopica </I>infections. There is also a lack of evidence for <I>L infantum </I>and<I> L donovani</I>: of the 41 new studies included in this updated systematic review, only two studies assessed <I>L donovani-</I>infected participants, and another one assessed the efficacy of a treatment in one <I>L infantum-</I>infected participant together with 66<I> L major- </I>and one<I> L tropica-</I>infected participants<I>. </I>Twenty studies reported <I>L major,</I> <I>L tropica,</I> or both.</P>
<P>Most included participants were adults, and all were immunocompetent; thus, our findings are not necessarily applicable to subsets of people such as women of childbearing age, children, people with co-morbid conditions, and immunocompromised individuals with no drug interactions.</P>
<P>The difficulty in determining the actual time point for cure in clinically significant terms in these studies is due to a lack of any universal measure for successful cure in OWCL. In fact, we found that most of the included RCTs did not explore cure rates past three months after treatment cessation. On the contrary, in most cases they assessed the primary outcome at the end of treatment or before three months.</P>
<P>The applicability of the results of this review to clinical practice is limited. The most important limitation in order to determine a specific conclusion for clinical practice is the short follow-up period reported in most studies. This impedes finding the real cure rate for OWCL because it is not possible to clearly confirm healing without long-term assessment (e.g. until at least six months after treatment has finished). There are no studies evaluating liposomal amphotericin B as a systemic treatment. Currently, because of the toxicity of pentavalent antimonials in most developed countries when systemic treatment is needed for OWCL, liposomal amphotericin B could be a good option, but at the time of writing there was no published information regarding its effectiveness.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-11-14 12:40:43 +0000" MODIFIED_BY="[Empty name]">
<P>Most included trials were poorly designed and reported. Poor reporting is a major issue, and most studies were at unclear risk for one or more important bias domains in the 'Risk of bias' assessment. Risk of bias was generally moderate due to performance, attrition, or reporting bias. Most studies did not guard properly against performance bias (by blinding participants and healthcare professionals). Blinded outcome assessment was unclear. Adequate randomisation was reported in 47.2% (42/89) of the included studies. Only 13.5% (12/89) reported adequate allocation concealment. Double-blinding was found in 44.9% (40/89) of the studies. There was inadequate description of baseline characteristics in 10.1% (9/89) of the studies. Thirty point three per cent (27/89) of the studies reported sample size calculation. Only two studies assessed compliance (<LINK REF="STD-Firooz-2006" TYPE="STUDY">Firooz 2006</LINK>; <LINK REF="STD-Lynen-1992" TYPE="STUDY">Lynen 1992</LINK>). The causative parasite was not mentioned in 32.6% (29/89) of the studies, and 34.8% (31/89) of the trials mentioned the endemic nature of the parasite in the area, assuming that was the species causing the disease. The timing for outcome assessment was not reported in 2.2% (2/89) of the trials.</P>
<P>Because resources for clinical research into neglected diseases are limited, there is a need to prioritise and carry out properly designed clinical trials. We found many mistakes in the write-up of published manuscripts. Thus, it is essential that submitted journal manuscripts undergo rigorous peer review.</P>
<P>For the two main comparisons, we created 'Summary of findings' tables and conducted GRADE assessments on the certainty of evidence for the key outcomes, which we found to be very low. Risk of bias, as highlighted above, was one of the reasons for downgrading the evidence. We also downgraded evidence for imprecision, as many of the confidence intervals were very wide, likely due to the small sample size and low number of events in many of the studies assessed. Furthermore, in two cases (for 'participants complete cure' in the comparison itraconazole versus placebo, and 'microbiological/histopathological cure of skin lesions' in the comparison paromomycin ointment versus vehicle), we downgraded evidence for inconsistency due to the high I² values and the inconsistent direction or size of effect. In addition, we also observed indirectness in the outcomes measured in the comparison paromomycin ointment versus vehicle, as the evidence assessed only focused on young people.</P>
<P>Overall, considerable numbers of participants withdrew or were lost to follow-up. Most trial authors stated that they performed an adherence assessment, but results were seldom shown in the assessed studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-11-02 13:44:12 +0000" MODIFIED_BY="[Empty name]">
<P>Studies with more positive effects are more likely to be published than those with less conclusive results (<LINK REF="REF-Chalmers-2009" TYPE="REFERENCE">Chalmers 2009</LINK>), or those written in languages other than English (<LINK REF="REF-Bigby-2003" TYPE="REFERENCE">Bigby 2003</LINK>). To tackle the problem of publication bias, we wrote to authors from endemic countries and the WHO asking for information. Besides, we searched databases of ongoing trials and others as well. However, the fact that eight studies have not yet been incorporated and are awaiting classification may be a source of potential bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-11-02 13:53:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="REF-Khatami-2007" TYPE="REFERENCE">Khatami 2007</LINK> performed a non-Cochrane systematic review on acute Old World cutaneous leishmaniasis. They included 50 studies with a total of 5515 participants. However, we detected quite a few inconsistent results. Firstly, review authors cited 51 RCTs instead of the 50 reported in the abstract and the Materials and methods, and we excluded three of these in our review for several reasons (<LINK REF="STD-Dogra-1986" TYPE="STUDY">Dogra 1986</LINK>; <LINK REF="STD-El-On-1992" TYPE="STUDY">El On 1992</LINK>; <LINK REF="STD-Trau-1987" TYPE="STUDY">Trau 1987</LINK>): one was a cross-over trial, which is an inappropriate design for evaluating potential curative treatments in an infection (<LINK REF="STD-El-On-1992" TYPE="STUDY">El On 1992</LINK>), and we considered the generation of the randomisation sequence to be inadequate in the other two. We considered another four trials to be non-randomised in our review (<LINK REF="REF-Crawford-2005" TYPE="REFERENCE">Crawford 2005</LINK>; <LINK REF="REF-el_x002d_Safi-1990" TYPE="REFERENCE">el-Safi 1990</LINK>; <LINK REF="REF-Mapar-2001" TYPE="REFERENCE">Mapar 2001</LINK>; <LINK REF="REF-Vardy-2001" TYPE="REFERENCE">Vardy 2001</LINK>). One RCT that <LINK REF="REF-Khatami-2007" TYPE="REFERENCE">Khatami 2007</LINK> included dealt with two case reports (<LINK REF="REF-el_x002d_On-1985" TYPE="REFERENCE">el-On 1985</LINK>). Secondly, if clinical trials reported in the paper's tables III to VII are included, review authors mentioned only 47 studies, while omitting 4. However, we do agree with <LINK REF="REF-Khatami-2007" TYPE="REFERENCE">Khatami 2007</LINK> in terms of the variable quality and methods of RCTs, providing weak evidence for treatment of OWCL, and regarding the importance of properly designing RCTs to improve their quality and to provide better evidence for the treatment of OWCL.</P>
<P>Two non-systematic reviews gathered evidence on Old World cutaneous leishmaniasis treatments (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014;</LINK> <LINK REF="REF-Monge_x002d_Maillo-2013" TYPE="REFERENCE">Monge-Maillo 2013</LINK>). The fact that these reviews did not use a systematic approach confers many biases and does not assure inclusion of all published studies. One study was more restrictive on selecting the studies and included only controlled clinical trials (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014</LINK>), whereas the other was more permissive and also included other published data based on retrospective studies and large case series. However, review authors analysed the methodology of each of the studies, considering that only clinical trials were able to give a high quality of evidence (<LINK REF="REF-Monge_x002d_Maillo-2013" TYPE="REFERENCE">Monge-Maillo 2013</LINK>). Moreover, these studies were not so restrictive regarding the period of follow-up needed and considered all the end points reported (percentages of lesions and of participants cured). In this way review authors considered certain therapeutic regimens such as dapsone for <I>L tropica</I> or itraconazole for <I>L major</I> to have a a higher quality of evidence than in the Cochrane Review. Even though these reviews (<LINK REF="REF-Blum-2014" TYPE="REFERENCE">Blum 2014</LINK>, <LINK REF="REF-Monge_x002d_Maillo-2013" TYPE="REFERENCE">Monge-Maillo 2013</LINK>) do not have the methodological rigour of a Cochrane Review, they are relevant in clinical practice because they give therapeutic recommendations stratified according to their level of evidence and <I>Leishmania </I>species implicated.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-11-15 14:21:28 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-11-15 14:21:28 +0000" MODIFIED_BY="[Empty name]">
<P>We have updated information from randomised controlled trials (RCTs) of treatments for Old World cutaneous leishmaniasis (OWCL) and summarised the best available evidence using quantitative and qualitative methods. We have endeavoured to provide information to help clinicians choose the most appropriate treatment. We have been careful not to be too prescriptive because the purpose of this systematic review is to present information rather than offer advice.</P>
<P>There are few treatments for CL with robust evidence from multiple randomised trials. This may be because OWCL can heal spontaneously &#8211; in many cases within a couple of months &#8211; without any need for therapeutic intervention. <I>L major</I>-caused CL can heal spontaneously in 40% to 70% of cases at 3 months and close to 100% at 12 months. Spontaneous cure rates for <I>L tropica</I>-caused CL are 1% at 3 months, 68% at 12 months, and usually close to 100% in three years (<LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>; <LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>; <LINK REF="REF-Zakraoui-1995" TYPE="REFERENCE">Zakraoui 1995</LINK>). Therefore, in many cases people with CL do not receive any drug. When clinicians do prescribe treatment, they usually prefer less toxic local treatments, reserving systemic treatments (azole drugs, miltefosine, antimonials, amphotericin B formulations) for complex cases.</P>
<P>We cannot make firm recommendations about the use of our two key comparisons.</P>
<UL>
<LI>Itraconazole versus placebo.</LI>
<LI>Paromomycin ointment (15% plus 10% urea) versus vehicle.</LI>
</UL>
<P>Due to the very low certainty of the evidence, and even though our analyses favoured itraconazole in terms of complete cure and lesions cured, we cannot be sure our results are conclusive. Similarly, although we found no difference between paromomycin ointment and vehicle in terms of these same outcomes, the very low certainty of the evidence casts doubt on our results, as it also does we do when we report more mild adverse effects with itraconazole and paromomycin ointment.</P>
<P>Our other key outcomes of microbiological or histopathological cure of skin lesions and speed of healing (i.e. time taken to be cured) were not measured for these key comparisons. None of the included studies assessed participant-focused measures of success, such as quality of life and degree of functional and aesthetic impairment.</P>
<P>We have identified gaps in knowledge that imply difficulties and limits in terms of clinical practice. RCTs that compare local versus systemic treatment are scarce, and the results discordant.</P>
<P>Also, there is in many cases a lack of knowledge on when treatment is really needed, since OWCL can also heal spontaneously.</P>
<P>Although we included 89 studies in this review, most of them explore different therapeutic regimens: not only different drugs, but even the same drug administered locally or systemically or with different doses or regimens. This means that only one RCT evaluated most regimens with a specific <I>Leishmania </I>species and with a different clinical presentation, which may reduce the strength of the recommendation and limit the possibility to extrapolate the results to other <I>Leishmania</I> species.</P>
<P>Twenty-nine studies did not isolate the <I>Leishmania</I> species. This can make it difficult to apply the result to clinical practice because a particular therapeutic regimen may have good results among a specific <I>Leishmania </I>species but not with another OWCL species. In addition, the same <I>Leishmania</I> species may vary its response to a certain treatment when the only difference is the geographical area where the infection was acquired (<LINK REF="REF-Monge_x002d_Maillo-2013" TYPE="REFERENCE">Monge-Maillo 2013</LINK>). Therefore, it may be difficult for physicians to extrapolate the published results to their daily clinical practice.</P>
<P>Before starting treatment for localised CL, and especially in the zoonotic form, people with OWCL need to be informed of the possibility of spontaneous healing and the lack of evidence for some treatments. Healthcare practitioners can still play an important role in providing information and wound healing management even if there is no good evidence for any special regimen of healing support.</P>
<P>The eight studies in <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> may alter the conclusions of the review once assessed.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-11-10 12:24:03 +0000" MODIFIED_BY="[Empty name]">
<P>This updated systematic review has identified the need for large, well-conducted RCTs to assess the benefits and harms of interventions for OWCL.</P>
<SUBSECTION>
<HEADING LEVEL="3">Design</HEADING>
<P>We considered only one RCT to be at low risk of bias in all domains (<LINK REF="STD-Ranawaka-2015" TYPE="STUDY">Ranawaka 2015</LINK>). To encourage the implementation of well-designed clinical trials specifically aimed at developing effective treatments (both primary and adjuvant), <LINK REF="REF-Gonz_x00e1_lez-2010" TYPE="REFERENCE">González 2010</LINK> developed guidelines for clinical trials of cutaneous leishmaniasis. However, it is evident from the newly included RCTs that improvement of study quality and standardisation of outcomes is still needed. The COMET (Core Outcome Measures in Effectiveness Trials) Initiative (<A HREF="http://www.cometinitiative.org/">www.cometinitiative.org</A>) is working to improve the standardisation of study outcomes by raising awareness of the need for systematised methodologies that acknowledge the complexity of CL and define reproducible, measurable, and clinically meaningful outcomes (<LINK REF="REF-Olliaro-2013" TYPE="REFERENCE">Olliaro 2013</LINK>). Future trials need to ensure they follow this guidance and also adhere to the CONSORT Statement (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>), especially to improve the reporting of important bias domains, the causative parasite, and timing of outcome assessment. Future studies should also be sufficiently powered.</P>
<P>Resources are particularly limited for research into neglected diseases in LMICs, even those that present major public health problems. Cost and licensing entanglements (freedom to operate) need to be considered before investing money in conducting new trials. Prioritisation for clinical research in OWCL is a necessity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>A number of interventions are currently used in women of childbearing age and children, in those with comorbidities, and in immunocompromised individuals with no drug interactions. Future trials should assess safety and efficacy in those subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Leishmania species</HEADING>
<P>The current evidence for different types of clinical management of OWCL and particularly for species such as <I>L infantum</I>,<I> L aethiopica</I>,<I> L major</I>,<I> L tropica</I>, and<I> L donovani </I>is either lacking or of very low quality. Eighteen studies did not even report the species of leishmaniasis, which can theoretically be easily determined with the use of new DNA techniques. However, these techniques require an investment in infrastructures that is unaffordable for the resource-restricted laboratories located in disease-endemic countries. Of the 23 studies that reported the <I>Leishmania</I> species, only 11 (48%) confirmed which caused the development of the disease, and the other 12 mentioned the endemic nature of a specific parasite strain and assumed it was the disease-causing species. Since treatment sensitivity is species-dependent, species identification is critical in future trials, for the choice of the best treatment outcome, with the fewest side effects and late complications (<LINK REF="REF-de-Vries-2015" TYPE="REFERENCE">de Vries 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>None of the studies addressed measurements of quality of life, degree of functional and aesthetic impairment, or relevant issues such as drug resistance or change in ability to detect <I>Leishmania</I>. Outcomes evaluating participants' values and preferences are needed to ensure greater responsiveness of practice guidelines and support shared decision-making.</P>
<P>With only limited data on prevention of scarring, the development of successful approaches to enhance wound healing or diminish scar formation within targeted areas, or both, will lead to a lower risk of developing scars in these sites. These issues are also possible future trial priorities.</P>
<P>Reducing adverse effects derived from treatment should also be a priority in research. Intramuscular or intravenous drugs are associated with more severe adverse effects. There is a need for less painful and better-tolerated novel treatment modalities, particularly for children. Alternatives to intramuscular or intravenous treatments should be a research priority, as well as efficacious, well-tolerated and inexpensive oral agents with enough sensitivity to treat all target species, with few serious adverse effects.</P>
<P>Future studies should assess the long-term effects of treatment, as healing cannot be clearly confirmed without a long-term assessment (e.g. at least six months after treatment has finished). For this, it is important to make an a priori decision about the postintervention time frame, based on the maximum length of time after the event during which improvement is attributed to the intervention (<LINK REF="REF-Goodman-2007" TYPE="REFERENCE">Goodman 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Future trials should aim at assessing the efficacy of treatments, ideally administered with a single dose of drug or with a short regimen, as this improves adherence. Other lines of research on interventions are for oral or self-administered treatments requiring minimal supervision (the route of administration can be topical but oral is preferred).</P>
<P>Although frequently used and recommended for the treatment of localised OWCL, we found limited evidence on the use of wound healing to treat OWCL, so this is an important area to test.</P>
<P>Furthermore, as highlighted in the previous review, there is a need for more evidence of the effectiveness and safety of different anti-<I>Leishmania</I> drugs compared with placebo in self-healing forms of leishmaniasis or with traditional first-line antimonials in complicated form, as the basis to recommend alternative safe, efficacious, and affordable treatments. The number of new studies using an active drug as a comparator has doubled, contrasting with fewer placebo-controlled studies.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-11-20 09:45:19 +0000" MODIFIED_BY="[Empty name]">
<P>The authors wish to acknowledge: Alireza Firooz for translating and extracting data from Iranian papers and Nieves Plana for her help in developing this review.</P>
<P>The Cochrane Skin editorial base wishes to thank Sam Gibbs, Cochrane Dermatology Editor for this review; Matthew Grainge, Statistical Editor; Ching-Chi Chi, Methods Editor; the clinical referees, Sabha Mushtaq and Iraj Sharifi; and Meggan Harris, who copy-edited the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-11-20 09:44:10 +0000" MODIFIED_BY="[Empty name]">
<P>Julio Heras-Mosteiro: none known.<BR/>Begoña Monge-Maillo: none known.<BR/>Mariona Pinart: none known.<BR/>Patricia Lopez Pereira: none known.<BR/>Ludovic Reveiz: none known. Ludovic Reveiz has contributed to this review in a personal capacity and during his spare time. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the organisation where he works.<BR/>Emely Garcia-Carrasco: none known.<BR/>Pedro Campuzano Cuadrado: none known.<BR/>Ana Royuela: none known.<BR/>Irene Mendez Roman: none known.<BR/>Rogelio López-Vélez: none known.</P>
<P>Iraj Sharifi, one of the clinical referees, was a co-author on the included studies <LINK REF="STD-Khatami-2012" TYPE="STUDY">Khatami 2012</LINK> and <LINK REF="STD-Daie-Parizi-2015" TYPE="STUDY">Daie Parizi 2015</LINK>.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-11-20 09:45:28 +0000" MODIFIED_BY="[Empty name]">
<P>JHM was the contact person with the editorial base; he coordinated contributions from the co-authors and wrote the final draft of the review.<BR/>PLP, EGC, BMM, and JHM screened papers against eligibility criteria.<BR/>PLP obtained data on ongoing and unpublished studies.<BR/>MP, LR, JHM, and PLP appraised the quality of papers.<BR/>MP, LR, PLP, EGC, PC, and JHM extracted data for the review and sought additional information about papers.<BR/>JHM, PLP, EGC, BMM, MP, LR, RLV, and PC entered data into RevMan.<BR/>AR, JHM, BMM, and RLV analysed and interpreted data.<BR/>AR and JHM worked on the Methods sections.<BR/>BMM and RLV drafted the clinical sections of the Background and responded to the clinical comments of the referees.<BR/>AR and JHM responded to the methodology and statistics comments of the referees.<BR/>IMR was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes were relevant to consumers.<BR/>JHM Is the guarantor of the update.</P>
<SUBSECTION>
<HEADING LEVEL="2">Disclaimer</HEADING>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Skin Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-11-14 12:41:44 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Differences between the protocol and the current update</HEADING>
<P>For differences between other published versions, please see the 'Differences between protocol and review' section within the original publications.</P>
<P>The protocol of this review was first entitled 'Interventions for solitary or limited cutaneous leishmaniasis'. However, the clinical subject was split into two reviews. The title of this review was amended to 'Interventions for Old World cutaneous leishmaniasis' (<LINK REF="REF-Gonzalez-2008" TYPE="REFERENCE">Gonzalez 2008</LINK>). A Cochrane Review entitled 'Interventions for American cutaneous and mucocutaneous leishmaniasis' was also published (<LINK REF="REF-Gonz_x00e1_lez-2009" TYPE="REFERENCE">González 2009</LINK>). This decision stemmed from the fact that the <I>Leishmania</I> species in the geographical areas involving the Old World differ from the ones affecting the New World. Due to the title change and also in response to referee comments, we modified the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> considerably. Also, our <LINK TAG="OBJECTIVES" TYPE="SECTION">Objectives</LINK> are now focused on the localised form of cutaneous leishmaniasis (CL) in the Old World rather than the solitary or limited form of CL.</P>
<P>Compared with the published protocol, there were some alterations in the tasks completed by review authors: JHM, PC, PLP, BMM, or EGM checked the titles and abstracts identified from the searches rather than UG and LR; BMM and EGM obtained the full text study for independent assessment when it was unclear if a study was relevant rather than NH and WF. Any disagreements were discussed with AR rather than UG, and MP, LR, JHM, or PLP carried out data extraction rather than MC, NH, or UG. This is because they are no longer authors of the updated version of the systematic review.</P>
<P>
<B>Types of participants</B>: we modified this to 'immunocompetent people who have localised OWCL' in accordance with the aforementioned changes.</P>
<P>
<B>Types of interventions</B>: we added a list of interventions in response to past referees' comments and to ease readability. We also changed the scope of the interventions from 'all doses and regimens of therapeutic interventions (including topical, systemic, and non-pharmacological treatments) for solitary or localised cutaneous leishmaniasis' to interventions for Old World cutaneous leishmaniasis, in accordance with the aforementioned changes. We also replaced placebo as a comparison with vehicle because a topical comparison in an RCT should correctly be termed a vehicle rather than a placebo, as the vehicle in a dermatologic drug product enhances delivery and efficacy of the active compound.</P>
<P>
<B>Types of outcome measures</B>: also following advice from past referees, we clarified the primary outcomes, and we added a phrase to define emergence of resistance to the tertiary outcomes. We also added a second primary outcome following advice from past referees: 'Percentage of participants with a complete cure after the end of treatment'. We omitted the term "around 3 months" in our primary outcome because it was not precise. We decided not to limit both primary outcomes by length of follow-up since the studies reporting these outcomes prior to 3 months of follow-up may report interesting clinical information.</P>
<P>
<B>Electronic searches</B>: for the update of this review, we did not search the CINAHL database. This database focuses on nursing and allied health literature, content not particularly relevant to our review topic. We did not search the Cochrane Database of Abstracts of Reviews of Effectiveness (DARE) or MedCarib. <A HREF="http://community.cochrane.org/glossary/5#term204">DARE</A> contains information on systematic reviews, and the MedCarib database is focused on the Caribbean region. We did not update our search of the American College of Physicians (ACP) journal club. We considered these databases unlikely to yield further references to relevant trials, based on our search results from the previous edition of this review. For the update of this review, we searched the following databases, which we considered relevant for the identification of ongoing trials.</P>
<UL>
<LI>The US National Institutes of Health Ongoing Trials Register (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>).</LI>
<LI>The Australian New Zealand Clinical Trials Registry (<A HREF="http://www.anzctr.org.au">www.anzctr.org.au</A>).</LI>
<LI>The World Health Organization International Clinical Trials Registry platform (<A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>).</LI>
<LI>The EU Clinical Trials Register (<A HREF="http://www.clinicaltrialsregister.eu/">www.clinicaltrialsregister.eu/</A>).</LI>
</UL>
<P>
<B>Searching other resources</B> &gt; <B>Unpublished literature</B>: although planned in the protocol, we did not contact Centro Dermatológico Federico Lleras Acosta, Colombia, because the Leishmania species in Colombia differ from the ones affecting the Old World. Instead we wrote to National Programme Managers, General Coordinators, Directors, Clinicians, and WHO-EMRO Regional Officers of endemic countries in order to find relevant studies. Although planned in the protocol, we did not update our search of the conference proceedings. Conference proceedings were considered unlikely to yield further references to relevant trials, based on our search results from the previous edition of this review.</P>
<P>
<B>Searching other resources </B>&gt;<B> Adverse effects</B>: although planned in the protocol, we did not contact adverse reaction-reporting bodies. The review team considered it preferable and more efficient to search MEDLINE for adverse or side effects using the search strategy in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
<P>
<B>Data collection and analysis</B>: we updated some of the methods from what we had planned in the protocol, which was published many years ago.</P>
<P>
<B>Measures of treatment effect</B>: we planned in the protocol to express results as number needed to treat where appropriate, for a range of plausible control event rates. We did not do this because the great variety found among different participant populations made it impossible to obtain a range of plausible control event rates. As the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> says, "Risk ratios and relative risk reductions remain crucial because relative effect tends to be substantially more stable across risk groups than does absolute benefit" (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We decided to describe hazard ratios (HR) for time-to-event outcomes data when the studies did. We have followed the recommendation, "Conducting a meta-analysis using summary information from published papers or trial reports is often problematic as the most appropriate summary statistics are typically not presented", and we have not calculated them because we did not have enough information from studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>
<B>Assessment of heterogeneity</B>: In the protocol, we had not planned how to assess clinical heterogeneity, but we recorded this in the update. Also, we had planned to explore reasons for heterogeneity using sensitivity and/or subgroup analyses, but we did not do this because there were too few studies to perform a sensitivity and/or subgroup analyses.</P>
<P>
<B>Data synthesis</B>: Although not planned in the protocol, we decided to only undertake data synthesis if we were able to identify two or more studies investigating similar treatments and reporting data that could be pooled. We did this because the previous systematic review chose this approach, and we consider that defining a minimum number of studies is necessary to be informative in the data synthesis phase. Where it was not possible to perform a meta-analysis, we summarised the data for each trial.</P>
<P>We decided not to meta-analyse studies when I² was above 75% and effect estimates crossed the no-effect line. However, we did meta-analyse studies with a high I² if none of the confidence intervals crossed the line of no effect, and we discuss the reasons for such significant heterogeneity.</P>
<P>Although not planned in the protocol, where an ITT was not stated, we used the numbers originally randomised to the groups in order to calculate effect estimates. We did this to avoid overestimating the effect of the intervention (to reduce attrition bias). Concerning the losses to follow-up, it was not always possible to determine within which arm the losses occurred, and therefore perform ITT analyses.</P>
<P>In the protocol, we had planned that for each trial, we would report other commonly reported outcomes in a table with the cure rates at follow-up, based on the reported clinical, microbiological, histopathological, or polymerase chain reaction (PCR) results. We did not do this because there were few studies assessing all outcomes. In our manuscript we stated that: "Two RCTs reported results where <I>Leishmania</I> was detected by parasitological diagnostic methods (e.g. PCR or culture, positive smears) (<A HREF="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=106203061613533394&amp;versionPK1=z1606071523005637262921402807851&amp;versionPK2=z1607131000335293690867293892488#STD-Jaffary-2014A">Jaffary 2014A</A>; <A HREF="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=106203061613533394&amp;versionPK1=z1606071523005637262921402807851&amp;versionPK2=z1607131000335293690867293892488#STD-Jebran-2014">Jebran 2014</A>). No studies reported emergence of resistance.."</P>
<P>
<B>Unit of analysis issues</B>: in the protocol we planned to list quasi-randomised and non-randomised controlled studies but not discuss them further; however, in the review, we decided to focus only on RCTs, as in our inclusion criteria.</P>
<P>
<B>Dealing with missing data</B>: in the protocol, we did not specify how to deal with missing data; therefore, in this review, we specified that we would treat missing data as treatment failures.</P>
<P>
<B>Reporting bias: </B>in the protocol we did not specify if we would investigate reporting bias. In the review we planned to investigate it but was unable to due to low number of studies included in the meta-analyses. </P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-05-18 12:22:03 +0100" MODIFIED_BY="Laura Prescott "/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-11-22 09:52:20 +0000" MODIFIED_BY="Laura Prescott">
<STUDIES MODIFIED="2017-10-19 10:47:42 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-10-19 10:47:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adam-2009" MODIFIED="2016-10-03 13:04:02 +0100" MODIFIED_BY="[Empty name]" NAME="Adam 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-03 13:04:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adam I, Hagelnur A</AU>
<TI>Artesunate plus sulfamethoxypyrazine/pyrimethamine for the treatment of cutaneous leishmaniasis: a double-blind, placebo-controlled clinical trial</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>4</NO>
<PG>380-1</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:04:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831868"/><IDENTIFIER MODIFIED="2016-10-03 13:04:02 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19409761 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831867"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Fouzan-1991" MODIFIED="2016-10-03 13:05:26 +0100" MODIFIED_BY="[Empty name]" NAME="Al-Fouzan 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-10-03 13:05:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>al-Fouzan AS, al-Saleh QA, Najem NM, Rostom AI</AU>
<TI>Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole</TI>
<SO>International Journal of Dermatology</SO>
<YR>1991</YR>
<VL>30</VL>
<NO>7</NO>
<PG>519-21</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:05:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831870"/><IDENTIFIER MODIFIED="2016-10-03 13:05:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1663089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831869"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Hamdi-2010" MODIFIED="2016-10-03 13:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Al Hamdi 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-03 13:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al Hamdi K, Awad AH, Moker HM</AU>
<TI>Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis</TI>
<SO>Eastern Mediterranean Health Journal</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>1</NO>
<PG>89-93</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:06:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831872"/><IDENTIFIER MODIFIED="2016-10-03 13:06:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20214164"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831871"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alkhawajah-1997" MODIFIED="2016-10-03 13:17:30 +0100" MODIFIED_BY="[Empty name]" NAME="Alkhawajah 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-03 13:17:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alkhawajah AM, Larbi E, al-Gindan Y, Abahussein A, Jain S</AU>
<TI>Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>8</NO>
<PG>899-905</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:17:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831874"/><IDENTIFIER MODIFIED="2016-10-03 13:17:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9579209"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831873"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alrajhi-2002" MODIFIED="2016-10-03 13:19:03 +0100" MODIFIED_BY="[Empty name]" NAME="Alrajhi 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-10-03 13:19:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH</AU>
<TI>Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania major</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>12</NO>
<PG>891-5</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:19:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831876"/><IDENTIFIER MODIFIED="2016-10-03 13:19:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11907288"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831875"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alsaleh-1995" MODIFIED="2016-10-03 13:20:18 +0100" MODIFIED_BY="[Empty name]" NAME="Alsaleh 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-03 13:20:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alsaleh QA, Dvorak R, Nanda A</AU>
<TI>Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait</TI>
<SO>International Journal of Dermatology</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>7</NO>
<PG>495-7</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:20:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831878"/><IDENTIFIER MODIFIED="2016-10-03 13:20:18 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7591417"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831877"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aronson-2010" MODIFIED="2016-10-03 13:21:19 +0100" MODIFIED_BY="[Empty name]" NAME="Aronson 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-03 13:21:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, et al</AU>
<TI>A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>3</NO>
<PG>e628</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:21:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831880"/><IDENTIFIER MODIFIED="2016-10-03 13:21:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20231896"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831879"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asilian-1995" MODIFIED="2016-10-03 13:22:39 +0100" MODIFIED_BY="[Empty name]" NAME="Asilian 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-03 13:22:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P</AU>
<TI>A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paramomycin) ointment for treatment of cutaneous leishmaniasis in Iran</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>6</NO>
<PG>648-51</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:22:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831882"/><IDENTIFIER MODIFIED="2016-10-03 13:22:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8561269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831881"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asilian-2003" MODIFIED="2016-10-03 13:23:53 +0100" MODIFIED_BY="[Empty name]" NAME="Asilian 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-03 13:23:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asilian A, Jalayer T, Nilforoosshzadeh M, Ghassemi RL, Peto R, Wayling S, et al</AU>
<TI>Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2003</YR>
<VL>81</VL>
<NO>5</NO>
<PG>353-9</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:23:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831884"/><IDENTIFIER MODIFIED="2016-10-03 13:23:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12856053"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831883"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asilian-2004a" MODIFIED="2017-04-19 10:31:11 +0100" MODIFIED_BY="[Empty name]" NAME="Asilian 2004a" YEAR="2004">
<REFERENCE MODIFIED="2017-04-19 10:31:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asilian A, Sadeghinia A, Faghihi G, Momeni A</AU>
<TI>Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryothrapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>4</NO>
<PG>281-3</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:25:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831886"/><IDENTIFIER MODIFIED="2016-10-03 13:25:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15090013"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831885"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asilian-2004b" MODIFIED="2016-10-03 13:28:20 +0100" MODIFIED_BY="[Empty name]" NAME="Asilian 2004b" YEAR="2004B">
<REFERENCE MODIFIED="2016-10-03 13:28:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asilian A, Sharif A, Faghihi G, Enshaeieh Sh, Shariati F, Siadat AH</AU>
<TI>Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>10</NO>
<PG>736-8</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:28:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831888"/><IDENTIFIER MODIFIED="2016-10-03 13:28:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 15485530"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831887"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asilian-2006" MODIFIED="2016-10-03 13:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Asilian 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-03 13:29:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asilian A, Davami M</AU>
<TI>Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial</TI>
<SO>Clinical &amp; Experimental Dermatology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>634-7</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:29:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831890"/><IDENTIFIER MODIFIED="2016-10-03 13:29:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 16780497"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831889"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asilian-2014" MODIFIED="2016-10-03 13:34:02 +0100" MODIFIED_BY="[Empty name]" NAME="Asilian 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-03 13:34:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asilian A, Omrani Sh, Nilforoushzadeh MA</AU>
<TI>Comparing the effects of topical miltefosine and glucantime in treatment of cutaneous leishmaniasis</TI>
<SO>Journal of Isfahan Medical School</SO>
<YR>2014</YR>
<VL>31</VL>
<NO>269</NO>
<PG>2257-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831891"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ben-Salah-1995" MODIFIED="2016-10-03 13:37:41 +0100" MODIFIED_BY="[Empty name]" NAME="Ben Salah 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-03 13:37:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A, et al</AU>
<TI>A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>2</NO>
<PG>162-6</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:37:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831894"/><IDENTIFIER MODIFIED="2016-10-03 13:37:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7677218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831893"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ben-Salah-2009" MODIFIED="2016-10-03 13:39:00 +0100" MODIFIED_BY="[Empty name]" NAME="Ben Salah 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-03 13:39:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, et al</AU>
<TI>WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>5</NO>
<PG>e432</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:39:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831896"/><IDENTIFIER MODIFIED="2016-10-03 13:39:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19415122"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831895"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ben-Salah-2013" MODIFIED="2016-10-03 13:40:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ben Salah 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-03 13:40:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, et al</AU>
<TI>Topical paromomycin with or without gentamicin for cutaneous leishmaniasis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>6</NO>
<PG>524-32</PG>
<IDENTIFIERS MODIFIED="2016-10-03 13:40:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831898"/><IDENTIFIER MODIFIED="2016-10-03 13:40:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23388004 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831897"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bumb-2013" MODIFIED="2016-10-04 10:07:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bumb 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-04 10:07:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bumb RA, Prasad N, Khandelwal K, Aara N, Mehta RD, Ghiya BC, et al</AU>
<TI>Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India</TI>
<SO>British Journal of Dermatology</SO>
<YR>2013</YR>
<VL>168</VL>
<NO>5</NO>
<PG>1114-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:07:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831900"/><IDENTIFIER MODIFIED="2016-10-04 10:07:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23298394"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831899"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daie-Parizi-2015" MODIFIED="2016-10-04 10:08:51 +0100" MODIFIED_BY="[Empty name]" NAME="Daie Parizi 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-04 10:08:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daie Parizi MH, Karvar M, Sharifi I, Bahrampour A, Heshmat Khah A, Rahnama Z, et al</AU>
<TI>The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy: A single-blind randomized clinical trial</TI>
<SO>Dermatologic Therapy</SO>
<YR>2015</YR>
<VL>28</VL>
<NO>3</NO>
<PG>140-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:08:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068478"/><IDENTIFIER MODIFIED="2016-10-04 10:08:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25847678"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-11-03 11:37:02 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dandashli-2005" MODIFIED="2016-10-04 10:10:26 +0100" MODIFIED_BY="[Empty name]" NAME="Dandashli 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-04 10:10:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dandashi A</AU>
<TI>Treatment of cutaneous leishmaniasis with fluconazole: a randomized double-blind, placebo-controlled trial</TI>
<SO>Journal of the European Academy of Dermatology and Venereology : JEADV</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>Suppl 2</NO>
<PG>43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831902"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831901"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dastgheib-2012" MODIFIED="2016-10-04 10:21:29 +0100" MODIFIED_BY="[Empty name]" NAME="Dastgheib 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 10:21:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dastgheib L, Naseri M, Mirashe Z</AU>
<TI>Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: a randomized controlled clinical trial</TI>
<SO>International Journal of Dermatology</SO>
<YR>2012</YR>
<VL>51</VL>
<NO>12</NO>
<PG>1508-11</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:21:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831904"/><IDENTIFIER MODIFIED="2016-10-04 10:21:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23171020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831903"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-1990" MODIFIED="2016-10-04 10:22:58 +0100" MODIFIED_BY="[Empty name]" NAME="Dogra 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-10-04 10:22:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra J, Aneja N, Lal BB, Mishra SN</AU>
<TI>Cutaneous leishmaniasis in India: Clinical experience with itraconazole (R51 211 Janssen)</TI>
<SO>International Journal of Dermatology</SO>
<YR>1990</YR>
<VL>29</VL>
<NO>9</NO>
<PG>661-2</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:22:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831906"/><IDENTIFIER MODIFIED="2016-10-04 10:22:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 2177041"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831905"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-1991" MODIFIED="2016-10-04 10:23:43 +0100" MODIFIED_BY="[Empty name]" NAME="Dogra 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-10-04 10:23:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra J</AU>
<TI>A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1991</YR>
<VL>85</VL>
<NO>2</NO>
<PG>212-3</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:23:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831908"/><IDENTIFIER MODIFIED="2016-10-04 10:23:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1887473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831907"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-1992" MODIFIED="2016-10-04 10:25:37 +0100" MODIFIED_BY="[Empty name]" NAME="Dogra 1992" YEAR="">
<REFERENCE MODIFIED="2016-10-04 10:25:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra J</AU>
<TI>Cutaneous leishmaniasis in India: evaluation of oral drugs (dapsone versus itraconazole)</TI>
<SO>European Journal of Dermatology</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>568-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831910"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831909"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-1996" MODIFIED="2016-10-04 10:29:50 +0100" MODIFIED_BY="[Empty name]" NAME="Dogra 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-10-04 10:29:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra J, Saxena VN</AU>
<TI>Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease</TI>
<SO>International Journal for Parasitology</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>12</NO>
<PG>1413-5</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:29:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831912"/><IDENTIFIER MODIFIED="2016-10-04 10:29:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9024895"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831911"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ejaz-2014" MODIFIED="2016-10-04 10:31:00 +0100" MODIFIED_BY="[Empty name]" NAME="Ejaz 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-04 10:31:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ejaz A, Qadir SNUR, Malik N, Bari AU</AU>
<TI>Comparison of low-dose meglumine antimoniate/ allopurinol combination therapy with full dose meglumine antimoniate alone in the treatment of cutaneous leishmaniasis - A randomized controlled trial</TI>
<SO>Journal of Pakistan Association of Dermatologists</SO>
<YR>2014</YR>
<VL>24</VL>
<NO>2</NO>
<PG>108-114</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:31:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831914"/><IDENTIFIER MODIFIED="2016-10-04 10:31:00 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="373774478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831913"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Sayed-2010" MODIFIED="2016-10-04 10:31:56 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayed 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-04 10:31:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Sayed M, Anwar AE</AU>
<TI>Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study</TI>
<SO>Journal of the European Academy of Dermatology and Venereology : JEADV</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>3</NO>
<PG>335-40</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:31:56 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831916"/><IDENTIFIER MODIFIED="2016-10-04 10:31:56 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19744259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831915"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emad-2011" MODIFIED="2016-10-04 10:33:08 +0100" MODIFIED_BY="[Empty name]" NAME="Emad 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-04 10:33:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emad M, Hayati F, Fallahzadeh MK, Namazi MR</AU>
<TI>Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>3</NO>
<PG>606-8</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:33:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831918"/><IDENTIFIER MODIFIED="2016-10-04 10:33:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21315963"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831917"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esfandiarpour-2002" MODIFIED="2017-06-15 10:13:19 +0100" MODIFIED_BY="[Empty name]" NAME="Esfandiarpour 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-06-15 10:13:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esfandiarpour I, Alavi A</AU>
<TI>Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>8</NO>
<PG>521-4</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:33:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831920"/><IDENTIFIER MODIFIED="2016-10-04 10:33:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12207774"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831919"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faghihi-2003" MODIFIED="2016-10-04 10:34:45 +0100" MODIFIED_BY="[Empty name]" NAME="Faghihi 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-04 10:34:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faghihi G, Tavakoli-kia R</AU>
<TI>Topical paromomycin vs intralesional meglumine antimoniate in cutaneous leishmaniasis</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>1</NO>
<PG>13-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:34:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831922"/><IDENTIFIER MODIFIED="2016-10-04 10:34:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12558620"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831921"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farajzadeh-2015" MODIFIED="2016-10-04 10:37:35 +0100" MODIFIED_BY="[Empty name]" NAME="Farajzadeh 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-04 10:37:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farajzadeh S, Esfandiarpour I, Haghdoost AA, Mohammadi S, Mohebbi A, Mohebbi E, Mostafavi M</AU>
<TI>Comparison between combination therapy of oral terbinafine and cryotherapy versus systemic meglumine antimoniate and cryotherapy in cutaneous leishmaniasis: a randomized clinical trial</TI>
<SO>Iranian Journal of Parasitology</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:37:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831924"/><IDENTIFIER MODIFIED="2016-10-04 10:37:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25904940"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831923"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fekri-2015" MODIFIED="2016-10-04 10:39:35 +0100" MODIFIED_BY="[Empty name]" NAME="Fekri 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-04 10:39:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fekri A, Rahnama Z, Khalili M, Dookhani AP, Khazaeli P, Beigi KB</AU>
<TI>The efficacy of co-administration of topical niosomal dapsone gel and intralesional injection of glucantime in cutaneous leishmaniasis in comparison with cryotherapy plus intralesional injection of glucantime</TI>
<SO>Journal of Kerman University of Medical Sciences</SO>
<YR>2015</YR>
<VL>22</VL>
<NO>2</NO>
<PG>117-32</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:39:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831926"/><IDENTIFIER MODIFIED="2016-10-04 10:39:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="603502875"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831925"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Firooz-2005" MODIFIED="2016-10-04 10:40:49 +0100" MODIFIED_BY="[Empty name]" NAME="Firooz 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-04 10:40:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, et al</AU>
<TI>Intralesional injection of 2% zinc sulphate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial</TI>
<SO>Journal of Drugs in Dermatology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>1</NO>
<PG>73-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:40:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831928"/><IDENTIFIER MODIFIED="2016-10-04 10:40:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15696988"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831927"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Firooz-2006" MODIFIED="2016-10-04 10:42:06 +0100" MODIFIED_BY="[Empty name]" NAME="Firooz 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-04 10:42:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, et al</AU>
<TI>Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial</TI>
<SO>Archives of Dermatology</SO>
<YR>2006</YR>
<VL>142</VL>
<NO>12</NO>
<PG>1575-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:42:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831930"/><IDENTIFIER MODIFIED="2016-10-04 10:42:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17178983 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831929"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gholami-2000" MODIFIED="2016-10-04 10:44:46 +0100" MODIFIED_BY="[Empty name]" NAME="Gholami 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-10-04 10:44:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gholami A, Khamesipour A, Momeni A, Ghazanfari T, Nilforoushzadeh MA, Darajeh Z, et al</AU>
<TI>Treatment of cutaneous leishmaniasis with 5% garlic cream: a randomized, double-blind study</TI>
<SO>Iranian Journal of Dermatology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>3</NO>
<PG>2-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:44:46 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-04 10:44:46 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00454251"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831932"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831931"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harms-1991" MODIFIED="2016-10-04 10:46:12 +0100" MODIFIED_BY="[Empty name]" NAME="Harms 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-10-04 10:46:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harms G, Chehade AK, Douba M, Roepke M, Mouakeh A, Rosenkaimer F, et al</AU>
<TI>A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1991</YR>
<VL>85</VL>
<NO>2</NO>
<PG>214-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:46:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831934"/><IDENTIFIER MODIFIED="2016-10-04 10:46:12 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1909469"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831933"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iraji-2004" MODIFIED="2016-10-04 10:51:22 +0100" MODIFIED_BY="[Empty name]" NAME="Iraji 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-04 10:51:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iraji F, Vali A, Asilian A, Shahtalebi M, Momeni AZ</AU>
<TI>Comparison of intralesionally injected zinc sulphate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis</TI>
<SO>Dermatology</SO>
<YR>2004</YR>
<VL>209</VL>
<NO>1</NO>
<PG>46-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:51:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831936"/><IDENTIFIER MODIFIED="2016-10-04 10:51:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15237267"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831935"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iraji-2005" MODIFIED="2016-10-04 10:52:29 +0100" MODIFIED_BY="[Empty name]" NAME="Iraji 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-04 10:52:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iraji F, Sadeghinia A</AU>
<TI>Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:52:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831938"/><IDENTIFIER MODIFIED="2016-10-04 10:52:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15701249"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831937"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffar-2006" MODIFIED="2017-04-19 10:53:32 +0100" MODIFIED_BY="[Empty name]" NAME="Jaffar 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-04-19 10:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffar H</AU>
<TI>Rifampicin in cutaneous leishmaniasis - a therapeutic trial in Saudi Arabia</TI>
<SO>Journal of Pakistan Association of Dermatologists</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>4-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 10:53:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831940"/><IDENTIFIER MODIFIED="2016-10-04 10:53:53 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="44265597"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831939"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffary-2010" MODIFIED="2017-04-19 10:53:02 +0100" MODIFIED_BY="[Empty name]" NAME="Jaffary 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-04-19 10:53:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffary F, Nilforoushzadeh MA, Ansari N, Rahimi M</AU>
<TI>Treatment of cutaneous leishmaniasis: cassia fistula fruit gel-intralesional glucantime Vs. placebo gel- intralesional glucantime combination</TI>
<SO>Tehran University Medical Journal</SO>
<YR>2010</YR>
<VL>67</VL>
<NO>10</NO>
<PG>705-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831942"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831941"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffary-2014a" MODIFIED="2016-10-04 13:53:47 +0100" MODIFIED_BY="[Empty name]" NAME="Jaffary 2014a" YEAR="2014">
<REFERENCE MODIFIED="2016-10-04 13:53:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffary F, Nilforoushzadeh MA, Tavakoli N, Zolfaghari B, Shahbazi F</AU>
<TI>The efficacy of Achilles millefolium topical gel along with intralesional injection of glucantime in the treatment of acute cutaneous leishmaniasis major</TI>
<SO>Advanced Biomedical Research</SO>
<YR>2014</YR>
<VL>3</VL>
<PG>111</PG>
<IDENTIFIERS MODIFIED="2016-10-04 13:53:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831944"/><IDENTIFIER MODIFIED="2016-10-04 13:53:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 24804185 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831943"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffary-2014b" MODIFIED="2016-10-04 13:59:07 +0100" MODIFIED_BY="[Empty name]" NAME="Jaffary 2014b" YEAR="2014">
<REFERENCE MODIFIED="2016-10-04 13:59:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffary F, Nilforoushzadeh MA, Moradi S, Derakhshan R, Ansari N</AU>
<TI>Concentrated extracts of Cassia fistula versus intralesional injection of meglumine antimoniate in treatment of acute cutaneous leishmaniasis</TI>
<SO>Journal of Skin and Stem Cell</SO>
<YR>2014</YR>
<VL>1</VL>
<NO>1</NO>
<PG>e16631</PG>
<IDENTIFIERS MODIFIED="2016-10-04 13:59:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831946"/><IDENTIFIER MODIFIED="2016-10-04 13:59:07 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="604236618"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831945"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jebran-2014" MODIFIED="2016-10-04 14:00:50 +0100" MODIFIED_BY="[Empty name]" NAME="Jebran 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-04 14:00:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, et al</AU>
<TI>Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2014</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e2694</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:00:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831948"/><IDENTIFIER MODIFIED="2016-10-04 14:00:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24551257 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831947"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jowkar-2012" MODIFIED="2016-10-04 14:01:51 +0100" MODIFIED_BY="[Empty name]" NAME="Jowkar 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 14:01:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jowkar F, Dehghani F, Jamshidzadeh A</AU>
<TI>Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis?</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>2</NO>
<PG>131-5</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:01:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831950"/><IDENTIFIER MODIFIED="2016-10-04 14:01:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 20964568 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831949"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kashani-2010" MODIFIED="2016-10-04 14:02:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kashani 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-04 14:02:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kashani MN, Sadr B, Nilforoushzadeh MA, Arasteh M, Babakoohi S, Firooz A</AU>
<TI>Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun</TI>
<SO>International Journal of Dermatology</SO>
<YR>2010</YR>
<VL>49</VL>
<NO>9</NO>
<PG>1034-7</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:02:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831952"/><IDENTIFIER MODIFIED="2016-10-04 14:02:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 20883265 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831951"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khatami-2012" MODIFIED="2016-10-04 14:04:03 +0100" MODIFIED_BY="[Empty name]" NAME="Khatami 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 14:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khatami A, Rahshenas M, Bahrami M, Ghoorchi MH, Eskandari SE, Sharifi I, et al</AU>
<TI>Miltefosine in treatment of cutaneous leishmaniasis: a randomized controlled trial (Poster P-31). 6th International Dermato-Epidemiology Association Congress, Malmo, Sweden, 26-28 August 2012</TI>
<SO>British Journal of Dermatology</SO>
<YR>2012</YR>
<VL>167</VL>
<NO>2</NO>
<PG>e23</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:04:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831954"/><IDENTIFIER MODIFIED="2016-10-04 14:04:03 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="71050777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831953"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khatami-2013" MODIFIED="2016-10-04 14:06:36 +0100" MODIFIED_BY="[Empty name]" NAME="Khatami 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-04 14:06:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S, et al</AU>
<TI>Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial</TI>
<SO>PloS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>6</NO>
<PG>e66123</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:06:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831956"/><IDENTIFIER MODIFIED="2016-10-04 14:06:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23826087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831955"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochar-2000" MODIFIED="2016-10-04 14:15:37 +0100" MODIFIED_BY="[Empty name]" NAME="Kochar 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-10-04 14:15:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit SK</AU>
<TI>The role of rifampicin in the management of cutaneous leishmaniasis</TI>
<SO>QJM : Monthly Journal of the Association of Physicians</SO>
<YR>2000</YR>
<VL>93</VL>
<NO>11</NO>
<PG>733-7</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:15:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831958"/><IDENTIFIER MODIFIED="2016-10-04 14:15:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11077029"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831957"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kochar-2006" MODIFIED="2016-10-04 14:16:39 +0100" MODIFIED_BY="[Empty name]" NAME="Kochar 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-04 14:16:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kochar DK, Saini G, Kochar SK, Sirohi P, Bumb RA, Mehta RD, et al</AU>
<TI>A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis</TI>
<SO>Journal of Vector Borne Diseases</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>4</NO>
<PG>161-7</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:16:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831960"/><IDENTIFIER MODIFIED="2016-10-04 14:16:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17175700"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831959"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larbi-1995" MODIFIED="2016-10-04 14:17:47 +0100" MODIFIED_BY="[Empty name]" NAME="Larbi 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-04 14:17:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larbi EB, al-Khawajah A, al-gindan Y, Jain S, Abahusain A, al-Zayer A</AU>
<TI>A randomized, double-blind, clinical trial of topical clotrimazole versus mizonazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>2</NO>
<PG>166-8</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:17:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831962"/><IDENTIFIER MODIFIED="2016-10-04 14:17:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7872446"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831961"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Layegh-2007" MODIFIED="2016-10-04 14:19:34 +0100" MODIFIED_BY="[Empty name]" NAME="Layegh 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-04 14:19:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T</AU>
<TI>Efficacy of azitromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>1</NO>
<PG>99-101</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:19:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831964"/><IDENTIFIER MODIFIED="2016-10-04 14:19:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17620637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831963"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Layegh-2009" MODIFIED="2017-04-19 10:54:07 +0100" MODIFIED_BY="[Empty name]" NAME="Layegh 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-04-19 10:54:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T</AU>
<TI>Efficacy of cryotherapy versus intralesional meglumine antimoniate (Glucantime) for treatment of cutaneous leishmaniasis in children</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>80</VL>
<NO>2</NO>
<PG>172-5</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:24:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831966"/><IDENTIFIER MODIFIED="2016-10-04 14:24:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19190206"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831965"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Layegh-2011" MODIFIED="2016-10-04 14:26:10 +0100" MODIFIED_BY="[Empty name]" NAME="Layegh 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-04 14:26:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar Malekshah P, Moghiman T, Ashraf H, et al</AU>
<TI>Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis</TI>
<SO>Journal of Parasitology Research</SO>
<YR>2011</YR>
<VL>2011</VL>
<PG>656523</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:26:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831968"/><IDENTIFIER MODIFIED="2015-06-30 09:06:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1155/2011/656523"/><IDENTIFIER MODIFIED="2016-10-04 14:26:10 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22174993 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831967"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lynen-1992" MODIFIED="2016-10-04 14:31:03 +0100" MODIFIED_BY="[Empty name]" NAME="Lynen 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-10-04 14:31:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lynen L, Van Damme W</AU>
<TI>Local application of diminazene aceturate: an effective treatment for cutaneous leishmaniasis?</TI>
<SO>Annales de la Société Belge de Médecine Tropicale</SO>
<YR>1992</YR>
<VL>72</VL>
<NO>1</NO>
<PG>13-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:31:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831970"/><IDENTIFIER MODIFIED="2016-10-04 14:31:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1567264"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831969"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maleki-2012" MODIFIED="2016-10-04 14:32:01 +0100" MODIFIED_BY="[Empty name]" NAME="Maleki 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 14:32:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maleki M, Karimi G, Tafaghodi M, Raftari S, Nahidi Y</AU>
<TI>Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis</TI>
<SO>Indian Journal of Dermatology</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>2</NO>
<PG>118-22</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:32:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831972"/><IDENTIFIER MODIFIED="2016-10-04 14:32:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 22615508"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831971"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mapar-2010" MODIFIED="2016-02-12 17:23:30 +0000" MODIFIED_BY="[Empty name]" NAME="Mapar 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-02-12 17:23:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mapar MA, Omidian M</AU>
<TI>Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis</TI>
<SO>Jundishapur Journal of Microbiology</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>2</NO>
<PG>79-83</PG>
<IDENTIFIERS MODIFIED="2015-06-30 09:10:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831974"/><IDENTIFIER MODIFIED="2015-06-30 09:10:23 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE=" 2010406291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831973"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mashood-2001" MODIFIED="2016-10-04 14:37:41 +0100" MODIFIED_BY="[Empty name]" NAME="Mashood 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-10-04 14:37:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mashhood AA, Hussain K</AU>
<TI>Efficacy of allopurinol compared with pentostam in the treatment of old world cutaneous leishmaniasis</TI>
<SO>Journal of the College of Physicians and Surgeons--Pakistan : JCPSP</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>6</NO>
<PG>367-70</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:37:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831976"/><IDENTIFIER MODIFIED="2016-10-04 14:37:10 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2001264054"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831975"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohebali-2007" MODIFIED="2016-10-04 14:39:04 +0100" MODIFIED_BY="[Empty name]" NAME="Mohebali 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-04 14:39:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al</AU>
<TI>Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran</TI>
<SO>Acta Tropica</SO>
<YR>2007</YR>
<VL>103</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:39:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831978"/><IDENTIFIER MODIFIED="2016-10-04 14:39:04 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17586452"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831977"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Momeni-1996" MODIFIED="2016-10-04 14:40:36 +0100" MODIFIED_BY="[Empty name]" NAME="Momeni 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-10-04 14:40:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Momeni AZ, Jalayer T, Emamjomeh M, Bashardost N, Ghassemi RL, Meghdadi M, et al</AU>
<TI>Treatment of cutaneous leishmaniasis with itraconazole. Randomized doubl-blind study</TI>
<SO>Archives of Dermatology</SO>
<YR>1996</YR>
<VL>132</VL>
<NO>7</NO>
<PG>784-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:40:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831980"/><IDENTIFIER MODIFIED="2016-10-04 14:40:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8678570"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831979"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Momeni-2002" MODIFIED="2016-10-04 14:41:29 +0100" MODIFIED_BY="[Empty name]" NAME="Momeni 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-10-04 14:41:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Momeni AZ, Reiszadae MR, Aminjavaheri M</AU>
<TI>Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate</TI>
<SO>International Journal of Dermatology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>7</NO>
<PG>441-3</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:41:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831982"/><IDENTIFIER MODIFIED="2016-10-04 14:41:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12121563"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831981"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Momeni-2003" MODIFIED="2016-10-04 14:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Momeni 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-04 14:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Momeni AZ, Aminjavaheri M, Omidghaemi MR</AU>
<TI>Treatment of cutaneous leishmaniasis with ketoconazole cream</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>1</NO>
<PG>26-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:42:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831984"/><IDENTIFIER MODIFIED="2016-10-04 14:42:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12745852"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831983"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mostafavi-2013" MODIFIED="2016-10-04 14:43:51 +0100" MODIFIED_BY="[Empty name]" NAME="Mostafavi 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-04 14:43:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mostafavi SA, Shatalebi MA, Attar AM, Hejazi H, Mottaghinejad A, Fadaei R, et al</AU>
<TI>Preparation and evaluation of clinical effects of glucantime gel mask</TI>
<SO>Journal of Isfahan Medical School</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>231</NO>
<PG>389-99</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:43:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831986"/><IDENTIFIER MODIFIED="2016-10-04 14:43:51 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2014593999"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831985"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mujtaba-1999" MODIFIED="2016-10-04 14:44:43 +0100" MODIFIED_BY="[Empty name]" NAME="Mujtaba 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-10-04 14:44:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mujtaba G, Khalid M</AU>
<TI>Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>1999</YR>
<VL>38</VL>
<NO>8</NO>
<PG>607-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:44:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831988"/><IDENTIFIER MODIFIED="2016-10-04 14:44:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10487452"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831987"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nassiri_x002d_Kashani-2005" MODIFIED="2016-10-04 14:45:50 +0100" MODIFIED_BY="[Empty name]" NAME="Nassiri-Kashani 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-04 14:45:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nassiri-Kashani M, Firooz A, Khamesipour A, Mojtahed F, Nilforoushzadeh M, Hejazi H, et al</AU>
<TI>A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis</TI>
<SO>Journal of the European Academy of Dermatology and Venereology: JEADV</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>1</NO>
<PG>80-3</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:45:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831990"/><IDENTIFIER MODIFIED="2016-10-04 14:45:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15649196"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831989"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2004" NAME="Nilforoushzadeh 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA</AU>
<TI>Efficacy of combined triple therapy (paromomycin ointment, cryotherapy and intralesional Glucantime) in comparison with intralesional Glucantime for treatment of acute cutaneous leishmaniasis</TI>
<SO>Iranian Journal of Dermatology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>7</NO>
<PG>136-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831992"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831991"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2006" MODIFIED="2017-07-01 11:55:08 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-07-01 11:55:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Jaffary F, Reiszadeh MR</AU>
<TI>Comparative effect of topical trichloroacetic acid and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis</TI>
<SO>International Journal of Pharmacology</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>6</NO>
<PG>633-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:50:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831994"/><IDENTIFIER MODIFIED="2016-10-04 14:50:50 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2007084731"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-04 14:50:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Reiszadeh MR, Jafari F</AU>
<TI>Topical trichloroacetic acid compared with intralesional glucantime injection in the treatment of acute wet cutaneous leishmaniasis: An open clinical trial</TI>
<SO>Iranian Journal of Dermatology</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>6</NO>
<PG>34-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831995"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831993"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2007" MODIFIED="2016-10-04 14:52:54 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-04 14:52:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Jaffary F, Moradi S, Derakhshan R, Haftbaradaran E</AU>
<TI>Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutanneous leishmaniasis</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:52:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831997"/><IDENTIFIER MODIFIED="2016-10-04 14:52:54 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17466071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831996"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2008" MODIFIED="2016-10-04 14:54:01 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-04 14:54:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A</AU>
<TI>A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis</TI>
<SO>Journal of Vector Borne Diseases</SO>
<YR>2008</YR>
<VL>45</VL>
<NO>4</NO>
<PG>287-91</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:54:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2831999"/><IDENTIFIER MODIFIED="2016-10-04 14:54:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19248655"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2831998"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2012" MODIFIED="2017-04-19 10:31:44 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-04-19 10:31:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Naeeni FF, Sattar N, Haftbaradaran E, Jaffary F, Askari G</AU>
<TI>The effect of intralesional meglumine antimoniate (Glucantime) versus a combination of topical trichloroacetic acid 50% and local heat therapy by non-ablative radiofrequency on cutaneous leishmaniasis lesions</TI>
<SO>Journal of Research in Medical Sciences</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>1 Suppl 1</NO>
<PG>S97-S102</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:55:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832001"/><IDENTIFIER MODIFIED="2016-10-04 14:55:26 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2013471627"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832000"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2013" MODIFIED="2016-10-04 14:56:47 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-04 14:56:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Siadat AH, Ansari N, Haftbaradaran E, Ahmadi E</AU>
<TI>A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional laser plus glucantime on cutaneous leishmaniasis lesions</TI>
<SO>Journal of Isfahan Medical School</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>221</NO>
<PG>2450-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:56:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832003"/><IDENTIFIER MODIFIED="2016-10-04 14:56:47 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2013245548"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832002"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2014a" MODIFIED="2016-10-04 14:58:01 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2014a" YEAR="2014">
<REFERENCE MODIFIED="2016-10-04 14:57:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Siadat AH, Haftbaradaran E, Minaravesh M</AU>
<TI>Comparative study of the efficacy of CO2 and fraxel lasers in treatment of cutaneous leishmaniasis scars</TI>
<SO>Journal of Isfahan Medical School</SO>
<YR>2014</YR>
<VL>31</VL>
<NO>269 SPEC.ISSUE</NO>
<PG>2277-84</PG>
<IDENTIFIERS MODIFIED="2016-10-04 14:57:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068480"/><IDENTIFIER MODIFIED="2016-10-04 14:57:49 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2014574591"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2014b" MODIFIED="2016-10-04 15:01:29 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2014b" YEAR="2014">
<REFERENCE MODIFIED="2016-10-04 15:01:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Jaffary F, Derakhsahan R, Haftbaradaran E</AU>
<TI>Comparison between intralesional meglumine antimoniate and combination of trichloroacetic acid 50% and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis: a randomized clinical trial</TI>
<SO>Journal of Stem Cells</SO>
<YR>2014</YR>
<VL>1</VL>
<NO>1</NO>
<PG>e16633</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:01:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068482"/><IDENTIFIER MODIFIED="2015-11-17 15:12:10 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.5812/jssc.16633"/><IDENTIFIER MODIFIED="2016-10-04 15:01:29 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2015013267"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-11-17 15:06:42 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068481"/><IDENTIFIER MODIFIED="2015-11-17 15:06:42 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.5812/JSSC.16633"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x00d6_zg_x00f6_ztasi-1997" MODIFIED="2016-10-04 15:02:50 +0100" MODIFIED_BY="[Empty name]" NAME="Özgöztasi 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-04 15:02:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Özgöztasi O, Baydar I</AU>
<TI>A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey</TI>
<SO>International Journal of Dermatology</SO>
<YR>1997</YR>
<VL>36</VL>
<NO>1</NO>
<PG>61-3</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:02:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832009"/><IDENTIFIER MODIFIED="2016-10-04 15:02:50 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1997097334"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832008"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranawaka-2010" MODIFIED="2016-10-04 15:05:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ranawaka 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-04 15:05:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranawaka RR, Weerakoon HS</AU>
<TI>Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>5</NO>
<PG>286-93</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:05:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832013"/><IDENTIFIER MODIFIED="2016-10-04 15:05:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 20438389"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832012"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranawaka-2015" MODIFIED="2017-10-19 10:47:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ranawaka 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-10-19 10:47:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranawaka RR, Weerakoon HS, Silva SH</AU>
<TI>Randomized, double-blind, controlled, comparative study on intralesional 10% and 15% hypertonic saline versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2015</YR>
<VL>54</VL>
<NO>5</NO>
<PG>555-63</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:09:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832015"/><IDENTIFIER MODIFIED="2016-10-04 15:09:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 25600472"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832014"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reithinger-2005" MODIFIED="2016-10-04 15:13:08 +0100" MODIFIED_BY="[Empty name]" NAME="Reithinger 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-04 15:13:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, et al</AU>
<TI>Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>8</NO>
<PG>1148-55</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:13:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832017"/><IDENTIFIER MODIFIED="2016-10-04 15:13:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15791515"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832016"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadeghian-2006a" MODIFIED="2016-10-04 15:14:49 +0100" MODIFIED_BY="[Empty name]" NAME="Sadeghian 2006a" YEAR="2006">
<REFERENCE MODIFIED="2016-10-04 15:14:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadeghian G, Nilforoushzadeh MA</AU>
<TI>Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>7</NO>
<PG>819-21</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:14:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068484"/><IDENTIFIER MODIFIED="2016-10-04 15:14:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16863518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadeghian-2006b" MODIFIED="2016-10-04 15:17:26 +0100" MODIFIED_BY="[Empty name]" NAME="Sadeghian 2006b" YEAR="2006B">
<REFERENCE MODIFIED="2016-10-04 15:17:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadeghian G, Nilfroushzadeh MA, Siadat AH</AU>
<TI>A comparison between intralesional hypertonic sodium chloride solution and meglumine antimoniate in the treatment of cutaneous leishmaniasis</TI>
<SO>Egyptian Dermatology Online Journal</SO>
<YR>2</YR>
<VL>1</VL>
<PG>8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832021"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832020"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadeghian-2007" MODIFIED="2016-10-04 15:18:33 +0100" MODIFIED_BY="[Empty name]" NAME="Sadeghian 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-04 15:18:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadeghian G, Nilfroushzadeh MA, Iraji F</AU>
<TI>Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2007</YR>
<VL>32</VL>
<NO>4</NO>
<PG>371-4</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:18:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832023"/><IDENTIFIER MODIFIED="2016-10-04 15:18:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17376205"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832022"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Safi-2012" MODIFIED="2016-10-04 15:19:57 +0100" MODIFIED_BY="[Empty name]" NAME="Safi 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 15:19:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Safi N, Davis GD, Nadir M, Hamid H, Robert LL, Case AJ</AU>
<TI>Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial</TI>
<SO>Military Medicine</SO>
<YR>2012</YR>
<VL>177</VL>
<NO>3</NO>
<PG>345-351</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:19:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832025"/><IDENTIFIER MODIFIED="2016-10-04 15:19:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 22479925"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832024"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salmanpour-2001" MODIFIED="2016-10-04 15:21:08 +0100" MODIFIED_BY="[Empty name]" NAME="Salmanpour 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-10-04 15:21:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salmanpour R, Handjani F, Nouhpisheh MK</AU>
<TI>Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>159-62</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:21:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832027"/><IDENTIFIER MODIFIED="2016-10-04 15:21:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12243707 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832026"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salmanpour-2006" MODIFIED="2016-10-04 15:22:01 +0100" MODIFIED_BY="[Empty name]" NAME="Salmanpour 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-04 15:22:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salmanpour R, Razmavar MR, Abtahi N</AU>
<TI>Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>9</NO>
<PG>1115-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:22:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832029"/><IDENTIFIER MODIFIED="2016-10-04 15:22:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16961529"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832028"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shamsi-Meymandi-2011" MODIFIED="2016-09-20 10:54:45 +0100" MODIFIED_BY="[Empty name]" NAME="Shamsi Meymandi 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-09-20 10:54:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shamsi Meymandi S, Zandi S, Aghaie H, Heshmatkhah A</AU>
<TI>Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate</TI>
<SO>Journal of the European Academy of Dermatology and Venereology : JEADV</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>5</NO>
<PG>587-91</PG>
<IDENTIFIERS MODIFIED="2016-09-20 10:53:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068486"/><IDENTIFIER MODIFIED="2016-09-20 10:53:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20666876"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shanehsaz-2015" MODIFIED="2017-07-02 08:27:17 +0100" MODIFIED_BY="[Empty name]" NAME="Shanehsaz 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-02 08:27:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shanehsaz SM, Ishkhanian S</AU>
<TI>A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis</TI>
<SO>International Jornal of Dermatology</SO>
<YR>2015</YR>
<VL>54</VL>
<NO>7</NO>
<PG>834-8</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:24:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832035"/><IDENTIFIER MODIFIED="2016-10-04 15:24:18 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26108265"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-01-10 18:47:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shanehsaz SM, Ishkhanian S</AU>
<TI>Therapeutic and adverse effects of standarddose and low-dose meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients</TI>
<SO>Journal of Pakistan Association of Dermatologists</SO>
<YR>2014</YR>
<VL>24</VL>
<NO>2</NO>
<PG>115-121</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068487"/><IDENTIFIER TYPE="EMBASE" VALUE="2014549292"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832034"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharquie-1997" MODIFIED="2016-10-04 15:25:16 +0100" MODIFIED_BY="[Empty name]" NAME="Sharquie 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-04 15:25:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE, Najim RA, Farjou IB</AU>
<TI>A compararive controlled trial of intralesionally- administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against cutaneous leishmaniasis</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>4</NO>
<PG>169-73</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:25:16 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832037"/><IDENTIFIER MODIFIED="2016-10-04 15:25:16 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9499605"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832036"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharquie-2001" MODIFIED="2016-10-04 15:26:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sharquie 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-10-04 15:26:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE, Najim RA, Farjou IB, Al-timimit DJ</AU>
<TI>Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>1</NO>
<PG>21-6</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:26:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832039"/><IDENTIFIER MODIFIED="2016-10-04 15:26:38 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11260171"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832038"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shazad-2005" MODIFIED="2017-04-19 10:54:50 +0100" MODIFIED_BY="[Empty name]" NAME="Shazad 2005" YEAR="2005">
<REFERENCE MODIFIED="2017-04-19 10:54:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shazad B, Abbaszadeh B, Khamesipour A</AU>
<TI>Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major</TI>
<SO>European Journal of Dermatology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>2</NO>
<PG>85-7</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:27:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832041"/><IDENTIFIER MODIFIED="2016-10-04 15:27:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15757817"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832040"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stahl-2014" MODIFIED="2017-07-14 13:35:55 +0100" MODIFIED_BY="[Empty name]" NAME="Stahl 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-07-14 11:55:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stahl HC, Ahmadi F, Schleicher U, Sauerborn R, Bermejo JL, Amirih ML, et al</AU>
<TI>A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>619</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832043"/><IDENTIFIER TYPE="PUBMED" VALUE="25420793"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832042"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yazdanpanah-2011" MODIFIED="2016-10-04 15:29:17 +0100" MODIFIED_BY="[Empty name]" NAME="Yazdanpanah 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-04 15:29:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, et al</AU>
<TI>Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis</TI>
<SO>Dermatology Research &amp; Practice</SO>
<YR>2011</YR>
<VL>269515</VL>
<PG>1-4</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:29:17 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832045"/><IDENTIFIER MODIFIED="2015-06-30 09:01:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1155/2011/269515"/><IDENTIFIER MODIFIED="2016-10-04 15:29:17 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="  21747837"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832044"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zerehsaz-1999" MODIFIED="2016-10-04 15:30:08 +0100" MODIFIED_BY="[Empty name]" NAME="Zerehsaz 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-10-04 15:30:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zerehsaz F, Salmanpour R, Farhad H, Ardehali S, Panjehshahin MR, Tabei SZ, et al</AU>
<TI>A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran</TI>
<SO>International Journal of Dermatology</SO>
<YR>1999</YR>
<VL>38</VL>
<NO>8</NO>
<PG>610-2</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:30:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832047"/><IDENTIFIER MODIFIED="2016-10-04 15:30:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 10487453"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832046"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-07-14 11:56:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alavi_x002d_Naini-2012" MODIFIED="2016-10-04 15:44:39 +0100" MODIFIED_BY="[Empty name]" NAME="Alavi-Naini 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 15:44:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alavi-Naini R, Fazaeli A, O'Dempsey T</AU>
<TI>Topical treatment modalities for old world cutaneous leishmaniasis: a review</TI>
<SO>Prague Medical Report</SO>
<YR>2012</YR>
<VL>113</VL>
<NO>2</NO>
<PG>105-18</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:44:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832049"/><IDENTIFIER MODIFIED="2016-10-04 15:44:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22691282"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832048"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banihashemi-2015" MODIFIED="2016-10-04 15:45:42 +0100" MODIFIED_BY="[Empty name]" NAME="Banihashemi 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-10-04 15:45:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banihashemi M, Yazdanpanah MJ, Amirsolymani H, Yousefzadeh H</AU>
<TI>Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate</TI>
<SO>Journal of Cutaneous Medicine and Surgery</SO>
<YR>2015</YR>
<VL>19</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:45:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832051"/><IDENTIFIER MODIFIED="2016-10-04 15:45:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 25775661"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832050"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bumb-2010" MODIFIED="2016-10-04 15:46:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bumb 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-04 15:46:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bumb RA, Mehta RD, Ghiya BC, Jakhar R, Prasad N, Soni P, et al</AU>
<TI>Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>163</VL>
<NO>4</NO>
<PG>854-8</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:46:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832053"/><IDENTIFIER MODIFIED="2016-10-04 15:46:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 20500797"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832052"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-1986" MODIFIED="2016-10-04 15:49:23 +0100" MODIFIED_BY="[Empty name]" NAME="Dogra 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-10-04 15:49:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra J, Lal BB, Misra SN</AU>
<TI>Dapsone in the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>1986</YR>
<VL>25</VL>
<NO>6</NO>
<PG>398-400</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:49:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832055"/><IDENTIFIER MODIFIED="2016-10-04 15:49:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3531044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832054"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-1994" MODIFIED="2016-10-04 15:50:55 +0100" MODIFIED_BY="[Empty name]" NAME="Dogra 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-10-04 15:50:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra J, Aneja N</AU>
<TI>Leishmaniasis and itraconazole: a controlled clinical trial on cutaneous subtypes</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>4</NO>
<PG>309-11</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:50:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832057"/><IDENTIFIER MODIFIED="2016-10-04 15:50:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18611622"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832056"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorlo-2012" MODIFIED="2016-10-04 15:53:13 +0100" MODIFIED_BY="[Empty name]" NAME="Dorlo 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-04 15:53:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ</AU>
<TI>Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2012</YR>
<VL>67</VL>
<NO>11</NO>
<PG>2576-97</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:53:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832059"/><IDENTIFIER MODIFIED="2016-10-04 15:53:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 22833634 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-On-1992" MODIFIED="2016-10-04 15:54:33 +0100" MODIFIED_BY="[Empty name]" NAME="El On 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-10-04 15:54:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>el-On J, Halevy S, Grunwald MH, Weinrauch L</AU>
<TI>Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double blind control study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1992</YR>
<VL>27</VL>
<NO>2 Pt 1</NO>
<PG>227-31</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:54:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832061"/><IDENTIFIER MODIFIED="2016-10-04 15:54:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1430361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832060"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frankenburg-1993" MODIFIED="2016-10-04 15:55:23 +0100" MODIFIED_BY="[Empty name]" NAME="Frankenburg 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-10-04 15:55:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frankenburg S, Gross A, Jonas F, Klaus S</AU>
<TI>Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>1993</YR>
<VL>32</VL>
<NO>1</NO>
<PG>68-70</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:55:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832063"/><IDENTIFIER MODIFIED="2016-10-04 15:55:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8425810"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832062"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2009" MODIFIED="2016-10-04 15:56:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-04 15:56:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim DH, Chung HJ, Bleys J, Ghohestani RF</AU>
<TI>Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>2</NO>
<PG>e381</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:56:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832065"/><IDENTIFIER MODIFIED="2016-10-04 15:56:07 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19221595"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832064"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moosavi-2005" MODIFIED="2016-10-04 15:57:05 +0100" MODIFIED_BY="[Empty name]" NAME="Moosavi 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-04 15:57:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moosavi Z, Nakhli A, Rassaii S</AU>
<TI>Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>12</NO>
<PG>1064-5</PG>
<IDENTIFIERS MODIFIED="2016-10-04 15:57:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832067"/><IDENTIFIER MODIFIED="2016-10-04 15:57:05 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 16409282"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2010" MODIFIED="2016-10-04 16:04:25 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-04 16:04:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali NM, Fariba J, Elaheh H, Ali N</AU>
<TI>The efficacy of 5% trichoroacetic acid cream in the treatment of cutaneous leishmaniasis lesions</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>2</NO>
<PG>136-9</PG>
<IDENTIFIERS MODIFIED="2016-10-04 16:04:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832069"/><IDENTIFIER MODIFIED="2016-10-04 16:04:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 21034291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832068"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilforoushzadeh-2011" MODIFIED="2016-10-04 16:05:22 +0100" MODIFIED_BY="[Empty name]" NAME="Nilforoushzadeh 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-04 16:05:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilforoushzadeh MA, Jaffary F, Ansari N, Moradi S, Siadat AH</AU>
<TI>The comparison between trichloroacetic acid 50% and CO2 laser in the treatment of cutaneous leishmaniasis scar</TI>
<SO>Indian Journal of Dermatology</SO>
<YR>2011</YR>
<VL>56</VL>
<NO>2</NO>
<PG>171-3</PG>
<IDENTIFIERS MODIFIED="2016-10-04 16:05:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832071"/><IDENTIFIER MODIFIED="2016-10-04 16:05:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 21716542"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siavash-2013" MODIFIED="2016-10-04 16:07:36 +0100" MODIFIED_BY="[Empty name]" NAME="Siavash 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-04 16:07:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shanehsaz SM, Ishkhanian S</AU>
<TI>Electrocardiographic and biochemical adverse effects of meglumine antimoniate during the treatment of Syrian cutaneous leishmaniasis</TI>
<SO>Egyptian Dermatology Journal</SO>
<YR>2013</YR>
<VL>9</VL>
<NO>1</NO>
<PG>5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832075"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1995" MODIFIED="2016-10-04 16:08:48 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-04 16:08:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh S, Singh R, Sundar S</AU>
<TI>Failure of ketaconazole in oriental sore in India</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>4</NO>
<PG>202-3</PG>
<IDENTIFIERS MODIFIED="2016-10-04 16:08:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832077"/><IDENTIFIER MODIFIED="2016-10-04 16:08:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8904156"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trau-1987" MODIFIED="2016-10-04 16:09:49 +0100" MODIFIED_BY="[Empty name]" NAME="Trau 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-10-04 16:09:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trau H, Schewach-Millet M, Shoham J, Doerner T, Shor R, Passwell JH</AU>
<TI>Topical application of human fibroblast interferon (IFN) in cutaneous leishmaniasis</TI>
<SO>Israel Journal of Medical Sciences</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1125-7</PG>
<IDENTIFIERS MODIFIED="2016-10-04 16:09:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832079"/><IDENTIFIER MODIFIED="2016-10-04 16:09:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3325468"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832078"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-04-19 10:51:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Farajzadeh-2016a" MODIFIED="2017-04-19 10:39:32 +0100" MODIFIED_BY="[Empty name]" NAME="Farajzadeh 2016a" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:37:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farajzadeh S, Hakimi Parizi M, Haghdoost AA, Mohebbi A, Mohammadi S, Pardakhty A, et al</AU>
<TI>Comparison between intralesional injection of zinc sulfate 2 % solution and intralesional meglumine antimoniate in the treatment of acute old world dry type cutaneous leishmaniasis: a randomized double-blind clinical trial</TI>
<SO>Journal of Parasitic Diseases</SO>
<YR>2016</YR>
<VL>40</VL>
<NO>3</NO>
<PG>935-9</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:37:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068489"/><IDENTIFIER MODIFIED="2017-04-19 10:37:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27605813"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068488"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farajzadeh-2016b" MODIFIED="2017-04-19 10:40:01 +0100" MODIFIED_BY="[Empty name]" NAME="Farajzadeh 2016b" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:34:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farajzadeh S, Heshmatkhah A, Vares B, Mohebbi E, Mohebbi A, Aflatoonian M, et al</AU>
<TI>Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial</TI>
<SO>Journal of Parasitic Diseases</SO>
<YR>2016</YR>
<VL>40</VL>
<NO>4</NO>
<PG>1159-64</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:34:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068491"/><IDENTIFIER MODIFIED="2017-04-19 10:33:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s12639-014-0641-1"/><IDENTIFIER MODIFIED="2017-04-19 10:34:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27876906"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068490"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanif-2016" MODIFIED="2017-04-19 10:41:52 +0100" MODIFIED_BY="[Empty name]" NAME="Hanif 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:41:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanif MM, Akram K, Mustafa G</AU>
<TI>Intralesional versus oral chloroquine in cutaneous leishmaniasis: comparison of outcome, duration of treatment and total dose of drug</TI>
<SO>Journal of the College of Physicians and Surgeons Pakistan</SO>
<YR>2016</YR>
<VL>26</VL>
<NO>4</NO>
<PG>260-2</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:41:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068493"/><IDENTIFIER MODIFIED="2017-04-19 10:41:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27097693"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068492"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffary-2016" MODIFIED="2017-04-19 10:44:20 +0100" MODIFIED_BY="[Empty name]" NAME="Jaffary 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:44:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E</AU>
<TI>A comparison between the effects of Glucantime, topical trichloroacetic acid 50% plus Glucantime, and fractional carbon dioxide laser plus Glucantime on cutaneous leishmaniasis lesions</TI>
<SO>Dermatology Research and Practice</SO>
<YR>2016</YR>
<VL>2016</VL>
<PG>6462804</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:44:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068495"/><IDENTIFIER MODIFIED="2017-04-19 10:44:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27148363"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Na_x002d_Bangchang-2016" MODIFIED="2017-04-19 10:46:55 +0100" MODIFIED_BY="[Empty name]" NAME="Na-Bangchang 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:46:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Na-Bangchang K, Ahmed O, Hussein J, Hirayama K, Kongjam P, Aseffa A, et al</AU>
<TI>Exploratory, phase II controlled trial of shiunko ointment local application twice a day for 4 weeks in Ethiopian patients with localized cutaneous leishmaniasis</TI>
<SO>Evidence-Based Complementary and Alternative Medicine</SO>
<YR>2016</YR>
<VL>2016</VL>
<PG>5984709</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:46:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068497"/><IDENTIFIER MODIFIED="2017-04-19 10:46:44 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27195014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068496"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rajabi-2016" MODIFIED="2017-04-19 10:48:12 +0100" MODIFIED_BY="[Empty name]" NAME="Rajabi 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:48:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajabi O, Layegh P, Hashemzadeh S, Khoddami M</AU>
<TI>Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis</TI>
<SO>Dermatologic Therapy</SO>
<YR>2016</YR>
<VL>29</VL>
<NO>5</NO>
<PG>358-63</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:48:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068499"/><IDENTIFIER MODIFIED="2017-01-09 22:52:09 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/dth.12357"/><IDENTIFIER MODIFIED="2017-04-19 10:48:12 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27073044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-09 22:53:00 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068498"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Refai-2016" MODIFIED="2017-04-19 10:51:22 +0100" MODIFIED_BY="[Empty name]" NAME="Refai 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-04-19 10:51:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Refai W, Madarasingha N, Weerasingha S, Senarath U, De Silva A, Fernandopulle R, et al</AU>
<TI>Efficacy, safety and cost-effectiveness of thermotherapy for L. donovani-induced cutaneous leishmaniasis: a randomized controlled clinical trial</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2016</YR>
<VL>45</VL>
<PG>74</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:51:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:51:22 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-01142616"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068501"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7068500"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sattar-2012" MODIFIED="2017-01-09 11:26:30 +0000" MODIFIED_BY="[Empty name]" NAME="Sattar 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-01-09 11:26:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sattar FA, Ahmed F, Ahmed N, Sattar SA, Malghani MA, Choudhary MI</AU>
<TI>A double-blind, randomized, clinical trial on the antileishmanial activity of a Morinda citrifolia (Noni) stem extract and its major constituents</TI>
<SO>Natural Product Communications</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>2</NO>
<PG>195-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2832073"/><IDENTIFIER TYPE="PUBMED" VALUE=" 22474954"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832072"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-10-04 16:24:11 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACTRN12614001288617" MODIFIED="2016-10-04 16:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12614001288617" YEAR="">
<REFERENCE MODIFIED="2016-10-04 16:15:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12614001288617</AU>
<TI>A clinical trial to assess the safety and effect of heat therapy in comparison to standard intra-lesional sodium stibogluconate for cutaneous leishmaniasis</TI>
<TO>In patients with cutaneous leishmaniasis, thermotherapy was compared with standard intra-lesional therapy with regard to efficacy and safety</TO>
<SO>anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12614001288617</SO>
<YR>Date first received: 10 December 2014</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068502"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-IRCT138904091159N7" MODIFIED="2016-10-04 16:17:38 +0100" MODIFIED_BY="[Empty name]" NAME="IRCT138904091159N7" YEAR="">
<REFERENCE MODIFIED="2016-10-04 16:17:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT138904091159N7</AU>
<TI>Comparison between two groups in the treatment of cutaneous leishmaniasis</TI>
<TO>Comparison between the efficacy of intralesional placebo and nitric oxide releasing patch versus placebo patch and glucantime in the treatment of cutaneous leishmaniasis</TO>
<SO>www.irct.ir/searchresult.php?id=1159&amp;number=7</SO>
<YR>Date first received: 2 September 2013</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068503"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832083"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-IRCT2013092414746N1" MODIFIED="2016-10-04 16:20:04 +0100" MODIFIED_BY="[Empty name]" NAME="IRCT2013092414746N1" YEAR="">
<REFERENCE MODIFIED="2016-10-04 16:20:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT2013092414746N1</AU>
<TI>Treatment of patients with ZCL</TI>
<TO>The effect of MJ1 (Topical dairy extract) versus routine care for treatment of cutaneous leishmaniasis (rural) in Isfahan Iran :a randomized controled clinical trial (RCTs) -</TO>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2013092414746N1</SO>
<YR>Date first received: 20 February 2014</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068504"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00840359" MODIFIED="2016-10-04 16:21:38 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00840359" YEAR="">
<REFERENCE MODIFIED="2016-10-04 16:21:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00840359</AU>
<TI>Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis</TI>
<TO>Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis</TO>
<SO>clinicaltrials.gov/ct2/show/NCT00840359</SO>
<YR>Date first received: 8 February 2009</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068505"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832085"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01050777" MODIFIED="2016-10-04 16:22:42 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01050777" YEAR="">
<REFERENCE MODIFIED="2016-10-04 16:22:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01050777</AU>
<TI>Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis</TI>
<TO>Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica</TO>
<SO>clinicaltrials.gov/ct2/show/NCT01050777</SO>
<YR>Date first received: 13 January 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068506"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SLCTR_x002f_2014_x002f_028" MODIFIED="2016-10-04 16:24:11 +0100" MODIFIED_BY="[Empty name]" NAME="SLCTR/2014/028" YEAR="">
<REFERENCE MODIFIED="2016-10-04 16:24:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>SLCTR/2014/028</AU>
<TI>Treatment for leishmaniasis</TI>
<TO>Randomized, double blind, controlled study on efficacy and safety of intralesional metronidazole vs intralesional sodium stibogluconate in L. donovani cutaneous leishmaniasis</TO>
<SO>slctr.lk/trials/276</SO>
<YR>Date first received: 18 October 2014</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7068507"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2832087"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-15 15:53:09 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-11-15 15:53:09 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adam-2008" MODIFIED="2016-10-05 13:28:19 +0100" MODIFIED_BY="[Empty name]" NAME="Adam 2008" TYPE="JOURNAL_ARTICLE">
<AU>Adam I, Elhardello OA, Elhadi MO, Abdalla E, Elmardi KA, Jansen FH</AU>
<TI>The antischistosomal efficacies of artesunate&#8211;sulfamethoxypyrazine&#8211;pyrimethamine and artemether&#8211;lumefantrine administered as treatment for uncomplicated <I>Plasmodium falciparum </I>malaria</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>1</NO>
<PG>39-44</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:28:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:28:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18186976"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Waiz-2004" MODIFIED="2016-10-05 13:31:50 +0100" MODIFIED_BY="[Empty name]" NAME="Al-Waiz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Al-Waiz M, Sharquie KE, Al-Assir M</AU>
<TI>Treatment of cutaneous leishmaniasis by intralesional metronidazole</TI>
<SO>Saudi Medical Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1512-3</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:30:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:30:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15494841"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alrajhi-2003" MODIFIED="2016-10-05 13:33:52 +0100" MODIFIED_BY="[Empty name]" NAME="Alrajhi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Alrajhi AA</AU>
<TI>Cutaneous leishmaniasis of the Old World</TI>
<SO>Skin Therapy Letter</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>1-4</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:33:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:33:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12728282"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alvar-2006" MODIFIED="2016-10-05 13:35:33 +0100" MODIFIED_BY="[Empty name]" NAME="Alvar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Alvar J, Yactayo S, Bern C</AU>
<TI>Leishmaniasis and poverty</TI>
<SO>Trends in Parasitology</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>12</NO>
<PG>552-7</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:35:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:35:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17023215"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alvar-2012" MODIFIED="2016-10-05 13:36:57 +0100" MODIFIED_BY="[Empty name]" NAME="Alvar 2012" TYPE="JOURNAL_ARTICLE">
<AU>Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al</AU>
<TI>Leishmaniasis worldwide and global estimates of its incidence</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>5</NO>
<PG>e35671</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:36:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:36:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22693548"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Amin-2006" MODIFIED="2016-10-05 13:38:10 +0100" MODIFIED_BY="[Empty name]" NAME="Amin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Amin SP, Phelps RG, Goldberg DJ</AU>
<TI>Mesotherapy for facial skin rejuvenation: a clinical, histologic, and electron microscopic evaluation</TI>
<SO>Dermatologic Surgery</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>12</NO>
<PG>1467-1472</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:37:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:37:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17199654"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aram-1987" MODIFIED="2017-10-09 09:21:35 +0100" MODIFIED_BY="[Empty name]" NAME="Aram 1987" TYPE="JOURNAL_ARTICLE">
<AU>Aram H, Leibovici V</AU>
<TI>Ultrasound-induced hyperthermia in the treatment of cutaneous leishmaniasis</TI>
<SO>Cutis</SO>
<YR>1987</YR>
<VL>40</VL>
<NO>4</NO>
<PG>350-3</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:21:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:21:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3677796"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arevalo-2007" MODIFIED="2016-10-05 13:40:26 +0100" MODIFIED_BY="[Empty name]" NAME="Arevalo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Arevalo I, Tulliano G, Quispe A, Spaeth G, Mathlashewski, Llanos-cuantas A, et al</AU>
<TI>Role of imiquimod and parenteral meglumine antimoniate in the intitial treatment of cutaneous lesihmaniasis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>12</NO>
<PG>1549-54</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:40:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:40:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17516397"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Babajev-1991" MODIFIED="2017-10-09 09:22:42 +0100" MODIFIED_BY="[Empty name]" NAME="Babajev 1991" TYPE="JOURNAL_ARTICLE">
<AU>Babajev KB, Babajev OG, Korepanov VI</AU>
<TI>Treatment of cutaneous leishmaniasis using a carbon dioxide laser</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1991</YR>
<VL>69</VL>
<NO>1</NO>
<PG>103-6</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:22:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:22:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1905204"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Badaro-1990" MODIFIED="2016-10-05 13:42:24 +0100" MODIFIED_BY="[Empty name]" NAME="Badaro 1990" TYPE="JOURNAL_ARTICLE">
<AU>Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al</AU>
<TI>Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>1</NO>
<PG>16-21</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:42:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:42:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2104665"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baryza-1995" MODIFIED="2016-10-05 13:43:13 +0100" MODIFIED_BY="[Empty name]" NAME="Baryza 1995" TYPE="JOURNAL_ARTICLE">
<AU>Baryza MJ, Baryza GA</AU>
<TI>The Vancouver Scar Scale: an administration tool and its interrater reliability</TI>
<SO>Journal of Burn Care Rehabilitation</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>5</NO>
<PG>535-8</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:43:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:43:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8537427"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bassiouny-1982" MODIFIED="2016-10-05 13:44:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bassiouny 1982" TYPE="JOURNAL_ARTICLE">
<AU>Bassiouny A, El Meshad M, Talaat M, Kutty K, Metawaa B</AU>
<TI>Cryosurgery in cutaneous leishmaniasis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1982</YR>
<VL>107</VL>
<NO>4</NO>
<PG>467-74</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:44:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:44:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7126453"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berman-1981" MODIFIED="2017-10-09 09:23:57 +0100" MODIFIED_BY="[Empty name]" NAME="Berman 1981" TYPE="JOURNAL_ARTICLE">
<AU>Berman JD, Neva FA</AU>
<TI>Effect of temperature on multiplication of Leishmania amastigotes within monocyte-derived macrophages in vitro</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1981</YR>
<VL>30</VL>
<NO>2</NO>
<PG>318-21</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:23:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:23:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7235124"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bigby-2003" MODIFIED="2016-10-05 13:47:44 +0100" MODIFIED_BY="[Empty name]" NAME="Bigby 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bigby M, Williams H</AU>
<TI>Appraising Systematic Reviews and Meta-analyses</TI>
<SO>Archives of Dermatology</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>6</NO>
<PG>795-798</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:47:44 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12810513"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blum-2012" MODIFIED="2016-10-05 13:48:47 +0100" MODIFIED_BY="[Empty name]" NAME="Blum 2012" TYPE="JOURNAL_ARTICLE">
<AU>Blum J, Lockwood DN, Visser L, Harms G, Bailey MS, Caumes E, et al</AU>
<TI>Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis</TI>
<SO>International Health</SO>
<YR>2012</YR>
<VL>4</VL>
<NO>3</NO>
<PG>153-63</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:48:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:48:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24029394"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blum-2014" MODIFIED="2016-10-05 13:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Blum 2014" TYPE="JOURNAL_ARTICLE">
<AU>Blum J, Buffet P, Visser L, Harms G, Bailey MS, Caumes E, et al</AU>
<TI>LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014</TI>
<SO>Journal of Travel Medicine</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>2</NO>
<PG>116-29</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:49:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:49:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24745041"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bogenrieder-2003" MODIFIED="2016-10-05 13:50:20 +0100" MODIFIED_BY="[Empty name]" NAME="Bogenrieder 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bogenrieder T, Lehn N, Landthaler M, Stolz W</AU>
<TI>Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device</TI>
<SO>Dermatology</SO>
<YR>2003</YR>
<VL>206</VL>
<NO>3</NO>
<PG>269-72</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:50:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:50:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12673089"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Borelli-1987" MODIFIED="2016-10-05 13:51:55 +0100" MODIFIED_BY="[Empty name]" NAME="Borelli 1987" TYPE="JOURNAL_ARTICLE">
<AU>Borelli D</AU>
<TI>A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1987</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>S57-63</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:51:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:51:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3027848"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bryceson-1994" MODIFIED="2016-10-05 13:53:40 +0100" MODIFIED_BY="[Empty name]" NAME="Bryceson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bryceson AD, Murphy A, Moody AH</AU>
<TI>Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>2</NO>
<PG>226-8</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:53:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:53:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8036683"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bygbjerg-1980" MODIFIED="2016-10-05 13:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="Bygbjerg 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bygbjerg IC, Knudsen L, Kieffer M</AU>
<TI>Failure of rifampicin therapy to cure cutaneous leishmaniasis</TI>
<SO>Archives of Dermatology</SO>
<YR>1980</YR>
<VL>116</VL>
<NO>9</NO>
<PG>988</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:54:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:54:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7416770"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cardo-2006" MODIFIED="2016-10-05 13:55:22 +0100" MODIFIED_BY="[Empty name]" NAME="Cardo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cardo LJ</AU>
<TI>Leishmania: risk to the blood supply</TI>
<SO>Transfusion</SO>
<YR>2006</YR>
<VL>46</VL>
<NO>9</NO>
<PG>1641-45</PG>
<IDENTIFIERS MODIFIED="2016-10-05 13:55:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 13:55:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16965594"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cauwenberg-1986" MODIFIED="2016-10-05 14:03:40 +0100" MODIFIED_BY="[Empty name]" NAME="Cauwenberg 1986" TYPE="JOURNAL_ARTICLE">
<AU>Cauwenberg G, De Doncker P</AU>
<TI>Itraconazole (R 51 211): a clinical review of its anti mycotic activity in dermatology, gynecology, and internal medicine</TI>
<SO>Drug Development Research</SO>
<YR>1986</YR>
<VL>8</VL>
<PG>317-23</PG>
<IDENTIFIERS MODIFIED="2016-10-05 14:03:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 14:03:40 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ddr.430080136"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-2009" MODIFIED="2016-10-05 14:10:23 +0100" MODIFIED_BY="[Empty name]" NAME="Chalmers 2009" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I, Glasziou P</AU>
<TI>Avoidable waste in the production and reporting of research evidence</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>374</VL>
<NO>9683</NO>
<PG>86-9</PG>
<IDENTIFIERS MODIFIED="2016-10-05 14:10:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-05 14:10:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19525005"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chunge-1985" MODIFIED="2016-10-06 13:08:04 +0100" MODIFIED_BY="[Empty name]" NAME="Chunge 1985" TYPE="JOURNAL_ARTICLE">
<AU>Chunge CN, Gachihi G, Muigai R, Wasunna K, Rashid JR, Chulay JD, et al</AU>
<TI>Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>5</NO>
<PG>715-8</PG>
<IDENTIFIERS MODIFIED="2016-10-06 13:08:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-06 13:08:04 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3006296"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crawford-2005" MODIFIED="2008-06-27 12:04:15 +0100" MODIFIED_BY="[Empty name]" NAME="Crawford 2005" TYPE="JOURNAL_ARTICLE">
<AU>Crawford R, Holmes D, Meymandi S</AU>
<TI>Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intralesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2005</YR>
<VL>52</VL>
<PG>S118</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Croft-2006" MODIFIED="2016-10-06 13:21:25 +0100" MODIFIED_BY="[Empty name]" NAME="Croft 2006" TYPE="JOURNAL_ARTICLE">
<AU>Croft SL, Seifert K, Yardley V</AU>
<TI>Current scenario of drug development for Leishmaniasis</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>2006</YR>
<VL>123</VL>
<NO>3</NO>
<PG>399-410</PG>
<IDENTIFIERS MODIFIED="2016-10-06 13:21:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-06 13:21:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16778319"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daie-Parizi-1992" MODIFIED="2016-10-10 11:40:32 +0100" MODIFIED_BY="[Empty name]" NAME="Daie Parizi 1992" TYPE="JOURNAL_ARTICLE">
<AU>Daie Parizi MH</AU>
<TI>Treatment of cutaneous leishmaniasis with local application of the tincture of Thioxolone and benzoxonium chloride (first research in the world) at annual congress of Iranian society of pediatrics, Tehran, Iran, Oct 1992</TI>
<SO>The Annual Book of Congress</SO>
<YR>1992</YR>
<VL>1</VL>
<PG>121-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daie-Parizi-1996" MODIFIED="2016-10-10 11:42:55 +0100" MODIFIED_BY="[Empty name]" NAME="Daie Parizi 1996" TYPE="JOURNAL_ARTICLE">
<AU>Daie Parizi MH, Shamsaddini S</AU>
<TI>Comparison between topical treatment with Thioxolone, Benzoxonium Chloride tincture and intralesional injection of Meglumine Antimoniate on cutaneous Leishmaniasis</TI>
<SO>Journal of Kerman University of Medical Sciences</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>1</NO>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2003" MODIFIED="2016-10-10 11:44:40 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Davies CR, Kaye P, Croft SL, Sundar S</AU>
<TI>Leishmaniasis: new approaches to disease control</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7385</NO>
<PG>377-82</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:44:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:44:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12586674 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Vries-2015" MODIFIED="2016-10-10 11:45:45 +0100" MODIFIED_BY="[Empty name]" NAME="de Vries 2015" TYPE="JOURNAL_ARTICLE">
<AU>de Vries HJ, Reedijk SH, Schallig HD</AU>
<TI>Cutaneous leishmaniasis: recent developments in diagnosis and management</TI>
<SO>American Journal of Clinical Dermatology</SO>
<YR>2015</YR>
<VL>16</VL>
<NO>2</NO>
<PG>99-109</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:45:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:45:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25687688"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Delamere-2008" MODIFIED="2016-06-02 10:48:46 +0100" MODIFIED_BY="[Empty name]" NAME="Delamere 2008" TYPE="JOURNAL_ARTICLE">
<AU>Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J</AU>
<TI>Interventions for alopecia areata</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<VL>2</VL>
<PG>CD004413</PG>
<IDENTIFIERS MODIFIED="2016-01-21 11:16:24 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-21 11:16:24 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004413.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-den-Boer-2011" MODIFIED="2017-04-19 10:15:33 +0100" MODIFIED_BY="[Empty name]" NAME="den Boer 2011" TYPE="JOURNAL_ARTICLE">
<AU>den Boer M, Argaw D, Jannin J, Alvar J</AU>
<TI>Leishmaniasis impact and treatment access</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1471&#8211;7</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:15:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:15:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21933305"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Desjeux-1996" MODIFIED="2016-10-10 11:46:59 +0100" MODIFIED_BY="[Empty name]" NAME="Desjeux 1996" TYPE="JOURNAL_ARTICLE">
<AU>Desjeux P</AU>
<TI>Leishmaniasis. Public health aspects and control</TI>
<SO>Clinical Dermatology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>5</NO>
<PG>417-23</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:46:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:46:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8889319"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dorlo-2011" MODIFIED="2016-10-10 11:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Dorlo 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dorlo TP, van Thiel PP, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, et al</AU>
<TI>Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>12</NO>
<PG>e1436</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:48:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:48:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 22180803"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2017-11-15 11:42:11 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Biasin meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629&#8211;34</PG>
<IDENTIFIERS MODIFIED="2017-11-13 05:37:20 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-11-13 05:37:20 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9310563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-el_x002d_On-1985" MODIFIED="2016-10-10 11:49:52 +0100" MODIFIED_BY="[Empty name]" NAME="el-On 1985" TYPE="JOURNAL_ARTICLE">
<AU>el-On J, Weinrauch L, Livshin R, Even-Paz Z, Jacobs GP</AU>
<TI>Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1985</YR>
<VL>291</VL>
<NO>6497</NO>
<PG>704-5</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:49:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:49:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3929905"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-el_x002d_Safi-1990" MODIFIED="2016-10-10 11:50:56 +0100" MODIFIED_BY="[Empty name]" NAME="el-Safi 1990" TYPE="JOURNAL_ARTICLE">
<AU>el-Safi SH, Murphy AG, Bryceson AD, Neal RA</AU>
<TI>A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>5</NO>
<PG>690-1</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:50:56 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:50:56 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2278070"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faber-2003" MODIFIED="2016-10-10 11:52:12 +0100" MODIFIED_BY="[Empty name]" NAME="Faber 2003" TYPE="JOURNAL_ARTICLE">
<AU>Faber WR, Oskam L, van Gool T, Kroon NC, Knegt-Junk KJ, Hofwegen H, et al</AU>
<TI>Value of diagnostic techniques for cutaneous leishmaniasis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>1</NO>
<PG>70-4</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:52:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:52:12 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12833011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fatima-2005" MODIFIED="2016-10-10 11:53:23 +0100" MODIFIED_BY="[Empty name]" NAME="Fatima 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fatima F, Khalid A, Nazar N, Abdalla M, Mohomed H, Toum AM, et al</AU>
<TI>In vitro assessment of anti - cutaneous leishmaniasis activity of some Sudanese plants</TI>
<SO>Turkiye Parazitoloji Dergisi</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>1</NO>
<PG>3-6</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:53:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:53:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17167733"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2014" MODIFIED="2016-10-10 11:55:46 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 2014" TYPE="OTHER">
<AU>US Food and Drugs Administration.</AU>
<TI>News and Events - FDA News Release 2014</TI>
<SO>www.fda.gov/NewsEvents/Newsroom/PrressAnnouncements/ucm389671.htm</SO>
<YR>(acessed prior to 10 October 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garnier-2002" MODIFIED="2017-04-19 10:16:07 +0100" MODIFIED_BY="[Empty name]" NAME="Garnier 2002" TYPE="JOURNAL_ARTICLE">
<AU>Garnier T, Croft SL</AU>
<TI>Topical treatment for cutaneous leishmaniasis</TI>
<SO>Current Opinion in Investigational Drugs (London, England : 2000)</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>4</NO>
<PG>538-44</PG>
<IDENTIFIERS MODIFIED="2016-10-10 11:57:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 11:57:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12090720"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gonz_x00e1_lez-2009" MODIFIED="2016-10-10 12:01:50 +0100" MODIFIED_BY="[Empty name]" NAME="González 2009" TYPE="COCHRANE_REVIEW">
<AU>González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA</AU>
<TI>Interventions for American cutaneous and mucocutaneous leishmaniasis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<VL>2</VL>
<NO>2</NO>
<PG>CD004834</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:01:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:01:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004834.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gonz_x00e1_lez-2010" MODIFIED="2016-10-10 12:02:49 +0100" MODIFIED_BY="[Empty name]" NAME="González 2010" TYPE="JOURNAL_ARTICLE">
<AU>González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, et al</AU>
<TI>Designing and reporting clinical trials on treatments for cutaneous leishmaniasis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>4</NO>
<PG>409-19</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:02:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:02:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20624067"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gonz_x00e1_lez-2015" MODIFIED="2016-10-10 12:04:03 +0100" MODIFIED_BY="[Empty name]" NAME="González 2015" TYPE="COCHRANE_REVIEW">
<AU>González U, Pinart M, Sinclair D, Firooz A, Enk C, Vélez ID, et al</AU>
<TI>Vector and reservoir control for preventing leishmaniasis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<VL>8</VL>
<NO>8</NO>
<PG>CD008736</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:03:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:03:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008736.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goodman-2007" MODIFIED="2016-10-10 12:05:02 +0100" MODIFIED_BY="[Empty name]" NAME="Goodman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Goodman AC</AU>
<TI>Beware the "Texas sharp shooter" in rate ratios of progression</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>334</VL>
<NO>7591</NO>
<PG>440</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:05:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:05:02 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17332546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gradoni-2017" MODIFIED="2017-11-15 15:52:58 +0000" MODIFIED_BY="[Empty name]" NAME="Gradoni 2017" TYPE="OTHER">
<AU>Gradoni L, López-Vélez R, Mokni M</AU>
<TI>World Health Organization. Manual on case management and surveillance of the leishmaniasis in the WHO European Region</TI>
<SO>www.who.int/leishmaniasis/resources/EURO_WHO_Leish_manual_on_case_management_and_surveillance_9789289052511_2017.pdf?ua=1</SO>
<YR>(accessed prior to 15 November 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2017-04-19 10:17:23 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:17:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:17:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18436948"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hepburn-2001" MODIFIED="2016-10-10 12:05:55 +0100" MODIFIED_BY="[Empty name]" NAME="Hepburn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hepburn NC</AU>
<TI>Management of cutaneous leishmaniasis</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>2</NO>
<PG>151-4</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:05:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:05:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11979125"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herwaldt-1999" MODIFIED="2016-10-10 12:06:54 +0100" MODIFIED_BY="[Empty name]" NAME="Herwaldt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Herwaldt BL</AU>
<TI>Leishmaniasis</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9185</NO>
<PG>1191-9</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:06:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:06:54 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10513726"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2017-04-19 10:18:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:18:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:18:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12958120"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-10-10 12:09:07 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d5928</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:09:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:09:07 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22008217"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ingram-2015" MODIFIED="2016-10-10 12:11:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ingram 2015" TYPE="COCHRANE_REVIEW">
<AU>Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, et al</AU>
<TI>Interventions for hidradenitis suppurativa</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>10</NO>
<PG>CD010081</PG>
<IDENTIFIERS MODIFIED="2016-01-21 11:15:00 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-21 11:15:00 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010081.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jha-1983" MODIFIED="2016-10-10 12:12:20 +0100" MODIFIED_BY="[Empty name]" NAME="Jha 1983" TYPE="JOURNAL_ARTICLE">
<AU>Jha TK</AU>
<TI>Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1983</YR>
<VL>77</VL>
<NO>2</NO>
<PG>204-7</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:12:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:12:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6868102"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jiang-2002" MODIFIED="2016-10-10 12:13:49 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jiang S, Meadows J, Anderson SA, Mukkada AJ</AU>
<TI>Antileishmanial activity of the antiulcer agent omeprazole</TI>
<SO>Antimicrobial agents and chemotherapy</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>8</NO>
<PG>2569-74</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:13:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:13:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12121934"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Junaid-1986" MODIFIED="2016-10-10 12:14:40 +0100" MODIFIED_BY="[Empty name]" NAME="Junaid 1986" TYPE="JOURNAL_ARTICLE">
<AU>Junaid AJ</AU>
<TI>Treatment of cutaneous leishmaniasis with infrared heat</TI>
<SO>International Journal of Dermatology</SO>
<YR>1986</YR>
<VL>25</VL>
<NO>7</NO>
<PG>470-2</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:14:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:14:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 3771049"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kager-1981" MODIFIED="2016-10-10 12:15:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kager 1981" TYPE="JOURNAL_ARTICLE">
<AU>Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH</AU>
<TI>Allopurinol in the treatment of visceral leishmaniasis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1981</YR>
<VL>75</VL>
<NO>4</NO>
<PG>556-9</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:15:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:15:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6275579"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karamian-2007" MODIFIED="2016-10-10 12:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Karamian 2007" TYPE="JOURNAL_ARTICLE">
<AU>Karamian M, Motazedian MH, Mehrabani D, Gholami K</AU>
<TI>Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B</TI>
<SO>Parasitology Research</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>5</NO>
<PG>1431-4</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:16:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:16:44 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17659388"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keiser-J-2007" MODIFIED="2016-10-10 12:18:17 +0100" MODIFIED_BY="[Empty name]" NAME="Keiser J 2007" TYPE="JOURNAL_ARTICLE">
<AU>Keiser J, Utzinger J</AU>
<TI>Artemisinins and synthetic trioxolanes in the treatment of helminth infections</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>6</NO>
<PG>605&#8211;12</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:17:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:17:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17975411"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kermode-2004" MODIFIED="2016-10-10 12:19:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kermode 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kermode M</AU>
<TI>Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses</TI>
<SO>Health Promotion International</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>1</NO>
<PG>95-103</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:19:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:19:07 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14976177"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khalid-2005" MODIFIED="2016-10-10 12:20:29 +0100" MODIFIED_BY="[Empty name]" NAME="Khalid 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fatima F, Khalid A, Nazar N, Abdalla M, Mohomed H, Toum AM, et al</AU>
<TI>In vitro assessment of anti -cutaneous leishmaniasis activity of some Sudanese plants</TI>
<SO>Türkiye Parazitoloji Dergisi</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>1</NO>
<PG>3-6</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:20:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:20:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17167733"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khatami-2007" MODIFIED="2016-10-10 12:23:51 +0100" MODIFIED_BY="[Empty name]" NAME="Khatami 2007" TYPE="JOURNAL_ARTICLE">
<AU>Khatami A, Firooz A, Gorouhi F, Dowlati Y</AU>
<TI>Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>2</NO>
<PG>335.e1-29</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:23:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:23:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17337090"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laguna-1999" MODIFIED="2016-10-10 12:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Laguna 1999" TYPE="JOURNAL_ARTICLE">
<AU>Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, et al</AU>
<TI>Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group</TI>
<SO>AIDS</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>9</NO>
<PG>1063-9</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:24:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:24:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="  10397536"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leibovici-1986" MODIFIED="2016-10-10 12:25:50 +0100" MODIFIED_BY="[Empty name]" NAME="Leibovici 1986" TYPE="JOURNAL_ARTICLE">
<AU>Leibovici V, Aram H</AU>
<TI>Cryotherapy in acute cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>1986</YR>
<VL>25</VL>
<NO>7</NO>
<PG>473-5</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:25:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:25:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 3533799"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lessa-2001" MODIFIED="2016-10-10 12:26:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lessa 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, et al</AU>
<TI>Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>65</VL>
<NO>2</NO>
<PG>87-9</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:26:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:26:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11508396"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mapar-2001" MODIFIED="2016-10-10 12:28:27 +0100" MODIFIED_BY="[Empty name]" NAME="Mapar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mapar MA, Kavoosi H, Dabbagh MA</AU>
<TI>Assessment of the effect of topical opium in treatment of cutaneous leishmaniasis</TI>
<SO>Iranian Journal of Dermatology</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>16</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masmoudi-2013" MODIFIED="2016-10-10 12:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Masmoudi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H</AU>
<TI>Old World cutaneous leishmaniasis: diagnosis and treatment</TI>
<SO>Journal of Dermatological Case Reports</SO>
<YR>2013</YR>
<VL>7</VL>
<NO>2</NO>
<PG>31-41</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:29:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:29:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23858338"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meawad-1997" MODIFIED="2017-10-19 10:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Meawad 1997" TYPE="JOURNAL_ARTICLE">
<AU>Meawad OB</AU>
<TI>Selective heat therapy in cutaneous leishmaniasis: a preliminary experience using the 585 nm pulsed dye laser</TI>
<SO>Journal of the European Academy of Dermatology and Venereology: JEADV</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>3</NO>
<PG>241-4</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:28:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:28:54 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="27286057"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Migdal-2011" MODIFIED="2016-10-10 12:33:48 +0100" MODIFIED_BY="[Empty name]" NAME="Migdal 2011" TYPE="JOURNAL_ARTICLE">
<AU>Migdal C, Serres M</AU>
<TI>Reactive oxygen species and oxidative stress</TI>
<SO>Medical Science</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>4</NO>
<PG>405-412</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:33:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:33:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21524406"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Minodier-2007" MODIFIED="2016-10-10 12:34:39 +0100" MODIFIED_BY="[Empty name]" NAME="Minodier 2007" TYPE="JOURNAL_ARTICLE">
<AU>Minodier P, Parola P</AU>
<TI>Cutaneous leishmaniasis treatment</TI>
<SO>Travel Medicine and Infectious Disease</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>3</NO>
<PG>150-8</PG>
<IDENTIFIERS MODIFIED="2016-10-10 12:34:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 12:34:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17448941"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Modabber-2007" MODIFIED="2016-10-10 13:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="Modabber 2007" TYPE="JOURNAL_ARTICLE">
<AU>Modabber F, Buffet PA, Torreele E, Milon G, Croft SL</AU>
<TI>Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006</TI>
<SO>Kinetoplastid Biology and Disease</SO>
<YR>2007</YR>
<VL>6</VL>
<PG>3</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:36:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:36:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17456237"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monge_x002d_Maillo-2013" MODIFIED="2016-10-10 13:37:20 +0100" MODIFIED_BY="[Empty name]" NAME="Monge-Maillo 2013" TYPE="JOURNAL_ARTICLE">
<AU>Monge-Maillo B, López-Vélez R</AU>
<TI>Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis</TI>
<SO>Drugs</SO>
<YR>2013</YR>
<VL>73</VL>
<NO>17</NO>
<PG>1889-920</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:37:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:37:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24170665"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monge_x002d_Maillo-2015" MODIFIED="2016-10-10 13:38:05 +0100" MODIFIED_BY="[Empty name]" NAME="Monge-Maillo 2015" TYPE="JOURNAL_ARTICLE">
<AU>Monge-Maillo B, López-Vélez R</AU>
<TI>Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2015</YR>
<VL>60</VL>
<NO>9</NO>
<PG>1398-404</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:37:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:37:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25601455"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2001" MODIFIED="2016-10-10 13:40:29 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moore OA, Smith LA, Campbell F, Seers K, McQuay KJ, Moore RA</AU>
<TI>Systematic review of the use of honey as a wound dressing</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>2</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:40:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:40:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11405898"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moskowitz-1999" MODIFIED="2016-10-10 13:41:27 +0100" MODIFIED_BY="[Empty name]" NAME="Moskowitz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moskowitz PF, Kurban AK</AU>
<TI>Treatment of cutaneous leishmaniasis: Retrospective and advances for the 21st century</TI>
<SO>Clinical Dermatology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>3</NO>
<PG>305-15</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:41:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:41:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10384870"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mosleh-2008" MODIFIED="2016-10-10 13:42:31 +0100" MODIFIED_BY="[Empty name]" NAME="Mosleh 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mosleh IM, Geith E, Natsheh L, Schönian G, Abotteen N, Kharabsheh S</AU>
<TI>Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>4</NO>
<PG>617-24</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:42:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:42:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18249466"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Munir-2008" MODIFIED="2016-10-10 13:43:44 +0100" MODIFIED_BY="[Empty name]" NAME="Munir 2008" TYPE="JOURNAL_ARTICLE">
<AU>Munir A, Janjua SA, Hussain I</AU>
<TI>Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis</TI>
<SO>Acta Dermatovenerologica Croatica: ADC</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>2</NO>
<PG>60-4</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:43:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:43:44 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18541100"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Musa-2005" MODIFIED="2016-10-10 13:44:30 +0100" MODIFIED_BY="[Empty name]" NAME="Musa 2005" TYPE="JOURNAL_ARTICLE">
<AU>Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM</AU>
<TI>Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>6</NO>
<PG>563-9</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:44:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:44:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16156969"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Najim-1998" MODIFIED="2016-10-10 13:45:21 +0100" MODIFIED_BY="[Empty name]" NAME="Najim 1998" TYPE="JOURNAL_ARTICLE">
<AU>Najim RA, Sharquie KE, Farjou IB</AU>
<TI>Zinc sulphate in the treatment of cutaneous leishmaniasis: an in vitro and animal study</TI>
<SO>Memórias do Instituto Oswaldo Cruz</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>6</NO>
<PG>831-7</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:45:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:45:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9921312"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neva-1984" MODIFIED="2017-10-09 09:30:14 +0100" MODIFIED_BY="[Empty name]" NAME="Neva 1984" TYPE="JOURNAL_ARTICLE">
<AU>Neva FA, Petersen EA, Corsey R, Bogaert H, Martinez D</AU>
<TI>Observations on local heat treatment for cutaneous leishmaniasis</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1984</YR>
<VL>33</VL>
<NO>5</NO>
<PG>800-4</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:30:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:30:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6091468"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Olliaro-2013" MODIFIED="2016-10-10 13:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Olliaro 2013" TYPE="JOURNAL_ARTICLE">
<AU>Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al</AU>
<TI>Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2013</YR>
<VL>7</VL>
<NO>3</NO>
<PG>e2130</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:49:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:49:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23556016"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pace-2014" MODIFIED="2016-10-10 13:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Pace 2014" TYPE="JOURNAL_ARTICLE">
<AU>Pace D</AU>
<TI>Leishmaniasis</TI>
<SO>Journal of Infection</SO>
<YR>2014</YR>
<VL>69</VL>
<NO>Suppl 1</NO>
<PG>S10-S18</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:52:46 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:52:46 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25238669"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Passwell-1986" MODIFIED="2016-10-10 13:53:56 +0100" MODIFIED_BY="[Empty name]" NAME="Passwell 1986" TYPE="JOURNAL_ARTICLE">
<AU>Passwell JH, Shor R, Shoham J</AU>
<TI>The enhancing effect of interferon-beta and -gamma on the killing of Leishmania tropica major in human mononuclear phagocytes in vitro</TI>
<SO>Journal of Immunology</SO>
<YR>1986</YR>
<VL>136</VL>
<NO>8</NO>
<PG>3062-6</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:53:56 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:53:56 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3082979"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pieper-2003" MODIFIED="2016-10-10 13:56:01 +0100" MODIFIED_BY="[Empty name]" NAME="Pieper 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pieper B, Caliri MH</AU>
<TI>Nontraditional wound care: A review of the evidence for the use of sugar, papaya/papain, and fatty acids</TI>
<SO>Journal of Wound, Ostomy, and Continence Nursing</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>4</NO>
<PG>175&#8211;83</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:55:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:55:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12851592"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pigott-2014" MODIFIED="2016-10-10 13:56:43 +0100" MODIFIED_BY="[Empty name]" NAME="Pigott 2014" TYPE="JOURNAL_ARTICLE">
<AU>Pigott DM, Golding N, Messina JP, Battle KE, Duda KA, Balard Y, et al</AU>
<TI>Global database of leishmaniasis occurrence locations, 1960-2012</TI>
<SO>Scientific Data</SO>
<YR>2014</YR>
<VL>30</VL>
<NO>1</NO>
<PG>140036</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:56:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:56:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25984344"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ponte_x002d_Sucre-2003" MODIFIED="2016-10-10 13:57:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ponte-Sucre 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ponte-Sucre A</AU>
<TI>Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy</TI>
<SO>Kinetoplastid Biology and Disease</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>1</NO>
<PG>14</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:57:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:57:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14613496"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ranawaka-2011" MODIFIED="2017-10-09 09:32:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ranawaka 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ranawaka RR, Weerakoon HS, Opathella N</AU>
<TI>Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>4</NO>
<PG>241-5</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:32:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:32:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20818996"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rathi-2005" MODIFIED="2017-10-09 09:33:50 +0100" MODIFIED_BY="[Empty name]" NAME="Rathi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rathi SK, Pandhi RK, Chopra P, Khanna N</AU>
<TI>Post-kala-azar dermal leishmaniasis: a histopathological study</TI>
<SO>Indian Journal of Dermatology, Venereology and Leprology</SO>
<YR>2005</YR>
<VL>71</VL>
<NO>4</NO>
<PG>250-53</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:33:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:33:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16394433"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reithinger-2005b" MODIFIED="2017-10-09 09:34:44 +0100" MODIFIED_BY="[Empty name]" NAME="Reithinger 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S</AU>
<TI>Social impact of leishmaniasis, Afghanistan</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>634-6</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:34:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:34:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15834984"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reithinger-2007" MODIFIED="2017-04-19 11:24:15 +0100" MODIFIED_BY="[Empty name]" NAME="Reithinger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S</AU>
<TI>Cutaneous leishmaniasis</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>9</NO>
<PG>581-96</PG>
<IDENTIFIERS MODIFIED="2017-04-19 11:24:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 11:24:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17714672"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez-1990" MODIFIED="2017-10-09 09:36:03 +0100" MODIFIED_BY="[Empty name]" NAME="Rodriguez 1990" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez ME, Inguanzo P, Ramos A, Perez J</AU>
<TI>Treatment of cutaneous leishmaniasis with CO2 laser radiation</TI>
<SO>Revista Cubana de Medicina Tropical</SO>
<YR>1990</YR>
<VL>42</VL>
<NO>2</NO>
<PG>197-202</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:35:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:35:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2128547"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez_x002d_Cuartero-1990" MODIFIED="2016-10-10 13:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="Rodriguez-Cuartero 1990" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Cuartero A, Pérez-Blanco FJ, López-Fernández A</AU>
<TI>Co-trimoxazole for visceral leishmaniasis</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>1</NO>
<PG>40</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:58:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:58:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2312176"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rohrich-2003" MODIFIED="2016-10-10 13:59:43 +0100" MODIFIED_BY="[Empty name]" NAME="Rohrich 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rohrich RJ, Janis EJ, Reisman NR</AU>
<TI>Use of off-label and non-approved drugs and devices in plastic surgery</TI>
<SO>Plastic and Reconstructive Surgery</SO>
<YR>2003</YR>
<VL>112</VL>
<NO>1</NO>
<PG>241-243</PG>
<IDENTIFIERS MODIFIED="2016-10-10 13:59:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 13:59:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12832901"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saab-2015" MODIFIED="2017-10-09 09:37:17 +0100" MODIFIED_BY="[Empty name]" NAME="Saab 2015" TYPE="JOURNAL_ARTICLE">
<AU>Saab M, El Hage H, Charafeddine K, Habib RH, Khalifeh I</AU>
<TI>Diagnosis of cutaneous leishmaniasis: why punch when you can scrape?</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2015</YR>
<VL>92</VL>
<NO>3</NO>
<PG>518-22</PG>
<IDENTIFIERS MODIFIED="2016-10-10 14:00:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 14:00:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25561563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sacks-1983" MODIFIED="2017-10-09 09:38:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sacks 1983" TYPE="JOURNAL_ARTICLE">
<AU>Sacks DL, Barral A, Neva F</AU>
<TI>Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1983</YR>
<VL>32</VL>
<NO>2</NO>
<PG>300-4</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:38:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:38:10 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6837841"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sampaio-1960" MODIFIED="2016-10-10 14:03:12 +0100" MODIFIED_BY="[Empty name]" NAME="Sampaio 1960" TYPE="JOURNAL_ARTICLE">
<AU>Sampaio SA, Godoy JT, Paiva L, Dillon NL, da Lacaz CS</AU>
<TI>The treatment of American (mucocutaneous) leishmaniasis with amphotericin B</TI>
<SO>Archives of Dermatology</SO>
<YR>1960</YR>
<VL>82</VL>
<PG>627-35</PG>
<IDENTIFIERS MODIFIED="2016-10-10 14:03:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 14:03:12 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="13745957"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sampaio-1997" MODIFIED="2016-10-10 14:05:11 +0100" MODIFIED_BY="[Empty name]" NAME="Sampaio 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sampaio RN, Marsden PD</AU>
<TI>Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B</TI>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>2</NO>
<PG>125-8</PG>
<IDENTIFIERS MODIFIED="2016-10-10 14:05:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 14:05:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9148335"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Savioli-2006" MODIFIED="2016-10-10 14:05:53 +0100" MODIFIED_BY="[Empty name]" NAME="Savioli 2006" TYPE="JOURNAL_ARTICLE">
<AU>Savioli L, Engels D, Daumerie D, Jannin J, Alvar J, Asiedu K, et al</AU>
<TI>Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization</TI>
<SO>PLoS medicine</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>6</NO>
<PG>e283</PG>
<IDENTIFIERS MODIFIED="2016-10-10 14:05:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 14:05:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16789805"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schallig-2002" MODIFIED="2016-10-10 14:07:31 +0100" MODIFIED_BY="[Empty name]" NAME="Schallig 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schallig HD, Oskam L</AU>
<TI>Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>8</NO>
<PG>641-51</PG>
<IDENTIFIERS MODIFIED="2016-10-10 14:07:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-10 14:07:18 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12167091"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schmidt_x002d_Ott-1999" MODIFIED="2016-10-11 08:47:57 +0100" MODIFIED_BY="[Empty name]" NAME="Schmidt-Ott 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt-Ott R, Klenner T, Overath P, Aebischer T</AU>
<TI>Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>1</NO>
<PG>85-90</PG>
<IDENTIFIERS MODIFIED="2016-10-11 08:47:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 08:47:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10492799"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schork-1967" MODIFIED="2017-11-15 11:44:25 +0000" MODIFIED_BY="[Empty name]" NAME="Schork 1967" TYPE="JOURNAL_ARTICLE">
<AU>Schork MA, Ramington RD</AU>
<TI>The determination of sample size in disease studies in which drop out or non-adherence is a problem</TI>
<SO>Journal of Chronic Diseases</SO>
<YR>1967</YR>
<VL>20</VL>
<NO>4</NO>
<PG>233-9</PG>
<IDENTIFIERS MODIFIED="2017-11-12 17:54:26 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-11-12 17:54:26 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6023231"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2017-10-09 09:46:22 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Altman DG, Moher D, for the CONSORT Group</AU>
<TI>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>152</VL>
<NO>11</NO>
<PG>726-32</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:46:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:46:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.7326/0003-4819-152-11-201006010-00232"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharifi-2010" MODIFIED="2017-04-19 10:20:00 +0100" MODIFIED_BY="[Empty name]" NAME="Sharifi 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sharifi I, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, et al</AU>
<TI>Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006</TI>
<SO>International Journal of Dermatology</SO>
<YR>2010</YR>
<VL>49</VL>
<NO>5</NO>
<PG>557-561</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:20:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:20:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20534092"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharquie-1988" MODIFIED="2017-11-15 11:45:36 +0000" MODIFIED_BY="[Empty name]" NAME="Sharquie 1988" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE, Al-Talib K, Chu AC</AU>
<TI>Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony</TI>
<SO>British Journal of Dermatology</SO>
<YR>1988</YR>
<VL>119</VL>
<NO>1</NO>
<PG>53-7</PG>
<IDENTIFIERS MODIFIED="2017-11-12 22:21:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-11-12 22:21:38 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2841964"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharquie-1995" MODIFIED="2016-10-11 08:49:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sharquie 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE</AU>
<TI>A new intralesional therapy for cutaneousd leishmaniasis with hypertonic sodium chloride solution</TI>
<SO>Journal of Dermatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>10</NO>
<PG>732-7</PG>
<IDENTIFIERS MODIFIED="2016-10-11 08:49:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 08:49:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8586751"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharquie-1996" MODIFIED="2016-10-11 08:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sharquie 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE, Al-Azzawi KE</AU>
<TI>Intralesional therapy for cutaneous leishmaniasis with 2% zinc sulfate solution</TI>
<SO>Journal of Pan-Arab League of Dermatologists</SO>
<YR>1996</YR>
<VL>7</VL>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharquie-1998" MODIFIED="2017-10-09 09:50:33 +0100" MODIFIED_BY="[Empty name]" NAME="Sharquie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE, Al-Hamamy H, El-Yassin D</AU>
<TI>Treatment of cutaneous leishmaniasis by direct current electrotherapy: the Baghdadin device</TI>
<SO>Journal of Dermatology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>4</NO>
<PG>234-7</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:50:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:50:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9609980"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simonsen-1999" MODIFIED="2016-10-11 09:02:37 +0100" MODIFIED_BY="[Empty name]" NAME="Simonsen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M</AU>
<TI>Unsafe injections in the developing world and transmission of bloodborne pathogens: a review</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1999</YR>
<VL>77</VL>
<NO>10</NO>
<PG>789-800</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:02:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:02:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10593026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sindermann-2006" MODIFIED="2016-10-11 09:03:38 +0100" MODIFIED_BY="[Empty name]" NAME="Sindermann 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sindermann H, Engel J</AU>
<TI>Development of miltefosine as an oral treatment for leishmaniasis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>Suppl 1</NO>
<PG>S17-20</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:03:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:03:38 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16730362"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Solomon-2011" MODIFIED="2017-04-19 10:26:24 +0100" MODIFIED_BY="[Empty name]" NAME="Solomon 2011" TYPE="JOURNAL_ARTICLE">
<AU>Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E</AU>
<TI>Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>8</NO>
<PG>973-7</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:26:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:26:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21129042"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Soto-2004" MODIFIED="2016-10-11 09:04:55 +0100" MODIFIED_BY="[Empty name]" NAME="Soto 2004" TYPE="JOURNAL_ARTICLE">
<AU>Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al</AU>
<TI>Miltefosine for new world cutaneous leishmaniasis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>9</NO>
<PG>1266-72</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:04:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:04:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15127339"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stojkovic-2007" MODIFIED="2016-10-11 09:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Stojkovic 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stojkovic M, Junghanss T, Krause E, Davidson RN</AU>
<TI>First case of typical Old World cutaneous leishmaniasis treated with miltefosine</TI>
<SO>International Journal of Dermatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>4</NO>
<PG>385-7</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:07:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:07:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17442078"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Storer-2005" MODIFIED="2016-10-11 09:09:06 +0100" MODIFIED_BY="[Empty name]" NAME="Storer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Storer E, Wayte J</AU>
<TI>Cutaneous leishmaniasis in Afghani refugees</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>2</NO>
<PG>80&#8211;3</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:09:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:09:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15842398"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stotland-2009" MODIFIED="2016-10-11 09:11:30 +0100" MODIFIED_BY="[Empty name]" NAME="Stotland 2009" TYPE="JOURNAL_ARTICLE">
<AU>Stotland M, Shalita AR, Kissling RF</AU>
<TI>Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris</TI>
<SO>American Journal of Clinical Dermatology</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>221-7</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:11:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:11:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19489655"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sundar-2007a" MODIFIED="2016-10-11 09:44:06 +0100" MODIFIED_BY="[Empty name]" NAME="Sundar 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, et al</AU>
<TI>Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions</TI>
<SO>Clinical infectious Diseases</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>5</NO>
<PG>556-61</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:12:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:12:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17682988"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sundar-2007b" MODIFIED="2016-10-11 09:44:10 +0100" MODIFIED_BY="[Empty name]" NAME="Sundar 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK</AU>
<TI>Injectable paromomycin for Visceral leishmaniasis in India</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<NO>25</NO>
<PG>2571-81</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:13:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:13:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17582067"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thakur-1996" MODIFIED="2016-10-11 09:15:48 +0100" MODIFIED_BY="[Empty name]" NAME="Thakur 1996" TYPE="JOURNAL_ARTICLE">
<AU>Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P</AU>
<TI>Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1996</YR>
<VL>90</VL>
<NO>3</NO>
<PG>319-22</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:15:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:15:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8758093"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Urcayo-1982" MODIFIED="2016-10-11 09:19:19 +0100" MODIFIED_BY="[Empty name]" NAME="Urcayo 1982" TYPE="JOURNAL_ARTICLE">
<AU>Urcayo FG, Zaias N</AU>
<TI>Oral ketoconazole in the treatment of cutaneous leishmaniasis</TI>
<SO>International Journal of Dermatology</SO>
<YR>1982</YR>
<VL>21</VL>
<NO>7</NO>
<PG>414-6</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:19:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:19:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6290403"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Uzun-2004" MODIFIED="2016-10-11 09:21:10 +0100" MODIFIED_BY="[Empty name]" NAME="Uzun 2004" TYPE="JOURNAL_ARTICLE">
<AU>Uzun S, Durdu M, Culha G, Allahverdiyev AM, Memisoglu HR</AU>
<TI>Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey</TI>
<SO>Journal of Parasitology</SO>
<YR>2004</YR>
<VL>90</VL>
<NO>4</NO>
<PG>853-9</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:21:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:21:10 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15357081"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Griensven-2014" MODIFIED="2017-10-09 09:52:55 +0100" MODIFIED_BY="[Empty name]" NAME="van Griensven 2014" TYPE="JOURNAL_ARTICLE">
<AU>van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J</AU>
<TI>Leishmaniasis in immunosuppressed individuals</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>4</NO>
<PG>286-299</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:52:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:52:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24450618"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Zuuren-2015" MODIFIED="2017-10-09 09:57:52 +0100" MODIFIED_BY="[Empty name]" NAME="van Zuuren 2015" TYPE="COCHRANE_REVIEW">
<AU>van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L</AU>
<TI>Interventions for rosacea</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>4</NO>
<PG>CD003262</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:57:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:57:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003262.pub5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vaneau-2007" MODIFIED="2017-10-09 09:55:39 +0100" MODIFIED_BY="[Empty name]" NAME="Vaneau 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vaneau M, Chaby G, Guillot B, Martel P, Senet P, Téot L, et al</AU>
<TI>Consensus panel recommendations for chronic and acute wound dressings</TI>
<SO>Archives of Dermatology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>10</NO>
<PG>1291-4</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:55:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:55:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17938343"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vardy-2001" MODIFIED="2017-10-09 09:56:25 +0100" MODIFIED_BY="[Empty name]" NAME="Vardy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vardy D, Barenholz Y, Naftoliev N, Klaus S, Gilead L, Frankenburg S</AU>
<TI>Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>2</NO>
<PG>184-6</PG>
<IDENTIFIERS MODIFIED="2017-10-09 09:56:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-09 09:56:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11355557"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weigel-2001" MODIFIED="2016-10-11 09:24:08 +0100" MODIFIED_BY="[Empty name]" NAME="Weigel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weigel MM, Armijos RX</AU>
<TI>The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador</TI>
<SO>Revista Panamericana de Salud Publica [Pan American Journal of Public Health]</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>6</NO>
<PG>395-404</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:24:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:24:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11820108"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weinrauch-1983a" MODIFIED="2016-10-11 09:26:40 +0100" MODIFIED_BY="[Empty name]" NAME="Weinrauch 1983a" TYPE="JOURNAL_ARTICLE">
<AU>Weinrauch L, Livshin R, El-On J</AU>
<TI>Cutaneous leishmaniasis treatment with ketoconazole</TI>
<SO>Cutis</SO>
<YR>1983</YR>
<VL>32</VL>
<NO>3</NO>
<PG>288-90, 294</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:26:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:26:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6313298"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weinrauch-1983b" MODIFIED="2016-10-11 09:27:34 +0100" MODIFIED_BY="[Empty name]" NAME="Weinrauch 1983b" TYPE="JOURNAL_ARTICLE">
<AU>Weinrauch L, Livshin R, Even-Paz Z, El-On J</AU>
<TI>Efficacy of ketoconazole in cutaneous leishmaniasis</TI>
<SO>Archives of Dermatology</SO>
<YR>1983</YR>
<VL>275</VL>
<NO>5</NO>
<PG>353-4</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:27:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:27:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6318670"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2016-10-11 10:31:39 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="OTHER">
<AU>World Health Organization (WHO)</AU>
<TI>Leishmaniasis. World Health Report 2002</TI>
<SO>www.who.int/whr/2002/annex/en/</SO>
<YR>(accessed 2 April 2004)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2007" MODIFIED="2016-10-11 10:33:28 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2007" TYPE="OTHER">
<AU>World Health Organization (WHO)</AU>
<TI>Control of leishmaniasis. Report by the Secretariat 22 March 2007</TI>
<SO>apps.who.int/gb/archive/pdf_files/WHA60/A60_10-en.pdf</SO>
<YR>(accessed before 11 October 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2008" MODIFIED="2017-10-19 11:23:30 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2008" TYPE="OTHER">
<AU>World Health Organization (WHO)</AU>
<TI>Report of the Fifth Consultative Meeting on Leishmania/HIV Co-infection. Addis Ababa, Ethiopia, 20-22 March 2007</TI>
<SO>www.who.int/leishmaniasis/resources/Leishmaniasis_hiv_coinfection5.pdf</SO>
<YR>(accessed before 11 October 2016)</YR>
<IDENTIFIERS MODIFIED="2016-10-11 10:29:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 10:29:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="WHO/CDS/NTD/IDM/2007.5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2016-10-11 10:24:19 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010" TYPE="OTHER">
<AU>World Health Organization (WHO)</AU>
<TI>Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva 22-26 March 2010. WHO technical report series 949</TI>
<SO>apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf</SO>
<YR>(accessed before 11 October 2016)</YR>
<IDENTIFIERS MODIFIED="2016-10-11 10:21:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 10:21:26 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN 9789241209496 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2016-10-11 10:26:50 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization (WHO)</AU>
<TI>Application for Inclusion of Miltefosina on WHO Model List of Essential Medicines. Submitted to the EML Secretariat for consideration. November 2010</TI>
<SO>www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf</SO>
<YR>(accessed 11 October 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wortmann-2010" MODIFIED="2016-10-11 10:27:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wortmann 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al</AU>
<TI>Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>83</VL>
<NO>5</NO>
<PG>1028-33</PG>
<IDENTIFIERS MODIFIED="2016-10-11 09:42:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-11 09:42:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21036832"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zakraoui-1995" MODIFIED="2017-04-19 10:28:20 +0100" MODIFIED_BY="[Empty name]" NAME="Zakraoui 1995" TYPE="JOURNAL_ARTICLE">
<AU>Zakraoui H, Ben Salah A, Ftaiti A, Marrakchi H, Zaatour A, Zaafouri B, et al</AU>
<TI>Spontaneous course of lesions of Leishmania major cutaneous leishmaniasis in Tunisia</TI>
<SO>Annales de Dermatologie et Venereogie</SO>
<YR>1995</YR>
<VL>122</VL>
<NO>6-7</NO>
<PG>405-7</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:28:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:28:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8526421"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zanger-2011" MODIFIED="2017-04-19 10:30:40 +0100" MODIFIED_BY="[Empty name]" NAME="Zanger 2011" TYPE="JOURNAL_ARTICLE">
<AU>Zanger P, Kotter I, Raible A, Gelanew T, Schonian G, Kremsner PG</AU>
<TI>Case report: Successful treatment of cutaneous leishmaniasis caused by Leishmania aethiopica with liposomal amphothericin B in an immunocompromised traveler returning from Eritrea</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2011</YR>
<VL>84</VL>
<NO>5</NO>
<PG>692-4</PG>
<IDENTIFIERS MODIFIED="2017-04-19 10:30:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 10:30:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21540377"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zeglin-2009" MODIFIED="2017-11-15 11:49:22 +0000" MODIFIED_BY="[Empty name]" NAME="Zeglin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Zeglin O</AU>
<TI>Infectiology and Tropical Dermatology Part 17: cutaneous leishmaniasis - a casuistry with after assessment</TI>
<TO>Infektiologie und Tropendermatologie - Teil 17: kutaneleishmaniasis - eine kasuistik mit nachbegutachtung</TO>
<SO>Dermatology</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>246ff</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-04-19 11:59:23 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gonzalez-2008" MODIFIED="2017-04-19 11:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzalez 2008" TYPE="COCHRANE_REVIEW">
<AU>González U, Pinart M, Reveiz L, Alvar J</AU>
<TI>Interventions for Old World cutaneous leishmaniasis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-04-19 11:59:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-19 11:59:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005067.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-11-14 15:46:54 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-14 15:46:54 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-11-14 12:42:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adam-2009">
<CHAR_METHODS MODIFIED="2017-11-08 15:28:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Omdurman Hospital for Tropical Diseases, Sudan</P>
<P>
<I>Study period</I>: August 2007 to March 2008 (7 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 12:42:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: people with cutaneous leishmaniasis, confirmed microscopically by finding amastigotes in slit skin smears, if they had not received any previous treatment (Antimonial)</P>
<P>
<I>Exclusion criteria</I>: pregnant women, people weighing &lt; 10 kg, malnourished people and those with a history of allergy to sulphonamides or artemisinins</P>
<P>
<I>N randomised</I>: 41 (group 1: n = 20, group 2: n = 21)</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 41 (100%) (group 1: n = 20, group 2: n = 21)</P>
<P>
<I>Mean age (SD)</I>: group 1: 30.6 years (18.0), group 2: 28.5 years (15.3)</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>N lesions (mean, SD): group 1: 2.1 (1.4); group 2: 2.2 (1.3)</LI>
<LI>Size of lesion (median, IQR): group 1: 3.4 cm (1.5); group 2: 3.2 cm (1.3)</LI>
<LI>Creatinine (mean, SD): group 1: 0.9 mg/dL (0.3), group 2: 0.9 mg/dL (0.2 )</LI>
<LI>Alanine aminotransferase (mean, SD): group 1: 36.7 IU (9.5), group 2: 37.3 IU (4.5)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 12:53:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: AS + SMP (100 mg artesunate + 250 mg/12.5 mg sulphamethoxypyrazine/pyrimethamine) (Co-Arinate®; Dafra Pharma NV, Turnhout, Belgium). 4 tablets on 4 consecutive days were administered and repeated 4 times with 2-week intervals without treatment</LI>
<LI>
<I>Group 2</I>: matched placebo</LI>
</UL>
<P>
<I>Duration of intervention</I>: 8 weeks</P>
<P>
<I>Co-interventions</I>: pentosan was administered to participants who failed treatment with the study drug as well as to participants who had received placebo tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-14 12:42:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: disappearance and/or shrinkage of the lesions. Lesions were identified, measured and numbered by their specific location on the participant's body before treatment and after 36 days and 72 days. Reported at the end of treatment.</P>
<P>
<I>Adverse effects</I>: participants were questioned about expected adverse effects for 3 days (days 5&#8211;7) following administration of the doses. These were considered drug-related if they were not reported at presentation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 10:19:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: Dafra Pharma NV/SA, Turnhout, Belgium</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 12:42:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al-Hamdi-2010">
<CHAR_METHODS MODIFIED="2017-11-03 10:20:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective clinical trial</P>
<P>
<I>Setting/location</I>: outpatient clinic of Basra teaching hospital, south Iraq</P>
<P>
<I>Study period</I>: April 2004 to March 2005 (11 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 12:01:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania major </I>and <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: all patients with cutaneous leishmaniasis who were diagnosed clinically by the same dermatologist</P>
<P>
<I>Exclusion criteria</I>: &#8805; 20 lesions; pregnancy, lactation; hypersensitivity to pentavalent antimonials or local anaesthetic; serious medical illness, lesion in proximity to mucous membranes, face, or cartilage; implanted metallic devices; unwillingness to avoid procreation for at least 2 months</P>
<P>
<I>N randomised</I>: 38 participants, 70 lesions: group 1 = 35, group 2 = 35</P>
<P>
<I>Withdrawals</I>: group 1: 14 lesions; group 2: 8 lesions</P>
<P>
<I>N assessed</I>: lesions assessed: group 1: 21 (60%); group 2: 27 (77%)</P>
<P>
<I>Age range</I>: 1.5 to 64 years (1.5&#8211;45 years in group 1 and 3&#8211;64 years in group 2) with a mean of 21.1 years</P>
<P>
<I>Sex</I>: 52.5% males, 47.5% females</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>N lesions treated at start of study: group 1, 35; group 2, 35</LI>
<LI>N lesions per participant: group 1 - 1:7, 2:5, 3:1, &gt; 3:7; group 2 - 1:7, 2:8, 3:2, &gt; 3:5</LI>
<LI>N lesions by site - face and neck: group 1: 8, group 2: 3; upper limbs: group 1: 19, group : 10; lower limbs: group 1: 7, group 2: 18; trunk group 1: 1, group 2: 4</LI>
<LI>Mean lesion size before study: group 1, 1.74 cm, group 2, 1.70 cm</LI>
<LI>Range of lesion duration before study: group 1: 1 month&#8211;1 year; group 2: 1 month&#8211;5 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 12:42:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: hypertonic sodium chloride solution (HSCS) (7%) (7 g dissolved in 100 mL distilled water and autoclaved)</LI>
<LI>
<I>Group 2</I>: ciprofloxacin solution (2 mg/mL)</LI>
</UL>
<P>Both drugs were injected into the lesions in amounts of 0.1&#8211;0.5 mL according to the size of the lesion</P>
<P>
<I>Duration of intervention</I>: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: resolution of active lesion with or without scarring. A scoring system was specially designed as follows. The diameter of lesions was recorded in mm using a ruler and scored as: 0 (total healing); 1 (0 cm to &lt; 0.5 cm); 2 (0.5 cm to &lt; 1 cm); 3 (1 cm to &lt; 1.5 cm); 4 (1.5 cm to &lt; 2 cm); 5 (2 cm to &lt; 2.5 cm); or 6 (&#8805; 2.5 cm). The degree of induration was assessed by palpation in comparison with the participant's normal skin and given the following scores: 0, 0.5, 1, 1.5, 2, or 3. The degree of erythema was assessed visually and scored as: 0, 0.5, 1, 1.5, 2, or 3. Ulceration was scored as: 1 (present) or 0 (absent). The scores of these 4 parameters were added to give a total score for each lesion.</P>
<P>Time points reported: the changes in total score between weeks: lesions were assessed at the start and again at 2-week intervals after treatment for 8 weeks: 0, 2, 4, 6, and 8 weeks of treatment. Follow-up continued for 8 weeks until complete healing took place</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-06 12:47:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Kuwait</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-03 11:18:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I> or <I>L major</I> in the area</P>
<P>
<I>Inclusion criteria</I>: positive for leishmanial parasites (amastigotes) on microscopic examination. Women of childbearing age were instructed to use potent and adequate contraceptive measures before the initiation of treatment.</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: 24. Oral itraconazole: 15; placebo: 9</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: N = 24. Oral itraconazole: 15; placebo: 9</P>
<P>
<I>Age range</I>: 12-52 years</P>
<P>
<I>Sex</I>: male/female: 13/11</P>
<P>
<I>Baseline data</I>: single or multiple lesions, active being nodule, nodule-ulcerative, or ulcerative. The site of lesions including both groups was 75% on upper limbs; 46% on lower limbs; 25% on the face, and 4% on the trunk. The duration of the lesion varied between 1 and 14 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-03 11:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: oral itraconazole 200 mg twice daily. There was a 12-year-old boy who was given a dose of 100 mg once daily (3 mg/kg per day)</LI>
<LI>
<I>Group 2</I>: placebo capsules twice daily during meals.</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6-8 weeks</P>
<P>
<I>Duration of follow-up</I>: 12 weeks post-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' 2 months after treatment. The response to treatment was graded as excellent (reduction in size of lesion by 80% up to complete clearance); good (reduction in size of lesion by 50%) and poor when there is minimal or no change of lesion.</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur within 6 months and 1, 2, and 3 years (for a period up to 3 months after suspension of the drug)</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 8 weeks and 12 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:53:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alkhawajah-1997">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Al-Ahssa, Saudi Arabia</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-03 12:51:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I> in the area</P>
<P>
<I>Inclusion criteria</I>: only a few (1-3) simple lesions, on a non-facial site; clinically confirmed CL by direct slit smears and/or in skin-punch biopsies of the active, infiltrated edge of a representative lesion.</P>
<P>
<I>Exclusion criteria</I>: multiple or disseminated lesions, lesions aged &gt; 6 months, pregnancy, chronic illness, immunologically compromised condition, hyperallergic reaction to the trial drugs, treatment with regular medications which may affect specific therapy, treatment with antileishmanial drugs within the previous 6 months, the presence of scars of previously healed lesions</P>
<P>
<I>N</I> <I>participants (lesions) randomised</I>: 80. IMMA group: 40 (77); ILMA group: 40 (70)</P>
<P>
<I>Withdrawals</I>: 13 (13). IMMA group: 9 (9); ILMA group: 4 (4)</P>
<P>
<I>N assessed</I>: 67. IMMA group: 31 (68); ILMA group: 36 (66)</P>
<P>
<I>Mean age (range)</I>: range 13-42 years. IMMA group: 29.8 years (15-41); ILMA group: 31.5 years (13-42)</P>
<P>
<I>Sex</I>: male: 48, female: 19</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Lesion type in the IMMA group were: nodular 20%; nodular-ulcerative 24%; flat-ulcerative 19%; and plaque-like 5%</LI>
<LI>Lesion type in the ILMA group were: nodular 24%; nodular-ulcerative 18%; flat-ulcerative 15%; and plaque-like 9%</LI>
<LI>Lesion site (% of lesions) in the IMMA group: shoulder 7; upper arm 11; lower arm 14; elbow 1; hand 10; thigh 5; knee 4; leg 12; and foot 4</LI>
<LI>Lesion site (% of lesions) in the ILMA group: shoulder 5; upper arm 9; lower arm 11; elbow 2; hand 8; thigh 7; knee 3; leg 12; and foot 9</LI>
<LI>IMMA group: median size of lesion (MSL) 1.8 cm²; median duration of lesions before therapy (MDLBT): 72.7 days</LI>
<LI>ILMA group: MSL: 1.2 cm². MDLBT: 67.9 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:53:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: IMMA 15 mg/kg/d daily on 6 days/week up to 12 injections</LI>
<LI>
<I>Group 2</I>: ILMA 0.2 to 0.8 mL/lesion every other day over a 30 day period or until lesion had blanched</LI>
</UL>
<P>
<I>Duration of intervention</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 15 days</LI>
<LI>
<I>Group 2</I>: 30 days</LI>
</UL>
<P>
<I>Duration of follow-up</I>: 1 month post-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of lesions 'cured' at the end of treatment</P>
<P>
<I>Secondary outcomes</I>: prevention of scarring </P>
<P>
<I>Adverse effects </I>
</P>
<P>Time points reported: days 15, 30</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none described</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:53:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alrajhi-2002">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Al-Ahsaa and Ryyadh, Saudi Arabia</P>
<P>
<I>Study period</I>: 15 months</P>
<P>
<I>Sample size calculation</I>: to detect a difference of 22% in the rate of healing between the placebo group and the treatment group, assuming a healing rate of 45% in the placebo group, with a power of 90% and a two-sided type I error of 5%, 101 subjects were needed in each group. To compensate for loss to follow-up, 25% more participants were to be enrolled in each group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 10:36:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>:<I> L major</I> 56 participants (27%)</P>
<P>
<I>Inclusion criteria</I>: age &gt; 12 years, presence of lesions parasitologically confirmed leishmaniasis, non-use of antileishmanial therapy during previous 2 months</P>
<P>
<I>Exclusion criteria</I>: pregnancy, potential for pregnancy, breastfeeding; presence of lesions on the face or ears; presence of more than 10 lesions; history of liver disease; elevated serum, creatinine concentration, abnormal results on liver-function tests; allergy to fluconazole</P>
<P>
<I>N randomised</I>: 209. 106 were assigned to the fluconazole group, and 103 were assigned to the placebo group</P>
<P>
<I>Withdrawals</I>: 63 received the container of capsules at the first visit and never returned for follow-up: 37 participants assigned to receive placebo and 26 participants of fluconazole group</P>
<P>One participant in the placebo group, who was therefore excluded from the analyses.</P>
<P>
<I>N assessed</I>: 145. Fluconazole group: 80, placebo group: 65</P>
<P>
<I>Age and sex</I>: not described</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Intervention group: MNL: 3.1, MSL: 17 mm, MDLBT: 9.2 weeks</LI>
<LI>Control group: MNL: 3.7, MSL: 19 mm, MDLBT: 7.7 weeks</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:53:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: fluconazole orally 200 mg</LI>
<LI>
<I>Group 2</I>: placebo 200 mg</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
<P>
<I>Co-interventions</I>: SSG was offered during follow-up if oral therapy was considered to have failed (14 participants in the fluconazole group and 33 in the placebo group)</P>
<P>
<I>Duration of follow-up</I>: 1 year post-treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: </P>
<UL>
<LI>Percentage of participants 'cured' 3 months after treatment</LI>
<LI>Speed of healing (time taken to be 'cured')</LI>
</UL>
<P>
<I>Adverse effects </I>
</P>
<P>Time points reported: 6 weeks, 3 months of follow-up, 1 year post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 13:08:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Baseline imbalances</I>: because of the criteria for inclusion and the limited number of women at risk for <I>Leishmania</I> in the study areas, there was only one female participant. Most of the participants were foreign construction workers or farmers originally from countries where CL is not endemic. One of 5 participants was a local national.</P>
<P>
<I>Study funding sources</I>: supported in part by a grant (no. 146-1414) from Pfizer and the Ministry of Health of Saudi Arabia</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:18:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alsaleh-1995">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Kuwait</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> spp not specified</P>
<P>
<I>Inclusion criteria</I>: only the smear-positive cases included in the study</P>
<P>
<I>Exclusion criteria</I>: participants younger than 14 years and pregnant nursing women</P>
<P>
<I>N randomised</I>: 33. Group 1, ketoconazole 600 mg: 18; Group 2, ketoconazole 800 mg: 15</P>
<P>
<I>Withdrawals</I>: 7. Group 1: 3, Group 2: 4</P>
<P>
<I>N assessed</I>: 26. Group 1: 15, Group 2: 11</P>
<P>
<I>Age range</I>: 14-66 years</P>
<P>
<I>Sex (male/female)</I>: 26/7</P>
<P>
<I>Severity of illness</I>: 1-8 lesions. Site of the lesions in the ketoconazole 600 mg group: 46% on the upper extremities and 24/% on the lower extremities. In the ketoconazole 800 mg: 58% on the upper extremities; 21% on the lower extremities and 21% on head and neck</P>
<P>Ketoconazole 600 mg: MNL: 3.56 (range 2-8). MDLBT: 3.4 months (range 1.5-7)</P>
<P>Ketoconazole 800 mg: MNL: 3.27 (range 1-6). MDLBT: 4.5 months (range 1-12)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-03 13:12:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ketoconazole 600 mg daily</LI>
<LI>
<I>Group 2</I>: ketoconazole 800 mg daily</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks or until the participant was cured (whatever occurred early)</P>
<P>
<I>Duration of follow-up</I>: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' at the end of treatment ( If there was more than 90% improvement of these parameters: re-epithelisation and decrease in the size and inflammation of the lesions, with a negative smear for <I>Leishmania </I>parasites)</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur within 6 months</P>
<P>
<I>Adverse effects </I>
</P>
<P>Time points reported: 1, 2, 4, 6, 8 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:54:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aronson-2010">
<CHAR_METHODS MODIFIED="2017-11-03 13:15:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Walter Reed Army Medical Center (WRAMC) in Washington</P>
<P>
<I>Study period</I>: 24 months (2004-6)</P>
<P>
<I>Sample size calculation</I>: a sample size of 27 participants per treatment group was planned, assuming a 73% cure rate for ThermoMed (TM), 99% for SSG, controlling for a probability of a type I error at alpha = 0.05 and was predicted to have 80% power to determine a 26% difference in outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:19:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: eligible participants were Department of Defense healthcare beneficiaries with parasitologically confirmed cutaneous leishmaniasis. At Walter Reed Army Medical Center (WRAMC) in Washington. All participants were likely infected in Iraq or Kuwait. All were treatment naive.</P>
<P>
<I>Exclusion criteria</I>: 20 lesions; pregnancy, lactation; hypersensitivity to pentavalent antimonials or local anaesthetic; serious medical illness; lesion in proximity to mucous membranes, face, or cartilage; implanted metallic devices; unwillingness to avoid procreation for at least 2 months</P>
<P>
<I>N randomised</I>: 56, IVSSG: 28. Localised TM device heat treatment: 28</P>
<P>Participants with clinical failure at 2 months were offered cross-over treatment. Afer 2 months: SSG: 29 (&#8722;1, +3), TM: 25 (&#8722;3, +1).</P>
<P>
<I>Withdrawals</I>: 2. TM: 1 (lesion not amenable to heat), SSG: 1 (not confirmed <I>L major</I>)</P>
<P>
<I>N assessed</I>: 54 (96.43%) completed treatment: TM: 27 (96.43%), SSG: 27 (96.43%). 53 (94.64%) completed 12 months follow-up: TM: 27 (96.43%), SSG: 26 (92.86%)</P>
<P>
<I>Median age (range)</I>: TM: 25 years (20-53); SSG: 24 years (18-57)</P>
<P>
<I>Sex</I>: TM: males: 28 (100%), SSG: males: 27 (96%), females: 1 (4%)</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean number of lesions (range): TM: 2 (1-14), SSG: 3 (1-17)</LI>
<LI>Mean duration of lesions (range): TM: 126 days (45&#8211;231), SSG: 138 days (50&#8211;270)</LI>
<LI>Amastigotes present (%): TM: 22 (79), SSG: 18 (64)</LI>
<LI>Culture isoenzyme <I>L major</I>* (%): TM: 12/23 (52), SSG: 12/24 (50)</LI>
<LI>
<I>L major</I> spp PCR positive: TM: 28 (100), SSG: 27 (96)</LI>
<LI>Complicated leishmaniasis, presence of significant regional adenopathy or subcutaneous nodules (%): TM: 5 (18), SSG: 8 (29)</LI>
<LI>Location of the target lesion: TM: head and neck 11 (12%), arms 40 (43%), legs 27 (29%), back 11 (12%), chest 5 (5%). SSG: head and neck 6 (6%), arms 65 (67%), legs 14 (14%), back 3 (3%), chest 9 (9%)</LI>
<LI>MSL (range): TM: 155 mm² (9&#8211;1014), SSG: 110 mm² (9&#8211;1720)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:54:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: quote: "Localized ThermoMed (TM) device heat treatment: one treatment session using the ThermoMed Model 1.8 device (TM). Prior to thermotherapy, each lesion was cleansed, anaesthestized, moistened, and overlying eschar was removed. 2 trained physicians performed TM treatments. TheTM probe was placed on the skin, covering the lesion with 50uCTM treatments applied for 30 s in a grid fashion extending 4 mm into border skin. The lesion size determined the number of applications. Each lesion was then covered with a dressing (Coverlet, Beiersdorf-Jobst, Wilton CT) that was changed daily."</LI>
<LI>
<I>Group 2</I>: IVSSG 20 mg/kg/d for 10 doses (GlaxoSmithKline, UK)</LI>
</UL>
<P>
<I>Duration of intervention</I>: TM: 1 session. SSG: 10 days.</P>
<P>
<I>Co-interventions</I>: participants randomised to thermotherapy received oral antibiotics for secondary bacterial infections of the leishmaniasis lesion(s) prior to treatment. SSG arm participants were treated concurrently with antibiotics.</P>
<P>
<B>Follow-up</B>: 2, 6, and 12&#8211;24 months post-treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure of the lesions</I>: clinical cure was defined as complete epithelialisation or visually healed at 2 ± 1 month after completion of therapy and no reactivation in 12 months after the start of treatment. Clinical failure was less than complete epithelialisation or visually not healed at 2 ± 1 month after treatment completion. Relapse failure was defined as skin lesion persistence at the treatment site or elsewhere in the period up to 12 months after start of therapy, regardless of appearance at 2 ± 1 month after treatment completion</P>
<P>
<I>Laboratory cure of the lesions</I>: microbiological cure: they looked for an eradication of the infection</P>
<P>
<I>Time to healing</I>: survival analysis of time to healing for the 2 treatment arms</P>
<P>
<I>Adverse effects</I>: toxicity profile</P>
<P>Time points reported: 2, 6, 12 months. Toxicity profile: daily physician evaluations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 13:25:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this trial was supported by Walter Reed Army Medical Center, The North Atlantic Regional Medical Command, and the US Army Medical and Materiel Development Agency.</P>
<P>
<I>Possible conflicts of interest</I>: the authors have declared that no competing interests exist</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:54:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asilian-1995">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: 8 primary health centres around Borkhar, north of Isfahan, Iran</P>
<P>
<I>Study period</I>: 14 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 10:37:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: infections here were thought to be caused entirely by <I>L major</I> parasites, although there is probably some <I>L tropica</I> infection within the city of Isfahan</P>
<P>
<I>Inclusion criteria</I>: 2 years or older, single lesion that was parasitologically positive, &lt; 5 cm in diameter, at least 3 cm from the eyes, lesion present &lt; 4 months</P>
<P>
<I>Exclusion criteria</I>: pregnant or nursing mothers, previously treated for leishmaniasis, intercurrent illness or a history of allergy to aminoglycoside</P>
<P>
<I>N randomised</I>: 251, aminosidine group: 126 (134 lesions); placebo group: 125 (134 lesions)</P>
<P>
<I>Withdrawals</I>: not described</P>
<P>
<I>N assessed</I>: aminosidine group: 123 lesions; placebo group: 123 lesions</P>
<P>
<I>Age (years)</I>: aminosidine group: &lt; 15 years: 114, &gt;15 years: 12; placebo group: &lt; 15 years: 105, &gt; 15 years: 20</P>
<P>
<I>Sex</I> (male/female): aminosidine group: 64/62; placebo group: 67/58</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>12 to 17 participants had papular lesions; 12 to 16 nodular; 76 to 79 nodule-ulcerative; 11 to 12 flat-ulcerative, and 13 to 20 plaque-like lesions.</LI>
<LI>
<I>Site of lesion</I>: aminosidine group: limb: 82, head: 35, trunk: 9; placebo group: limb: 90, head: 28, trunk: 7</LI>
<LI>PR (15% aminosidine and 10% urea): MNL: 1, MDLBT: 1.5 weeks</LI>
<LI>Vehicle: MNL: 1, MDLBT: &lt; 4 weeks</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:54:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: paromomycin (PR) (15% aminosidine and 10% urea) in petroleum ointment twice a day</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: vehicle</LI>
</UL>
<P>
<I>Duration of intervention</I>: 14 days<BR/>
</P>
<P>
<I>Co-interventions</I>: additional treatment, usually parenteral antimony, was given if lesions were judged to have worsened (25 participants in the PR-treated group and 28 in the placebo group)</P>
<P>
<I>Duration of follow-up</I>: 105 days after starting treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' 2.5 months after treatment. Definite cure was defined as complete epithelialisation on days 45 or 105</P>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesion</P>
<P>Time points reported: 15, 45, 105 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 13:34:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this work was supported in part by he UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) and Isfahan University of Medical Sciences</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:17:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asilian-2003">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: 3 primary health centres around Borkhar district north of Isfahan, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: determined on the basis of a 2-week cure rate of 50% at day 45 and unexpected 4-week cure rate of 70%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-03 13:36:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: participants with a single parasitologically confirmed lesion, &lt; 5 cm in diameter</P>
<P>
<I>Exclusion criteria</I>: lesions duration &gt; 4 months and &lt; 2 years, pregnant or nursing mothers, treated previously, any intercurrent illness or history of allergy to aminoglycoside</P>
<P>
<I>N randomised</I>: 233. 117 were allocated to receive 4 weeks of active treatment and 116 to receive 2 weeks of active treatment</P>
<P>
<I>Withdrawals</I>: 17, 9 in 4 weeks of active treatment and 8 in 2 weeks of active treatment</P>
<P>
<I>N assessed</I>: 216, 108 in each group.</P>
<P>
<I>Mean age (SD)</I>: 4 weeks of active treatment: 9.2 years (8.9); 2 weeks of active treatment: 9.0 years (8.8)</P>
<P>
<I>Sex</I> <I>ratio (male/female)</I>: 4 weeks of active treatment: 47/53; 2 weeks of active treatment: 44/56</P>
<P>
<I>Baseline data</I>: ulcerated lesion (SD): 4 weeks of active treatment 85 (79); 2 weeks of active treatment 95 (88)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 15:12:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: PR (aminosidine) ointment for 4 weeks n = 117. Mean number of lesions: 1.</LI>
<LI>
<I>Group 2</I>: PR (aminosidine) ointment for 2 weeks followed by 2 weeks of paraffin = 116. Mean number of lesions: 1</LI>
</UL>
<P>
<I>Co-interventions</I>: if lesions were bad enough, they were treated with antimonate</P>
<P>
<I>Duration of follow-up</I>: 105 days after starting treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 08:17:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: 'Clinical cure' was defined as &gt; 50% re-epithelialisation of the original lesion, and 'clinical and parasitological cure' as either complete re-epithelialisation or clinical cure plus a parasitologically negative smear. The primary study endpoints were clinical cure and clinical and parasitological cure at day 29, when the 4 weeks of active treatment ended</P>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: days 29, 45, 105</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 08:11:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this investigation was supported by the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases</P>
<P>
<I>Possible conflicts of interest</I>: none declared </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:19:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asilian-2004a">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Diseases and Leishmania Research Center of Isfahan (Iran)</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:19:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> but spp not declared</P>
<P>
<I>Inclusion criteria</I>: confirmed diagnosis parasitologically and clinically, lesions with duration of &lt; 8 weeks</P>
<P>
<I>Exclusion criteria</I>: participants with a history of &gt; 8 weeks, those with allergy to antimonials, lactating or pregnant women</P>
<P>
<I>N randomised participants (lesions)</I>: 400 (539). Combined cryotherapy and ILMA: 100 (149), cryotherapy alone: 200 (230), ILMA alone: 100 (160)</P>
<P>
<I>Withdrawals</I>: 30 participants (46 lesions)</P>
<P>
<I>N assessed (lesions)</I>: 370 (493). Group 1: 93 (132); group 2: 185 (210); group 3: 92 (151)</P>
<P>
<I>Age</I>: range 2-65 years. Mean: group 1, 32 years; group 2, 27 years; group 3, 25 years</P>
<P>
<I>Sex (male/female)</I>: 186/184. Group 1, 46/47; group 2, 95/90; group 3, 45/47</P>
<P>
<I>Baseline data</I>: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 13:13:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: combined cryotherapy + ILMA: cryotherapy involved the application of liquid nitrogen via a cotton swab for 10-25 s until the lesion and 1&#8211;2 mm of surrounding normal tissue appeared frozen. Then, after thawing, ILMA was administered, enough to blanch the lesion and a 1 mm rim of surrounding normal skin (only participants in groups 1 and 3 received ILMA). Generally, 0.5-2 cm³ of the solution (Glucantime) was required for individual lesions, depending on their size.</LI>
<LI>
<I>Group 2</I>: cryotherapy alone</LI>
<LI>
<I>Group 3</I>: ILMA alone</LI>
</UL>
<P>Different modalities of treatment were not given to the same participant in different lesions (i.e. each participant received ILMA alone, cryotherapy alone, or combined cryotherapy and ILMA).</P>
<P>
<I>Duration of intervention</I>: fortnightly until complete cure or for up to 6 weeks</P>
<P>
<I>Duration of follow-up</I>: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:27:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' 2.5 months after treatment</P>
<P>
<I>Adverse effects</I>: mild adverse side effects, such as postinflammatory hypopigmentation and hyperpigmentation</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 13:08:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Baseline imbalances</I>: in number of participants and lesions among the groups</P>
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 12:43:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asilian-2004b">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin and Leishmaniasis Research Center of Isfahan (Iran)</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 12:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not reported</P>
<P>
<I>Inclusion criteria</I>: age 7-70 years, disease confirmed clinically and by laboratory methods, lesions present, surface area of lesions &#8804; 5 cm²</P>
<P>
<I>Exclusion criteria</I>: disease duration &gt; 4 months; pregnant or breastfeeding; chronic disease; immune suppression; and sporotrichoid forms</P>
<P>
<I>N participants randomised (lesions)</I>: 233 (433). 123 (183) were included in the CO&#8322; laser group and 110 (250) in the IMMA group</P>
<P>
<I>Withdrawals</I>: 59 (112). CO&#8322; laser group: 40 (72), IMMA group: 19 (40)</P>
<P>
<I>N assessed</I> <I>(lesions)</I>: 174 (321). CO&#8322; laser group: 83 (111), IMMA group: 91 (210)</P>
<P>
<I>Age</I>: range 12-60 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 55/68 included in the CO&#8322; laser group; 40/70 in the IMMA group (control group)</P>
<P>
<I>Baseline imbalances</I>: no</P>
<P>
<I>Severity Illness</I>: in 47% of cases, participants had one lesion and in 53% of cases they had 2-5 lesions. There were more lesions on the upper limbs (43%), and lesions were &lt; 5 cm². In the remaining, the lesion duration was 2-4 months.</P>
<P>Mean number of lesions: CO&#8322; laser group: 1.49; IMMA group: 2.27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 10:12:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: CO&#8322; laser (30 W, continuous) was applied to the lesion and an area 2-3 mm around it. This procedure was repeated until the ulcer bed turned brown. After completion of the procedure, the ulcer was covered with 2% erythromycin ointment.</LI>
<LI>
<I>Group 2</I>: IMMA 50 mg/kg/d for 15 days and after 15 days of rest, this treatment was repeated.</LI>
</UL>
<P>
<I>Co-interventions</I>: in the first group, lesions were locally anaesthetised by injection of 1%&#8211;2% lidocaine</P>
<P>
<I>Duration of follow-up</I>: 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 10:12:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: </P>
<UL>
<LI>Percentage of lesions 'cured' 1.5 months after treatment</LI>
<LI>Speed of healing (time taken to be 'cured')</LI>
<LI>Prevention of scarring</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: none described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:59:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asilian-2006">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Department of Dermatology, Isfahan University of Medical Sciences (Iran)</P>
<P>
<I>Study period</I>: September 2004 to May 2005 (8 months)</P>
<P>
<I>Sample size calculation</I>: after following a formula, sample size and number of lesions would be a maximum of 20 participants and 40 lesions, respectively, for each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:59:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: confirmation of typical CL by positive Giemsa-stained direct smear for Leishman-Donovan bodies</P>
<P>
<I>Exclusion criteria</I>: &gt; 2 lesions, lesions with &gt; 20 mm induration diameter, duration of the disease &gt; 2 months, previous use of any anti-leishmanial treatments, pregnant or nursing women, children &lt; 5 years of age, serious concomitant medical problems, history of seizure, photosensitivity</P>
<P>
<I>N participants randomised (lesions)</I>: 60 (99). Photodynamic therapy (PDT): 20 (31); topical paromomycin: 20 (35); vehicle: 20 (33)</P>
<P>
<I>Withdrawals</I> (n = 3): 1 participant with one lesion in topical paromomycin group and 2 participants with 3 lesions (one participant had 2 lesions and the other had one) in vehicle group did not complete the study because they used the ointment irregularly</P>
<P>
<I>N assessed</I> <I>(lesions)</I>: 57 (95). Photodynamic therapy (PDT): 20 (31); topical paromomycin: 19 (34); placebo: 18 (30)</P>
<P>
<I>Age</I>: range 5-59 years. Mean (SD): PDT 22.2 years (15); topical paromomycin: 24.2 years (17);</P>
<P>vehicle 22.3 years (15)</P>
<P>
<I>Sex</I> <I>(n, (%))</I>: PDT: female: 12 (60)/male: 8 (40); topical paromomycin: female: 8 (42.1)/male: 11 (57.9); vehicle: female: 11 (61.1)/male: 7 (38.9)</P>
<P>
<I>Severity of illness</I>: the most common sites of lesions (&lt; 10) were on the extremities.</P>
<P>
<I>Total number of lesions</I>: PDT 31; topical paromomycin 34; vehicle 30</P>
<P>MNL: PDT 1.55; topical paromomycin 1.75, vehicle 1.65</P>
<P>Mean duration of lesions (SD): PDT 38 days (11); topical paromomycin 35 days (11); vehicle 36 days (11.6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:14:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: PDT ( 10% 5-aminolevulinic acid (5-ALA) hydrochloride in a water-in-oil cream, applied topically). Lesions irradiated using visible red light at 100 J/cm² per treatment session, repeated weekly for 4 weeks</LI>
<LI>
<I>Group 2</I>: PR (15% PR sulphate + 12% MBCL) in a soft white paraffin-based ointment applied topically twice daily at 1 mm thickness over the total surface of the lesion(s) for 28 days.</LI>
<LI>
<I>Group 3</I>: vehicle applied twice daily at 1 mm thickness over the total surface of the lesion(s) for 28 days.</LI>
</UL>
<P>
<I>Duration of intervention</I>: 4 weeks</P>
<P>
<I>Duration of follow-up</I>: these groups were followed for 2 months after the end of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 10:24:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of lesions 'cured' 2 months after treatment; prevention of scarring</P>
<P>
<I>Scale</I>: 'complete improvement' was defined as loss of induration and other signs of inflammation, complete re-epithelialisation and return to normal skin texture as well as 'parasitological cure', i.e. a negative Giemsa-stained direct smear. 'Partial improvement' was considered as flattening, reduction in size and induration without complete re-epithelialisation. All lesions showing no decrease in size or induration were regarded as 'treatment failures'.</P>
<P>
<I>Adverse effects </I>
</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: days 7, 14, 21, 28, 90</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 12:00:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asilian-2014">
<CHAR_METHODS MODIFIED="2017-11-06 10:24:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, clinical trial</P>
<P>
<I>Setting/location</I>: Skin and Leishmaniasis Research Center of Isfahan, Barkhar Health Center and Department of Dermatology, Isfahan University of Medical Sciences (Iran)</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 12:00:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: fewer than 4 lesions of &lt; 1 month old and &lt; 3 cm, lesions not located on the face, &gt; 15 years of age, lesions located neither on muscles nor were sporotrichoid lesions; receiving no medication for leishmaniasis</P>
<P>
<I>Exclusion criteria</I>: history of susceptibility to MA or miltefosine; pregnant or breastfeeding; immunosuppressed; had taken systemic medication interfering with p-450 enzyme; or history of kidney, liver, and heart failure</P>
<P>
<I>N randomised</I>: 64. Topical miltefosine: 32, ILMA: 32</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 64 (100%). Topical miltefosine: 32, ILMA: 32</P>
<P>
<I>Mean age (SD)</I>: 23.12 years (13.30)</P>
<P>
<I>Sex</I>: topical miltefosine: 17 males (53%) and 15 females (47%). ILMA: 16 males (50%) and 16 females (50%)</P>
<P>
<I>Baseline data</I>: mean (SD) size of the lesions before treatment in the group treated with miltefosine and ILMA was 4.4 cm (3.1) and 2.3 cm (2.2), respectively.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:54:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: topical miltefosine (ointment 6%), once daily (28 days) in a way that the lesion was completely smeared with the ointment</LI>
<LI>
<I>Group 2</I>: ILMA, twice a week (up to 28 days)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 10:32:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: cure of cutaneous leishmaniasis was defined as follows:</P>
<UL>
<LI>Complete cure: the lesion was flat, no induration observed, epidermal crease observed.</LI>
<LI>Partial cure: reduction in size of the lesions, but no epidermal creases observed.</LI>
<LI>Uncured: clinically no reduction observed in the lesion size or even an increase in the lesion size observed. </LI>
</UL>
<P>
<I>Adverse effects</I>: participants were questioned about expected adverse effects for 3 days (days 5&#8211;7) following administration of the doses. These were considered drug-related if they were not reported at presentation.</P>
<P>Time points reported: at the end of treatment, 1 month after treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 12:00:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ben-Salah-1995">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Sidi- Bouzid. Tunisia</P>
<P>
<I>Study period</I>: 9 months</P>
<P>
<I>Sample size calculation</I>: the ideal sample size was estimated to be 120 based on a rate of success of treatment of 80%, 30%-45% self-healing in the vehicle group (type I error = 0.01and type II error = 0.10), and 10%-20% loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 12:00:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>major</I>
</P>
<P>
<I>Inclusion criteria</I>: aged 2-60 years, single lesion diagnosed by the presence of parasite in stained dermal smears, no previous anti-leishmanial treatment</P>
<P>
<I>Exclusion criteria</I>: known allergy, adverse reactions to aminoglycoside antibiotics, multiple lesions, an active lesion measuring &gt; 5 cm in diameter, if their ulcerated lesion had already persisted for more than 4 months, lesions &lt; 3 cm from the eye, who by the physician's judgment required systemic antimonial treatment: participants with serious concomitant diseases, under medication for other illnesses likely to interfere with this study; pregnant women or nursing mothers.</P>
<P>
<I>N randomised</I>: 132. Paromomycin group: 66; vehicle: 66</P>
<P>
<I>Withdrawals</I>: 17. Paromomycin group: 9; vehicle: 8</P>
<P>
<I>N assessed</I>: 115. Paromomycin group: 57; vehicle: 58</P>
<P>
<I>Mean age (SD)</I>: paromomycin group: 19.2 years ( 2.31); vehicle: 18.2 years (1.65)</P>
<P>
<I>Sex</I> <I>(ratio M</I>:<I>F)</I>: paromomycin group: 1.04; vehicle: 1.07</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Location of the lesions: paromomycin group: upper limbs: 47.4%, lower limbs: 38.6% trunk: 5.3%, face: 8.8%. Vehicle: upper limbs: 41.4%, lower limbs: 51.7%, trunk: 3.5%, face: 3.5%</LI>
<LI>Description of the lesions: paromomycin group: papular: 21.0%, nodular: 21.0%, nodo-ulcerative: 73.7%, flat and ulcerative: 5.2%. Vehicle: papular: 19.0%, nodular: 17.2% nodo-ulcerative: 74.1%, flat and ulcerative 7.0%</LI>
<LI>Days from appearance of lesion to onset of treatment (mean (SD)): paromomycin group: 39.7 (2.95). Vehicle: 33.5 (2.75)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 10:40:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 15% PR and 10% urea in soft white paraffin ointment</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: vehicle (10% urea in soft white paraffin)</LI>
</UL>
<P>
<I>Duration of intervention</I>: twice daily for 14 days</P>
<P>
<I>Duration of follow-up</I>: 105 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants with complete re-epithelisation of the lesion, 2.5 months after treatment initiation (105 days)</P>
<P>
<I>Parasitological cure</I>: percentage of lesions with negative smear and culture, 2.5 months after treatment initiation (105 days)</P>
<P>
<I>Adverse effects </I>
</P>
<P>Time points reported: days 15, 45, 105</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 12:06:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this investigation received funding from the United Nations Development Program/World Bank/World Health Organization Special Program for Research and TraininginTropical Diseases(grant ID:TDK910677)</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 12:00:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ben-Salah-2009">
<CHAR_METHODS MODIFIED="2017-11-08 15:28:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Sidi Bouzid,Tunisia, and Paris, France</P>
<P>
<I>Study period</I>: 22 months</P>
<P>
<I>Sample size calculation</I>: the protocol calculated a sample size of 50 participants per group with 80 percent power and a Type I error rate of 5 percent to detect a 30% difference in the proportion of participants achieving CCR, assuming a CCR proportion of 35% in the vehicle group and 65 percent in WR279, 396 participants, with a 5% expected rate of loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 12:00:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>, <I>L tropica</I>, <I>L infantum</I>
</P>
<P>
<I>Inclusion criteria</I>: aged 5-75 years, presence of parasitologically confirmed CL, lesions that were primarily ulcerative (i.e. not purely verrucous or nodular) and measured &#8805; 1 cm² and &#8804; 5 cm².</P>
<P>
<I>Exclusion criteria</I>: history of known or suspected hypersensitivity or idiosyncratic reactions to aminoglycoside; previous use of antileishmanial drugs (within 3 months) or nephrotoxic or ototoxic drugs; prior diagnosis of leishmaniasis; more than 5 lesions, or a lesion in the face that in the opinion of the attending dermatologist could potentially cause significant disfigurement; significant medical problems as determined by history or laboratory studies; breastfeeding and pregnancy</P>
<P>
<I>N randomised</I>: 92. WR279,396: 50; vehicle: 42</P>
<P>
<I>Withdrawals</I> (n = 2): WR279,396: 1; vehicle: 1</P>
<P>
<I>N assessed (%)</I>: 90 (95.7). WR279,396: 49 (94.2), vehicle: 41 (97.6)</P>
<P>
<I>Age &lt; 18 years - n (%)</I>: WR278,396: 47 (94), vehicle: 33 (79)</P>
<P>
<I>Sex</I>: male: 54, female: 38</P>
<P>
<I>Severity of illness</I>: <I>N lesions</I>: 1: 54, 2: 16, 3: 13, 4 or 5: 9</P>
<P>
<I>Total lesion area (median, IQR)</I>: WR279,396: 128 (85 to 223), vehicle: 154 (70 to 264)</P>
<P>
<I>Index lesion area (median, IQR)</I>: WR279,396: 92 (55 to 141), vehicle: 115 (50 to 172)</P>
<P>
<I>Leishmania spp - n (%)</I>: <I>L major</I>: WR279,396: 32 (64), vehicle: 24 (57). <I>L Infantum</I>: WR279,396: 1 (2), placebo: 0 (0). <I>L tropica</I>: WR279,396: 1 (2), vehicle: 0 (0). Unidentified: WR279,396: 16 (32), placebo: 18 (43)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:54:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: WR279,396 is an off-white to yellowish, thick cream containing 15% (w/w) paromomycin-sulphate (Farmitalia) and 0.5% (w/w) gentamicin-sulphate (Schering) as active components.</LI>
<LI>
<I>Group 2</I>: the vehicle consisted of a cream without the active components and trace amounts of colorings agents to match the appearance and maintain the blind<B>.</B>
</LI>
</UL>
<P>
<I>Duration of intervention</I>: 20 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 08:42:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: defined as complete re-epithelialisation (i.e. length 6 width of ulceration = 060) of the index lesion by day 50 or a 50% re-epithelialisation by day 50 followed by complete re-epithelialisation on or before day 100 with no relapse ever having occurred from day 50 through day 180. Relapse was defined as an increase in the area of ulceration relative to the previous measurement. Participants who did not complete the 180-day period of observation were considered to have failed to achieve complete clinical response (CCR) because relapse could not be fully assessed.</P>
<P>
<I>Complete clinical response at the index lesion according to baseline characteristics</I>: influence of baseline factors on effect of treatment.</P>
<P>
<I>Time to healing</I>: time course of complete re-epithelialisation measured at 20, 50, 100, 180 days since start of treatment.</P>
<P>
<I>Adverse effects</I>: immediate: observed within 30 min of application. Delayed: observed just prior to next application</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 10:52:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the Office of the Surgeon General (OTSG), Chief, Human Subjects Protection Division, U.S. Army MRMC, Fort Detrick, MD 21702-5012. IND50,098 HSRRB Protocol#1791. Co-sponsor: Institute Pasteur, Rue du Dr. Roux, Paris, France</P>
<P>
<I>Possible conflicts of interest</I>: MG has no financial competing interests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-10 12:08:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ben-Salah-2013">
<CHAR_METHODS MODIFIED="2017-11-06 11:05:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial </P>
<P>
<I>Setting/location</I>: Sidi Bouzid, Tunisia</P>
<P>
<I>Study period</I>: January 2008 to July 2011 (42 months)</P>
<P>
<I>Sample size calculation</I>: the sample size of 375 participants was based on estimated rates of final clinical cure of 94% in the paromomycin &#8211; gentamicin group and 71% in the vehicle-control group, as shown in a previous study. On the basis of these rates, a sample size of 125 participants in each of these 2 groups provided a statistical power of 99% to detect a significant difference in the rates of final clinical cure rates (94% vs 71%).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 11:12:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: aged 5-65 years; good health besides cutaneous leishmaniasis if female; absence of pregnancy and lactation; the presence of &#8804; 5 lesions, with an index lesion that was ulcerative; lesions measured 1-5 cm in diameter; lesions confirmed to contain <I>Leishmania</I> by means of culture or microscopical examination of lesion material</P>
<P>
<I>Exclusion criteria</I>: included clinically significant lymphadenopathy or mucosal involvement, against which a topical agent would not be expected to be effective</P>
<P>
<I>N randomised</I>: 383 (129 were assigned to paromomycin&#8211;gentamicin; 128 were assigned to paromomycin; 126 were assigned to vehicle control)</P>
<P>
<I>Withdrawals</I>: 8 participants (4, paromomycin&#8211;gentamicin; 3, paromomycin; 1, vehicle control)</P>
<P>
<I>N assessed</I>: 375 participants (125 in each of the 3 groups)</P>
<P>
<I>Mean age (SD)</I>: 24 years (16) (paromomycin&#8211;gentamicin, 23 years (16); paromomycin, 25 years (16); vehicle 23 years (15)</P>
<P>
<I>Sex</I>: male 193 (51%) (paromomycin&#8211;gentamicin, 56 (45%); paromomycin, 68 (54%); vehicle control, 69 (55%))</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Paromomycin&#8211;gentamicin: total N of lesion in group: 243. Mean (SD) area of all lesion ulcers per participants: 126 mm² (121)</LI>
<LI>Paromomycin: total N of lesion in group: 272. Mean (SD) area of all lesion ulcers per participants: 90 mm² (75)</LI>
<LI>Vehicle control: total N of lesion in group: 282. Mean (SD) area of all lesion ulcers per participants: 98 mm² (112)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-10 12:08:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: paromomycin-gentamicin topical cream were manufactured by Teva Pharmaceuticals in accordance with Good Manufacturing Practices</LI>
<LI>
<I>Group 2</I>: paromomycin alone topical cream were manufactured by Teva Pharmaceuticals in accordance with Good Manufacturing Practices</LI>
<LI>
<I>Group 3</I>: vehicle control manufactured by Teva Pharmaceuticals in accordance with Good Manufacturing Practices</LI>
</UL>
<P>
<I>Duration of intervention</I>: 20 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Final cure of index lesion</I>
</P>
<P>
<I>Total re-epithelialisation of ulcerated lesions at 42 days</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 168 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 11:13:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the study was sponsored by the Office of the Surgeon General, Department of the Army</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 12:44:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bumb-2013">
<CHAR_METHODS MODIFIED="2017-11-06 11:14:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, phase I, open-label, clinical trial</P>
<P>
<I>Setting/location</I>: Department of Dermatology at SP Medical College and PBM Hospital, Bikaner, India</P>
<P>
<I>Study period</I>: June 2009 to December 2010 (19 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 12:44:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: aged &#8805; 4 years, 4 or fewer lesions, a parasitologically confirmed diagnosis of CL by demonstration of organisms (<I>L tropica </I>bodies) in the lesion smear or biopsy</P>
<P>
<I>Exclusion criteria</I>: included lesion size &gt; 5 cm diameter, prior treatment failure with SSG, treatment for CL within 2 months of enrolment into the study, any chronic condition that might prevent the patient from completing the study therapy and subsequent follow-up</P>
<P>
<I>N randomised</I>: 100; radiofrequency-induced heat therapy (RFHT): 50; ILSSG: 50</P>
<P>
<I>Withdrawals</I>: not described</P>
<P>
<I>N assessed</I>: 100</P>
<P>
<I>Median (range) age</I>: RFHT: 20 years (4-70); ILSSG: 20.5 years (4-85)</P>
<P>
<I>Sex</I>: RFHT: male 27, female 23; ILSSG: male 20, female 30</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Number of lesions: median (range); RFHT: 1 (1-7); ILSSG: 1 (1-4)</LI>
<LI>Number of lesions per participant (%): 1 lesion: RFHT, 30 (60); ILSSG: 32 (64). 2 lesions: RFHT, 14 (28); ILSSG: 13 (26). &gt; 2 lesions: RFHT, 6 (12); ILSSG, 5 (10)</LI>
<LI>Median size of lesions (range): RFHT, 2 cm (0.5-5); ILSSG, 2 cm (0.5-14)</LI>
<LI>Median duration of illness (range): RFHT, 3 months (1-9); ILSSG, 3 months (1-18)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:55:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: the RFHT group received a single application of a controlled and localised delivery of radiofrequencies into lesions for 30&#8211;60 s depending on the thickness of the lesion. The application was performed under local anaesthesia (1% lidocaine) using a current field radiofrequency generator (ThermoMed 1.8)</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: ILSSG group, the participants were treated with an intralesional injection of SSG (50 mg/cm² of lesion), twice a week for 7 injections</LI>
</UL>
<P>
<I>Duration of intervention</I>: RFHT, 5 days; ILSSG, 4 weeks</P>
<P>
<I>Co-interventions</I>: all participants were prescribed oral nonsteroidal anti-inflammatory drugs and topical antibacterial cream (fusidic acid cream) for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 11:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure rate</I>, assessed as follows:</P>
<UL>
<LI>Complete cure: the total re-epithelialisation of the lesions</LI>
<LI>Partial cure: decreased induration and erythema</LI>
</UL>
<P>Time points reported: 6, 8, 10, 12, 16, and 20 weeks after the initiation of treatment, and at 5, 6, 9, 12 and 18 months post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 11:23:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:55:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daie-Parizi-2015">
<CHAR_METHODS MODIFIED="2017-11-06 11:25:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised single blind parallel clinical trial</P>
<P>
<I>Setting/location</I>: Leishmaniasis Center in Dadbin Health Care Clinic in Kerman, Iran</P>
<P>
<I>Study period</I>: 15 months. Participants recruitment: 8 months (December 2012 to August 2013)</P>
<P>
<I>Sample size calculation</I>: based on the data from previous study, and by considering the confidence interval of 95%, sample size was determined as 23 lesions per group. Regarding to a possible loss in follow-up period, finally 32 lesions were allocated in each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 13:13:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L amastigote</I> (Leishman-Donovan bodies)</P>
<P>
<I>Inclusion criteria</I>: positive direct smear or documented skin biopsy for <I>L amastigote</I> (Leishman-Donovan bodies), &gt; 2 years of age, no previous therapy for leishmaniasis, ulcerated lesions for those lesions that were included in Thio-Ben + cryotherapy (TC) group</P>
<P>
<I>Exclusion criteria</I>: pregnancy, lesions on the eyelids and lips, having more than 5 lesions, positive history of confirmed immunodeficiency disorders or immunosuppression, disease duration for more than a year, positive history of allergy or hypersensitivity to thioxolone, benzoxonium chloride, or pentavalent antimony compounds.</P>
<P>
<I>N randomised</I>: 64 lesions of 47 participants, Thio-Ben + cryotherapy (TC) group (32 lesions, 22 participants), ILMA (32 lesions, 25 participants)</P>
<P>
<I>Withdrawals</I>: 16 lesions of 9 participants (10 lesions from TC and 6 from ILMA group) were removed from the study arms because of their poor adherence to the trial protocol and lost to follow-up. Additionally, one participant (with one lesion) was excluded because of developing a hypersensitive reaction to MA in the course of the treatment.</P>
<P>
<I>Lesions assessed</I>: 48 lesions in 47 participants. TC: 22, ILMA: 25</P>
<P>
<I>Mean age (SD)</I>: TC 23.5 years (16.4), ILMA 25.4 years (19.4)</P>
<P>
<I>Sex</I> <I>(n (%))</I>: TC: male 6 (27.2%), female: 16 (72.7%); ILMA: male 19 (76%), female: 6 (24%)</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Location of lesion: TC: face 5 (22.7%), elbow 1 (4.5%), hand 13 (59.1%), foot 1 (4.5%), ear 1 (4.5%), arm 1 (4.5%), neck 0. ILMA: face 6 (24%), elbow 3 (12%), hand 10 (40%), foot 2 (8%), ear 1 (4%), arm 2 (8%), neck 1 (4%)</LI>
<LI>Mean (SD) duration of disease: TC, 4.1 months (2.9); ILMA, 3.1 months (2.4)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:55:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 1&#8211;2 mL of tincture of Thio-Ben (depending on the size of the lesion) topically by a cotton swab that was held with a mild pressure on the lesion for about 3&#8211;4 min, every other day</LI>
<LI>
<I>Group 2</I>: ILMA containing 8.1% Sb5+ (81 mg/mL), once a week with the dose of 0.5&#8211;2 mL per lesion</LI>
</UL>
<P>
<I>Co-intervention</I>: in addition, at the beginning, and then every 2 weeks, cryotherapy with liquid nitrogen (&#8722;195°C) was performed for all lesions in both groups</P>
<P>
<I>Duration of intervention</I>: 3 months or until the lesion was cured, whichever came first</P>
<P>
<I>Duration of follow-up</I>: 6 months after the termination of the treatment to evaluate the incidence of relapse (reported at 1 month, 2 months, 5 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 08:17:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure of the lesions</I>:</P>
<UL>
<LI>Complete cure: complete subsidence of induration and re-epithelialisation of the lesion</LI>
<LI>Partial cure: reduction of the size of lesion by 50% and more</LI>
<LI>Improvement: reduction of the size of lesion by less than 50%</LI>
<LI>No response: no significant reduction of the size of lesion</LI>
<LI>Deterioration: any increase in the size of the lesion</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Relapse</I>: participants that developed with relapse of the lesions at the previously involved area</P>
<P>Time points reported: clinical cure was reported when it occurs or for a maximum of 3 months.</P>
<P>
<I>Adverse effects</I> were assessed at follow-up during therapy; they were the safety endpoints of the treatments, and 6 months after the termination of the treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 11:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this study was supported and funded by the Vice Chancellor for Research, Kerman University of Medical Sciences. The founder had no financial or proprietary interest in any material or method used in this study and had no role in study design, data collection and analysis, or preparation of the manuscript.</P>
<P>
<I>Possible conflicts of interest</I>: no conflict of interest</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-06 12:47:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dandashli-2005">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Aleppo, Syria </P>
<P>
<I>Study period</I>: June 2009 to December 2010 (19 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 11:35:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: not described</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: 79</P>
<P>
<I>Withdrawals</I>: 14</P>
<P>
<I>N assessed</I>: 65. 46 participants (264 lesions) in the fluconazole group and 19 participants (102 lesions) in the placebo group</P>
<P>
<I>Age (years)</I>: not described</P>
<P>
<I>Sex</I>: not described</P>
<P>
<I>Baseline data</I>: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 11:35:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: fluconazole orally 200 mg/d for 6 weeks</LI>
<LI>
<I>Group 2</I>: placebo orally for 6 weeks</LI>
</UL>
<P>
<I>Duration of follow-up</I>: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:37:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of lesions 'cured' (follow-up not reported)</P>
<P>
<I>Adverse effects </I>
</P>
<P>Time points reported: not described<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
<P>This is an abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:55:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dastgheib-2012">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: prospective randomised controlled trial</P>
<P>
<I>Setting/location</I>: dermatology clinic in Saadi Hospital, an academic center in Fars Province, Iran</P>
<P>
<I>Study period</I>: December 2008 to March 2010 (15 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 13:13:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: participants that presented with skin lesions suspicious of CL, not receiving any previous treatment, positive for leishmaniasis with direct smears</P>
<P>
<I>Exclusion criteria</I>: pregnant and nursing women; children &lt; 12 years old; lesions on the face; disease for more than 3 months; more than 5 active lesions; participants with any serious systemic disease or previous history of sensitivity to MA, allopurinol, or azithromycin; any difficulty in laboratory results before initial treatment (CBC diff, LFT, BUN, Cr); those who refused to sign the written informed consent form</P>
<P>
<I>N randomised</I>: 86 participants </P>
<P>
<I>Withdrawals</I>: 14 participants (6 in azithromycin + allopurinol group and 8 IMMA group) one lost follow-up because of adverse effect</P>
<P>
<I>N assessed</I>: 71 participants (36 azithromycin + allopurinol group and 35 IMMA group)</P>
<P>
<I>Mean age (SD; range)</I>: 38.2 years (12.6); range 16-64. Azithromycin + allopurinol group: 39.7 years (12.6); IMMA: 36.8 years (12.8)</P>
<P>
<I>Sex</I>: 28 females and 53 males (azithromycin + allopurinol group: 13 females and 23 males; IMMA group: 15 females and 20 males</P>
<P>
<I>Baseline data</I>: most participants in azithromycin + allopurinol group had more than 3 lesions (72.3%) and in the IMMA group most participants also had more than 3 lesions (65.8%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:55:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: azithromycin capsules (Tehran Chemie Pharmaceutical Company, Tehran, Iran) at a daily dose of 10 mg/kg (maximum dose of 500 mg) + allopurinol tablets (Hakim Pharmaceutical Company, Tehran, Iran) at a daily dose of 10 mg/kg (maximum doses 800 mg)</LI>
<LI>
<I>Group 2</I>: IMMA (Aventis Laboratories, France) at a dose of 20 mg/kg of antimony</LI>
</UL>
<P>
<I>Duration of intervention</I>: group 1, 2 months; group 2, 20 days. </P>
<P>
<I>Co-interventions</I>: in case of any secondary bacterial infection, participants were with oral cephalexin for 10 days after which the antileishmanial was administered</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:39:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure rate</I>, assessed as follows:</P>
<UL>
<LI>Complete response: complete re-epithelialisation and relief of induration</LI>
<LI>Partial response: more than 50% re-epithelialisation and decrease of induration and size of lesion</LI>
<LI>No response: &lt; 50% decrease of induration and size of lesion or worsening of lesion was considered as no response</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 2 months after completing treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: funded by deputy of research, Shiraz University of Medical Sciences</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:59:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogra-1990">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: India</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:59:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>tropic</I>a in the area</P>
<P>
<I>Inclusion criteria</I>: participants with cutaneous <I>Leishmania</I> confirmed by the presence of <I>L</I> <I>tropic</I>a bodies in the slit skin smear stained with Leishman stain.</P>
<P>
<I>Exclusion criteria</I>: women of child-bearing age</P>
<P>
<I>N randomised</I>: 20</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 20 (100%). Intervention group: 15, control group: 5</P>
<P>
<I>Age</I>: range 14-56 years.</P>
<P>
<I>Baseline data</I>: single or multiple lesions, the duration of the lesions varied from 4 to 16 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 11:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: itraconazole orally 4 mg/kg per day for 6 weeks (max 200 mg). MNL: 2. MDLBT: 9 weeks</LI>
<LI>
<I>Group 2</I>: control group (no treatment)</LI>
</UL>
<P>
<I>Duration of follow-up</I>: 6 weeks, but 3 months for relapses assessment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:41:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' at the end of treatment. The essential criteria for declaring the participant was cured was complete disappearance of the induration or redness in the nodular form and complete healing in the ulcerative form, accompanied by smear positivity conversion</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur within 3 months</P>
<P>
<I>Adverse effects </I>
</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: clinical cure: 4 weeks, clinical and parasitological cure: 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 12:44:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogra-1991">
<CHAR_METHODS MODIFIED="2017-11-14 12:44:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: India</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: the number of subjects was determined by the standard method of <LINK REF="REF-Schork-1967" TYPE="REFERENCE">Schork 1967</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 11:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropic</I>a in the area</P>
<P>
<I>Inclusion criteria</I>: demonstration of <I>Leishmania</I> from skin lesion by the slit smear technique.</P>
<P>
<I>Exclusion criteria</I>: pregnant women and children &lt; 12 years old, suffering from any chronic illness, immunocompromised, allergic to sulphones, prior therapy for cutaneous <I>Leishmania</I> in any form, patients with scars of healed leishmanial lesions, lesions of &gt; 4 months duration</P>
<P>
<I>N randomised</I>: 120. 60 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 120 (100%), 60 in each group</P>
<P>
<I>Age</I>: range 15-56 years</P>
<P>
<I>Sex</I>: 52 males/68 females</P>
<P>
<I>Baseline data</I>: the duration of the lesions ranged from 3 weeks to 3 months. Lesions were situated mainly on the exposed parts of the body (face, arms and feet). 46 participants (24 in dapsone group and 22 in placebo group) had a single lesion while 74 participants had multiple lesions (maximum 13).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 11:54:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: dapsone tablets (100 mg)</LI>
<LI>
<I>Group 2</I>: placebo tablets</LI>
</UL>
<P>
<I>Duration of intervention</I>: every 12 h for 6 weeks</P>
<P>
<I>Duration of follow-up</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:42:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' at the end of treatment</P>
<P>
<I>Secondary outcome</I>: adverse effects</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: clinical response: days 15 and 45. Clinical and parasitological response: 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Informed consent obtained</I>: yes</P>
<P>
<I>Study funding sources</I>: &#8212;</P>
<P>
<I>Possible conflicts of interest</I>: &#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-06 12:47:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogra-1992">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: India</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 11:56:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I> in the area</P>
<P>
<I>Inclusion criteria</I>: participants with localised CL and only smear positive cases</P>
<P>
<I>Exclusion criteria</I>: not being smear positive</P>
<P>
<I>N randomised</I>: 60, 20 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 60 (100%), 20 in each group</P>
<P>
<I>Age (years)</I>: &#8805; 15 years</P>
<P>
<I>Sex</I>: not described</P>
<P>
<I>Severity of illness</I>: 8, 11, and 12 participants had multiple lesions in the itraconazole, dapsone and placebo groups respectively.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 11:57:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: itraconazole 4 mg/kg/d (max. 200 mg)</LI>
<LI>
<I>Group 2</I>: dapsone 4 mg/kg in 2 doses/d</LI>
<LI>
<I>Group 3</I>: placebo control group</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
<P>
<I>Duration of follow-up</I>: 6 weeks, but 3 months for assessment of relapses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:42:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' at the end of treatment. Strict clinical and parasitological criteria were followed to asses cure.</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: healing rates at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-06 12:47:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogra-1996">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: India</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 11:58:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>:<I> L</I> <I>major and</I> <I>tropica</I> in the area</P>
<P>
<I>Inclusion criteria</I>: participants with localised CL. Demonstration of parasites from skin lesions by slit smear examination </P>
<P>
<I>Exclusion criteria</I>: women of child-bearing age, children &lt; 18 years old, participants suffering from any chronic illness, immunocompromised, prior therapy for CLs in any form, scars of healed leishmanial lesions, lesions of 4 months or more duration, participants showing abnormality in liver function tests</P>
<P>
<I>N randomised</I>: 20</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 20 (100%)</P>
<P>
<I>Age</I>: range 19-62 years</P>
<P>
<I>Sex</I>: 15 males/5 females</P>
<P>
<I>Baseline data</I>: the duration of the lesions ranged from 2 weeks to 16 weeks, they were mainly seen on exposed parts of the body. 9 had a single lesion and 11 participants had a multiple lesion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 11:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: itraconazole orally (2 100 mg capsules) for 6 weeks n = 10. 4/10 participants had single lesions.</LI>
<LI>
<I>Group 2</I>: placebo orally (2 capsules) for 6 weeks n = 10. 5/10 participants had single lesions.</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
<P>
<I>Duration of follow-up</I>: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:43:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' 3 months after treatment </P>
<P>
<I>Secondary outcome</I>: adverse effects</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: clinical response: day 15. Clinical and parasitological response: 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:55:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ejaz-2014">
<CHAR_METHODS MODIFIED="2017-11-06 12:01:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Pakistan at dermatology departments of Combined Military Hospital, Kharian Camtonment, Combines Military Hospital, Quetta and Combined Military Hospital, Muzaffarabad</P>
<P>
<I>Study period</I>: January 2008 to December 2010 (35 months)</P>
<P>
<I>Sample size calculation</I>: assuming equal-sized groups, keeping the equivalence trial design, standardised difference of 0.05 and power at 90%, sample size was calculated as 150 participants in each arm using Altman nomogram. A total of 300 participants were needed for the study and 24 extra participants were recruited to cater for dropouts.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 12:06:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: men and women over 18 years of age having parasitologically proven CL requiring systemic therapy, willing for admission to hospital for the study and regular follow-up visits, and consenting not to use any other treatment for CL during trial</P>
<P>
<I>Exclusion criteria</I>: pregnant, compromised immune system (i.e. diabetics or cancer patients), diffuse cutaneous or visceral leishmaniasis, complete or incomplete treatment with antimony compounds in the last 3 months, history of hepatic, renal, or cardiovascular disease</P>
<P>
<I>N randomised</I>: 324. Group 1: 151; group 2: 173</P>
<P>
<I>Withdrawals</I>: not described</P>
<P>
<I>N assessed</I>: 324 (100%)</P>
<P>
<I>Age</I>: mean 27.9 years (SD 6.5), range 17-48 years</P>
<P>
<I>Sex</I>: all were male soldiers</P>
<P>
<I>Baseline data</I>: most participants (39.2%) had a single lesion, but one participant had 15 lesions. Maximum lesions were found on exposed parts of body, arms and legs accounted for 42.3% and 47.2% of lesions respectively. Plaques were the most common morphological pattern seen (82.7%).</P>
<P>Mean (SD) size of lesions at baseline was 28.8 mm (16.1). Group 1: 29.7 mm (16.4); group 2: 28 mm (15.8). Mean induration at baseline was 17.5 mm (11.6). Group 1: 17.7 mm (11.5); group 2: 18 mm (12.8)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:55:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: IMMA (Glucantime, Lot No. 888, Aventis Laboratories, France) 20 mg/kg/d until clinical resolution or for 28 days maximum</LI>
<LI>
<I>Group 2</I>: IMMA 10 mg/kg/d + oral allopurinol (Zyloric &#8211; 300, Batch No. 2ZMAF, GlaxoSmithKline Pakistan Limited) 20 mg/kg/d</LI>
</UL>
<P>
<I>Duration of intervention</I>: 28 days maximum</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 12:07:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Successful treatment</I>: was defined as complete re-epithelialisation of the ulcer and disappearance of the induration, or reduction of more than 50% of the ulcer and the indurations areas in relation to the last clinical evaluation</P>
<P>
<I>Adverse effects</I>: serious adverse event was defined as life-threatening, or prolongation of existing hospitalisation, or causing persistent or significant disability. Non-serious adverse effects, not qualifying the above criteria were clinically judged by the investigator to be definitely related, probably related, possibly related, or not related to the trial medication.</P>
<P>Time points reported: follow-up phase lasted 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:56:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El_x002d_Sayed-2010">
<CHAR_METHODS MODIFIED="2017-11-08 15:28:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: the Saudi Hospital in Sanaa, Yemen</P>
<P>
<I>Study period</I>: 21 months; participants recruited from June 2006 to June 2007</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 12:15:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania </I>spp</P>
<P>
<I>Inclusion criteria</I>: all had the clinical signs of cutaneous leishmaniasis and a majority of their cutaneous lesions were found smear positive for mastigotes. 4 participants with a negative smear preparation were diagnosed by tissue culture using NNN (Novey, McNeal and Nicolle) medium</P>
<P>
<I>Exclusion criteria</I>: skin lesions of more than 8 weeks duration, allergic to antimonial drugs, lactating or pregnant</P>
<P>
<I>N participants randomised (lesions)</I>: N = 30: ILSSG, n = 10 participants (12 lesions), ILSSG + IMSSG, n = 10 (15), ILSSG + oral ketoconazole: n = 10 (13)</P>
<P>
<I>Withdrawals</I>: no</P>
<P>
<I>N assessed</I>: 30 (100%)</P>
<P>
<I>Age</I>: range 12-50 years (mean 23.5, SD 14). Group 1: 12-50 (24.3, SD 15); group 2: 13-48 years (22.5, SD 14); group 3: 12-49 years (25.1, SD 12)</P>
<P>
<I>Sex (male/female)</I>: group 1, 5/5; group 2, 7/3; group 3, 4/6</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Group 1: duration of disease (weeks) 2&#8211;5. Site: face 10, upper extremities: 2. Type of ulceration: nodules 5, plaques 7</LI>
<LI>Group 2: duration of disease (weeks) 3-7. Site: face 14, upper extremities: 1. Type of ulceration: nodules 8, plaques 7</LI>
<LI>Group 3: duration of disease (weeks) 2&#8211;8. Site: face 12, upper extremities: 1. Type of ulceration: nodules 6, plaques 7</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:56:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ILSSG (100 mg/mL) alone, following a treatment schedule on alternate day's injection</LI>
<LI>
<I>Group 2</I>: ILSSG + IMSSG injections. A part of the dose (calculated as 20 mg/kg/d) was injected intralesionally on days 1, 3, 5 as in group 1. The remaining amount of the total dose was given intramuscularly simultaneously on the same day.</LI>
<LI>
<I>Group 3</I>: ILSSG as in group 1 + oral ketoconazole (200 mg 3 times daily) for 4 weeks</LI>
</UL>
<P>
<I>Duration of intervention</I>: in all groups, treatment was continued until clearance or for a maximum of 3 treatment cycles at 4 week intervals (12 weeks)</P>
<P>
<I>Follow-up</I>: performed monthly for 6 months after the last treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:45:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: the cure was indicated by complete re-epithelialisation, the disappearance of oedema, induration and other signs of inflammation and a negative Giemsa-stained direct smear of a scraping of the skin at the lesion site. In the 4 participants diagnosed only by a positive culture before enrolment, the cure was indicated by a negative culture at the end of the 12 weeks.</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 4, 8, 13 weeks. Adverse effects: at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:56:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emad-2011">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:20:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>major</I>
</P>
<P>
<I>Inclusion criteria</I>: PCR-proven <I>L major</I> cutaneous infection, age &gt; 12 years, not using anti-<I>Leishmania</I> therapies during the past 2 months, duration of lesions &lt; 4 moths</P>
<P>
<I>Exclusion criteria</I>: pregnancy, breastfeeding, presence of lesions on ears and/or face, number of lesions &gt;10, history of liver or kidney disease</P>
<P>
<I>N randomised</I>: 120 participants (fluconazole 200 mg: 60; fluconazole 400 mg: 60)</P>
<P>
<I>Withdrawals</I>: 2 in the 400 mg group</P>
<P>
<I>N assessed</I>: 118 participants</P>
<P>
<I>Mean (SD) age</I>: fluconazole 200 mg, 36.45 years (15.34); fluconazole 400 mg, 35.38 years (13.81)</P>
<P>
<I>Sex (male/female)</I>: 65/55 (fluconazole 200 mg, 30/30; fluconazole 400 mg, 35/25)</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean number of lesions (SD): fluconazole 200 mg, 3.10 (2.08); fluconazole 400 mg, 3.21 (2.09)</LI>
<LI>Mean duration of lesions (SD): fluconazole 200 mg, 7.12 weeks (2.51); fluconazole 400 mg, 7.43 weeks (2.6)</LI>
<LI>Size of lesions (SD): fluconazole 200 mg, 19.84 mm (8.97); fluconazole 400 mg, 21.87 mm (8.93)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:56:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: high dose fluconazole 200 mg twice daily</LI>
<LI>
<I>Group 2</I>: low dose fluconazole100 mg twice daily</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:45:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Complete healing</I>: defined as complete re-epithelialisation of the lesions at intervals of 2, 4 and 6 weeks</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 6 weeks </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 12:25:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: grant from Shiraz University of Medical Sciences, Shiraz, Iran</P>
<P>
<I>Possible conflicts of interest</I>: none declared </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 12:45:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Esfandiarpour-2002">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 12:45:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I> in the area</P>
<P>
<I>Inclusion criteria</I>: positive direct smear or documented skin biopsy, not pregnant or nursing at the time of therapy, no serious systemic illness, no sensitivity to antimonial drugs or AL</P>
<P>
<I>Exclusion criteria</I>: not having received treatment for at least 2 months before entry into the study.</P>
<P>
<I>N randomised</I>: 150. 50 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 150 (100%). 50 in each group</P>
<P>
<I>Age</I>: mean age 14 years. Group 1 (AL): 14, group 2 (IMMA): 14.5, group 3 (AL + IMMA): 14</P>
<P>
<I>Sex</I>: male/female: 69/81. 23/27 in each group</P>
<P>
<I>Baseline data</I>: the common sites of involvement were the face and extremities. By groups were as follows: oral AL: face: 62%; upper limbs: 34%; lower limbs: 4%, and trunk: nil. IMMA: face: 48%; upper limbs: 38%; lower limbs: 14%, and trunk: nil. AL + IMMA: face: 78%; upper limbs: 15%; lower limbs: 6%, and trunk: 2%. Most participants had plaque-type, papular, and nodular lesions. By groups: AL: plaque: 64%, papule: 29%, and nodule: 7%. IMMA: plaque: 71%, papule: 18%, and nodule: 11%. AL + IMMA: plaque: 77%, papule: 19%, and nodule: 4%.</P>
<P>Mean number of lesions: group 1, 1.5; group 2, 1.8; group 3, 1.4. Most had multiple lesions (&#8804; 7 lesions)</P>
<P>Mean duration of lesions: group 1, 8 months; group 2, 7.4 months; group 3, 8 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 08:24:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: AL orally 15 mg/kg/d for 3 weeks</LI>
<LI>
<I>Group 2</I>: IMMA 30 mg/kg/d for 2 weeks</LI>
<LI>
<I>Group 3</I>: AL + IMMA simultaneously</LI>
</UL>
<P>
<I>Duration of follow-up</I>: one month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:46:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' at the end of treatment. The response to treatment was graded as excellent (reduction in the size of the lesion by at least 80% or complete clearance), good (reduction in the size of the lesion by 50%), and poor (minimal or no change in the lesion)</P>
<P>
<I>Secondary outcome</I>: adverse effects</P>
<P>Time points reported: end of treatment and 2 and 4 weeks later<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-06 12:35:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Faghihi-2003">
<CHAR_METHODS MODIFIED="2017-11-06 12:33:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Isfahan, Iran</P>
<P>
<I>Study period</I>: 15 months</P>
<P>
<I>Sample size calculation</I>: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-06 12:34:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I> is endemic in Isfahan</P>
<P>
<I>Inclusion criteria</I>: clinical and parasitological diagnosis of CL</P>
<P>
<I>Exclusion criteria</I>: pregnant or had &gt; 3 lesions, ulcerative lesions, lesions with cartilage or lymphatic involvement or hypersensitivity to the drug</P>
<P>
<I>N randomised</I>: 96 participants, 48 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I> <I>(lesions)</I>: 96 (190). 48 (95) in each group</P>
<P>
<I>Age (years)</I>: age range 1-48 years (mean age of 16 years old and a median of 14.5 years)</P>
<P>
<I>Sex</I>: male/female: 40/56</P>
<P>
<I>Baseline data</I>: all lesions treated were papules or early nodules with mean diameter of about 4 mm. Mean number of lesions per person in each group: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-06 12:34:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 15% PR sulphate and 10% urea in Eucerin ointment, applied twice daily at 1 mm thickness over the total surface of the lesion(s)</LI>
<LI>
<I>Group 2</I>: ILMA injections of 1.5 g/5 mL (maximum 12), weekly. The mean amount of solution required for each lesion was 0.2 mL to 0.8 mL.</LI>
</UL>
<P>
<I>Duration of intervention</I>: treatment was continued in both groups for 3 months or until complete recovery (return to the normal tissue texture without any atrophic changes or scar formation)</P>
<P>
<I>Duration of follow-up</I>: one year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' within 2 months after treatment. Complete recovery or cure was defined as re-epithelialisation and return to normal tissue texture in less than 2 months, with no residual scar or relapse after follow-up of up to 1 year</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur within one year; prevention of scarring</P>
<P>Time points reported: completely recovered (cured) (&lt; 2 months). Healed (in 2&#8211;3 months)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 12:35:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: Isfahan University of Medical Sciences (Pharmacy College and its Research Laboratory) and the Amin Leishmaniasis Research Group in Isfahan City</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 14:57:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farajzadeh-2015">
<CHAR_METHODS MODIFIED="2017-11-06 12:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Afzalipour Hospital, Kerman University of Medical Sciences, Iran</P>
<P>
<I>Study period</I>: 1 year (2011-12)</P>
<P>
<I>Sample size calculation</I>: a sample size of 40 participants per treatment group was planned, a probability of a type I error at alpha = 0.05 and beta = 0.1 to determine a 20% difference between topical terbinafine compared with control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:55:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: participants between 2-60 years and without serious medical illness were included, not have received any other leishmanicidal treatment during last 3 months, duration of their lesions should be less than 6 months</P>
<P>
<I>Exclusion criteria</I>: cardiac, hepatic, renal and other systemic diseases; pregnant and nursing women; hypersensitivity to trial drugs</P>
<P>
<I>N randomised</I>: 80, 40 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 80, 40 in each group</P>
<P>
<I>Mean (SD) age</I>: terbinafine: 16.3 years (14.8), IMMA: 20.74 years (19.4)</P>
<P>
<I>Sex (n, %)</I>: terbinafine: male 18 (45); female 18 (45); the sex of 4 (10) participants was unknown. IMMA: male: 16 (40); female: 18 (45); the sex of 6 (15) participants was unknown</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean duration of lesions (SD): terbinafine: 3.97 months (0.3). IMMA: 3.81 months (0.3)</LI>
<LI>Mean number of lesions (SD): terbinafine: 1.85 (1.3). IMMA: 1.93 (1.16)</LI>
<LI>Mean size of lesions (SD): terbinafine: 4.15 mm² (5.97). IMMA: 5.21 mm² (10.65)</LI>
<LI>The most frequent location of the lesions was on participants' face (terbinafine: n = 99, 45.8% vs IMMA: n = 93, 50%)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 14:57:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI> <I>Group 1:</I> oral terbinafine, 125 mg/d (for less than 20 kg body weight), 250 mg/d (20-40 kg body weight), 500 mg/d (for more than 40 kg body weight)</LI>
<LI>
<I>Group 2</I>: 15 mg/kg/d IMMA (Glucantime; Haupt Pharma in France)</LI>
</UL>
<P>
<I>Co-interventions:</I> Both groups received cryotherapy every 2 weeks for 4 weeks</P>
<P>
<I>Duration of intervention</I>: group 1: 4 weeks, group 2: 3 weeks</P>
<P>
<I>Duration of follow up:</I> patients were followed monthly for 3 months after the treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:52:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: clinical response was determined based on the following criteria:</P>
<UL>
<LI>Complete improvement (decrease in induration size &gt; 75%)</LI>
<LI>Partial improvement (decrease in induration size between 25% and 75%)</LI>
<LI>No improvement (decrease in induration size &lt; 25%)</LI>
</UL>
<P>
<I>Time to clinical cure</I>: development of oartial and complete response to treatment in IMMA and terbinafine groups.</P>
<P>Time points reported: the improving rate determined by measuring indurations at baseline, in the middle (day 10 for IMMA group and day14th for terbinafine group), and at the end of the study (day 21 for IMMA group and day 28 for terbinafine group)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-06 12:45:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: Kerman University of Medical Sciences accepted the financial support of this study</P>
<P>
<I>Possible conflicts of interest</I>: the authors declare that there is no conflict of interest.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 14:58:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fekri-2015">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Afzalipour hospital affiliated to Kerman University of Medical Sciences and Dadbin Health Center, Kerman/Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 14:58:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: &#8212;</P>
<P>
<I>Inclusion criteria</I>: age over 7 years, positive smear or biopsy, providing informed consent</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating, lesions on face, more than 5 lesions, duration longer than one year, size larger than 3 cm, any treatment in past month, history of allergy to MA or dapsone, systemic diseases, taking immunosuppressive drugs in past 6 months, lupoid or sporotrichoid forms</P>
<P>
<I>N randomised</I>: 73</P>
<P>
<I>Withdrawals</I>: 5</P>
<P>
<I>N assessed</I> <I>(lesions)</I>: 68 (73). Group 1: 33 (35); group 2: 35 (38)</P>
<P>
<I>Mean (SD) age</I>: 29.6 years (15.4) in group 1, 31.6 years (20.4) in group 2</P>
<P>
<I>Sex</I> <I>(male/female)</I>: intervention group: 17/16, group 2: 14/17</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Number of lesions: 38 lesions in group 1 and 35 in group 2</LI>
<LI>Mean±SD of duration of lesions (months): 4.6 ± 9.3 in group 1 and 3.7 ± 1.9 in group 2</LI>
<LI>Mean±IQR of the initial lesion size (mm2): 2 (1.4-2.9) in group 1 and 1.5 (1.1-3) in group 2</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:56:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: weekly ILMA + niosomal dapsone gel twice a day</LI>
<LI>
<I>Group 2</I>: weekly ILMA + cryotherapy every 2 weeks</LI>
</UL>
<P>
<I>Duration of intervention</I>: until complete healing or max 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 12:59:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing response</I>: complete healing (100% epithelialisation and loss of induration), moderate healing (50-99% epithelialisation and loss of induration), no response (less than 50% epithelialisation and loss of induration)</P>
<P>Time points reported: 16 weeks after beginning intervention, 1 year later for recurrence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: Kerman University of Medical Sciences</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:59:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Firooz-2005">
<CHAR_METHODS MODIFIED="2017-11-07 09:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Isfahan, Iran</P>
<P>
<I>Study period</I>: 6 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:59:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I> endemic in the area</P>
<P>
<I>Inclusion criteria</I>: the presence of parasitologically confirmed lesion(s) of CL, aged 12-60 years, and otherwise healthy on the basis of medical history and physical examination</P>
<P>
<I>Exclusion criteria</I>: women of childbearing age without adequate effective contraception; pregnant or breastfeeding; duration of lesions &gt; 8 weeks; the presence of lesions on face, joints or near the mucous membranes; the presence of &gt; 5 lesions or any lesion with a diameter &gt; 5 cm; history of any antileishmanial therapy in the past 4 weeks</P>
<P>
<I>N participants randomised</I> <I>(lesions)</I>: 72 (106). 36 (53) treated with zinc sulphate (ZS) and 36 (53) treated with ILMA</P>
<P>
<I>Withdrawals</I> <I>participants (lesions)</I>: 37 (56). ZS group 23 (34): unresponsive: 12, lost to follow-up: 5, non-medical events: 2, protocol deviation: 2, complications: 1, patient request: 1. ILMA 14 (22): unresponsive: 2, lost to follow-up: 10, non-medical events: 1, patient request: 1</P>
<P>
<I>N assessed</I> <I>(lesions)</I>: 35 (50). 13 (19) treated with ZS and 22 (31) treated with ILMA</P>
<P>
<I>Mean (SD) age</I>: 20.2. years (9.6). ZS group: 18.1 years (6.1); ILMA: 22.3 years (11.2)</P>
<P>
<I>Sex (male/female)</I>: 33/39. ZS group: 19/17; ILMA group: 14/22.</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Location of the lesions (n (%)): h<I>e</I>ad and neck: ZS group: 7 (13.2); ILMA group: 1 (1.9); trunk: ZS group: 3 (5.7); ILMA group: 1 (1.9); upper extremity: ZS group: 28 (52.8); ILMA group: 32 (60.4); lower extremity: ZS group: 15 (28.3); ILMA group: 19 (35.8)</LI>
<LI>ZS group: MNL (SD): 1.4 (0.8). MSL (SD): 7.6 mm (5.5). MDLBT: 5.8 weeks (2.0)</LI>
<LI>ILMA group: MNL (SD): 1.5 (0.8). MSL (SD): 7.9 mm (7.5). MDLBT: 5.5 weeks (2.3)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:27:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: IL 2% zinc sulphate</LI>
<LI>
<I>Group 2</I>: ILMA</LI>
</UL>
<P>
<I>Duration of intervention</I>: up to 6 weeks</P>
<P>
<I>Duration of follow-up</I>: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:56:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of lesions 'cured' 5 weeks after treatment. Complete re-epithelialisation of each ulcer with marked reduction in induration with or without scarring was considered as the main efficacy parameter.</P>
<P>
<I>Amount of injection into each lesion</I>
</P>
<P>
<I>Adverse effects</I>: the pain experienced by the participant (using a verbal analogue scale on a 0-10 scale) was recorded</P>
<P>Time points reported: 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this study was supported by a grant from Chancellery of Research, Tehran University of Medical Sciences.</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
<P>The plot and the figures were not matched accordingly</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-07 13:13:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Firooz-2006">
<CHAR_METHODS MODIFIED="2017-11-07 11:35:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Mashad, Iran</P>
<P>
<I>Study period</I>: 18 months</P>
<P>
<I>Sample size calculation</I>: 45 participants per treatment group were needed to have 80% power to detect a significant difference in the expected cure rate of 50% in the vehicle group and the desired cure rate of 80% in the imiquimod-treated group at week 8 with a type Ierror level of 0.05. To compensate for 20% estimated dropout, 54 participants would be required in each group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 11:43:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I> endemic in the area</P>
<P>
<I>Inclusion criteria</I>: parasitologically proven cases of CL based on positive smear or culture, otherwise healthy participants</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating women, duration of the lesions &gt; 6 months, number of lesions &gt; 5, any lesions &gt; 5 cm, history of any standard course of treatment with antimonials, history of allergy to antimonials, serious systemic illnesses, participation in any drug trials in the last 60 days</P>
<P>
<I>N participants randomised (lesions)</I>: 119 (252). 59 (128) participants in the imiquimod group and 60 (124) in the vehicle group</P>
<P>
<I>Withdrawals</I>: 30 participants. Imiquimod group (n = 17): 9 lost to follow-up, 4 inadequate efficacy, 3 protocol deviation, 1 consent withdrawal. Vehicle group (n = 13): 9 lost to follow-up, 2 inadequate efficacy, 2 protocol deviation</P>
<P>
<I>N assessed</I>: 89. 42 participants in the imiquimod group and 47 in the vehicle group</P>
<P>
<I>Mean (SD) age</I>: 27.0 years (SD 1, range 12-60). Imiquimod group: 7.4 years (13); vehicle group: 6.5 years (12)</P>
<P>
<I>Sex</I>: approximately 50%-55% of the participants were female (35/59 in the imiquimod group, and 31/60 in the vehicle group)</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Lesions were mainly located on the upper extremities (66.3%) and around 15% to 17% on the face and lower extremities</LI>
<LI>Location of lesions (n (%)): face: imiquimod group: 20 (15.6), vehicle group: 19 (15.3); trunk: imiquimod group: 1 (0.8); vehicle group: 1 (0.8); upper extremity: imiquimod group: 85 (66.4); vehicle group: 82 (66.1); lower extremity: imiquimod group: 22 (17.2); vehicle group: 22 (17.7)</LI>
<LI>Imiquimod group: MNL: 2.2. MDLBT: 13 weeks. MSL: 174 mm²</LI>
<LI>Vehicle group: MNL: 2.0. MDLBT: 13.2 weeks. MSL: 237 mm²</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 13:13:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: imiquimod cream 5% + IMMA</LI>
<LI>
<I>Group 2</I>: vehicle + IMMA</LI>
</UL>
<P>
<I>Duration of intervention</I>: imiquimod and vehicle 3 times per week for 28 days, IMMA 20 mg/kg/d for 14 days</P>
<P>
<I>Duration of follow-up</I>: 20 weeks after initiation of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 12:59:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' 3.5 months after treatment. Clinical cure of the participants, defined as more than 75% reduction in the size of lesions compared with baseline</P>
<P>
<I>Secondary outcomes</I>: the relapse rate (defined as a reappearance of lesions at the site or periphery of previously healed lesions or an increase in the size of lesions after initial improvement) was assessed 16 weeks after the end of treatment </P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of the treatment period (week 4) and 4 weeks later</P>
<P>Intention-to-treat analysis of rates of complete re-epithelialisation, clinical cure, and clinical improvement at weeks 4, 8,and 20 after initiation of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 12:07:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this study was supported by the Small Grants Scheme for Operational Research in Tropical and Other Communicable Diseases from the Joint World Health Organization Eastern Mediterranean Region Division of Communicable Diseases and the Special Program for Research and Training in Tropical Diseases.</P>
<P>
<I>Possible conflicts of interest</I>: the funding source was involved in the study design, in the writing of the manuscript, and in the decision to submit the manuscript for publication, but not in the collection, analysis, or interpretation of data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gholami-2000">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: 24 months</P>
<P>
<I>Sample size calculation</I>: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 11:48:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>:<I> L major</I>
</P>
<P>
<I>Inclusion criteria</I>: CL confirmed with direct smear, age 5-50 years, maximum number of lesions 3, duration of disease &lt; 100 days</P>
<P>
<I>Exclusion criteria</I>: previous treatment for leishmaniasis, use of immunosuppressives, history of chronic systemic disease, lesions on face, pregnancy or lactating, age &lt; 5 years, duration of disease &gt; 100 days</P>
<P>
<I>N randomised</I>: 197</P>
<P>
<I>Withdrawals</I>: 26</P>
<P>
<I>N assessed</I>: 171. 96 were treated with garlic 5% cream and 75 with vehicle</P>
<P>
<I>Mean age</I>: garlic, 18.5 years; vehicle, 23.7 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: garlic, 51/45; placebo, 38/37</P>
<P>
<I>Baseline data</I>: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 11:48:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: garlic cream 5%</LI>
<LI>
<I>Group 2</I>: vehicle</LI>
</UL>
<P>
<I>Duration of intervention</I>: both applied twice daily under occlusion with sterile gauze for 3 hours, for 20 days</P>
<P>
<I>Duration of follow-up</I>: 60 days (after the 3 week treatment, participants were followed for another period of 40 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:57:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' one month (40 days) after treatment</P>
<P>Time points reported: yes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
<P>We only have the abstract. The author (A Khamesipour) was contacted and kindly agreed to extract the data from the original paper written in Persian.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 14:59:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harms-1991">
<CHAR_METHODS MODIFIED="2017-11-07 11:49:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Aleppo, Syria</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 14:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: up to 3 lesions diagnosed clinically and parasitologically as CL; absence of chronic or intercurrent systemic disease</P>
<P>
<I>Exclusion criteria</I>: pregnancy and no prior antimonial medication</P>
<P>
<I>N randomised</I> <I>and withdrawals</I>: not reported</P>
<P>
<I>N participants assessed</I> <I>(lesions)</I>: 40 (75) ILMA: 20 (38); IFN-&#947;: 20 (37)</P>
<P>
<I>Mean age (range)</I>: ILMA: 21 years (6-60); IFN-&#947;: 27 years (12-57)</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 17/23. ILMA: 9/11; IFN-&#947;: 2/12</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Type of lesions (%). ILMA group: papular: 13; papular-nodular: 21; nodular-ulcerative: 61; plaque-form: 5. IFN-&#947; group: papular: 19; papular-nodular: 19; nodular-ulcerative: 62; plaque-form: none</LI>
<LI>Lesion site (%). ILMA group: upper extremity: 63; lower extremity: 18; face: 18; trunk: none. IFN-&#947; group: upper extremity: 59; lower extremity: 30; face: 8; trunk: 3</LI>
<LI>Median size (range) (mm) : ILMA group:15 x 14(4 x 4- 49 x 42);IFN-&#947; group: 13 x 11(7 x 7- 45 x 40)</LI>
<LI>Mean duration of lesions before treatment (range) (months): ILMA group: 2.5(1-6); IFN-&#947; group:2.5(2-8)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 11:58:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ILMA (1-3 mL)</LI>
<LI>
<I>Group 2</I>: IL Lyophilised recombinant IFN-&#947; (25 mg)</LI>
</UL>
<P>
<I>Duration of intervention</I>: once weekly for 5 weeks</P>
<P>
<I>Duration of follow-up</I>: 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 08:58:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of lesions 'cured' one month after treatment</P>
<P>Secondary outcome: adverse effects</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: weeks 3, 6, 10</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:01:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iraji-2004">
<CHAR_METHODS MODIFIED="2017-11-07 11:58:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Department of Dermatology, Isfahan Medical University, Iran</P>
<P>
<I>Study period</I>: 10 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:01:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> spp: due to a previous study in the area, it was likely that participants were infected with <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: proven leishmaniasis based on typical lesions of ACL and a positive direct smear. Number of lesions &lt; 4 and duration of lesion &lt; 12 weeks</P>
<P>
<I>Exclusion criteria</I>: cases of reinfection, pregnant or nursing women, those who had lesion on the face or joints and participants with sporotrichoid or erysipeloid lesions</P>
<P>
<I>N randomised</I>: 104. ILMA: 55, zinc sulphate (ZS): 49</P>
<P>
<I>Withdrawals</I>: 38. ILMA: 20, ZS: 18. 13 due to occurrence of new lesions: 7 from ILMA group and 6 from ZS group; 6 participants with sporotrichoid spread: 4 from the ILMA group and 2 from the ZS group; 19 participants lost to follow-up: 9 from the ILMA group and 10 from the ZS group</P>
<P>
<I>N assessed</I>: 66. ILMA: 35, ZS: 31</P>
<P>
<I>Mean age (range)</I>: ILMA: 11 years (2-67); ZS: 12 years (3-64)</P>
<P>
<I>Sex (male/female)</I>: 50/54. ILMA: 14/21; ZS: 17/14</P>
<P>
<I>Baseline imbalances</I>: sex distribution in each group</P>
<P>
<I>Severity of illness</I>: Mean duration of lesions (SD) (weeks): ILMA: 6.73 ±0.53 ;ZS: 7.64±0.12 .</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 12:11:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ILMA injection of 50 mL</LI>
<LI>
<I>Group 2</I>: IL ZS injection of 50 mL</LI>
</UL>
<P>In cases where there was a slight to mild improvement, another injection was given after 2 weeks</P>
<P>
<I>Duration of intervention</I>: 2-6 weeks</P>
<P>
<I>Duration of follow-up</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-14 15:01:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' at the end of treatment. The results of treatment were graded according to the system of <LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK> slight = 1, mild = 2, moderate = 3, marked = 4, 5 = total clearance of the lesion and parasite not detected in the affected area by smear</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 2, 4, 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:59:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iraji-2005">
<CHAR_METHODS MODIFIED="2017-11-07 12:16:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: the required sample size, 40 in each treatment group, was estimated, assuming one in every 4 cases would not provide full data, using the formula n = [Z1 &#8722; (a/2) + Z1 &#8722; b] 2 × [P1(1 &#8722; P1) + P2(1 &#8722; P2)]/(P1 &#8722; P2)2, and setting P1 (the paromomycin efficacy) to 0.7, P2 (the vehicle efficacy) to 0.3, a to 0.05, b to 0.1, Z1 &#8722; (a/2) to 1.96, and Z(1 &#8722; b) to 1.64</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:59:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>tropica</I> and <I>L major</I> are responsible for hyperendemic CL in rural areas and endemic CL in parts of many cities in Iran</P>
<P>
<I>Inclusion criteria</I>: had the clinical signs of CL and all of their cutaneous lesions were found smear-positive for amastigotes</P>
<P>
<I>Exclusion criteria</I>: cases who had first noticed a skin lesion &gt; 3 months previously, had lesions on their face, had lesions with diameter of &gt; 3 cm, had received previous treatment, or who were lactating or pregnant</P>
<P>
<I>N randomised</I>: 80, 40 in each group</P>
<P>
<I>Withdrawals</I>: 15. Intervention group: 10; control group: 5</P>
<P>
<I>N assessed</I>: 65. Intervention group: 30; control group: 35</P>
<P>
<I>Age</I>: range 8-55 years. Mean intervention group: 21.4 years; control group: 21.5 years</P>
<P>
<I>Sex (male/female)</I>: 33/32. Intervention group: 19/11; control group: 14/21</P>
<P>
<I>Baseline data</I>: mean duration of lesions (years): intervention group: 1.65; control group: 1.75</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 12:19:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: PR sulphate 15% + 10% urea applied to a 1 mm-thick layer twice daily</LI>
<LI>
<I>Group 2</I>: vehicle control group (Eucerin containing 10% urea) applied topically twice daily</LI>
</UL>
<P>
<I>Duration of intervention</I>: 30 days</P>
<P>
<I>Duration of follow-up</I>: for clinical and parasitological follow-up on day 30 and for only parasitological follow-up on day 60</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:03:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' one month after treatment, clinical and parasitological cure</P>
<UL>
<LI>Complete healing was defined as a reduction in the size and induration of the lesion(s) by at least 75% and lesion smears that appeared amastigote-free</LI>
<LI>Partial cure was defined as a reduction in the size and induration of the lesion(s) by &gt; 25% but &lt; 75%, and lesion smears that appeared amastigote-free.</LI>
<LI>Failure was defined as a reduction in the size and induration of the lesion(s) by &lt; 25% and/or an amastigote-positive smear</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: days 30 (clinical and parasitological follow-up) and 60 (parasitological follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:59:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaffar-2006">
<CHAR_METHODS MODIFIED="2017-11-09 11:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Saudi Arabia (Bahrain)</P>
<P>
<I>Study period</I>: 12 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 12:25:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: proved positive for <I>Leishmania</I> parasites (amastigotes) on microscopic examination or biopsy</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: 62. Rifampicin: 46; placebo: 16. </P>
<P>Rifampicin: 2 groups were analysed; group 1a (children aged 3-11 years - mean age, 7.5 years), and group 1b (adults aged 12-65 years - mean age, 33 years). 32 participants enrolled in group 1a and 30 in group 1b. Out of these, 8 participants in each group (16 in total) served as control to receive the placebo.</P>
<P>
<I>Withdrawals</I>: 21 participants lost to follow-up. Rifampicin: 12; placebo: 9</P>
<P>
<I>N assessed</I>: 41. Rifampicin: 34; placebo: 7. Number participants imbalanced between groups</P>
<P>
<I>Age</I>: range 3-65 years; mean 20 years</P>
<P>
<I>Sex (male/female)</I>: 43/19</P>
<P>
<I>Baseline data</I>: the duration of the lesions varied between 1 and 12 months (mean 2.6 months). The lesions of CL were single or multiple and were mostly over the extremities (upper limbs 51% and lower limbs 38%) and to a lesser extent on the face 30%. Most of the lesions were active being nodular, nodule-ulcerative, or ulcerative. 2 of the participants were members of the same family. However, the rest of the participants had a negative family history.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 12:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: rifampicin orally in a dose of 10 mg/kg/d</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: placebo</LI>
</UL>
<P>
<I>Duration of intervention</I>: 2 equally divided doses during meals for 4-6 weeks</P>
<P>
<I>Duration of follow-up</I>: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:03:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' 3 months after treatment</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur up to 3 months of follow-up</P>
<P>
<I>Adverse effects</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:56:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaffary-2010">
<CHAR_METHODS MODIFIED="2017-11-07 12:26:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Disease and Leishmaniasis Research Center of Isfahan (SDLRC), Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 12:27:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: not described</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: 140 participants</P>
<P>
<I>Withdrawals</I>: 64</P>
<P>
<I>N assessed</I>: 76 participants (47 with ILMA and topical <I>Cassia fistula </I>fruit gel and 29 participants in vehicle group)</P>
<P>
<I>Age</I>: not described</P>
<P>
<I>Sex</I>: not described</P>
<P>
<I>Baseline data</I>: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:56:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: <I>Cassia fistula </I>fruit gel + ILMA</LI>
<LI>
<I>Group 2</I>: vehicle gel + ILMA</LI>
</UL>
<P>
<I>Duration of intervention</I>: not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:04:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure</I>: complete cure, partial cure and treatment failure</P>
<P>
<I>Adverse effects</I> (itching and erythema)</P>
<P>Time points reported: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
<P>We only have the abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:57:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaffary-2014a">
<CHAR_METHODS MODIFIED="2017-11-07 12:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: double-blind, randomised controlled study</P>
<P>
<I>Setting/location</I>: Isfahan, Iran</P>
<P>
<I>Study period</I>: January 2009 to February 2010 (13 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:22:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: met the histological criteria for presence of parasite, age &gt; 5 years, acute leishmanial lesions smaller than 5 cm², fewer than 5 lesions, more than 3 months of disease duration</P>
<P>
<I>Exclusion criteria</I>: pregnancy, women of childbearing age, history of administration of immune suppressive drugs in the last 6 months or anti-leishmanial drugs in the last month</P>
<P>
<I>N randomised</I>: 60 participants, 30 in each group </P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 60, 30 in each group</P>
<P>
<I>Mean (SD) age</I>: 25.29 years (4.01). <I>Achillea millefolium</I> 5%: 25.8 years (3.7); vehicle: 24.6 years (4.2).</P>
<P>
<I>Sex</I>: 15 (25%) female; 45 (75%) male. <I>A millefolium</I>: 7 (23.3%) female, 23 (76.6%) male; vehicle: 8 (26.6%) female, 22 (73.3%) male)</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean number of lesions (SD): <I>A millefolium</I>: 1.56 (0.8); vehicle: 1.52 (0)</LI>
<LI>Type of lesions (%): <I>A millefolium</I>: papule 8/44 (18.1), ulcer 16/44 (36.3), plaque 10/44 (22.7), nodule 10/44 (22.7). vehicle: papule: 9/38 (23.6), ulcer: 16/38 (42.1), plaque: 11/38 (28.9), nodule: 12/38 (31.5)</LI>
<LI>Mean duration of lesions (SD): <I>A millefolium</I>: 3 months (0.5); vehicle: 2.7 months (0.7)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:57:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: topical gel of 5% <I>A millefolium </I>(yarrow (containing 5% polyphenol)</LI>
<LI>
<I>Group 2</I>: vehicle gel. The vehicle gel was prepared using the same material except for the plant extract and chlorophyll was used as colorings agent. Both gels were identical in terms of the colour and consistency</LI>
</UL>
<P>
<I>Duration of intervention</I>: 4 weeks</P>
<P>
<I>Co-interventions</I>: all participants received 4 weekly an injections of MA (Glucantime, Paris, France) at a dose of 20 mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-07 12:38:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Definition</I>: complete or partial cure of lesions</P>
<P>Time points reported: week 12 (visits months - 3)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-07 12:39:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:57:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaffary-2014b">
<CHAR_METHODS MODIFIED="2017-10-19 14:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised parallel clinical trial</P>
<P>
<I>Setting/location</I>: Skin Diseases and Leishmaniasis Research Center (SDLRC), Isfahan, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:13:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: 6-60 years old, with positive results of leishmaniasis smear test</P>
<P>
<I>Exclusion criteria</I>: size of lesion &gt; 3 cm, &gt; 5 lesions, lesion duration &gt; 12 weeks, lesion located on the eyelid or &lt; 2 cm away from the eye, pregnant or lactating</P>
<P>
<I>N randomised</I>: 165, 55 in each of 3 treatment groups</P>
<P>
<I>Withdrawals</I>: 7; 3 (5.5%), participants were in the concentrated boiled extract group and 2 (3.6%) participants in the other groups withdrew from the study due to the allergic reaction to the medications</P>
<P>
<I>N assessed</I>: 158. Concentrated boiled extract of <I>Cassia fistula</I>: 52; hydroalcoholic extract of <I>C fistula</I>: 53; ILMA: 53</P>
<P>
<I>Mean (SD) age</I>: boiled extract of <I>C fistula</I>: 20.6 years (12.4); hydroalcoholic extract of <I>C fistula</I>: 19.8 years (11.5); ILMA: 22.9 years (13.6)</P>
<P>
<I>Sex</I> <I>(n,(%))</I>: boiled extract of <I>C fistula</I>: male: 35 (63.6), female: 20 (36.4); hydroalcoholic extract of <I>C fistula</I>: male: 29 (52.7), female: 26 (47.3); ILMA: male: 25 (45.5), female: 30 (54.5)</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Location of lesions (n(%)):</LI>
<UL>
<LI>Concentrated boiled extract of <I>C fistula</I>: foot 9 (16.4), hand 25 (45.5), trunk 5 (9.1), head and neck 8 (14.5), hand and foot 8 (14.5).</LI>
<LI>Hydroalcoholic extract of <I>C fistula</I>: foot 11 (20), hand 23 (41.8), trunk 6 (11), head and neck 10 (18.2), hand and foot 5 (9.1).</LI>
<LI>ILMA: foot 8 (14.5), hand 24 (43.6), trunk 5 (9.1), head and neck 11 (20), hand and foot 7 (12.7)</LI>
</UL>
<LI>Mean number of lesions (SD):</LI>
<UL>
<LI>Concentrated boiled extract of <I>C fistula</I>: 1.8 (1.13)</LI>
<LI>Hydroalcoholic extract of Cassia fistula: 1.72 (0.98)</LI>
<LI>ILMA: 2.03 (1.07)</LI>
</UL>
<LI>Kind of lesions (n(%)): </LI>
<UL>
<LI>Concentrated boiled extract of <I>C fistula</I>: nodule 23 (41.8), papule 17 (30.9), papule and nodule 15 (27.3)</LI>
<LI>Hydroalcoholic extract of <I>C fistula</I>: nodule 30 (54.5), papule 11 (20), papule and nodule 14 (25.5)</LI>
<LI>ILMA: nodule 39 (70.9), papule 5 (9.1), papule and nodule 11 (20)</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:57:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: concentrated boiled extract of C fistula. 500 g of <I>C fistula</I> was powdered and then mixed with water with ratio of 1:3, then boiled for 30 minutes and concentrated by distillation in vacuum condition.</LI>
<LI>
<I>Group 2</I>: hydroalcoholic extract of Cassia fistula on the lesions. 500 g of <I>C fistula</I> was powdered and mixed with 70% ethanol with ratio of 1:3, then placed in a percolator. After 48 hours, extraction was performed. The extract was then concentrated using distillation in vacuum condition.</LI>
<LI>
<I>Group 3</I>: ILMA. 0.5-2 mL twice a week</LI>
</UL>
<P>
<I>Duration of intervention</I>: until complete resolution of the lesion (complete epithelialisation) or for a maximum duration of 4 weeks.</P>
<P>
<I>Follow-up</I>: 3 months after completing the project, they were examined every month to assess the recurrence of the lesions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:04:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical and parasitological cure</I>: lesions were considered completely cured (improvement), if the participants achieved both clinical and parasitological resolutions (negative results of direct smear). Participants were considered resistant to the treatment, if no clinical changes were observed in the lesion or it was worsened.</P>
<P>
<I>Time to healing</I>: comparison of complete cure time of the cutaneous Leishmaniasis lesions between 3 groups</P>
<P>
<I>Adverse effects</I>: allergic reaction to the medications</P>
<P>Time points reported: week 1, 2, 3, 4, 16, complete cure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-07 13:06:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the study was self-funded</P>
<P>
<I>Possible conflicts of interest</I>: there was no conflict of interest</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:02:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jebran-2014">
<CHAR_METHODS MODIFIED="2017-11-07 13:07:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Leishmania Clinic of the German Medical Service (GMS), Darwaze-e-Lahory, 1st district, Kabul, Afghanistan</P>
<P>
<I>Study period</I>: 36 months (2004-7)</P>
<P>
<I>Sample size calculation</I>: sample size was calculated based on the primary outcome (i.e. complete wound healing). A number of 40 participants each was calculated to be necessary to obtain a power of 80% (significance level 5%). A presumed dropout rate of 20% led to a minimum total enrolment of 100 participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:02:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: male or female participants of the GMS Clinic; 5 years of age or older; with non-ulcerated (papule/nodule) or ulcerated lesions (ulcer with or without crust); presence of at least one parasitologically confirmed CL lesion and no prior history of leishmaniasis and/or anti-parasitic treatment</P>
<P>
<I>Exclusion criteria</I>: participants below age 5; with the presence of CL lesion(s) on or immediately adjacent to the nose, lips or eyes; pregnancy, or serious co morbidities</P>
<P>
<I>N randomised</I>: 135. Group 1: 73; group 2: 62</P>
<P>
<I>Withdrawals</I>: due to protocol breach: group 1, n = 14; group 2, n = 8. Lost to follow-up: group 1, n = 21; group 2, n = 22</P>
<P>
<I>N assessed</I>: 113 (83.7%): group 1: 59 (80.82%); group 2: 54 (87.09%).</P>
<P>
<I>Mean age (range)</I>: group 1: 18.62 years (5-66); group 2: 18.16 years (6-63)</P>
<P>
<I>Sex (male/female)</I>: 93/42; group 1: n = 51/22; group 2: n = 42/20.</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Lesion type: group 1: papule or nodule: 24, ulcer: 49; group 2: papule or nodule: 17, ulcer: 45</LI>
<LI>Location of the target lesion: group 1: 22 face, 2 shoulder/neck, 42 upper extremity, 7 lower extremity; group 2: 14 face, 0 shoulder/neck, 44 upper extremity, 4 lower extremity</LI>
<LI>MLDBT (range): group 1: 2.92 months (1-12); group 2: 2.61 months (1-9)</LI>
<LI>Giemsa smear: group 1: G0 (no amastigotes (AM)): 2, G 1 (1&#8211;10 AM): 49, G2 (11&#8211;100 AM): 7, G3 (&gt; 100 AM): 15; group 2: G0 (no AM): 0, G 1 (1&#8211;10 AM): 40, G2 (11&#8211;100 AM): 11, G3 (&gt; 100 AM): 11</LI>
<LI>Parasite load in the 1st biopsy (<I>Leishmania </I>per gram tissue): mean (SEM): group 2: 9.14 (2.85) × 107; group 2: 1.54 (0.83) × 108.</LI>
<LI>Wound surface after EC treatment: mean (SEM): group I: 347.9 mm³ (23.39); group 2: 391.9 mm³ (27.80)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:57:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: superficial coagulation and removal of lesion tissue was performed using bipolar high-frequency electrocauterisation (EC; also termed high-frequency electrocoagulation) with the help of the electrosurgical Mini Cutter HMC 80 HF. After EC, a polyacrylate hydrogel with freshly prepared 0.045% (w/w) pharmaceutical sodium chlorite (sodium chlorosum, DAC N-055) gel was applied to the lesions, daily</LI>
<LI>
<I>Group 2</I>: superficial coagulation and removal of lesion tissue was performed using bipolar high-frequency electrocauterisation (EC; also termed high-frequency electrocoagulation) with the help of the electrosurgical Mini Cutter HMC 80 HF. After EC, a polyacrylate hydrogel without DAC N-055</LI>
</UL>
<P>
<I>Duration of intervention</I>: time to wound closure</P>
<P>
<I>Co-interventions</I>: systemic antibiotics were only given if bacteria were detected and the wound infection was severe. Neither local nor systemic antifungal therapy was allowed to exclude anti-protozoal effects on the <I>Leishmania</I> infection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:07:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome - time to wound closure (days)</I>: the time needed for complete epithelialisation of the lesion wound was defined and photodocumented.</P>
<P>
<I>Secondary outcome -</I> <I>microbiological cure</I>: the parasite load (<I>Leishmania</I>/g) of the lesions was taken prior to electrocauterisation (1st time), after wound closure (2nd) and after 6 months (3rd)</P>
<P>
<I>Adverse effects</I>: such as bacterial or fungal superinfections of the wounds, the formation or scars and the rate of re-ulcerations were monitored during the treatment and follow-up period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-07 13:59:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Possible conflicts of interest</I>: not described</P>
<P>
<I>Study funding sources</I>: this study was supported by the German-Academic Exchange Service (travel grants to KWS, AFJ and FM), the Senior Expert Service (travel grants to KWS) and the Interdisciplinary Center of Clinical Research at the Universitätsklinikum Erlangen (IZKF, project A49 to US and CB). The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:05:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jowkar-2012">
<CHAR_METHODS MODIFIED="2017-11-07 14:00:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: double-blind, randomised placebo-controlled clinical trial</P>
<P>
<I>Setting/location</I>: south of Iran</P>
<P>
<I>Study period</I>: October 2007 to January 2009 (15 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:05:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I> and <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: men and women aged at least 12 years old, positive smear and/or polymerase chain reaction (PCR) for CL, cutaneous lesions of less than 4 months' duration</P>
<P>
<I>Exclusion criteria</I>: pregnancy and lactation, facial lesions, lesions of more than 4 months' duration, complete or incomplete treatment with a systemic or topical medication within the previous month, drug sensitivity</P>
<P>
<I>N randomised</I>: 100 participants</P>
<P>
<I>Withdrawals</I>: 37 participants</P>
<P>
<I>N assessed</I>: 63 participants (36 in treatment and 27 in control group)</P>
<P>
<I>Age</I>: range 12-62 years (mean 32.6 (SD 12) in the treatment group and 33.1 (14) in the vehicle group)</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 35/28</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Location of lesion(s): treatment: arm 12, hand 5, wrist 5, leg 7, foot 5, trunk 1, neck 1; control: arm 5, hand 7, wrist 4, leg 5, foot 2, trunk 2, neck 2</LI>
<LI>Type of lesion: treatment: plaque 19 and nodule 17; control: plaque 14 and nodule 13</LI>
<LI>Origin of the lesion: treatment: rural 24 and urban 12; control: rural 17 and urban 10</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:57:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 3% sodium nitrite in aqueous cream</LI>
<LI>
<I>Group 2</I>: aqueous cream alone (vehicle)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 12 weeks</P>
<P>
<I>Co-interventions</I>: simultaneously, cryotherapy once a week and aqueous cream containing 3% salicylic acid (emulsifying ointment 30 g, phenoxyethanol 1 g and freshly boiled and cooled water 69 g)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:07:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical response</I>:</P>
<UL>
<LI>Complete clinical response: complete re-epithelialisation of the ulcer and disappearance of induration</LI>
<LI>Partial clinical response: reduction of more than 50% of the ulcer and induration in relation to the last clinical evaluation</LI>
<LI>Absence of clinical response: increase or reduction of less than 50% of the ulcer and the indurated area in relation to the last clinical evaluation</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not described</P>
<P>
<I>Possible conflicts of interest</I>: no conflicts of interest</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:05:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kashani-2010">
<CHAR_METHODS MODIFIED="2017-11-07 14:10:28 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Center for Research &amp; Training in Skin Diseases &amp; Leprosy, Tehran University of Medical Sciences, Tehran, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:05:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I> and <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: the participants with CL who attended to Center for Research &amp; Training in Skin Diseases &amp; Leprosy, Tehran University of Medical Sciences, Tehran, Iran. The diagnosis was based on clinical findings and physical examination and confirmed by Giemsa-stained direct smear of the lesion</P>
<P>
<I>Exclusion criteria</I>: ore than 5 lesions; lesions greater than 5 cm in diameter; received anti-CL treatment during the previous month; lesions on the face and around vital organs; diabetic individuals; pregnant, lactating female participants; subjects with active infectious diseases</P>
<P>
<I>N randomised</I>: 85. Group 1: mesotherapy administration of meglumine antimonate: 41. Group 2: ILMA injection: 44</P>
<P>
<I>Withdrawals</I>: 25. Group 1: 11 (7 lost to follow-up, 3 inadequate efficacy, 1 allergic reaction). Group 2: 14 (10 lost to follow-up, 2 inadequate efficacy, 2 allergic reaction)</P>
<P>
<I>N assessed</I>: 60 (70.59%). Group 1: 30 (73.17%), group 2: 30 (68.18%)</P>
<P>
<I>Mean (SD) age</I>: Group 1: 25.24 years (16), group 2: 24.32 years (15.26)</P>
<P>
<I>Sex (male/female)</I>: Group 1: 19/11, group 2: 17/13</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Group 1: type of lesions (n (%)): papule 2 (6.66), nodule 6 (20), plaque 22 (73.33). Location of lesions (n (%)): upper extremities 15 (50), lower extremities 9 (30), other 9 (20).Ulcer (mean(SD), cm) (mean(SD), cm) 1.80 (0.64). Erythema (mean(SD), cm) 2.25 (0.66). Induration 0.91 cm (0.41)</LI>
<LI>Group 2: type of lesions (n (%)): papule 3 (10), nodule 7 (23.33), plaque 20 (66.66). Location of lesions (n (%)): upper extremities 13 (43.33), lower extremities 10 (33.33), other 7 (23.33). Ulcer(mean(SD), cm) 1.86 (0.55). Erythema (mean(SD), cm) 2.34 (0.69). Induration (mean (SD)) 1.12 cm (0.682)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: "Inderm Mesotherapy Gun (Innovative Med. Inc., Irvine, CA, USA) was set to inject 0.05 mL of MA in each shot in the depth of 2 mm using a 30 G needle. The shots were repeated in each 5 mm of the lesion."</LI>
<LI>
<I>Group 2</I>: 0.1 mL of MA (Glucantime, Rhone-Poulenc, France) was injected intradermally in the periphery of the lesions using a 30-G needle. The shots were repeated in each 1 cm of lesion until the whole lesion was blanched.</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks or until complete cure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:10:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: 3 categories were defined for ulcer healing: complete cure: complete re-epithelialisation of the ulcer with loss of induration; partial cure: 25 to 99% re-epithelialisation of lesions; failure: less than 25% re-epithelialisation of lesions. Improvement of the lesions: ulcer improvement (cm), induration improvement (cm), induration improvement (cm), speed of improvement (cm/week), speed of erythema improvement (cm/week), scare size (cm)</P>
<P>
<I>Microbiological cure</I>: Leismanian body: negative, positive.</P>
<P>
<I>Pain severity during injection</I>: visual analogue scale (VAS; 0 to 10).</P>
<P>
<I>Amount of drug used (mL/cm</I>²<I>) and number of treatment sessions</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 3 months after treatment. Adverse effects: after the each treatment session.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 12:08:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this study was supported by a research grant from Center for Research &amp; Training in Skin Diseases &amp; Leprosy, Tehran University of Medical Sciences, Tehran, Iran</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:58:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khatami-2012">
<CHAR_METHODS MODIFIED="2017-11-03 09:46:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Bam and Mashhad in Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 14:30:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: parasitologically proven cases of CL; otherwise healthy subjects on the basis of medical history, physical examination and results of blood tests; age 12&#8211;50 years; body weight &gt;40 kg; willingness to participate in the trial and signing the informed consent</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: 138 participants (75 in IMMA and 63 in miltefosine)</P>
<P>
<I>Withdrawals</I>: 33 in IMMA and 32 in miltefosine</P>
<P>
<I>N assessed</I>: 42 in IMMA arm and 31 in miltefosine</P>
<P>
<I>Age (years)</I>: not described</P>
<P>
<I>Sex</I>: not described</P>
<P>
<I>Baseline data</I>: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<P>
<I>Group 1</I>: oral miltefosine 2.5/kg/d for 28 days</P>
<P>
<I>Group 2</I>: IMMA 60 mg/kg/d for 14 days</P>
<P>
<I>Duration of intervention</I>: not described</P>
<P>
<I>Co-interventions</I>: not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:10:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing of their lesions and occurrence</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: participants were evaluated weekly for 28 days and then 1 month later</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:06:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khatami-2013">
<CHAR_METHODS MODIFIED="2017-11-07 14:32:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, assessor-blind, controlled clinical trial</P>
<P>
<I>Setting/location</I>: Kashan, Tehran, Iran</P>
<P>
<I>Study period</I>: September 2008 to April 2010 (19 months)</P>
<P>
<I>Sample size calculation</I>: 56 lesions per treatment group were needed to have 80% power to detect a significant difference in the expected cure rate of 60% in the ILMA alone group and the desired cure rate of 85% in the ILMA and either silver or non-silver dressing-treated group at week 10 with a type I error level of 0.05. Compensating for a 20% loss-to-follow-up, recruiting 68 (round up to 70) lesions per treatment group looked reasonable.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:06:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>major</I>
</P>
<P>
<I>Inclusion criteria</I>: parasitologically confirmed cases of CL based on positive smear and/or culture; otherwise healthy subjects on the basis of medical history; age of 12-60 years; willingness to participate in the study and signing the informed consent form (by the participant or his/her parent/guardian in cases younger than 18 years).</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating women; duration of lesion more than 3 months; number of lesions more than 5; ulcer size greater than 5 cm in largest diameter; history of receiving full course standard treatment (antimonials); history of allergy to MA or silver; serious systemic illnesses (as judged by the physician); participation in any drug trials in the last 60 days; indication for systemic treatment with MA; presence of secondary bacterial infection of the lesion according to clinical appearance</P>
<P>
<I>N randomised</I>: 83 participants (158 lesions) ILMA: 26 participants (45 lesions); ILMA + non-silver dressing: 26 participants (53 lesions); ILMA + silver dressing: 31 participants (60 lesions)</P>
<P>
<I>Withdrawals</I>: 10 participants (18 lesions)</P>
<P>
<I>N assessed</I>: 73 (140 lesions)</P>
<P>
<I>Mean (SD) age</I>: 28.81 years (14.45). ILMA: 32.88 years (12.92); ILMA + non-silver dressing: 30.31 years (15.41); ILMA + silver dressing: 24.13 years (13.97)</P>
<P>
<I>Sex</I>: male 39; ILMA: male 8; ILMA + non-silver dressing: male 11; ILMA + silver dressing: male 20</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean duration of lesions (SD): 7.951 weeks (2.67); ILMA: 8.31 weeks (2.86); ILMA + non-silver dressing: 8.46 weeks (2.15); ILMA + silver dressing: 7.23 weeks (2.82)</LI>
<LI>Mean number of lesions (SD): 1.90 (1.21); ILMA: 1.77 (1.34); ILMA + non-silver dressing: 2.00 (1.47); ILMA + silver dressing: 1.94 (1.12)</LI>
<LI>Induration area median (IQR): 169 mm² (79-433); ILMA: 270 mm² (120-557); ILMA + non-silver dressing: 156 mm² (67-490); ILMA + silver dressing: 141 mm² (48-346).</LI>
<LI>Ulceration area median (IQR): 6 mm² (1-25); ILMA: 8 mm² (2-37); ILMA + non-silver dressing: 6 mm² (0-15); ILMA + silver dressing: 6 mm² (0-24)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: eligible participants were randomly allocated into 2 groups and treated for 6 weeks with either:</LI>
</UL>
<UL>
<UL>
<LI>Weekly injections of ILMA combined with application of a non-silver dressing (AtraumanH, Hartmann, CMC Consumer Medical Care GmbH, Germany) on the lesions, or</LI>
<LI>Weekly injections of ILMA combined with application of a silver containing dressing (AtraumanH Ag, Hartmann, CMC Consumer Medical Care GmbH, Germany) on the lesions.</LI>
</UL>
</UL>
<UL>
<LI>
<I>Group 2</I>: weekly injections of ILMA (GlucantimeH; Rhodia Laboratories, Rhone-Poulenc, France) alone</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:12:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I> (complete healing defined as more than 75% reduction, clinical improvement defined as 50%&#8211;75% reduction, and no response to treatment defined as less than 50% reduction in the size of the lesion compared with baseline)</P>
<P>
<I>Relapse</I>: defined as a reappearance of lesions at the site or periphery of previously healed lesions or an increase in the size of lesions after initial improvement was assessed 5 months after the termination of treatment</P>
<P>
<I>Adverse effects</I>: itching and burning, exudation, oedema, and dermatitis</P>
<P>Time points reported: oucomes were assessed at the end of the treatment period (end of week 6), then at 4 weeks and 5 months after the last treatment session</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 12:08:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the budget of the research project has been provided by the Vice-Chancellery of Research of Tehran University of Medical Sciences.</P>
<P>
<I>Possible conflicts of interest</I>: the authors have declared that no competing interests exist.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:46:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochar-2000">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: India</P>
<P>
<I>Study period</I>: 5 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: participants with a confirmed diagnosis of <I>L tropica</I>. The diagnosis was confirmed by demonstrations of <I>L tropica </I>bodies (amastigote stage of <I>L tropica </I>under oil immersion).</P>
<P>
<I>Exclusion criteria</I>: no mention about inclusion or exclusion criteria</P>
<P>
<I>N randomised</I>: 50. Rifampicin 1200 mg/d orally: 25; placebo: 25</P>
<P>
<I>Withdrawals</I>: 4. Rifampicin 1: 2 (lost to follow-up); placebo: 2 (withdrew due to exacerbation of lesions)</P>
<P>
<I>N assessed</I>: 46. Rifampicin: 23; placebo: 23</P>
<P>
<I>Mean (SD) age</I>: rifampicin 29.54 years (17.34); placebo: 26.96 years (10.96)</P>
<P>
<I>Sex (male/female)</I>: rifampicin: 10/13; placebo: 9/14</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Type of lesions (% rifampicin versus placebo): ulcerative: 21.7 versus 17.4, nodular: 30.4 versus 30.4; nodule-ulcerative: 17.4 versus 30.4, and erythematous plaques: 30.4 versus 21.7.</LI>
<LI>Regarding the distribution (%): face: 17.5 versus 20.9; neck; 3.5 versus 0; shoulder: 1.75 versus 0; arms: 17.5 versus 20.9; hand: 19.2 versus 18.6; legs: 28 versus 16.2; feet: 8.77 versus 20.9, and abdomen: 3.5 versus 2.32</LI>
<LI>Mean number of lesions (SD): rifampicin 2.92 (4.61); placebo 2.08 (0.78)</LI>
<LI>Mean duration of lesions (SD): rifampicin 3.58 months (6.14); placebo: 3.23 months (2.93)</LI>
<LI>Mean size of lesions (SD): rifampicin 31.91 mm² (15.99); placebo: 37.04 mm² (12.37)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 15:00:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: rifampicin 1200 mg/d orally</LI>
<LI>
<I>Group 2</I>: placebo capsules orally</LI>
</UL>
<P>
<I>Duration of intervention</I>: 2 divided doses for 4 weeks</P>
<P>
<I>Duration of follow-up</I>: 4 weeks</P>
<P>
<I>Co-interventions</I>: the 2 withdrew due to exacerbation of lesions in placebo group and were treated by another therapeutic regimen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:13:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' at the end of treatment: a cure was defined as complete healing and disappearance of the lesion or reversible hypopigmentation at the site of lesion. Incomplete or partial healing was defined as a reduction in the size of a lesion and the absence of parasites on smear. A treatment failure or non-healing was defined as the absence of any change in the lesion and persistence of parasites on smear</P>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: at the end of the treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kochar-2006">
<CHAR_METHODS MODIFIED="2017-11-07 15:01:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: hospital, Bikaner, India</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-07 15:13:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: participants with a confirmed diagnosis of anthroponotic CL.</P>
<P>
<I>Exclusion criteria</I>: &#8212;</P>
<P>
<I>N randomised</I>: 50. Intervention group: 25, placebo group: 25</P>
<P>
<I>Withdrawals</I>: 6 lost to follow-up. Intervention group: 2, placebo group: 4</P>
<P>
<I>N assessed</I>: 44. Intervention group: 23, placebo group: 21</P>
<P>
<I>Age</I>: intervention group: n = 12, 16-20 years; n = 5, 21-30 years; n = 3, 31-40 years; n = 2, 41-50 years; n = 2, 51-60 years; n = 0, 61-70 years. Placebo group: n = 10, 16-20 years; n = 4, 21-30 years; n = 5, 31-40 years; n = 3, 41-50 years; n = 2, 51-60 years; n = 1, 61-70 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 34/16. Intervention group: 17/8; placebo group: 17/8</P>
<P>Male predominance was probably due to the habit of sleeping in open spaces outside the house without mosquito nets and improper clothing during night when the sandflies are active.</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Type of lesion:</LI>
<UL>
<LI>Intervention group: erythematous nodular: 11; erythematous plaque: 3; ulcerative: 3; erythematous ulcerative: 2; nodular: 4; nodular ulcerative: 2</LI>
<LI>Placebo group: erythematous nodular: 9; erythematous plaque: 5; ulcerative: 2; erythematous ulcerative: 5; nodular: 2; nodular ulcerative: 2</LI>
</UL>
<LI>Ratio lesions:participant</LI>
<UL>
<LI>Intervention group: 1:14; 2:5; 3:5; &gt; 3:1</LI>
<LI>Placebo group: 1:14; 2:7; 3:4; &gt; 3:0</LI>
</UL>
<LI>Distribution of lesions:</LI>
<UL>
<LI>Intervention group: face: 4; neck: 3; arms: 6; hand: 9; back: 2; abdomen: 1; buttock: 1; legs: 4; foot: 3</LI>
<LI>Placebo group: face: 11; neck: 2; arms: 6; hand: 9; back: 2; abdomen: 3; buttock: 1; legs: 3; foot: 4</LI>
</UL>
<LI>Most cases were presented with 1 to 3 months of duration of the disease.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 13:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: rifampicin (1200 mg/d) in 2 divided doses + omeprazole 20 mg</LI>
<LI>
<I>Group 2</I>: placebo</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
<P>
<I>Duration of follow-up</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:13:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' at the end of treatment: complete healing; partial response; no response</P>
<P>Time points reported: at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:06:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larbi-1995">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Saudi Arabia</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:06:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>:<I> L major</I>
</P>
<P>
<I>Inclusion criteria</I>: only participants in whom parasites (amastigotes) were demonstrated were enrolled</P>
<P>
<I>Exclusion criteria</I>: pregnancy, chronic illness, immunocompromised or hyper allergic reaction to the trial drugs, treatment with regular medications such as antituberculous agents and steroids, which might have affected specific therapy, treatment with anti-leishmanial drugs within the previous months, the presence of scars of previously treated lesions</P>
<P>
<I>N randomised</I>: 58. 2% miconazole cream: 27; 1% clotrimazole cream: 31</P>
<P>
<I>Withdrawals</I>: 4: 2% miconazole cream: 4 (lost to follow-up); 1% clotrimazole cream: 0</P>
<P>
<I>N participants assessed (lesions)</I>: 54 (151). 2% miconazole cream:n23 (62); 1% clotrimazole cream: 31 (89)</P>
<P>
<I>Mean (SD) age</I>: 2% miconazole cream: 19.5 years (15.4); 1% clotrimazole cream: 21.5 years (12.8)</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 42/12. 2% miconazole cream: 17/6; 1% clotrimazole cream: 25/6</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Lesion type (%): 2% miconazole group: nodular: 21 (34%), nodule-ulcerative: 37 (59%) and papular: 4 (7%). 1% clotrimazole group: nodular: 36 (41%), nodule-ulcerative: 50 (56%) and papular: 4 (3%)</LI>
<LI>Location of lesions: 2% miconazole group(percentage): the lower limbs: 56%; upper limbs 39%; head, neck, upper chest: 5%. 1% clotrimazole group: lower limbs: 34%; upper limbs: 46%; head, neck, upper chest: 19%, abdomen and groin: 1%.</LI>
<LI>2% miconazole group: MNL: Saudi: 2.2 and non-Saudi 3.4. MSL (range): 1.02 cm (0.06-5). Mean duration of lesions before treatment (SD): 2.1 weeks (1.3)</LI>
<LI>1% clotrimazole group: MNL: Saudi: 2.3 and non-Saudi 3.5. MSL (range): 1.38 cm (0.05-6). Mean duration of lesions before treatment (SD): 2.3 weeks (1.2)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-07 15:20:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 2% miconazole cream</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: 1% clotrimazole cream</LI>
</UL>
<P>
<I>Duration of intervention</I>: twice daily for 30 consecutive days</P>
<P>
<I>Duration of follow-up</I>: 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:15:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of lesions 'cured' at the end of treatment. Response to treatment was based on results of repeated parasitologic evaluation and/or clinical changes using the same parameters as in the follow-up. On this basis, response to treatment was graded into 4 categories: </P>
<UL>
<LI>Lesion fully healed (lesions were completely healed and parasitologically negative</LI>
<LI>Size reduced (lesions showed a reduction in infiltration, erythema, and size with positive or negative parasitology</LI>
<LI>No change (lesions did not show any change in infiltration, erythema, size, and parasitology</LI>
<LI>Lesions worsened or size increased (there was an increase in the size of the lesion and a worsening of infiltration and erythema and positive parasitology)</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:58:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Layegh-2007">
<CHAR_METHODS MODIFIED="2017-11-03 11:32:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective</P>
<P>
<I>Setting/location</I>: dermatology department of Qaem University Hospital, Mashhad, Iran</P>
<P>
<I>Study period</I>: from October 2004 through November 2005 (13 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:22:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not reported (although they reported that CLL is endemic and <I>L tropica</I> and, less commonly, <I>L major</I> are the most prevalent species)</P>
<P>
<I>Inclusion criteria</I>: aged &gt; 2 years with CL of &lt; 6-months' duration; no treatment of the current infection during the last 3 months; and no history of a renal or liver disease</P>
<P>
<I>Exclusion criteria</I>: pregnant women; history of intolerance or allergy to Glucantime or macrolides;</P>
<P>simultaneous use of antacids containing Al and Mg, theophyline, phenytoin, barbiturates, carbamazepine, and cyclosporin</P>
<P>
<I>N randomised</I>: 49: azithromycin: 22 (35 lesions), IMMA: 27 (58 lesions).</P>
<P>
<I>Withdrawals</I>: 2 (azithromycin group)</P>
<P>
<I>N assessed</I>: 47 participants; 20 (29 lesions) in the azithomicin group and 27 (58 lesions) in the IMMA group.</P>
<P>
<I>Mean (SD) age</I>: range 4-70 years; azithromycin: 21.77 years (17.13) and IMMA: 22.78 years (13.17)</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 24/25; azithromycin: 8/14; IMMA: 16/11</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean number of lesions (SD): azithromycin: 1.86 (1.52) and IMMA: 2.15 (1.38)</LI>
<LI>Mean duration of lesions (SD): azithromycin: 4.28 months (1.39) and IMMA: 3.22 months (2.03)</LI>
<LI>Type of lesions:</LI>
<UL>
<LI>Papule and plaque: azithromycin: 27 (77.1%); IMMA: 49 (84.5%)</LI>
<LI>Nodular: azithromycin: 6 (17.1%); IMMA: 7 (12.1%)</LI>
<LI>Ulcerative: azithromycin: 2 (5.8%); IMMA: 2 (2.8%)</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: "daily oral dose of 500 mg of azithromycin for 5 days/month in adults and 10 mg/kg in children; treatment cycles were repeated monthly when no favourable response was achieved, up to a maximum duration of 4 months"</LI>
<LI>
<I>Group 2</I>: 60 mg/kg IMMA for 20 days</LI>
</UL>
<P>
<I>Duration of intervention</I>: up to 4 months (azithromicin) and 20 days (IMMA)</P>
<P>
<I>Co-interventions</I>: participants showing no favourable response after 4 months of azithromycin therapy would receive IMMA at the same dose as the other group, at the end of the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:17:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: clinical response was determined on the basis of the lesions' size, border, induration, and infiltration of papulonodular lesions; ulcerative lesions were evaluated on the basis of the ulcer depth, diameter, crusting, and the extent of re-epithelialisation</P>
<UL>
<LI>Complete or significant improvement: decrease in the induration size &gt; 75% or full re-epithelialisation of the le-scions and a negative direct skin smear (absence of parasites in the lesion)</LI>
<LI>No improvement: decrease in induration size &lt; 30%</LI>
<LI>Partial improvement: any changes between above criteria</LI>
</UL>
<P>
<I>Recurrence</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: participants in the azithromycin group were evaluated monthly up to a maximum of 4 months, but participants in the IMMA group were evaluated both at the end of the treatment period (day 20) and 45 days later. Recurrence was reported after the 16-week follow-up period.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:59:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Layegh-2009">
<CHAR_METHODS MODIFIED="2017-11-08 15:28:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Dermatology Clinic of Qaem Hospital in Mashad, Iran</P>
<P>
<I>Study period</I>: 10 months</P>
<P>
<I>Sample size calculation</I>: to detect a 22% difference in the cure rate between cryotherapy and ILMA groups and assuming a 57% cure rate in the cryotherapy group, with a 65% power and a 10% 2-sided type I error, 40 persons were needed in each group. The 79 participants who met our criteria were randomly divided into 2 groups: 40 participants received cryotherapy and 39 participants received ILMA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:59:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: positive direct skin smears for CL, were &#8804; 13 years of age, had visited the dermatology clinic from September 2006 through June 2007, and had lesions with a duration of &lt; 12 weeks to exclude any natural self-healing during follow-up</P>
<P>
<I>Exclusion criteria</I>: &gt; 13 years of age, had a lesion history &gt; 3 months, allergic to antimonial drugs, simultaneously using any other therapeutic method</P>
<P>
<I>N randomised</I>: 79. Cryotherapy: 40, ILMA: 39</P>
<P>
<I>Withdrawals</I>: 7: cryotherapy group: 4, ILMA: 3</P>
<P>
<I>N assessed</I>: 72 (91.14%): cryotherapy group: 36 (90%), ILMA: 36 (92.31%)</P>
<P>
<I>Mean (SD) age</I>: 6.8 years (3.4) in cryotherapy group and 6.2 years (3.4) in ILMA group</P>
<P>
<I>Sex (male/female)</I>: cryotherapy: 18/22; ILMA: 20/19</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean number of lesions (SD): cryotherapy: 1.9 (1.02); ILMA: 1.4 (0.76)</LI>
<LI>Location of lesions by site:</LI>
<UL>
<LI>Head and neck: cryotherapy: 24, ILMA: 31</LI>
<LI>Upper limb (hand): cryotherapy: 10, ILMA: 13</LI>
<LI>Lower limbs (foot): cryotherapy: 4, ILMA: 3</LI>
</UL>
<LI>Type of lesion:</LI>
<UL>
<LI>Papule/plaque: cryotherapy: 35, ILMA: 37</LI>
<LI>Nodule: cryotherapy: 2, ILMA: 3</LI>
<LI>Ulcer: cryotherapy: 1, ILMA: 2</LI>
</UL>
<LI>Mean duration of lesions (SD): cryotherapy: 11.2 weeks (11.8); ILMA: 12.1 weeks (18.4)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: cryotherapy group: liquid nitrogen (&#8722;195°C) was applied twice to the lesion. Each cycle was 10&#8211;15 s of freezing time with a thawing interval of 20 s. Care was taken to ensure that freezing reached up to a few millimetres within the healthy skin surrounding the lesion</LI>
<LI>
<I>Group 2</I>: ILMA (Glucantime; Specia, Paris, France) in a volume of 0.5&#8211;2 cm³ was injected into each lesion until the lesion was completely infiltrated (blanched)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:20:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: complete cure was defined as full re-epithelialisation; disappearance of oedema, induration, and other signs of inflammation; and a negative direct skin smear result. Score:</P>
<OL>
<LI>Complete improvement (full re-epithelialisation of the lesions and a negative direct skin smear result),</LI>
<LI>Significant improvement (decrease in induration size &gt; 75%),</LI>
<LI>Partial improvement (decrease in induration size between 50% and 75%,</LI>
<LI>Slight improvement (decrease in induration size between 25% and 50%</LI>
<LI>No improvement (decrease in induration size &lt; 25%)</LI>
</OL>
<P>
<I>Time to healing</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment and 6 months (clinical cure); at 4, 5 and 6 weeks (time to healing); at the end of treatment, after 6 weeks (adverse effects)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:58:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Layegh-2011">
<CHAR_METHODS MODIFIED="2017-11-08 15:28:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Dermatology Clinic of Ghaem Hospital, Mashhad, Iran</P>
<P>
<I>Study period</I>: March 2008 to September 2010 (30 months)</P>
<P>
<I>Sample size calculation</I>: to detect a 35% difference in the cure rate between the 2 groups of liposomal AmB and ILMA, assuming a 90% cure rate in liposomal AmB group with a 95% power and a 5% 2-sided type I error, 36 subjects were required in each group. Also regarding a loss to follow-up of 20%, this number was raised to 50 participants for each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:22:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>, <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: cutaneous leishmaniasis approved by either a direct smear stained with Giemsa or a positive skin biopsy of lesions with less than 6-month duration, in cases with a previous history of anti-leishmaniasis therapy, a 3-month treatment-free interval from the last treatment course</P>
<P>
<I>Exclusion criteria</I>: pregnancy, breastfeeding, taking any other specific treatment while participating in the study, past medical history of any local or systemic disease during the last 2 months, a significant underlying disease such as cardiac, renal, or liver dysfunction</P>
<P>
<I>N randomised</I>: 110. Group 1: 50; group 2: 60</P>
<P>
<I>Withdrawals</I>: 34 did not adhere. Group 1: 11; group 2: 23</P>
<P>
<I>N assessed</I>: group 1: 39 (78%); group 2: 37 (61.7%)</P>
<P>
<I>Mean (SD) age</I>: group 1: 20.54 years (18.72); group 2: 25.30 years (15.70)</P>
<P>
<I>Sex (male/female)</I>: group 1: 23/27; group 2: 21/39</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Mean number of lesions (SD): group 1: 1.91 (1.02); group 2: 1.4 (0.76)</LI>
<LI>Location of the target lesion:</LI>
<UL>
<LI>Group 1: head and neck, 26; hand, 18; leg and trunk, 6</LI>
<LI>Group 2: head and neck, 22; hand 32; leg and trunk, 6</LI>
</UL>
<LI>Type of lesions:</LI>
<UL>
<LI>Group 1: papule/plaque, 33; nodule, 8; ulcer, 9</LI>
<LI>Group 2: papule/plaque, 53; nodule, 5; ulcer, 2</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: liposomal AmB was administered as 3&#8211;7 drops twice daily according to the lesion size</LI>
<LI>
<I>Group 2</I>: ILMA (Glucantime; Specia, Paris, France) was injected into each lesion once a week, to the point when the lesion's surface became fully infiltrated and up to a maximum dose of 2 mL</LI>
</UL>
<P>
<I>Duration of intervention</I>: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:21:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical response</I>: determined on the basis of the lesion induration size of and the extent of re-epithelialisation in ulcerative ones. Scales: clinical response: </P>
<UL>
<LI>Slight improvement: decrease in induration size up to 25%</LI>
<LI>Mild improvement: decrease in induration size between 25 and 50%</LI>
<LI>Moderate improvement: decrease in induration size between 50 and 75%</LI>
<LI>Marked improvement: decrease in induration size more than 75%</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment, and 6 months after termination. Adverse effects were reported at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lynen-1992">
<CHAR_METHODS MODIFIED="2017-11-08 09:48:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: school children, Sudan</P>
<P>
<I>Study period</I>: 80 days</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:21:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> spp not specified but <I>L major</I> was presumed to be the causative parasite.</P>
<P>
<I>Inclusion criteria</I>: all positive smears</P>
<P>
<I>Exclusion criteria</I>: children who had received diminazene aceturate or previous treatment in hospital</P>
<P>
<I>N randomised</I>: 70. 35 in each group</P>
<P>
<I>Withdrawals</I>: 8. Berelin: 3; Savlon: 5. 2 children in Berelin group were not enrolled because they received diminazene aceturate before. 2 in Savlon group were excluded because they were treated for CL in the hospital</P>
<P>
<I>N assessed</I>: 62. Berelin: 32; Savlon: 30</P>
<P>
<I>Mean (SD) age</I>: Berelin: 9.3 years (4.6); Savlon: 10.4 years (2.8)</P>
<P>
<I>Sex (male/female)</I>: Berelin: 18/15; Savlon: 20/13</P>
<P>
<I>Baseline imbalances</I>: comparability with regard to sex, age, number, size, duration and location of ulcer, and previous treatment taken</P>
<UL>
<LI>Size of lesion (% (n/N)): small lesions (&lt; 2 cm): Berelin: 58% (19/33); Savlon: 61% (20/33); big lesions (&#8805; 2 cm): Berelin: 42% (14/33); Savlon: 39% (13/33)</LI>
<LI>Duration (% (n/N)): &#8804; 2 months: Berelin: 52% (17/33); Savlon: 64% (21/33). &gt;2 months: Berelin: 48% (16/33); Savlon: 36% (12/33)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 09:49:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: Berelin (1.05 g diminazene aceturate in 2.36 g of granulate, dissolved in 12.5 cc of distilled water) daily except on Fridays for 50 days</LI>
<LI>
<I>Group 2</I>: Savlon (cetrimide 15% + chlorhexidine 1.5% in a 2% solution) for 50 days</LI>
</UL>
<P>
<I>Duration of treatment</I>: 50 days</P>
<P>
<I>Duration of follow-up</I>: one month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:22:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>: percentage of participants 'cured' at the end of treatment. Cure was defined when the skin lesion was completely closed and covered with scar tissue, without the possibility to evoke secretions on pressure and if this apparent cure was sustained for at least 2 weeks</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur 20 to 35 days after cure</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment and at the end of follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:06:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maleki-2012">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Imam Reza Hospital in Mashhad, Iran</P>
<P>
<I>Study period</I>: March to September 2004 (7 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: confirmation of cutaneous leishmaniasis based on direct smear, &#8804; 3 lesions, duration of the disease &lt; 12 weeks, aged 7-60 years, completion of informed consent form by participant or parents of minor participants, dry cutaneous leishmaniasis</P>
<P>
<I>Exclusion criteria</I>: pregnant or breastfeeding women; children &lt; 7 years, lesions on ear, nose, joints, and near the eye; &gt; 3 lesions; application of any kind of treatment for cutaneous leishmaniasis, duration of the disease longer than 12 weeks (to omit spontaneous healing cases during the follow-up period), recurrent infection, wet cutaneous leishmaniasis</P>
<P>
<I>N randomised</I>: 45 participants</P>
<P>
<I>Withdrawals</I>: 11</P>
<P>
<I>N assessed</I>: 34 participants (24, group 1; 10, group 2)</P>
<P>
<I>Age</I>: not described</P>
<P>
<I>Sex</I>: not described</P>
<P>
<I>Baseline data</I>: mean size of lesions (SD): group 1, 1.27 cm (0.81); group 2, 0.98 cm (0.61)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:58:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: 2 bouts of intralesional 2% zinc sulphate was performed twice within 2 weeks interval</LI>
<LI>
<I>Group 2</I>: 6 weekly bouts of ILMA</LI>
</UL>
<P>
<I>Duration of intervention</I>: group 1, 2 weeks; group 2, 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:23:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical response</I>
</P>
<UL>
<LI>Slight: partial reduction of erythema and oedema</LI>
<LI>Mild: reduction of lesion size up to 30%</LI>
<LI>Moderate: reduction of lesion size between 30% and 60%</LI>
<LI>Marked: reduction of lesion size more than 60% or negative smear</LI>
<LI>Total tolerance: complete healing of the lesion with negative smear</LI>
</UL>
<P>Time points reported: 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:59:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mapar-2010">
<CHAR_METHODS MODIFIED="2017-11-08 10:06:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Ahvaz city, southern Iran</P>
<P>
<I>Study period</I>: 12 months (2002)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 10:10:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: clinically and parasitologically positive (Leishman bodies in Giemsa-stained direct smear of the lesion scrapings), duration of lesions &lt; 3 months, aged 15-40 years, no evidence of secondary bacterial infections, no mucosal involvement, no history of previous treatment of cutaneous leishmaniasis, or of allergic reactions to MA or metronidazole</P>
<P>
<I>Exclusion criteria</I>: history of underlying disease (such as cardiac, renal, or pulmonary); pregnant or breastfeeding; cutaneous leishmaniasis localised on or near the joints</P>
<P>
<I>N randomised</I>: 36. Group 1: 18, group 2: 18</P>
<P>
<I>Withdrawals</I>: 8. Group 1: 2, group 2: 6</P>
<P>
<I>N assessed</I>: 28 (77.78%). Group 1: 16, group 2: 12</P>
<P>
<I>Age</I>: mean 28.8 years (range 15-40)</P>
<P>
<I>Sex (male/female)</I>: 21/15</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Total lesions: group 1: 29, group 2: 27</LI>
<LI>Group 1: lesions were of dry types (without any discharge), the longest diameters of the lesions were 0.5-2.5 cm</LI>
<LI>Group 2: clinically dry type skin lesions. The longest diameters of the lesions were 0.5-2.5 cm</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:59:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: weekly ILMA injections (150-600 mg = 0.5-2 mL of MA ampoule for each skin lesion). Intralesional injections were administered intradermally enough to blanch the lesions surface.</LI>
<LI>
<I>Group 2</I>: weekly IL metronidazole (500 mg/100 mL vials were made by Fresenius, Bad Homburg), injected intradermally into each skin lesion enough to blanch the lesions surface (0.5-2 mL for each lesion)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:25:29 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>
<I>Clinical cure of the lesions</I>: clinical criteria for cure were: complete re-epithelialisation, disappearance of oedema, induration, and other signs of inflammation, flattening of the lesions and change of colour from erythematous to blue or dark grey</LI>
<LI>
<I>Adverse effects</I>: local or systemic adverse effect. Pain of intralesional injection. Local inflammatory reactions with oedema and induration. In both groups the participants complained of severe pain at the site of injections but group 2 had unbearable terrible pain</LI>
</UL>
<P>Time points reported: clinical cure: after 8 injections. Adverse effects: after the treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mashood-2001">
<CHAR_METHODS MODIFIED="2017-11-08 10:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: skin department of PNS Shifa, a naval hospital in Karachi. Endemic areas of Balochistan province, Pakistan</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:18:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> spp not mentioned</P>
<P>
<I>Inclusion criteria</I>: never received any treatment for their skin disease</P>
<P>
<I>Exclusion criteria</I>: very young and very old people, those who had received some treatment for the disease, people suffering from diffuse CL or leishmaniasis recidivans, people with some known cardiac, renal or hepatic disease</P>
<P>
<I>N randomised</I>: 40. 20 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>Participants assessed: 40 (100%). 20 in each group</P>
<P>
<I>Age</I>: range 20-40</P>
<P>
<I>Sex</I>: 100% male</P>
<P>
<I>Baseline data.</I> Nodular, ulcerative and crusted forms were the most common morphological patterns seen. Most lesions were on hands and feet.</P>
<UL>
<LI>Group 1: MSL: 570.7 mm². MDLBT (range): 8.6 weeks (4-20)</LI>
<LI>Group 2: MSL: 960.3 mm². MDLBT: 12.6 weeks (8-24)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:15:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: oral AL 20 mg/kg/d in 3-4 divided doses tablet</LI>
<LI>
<I>Group 2</I>: IVSSG 20 mg/kg/d</LI>
</UL>
<P>
<I>Duration of intervention</I>: 15 days</P>
<P>
<I>Duration of follow-up</I>: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:25:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' at the end of treatment</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 11:54:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohebali-2007">
<CHAR_METHODS MODIFIED="2017-11-08 10:16:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Golestan province, in northeastern Iran</P>
<P>
<I>Study period</I>: 20 November 2005 to 20 July 2006 (8 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 11:54:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>major</I>
</P>
<P>
<I>Inclusion criteria</I>: observation of Leishman bodies (amastigotes) in dermal lesions, no previous use of anti-leishmanial drugs, no previously confirmed leishmaniasis (by scar or clinically compatible history), no pregnant or lactating women, no acute or chronic medical condition and no history of allergy, female participants of childbearing age were included after giving consent for effective contraception during therapy and until 3 months thereafter</P>
<P>
<I>Exclusion criteria</I>: not explicitly reported, but can be inferred from the above inclusion criteria</P>
<P>
<I>N randomised</I>: 63. Group 1: 32; group 2: 31</P>
<P>
<I>Withdrawals</I>: 5. Group 1: 4 (lost after first week because lack of gastrointestinal tolerance); group 2: 1 (lost to follow-up after 3 months)</P>
<P>
<I>N assessed</I>: 63 (100%). Group 1: 28; group 2: 30</P>
<P>
<I>Mean age</I>: group 1: 20.2 years; group 2: 16.8 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 35/28. Group 1: 19/13; group 2: 16/15</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Location of the target lesion (%): &lt; 20% of lesions were located on the face in each group: group 1: 12.5%; group 2: 16.1%</LI>
<LI>Mean number of lesions (range): group 1: 2.7 (1-15); group 2: 2.5 (1-10)</LI>
<LI>Mean size of lesions (range): group 1: 27.1 mm² (0.9-80.0); group 2: 19.3 mm² (3-67.3)</LI>
<LI>Mean duration of lesions: group 1: 45.5 days; group 2: 43.6 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:28:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: miltefosine orally 2.5 mg/kg daily for 28 days. Miltefosine capsules were administered as follows: 9-14 kg, 3 capsules of 10 mg; 15-29 kg, 1 capsule of 50 mg; 30-45 kg, 2 capsules of 50 mg; 46-84 kg, 3 capsules of 50 mg</LI>
<LI>
<I>Group 2</I>: IMMA at 20 mg SbV&#8309;/kg body weight daily for 14 days</LI>
</UL>
<P>
<I>Duration of intervention</I>: miltefosine: 28 days. IMMA: 14 days</P>
<P>
<I>Duration of follow-up</I>: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:26:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' 3 months after treatment</P>
<P>
<I>Secondary outcomes</I>: duration of remission and percentage of people with treated lesions that recur within 6 months</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 2 weeks, 3 months, 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 10:28:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this study was financially supported by Medical Sciences/University of Tehran, Iran (from grant for full professor)</P>
<P>
<I>Possible conflicts of interest</I>: not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 12:01:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Momeni-1996">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: assuming a 30% spontaneous cure rate with placebo and the minimum usefulness of a 60% cure rate with itraconazole, and a 10% dropout rate, the sample size was calculated as 70 individuals in each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 12:01:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: age &gt; 12 years, diagnosis of CL confirmed by laboratory test results, no previous treatment for leishmaniasis, no serious concomitant medical problems</P>
<P>
<I>Exclusion criteria</I>: age &lt; 12 years, pregnant and nursing women, patients who had lesions on the face, lesions lasting &gt; 4 months</P>
<P>
<I>N randomised</I>: 140. Itraconazole: 70; placebo: 70</P>
<P>Withdrawals: itraconazole: 5</P>
<P>
<I>N assessed</I> <I>(lesions)</I>: 131. Itraconazole: 65 (219); placebo: 66 (262)</P>
<P>
<I>Age</I>: mean 26.3 years (range 12-46)</P>
<P>
<I>Sex (male/female)</I>: 90/41. Itraconazole: 44/21; placebo: 46/20</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Number of lesions: itraconazole: 219; placebo: 262</LI>
<LI>Mean duration of lesions (SD): itraconazole: 38 days (1.45 months); placebo: 45 days (1.5 months)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:32:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: itraconazole orally 7 mg/kg/d (max. 400 mg per day)</LI>
<LI>
<I>Group 2</I>: placebo capsules</LI>
</UL>
<P>
<I>Duration of intervention</I>: 3 weeks</P>
<P>
<I>Duration of follow-up</I>: 51 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:26:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' 51 days after treatment</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment (day 21); on day 51 (1 month after the end of treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this work was supported by the World Health Organization Special Program for Research and Training in Tropical Diseases and the research programme of Isfahan University of the Medical Sciences.</P>
<P>
<I>Possible conflicts of interest</I>: not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Momeni-2002">
<CHAR_METHODS MODIFIED="2017-11-08 10:34:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Research Centre in Isfahan city. Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:22:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>major</I>
</P>
<P>
<I>Inclusion criteria</I>: age &gt; 5 years, diagnosis of CL confirmed by laboratory test results, no previous treatment for leishmaniasis, no serious concomitant medical problems, signed written informed consent</P>
<P>
<I>Exclusion criteria</I>: pregnant and nursing women, age &lt; 5 years, lesions lasting for &gt; 4 months</P>
<P>
<I>N randomised</I>: 72. Group 1: 36; group 2: 36</P>
<P>
<I>Withdrawals</I>: 6, lost to follow-up. Group 1: 5; group 2: 1</P>
<P>
<I>N participants assessed</I> <I>(lesions)</I>: 66 (196). Group 1: 31 (91); group 2: 35 (105)</P>
<P>
<I>Mean age (male/female)</I>: 21.9 years/17.6 years (range 5-48 years). Group 1: 23.6 years/17.4 years; group 2: 20.2 years /18.1 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 50 (75.7%)/16 (24.3%). Group 1: 26/5; group 2: 24/11</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Number of lesions: group 1: 91; group 2: 105</LI>
<LI>Mean duration of lesions (SD): group 1: 46.7 days (1.67 months); group 2: 45 days (1.58 months)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:36:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: AL 20 mg/kg per day + low-dose IMMA 30 mg/kg/d for 20 days</LI>
<LI>
<I>Group 2</I>: IMMA 60 mg/kg/d for 20 days</LI>
</UL>
<P>
<I>Duration of intervention</I>: 20 days</P>
<P>
<I>Duration of follow-up</I>: 51 days (1 month after the end of treatment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:26:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' 51 days after treatment. On day 21 (end of therapy), the clinical response to treatment was coded subjectively as: apparent cure, partial response, and failure. After 1 month of follow-up (day 51), the participants were described as showing definitive cure if all the lesions had healed and direct smears of the lesions were negative</P>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Tertiary outcomes</I>: microbiological or histopathological cure of skin lesions</P>
<P>Time points reported: day 21, and 1 month after the end of treatment: day 51</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:20:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Momeni-2003">
<CHAR_METHODS MODIFIED="2017-11-08 10:37:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: endemic areas in the north of Isfahan city, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: sample size calculation was based on 90% significance and 90% power to detect a difference between vehicle and ketoconazole. Assuming a 15% spontaneous cure with placebo, a minimum usefulness of a 60% cure with ketoconazole cream and about a 10% dropout, the sample size was calculated as 45 individuals in each group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:20:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> spp: <I>L major</I> and <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: age &gt; 5 years, laboratory-confirmed diagnosis of CL, no previous treatment for leishmaniasis, no serious concomitant medical problems</P>
<P>
<I>Exclusion criteria</I>: pregnant and nursing women, lesions on the face, lesions of &gt; 4 months duration</P>
<P>
<I>N randomised</I>: 90</P>
<P>
<I>Withdrawals</I>: 17</P>
<P>
<I>N assessed</I>: 73</P>
<P>
<I>Age</I>: mean 19.9 years (range 6-60)</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 45/28</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Total number of lesions: 59 (group 1) and 43 (group 2)</LI>
<LI>Mean duration of lesions: 38 days (group 1) and 42 days (group 2)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:40:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ketoconazole cream</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: vehicle</LI>
</UL>
<P>
<I>Duration of intervention</I>: twice daily for 21 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:27:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: clinical response to treatment was coded subjectively as: apparent cure, partial response or failure. Definitive cure was defined if at day 51, the lesions were healed and direct smears of the lesions were negative.</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: the clinical response of the lesions was reported on days 21 (end of therapy) and 51</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: supported by a research programme of Isfahan University of Medical Sciences</P>
<P>
<I>Possible conflicts of interest</I>: not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:59:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mostafavi-2013">
<CHAR_METHODS MODIFIED="2017-11-08 10:41:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: skin and CL clinic in Gaz in Isfahan, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 10:44:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: size of ulcer less than 5 cm in diameter, &#8804; 5 lesions, duration of disease &lt; 3 months</P>
<P>
<I>Exclusion criteria</I>: patients who had lesions on the face near the eyes or on the nose or ears,</P>
<P> pregnancy, lactation, lupoid or sporotrichoid lesions, use of immunosuppressor drugs in the past 6 months and severe adverse effects, exacerbation of the disease</P>
<P>
<I>N randomised</I>: 40 participants (19 in prepared gel group and 21 vehicle gel mask)</P>
<P>
<I>Withdrawals</I>: 1 participant in prepared gel group</P>
<P>
<I>N assessed</I>: 39. 21 (100%) in vehicle gel group, and 18 in prepared gel group</P>
<P>
<I>Mean age</I>: 28.2 years</P>
<P>
<I>Sex (male/female)</I>: 25/15</P>
<P>
<I>Baseline data</I>: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:59:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: MA gel mask. Prepared by using polyvinyl alcohol (PVA), sodium carboxymethylcellulose, and hydroxypropyl methylcellulose as the base polymer and glycerin as the plasticizer, applied twice a day</LI>
<LI>
<I>Group 2</I>: vehicle gel mask, applied twice a day</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
<P>
<I>Co-interventions</I>: all of the participants received the standard treatment including ILMA weekly and cryotherapy every 2 weeks for a maximum of 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:28:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Treatment outcome</I>, defined as:</P>
<UL>
<LI>Complete healing: complete disappearance of the lesion</LI>
<LI>Moderate improvement: reduction in the size of the lesion more than 50%</LI>
<LI>Mild improvements: reduction in the size of the lesion less than 50%</LI>
<LI>No change: no considerable change in the size of the lesion</LI>
<LI>Worsening: increase in the size of lesion</LI>
<LI>Relapse: recurrence of lesion after complete healing</LI>
</UL>
<P>Time points reported: 2 months after the end of treatment for relapse</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mujtaba-1999">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Pakistan</P>
<P>
<I>Study period</I>: around 4-5 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 10:50:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania</I> spp not mentioned</P>
<P>
<I>Inclusion criteria</I>: clinical diagnosis of CL and positive Giemsa-stained smear of parasite</P>
<P>
<I>Exclusion criteria</I>: &gt; 5 lesions and pregnant women</P>
<P>
<I>N participants randomised (lesions)</I>: 104 (215). Group 1: n = 49 (111); group 2: n = 55 (104)</P>
<P>
<I>Withdrawals</I>: 8</P>
<P>
<I>N assessed</I>: 96. group 1: n = 49; group 2, n = 47</P>
<P>
<I>Age</I>: </P>
<UL>
<LI>0-10 years: group 1, 11; group 2, 12</LI>
<LI>11-20 years: group 1, 19; group 2, 17</LI>
<LI>21-30 years: group 1, 10; group 2, 11</LI>
<LI>&gt; 30 years: group 1, 9; group 2, 7</LI>
</UL>
<P>
<I>Sex (male/female)</I>: 58/38</P>
<P>
<I>Baseline imbalances</I>: comparability regarding age, sex, number, and site of lesions and duration of the disease</P>
<UL>
<LI>Duration of the disease (months)</LI>
<UL>
<LI>0&#8211;2: group 1, 12; group 2, 11</LI>
<LI>3-4: group 1, 13; group 2, 12</LI>
<LI>5&#8211;6: group 1, 11; group 2, 13</LI>
<LI>&gt;6: group 1, 13; group 2, 11</LI>
</UL>
<LI>No. of lesions in individual participants</LI>
<UL>
<LI>1: group 1, 21; group 2, 19</LI>
<LI>2: group 1, 12 ; group 2, 11</LI>
<LI>3: group 1, 11; group 2, 10</LI>
<LI>&gt; 3: group 1, 5; group 2, 7</LI>
</UL>
<LI>Total number of lesions at various anatomic sites in all participants</LI>
<UL>
<LI>Upper limbs: group 1, 48; group 2, 45</LI>
<LI>Face: group 1, 33; group 2, 31</LI>
<LI>Lower limbs: group 1, 29; group 2, 28</LI>
<LI>Trunk: group 1, 1; group 2, 0</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:49:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ILMA injections weekly until complete cure or up to 8 weeks</LI>
<LI>
<I>Group 2</I>: ILMA injections fortnightly until complete cure or up to 8 weeks</LI>
</UL>
<P>
<I>Duration of intervention</I>: until complete cure or up to 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 10:51:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing</I>: complete cure (100%); partial (&gt; 50%; &lt; 50%); failure (nil)</P>
<P>
<I>Speed of healing (time taken to be 'cured')</I>
</P>
<P>
<I>Duration of remission and percentage of people with treated lesions that recur within 6 months and 1, 2</I>, and<I> 3 years</I>:<I> time assessment not specified</I>
</P>
<P>
<I>Prevention of scarring</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at 2, 4, 6 and 8 weeks of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:24:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<CHAR_METHODS MODIFIED="2017-11-08 10:52:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: October 2000 to February 2001 (5 months)</P>
<P>
<I>Sample size calculation</I>: to detect a clinically relevant difference of at least 25% between placebo (35% estimated response rate) and itraconazole (60% estimated response rate) in the primary outcome parameter with a power of 90% and a 2-sided type I error of 5%, a total of 164 subjects (82 in each group) were required. To compensate for dropouts, 20% more participants were enrolled in each group (in total 200 participants).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:24:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L</I> <I>major</I>
</P>
<P>
<I>Inclusion criteria</I>: aged 12-60 years; presence of parasitologically confirmed lesion(s) of CL; healthiness on the basis of physical examination, medical history, and the results of blood biochemistry and haematology, carried out &lt; 2 weeks before the start of the trial</P>
<P>
<I>Exclusion criteria</I>: women of child-bearing age without adequate effective contraception, pregnant or breastfeeding, duration of lesions &gt; 45 days, presence of lesions on the face or near the mucous membranes, &gt; 5 lesions, any lesion with a diameter &gt; 3 cm, history of any systemic antileishmanial therapy, known hypersensitivity/allergy to itraconazole, receiving any drug with known interaction with itraconazole</P>
<P>
<I>N randomised</I>: 200</P>
<P>
<I>Withdrawals</I>: 42 in total. 17 in the Itraconozale group and 25 in the placebo group</P>
<P>
<I>N assessed</I>: 158</P>
<P>
<I>Age</I>: not described</P>
<P>
<I>Baseline imbalances</I>: comparable with regard to age, sex, and duration of the lesions</P>
<UL>
<LI>Group 1: mean number of lesions: 2.5, mean size of lesions: 7.76 mm</LI>
<LI>Group 2: mean number of lesions: 2.2, mean size of lesions: 8.58 mm</LI>
<LI>Duration of &lt; 45 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 10:58:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: itraconazole 200 mg once daily</LI>
<LI>
<I>Group 2</I>: placebo</LI>
</UL>
<P>
<I>Duration of intervention</I>: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:29:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: for clinical assessment a 5-point scoring system was employed: cure (complete re-epithelialisation of all of the lesions), moderate improvement (more than 50% reduction in the size of the lesions), mild improvement (less than 50% reduction in the size of the lesions), no change, and worsening</P>
<P>
<I>Adverse effects</I>: at each visit, all of the participants were asked about any adverse effects.</P>
<P>Time points reported: after completion of treatment (8 weeks), and at the end of the 3 months follow-up (healing rates)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: supported by a grant from Janssen-Cilag Pharmaceuticals Inc.</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2004">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 11:01:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not mentioned</P>
<P>
<I>Inclusion criteria</I>: CL confirmed with direct smear, aged 1-20 years, maximum number of lesions 3, maximum size of lesion 5 cm, duration of disease less than 8 weeks</P>
<P>
<I>Exclusion criteria</I>: history of allergy to MA, pregnancy or lactating</P>
<P>
<I>N randomised</I>: 210</P>
<P>
<I>Withdrawals</I>: 53: 29/105 in group 1 and 24/105 in group 2</P>
<P>
<I>N assessed</I>: 157. Group 1: 76, group 2: 81</P>
<P>
<I>Age</I>: not described</P>
<P>
<I>Baseline data</I>: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 11:02:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: combination triple therapy consisting of: 15% PR + 10% urea applied twice daily for 4 weeks, cryotherapy with liquid nitrogen repeated every 2 weeks till complete healing or for a maximum of 3 sessions, ILMA twice every week till complete healing or for a maximum of 6 weeks (in sessions that both cryotherapy and injections were used, cryo was done before injections)</LI>
<LI>
<I>Group 2</I>: ILMA twice every week till complete healing or for a maximum of 6 weeks</LI>
</UL>
<P>
<I>Duration of intervention</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:30:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' 2 weeks after treatment</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: not described</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2006">
<CHAR_METHODS MODIFIED="2017-11-08 11:03:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Disease and Leishmaniasis Research Center (SDLRC), Isfahan, Iran</P>
<P>
<I>Study period</I>: around 5 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:14:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not mentioned</P>
<P>
<I>Inclusion criteria</I>: CL confirmed with direct smear</P>
<P>
<I>Exclusion criteria</I>: pregnant or nursing mothers, treated previously for CL, any known intercurrent illness or a history of allergy to MA, palpebral lesions, having &gt; 5 lesions, lesion &gt; 3 cm, duration of lesions was &gt; 12 weeks</P>
<P>
<I>N randomised</I>: 80: 40 in each group</P>
<P>
<I>Withdrawals</I>: 7</P>
<P>
<I>N assessed</I>: 73: 38 in group 1 and 35 in group 2</P>
<P>
<I>Age</I>: range 5-75 years</P>
<P>
<I>Baseline data</I>: the most common clinical type of the lesions in both groups was papule (50% in TCA and 44% in the ILMA group) and nodule (25% in TCA and 24% in the ILMA group).</P>
<P>Mean number of lesions: TCA: 1.2; ILMA: 1.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 11:05:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: TCA 50% (wt/vol) was applied on the lesions every 2 weeks up to 3 times</LI>
<LI>
<I>Group 2</I>: ILMA weekly up to 6 weeks</LI>
</UL>
<P>
<I>Duration of intervention</I>: up to 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 11:06:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing</I>: complete cure was defined as complete healing and re-epithelialisation of the lesion(s); partial care as partial clinical improvement with reduction in erythema, induration and size of the lesions; treatment failure as the absence of any change or worsening of the lesion(s)</P>
<P>
<I>Duration of remission and percentage of people with treated lesions that recur after 3 months of follow-up</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Microbiological or histopathological cure of skin lesions</I>
</P>
<P>Time points reported: after the last treatment session, 1 and 3 months post-treatment. Complete cure was reported at 4 and 6 weeks of the treatment period. Recurrence was assessed at 3 months follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 15:15:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2007">
<CHAR_METHODS MODIFIED="2017-11-08 11:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Disease and Leishmaniasis Research Center (SDLRC), Isfahan, Iran</P>
<P>
<I>Study period</I>: 4 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:15:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not mentioned</P>
<P>
<I>Inclusion criteria</I>: CL confirmed with direct smear, no history of systemic or topical therapy for CL, absence of the malnutrition or severe predisposing disease such as cardiac, renal or hepatic disease and other contraindication for MA</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating mothers, lesions &gt; 3 months old and treated with the drugs that had interaction with MA</P>
<P>
<I>N randomised</I>: 100, 50 in each group</P>
<P>
<I>Withdrawals</I>: 23 (13 in the honey group and 10 in the ILMA group). However, in the abstract authors stated that 10 participants left the study.</P>
<P>
<I>N assessed</I>: 90 (45 in each group)</P>
<P>
<I>Age</I>: range 7-70 years</P>
<P>
<I>Baseline data</I>: the most common clinical type of the lesions in both groups was plaque (60% in honey + ILMA and 55.6% in the ILMA-alone group). Mean number of lesions: honey + ILMA: 1.3; ILMA: 1.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 11:08:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: topical honey soaked gauze twice daily + ILMA</LI>
<LI>
<I>Group 2</I>: ILMA</LI>
</UL>
<P>
<I>Duration of intervention</I>: once weekly until complete healing of the ulcer or for maximum of 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:33:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing</I>: complete healing was defined as disappearance of the induration and complete re-epithelialisation of the ulcer. Complete healing of the lesions was defined as complete clinical and parasitological healing (negative direct smear); partial healing of the lesions was defined as the decrease of the size and indurations of the lesions; non-responsive was defined as no clinical change or progression of the lesions</P>
<P>
<I>Speed of healing (time taken to be 'cured')</I>: expressed as mean healing time</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: assessed weekly for 6 consecutive weeks and at the end of the 2nd, 3rd, and 4th month. Cure was assessed at the end of treatment and follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 11:09:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: no competing interests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:59:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2008">
<CHAR_METHODS MODIFIED="2017-11-08 11:10:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Skin Diseases and Leishmaniasis Research Center. Isfahan, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 11:12:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica </I>and <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: all the participants had positive smear for <I>Leishmania </I>body and had not received any topical or systemic therapy for leishmaniasis, aged 7-70 years, lesion not more than 3 months</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating; history of cardiac, renal, hepatic diseases; any contraindication for the treatment </P>
<P>
<I>N randomised</I>: 150. Group 1: 50; group 2: 50; group 3: 50</P>
<P>
<I>Withdrawals</I>: 26. Group 1: 7; group 2: 14; group 3: 5</P>
<P>
<I>N assessed</I>: 124 (82.66%). Group 1: 43 (86%); group 2: 36 (72%); group 3: 45 (90%)</P>
<P>
<I>Mean (SD) age</I>: group 1: 33.1 years (17.5); group 2: 27.8 years (9.8); group 3: 29.1 years (14.7)</P>
<P>
<I>Sex (male/female)</I>: 88 (70.97%)/36 (29.03%)</P>
<UL>
<LI>Group 1: 32 (74.4%)/11 (25.6%)</LI>
<LI>Group 2: 23 (63.9%)/13 (36.1%)</LI>
<LI>Group 3: 33 (73.3%)/12 (26.66%)</LI>
</UL>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Type of lesion (no numbers): papule, nodule, plaque, ulcer, sporotrichid</LI>
<LI>Location of lesion (no numbers): face and neck, upper extremity, lower extremity, trunk</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:59:28 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: IMMA 60 mg/kg/d + placebo</LI>
<LI>
<I>Group 2</I>: IMMA 30 mg/kg/d + 40 mg oral omeprazole for 3 weeks. Low dose of MA was prepared by adding normal saline to MA</LI>
<LI>
<I>Group 3</I>: IMMA 30 mg/kg/d + oral placebo for 3 weeks</LI>
</UL>
<P>The oral placebo was identical in appearance to omeprazole capsules and was administered in the similar way</P>
<P>
<I>Duration of intervention</I>: 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:34:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: rate of complete response, 3 months (12 weeks) after starting treatment. <I>Scale</I>: complete healing of the lesions was regarded as complete clinical and parasitological healing (negative direct smear). Partial healing of the lesions was regarded as decrease of the size and indurations of the lesions, and no response was regarded as no clinical change or progression of the lesions.</P>
<P>
<I>Time to healing</I>: proportion of complete improvement in the 3 groups during the course of treatment</P>
<P>
<I>Adverse effects</I>: at the end of treatment</P>
<P>Time points reported: clinical cure: 12 weeks. Time to healing: 2, 4, 6, 8, 12 weeks. Adverse effects: at the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: they declared no competing interests.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:59:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2012">
<CHAR_METHODS MODIFIED="2017-11-08 11:15:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Isfahan University of Medical Science, Isfahan, Iran</P>
<P>
<I>Study period</I>: March 2008 to March 2009 (12 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:19:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: unclear</P>
<P>
<I>Exclusion criteria</I>: pregnant, children &lt; 5 years, palpebral lesions (less than 20 mm from palpebral margin), &gt; 5 lesions, &gt; 12 weeks duration of leishmaniasis, history of any specific anti-leishmaniasis therapy, significant underlying diseases</P>
<P>
<I>N randomised</I>: 80 lesions </P>
<P>
<I>Withdrawals</I>: 4 lesions </P>
<P>
<I>N assessed</I>: 76 lesions (38 lesions in each group) and 60 patients (30 patients in each group)</P>
<P>
<I>Mean (SD) age</I>: 5.11 years (13.3) (range 5-50)</P>
<P>
<I>Sex</I>: unclear</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Lesions according to sex:</LI>
<UL>
<LI>Female: group 1, 16 (42.1%); group 2, 23 (60.5%)</LI>
<LI>Male: group 1, 22 (57.9%) and group 2, 15 (39.5%)</LI>
</UL>
<LI>Mean size of lesions at the beginning of study was not different between groups (P = 0.58) and was 2.66 cm (SD 0.37) in group and 13.18 cm (SD 0.89) in group 2</LI>
<LI>Location of lesion:</LI>
<UL>
<LI>61/76 lesions in the upper extremities or head: 30/38 lesions (78.9%) in group 1 and 31/38 lesions (81.5%) in group 2</LI>
<LI>15/76 lesions in the lower extremities: 8 lesions (21.05%) in group 1 and 7 lesions (18.4%) in group 2</LI>
</UL>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:59:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: after cleansing the lesion with alcohol, TCA 50% (Merck, Berlin, Germany) was applied onto the lesion using a cotton swab, until frosting the lesion, once a week and for up to 2 weeks. Afterwards, a controlled localised heating of the lesions was performed using an RF heat generator (4 MHz, maximum output 90 W; Ellman International Inc, NY, USA). The area was heated to 42°C surface temperature for 30 s once a week and for 4 consecutive weeks</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: ILMA (Sanofi&#8208;Aventis, France) administered twice a week and continued up to 8 weeks until absolute healing of lesions</LI>
</UL>
<P>
<I>Duration of intervention</I>: non-ablative radiofrequency + topical TCA 50%: 4 weeks; ILMA: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:35:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Treatment responses</I>: </P>
<UL>
<LI>Complete cure: complete clinical healing was defined as complete re-epithelialisation of the lesions, flattening of the lesions and lack of indurations along with negative direct smear</LI>
<LI>Partial cure: partial clinical improvement along with decreased size of indurations, erythematic areas, and lesions at the end of the treatment</LI>
<LI>Non-cure or treatment failure: no clinical improvements along with unchanged or even increased size of lesions</LI>
</UL>
<P>Time points reported: 6 months of treatment </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 11:57:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:46:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2013">
<CHAR_METHODS MODIFIED="2017-11-08 11:27:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Cutaneous Leishmaniasis and Skin Diseases Research Center, Isfahan, Iran</P>
<P>
<I>Study period</I>: 2010 to 2011 (12 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:46:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: age older than 5 years, diameter less than 3 cm, the duration of disease less than 12 weeks, lesions with less than 2 cm distance from eyelid, &lt; 5 lesions</P>
<P>
<I>Exclusion criteria</I>: pregnancy; lactation; colloid scar; lesions on cartilage, eyelids or joints; history of using other drugs against CL, treatment with immune system inhibitors</P>
<P>
<I>N randomised</I>: 90 (30 people in each group)</P>
<P>
<I>Withdrawals</I>: not described</P>
<P>
<I>N assessed</I>: 90 (30 people in each group)</P>
<P>
<I>Mean (SD) age</I>: 24.5years (14)</P>
<P>
<I>Sex (male/female)</I>:21/9, 23/7 and 21/9</P>
<P>
<I>Baseline data</I>: Number of lesions:single lesion in 53 (58.9%), 2 lesions in 29 (32.2%) and 3 lesions in 8 patients (8.9%).</P>
<P>
<I>The type of lesion: </I>plaque in 32 patients (35.6%), nodule in 44 (48.4%), plaque and nodule in 8 (8.9%), and papule in 6 patients (6.7%)</P>
<P>
<I>Distribution of lesions:</I> hand 43, foot 15, face 8, trunk 5, hand and trunk 4, hand</P>
<P>and neck 4, neck 4, hand and foot 4, hand and face 2, ear 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:46:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: ILMA twice a week for a maximum of 8 subsequent weeks. The tip of the insulin syringe was entered from a point out side of the lesion at the periphery of lesion and the injection was continued until the whole area was blanched. This was repeated in all areas of the lesion until whole lesion was blanched.</LI>
<LI>
<I>Group 2</I>: ILMA + TCA 50% solution. Simultaneously with the MA injection twice a week, the TCA solution 50% was applied with cotton applicator once a week for 8 consecutive weeks until the lesion was frosted. The participants were visited at the beginning of the treatment and after 3 and 6 months. Final evaluation was done in the 6th month.</LI>
<LI>
<I>Group 3</I>: ILMA + fractional laser. In this group IL injection was done twice a week with fractional laser every 2 weeks. The laser used was Dosis M&amp;M, Q ray FRX system with energy of 25, 1 pass, dots cycle 6 and pixel pitch of 1 mm. In each session, before treatment with laser, first lesion was cleaned with a mild cleanser and 70% then alcohol. The laser treatment was done by an experienced dermatologist every 2 weeks for 2 sessions after IL injection.</LI>
</UL>
<P>All patients in three groups were followed weekly for 3 months and then after 4 and 6 months to assess improvement of lesions and size of scar.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:37:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical response</I>, according to standard quartile grading:</P>
<UL>
<LI>0 &lt; 25% (mild improvement)</LI>
<LI>25% &lt; score 1 &lt; 50% (moderate improvement)</LI>
<LI>50% &lt; score 2 &lt; 75% (good improvement)</LI>
<LI>&lt; 75% (very good improvement)</LI>
</UL>
<P>The quantitative 4-point scale used included:</P>
<UL>
<LI>0 = unchanged size</LI>
<LI>1 = the scar size became a bit small</LI>
<LI>2 = the scar size became very small</LI>
<LI>3 = the scar is almost removed</LI>
</UL>
<P>Time points reported: 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 11:57:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: Isfahan University of Medical Sciences</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:07:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2014a">
<CHAR_METHODS MODIFIED="2017-11-08 11:38:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: prospective randomised controlled trial</P>
<P>
<I>Setting/location</I>: Central Research Center of Skin Diseases and Leishmaniasis and Novin Laser Center; Isfahan, Iran</P>
<P>
<I>Study period</I>: June 2010 to September 2011 (15 months)</P>
<P>
<I>Sample size calculation</I>: sample size was calculated as 60 cases in each group with further rate of 10% dropouts and exclusions</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:07:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: leishmaniasis scar diagnosed clinically on participants by a dermatologist</P>
<P>
<I>Exclusion criteria</I>: pregnancy, lactation, colloid scar, treatment with immune system inhibitors,</P>
<P>use of isotretinoin or fillers for the past 6 months, use of dermabrasion or skin resurfacing for the past 12 months, skin types of IV to V1</P>
<P>
<I>N randomised</I>: 120 (60 people in case group and 60 in control group)</P>
<P>
<I>Withdrawals</I>: not described</P>
<P>
<I>N assessed</I>: not described</P>
<P>
<I>Mean (SD) age</I>: 27.21 years (11.52) (range 6-45)</P>
<P>
<I>Sex (male/female)</I>: 51%/49%</P>
<P>
<I>Baseline imbalances</I>: none</P>
<P>
<I>Severity of illness</I>: mean (SD) scar size: laser CO&#8322; group: 2.3 cm (0.3) and fractional CO&#8322; laser: 3.4 cm (0.4)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:59:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: ablative CO&#8322; laser after applying the topical anaesthetic on scar site with pulsed CO&#8322;, duration: 10 ns, frequency: use of 20 kHz, and power: 25 Kw for one session. The participants were visited at the beginning of the treatment and after 3 and 6 months. Final evaluation was done in the 6th month.</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: fractional laser in each session by energy: 25, one pulse, pass: 1, dot cycle: 6, with the system of Qray FRX, Dosis M and M</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:37:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical response</I>, according to standard quartile grading:</P>
<UL>
<LI>0 &lt; 25% (mild improvement)</LI>
<LI>25% &lt; score 1 &lt; 50% (moderate improvement)</LI>
<LI>50% &lt; score 2 &lt; 75% (good improvement)</LI>
<LI>&lt; 75% (very good improvement)</LI>
</UL>
<P>The quantitative 4-point scale used included:</P>
<UL>
<LI>0 = unchanged size</LI>
<LI>1 = the scar size became a bit small</LI>
<LI>2 = the scar size became very small</LI>
<LI>3 = the scar is almost removed</LI>
</UL>
<P>Time points reported: 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 11:57:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: Isfahan University of Medical Sciences</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 09:00:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2014b">
<CHAR_METHODS MODIFIED="2017-11-08 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Disease and Leishmaniasis Research Center, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 11:49:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: participants with positive direct smear for CL; 6-60 years of age; without any previous history of systemic or topical therapy for CL; lesions &lt; 3 cm, &lt; 12 week duration, and not located within 2 cm distance of palpebral margin</P>
<P>
<I>Exclusion criteria</I>: pregnant and lactating women</P>
<P>
<I>N randomised</I>: 200 participants</P>
<P>
<I>Withdrawals</I>: not described</P>
<P>
<I>N assessed</I>: 187; group 1: 91; group 2: 96</P>
<P>
<I>Mean (SD) age</I>: 10.7 years (22.04); group 1: 10 years (20.6); group 2: 11.3 years (23.3)</P>
<P>
<I>Sex (male/female)</I>: 101/86</P>
<P>
<I>Baseline data</I>: mean (SD) lesion area was 329 mm² (118.7) in group 1 and 359 mm² (55.6) in group 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:00:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ILMA + 50% TCA was performed twice a week</LI>
<LI>
<I>Group 2</I>: ILMA alone was performed twice a week</LI>
</UL>
<P>
<I>Duration of intervention</I>: complete resolution of the lesions or end of 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 11:49:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: complete re-epithelialisation of the lesion and lack of induration. Clinical response was measured at the end of treatment and was defined as complete cure (negative direct smear and clinical healing), partial cure (partial clinical improvement with decreasing erythema, induration, and lesion size), non-cure or treatment failure (no clinical change or worsening of the lesions)</P>
<P>Time points reported: 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 11:49:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the study is self-funded</P>
<P>
<I>Possible conflicts of interest</I>: there is no conflict of interest</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 12:00:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranawaka-2010">
<CHAR_METHODS MODIFIED="2017-11-08 15:28:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Anuradhapura Teaching Hospital, Anuradhapura, Sri Lanka</P>
<P>
<I>Study period</I>: 32 months. Participant selection: April 2006 to June 2007 (15 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 12:00:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L donovani</I>
</P>
<P>
<I>Inclusion criteria</I>: participants with CL who attended to Anuradhapura Teaching Hospital, Anuradhapura, Sri Lanka from April 2006 to June 2007</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: a total of 154 participants with 229 lesions were included in the study. IL 7% HSCS: 67; ILSSG: 87</P>
<P>
<I>Withdrawals</I>: (4.5%: 7/154). HSCS: 3, ILSSG: 4</P>
<P>
<I>N assessed</I>: 147 (95.45%) CL participants with 222 lesions completed treatments. HSCS: 64 (95.52%); ILSSG: 83 (95.40%).</P>
<P>
<I>Age</I>: mean 32 years (range 16 months to 74 years)</P>
<P>
<I>Sex (male/female)</I>: 99/55, M:F ratio of 1.8:1</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>N lesions: HSCS: 93, ILSSG: 136</LI>
<LI>Location of the target lesion: head and neck 41, upper limb 123, lower limb 43, trunk 14, buttock 1. 93.2% of lesions being on exposed parts of the body</LI>
<LI>Clinical presentation (n(%)): papules &#8804; 1 cm diameter: 52 (23.6%); nodules &gt; 1 cm diameter: 28 (12.7%); plaques: 14 (6.34%); central ulcer with erythematous induration around the lesion: 121 (55%); chronic non-healing ulcers with undermined edges without surrounding induration; 5 (2.2%)</LI>
<LI>19 lesions were wet lesions and all others (91.4%) were dry lesions</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:00:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: HSCS was prepared by dissolving 12.2 g of sodium chloride in 200 mL of 0.9% sodium chloride (normal saline) solutions. The solution was injected intralesionally and not subcutaneously</LI>
<LI>
<I>Group 2</I>: ILSSG (Pentostam)</LI>
</UL>
<P>
<I>Duration of intervention</I>: HSCS: 1-29 weeks, depending on the size and the duration of the lesions (mean 8.78 weeks). SSG: 1-13 weeks, depending on the size and the duration of the lesions (mean 5.11 weeks)</P>
<P>Participants were seen weekly for the first 3 injections; fortnightly for the fourth and fifth injections; then monthly until cure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:40:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>: the percentage of lesions that were cured with SSG and HSCS</P>
<P>
<I>Number of injections required per each lesion in total for cure</I> (scales: 1-10 injections)</P>
<P>
<I>Adverse effects</I>: systemic side effects with SSG or HSCS. Local side effects: pain during injection. Scarring after healing, postinflammatory hyperpigmentation</P>
<P>Time points reported: at the end of treatment. Participants were followed-up every 3 months after cure for 18 months to assess recurrences and evidence of visceralisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 11:57:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 09:00:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranawaka-2015">
<CHAR_METHODS MODIFIED="2017-11-08 12:01:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised double-blind clinical trial</P>
<P>
<I>Setting/location</I>: Skin Clinic of Anuradhapura Teaching Hospital, Sri Lanka</P>
<P>
<I>Study period</I>: January 2012 to February 2013 (14 months)</P>
<P>
<I>Sample size calculation</I>: approximately 473 participants per group were required to enable the detection of a treatment difference of 5% with a lowest cure rate of one group of 90%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 12:07:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L donovani</I>
</P>
<P>
<I>Inclusion criteria</I>: the study recruited participants with suspected CL who consented to participation.</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating women, subjects with a history of cardiac, renal, or hepatic disease</P>
<P>
<I>N participants randomised (lesions)</I>: 444 (643). 10% HSCS: 192 (297); 15% HSCS: 82 (101); ILSSG: 170 (245)</P>
<P>
<I>Withdrawals (lesions)</I>: 17 (20) lost to follow-up. 10% HSCS: 8 (7); 15% HSCS: 3 (3); ILSSG: 6 (10)</P>
<P>
<I>N assessed (lesions)</I>: 427 (623); 10% HSCS: 79 (98); 15% HSCS: 184 (290); ILSSG: 164 (235)</P>
<P>
<I>Age</I>: mean 32.7 years (range 14 months to 88 years). Most (60.8%) were aged 16&#8211;45 years </P>
<P>
<I>Sex (male/female)</I>: 286/158</P>
<P>
<I>Baseline data</I>: the average delay in presentation was 8 months (range: 4 weeks to 5 years). 91% of lesions were located on exposed areas of the body. Most (69.8%) participants had a single lesion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:00:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: 10% HSCS, prepared by dissolving 18.2 g of medical sodium chloride in 200 mL of 0.9% sodium chloride (normal saline) solutions</LI>
<LI>
<I>Group 2</I>: 15% HSCS, prepared by dissolving 28.2 g of medical sodium chloride in 200 mL of 0.9% sodium chloride (normal saline) solutions</LI>
<LI>
<I>Group 3</I>: ILSSG</LI>
</UL>
<P>
<I>Duration of intervention</I>: participants were seen weekly for the first 3 injections, fortnightly for the 4th and 5th injections, and then monthly until a cure was achieved.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 08:22:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical and parasitological cure</I>: responses were graded as slight (10% improvement from the initial status of the lesion), mild (20%&#8211;30% improvement), moderate (50% improvement), marked (80%&#8211;90% improvement), or as total if the lesion had cleared and parasites were not detected in the affected area by smear or culture. Both marked improvements and total clearance were considered to represent a cure. Reported at the end of treatment.</P>
<P>
<I>Duration of treatment</I>: in weeks, mean (range)</P>
<P>
<I>Time required to achieve the cure of the lesion</I>: mean and median times taken for cure for the different treatments groups. Every 5 weeks until achieve 30 weeks.</P>
<P>
<I>Injections per lesion</I>
<B>, </B>mean (range): number of injections for cure per lesion</P>
<P>
<I>Relapse</I>: <I>L recidivans</I>
</P>
<P>
<I>Adverse effects</I>: <I>local side effects</I>: at the site of the lesion caused by the injections: pain during injections, postinflammatory hyperpigmentation, scarring, postinflammatory depigmentation, ulceration and necrosis, <I>L recidivans</I>. <I>Systemic side effects</I>: no systemic or significant local side effects with either SSG or 10% HSCS.</P>
<P>Time points reported: participants were followed up every 3 months after cure for more than 6 months to assess recurrences and evidence of visceralisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:17:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reithinger-2005">
<CHAR_METHODS MODIFIED="2017-11-08 12:14:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Khair Khana Clinic; Kabul, Afghanistan</P>
<P>
<I>Study period</I>: 100 days</P>
<P>
<I>Sample size calculation</I>: to detect a 20% difference in the cure rate between the SSG and thermotherapy groups, assuming an 80% cure rate in the SSG groups, with a 90% power and a 5% 2-sided type I error, 98 subjects were needed in each group. To compensate for anticipated loss to follow-up, 40% more participants were enrolled in each group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 12:18:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: age &gt; 5 years; the presence of a single, parasitologically confirmed CL lesion;</P>
<P> no prior history of disease and/or antimonial treatment</P>
<P>
<I>Exclusion criteria</I>: the presence of a CL lesion located on or immediately adjacent to the nose, lips, or eyes; pregnancy; breastfeeding; major surgery in the previous 3 months; presence of any uncontrolled medical condition; anticipated unavailability for follow-up</P>
<P>
<I>N randomised</I>: 431. Group 1: 148, group 2: 144, group 3: 139</P>
<P>
<I>Withdrawals</I>: 172 in total: 30 decided to withdraw after allocation and 142 did not complete the 4 visits or the follow-up</P>
<P>
<I>N assessed</I>: 259. Group 1: 93, group 2: 58, group 3: 108</P>
<P>
<I>Age</I>: range 10-20 years</P>
<P>
<I>Sex (male/female)</I>: 200/201</P>
<P>
<I>Baseline data</I>: the lesions were primarily located on the face (43.4% of participants), on the hands (38.2%), legs (15.9%) and arms (2.4%)</P>
<UL>
<LI>Group 1: MNL: 1. MSL: 12.75 mm. MDLBT: 6 months</LI>
<LI>Group 2: MNL: 1. MSL: 13.75 mm. MDLBT: 5.5 months</LI>
<LI>Group 3: MNL: 1. MSL: 10.25 mm. MDLBT: 6 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 12:18:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ILSSG, 5 injections of 2-5 mL every 5-7 days depending on the lesion size for up to 29 days</LI>
<LI>
<I>Group 2</I>: IMSSG (20 mg/kg) daily for 21 days</LI>
<LI>
<I>Group 3</I>: thermotherapy using radiofrequency waves (1 treatment of &gt; 1 consecutive application at 50ºC for 30 s depending on lesion size)</LI>
</UL>
<P>
<I>Duration of intervention</I>: not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 08:17:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Percentage of p</I>articipant<I>s 'cured' at 100 days after treatment initiation and by time to cure</I>: cure was defined as the complete re-epithelialisation of the CL lesion, with no evidence of papules, inflammation, or induration</P>
<P>
<I>Speed of healing (time taken to be 'cured')</I>
</P>
<P>
<I>Adverse effects</I>: the occurrence of adverse effects was evaluated blindly by means of participant interviews and physical examinations during follow-up visits</P>
<P>Time points reported: trial endpoint was 100 days after start of therapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 12:19:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the HNI Malaria and Leishmaniasis Control Program is funded by the European Union. This study was supported by the United Nation Children's Fund/United Nation Development Program/WorldBank/World Health Organization Special Program for Research and Training in Tropical Diseases, the Afghan Research Evaluation Unit, and the Leveen Family Fund.</P>
<P>
<I>Possible conflicts of interest</I>: since March 2004, R Reithinger has been a part-time employee of Thermosurgery Technologies. All other authors: no conflicts</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:12:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadeghian-2006a">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: 3 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 12:28:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: CL in whom the diagnosis was confirmed by laboratory demonstration of the parasite in the lesions by direct smear</P>
<P>
<I>Exclusion criteria</I>: allergic to antimonial drugs or pentoxifylline, lactating or pregnant, history of systemic illness</P>
<P>
<I>N randomised</I>: 64, 32 in each group</P>
<P>
<I>Withdrawals</I>: 1 participant withdrew from the MA + placebo group</P>
<P>
<I>N participants assessed (lesions)</I>: 63. Group 1: 32 (143), group 2: 31 (164)</P>
<P>
<I>Mean age</I>: group 1: 27 years, group 2: 31 years</P>
<P>
<I>Sex (male/female)</I>: 29/34</P>
<P>
<I>Baseline data</I>: duration of the disease approximately 1.3 months. </P>
<UL>
<LI>Group 1: 59.5% had plaque, 24.5% nodule and 16% papule type of lesions, and they were primarily located in the face (35%), upper limbs (24.5%), lower limbs (21%) and trunk (19.5%). MNL: 4, MDLBT: 1.2 months</LI>
<LI>Group 2: 42.7% had plaque, 33.6% nodule and 23.7% papule type of lesions, and they were primarily located in the face (33.5%), upper limbs (24.3%), lower limbs (22%) and trunk (20.2%). MNL: 5, MDLBT: 1.3 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:12:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: IMMA (20 mg pentavalent antimony/kg/d) + pentoxifylline (400 mg 3 times daily)</LI>
<LI>
<I>Group 2</I>: IMMA (20 mg pentavalent antimony/kg/d) + placebo (3 tablets daily)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 20 days</P>
<P>
<I>Duration of follow-up</I>: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:44:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>:</P>
<UL>
<LI>Complete improvement defined as flattened lesions, no induration and appearance of epidermal creases</LI>
<LI>Partial improvement defined as reduction in the size of the lesions but without the appearance of epidermal creases</LI>
<LI>Poor response defined as no reduction in the size of the lesions</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: after end of treatment and 3 months' follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not described</P>
<P>
<I>Possible conflicts of interest</I>: not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 12:34:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadeghian-2006b">
<CHAR_METHODS MODIFIED="2017-11-08 12:34:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Diseases and Leishmaniasis Research Center in Isfahan, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 12:32:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>:<I> L</I> <I>major</I> endemic in the area.</P>
<P>
<I>Inclusion criteria</I>: participant with positive smear for Leishman bodies, of both sexes and &gt; 5 years old who did not have indication for systemic therapy</P>
<P>
<I>Exclusion criteria</I>: facial lesions or lesions on joints, sporotrichoid type, lupoid leishmaniasis, erysipeloid type and other atypical forms of CL, pregnant women, history of cardiovascular and renal diseases</P>
<P>
<I>N randomised</I>: 72, 36 in each group</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 72</P>
<P>
<I>Mean age</I>: HSCS, 20.52 years; ILMA group, 18.67 years</P>
<P>
<I>Baseline data</I>: the most common site of lesions was on the extremities and the least common site was the trunk in both groups. The size range of lesions were from 0.5-4 cm² (IL HSCL group) and from 0.5-4 cm² (ILMA group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 12:32:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: IL HSCL (NaCl 5%; 0.5 to 1 mL)</LI>
<LI>
<I>Group 2</I>: ILMA (0.5-1 mL)</LI>
</UL>
<P>
<I>Duration of intervention</I>: weekly 6-10 weeks</P>
<P>
<I>Duration of follow-up</I>: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:45:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing</I>: complete improvement is defined as completely clinical re-epithelialisation with no signs of induration and inflammation with negative smear for Leishman bodies at the end of the treatment period. Partial improvement is defined as the re-epithelialising lesion has become smaller but not cured. If the lesion has become larger or has not been differed it will be called as no response to treatment.</P>
<P>Time points reported: at 6 and 10 weeks of treatment and 6 months follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not described</P>
<P>
<I>Possible conflicts of interest</I>: not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-08 15:24:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadeghian-2007">
<CHAR_METHODS MODIFIED="2017-11-08 12:34:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Skin Diseases and Leishmaniasis Research Center, Iran</P>
<P>
<I>Study period</I>: 7 months</P>
<P>
<I>Sample size calculation</I>: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:24:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not reported</P>
<P>
<I>Inclusion criteria</I>: smear from a suspected CL lesion was confirmed positive for <I>Leishmania</I>
</P>
<P>
<I>Exclusion criteria</I>: pregnant women, children &lt; 5 years of age, patients with facial lesions, those who had already received or were under other specific antileishmanial therapy, significant underlying diseases</P>
<P>
<I>N randomised</I>: 117</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N participants assessed (lesions)</I>: 117: 57 (83) lesions in group 1 and 60 (94) in group 2</P>
<P>
<I>Mean age</I>: group 1, 25.12 years; group 2, 22.6 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: group 1, 37/20; group 2, 29/31</P>
<P>
<I>Baseline data</I>: the shape of lesions was papule, nodule and plaque-like. Lesions were located in the trunk and upper and lower limbs.</P>
<UL>
<LI>Group 1: mean number of lesions: 1.4. Mean duration of lesions: 4.42 weeks. Mean largest diameter: 15.6 mm</LI>
<LI>Group 2: mean number of lesions: 1.5. Mean duration of lesions: 3.85 weeks. Mean largest diameter: 14.7 mm</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 12:37:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: controlled localised heating using an RF heat generator (4 MHz, maximum output 90 W). The affected area was heated to 50ºC surface temperature for 30 s</LI>
<LI>
<I>Group 2</I>: ILMA. The volume of the drug was 0.1-4 mL (each mL contains 85 mg MA), depending on lesion size</LI>
</UL>
<P>
<I>Duration of intervention</I>: once weekly for 4 consecutive weeks</P>
<P>
<I>Duration of follow-up</I>: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Percentage of participants 'cured'</I>:</P>
<UL>
<LI>Complete (lesions flattened, no induration, and epidermal creases appeared)</LI>
<LI>Partial (size of the lesion decreased but without the appearance of epidermal creases)</LI>
<LI>Poor (size of induration was unchanged or had increased)</LI>
</UL>
<P>
<I>Duration of remission and percentage of people with treated lesions that recur within 6 months</I>
</P>
<P>
<I>Prevention of scarring </I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment, and 6 months after</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-08 12:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: technical and financial support from the joint WHO Eastern Mediterranean Region (EMRO), Division of Communicable Diseases (DCD) and the WHO Special Program for Research and Training in Tropical Diseases (TDR): the EMRO/TDR Small Grant Scheme for Operational Research in Tropical and other Communicable Disease.</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:13:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Safi-2012">
<CHAR_METHODS MODIFIED="2017-11-08 12:53:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Leishmaniasis clinic of the National Malaria and Leishmaniasis Control Program in Darul-Aman District, Kabul City, Afghanistan</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: to detect an 8% difference in the cure rate between the current standard therapy (ILMA) and thermotherapy by radio frequency groups, assuming 90% cure rate in the conventional therapy with an 80% power and a 5% type I error, 174 subjects were needed in each group. To compensate for anticipated loss to follow-up, sample size inflated by 10%. Hence, the final sample size, figuring research design, rounded to nearest 10 turned out to be 390 subjects, with 195 assigned to each treatment group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:13:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: aged &gt; 5 years; presence of a single, parasitologically confirmed CL lesion</P>
<P>
<I>Exclusion criteria</I>: history of previous infections from anthroponotic CL that was treated with antimonial medications, lesions located within 2 cm of the eyelids or on the lips or nose</P>
<P>
<I>N randomised</I>: 390 (195 assigned to each treatment group)</P>
<P>
<I>Withdrawals</I>: 8 participants (6 in group 1; 2 in group 2).</P>
<P>
<I>N assessed</I>: 382 (189 in group 1; 193 in group 2).</P>
<P>
<I>Median (interval) age</I>: group 1, 14 years (5-70); group 2, 13 years (5-75)</P>
<P>
<I>Sex (male/female)</I>: group 1, 85/104; group 2, 92/101</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Mean (SD) systolic blood pressure: group 1, 116.2 mmHg (13.5); group 2, 113 mmHg (13.6)</LI>
<LI>Mean (SD) diastolic blood pressure: group 1, 72.4 mmHg (7.9); group 2, 72.2 mmHg(10.7)</LI>
<LI>Mean (SD) body weight: group 1, 42.5 kg (23.3); group 2, 39.01 kg (18.3)</LI>
<LI>Location of lesion (n (%))</LI>
<UL>
<LI>Group 1: face/neck: 161 (50.8), upper extremity 26 (48.1), lower extremity 2 (25)</LI>
<LI>Group 2: face/neck: 156 (49.2), upper extremity 28 (51.9), lower extremity 6 (75), trunk 3 (100)</LI>
</UL>
<LI>Type of lesion (n (%))</LI>
<UL>
<LI>Group 1: nodule 69 (41.1), papule 120 (57.7)</LI>
<LI>Group 2: ulcer 6 (100), nodule 99 (58.9), and papule 88 (42.3)</LI>
</UL>
<LI>Size of the lesion: group 1: median 1 cm² and size interval 1-4; group 2, median 2 cm² and size interval 1 -4.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:00:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: single application of thermotherapy by radio frequency producing localised heat of 50°C (122°F) for 30 s</LI>
</UL>
<UL>
<LI>
<I>Group 2</I>: 5 injections of ILMA (2-7 mL depending on the size of the lesion). The injections were given in 7-day intervals for 5 weeks.</LI>
</UL>
<P>
<I>Duration of intervention</I>: 5 weeks in ILMA group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:47:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure </I>was defined as complete re-epithelialisation of the lesion with no inflammation and resolution of the papule and/or nodule. Failure was defined as no improvement, with the lesion unchanged or worse compared with its status at the start of treatment. Lesions that showed some improvement but did not meet the criteria for cure were considered treatment failures</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 6 months after treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salmanpour-2001">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iran</P>
<P>
<I>Study period</I>: 18 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:24:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>:<I> Leishmania </I>spp: <I>L tropica</I> and <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: patient with CL confirmed parasitologically by direct skin smears or skin biopsies.</P>
<P>
<I>Exclusion criteria</I>: children &lt; 3 years of age, pregnant and lactating women, cases with concomitant renal, liver or heart disease, and any event of any laboratory abnormality prior to initiation of treatment</P>
<P>
<I>N randomised</I>: 96</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 96 (100%): 64 in the ketoconazole group and 32 in the ILMA group</P>
<P>
<I>Age</I>: range 3-64 years</P>
<P>
<I>Sex (male/female)</I>: 44/52</P>
<P>
<I>Baseline data</I>: </P>
<P>In the ketoconazole group:</P>
<UL>
<LI>Mean duration of lesions (SD): 2.6 months (1.4)</LI>
<LI>Mean number of lesions: 2.5</LI>
</UL>
<P>In the MA group:</P>
<UL>
<LI>Mean duration of lesions (SD): 3.1 months (1.4)</LI>
<LI>Mean number of lesions: 2.3</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 13:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ketoconazole orally (adults: 600 mg/d for 30 days and children: 10 mg/kg/d for 30 days)</LI>
<LI>
<I>Group 2</I>: ILMA 6 injections (some received up to 8)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 30 days in the ketoconazole group. There is no mention about frequency of injections in MA group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:48:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>:</P>
<UL>
<LI>Cured if lesions had completely re-epithelialised with little or no scarring at 6 weeks post-treatment.</LI>
<LI>Failure if participants showed one of the following findings: &lt; 25% reduction in the diameter of induration after 4 weeks of treatment; the persistence of lesions 6 weeks post-treatment</LI>
<LI>Relapse of disease after initial healing at 6 weeks post-treatment</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: participants were followed every 2 weeks for the duration of the treatment and every 6 weeks after cessation of treatment up to 24 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salmanpour-2006">
<CHAR_METHODS MODIFIED="2017-11-08 13:41:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Dermatology Clinic of Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran</P>
<P>
<I>Study period</I>: unclear</P>
<P>
<I>Sample size calculation</I>: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 13:41:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not reported</P>
<P>
<I>Inclusion criteria</I>: participant with CL confirmed</P>
<P>
<I>Exclusion criteria</I>: not described</P>
<P>
<I>N randomised</I>: 60</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 60 participants distributed into the 3 groups of equal number (n = 20)</P>
<P>
<I>Age</I>: not reported</P>
<P>
<I>Sex</I>: not reported</P>
<P>
<I>Baseline data</I>: lesions were located on the head, neck and lower and upper extremities. Lesion duration was divided in 2 groups: a duration of &lt; 3 months and &gt; 3 months. Regarding lesion size, the authors divided the sizes in 3 groups: &lt; 1 cm, 1-3 cm and &gt; 3 cm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 13:42:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: cryotherapy. The freezing time was 10-30 s with a thawing interval of 20 s</LI>
<LI>
<I>Group 2</I>: cryotherapy + ILMA. The participants first received cryotherapy and after 5-10 min were given ILMA</LI>
<LI>
<I>Group 3</I>: ILMA. The solution was injected into each lesion (0.2 to 1.5 cm³ per session per week, depending on the size)</LI>
</UL>
<P>
<I>Duration of intervention</I>: weekly for a total of 6-8 times for each case</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured': timing not reported</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:16:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shamsi-Meymandi-2011">
<CHAR_METHODS MODIFIED="2017-11-08 13:44:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: dermatology clinic and leishmaniasis research centre of Afzalipour hospital of Kerman, province of Iran</P>
<P>
<I>Study period</I>: 21 months</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:16:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: aged 7&#8211;60 years, confirmed CL</P>
<P>
<I>Exclusion criteria</I>:<B> c</B>hronic systemic disease (such as renal failure, myocarditis, hepatitis and pancreatitis), immune suppression, breastfeeding, pregnancy, sporotrichoid and lupoid forms, maximum diameter of lesions &gt; 3 cm, disease duration more than 1 year, more than 2 lesions present, history of sensitisation to MA,facial and joint lesions, receiving other specific anti <I>Leishmania</I> therapies</P>
<P>
<I>N randomised</I>: 191. Group 1: 96, group 2: 95</P>
<P>
<I>Withdrawals</I>: group 1: 16 (14: no follow-up, 2 enrolled in other treatment), group 2: 15 (8 no follow-up, 4 enrolled in other treatment, 3 did not adhere to treatment schedule)</P>
<P>
<I>N assessed</I>: 160 (83.77%). Group 1: participants: 80 (83.33%), group 2: participants: 80 (84.21%)</P>
<P>
<I>Age</I>: range 7-60 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: Randomised patients: group 1: 50(52%)/46 (48%), group 2 39 (41%)/56 (59%). Assessed patients: group 1: 42 (50%)/38 (46%); group 2: 31 (39%)/49 (61%)</P>
<P>
<I>Baseline data (N lesions)</I>: group 1: 80, GB: 80</P>
<P>Location<I> of the target lesion</I>:</P>
<UL>
<LI>Group 1: head and neck 1 (1.3%), upper limb 68 (85%), lower limb 7 (8.8%), trunk 4 (5%)</LI>
<LI>Group 2: head and neck 5 (6.3%), upper limb 64 (80%), lower limb 10 (12.5%), trunk 1 (1.3%)</LI>
</UL>
<P>
<I>Type of lesions</I>: </P>
<UL>
<LI>Group 1: plaque or ulcerated plaque 33 (40.5%), nodule or ulcerated nodule 47 (59.5)</LI>
<LI>Group 2: plaque or ulcerated plaque 25 (31.3%), nodule or ulcerated nodule 55 (68.7%)</LI>
</UL>
<P>
<I>Case type</I>:</P>
<P>New, group 1: 67 (83.3%); group 2: 69 (86.3%)</P>
<P>Recurrence, group 1: 0 (0%); group 2: 1 (1.3%)</P>
<P>Failure of previous treatment, group 1: 8 (10%); group 2: 0 (0%)</P>
<P>Missed previous treatment, group 1: 5 (6.3%); group 2: 10 (12.5%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 13:52:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: CO&#8322; laser. Lesions were locally anaesthetised by injection of 2% lidocaine. The CO&#8322; laser (6&#8211;8 W continuous wave) was applied to the lesions and an area 2&#8211;3 mm² around it. The procedure was repeated until the ulcer bed turned brown (maximum 3&#8211;5 times)</LI>
<LI>
<I>Group 2</I>: participants were treated with combined cryotherapy (biweekly) and ILMA (weekly). Cryotherapy with liquid nitrogen was performed using dipstick technique. Then ILMA (Amp 1.5 gr in 5 Ml solution) was injected in lesions</LI>
</UL>
<P>
<I>Duration of intervention</I>: 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:49:36 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure of the lesions</I>: defined as complete re-epithelialisation of 100% (± scar), complete flattening of induration</P>
<P>
<I>Laboratory cure of the lesions</I>: negative smear of the lesions compared with baseline</P>
<P>Cure rate based on weeks of follow-up</P>
<P>
<I>Adverse effects</I> of 2 types of treatments</P>
<P>Time points reported: weeks 2, 6, 12 and 16</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-19 14:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:22:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shanehsaz-2015">
<CHAR_METHODS MODIFIED="2017-11-03 09:46:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised double-blind placebo-controlled clinical trial</P>
<P>
<I>Setting/location</I>: Aleppo University Hospital Clinic, Aleppo, Syria</P>
<P>
<I>Study period</I>: 12 months (from July 2009 to July 2010)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:16:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not described</P>
<P>
<I>Inclusion criteria</I>: parasitological confirmation; aged 5&#8211;65 years; normal values of liver, kidney, and pancreas function tests and electrocardiogram before treatment</P>
<P>
<I>Exclusion criteria</I>: pregnant and lactating women; history of cardiac, renal, and hepatic diseases; treatment with other drugs during the month before commencement of the study</P>
<P>
<I>N randomised</I>: 90, 30 in each group</P>
<P>
<I>Withdrawals</I>: not described, but it seems that there were no dropouts</P>
<P>
<I>N assessed</I>: 90, 30 in each group</P>
<P>
<I>Sex (male/female)</I>: group 1, 21 (70%)/9 (30%); group 2, 17 (56.7%)/13 (43.4%); group 3, 20 (66.7%)/10 (33.3%)</P>
<P>
<I>Mean (SD) age</I>: group 1, 26.3 years (11.2); group 2, 24.2 years (12.5); group 3, 25.1 years (12.4)</P>
<P>
<I>Baseline data</I>:</P>
<P>Mean number of lesions (SD): group 1, 3.0 (1.92); group 2, 3.0 (1.92); group 3, 3.0 (1.92)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 13:56:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: IMMA 60 mg/kg/d (Glucantime; Aventis, Paris Cedex, France) + oral placebo. The drug was available in 5 mL vials.</LI>
<LI>
<I>Group 2</I>: IMMA 30 mg/kg/d + oral cimetidine 1200 mg/d</LI>
<LI>
<I>Group 3</I>: IMMA 30 mg/kg/d and oral placebo</LI>
</UL>
<P>
<I>Duration of intervention</I>: 3 weeks for 3 groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 08:22:28 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical and parasitological cure</I>: the effectiveness of the treatment was classified in 3 levels: complete response of the lesions was regarded as complete clinical and parasitological healing (negative direct smear). Partial response of the lesions was regarded as decrease of the size and indurations of the lesions, and no response was regarded as no clinical change or progression of the lesions</P>
<P>
<I>Time to healing</I>: proportion of complete response in 3 groups during the course of treatment</P>
<P>
<I>Adverse effects</I>: complications</P>
<P>Time points reported: clinical and parasitological cure: 12 weeks. Adverse effects: 6, 8, 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 12:09:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: this project was funded by the University of Aleppo, Aleppo, Syria</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:18:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharquie-1997">
<CHAR_METHODS MODIFIED="2017-11-08 13:58:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Baghdad, Iraq</P>
<P>
<I>Study period</I>: October 1994 to November 1995 (8 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:02:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania </I>spp: <I>L major</I> and <I>L tropica</I> endemic in the area</P>
<P>
<I>Inclusion criteria</I>: confirmed cases of CL by smear or culture, or both; acute CL with a history of 12 weeks or less</P>
<P>
<I>Exclusion criteria</I>: cases of reinfection</P>
<P>
<I>N randomised</I>: 85</P>
<P>
<I>Withdrawals</I>: 22 participants (participants who did not show up after the first or second injection were excluded). Losses were not reported by group</P>
<P>
<I>N assessed</I>: 63. Group 1, 19; group 2, 17; group 3, 18; group 4, 9</P>
<P>
<I>Age</I>: range 3 months to 65 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 28/37</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Group 1: MNL: 2.0. MDLBT: 6.89 weeks</LI>
<LI>Group 2: MNL: 2.35. MDLBT: 7.65 weeks</LI>
<LI>Group 3: MNL: 1.94. MDLBT: 7.00 weeks</LI>
<LI>Group 4: MNL: 4.22. MDLBT: 8.89 weeks</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:02:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: IL ZS with a solution of 2%</LI>
<LI>
<I>Group 2</I>: IL 7% HSCS</LI>
<LI>
<I>Group 3</I>: ILSSG 100 mg/mL</LI>
<LI>
<I>Group 4</I>: a few lesions on unimportant and unexposed parts of the body were left as controls</LI>
</UL>
<P>
<I>Duration of intervention</I>: not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-14 15:17:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing</I>: responses were graded according to scale (<LINK REF="REF-Sharquie-1988" TYPE="REFERENCE">Sharquie 1988</LINK>):</P>
<UL>
<LI>Slight: decreased erythema and oedema of the lesion; mild: reduction in the size of the lesion of up to 30%</LI>
<LI>Moderate: reduction in the size of the lesion of 30%-60%</LI>
<LI>Marked: reduction in the size of the lesion by &#8805; 60% and parasite not detected in the lesion by smear and/or culture</LI>
<LI>Total clearance of the lesion: with parasites not detected in the affected area by smear and/or culture</LI>
</UL>
<P>
<I>Speed of healing</I> <I>(time taken to be 'cured')</I>; expressed in days</P>
<P>
<I>Prevention of scarring</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: participants were followed up every 10-15 days for a period of 45 days. At the end of the 6 weeks follow-up period, the lesions were reassessed and parasitological proof of cure or otherwise was sought by smear and/or culture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:18:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharquie-2001">
<CHAR_METHODS MODIFIED="2017-11-08 14:03:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Iraq (outpatient department)</P>
<P>
<I>Study period</I>: October 1994 to May 1995 and November 1995 to May 1996 (15 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:18:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I> and <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: CL confirmed by smear/culture; acute CL of &#8804; 12 weeks duration (to exclude the possibility of self healing); those for whom systemic treatment was indicated including those for whom having multiple lesions ( &gt; 5) or large lesions ( &gt; 4 cm²), that could not be injected, or who had lesions near to critical areas such as the eye; very young children for whom no local injection was attempted; participants who refused local treatment (2%)</P>
<P>
<I>Exclusion criteria</I>: received antileishmanial treatment, either local or systemic, cases of reinfection</P>
<P>
<I>N randomised</I>: 130. Group 1, 39; group 2, 37; group 3, 39; group 4, 15</P>
<P>
<I>Withdrawals</I>: 27. Group 1, 8; group 2, 8; group 3, 7; group 4, 3</P>
<P>
<I>N assessed</I>: 104. Group 1, 31; group 2, 29; group 3, 32; group 4, 12</P>
<P>
<I>Mean (SEM) age</I>: group 1, 20.57 years (3.20); group 2, 22.55 years (2.72); group 3, 13.83 years (2.45); group 4, 25.74 years (4.45)</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 62/68. Group 1, 13/18; group 2, 19/10; group 3, 11/21; group 4, 6/6</P>
<P>
<I>Baseline data</I>: </P>
<UL>
<LI>Lesions (Total): group 1, 161; group 2, 145; group 3, 149; group 4, 42</LI>
<LI>Mean number of lesions (SEM): group 1, 5.19 (0.56); group 2, 5.00 (0.73); group 3, 4.65 (0.7); group 4, 3.50 (0.88)</LI>
<LI>Site of lesion (groups 1, 2, 3, and 4, respectively)</LI>
<UL>
<LI>Head and neck: 45; 19; 50; 3</LI>
<LI>Lower limb: 21; 57; 52; 24</LI>
<LI>Upper limb: 90; 69; 44; 14</LI>
<LI>Trunk: 5;2;3;1</LI>
</UL>
<LI>-Type of lesion:</LI>
<UL>
<LI>Wet: group 1, 41; group 2, 32; group 3,: 20; group 4, 7.</LI>
<LI>Dry: group 1, 120; group 2, 113; group 3, 129; group 4, 36.</LI>
</UL>
<LI>Mean duration of lesions (SEM): group 1, 8.1 weeks (0.56); group 2, 7.95 weeks (0.49); group 3, 8.50 weeks (0.54); group 4, 8.89 weeks (1.11)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:18:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: ZS orally 2.5 mg/kg</LI>
<LI>
<I>Group 2</I>: ZS orally 5 mg/kg</LI>
<LI>
<I>Group 3</I>: ZS orally 10 mg/kg</LI>
<LI>
<I>Group 4</I>: without treatment</LI>
</UL>
<P>
<I>Duration of intervention</I>: ZS groups one capsule every 8 hours</P>
<P>
<I>Duration of follow-up</I>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-14 15:18:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing</I>: responses were graded according to scale (<LINK REF="REF-Sharquie-1988" TYPE="REFERENCE">Sharquie 1988</LINK>):</P>
<UL>
<LI>Slight: decreased erythema and oedema of the lesion; mild: reduction in the size of the lesion of up to 30%</LI>
<LI>Moderate: reduction in the size of the lesion of 30%-60%</LI>
<LI>Marked: reduction in the size of the lesion by &#8805; 60% and parasite not detected in the lesion by smear and/or culture</LI>
<LI>Total clearance of the lesion: with parasites not detected in the affected area by smear and/or culture</LI>
</UL>
<P>
<I>Speed of healing</I> <I>(time taken to be 'cured')</I>; expressed in days</P>
<P>
<I>Prevention of scarring</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: participants were followed up every 10-15 days for a period of 45 days. At the end of the 6 weeks follow-up period, the lesions were reassessed and parasitological proof of cure or otherwise was sought by smear and/or culture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shazad-2005">
<CHAR_METHODS MODIFIED="2017-11-08 14:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Military Base Clinic, Iran</P>
<P>
<I>Study period</I>: January to October 2001 (10 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:18:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: proven cases of CL, healthy apart from CL, lesions not in close proximity to a vital organ or joint, number of lesions 1 to 3, ulcer size &lt; 5 cm in diameter, onset of the lesions &lt; 3 months, no previous standard anti-<I>Leishmania</I> treatment, no history of allergy to the paromomycin family</P>
<P>
<I>Exclusion criteria</I>: not reported</P>
<P>
<I>N randomised</I>: 60, 30 in each group</P>
<P>
<I>Withdrawals</I>: 4. Group 1: 1; group 2: 3,</P>
<P>
<I>N assessed</I>: 36. Group 1: 29; group 2: 27</P>
<P>
<I>Age</I>: Group 1: approx 20.6 years; group 2: approx 21.7 years</P>
<P>
<I>Sex</I>: all men</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Group 1: 76.7% had ulcerative, 8.3% nodular, and 15% papular type of lesions, and they were primarily located in the head and neck (25%), upper extremities (41.7%), lower extremities (31.7%) and trunk (1.7%). MNL: 2. MSL 21.7 mm. MDLBT: 37.8 days</LI>
<LI>Group 2: 69.7% had ulcerative, 11.8% nodule, and 18.4% papule type of lesions, and they were primarily located in the head and neck (13.2%), upper extremities (47.4%), lower extremities (36.8%) and trunk (2.6%). MNL: 2.4. MSL: 25 mm. MDLBT: 39 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 08:14:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 15% PR sulphate and 10% urea. Dose: 0.5 mg/mm²/d</LI>
<LI>
<I>Group 2</I>: intradermal MA every other day</LI>
</UL>
<P>
<I>Duration of intervention</I>: 20 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 09:56:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>:</P>
<UL>
<LI>Complete cure was defined as complete re-epithelialisation of all lesions at one week after cessation of treatment. Participants with multiple lesions were considered to be cured if all the lesions were healed.</LI>
<LI>Partial cure (parasitological cure) was defined when clinical cure had not occurred in any lesion in a participant but no <I>L amastigote</I> was found in a direct smear of the lesions(s), 3 slides were prepared, and stained from each active ulcer, and 1000 fields were checked (approximately 3 slides).</LI>
<LI>Failure of treatment was defined as no clinical cure and no parasitological cure at one week after cessation of treatment; relapse was defined as a reappearance of the lesion after complete cure.</LI>
</UL>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: follow-up and clinical evaluation were performed at week 1 and 6 after completion of treatment. Participants were visited once at 6 months after treatment was completed. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-14 15:19:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stahl-2014">
<CHAR_METHODS MODIFIED="2017-11-08 14:20:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: single-centre, 3-armed, open label, randomised, controlled, phase IIb trial</P>
<P>
<I>Setting/location</I>: Leishmania and Malaria Centre (LMC) of the Provincial Balkh Civil Hospital Mazar-e-Sharif (Afghanistan)</P>
<P>
<I>Study period</I>: November 2010 to March 2011 (15 months)</P>
<P>
<I>Sample size calculation</I>: the sample size calculation was based on the per protocol (PP) analysis, defined as all participants evaluable with respect to the primary endpoint</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:32:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: in 44/69 participants analysed, 28 (64%) lesions were infected with <I>L tropica</I> and 16 (36%) with <I>L major</I>
</P>
<P>
<I>Inclusion criteria</I>: CL lesions with <I>Leishmania</I>-positive Giemsa smears without prior CL treatment</P>
<P>
<I>Exclusion criteria</I>: age &lt; 12 years; more than one skin lesion (to exclude intra-individual variations in this phase IIb analysis); lesion age &gt; 3 months; lesions located on eye lids, lips or nose; drug addiction; coinfection with <I>Mycobacterium tuberculosis</I>, HIV, or diabetes</P>
<P>
<I>N randomised</I>: 87 participants: group 1, 24 (27.5%), group 2, 32 (36.8%), and group 3, 31 (35.6%)</P>
<P>
<I>Withdrawals</I>: lost after registration: group 2, 3; group 3, 3. Not followed up for the full treatment period: SSG, 1; group 2, 6; group 3, 3. Mixed treatment: group 3, 2</P>
<P>
<I>N assessed</I>: 81 (93.10%). group 1: 24; group 2: 29; group 3: 28</P>
<P>
<I>Mean age</I>: 29 years (95% CI 25&#8211;33)</P>
<P>
<I>Sex (male/female)</I>: 32 (46%)/37 (54%)</P>
<P>
<I>Baseline data</I>: comparable in all 3 regimens</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:19:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: intradermal injections of 0.6 mL SSG according to a protocol used by <LINK REF="REF-Zeglin-2009" TYPE="REFERENCE">Zeglin 2009</LINK>
</LI>
<LI>
<I>Group 2</I>: aseptic MWT with 0.045% DAC N-055 following a single initial superficial wound debridement with HF-EC, which was performed under local anaesthesia after wound cleansing and disinfection with gauzes soaked in physiological saline solution containing 320 ppm chlorine dioxide (pH 5.5 acidified 0.09% DAC N-055) for 15 min</LI>
<LI>
<I>Group 3</I>: MWT with 0.045% DAC N-055 alone</LI>
</UL>
<P>
<I>Duration of intervention</I>: for all groups: daily treatments (with the exception of Fridays) during the first week, followed by topical treatments at the centre twice a week until the end of week 4 and thereafter once a week until wound closure</P>
<P>In group 1, the SSG treatment was discontinued after week 4. In groups 2 and 3, participants dressed their lesion themselves after week 4 with the topical NaClO&#8322;-basic-crème between their visits at the centre until lesion closure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:36:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome </I>was the ratio of closed versus open wounds at day 75 (D75) in the PP analysis for each regimen</P>
<P>
<I>Speed of healing</I>: not reported in Methods</P>
<P>
<I>Adverse effects</I>: not reported in Methods</P>
<P>6 visits were scheduled in the first week, 2 visits per week from weeks 2 to 4, and 1 visit per week thereafter until complete wound closure. Follow-up visits were required once a month until day 180 after treatment start</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-07-14 12:17:03 +0100" MODIFIED_BY="[Empty name]">
<P>The funders had no role in study design, data collection, data analysis, and interpretation, decision to publish, or preparation of the manuscript. KWS and HCS are members of the Board and CB is a member of the non-profit NGO Waisenmedizin PACEM e.V. promoting access to essential medicine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yazdanpanah-2011">
<CHAR_METHODS MODIFIED="2017-11-08 14:38:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised, prospective, double-blind trial</P>
<P>
<I>Setting/location</I>: Dermatology Department, Ghaem Hospital, Mashhad University of Medical Sciences, Iran</P>
<P>
<I>Study period</I>: October 2006 to May 2008 (19 months)</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 15:24:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: proven acute CL by a positive direct smear were selected for this study. Duration of lesions less than 6 months and no anti-leishmaniasis treatment received during 2 months ago</P>
<P>
<I>Exclusion criteria</I>: pregnant or nursing women, participants with hepatic, renal, and heart diseases</P>
<P>
<I>N randomised</I>: 115. Group 1: 30, group 2: 85</P>
<P>
<I>Withdrawals</I>: excluded because of side effects: group 2, 6. Not followed up for the full treatment period: group 1, 4; group 2, 5</P>
<P>
<I>N assessed</I>: 100 (86.96%). Group 1: 26 (86.67%); group 2: 74 (87.06%)</P>
<P>
<I>Mean (SD) age</I>: group 1, 32 years (23), group 2: 25 years (19)</P>
<P>
<I>Sex (male/female)</I>: group 1, 11/15, group 2: 39/35</P>
<P>
<I>Baseline data</I>:</P>
<UL>
<LI>Total lesions: group 1, 43; group 2, 127</LI>
<LI>Location of the target lesion:</LI>
<UL>
<LI>Group 1: head and neck 19 (44.3%), upper limb 18 (44.9%), lower limb 5 (11.6%), trunk 1 (2.3%)</LI>
<LI>Group 2: head and neck 56 (44.1%), upper limb 56 (44.1%), lower limb 14 (11%), trunk 1 (0.8%)</LI>
</UL>
<LI>Mean duration of lesions (SD): group 1, 4.5 months (1.5); group 2, 4 months (1.5)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:47:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>:</P>
<UL>
<LI>
<I>Group 1</I>: received oral zinc sulphate (ZS) in a dose of 10 mg/kg/d during 45-day period before meal in 3 divided times</LI>
<LI>
<I>Group 2</I>: IMMA (Glucantime; MA, Specia, Paris, France) 20 mg/kg/d for 20 days with a maximum of 3 vials</LI>
</UL>
<P>
<I>Duration of intervention</I>: group 1: 45 days, group 2: 20 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-08 14:47:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Decreased indurations of lesion</I> (lesions were measured by palpation and ruler): in aspect of response to treatment in comparison with first visit participants graded as 4 improvement rate groups: </P>
<OL>
<LI>Slight (up to 25% decreased indurations of lesion)</LI>
<LI>Mild (25%&#8211;50% decreased indurations of lesion)</LI>
<LI>Moderate (more than 50% and less than 75% decreased indurations of lesion)</LI>
<LI>Total clearance (75% or more improvement or complete re-epithelialisation without any indurations)</LI>
</OL>
<P>
<I>Decreased indurations of lesion after 45 days from completing treatment period</I>: the same scale</P>
<P>
<I>Adverse effects</I>: severe muscular pain and topical reaction of inoculation site (severe erythema and pruritus)</P>
<P>Time points reported: at the end of clinical treatment. After 45 days from completing treatment period.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zerehsaz-1999">
<CHAR_METHODS MODIFIED="2017-11-08 14:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Fars province, Iran</P>
<P>
<I>Study period</I>: not described</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-08 14:49:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania </I>spp: <I>L major</I> and <I>L tropica</I> in the area</P>
<P>
<I>Inclusion criteria</I>: diagnosed as having CL based on positive smears from lesions, and in some cases, cultures and histopathologic studies were also performed.</P>
<P>
<I>Exclusion criteria</I>: pregnant, nursing, or serious concomitant diseases.</P>
<P>
<I>N randomised</I>: 171</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 171 participants: 86 participants in the herbal extract Z-HE group and 85 participants in the IMMA (15 to 20 mg/kg/d)</P>
<P>
<I>Age</I>: range 10 months to 69 years</P>
<P>
<I>Sex</I> <I>(male/female)</I>: 84/87</P>
<P>
<I>Baseline data</I>: the duration of the disease was &lt; 4 months. Most participants had papular and papulonodular lesion(s), although other clinical forms including ulcerative, eczematoid, hyperkeratotic, and erysipeloid types were also present. Most participants had multiple lesions, and the most common sites were the face and the extremities.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:50:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: herbal extract Z-HE as a black paste applied to the lesions and covered by a dressing for 5 consecutive days + placebo (saline) injected (0.5 mL) for 20 consecutive days</LI>
<LI>
<I>Group 2</I>: IMMA (15-20 mg/kg/d) for 20 consecutive days + vehicle (petrolatum and charcoal powder) applied on the lesions as a black paste covered by a dressing for 5 consecutive days</LI>
</UL>
<P>
<I>Duration of intervention</I>: 20 consecutive days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 10:00:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: complete cure was defined as clinical improvement with complete healing and re-epithelialisation of the lesion(s), partial cure as partial clinical improvement with reduction in infiltration erythema, and size of the lesion(s), and failure as the absence of any changes in the lesion(s) or progression and worsening of the lesion(s)</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 6 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<CHAR_METHODS MODIFIED="2017-11-06 12:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study design</I>: randomised controlled trial</P>
<P>
<I>Setting/location</I>: Turkey</P>
<P>
<I>Study period</I>: around 8 weeks</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 08:22:28 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>Leishmania </I>spp: <I>L tropica</I> in the area</P>
<P>
<I>Inclusion criteria</I>: confirmed diagnosis of CL</P>
<P>
<I>Exclusion criteria</I>: pregnant, nursing, or serious concomitant diseases</P>
<P>
<I>N randomised</I>: 72</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 72 (100%): 40 participants in group 1 and 32 participants in group 2</P>
<P>
<I>Age</I>: most were children aged 10 years or younger</P>
<P>
<I>Sex</I>: both sexes</P>
<P>
<I>Baseline data</I>: the most common site of the lesion was the face and most of the participants had one papulonodular lesion, with duration of the lesions varying from 1 to 12 months</P>
<UL>
<LI>Group 1: MNL: 1. MDLBT: 4.3 months</LI>
<LI>Group 2: MNL: 1. MDLBT: 4.3 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-08 14:54:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of interventions</I>: </P>
<UL>
<LI>
<I>Group 1</I>: 15% PR sulphate + 12% MBCL twice daily for 15 days</LI>
<LI>
<I>Group 2</I>: ketoconazole orally 400 mg per day for 30 days (reduced to 200 mg if participants &lt; 12 years old)</LI>
</UL>
<P>
<I>Duration of intervention</I>: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-06 10:00:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Healing rates</I>: percentage of participants 'cured' one month after treatment</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: at the end of treatment and 4 weeks post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: not reported</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>ACL</B>: anthroponotic cutaneous leishmaniasis; <B>AL</B>: allopurinol; <B>CCR</B>: complete clinical response; <B>CL</B>: cutaneous leishmaniasis; <B>HF-EC</B>: high frequency electrocauterisation; <B>HSCS</B>: hypertonic sodium chloride solution; <B>IL</B>: intralesional; <B>ILMA</B>: intralesional meglumine antimoniate; <B>ILSSG</B>: intralesional sodium stibogluconate; <B>IM</B>: intramuscular; <B>IMMA</B>: intramuscular meglumine antimoniate; <B>IQR</B>: interquartile range; <B>IV</B>: intravenous; <B>MA</B>: meglumine antimoniate; <B>MBCL</B>: methyl benzethonium chloride; <B>MDLBT</B>: median duration of lesions before therapy; <B>MNL</B>: median number of lesions; <B>MSL</B>: median size of lesions; <B>MWT</B>: moist wound treatment; <B>PDT</B>: topical photodynamic therapy; <B>PR</B>: paromomycin; <B>RF</B>: radiofrequency; <B>RFHT</B>: radiofrequency heat therapy; <B>SD</B>: standard deviation, <B>SEM</B>: standard error of the mean; <B>SSG</B>: sodium stibogluconate; <B>TCA</B>: trichloroacetic acid; <B>TM</B>: ThermoMed; <B>ZS</B>: zinc sulphate;</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-11-11 23:22:58 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-10-26 20:21:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alavi_x002d_Naini-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-26 20:21:34 +0000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:01:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banihashemi-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria of the patients: patients with lupoid leishmaniasis, chronic recurrent leishmaniasis, that typically follows an acute form of cutaneus leishmaniasis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:01:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bumb-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:01:47 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT. "Selected patients were categorised into two groups (groups A and B) of 110 persons each. Alternate patients were included in group A and B, respectively"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:02:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogra-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:02:09 +0000" MODIFIED_BY="[Empty name]">
<P>They stated that participants were randomly selected for the study, but not randomly assigned to the treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:02:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dogra-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:02:11 +0000" MODIFIED_BY="[Empty name]">
<P>They stated that participants were randomly selected for the study, but not randomly assigned to the treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-26 20:17:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dorlo-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-26 20:17:41 +0000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-El-On-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frankenburg-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>It measured immunity parameters but did not show any clinical results.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:02:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:02:22 +0000" MODIFIED_BY="[Empty name]">
<P>This was a meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-10-23 13:34:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moosavi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-10-23 13:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>The method of generation of randomisation was inappropriate. The author was contacted and stated that after enrolling the participants, they did consecutively allocate ILMA for odd number participants and used topical paromomycin for even number participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:02:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:02:35 +0000" MODIFIED_BY="[Empty name]">
<P>They stated that participants were randomly selected for the study, but not randomly assigned to the treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:02:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilforoushzadeh-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:02:37 +0000" MODIFIED_BY="[Empty name]">
<P>Included immunocompromised and chronically ill patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-09 09:02:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siavash-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-09 09:02:45 +0000" MODIFIED_BY="[Empty name]">
<P>Only studied electrocardiogram and biochemical adverse effects of meglumine antimoniate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-11-11 23:22:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-11 23:22:58 +0000" MODIFIED_BY="[Empty name]">
<P>They stated that participants in both groups were randomly selected. However, they did not have an initial population eligible for the study that was randomly divided in the 2 treatment groups. But rather one group of people that were randomly selected for one group and another group of participants that were also randomly selected to form part of the other group. Besides, the duration of treatments was not the same and the follow-up was also different for both treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-21 14:18:19 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Trau-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-21 14:18:19 +0100" MODIFIED_BY="Diane A  Horsley">
<P>No clear data is available for multiple lesions. Only lesions from participants with multiple lesions were randomised. The lesions from participants with single lesions a cross-over study was performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>RCT</B>: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-11-14 15:22:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2017-11-09 09:15:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farajzadeh-2016a">
<CHAR_METHODS MODIFIED="2017-11-09 09:11:05 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind randomised controlled trial</P>
<P>This study was carried out in some clinics of Kerman University of Medical Sciences (Iran), from October 2008 to December 2010.</P>
<P>
<I>Sample size calculation</I>: a sample size of 40 participants per treatment group was planned, a probability of a type I error at alpha = 0.05 and beta = 0.1 to determine a 20% difference between intralesional injection of ZS 2 % solution with ILMA (Glucantime)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:15:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L tropica</I>
</P>
<P>
<I>Inclusion criteria</I>: the presence of parasitological confirmed lesion(s) of CL and aged 5&#8211;60 years</P>
<P>
<I>Exclusion criteria</I>: disease duration more than 6 months, those with a history of hypersensitivity to MA (Glucantime) or ZS, pregnant or nursing women, those with more than 5 lesions, those with lesions with size of 5 cm or more, and a history of any anti-leishmanial therapy during last 4 weeks</P>
<P>
<I>N randomised</I>: 80, 40 in each group</P>
<P>
<I>Withdrawals</I>: 34, 18 in the ZS-treated group and 16 patients in the MA (Glucantime)-treated group (lost to follow-up in all of the participants except in one in the ZS-treated group, who had severe necrosis)</P>
<P>
<I>N assessed</I>: 46; 22 patients in the ZS-treated group and 24 patients in the MA (Glucantime)-treated group</P>
<P>There was no significant difference between compared groups' baseline characteristics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: intralesional injection of ZS 2% vials once a week for 10 weeks or sooner in case of complete resolution of the lesions</P>
<P>
<I>Group 2</I>: ILMA once a week for 10 weeks or sooner in case of complete resolution of the lesions</P>
<P>
<I>Co-intervention</I>: in both groups cryotherapy was performed once every other week for 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:15:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical response</I>: no response to treatment was defined if the area of a lesion decreased less than 75%, partial treatment if decreased 75% to 99%, and complete treatment if decreased 100% compared to its baseline area</P>
<P>
<I>Time to healing</I> (partial/complete treatment)</P>
<P>
<I>Adverse effects</I>: there were no major side effects in either group. Pain was observed in all participants of both groups. In ZS group 4 participants developed necrosis of the site of the injection while this was not observed in MA (Glucantime) group at all</P>
<P>Time points reported: on average, each participant was followed for 4.1 weeks (SD 2.6).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 09:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: there is no conflict of interest</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-14 15:19:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farajzadeh-2016b">
<CHAR_METHODS MODIFIED="2017-11-09 09:11:24 +0000" MODIFIED_BY="[Empty name]">
<P>Triple-blind randomised controlled trial</P>
<P>Performed in Shahid Dadbin Clinic of Leishmaniasis Research Center (Iran), at Kerman University of Medical Sciences, between 2008 and 2010</P>
<P>
<I>Sample size calculation</I>: a sample size of 44 participants per treatment group was planned with a probability of a type I error at alpha = 0.05 and beta = 0.1 to determine a 20% difference between topical terbinafine and vehicle in outcome.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:19:56 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: <I>L major </I>and <I>L tropica</I> in the area</P>
<P>
<I>Inclusion criteria</I>: &lt; 2 years of age; parasitological diagnosis of cutaneous leishmaniasis from all lesions with direct smear; ulcerative lesions with duration of less than one month that were not on exposed areas or joints; the size of lesions has to be &lt; 3 cm; &#8804; 3 lesions; no anti-leishmanial therapy during last 2 weeks, and with no history of hypersensitivity to MA</P>
<P>
<I>Exclusion criteria</I>: pregnant or nursing women, patients with hepatic, renal, or heart diseases</P>
<P>
<I>N randomised</I>: 88, 44 in each group</P>
<P>
<I>Withdrawals</I>: 36 in topical terbinafine + MA; 29 in vehicle + MA</P>
<P>
<I>N assessed</I> <I>(3 months)</I>: 9 in topical terbinafine + MA; 15 in vehicle + MA</P>
<P>There are significant differences between participants' sex in intervention and control groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:18:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: IMMA 20 mg/kg/d + topical terbinafine for 20 days</P>
<P>3 months follow-up after completing of the treatment phase</P>
<P>
<I>Group 2</I>: IMMA 20 mg/kg/d + vehicle (Mahan Vaseline) for 20 days</P>
<P>
<I>Visited at days</I>: 0, 14, 30 and 44</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:18:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Clinical cure</I>, defined as:</P>
<UL>
<LI>Complete improvement: full re-epithelialisation for ulcerative lesions and decrease in induration size(75%, with or without a negative direct smear result)</LI>
<LI>Partially improved: decrease in the indurations size between 25% and 75%</LI>
<LI>No change: decrease in the indurations size of 25%</LI>
</UL>
<P>
<I>Time to healing</I> (partial/complete treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 09:18:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: there is no conflict of interest.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-09 09:21:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanif-2016">
<CHAR_METHODS MODIFIED="2017-11-09 09:19:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled study</P>
<P>Department of Dermatology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, Pakistan, from November 2013 to June 2014</P>
<P>
<I>Sample size</I>: was calculated by using a formula for 2 proportions; expected proportion for duration of treatment in one group was taken as 55, and in second group 51 days; power of study was taken as 80, and standard error of 5%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:20:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Type of Leishmania</I>: not reported</P>
<P>
<I>Inclusion criteria</I>: patients of all age groups except neonates, with single or multiple parasitologically confirmed lesions of cutaneous leishmaniasis with no past history of disease and not previously treated with SSG or MA</P>
<P>
<I>Exclusion criteria</I>: retinal abnormality or visual field defects, pregnancy, hepatic dysfunction, known hypersensitivity to chloroquine and those having visceral leishmaniasis</P>
<P>
<I>N randomised</I>: 86; 48 intralesional chloroquine, 38 oral chloroquine</P>
<P>
<I>Withdrawals</I>: 0</P>
<P>
<I>N assessed</I>: 86; 48 intralesional chloroquine, 38 oral chloroquine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:20:29 +0000" MODIFIED_BY="[Empty name]">
<P>Intralesional and oral chloroquine administration</P>
<P>
<I>Co-interventions</I>: lesions with secondary bacterial infection before, during, or after treatment were treated with topical antibiotics. If such infections required systemic treatment, an antibiotic that has no activity against <I>Leishmania </I>(e.g. erythromycin) was given.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:21:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure</I> was defined as the complete re-epithelialisation of the ulcerated lesions, with no evidence of papules, inflammation, or induration</P>
<P>Quantitative variables like, <I>duration, cost</I> and <I>total dose of treatment</I> were calculated</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: &lt; 4 weeks, 5-8 weeks, &#8805; 9 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 09:21:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-09 09:24:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jaffary-2016">
<CHAR_METHODS MODIFIED="2017-10-19 14:12:23 +0100" MODIFIED_BY="[Empty name]">
<P>Interventional randomised controlled study was conducted in the Skin Disease and Leishmaniasis Research Center of Isfahan University of Medical Sciences, Isfahan, Iran, between April 2010 and May 2011</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:23:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Leishmania type</I>: not described</P>
<P>
<I>Inclusion criteria</I>: patients older than 5 years with biopsy-confirmed cutaneous leishmaniasis were eligible if they had the following criteria: lesion diameter &lt; 3 cm, disease duration &lt; 12 weeks, lesion-to-eyelid distance &gt; 2 cm, and no history of systemic or topical therapy for cutaneous leishmaniasis</P>
<P>
<I>Exclusion criteria</I>: pregnancy, lactation, immunosuppressive therapy, and serious side effects of medication</P>
<P>
<I>N randomised</I>: 90. 30 in each group (ILMA (Glucantime) alone, ILMA + TCA 50%, or fractional CO&#8322; laser) </P>
<P>
<I>Withdrawals</I>: 14</P>
<P>
<I>N assessed</I>: 76 participants (84.5%) completed treatment and were followed up for 60 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:23:16 +0000" MODIFIED_BY="[Empty name]">
<P>ILMA alone, ILMA + TCA 50% or fractional CO&#8322; laser for up to 8 weeks</P>
<P>Participants in all 3 groups were followed up weekly for the next 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:24:01 +0000" MODIFIED_BY="[Empty name]">
<P>The <I>clinical response</I> was rated as complete improvement (complete re-epithelialisation of the lesion with negative direct skin smear result), partial improvement (50%&#8211;75% improvement of the lesion size), and no change in the lesion appearance.</P>
<P>
<I>Time to healing</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>The improvement of scar was also evaluated according to the <I>participant's satisfaction, the morphology of the lesion, the level of induration, and the level of atrophy</I> and scored as follows: score of 1 (less than 5% improvement), score of 2 (25% to 50% improvement), score of 3 (51% to 75% improvement), and score of 4 (76% to 100% improvement)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 09:24:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: there is no conflict of interest.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-14 15:22:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Na_x002d_Bangchang-2016">
<CHAR_METHODS MODIFIED="2017-11-09 09:24:43 +0000" MODIFIED_BY="[Empty name]">
<P>Exploratory phase II, randomised, vehicle-controlled, single-centre (Ankober Health Center, North Shewa zone of Amhara region, Ethiopia) study</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:22:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Leishamania type</I>: not described</P>
<P>
<I>Inclusion criteria</I>: patients with localised cutaneous leishmaniasis (LCL) aged 18&#8211;65 years with a new, uncomplicated, localised, single lesion on the face or arms and positive parasite smear by microscopy</P>
<P>
<I>Exclusion criteria</I>: cutaneous leishmaniasis with secondary infection, concomitant diseases (mucocutaneous or visceral leishmaniasis), history of anti-leishmanial treatment within the past 6 months, abnormality of biochemical and/or haematological laboratory tests, known hypersensitivity to any of the Shiunko components, or pregnancy (positive urine HCG test), breastfeeding, or possibility of becoming pregnant during the study</P>
<P>
<I>N randomised</I>: 40 were randomised to receive vehicle and Shiunko ointment (20 participants for each group)</P>
<P>
<I>Withdrawals</I>: 2 participants did not receive complete treatment, and 9 were not completely followed up. In the vehicle group, 2 and 5 cases did not have complete treatment and follow-up, respectively. </P>
<P>
<I>N assessed</I>: 38 participants had complete treatment and 31, complete follow-up. In the vehicle group, 18 and 15 cases had complete treatment and follow-up, respectively. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:40:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: the composition of Shiunko was as follows: 2.04 g shikon, 1.02 g tohki, 16.92 g sesame oil, and 6.76 g honeycomb wax</P>
<P>
<I>Group 2</I>: the vehicle contained 20 g wax</P>
<P>
<I>Co-interventions</I>: cryotherapy was to be offered to all participants who were withdrawn or discontinued from the study for safety reasons</P>
<P>Vehicle and Shiunko ointment applied on the lesion twice a day for 4 weeks</P>
<P>Follow-up: 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:41:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure</I>: <I>complete cure</I> was defined as complete wound closure and re-epithelialisation without inflammation or infiltration and absence of parasite (amastigotes) within 12 weeks after the end of treatment. <I>Partial response</I> was defined as improvement of <I>Leishmania </I>signs (skin oedema, erythema, and/or hardening) and/or reduction in size but not total disappearance of the lesion and absence of parasite (amastigotes) within 12 weeks after the end of treatment. <I>Treatment failure</I> was defined as failure of the lesion size to decrease and/or lack of lesion sign improvement or re-epithelialisation and/or presence of leishmanial amastigotes in the lesion 12 weeks after end of treatment (week 16)</P>
<P>
<I>Adverse effects</I>
</P>
<P>
<I>Clinical and parasitological</I> <I>assessments</I> were performed before treatment, weekly for 4 weeks, and then 4, 8, and 12 weeks after the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-03 12:09:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: the study was supported by the Institute of Tropical Medicine, Nagasaki University (Japan), ArmauerHansen Research Institute (Ethiopia), and Okusa Co., Ltd. (Japan).</P>
<P>
<I>Possible conflicts of interest</I>: there is no conflict of interest.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-09 09:44:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rajabi-2016">
<CHAR_METHODS MODIFIED="2017-11-09 09:41:33 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical randomised trial conducted from March 2008 through 2009 in the dermatology department of Quaem University Hospital, Mashhad, Iran</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:42:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Leishamania type</I>: not described</P>
<P>
<I>Inclusion criteria</I>: positive smear for leishmaniasis with disease duration of less than 12 weeks, no treatment for the current condition before and volunteer to participate in the study</P>
<P>
<I>Exclusion criteria</I>: pregnancy, breastfeeding, history of simultaneous treatment with other methods before or during the trial, history of local cutaneous or systemic diseases in the past 2 months, history of intolerance or allergy to macrolides, severe underlying diseases such as cardiovascular, renal, or hepatic diseases</P>
<P>
<I>N randomised</I>: 96; 26 (43 lesions) azithromycin, 40 (54 lesions) MA (Glucantime)</P>
<P>
<I>Withdrawals</I>: 2 azithromycin group</P>
<P>
<I>N assessed</I>: 94; 24 (40 lesions) azithromycin, 40 (54 lesions) MA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:42:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: topical liposomal form of azithromycin was administered for the first group twice daily.<BR/>
<I>Group 2</I>: the other group was treated by weekly ILMA with a volume of 0.5&#8211;2 cm³ into each lesion till complete blanching of the lesion occurred</P>
<P>Clinical evaluations were performed every week during the treatment course (8 weeks) by a single dermatologist in both groups.</P>
<P>The participants were followed up for recurrence or complications 6 and 12 months after the end of the treatment course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:44:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Complete cure</I> was defined as full re-epithelialisation, disappearance of oedema, induration, and other signs of inflammation, and a negative direct skin smear result</P>
<P>
<I>Improvement rate (%)</I>: complete improvement (full re-epithelialisation of the lesions for ulcerative ones or disappearance of induration and erythema; significant improvement (decrease in induration size &gt; 60%); moderate improvement (decrease in induration size between 30% and 60%; slight improvement (decrease in induration size of &lt; 30%).</P>
<P>
<I>Adverse effects</I>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-09 08:23:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Study funding sources</I>: none declared</P>
<P>
<I>Possible conflicts of interest</I>: none declared</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-09 09:45:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Refai-2016">
<CHAR_METHODS MODIFIED="2017-11-09 09:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>Interventional randomised study</P>
<P>
<I>Setting</I>: Sri Lanka</P>
<P>
<I>Sample size calculation</I>: not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:45:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Leishmania type</I>:<I> L donovani</I>
</P>
<P>
<I>Inclusion criteria</I>: Laboratory-confirmed CL patients with single lesions</P>
<P>
<I>Exclusion criteria</I>: &#8212;</P>
<P>
<I>N randomised</I>: test group (n = 98); control group (n = 115)</P>
<P>
<I>Withdrawals</I>: &#8212;</P>
<P>
<I>N assessed</I>: &#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:45:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: single session of radiofrequency induced heat therapy (RFHT) at 50ºC for 30 s</P>
<P>
<I>Group 2</I>: received weekly ILSSG until cure or 10 doses</P>
<P>Participants were followed up fortnightly for 12 weeks to assess clinical response and adverse effects.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:45:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Cure rate</I>
</P>
<P>
<I>Adverse effects</I>
</P>
<P>Time points reported: 8, 10, and 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-10-05 17:18:30 +0100" MODIFIED_BY="[Empty name]">
<P>Poster</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-09 09:45:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sattar-2012">
<CHAR_METHODS MODIFIED="2017-11-09 09:45:43 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-01-09 11:26:30 +0000" MODIFIED_BY="[Empty name]">
<P>40 participants (no more data described in abstract)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-21 10:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Topical ointment prepared from the stem extract of Morinda citrifolia (no more data described in abstract)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-01-09 11:26:30 +0000" MODIFIED_BY="[Empty name]">
<P>Improvement (no more data described in abstract)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-01-09 11:26:30 +0000" MODIFIED_BY="[Empty name]">
<P>Article request to authors</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>
<B>CL</B>: cutaneous leishmaniasis; <B>HCG</B>: human chorionic gonadotropin; <B>ILMA</B>: intralesional meglumine antimoniate; <B>IM</B>: intramuscular; <B>MA</B>: meglumine antimoniate; <B>SSG</B>: sodium stibogluconate; <B>ZS</B>: zinc sulphate.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-11-14 15:23:07 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-11-09 09:54:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12614001288617">
<CHAR_STUDY_NAME MODIFIED="2015-11-28 11:20:23 +0000" MODIFIED_BY="[Empty name]">
<P>A clinical trial to assess the safety and effect of heat therapy in comparison to standard intra-lesional sodium stibogluconate for cutaneous leishmaniasis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-11-09 09:48:29 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:51:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Inclusion criteria</I>: suggestive skin lesions (papules, nodules, plaques, ulcers and nodule-ulcers) who were clinically diagnosed by a consultant dermatologist and parasitologically confirmed as CL</P>
<P>
<I>Exclusion criteria</I>: non-localised leishmaniasis (VL, MCL, leishmaniasis recidivans, diffuse cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis); use of prior concomitant treatment for leishmaniasis including any traditional medicines; lesions close to nasal, oral, urogenital, anal areas (mucosae) and the eyes; multiple lesions; any chronic or concomitant illnesses and people on pace makers and any metallic devices; pregnancy and breastfeeding mothers; children &lt; 12 years of age; immunocompromised states including HIV/AIDS and use of immunosuppressants like steroids; alcohol abuse; not capable of understanding and complying with the study protocol; known hypersensitivity or allergy to treatment</P>
<P>
<I>Age</I>: 12-90 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 09:53:12 +0000" MODIFIED_BY="[Empty name]">
<P>The device used was the ThermoMed 1.8, ThermoSurgery Technologies portable battery operated device. The generator has received clearance by the US Food and Drug Administration for the treatment of CL. It delivers precisely controlled localised radiofrequency waves to selectively destroy diseased tissue. Heat therapy was administered as a single session. The lesion and surrounding normal skin was cleaned with normal saline. Then the area was anaesthetised with 2% lignocaine using a 1 cc syringe. The device was used in according to manufacturers instructions (ThermoMed 1.8; Thermosurgery). It generates a 6.78 mHz frequency applied with a hand set that is attached to 2 applicator electrodes which were placed on the diseased skin. A temperature of 50ºC was applied for 30 s to cover an area about 49-73 mm², according to the size of electrodes (3 sizes are provided). Then the applicator is moved to another area of the lesion until the entire area is treated. Once treatment begins the temperature is measured by a thermistor embedded in the applicator which ensures that the applied temperature remains constant. After treatment the lesions were covered with gauze to prevent secondary infections and participants were given an antibiotic cream (soframycin 1% per 30 g depending on the size of lesion to cover the lesion) to be applied twice a day for 3 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 09:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Recurrence</I>
</P>
<P>
<I>Treatment efficacy</I> was measured by the percentage of participants clinically cured by 8 weeks, 10 weeks, 12 weeks and 16 weeks after initiation of treatment in both groups.</P>
<UL>
<LI>Cure was defined as complete re-epithelialisation of the CL lesion with no evidence of papules, active inflammation or induration.</LI>
<LI>Partially cured if healing was 50%-100%</LI>
<LI>Non-responders or treatment failures were those who had lesions that were less than 50% healed at the end of 3 months or if new lesions occur while on treatment</LI>
</UL>
<P>Any adverse effects like secondary bacterial infections, allergy to treatment or hypersensitivity and worsening of the lesion clinically was recorded during or after treatment with either therapy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-28 11:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>December 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-11-09 09:54:13 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Fathima Wardha Refa</P>
<P>PGIM address: No. 160, Professor Nandadasa Kodagoda Mawatha (Norris Canal Road), 00700, Colombo 7. 2.Department of Parasitology, Faculty of Medicine Colombo University of Colombo address: No 25, Kynsey Road, Colombo 8 0080, Sri Lanka. 7 MACLEOD ROAD COLOMBO 4, Sri Lanka</P>
<P>+94 727800003 or +94 11 2580093 or+94 11 2699284</P>
<P>wardharefai@yahoo.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-09 09:54:32 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-14 15:22:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT138904091159N7">
<CHAR_STUDY_NAME MODIFIED="2016-12-20 09:18:34 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison between the efficacy of intralesional placebo and nitric oxide releasing patch versus placebo patch and Glucantime in the treatment of cutaneous leishmaniasis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-11-09 09:55:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 09:58:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Inclusion criteria</I>: diagnosis of acute zoonotic cutaneous leishmaniasis, proven parasitology by direct smear; aged 18-50 years; lesion diameter &#8804; 3 cm; 1 lesion, not located on the face near the eyes, joints, cartilage, on the nose and ears; &lt; 3 months passed from diseases times</P>
<P>
<I>Exclusion criteria</I>: pregnancy and lactation; risk of presence or incidence of sporotrichoid or satellite lesions; history of hepatitis, heart, or kidney disorder; taking immunosuppressive medications (over the last 6 months); local or systemic treatment against leishmaniasis in the last 3 months; history of heart attack or high blood pressure; liver disease; anaemia; history of surgery for head and brain haemorrhage; taking blood pressure medications, antidepressants, or drugs used for angina</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-14 15:22:41 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: nitroglycerin patch (the pharmacy of Nour and Ali Asghar hospital in Isfahan) once a day covering 5.08 to 7.62 cm of lesion + intralesional injection of placebo (injection of distilled water) once a week (15-30 mg) until whitening of base of the ulcer for 8 weeks or until complete cure</P>
<P>
<I>Group 2</I>: ILMA (Meglusan) from Avenue de Scheut company in Belium, once a week (15-30 mg) until whitening of base of the ulcer + placebo patch (the pharmacy of Nour and Ali Asghar hospital in Isfahan) once a day covering 5.08 to 7.62 cm of lesion for 8 weeks or until complete cure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 10:05:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Improvement rate</I>. Timepoint: 1, 2, 3, 4, 7, 8 weeks during treatment and 12, 16, 20 weeks after end of treatment. Method of measurement: observation and examination</P>
<P>
<I>Induration</I>. Timepoint: 1, 2, 3, 4, 7, 8, 12, 16, 20 weeks after end of treatment. Method of measurement: physical examination</P>
<P>
<I>Lesion area</I>. Timepoint: 8, 12, 20 weeks after end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-28 11:36:45 +0000" MODIFIED_BY="[Empty name]">
<P>August 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-11-28 11:38:48 +0000" MODIFIED_BY="[Empty name]">
<P>Fariba Jaffary</P>
<P>Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Sedigheh Tahereh (AS) Research Centers Complex, Khorram Ave., Isfahan, Iran Isfahan Iran, Islamic Republic Of Iran.</P>
<P>00983113373736</P>
<P>jaffary@pharm.mui.ac.ir</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-09 10:05:21 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-14 15:23:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT2013092414746N1">
<CHAR_STUDY_NAME MODIFIED="2017-11-09 10:05:26 +0000" MODIFIED_BY="[Empty name]">
<P>The effect of MJ1 (topical dairy extract) versus routine care for treatment of cutaneous leishmaniasis (rural) in Isfahan Iran:a randomised controlled clinical trial (RCTs)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-11-09 10:05:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-14 15:23:07 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Inclusion criteria</I>: cutaneous leishmaniasis of parasitology confirmed that they have not been previously treated; any other medical problem (such as heart disease, renal, hepatic, or haematological); available for follow-up; informed consent to participate in the study</P>
<P>
<I>Exclusion criteria</I>: secondary infections, history of allergic reactions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 10:11:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: in this group patients apply MJ1 skin cream 3 times a day, they are trained to use it for a month with a diameter of 3 mm on the rub of the lesion without dressing</P>
<P>
<I>Group 2</I>: skin cream MJ1 - 3 times a day - for a month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 10:12:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Lesion size</I>, lesion diameters measured</P>
<P>Timepoint: 1, 2, 3, 4 and 8 weeks after starting treatment, participants are evaluated.</P>
<P>Method of measurement: at each visit, the 2 dimensions are measured and the area calculated</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-28 11:44:06 +0000" MODIFIED_BY="[Empty name]">
<P>December 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-11-09 10:12:04 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Mohsen Janghorbani</P>
<P>Hezar jarib Street, School of Public Health, Isfahan University of Medical Sciences Isfahan Iran, Islamic Republic Of</P>
<P>00983117922774</P>
<P>janghorbani@hlth.mui.ac.ir</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-09 10:12:17 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-09 10:14:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00840359">
<CHAR_STUDY_NAME MODIFIED="2017-11-09 10:12:54 +0000" MODIFIED_BY="[Empty name]">
<P>Phase 2 study of the efficacy of daylight activated photodynamic therapy in the treatment of cutaneous leishmaniasis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-11-09 10:13:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel assignment, open label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 10:13:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Age:</I> &#8805; 18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 10:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: photodynamic therapy Application of Metvix 16% cream followed by exposure to daylight for 2.5 h</P>
<P>
<I>Group 2</I>: cryotherapy for 2 times 20 s</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-28 11:49:04 +0000" MODIFIED_BY="[Empty name]">
<P>Eradiation of amastigotes</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-28 11:49:08 +0000" MODIFIED_BY="[Empty name]">
<P>September 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-11-09 10:14:02 +0000" MODIFIED_BY="[Empty name]">
<P>Prof Claes D. Enk, Hadassah Medical Organization</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-09 10:12:21 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-09 10:22:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01050777">
<CHAR_STUDY_NAME MODIFIED="2017-11-09 10:14:40 +0000" MODIFIED_BY="[Empty name]">
<P>Pilot study of efficacy of topical nano-liposomal meglumine antimoniate (Glucantime) or paromomycin in combination with systemic Glucantime for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by <I>Leishmania tropica</I>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-11-09 10:14:49 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel assignment, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 10:21:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Inclusion criteria</I>: aged 12-60 years; parasitologically proven CL due to<I> L tropica</I>; history of failure to at least one full course of systemic meglumine antimoniate (Glucantime); general good health based on history and physical examination; &#8804; 4 lesions; lesion size &lt; 3 cm; signed informed consent voluntarily and knowingly; guardian's signature for volunteer less than 18 years old</P>
<P>
<I>Exclusion criteria</I>: pregnant or lactating women and those who are planning to be pregnant in next 60 days; use of other types of treatment for CL; involvement in any other drug or vaccine trial during the study period; known heart, kidney, liver diseases based on history and physical exam; abnormal ECG</P>
<P>
<I>Age</I>: 12-60 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 10:22:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: liposomal paromomycin (liposomes containing 10% paromomycin&#8232;) + liposomal MA </P>
<P>
<I>Group 2</I>: liposomal MA (Glucantime)</P>
<P>
<I>Group 3</I>: placebo + liposomal MA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 10:22:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Complete cure</I> equal to complete re-epithelialisation of all lesions</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-28 11:52:29 +0000" MODIFIED_BY="[Empty name]">
<P>March 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-11-28 11:52:32 +0000" MODIFIED_BY="[Empty name]">
<P>Ali Khamesipour, Tehran University of Medical Sciences</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-09 10:12:25 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-09 10:25:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SLCTR_x002f_2014_x002f_028">
<CHAR_STUDY_NAME MODIFIED="2017-11-08 15:28:28 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled study on efficacy and safety of intralesional metronidazole vs intralesional sodium stibogluconate in <I>L donovani</I> cutaneous leishmaniasis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-10-19 11:19:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-09 10:23:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Inclusion criteria</I>: &gt; 12 years of age, positive slit skin smear and/or skin biopsy for <I>Leishmania </I>parasites</P>
<P>
<I>Exclusion criteria</I>: pregnancy, breastfeeding, known renal impairment, known liver impairment, congestive cardiac failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-09 10:24:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: intralesional metronidazole 0.2-4 mL per lesion depending on the size of the lesion, weekly until cure or maximum of 10 injections</P>
<P>
<I>Group 2</I>: intralesional stibogluconate 0.2-4 mL per lesion depending on the size of the lesion, weekly until cure or maximum of 10 injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-09 10:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Rate of clinical cure</I>
</P>
<P>
<I>Adverse effects</I> &#8211; anticipated local side effects are pain, ulceration, scarring, postinflammatory hyperpigmentation or depigmentation. Systemic side effects are not anticipated as the drug is given intralesionally.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-11-28 12:02:28 +0000" MODIFIED_BY="[Empty name]">
<P>November 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-11-09 10:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>Ranthilaka R Ranawaka</P>
<P>0112855200</P>
<P>ranthilaka37@yahoo.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-09 10:12:29 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>
<B>CL</B>: cutaneous leishmaniasis; <B>ECG</B>: electrocardiogram; <B>ILMA</B>: intralesional meglumine antimoniate.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-11-14 15:07:47 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-09 08:16:39 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:16:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Quote: "A computer-generated block-randomisation, blinded to the treating physician, was used to allocate patients to the two treatment arms"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:54:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:41:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>Quote: "The participants were randomly divided into two groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 13:02:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>Quote: "enrolled patients were randomly assigned to one of two treatment groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 13:08:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>Quote: "the randomisation sequence was generated from a random-number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:41:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:37:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>The statistician (RH) generated the randomisation plan in blocks of 4 subjects using www.randomization.com. The research pharmacist made assignments using the randomisation plan in sequential order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 09:26:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>Randomisation of treatment was carried out in Geneva (Switzerland) but did not state how that was done. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 08:12:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>Computer-generated randomisation list after participants returned their first used tube after 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:41:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>Quote: "The 400 patients were randomly divided into three groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:06:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>Comment: the author was contacted. The randomisation was through coin flip method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 14:45:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>Quote: "The participants were randomly divided into three groups of 20 subjects each, using computer-based randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:41:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into two groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-18 09:38:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>Quote: "The tubes containing drug or placebo were supplied by the WHO/TDR, randomly numbered, and were given in numerical order to patients as they were admitted into the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:03:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>Quote: "A sequence of genuine random numbers for the randomisation procedure was obtained from the 'fourmilab.ch/hotbits' website by a member of the Department of Chemical Information, Walter Reed Army Institute of Research, Silver Spring, Maryland and purged of duplicates.</P>
<P>The random numbers are generated by a process which takes advantage of the inherent uncertainty in the quantum mechanical laws of nature. Specifically, they are generated by timing successive pairs of radioactive decays detected by a Geiger-Muëller tube interfaced to a computer. This process is better than the pseudo-random number algorithms typically used in computer programs. The randomisation of the study drugs was done by an independent group, Fischer BioServices, Rockville, Maryland a contractor to The U.S. Army Medical Research Acquisition Activity (USAMRAA), Ft. Detrick, Maryland."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:39:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>Quote: "A permuted block randomisation schema was generated using nQuery, employing random block sizes, for the first 330 randomisation numbers. As 7 subjects were randomised that did not receive treatment at the time when the new randomisation list was generated, the plan in generating the new list was to balance the assignments in the new list for these 7 subjects to achieve the 1:1:1 allocation balance overall. The second randomisation was performed using SAS Version 9.2."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:24:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>Quote: "The patients were N randomised in a 1:1 ratio"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 11:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>Randomised allocation was performed by blocked randomisation method with block size of 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:36:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>Quote: "randomly assigned to treatment"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:45:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>Quote: "A total of 71 participants who met the inclusion criteria in the trial were randomly divided into two treatment groups according to simple even and odd number allocation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>Proportion of 2 to 4:1</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:55:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>Quote: "... and was randomly allocated to receive either tablets of dapsone (100 mg) or placebo tablets which were identical in appearance"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 12:05:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:42:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>Quote: "Patients were allocated randomly to receive capsules of itraconazole 100 mg or identical placebo".</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:41:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>Simple randomisation through a random number table and allocation ratio being 1:1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:18:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:16:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>Quote: "The patients were then randomized into two equal groups to receive either fluconazole 100 mg or 200 mg twice daily."</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:42:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Quote: "the patients were randomly divided into three groups."</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 10:43:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>Quote: "In the period of recruitment, [&#8230;] they were randomised by fixed block random allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>The randomisation sequence was obtained by the use of a randomisation table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:59:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 13:40:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 11:44:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>Quote: "randomly divided into 2 groups according to a list made by a simple randomisation block design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-17 08:32:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>List generated by a computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 13:41:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>Random numbers table method used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:12:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 10:43:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>Quote: "The cases enrolled were assigned to two treatment groups, placebo or paromomycin, using computer-based randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:26:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>Quote: "Randomized"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:16:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>Quote: "140 patients with cutaneous leishmaniasis referring to Skin Diseases and Leishmaniasis Research Center of Isfahan (SDLRC) were randomly allocated in two groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>Quote: "During this double-blind randomised study, 60 patients were randomised into two treatment groups by using random allocation computer software."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:19:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>The participants were randomly allocated to 3 groups using table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 13:59:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>Quote: "subjects were randomly assigned with the help of a GMS computer at a ratio of 1:1"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 14:09:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>Quote: "This investigation was designed as a 12-week, double blind, N randomised, placebo-controlled study and its protocol was approved by the ethics committee of the vice chancellor of research affairs of Shiraz University."</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:59:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomised according to a computer generated simple randomisation list to be treated with intralesional injection of MA using either the classic method or mesotherapy gun."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 14:30:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>Quote:"This open N randomised controlled trial was carried out in Bam and Mashhad in Iran &#8230;"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 14:50:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>Quote: "A random sequence generated by using the online software Random Sequence Generator, which is available at URL: www.random.org [22]. It was done by an investigator with no clinical involvement in the trial. R. Talaee was responsible for enrolment of the patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:44:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>"Randomized"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:13:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>"Randomized"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:20:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>Quote: "Randomization was carried out by using a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:29:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>Quote: "The 49 patients who met our inclusion criteria were randomly divided into two groups."</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:44:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 08:52:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>Quote: "The 110 patients who met our inclusion criteria were randomly divided into two groups."</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 09:52:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:04:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>Quote: "This N randomised controlled trial was performed from March to September 2004 on patients with cutaneous leishmaniasis admitted to Imam Reza Hospital in Mashhad"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 20:01:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>The method of randomisation was selecting a card among 36 cards with odd or even numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:44:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:28:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>Quote: "For randomisation of patients into two groups, we used balanced block method"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:45:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>Quote: "Carried out by the WHO Special Programme for Research and Training in Tropical Diseases group in Geneva, Switzerland"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:35:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>Quote: "Seventy-two patients were assigned randomly to two groups." </P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:16:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>Quote: "The study was designed as a double-blind, N randomised, placebo-controlled trial"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:45:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into two groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:16:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into two treatment groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:58:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>Quote: "The randomisation sequence was generated from a random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:45:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-17 08:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>Random digit table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 13:58:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>Quote: "Random allocation software (ver 1.0, May 2004; Saghaei)"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:21:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>Participants were selected and randomised by random allocation software into 3 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:25:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Quote: "This computer&#8208;based randomised controlled trial was conducted from March 2008 to March 2009"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:46:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:46:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 20:02:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>Random allocation software (version 1.0, May 2004, Saghaei) was used for randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 10:52:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>The treatment options were documented separately and packed in opaque envelopes numbered consecutively according to the randomisation schedule at a ratio of 2: 2: 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:19:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>Quote: "Patients then proceeded to pick 1 of 3 identical cardboard pieces out of a hat (the cardboard had been labelled with different treatment codes on one of its sides, the codes being non-visible to the patient). After patients were randomly assigned to receive a treatment, the cardboard piece picked was returned to the hat."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into two groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:33:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>Quote: "This N randomised controlled clinical trail study with simple sampling." "72 patients randomly divided in two equal groups".</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:38:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>Quote: "Patients were randomly allocated to one of two treatment groups using a random number list generated by Epi Info (a software package designed to provide easy form and database construction, data entry, and analysis with epidemiologist statistics, map sand graphs)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:35:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>Quote: "Patients were asked to pick one of two identical cardboard pieces out of a box (the cardboard had been labelled with different treatment codes on one of its sides) for their group assignment. After patients were assigned to a treatment group, the cardboard piece picked was returned to the box."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:39:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>Quote: "Patients were randomly allocated to two treatment groups using a simple randomisation method"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:22:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>The randomisation sequence was generated by the use of a randomisation Table. A simple block randomisation list with block size of 4 was prepared by a member of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:21:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>Participants were recruited and randomised by random allocation software into 3 treatment groups of 30 subjects each.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:36:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Quote: "Each patient was randomly assigned to one of the 3 regimens by the random allocation generator in the computer-based Leishmedoc system."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:48:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>Quote: "Using simple randomisation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:48:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:54:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>Quote: "Patients were divided randomly into two treatment groups"</P>
<P>Comment: insufficient detail was reported about the method used to generate the allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-11-08 14:51:07 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:19:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 12:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into two groups"</P>
<P>No further information about allocation concealment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>Quote: "enrolled patients were randomly assigned to one of two treatment groups"</P>
<P>Comment: no further information about allocation concealment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>Quote: "The randomisation sequence was generated from a random-number table"</P>
<P>Comment: no further information about allocation concealment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 13:12:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>No information about allocation concealment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 12:42:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>The allocation sequence was unavailable to investigators until completion of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 08:12:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>Quote: "The 400 patients were randomly divided into three groups"</P>
<P>Comment: no further information was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 10:13:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>Comment: the author was contacted. The randomisation was through coin flip method, but the method to conceal the allocation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-18 09:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>No information about allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 10:32:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-18 09:38:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>Quote: "The tubes containing drug or placebo were supplied by the WHO/TDR, randomly numbered, and were given in numerical order to patients as they were admitted into the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:04:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>The randomisation of the study drugs was done by an independent group; however, allocation concealment is not fully described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:39:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>The randomisation of the study drugs was done by an independent group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:33:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>Randomised allocation was performed by blocked randomisation method and was prepared by the analyst of the research team who had no clinical involvement in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:36:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>Quote: "randomly assigned to treatment"</P>
<P>Comment: no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:49:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:55:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>Quote: "... and was randomly allocated to receive either tablets of dapsone (100 mg) or placebo tablets which were identical in appearance"</P>
<P>Comment: no further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 12:03:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:00:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>Quote: "Patients were allocated randomly to receive capsules of itraconazole 100 mg or identical placebo".</P>
<P>Comment: no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>"Randomisation sequence generation and allocation of medicine was done by lead investigators at the three research set ups"</P>
<P>Comment: no information on the method of allocation concealment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 12:55:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:26:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Quote: "the patients were randomly divided into three groups."</P>
<P>Comment: no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:35:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 14:58:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>A simple block randomisation list with a block size of 4 was accumulated by a team member who was not involved in the enlistment and follow-up of the participants. The randomisation allocation concealment was carried out by sending the randomisation numbers in envelopes to a dermatologist who was responsible for giving the assigned treatment after each participant was en-rolled<I>.</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:59:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 11:32:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>The randomisation sequence was concealed from the investigators until the data entry was completed and the data bank was locked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:45:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>Quote: "The randomisation allocation concealment was performed by sending the randomisation numbers in envelopes to a pharmacist who was responsible for giving the assigned treatment after each eligible patient was enrolled."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 12:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 11:58:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>Comment: no information about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:12:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:20:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:26:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>Comment: "Randomized" but no further information was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-03 12:12:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>Quote: "RS and KWS were responsible for the enrolment of the patients and their assignment to the treatment groups."</P>
<P>Comment: not further information was provided regarding the method for allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 14:21:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>Quote: "The method for randomisation concealment was to use sequentially numbered, opaque, sealed envelopes (SNOSE). The envelopes were kept in a safe box, which was only accessible to A. Khatami who was responsible for assigning the patients to the interventions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:01:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>Comment: "Randomized" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:13:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>Comment: "Randomized" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 12:19:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 12:24:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:13:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 14:49:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 14:53:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:32:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 14:57:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 14:59:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 13:32:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 12:46:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:58:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>Quote: "Concealed from the investigator until the data entry was completed and the data bank was locked"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 12:47:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 12:48:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 12:49:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:13:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 13:53:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 17:35:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:21:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>Participants with confirmed cutaneous leishmaniasis referred to the Skin Diseases and Leishmaniasis Research Center were selected and randomised by random allocation software into 3 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 13:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-03 12:47:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>The allocation sequence was concealed from the researcher who enrolled and assessed the participants by the use of sequentially numbered, opaque, sealed, and stapled envelopes that were impermeable even to intense light.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:29:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>Study was described as "double blind" but has no description about allocation method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 12:54:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:38:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:39:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:43:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:53:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>Quote: "The randomisation allocation concealment was performed by sending the randomisation number in envelopes to a member who was responsible for giving the assigned treatment after each eligible patient was enrolled. The recruited patients were referred to this member to receive their assigned treatments."</P>
<P>Comment: unclear because no mention of opaque and numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-03 13:09:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:02:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:12:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:19:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-14 12:17:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:48:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:51:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-30 13:02:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-07-18 12:32:48 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-11-09 08:30:56 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:19:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Quote: "a double-blind, placebo controlled clinical trial"; "blinded to the treating physician&#8230;"</P>
<P>Comment: not fully reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:54:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>Not reported; probably an open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-17 22:57:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>The drug and the placebo were supplied in capsules with the same shape.</P>
<P>No information about blinding of personnel was provided but it is not likely to add risk of bias being oral administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-12-29 13:22:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>No information about blinding of participants and personnel was provided but the different administration via of the drug is impossible to blind, although it is unlikely to add risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>Quotes: "assigned to receive either fluconazole (Diflucan, Pfizer, New York) in the form of a 200-mg capsule once daily for six weeks or a matching placebo"</P>
<P>"An independent observer evaluated the rates of compliance and side effects by interviewing patients and counting their remaining capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-30 13:12:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>No information about blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-30 13:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-10-19 14:44:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>Identical ointment tubes were numbered and allocated to consecutive eligible participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 08:18:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>The vehicle and active ointments looked and smelled identical.</P>
<P>Outcome is not likely to be influenced by the lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-18 08:44:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>Treatment doesn't appear as blinded and the different treatments are difficult to blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 10:13:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>No data provided, but the treatment is unlikely to be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>Quote: "Subjects in both the paromomycin and placebo groups and the clinician treating them were blinded with respect to the topical treatment received. However, it was not possible to blind subjects in the PDT group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-18 09:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>Quote: "The code remained unknown to patients and investigators until the study had been completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 11:04:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>The vehicle lacked the active components and trace amounts of colorings agents to match the appearance and maintain the blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-30 19:39:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>The placebo consisted of the vehicle without the active components and trace amounts of colorings agents to match the appearance and maintain the blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 11:34:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>Blinding was impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-18 09:47:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>No information about blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 11:49:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 11:55:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>Quote: "double-blind therapeutic trial"</P>
<P>Comment: participants looks like blinded but no description about personnel blinding were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-19 12:03:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 12:00:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>Quote: "double-blind therapeutic trial"</P>
<P>Comment: participants looks like blinded but no description about personnel blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 12:52:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 14:19:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 12:26:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 12:07:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Comment: the treatment it is not possible to blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-02-20 16:01:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>Treatment description do not appear as blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-06 12:46:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>Different administration of treatments: oral terbinafine and IMMA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-11 08:25:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 11:32:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>Quote: "Double-blind"</P>
<P>Comment: the preparation and coding of drugs were done by a pharmacist outside of the research team and investigators were blinded to them</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-02-20 16:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>Treatment unlikely to be blinded. This study was a single-blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-19 12:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 11:56:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>Comment: no information about blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-09 08:29:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>Participants were treated randomly with intralesional injection of any of 2 similar 50-mL vials marked A (MA) or B (ZS) by an independent physician. ZS solution was prepared by dissolving 2 g ZS (ZNSO<SUB>4</SUB>W 7H<SUB>2</SUB>O) per 100 mL of bidistilled deionised water.</P>
<P>The blinding was unlikely to have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 12:20:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>Study was described as "double blind" but no description about allocation method was given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-10-19 11:25:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>Quote: "Each subject in the control group was given placebo, which was supplied, in capsules/suspension identical in shape and colour to that given in the rifampicin group."</P>
<P>Participants look blinded but no information about personnel were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 12:29:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>Comment: the vehicle came exactly in the same colour and shape as the drug and the application procedure was also the same. We think the outcome is unlikely to be influenced by lack of blinding of personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 12:39:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>Quote: "During this double-blind randomised study ..."</P>
<P>Quote: "Both gels were identical in terms of the colour and consistency."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 13:06:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>Different administration of treatments: 2 groups: apply the extract-soaked gauze; third group: ILMA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>Quote: "The participants, the medical personnel treating and evaluating the patients, the investigators analysing the clinical course of treated lesions, as well as the lab members performing the parasitological analyses were blinded. The preparation of the two different gels (marked as jelly A and B), which could not be visually distinguished, was performed by a technician who was not involved in the treatment of patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 14:09:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>Quote: "The identically coded and packaged creams were applied two times daily."</P>
<P>Quote: "The study was blinded to both the patients and the assessing physician."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 14:21:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 14:31:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>Quote:"This open N randomised controlled trial was carried out in Bam and Mashhad in Iran &#8230;"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 15:01:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>Comment: "Double-blinded" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 15:13:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>Comment: "Double-blinded" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-07 15:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>Quote: "Patients admitted into the trial were given unlabeled tubes containing either 1% clotrimazole cream or 2% miconazole"</P>
<P>Comment: we think that the outcome is unlikely to be influenced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:10:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 09:52:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>A double-blind study design was attempted, but could not be sustained as Savlon is a well-known product and soapy on application</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:13:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-19 14:49:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 10:29:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>Quote: "This study was an open-label, N randomised comparison of miltefosine to meglumine antimonate in 63 patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-20 18:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>Identical capsules containing 100 mg of itraconazole or placebo were used in the study. The 2 treatment groups received either itraconazole as coded capsules for 21 days or placebo as coded capsules with the same dosages.</P>
<P>Review authors judge that the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-19 14:57:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 10:41:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>Quote: "Placebo and ketoconazole creams were identical cream containing either 25 ketoconazole 2% or placebo were used in the study. The two treatment groups received either the ketoconazole cream or placebo twice daily for 21 days as coded tubes with the same dosage"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:33:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 10:51:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>Quote: "Patients in group A were treated with weekly and those in group B with fortnightly intralesional injections"</P>
<P>Comment: we think the outcome is likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 10:58:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>"Patients were randomly allocated to receive either itraconazole in the form of two 100-mg capsules or identical placebo capsules once daily for 8 weeks."</P>
<P>Comment: we think the outcome is unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-30 12:47:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 11:06:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>Quote: "Unblindness is a limitation of this study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-19 15:33:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>We think the outcome is likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-09 08:30:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>The oral placebo was completely similar to omeprazole capsules and was administered in the similar way; low dose of IMMA was prepared by addition of normal saline to IMMA</P>
<P>Both the investigating physicians and the participants were blinded to the type of treatment and drug codes were revealed only at the end of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-17 15:21:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Impossible for blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:17:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 11:50:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 11:59:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>Quote: "double blind"</P>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-10-19 15:26:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>The participants and the investigator (who assessed the participants for their clinical response) were blind to the type of therapy allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 12:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>Comment: no blinding of participants and personnel seemed to be performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 12:29:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>Study was described as "double blind" but has no description about the blinding method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-30 12:54:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 12:38:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>Group 1 was treated with controlled localised heating using an RF heat generator. Group 2 was treated with ILMA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-03 10:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-09 08:30:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>Group 1, which included 64 participants, was designated as the group treated with oral ketoconazole. Group 2, which included 32 participants, was designated as the group that received ILMA. The outcome is likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 13:43:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>The outcome is likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:24:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 13:57:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>No blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; the oral placebo was completely identical in appearance to the cimetidine tablet, they were the same colour, and drug codes were revealed only at the end of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-20 19:28:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 14:12:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 14:19:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>Study was described as open and no blinding was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 14:36:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Study was described as open and no blinding was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-18 13:28:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-20 19:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-08 14:54:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>Quote: "An open-labeled, N randomised controlled trial to evaluate the efficacy of paromomycin ointment as compared with ketoconazole" </P>
<P>Comment: we think the outcome is likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2017-11-09 08:16:33 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:54:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>Not reported; probably an open trial. No information on how lesions were assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-30 19:00:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>No blinding of outcome assessment was described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:47:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>Quote: "Lesions were assessed, whenever a patient came for his or her injection (s), by an observer who was unaware of the treatment the patient was receiving."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-17 23:12:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>No further information about blinding of outcome assessment was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-30 13:12:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>No information about blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-07-18 12:42:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>Sequential photographs were independently assessed by blinded leishmaniasis experts, who were clinicians experienced in the treatment of CL, with a tiebreaker assessment when needed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 11:56:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 12:12:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>The clinical and parasitological evaluators were blinded to each other's assessment.</P>
<P>All efforts were made to reduce the introduction of bias into this study; however, duration of the lesion, which was self-reported by the participants or their guardians, could introduce bias if the durations were significantly different in the 2 arms by chance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-18 08:45:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>No information about blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-18 09:06:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>No information provided about blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>Quote: "The dermatologist was not aware of the type of the treatment that the patient was receiving."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-20 11:32:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>Open trials. Photography was done from all the lesions both at the first visit and all the follow-up visits</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-18 09:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>Quote: "The code remained unknown to patients and investigators until the study had been completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 11:04:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>"Investigators, who were blinded to whether participants received WR279,396 or placebo-vehicle, evaluated lesions for clinical response on D20 (i.e. the end of the treatment period), D50 (i.e., 30 days after the conclusion of treatment), D100, and D180". Investigators measured all lesions in 2 perpendicular directions and took photographs at the following time points: prior to therapy, at the end of therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 11:51:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 11:24:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>Quote: "The clinician who recorded healing was blinded to the modality of treatment."</P>
<P>Comment: not clear how the assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 11:34:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>Assessing the outcomes and data analyst were blinded to group assignment. The photographs were reviewed by the dermatologist of the research team who was blinded to study groups. The photographs did not contain any indicator that could help differentiate the group of the lesion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-18 09:47:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>No information about blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 11:49:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 11:55:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>Quote: "double-blind therapeutic trial"</P>
<P>Comment: no further information about blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 12:03:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 12:00:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>Quote: "double-blind therapeutic trial"</P>
<P>Comment: participants looks like blinded but no description about assessment blinding was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 12:08:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>Outcome assessors were blinded from the treatment groups; however, it is not clear how this was done. No placebo was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>Quote: "A follow-up assessment was performed by the treating clinician, the patient and by comparing the serial photographs"</P>
<P>Comment: open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 12:26:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 11:56:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Comment: no reference to the outcome assessment blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>In statistical methods section, quote "There was no blinding method used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-06 12:46:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>This study was an assessor blind trial in which the outcome assessor was unaware of the drugs used by the participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-11 08:25:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 12:08:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-02-20 16:03:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>Quote: "To keep the trial blinded, the physicians who were responsible for evaluation of patients were uninvolved in the process of allocation and drug dispensing and were unaware of the drug used by the patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 12:13:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 11:56:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>Comment: no information about blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-07 12:13:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-07 12:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>No blinding of outcome assessment described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-18 10:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>Comment: "Double-blinded" but no further information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-03 12:12:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>Quote: "The participants, the medical personnel treating and evaluating the patients, the investigators analysing the clinical course of treated lesions, as well as the lab members performing the parasitological analyses were blinded. The preparation of the two different gels (marked as jelly A and B), which could not be visually distinguished, was performed by a technician who was not involved in the treatment of patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-09 08:16:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>Quote: "The study was blinded to both the patients and the assessing physician."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-07 14:29:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-07 14:31:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>Quote:"This open N randomised controlled trial was carried out in Bam and Mashhad in Iran&#8230;"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>Quote: "An assessor who was blinded to the type of treatment visited the patients at weekly intervals during the treatment period and 1- month and 5 months after the last treatment session"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-07 15:01:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>Comment: "Double-blinded" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-07 15:13:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>Comment: "Double-blinded" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 12:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 15:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>Open trial; lesions of all participants were photographed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 12:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 10:13:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 14:49:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 14:54:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 10:33:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>Insufficient information to permit judgment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 14:57:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-19 15:00:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-20 11:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>Open trials. Photography was done from all the lesions both at the first visit and all the follow-up visits</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-30 12:46:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-30 12:46:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-30 12:47:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-30 12:48:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-10-30 12:49:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 11:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 11:25:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Quote: "The examinations and measurements were performed by the investigators who were blinded to the type of treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-17 15:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Quote "Evaluation of patients were done by two physicians who were not aware of the treatment group. These two physicians did the evaluations separately. The reduction in this size of ulcer and the scar was compared with the same lesion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 11:43:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>Quotes: "A photo was taken from patients before and after treatment with a digital camera ... Evaluation of participants were done by 2 physicians who were not aware of the treatment group. These 2 physicians did the evaluations separately. The reduction in this size of ulcer and the scar was compared with the same lesion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 11:50:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>Quote: "The measurements were done before treatment and at the end of eighth week by the investigators who were blinded to the type of treatment."</P>
<P>Comment: Lesions were photographed before and after completion of the treatment course.</P>
<P>Not clear how blinding was preserved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 12:00:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>Quote: "double blind", "At each visit the patients were examined by the primary investigator who was blind to the therapy"</P>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 15:26:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>At each visit, the participant was examined by the primary investigator, who was blinded to the therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 12:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>Quote: "The occurrence of adverse effects was evaluated blindly by means of patient interviews and physical examinations during follow-up visits", "Microscopic examination was performed blindly."</P>
<P>
<I>Comment</I>: microscopic examination and adverse effects were performed blindly but no description about clinical examination was given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 12:29:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>No blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-30 19:06:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-30 19:17:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>Quote: "Follow-up evaluation was made by clinical assessment of treated lesions by a second dermatologist who was blinded to the method of treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-03 10:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 15:28:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 13:43:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 13:53:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-03 13:09:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 14:02:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 14:12:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 14:19:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>Study was described as open and no blinding was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Quote: "the present trial could not be conducted as either a double or a single blinded trial due to the physical nature of the applied interventions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 14:48:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>Not done. At each visit all lesions were reexamined by the same dermatologist. The size and induration of lesions were measured by palpation and ruler. No photographs were taken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2017-11-08 14:51:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-11-30 18:00:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-14 15:07:47 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 13:05:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Dropouts are unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 12:43:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>After excluding participants who defaulted on treatment, 21/35 lesions were analysed in group 1 (HSCS) and 27/35 in group 2 (ciprofloxacin)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 19:36:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-19 10:51:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>No information about dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-09 08:22:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>High rate of drops out: 63/209 (30.14%). Missing outcome data imbalanced in numbers across groups. Fluconazole orally 200 mg: 26. Placebo group: 37. An ITT analysis was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 16:55:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 19:12:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>2/56 withdrawals. An ITT analysis was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-03 13:34:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups (16 drops out of 251, 10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-20 19:37:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-23 10:29:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>No good information about adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 10:13:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>Imbalance in the missing data between the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-23 10:29:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>No defaults were included in the analyses. No good information about adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-18 13:30:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 13:22:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>No defaults were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-03 12:26:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>49 of 50 participants randomised to WR279,396 and 41 of 42 participants randomised to placebo-vehicle completed the study. With one exception, applications of study drugs were conducted according to the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 13:22:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>Quote: "The modified intention-to-treat population consisted of patients who received at least one dose of study treatment. We tested two hypotheses using a fixed testing-sequence procedure with an overall two-sided alpha level of 0.05 or less."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 11:24:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>No information about numbers or reasons for withdrawals during treatment. It seems that there was withdrawals only in the follow-up: 44% at 18 months in RFHT group and 16% at 18 months in the SSG group. Losses to follow-up were heterogeneous between groups and no ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 11:35:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>The numbers of withdrawals were high in both groups: 31.25% (10/32) in TC group and 18.75 % (6/32) in the ILMA group. Participants were removed from the study arms because of their poor adherence to the trial protocol and lost to follow-up. No intention-to-treat analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-23 10:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>Quote: "Side effects were mild and similar in both groups"</P>
<P>Comment: no further information on adverse effects was provided. Withdrawals: 14/79 (17.7%) and no ITT analyses were performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 11:45:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>Quote: "Fourteen of 86 patients dropped out due to poor compliance (six patients in the combination therapy and eight in the Glucantime group). The number and reason for their withdrawal were almost the same in both treatment groups. One patient also developed GI complications and headache while taking the combination therapy of azithromycin and allopurinol; therefore, overall 71 subjects completed the study."</P>
<P>Comment: no ITT analyses were performed. However, withdrawals accounted for &lt;20% and were homogeneous among the treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 11:49:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-20 16:00:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>All relevant outcome data were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-19 12:04:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 17:10:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 17:46:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>Quote: "There were 18 dropouts due to various complications, 9 belonging to each group"</P>
<P>Comment: ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-19 14:55:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>All participants completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-03 12:13:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>2 dropouts were reported in the fluconazole 400 mg group. ITT analysis were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 12:33:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Comment: no missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-06 12:35:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-03 11:54:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-11 08:34:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>No reasons for missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-09 08:29:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>High rate of dropouts (37/72, 54%). Missing outcome data imbalanced in numbers and reasons across intervention groups. ZS group: 23. ILMA group: 14. 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 11:44:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>Withdrawals: 30/119 (25.2%); no ITT analyses performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 11:48:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>Low rates of dropouts (26/197; &lt; 25%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 17:22:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>No losses to follow-up were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-20 18:15:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 12:20:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>No data about dropouts were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 12:26:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>There is a 38.87% of follow-up, the percentage is very different between the groups, and it isn't explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-03 18:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>There is no information about withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 12:39:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>No losses to follow-up were reported, therefore ITT analyses performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 13:07:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>The numbers and reasons (allergic reaction to the medications) of withdrawals were similar and small in 2 of the groups 3.5% (3/28) in concentrated boiled group vs 3.6% (2/28) in the other groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 14:00:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>14 participants of group 1 and 8 participants of group 2 were retrospectively excluded due to deviations from the study protocol.</P>
<P>For the follow-up analysis, 6 months after wound healing, only 70 participants could be included, as 21 participants of group I and 22 participants of group II did not observe their appointments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-19 15:08:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>100 participants were enrolled but only 63 completed the study. Reasons for withdrawal were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-19 15:08:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>14/44 participants with the conventional technique and 11/41 with mesotherapy gun withdrawn the study (29.4%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 14:31:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>Losses to follow-up quite high (around 50%)</P>
<P>Intervention group: 32/63= 50.8%</P>
<P>Control group: 33/75= 44%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 14:51:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>An intent-to-treat analysis was performed at 2 time points (end of the treatment period (day 42) and one month later (day 72)). The numbers of and the reasons for withdrawals were not significantly different between the 3 groups: 11% ILMA group; 19% ILMA + non-silver and 6.45% ILMA + silver</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 17:52:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 17:29:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 15:20:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>Of 27 participants treated with 2% miconazole, 4 defaulted and were lost to follow-up; they were excluded from analysis" (4/27 = 14.28%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-07 15:30:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>48 of 50 participants randomised completed the study. 2/20 participants of the azithromycin group withdrew because of adverse effects. Applications of study drugs were conducted according to the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 08:16:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>4 participants in the cryotherapy group and 3 participants in the ILMA group were excluded because they received 2 medications simultaneously, did not complete the treatment course, did not visit the clinic for follow-up 6 months later, or changed their address and were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 08:53:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>ITT analyses performed</P>
<P>Losses to follow-up per group:</P>
<P>Intervention group: 11/50 (22%)</P>
<P>Control group: 23/60 (38.3%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 09:53:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>Low rates of dropouts (8/70, &lt; 2.5%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 10:05:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>45 participants were randomised into 2 groups. 11 were lost to follow-up (24%).</P>
<P>No ITT analyses were performed</P>
<P>High imbalance between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-19 15:12:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>28/36 participants completed the study (77.8%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-19 14:50:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 10:29:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>Imbalance in numbers and reasons for missing data across intervention groups (4/32 = 12.5% miltefosine group; 1/31=3.22% IMMA group)</P>
<P>Comment: the results for the dropouts were not excluded from the statistical analysis.</P>
<P>We think missing outcome data likely to be related to true outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-20 19:14:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 10:37:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>Imbalance in numbers across intervention groups: 5/36 (13.89%), AL + IMMA group; 1/36 (2.78%), IMMAgroup.</P>
<P>We think missing outcome data likely to be related to true outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 13:56:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-18 13:33:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 10:51:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>Dropouts: 8/104: 7.6% lost to follow-up</P>
<P>Comment: the results for the defaulters were excluded from the statistical analysis. We think missing outcome data unlikely to be related to true outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 10:58:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>Imbalance in numbers and reasons for missing data across intervention groups (17% itraconozale group; 25% placebo group).</P>
<P>Comment: the results for the defaulters were not excluded from the statistical analysis. We think missing outcome data likely to be related to true outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 11:03:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>High rates of dropouts: 53/210 (25.2%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 11:06:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>Quote: "For 80 patients, which participated in the study, 73 cases completed the study"</P>
<P>Comment: the results for the dropouts were excluded from the statistical analysis.</P>
<P>We think missing outcome data likely to be related to true outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 11:10:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>Balance in numbers and reasons for missing data across intervention groups (13/45 (28.8%) in honey + ILMA group; 10/45 (22.2%) in ILMA-alone group)</P>
<P>Comment: the results for the defaulters were excluded from the Kaplan-Meyer analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 11:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 11:25:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Originally 80 lesions were studied and randomly assigned to the 2 groups. However, due to missing data, only 76 were finally included in the analysis. No ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-25 09:36:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-14 15:07:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 11:50:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>From a total of 200 randomised participants, 96 participants in ILMA group and 91 participants in the combination group completed the study</P>
<P>Losses to follow-up were below 25% and homogeneous between the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:00:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>4.5% (7/154) did not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>The numbers of withdrawals were similar and small in the 3 groups: 4.1% (8/192) in group 1, 3.6% (3/82) in group 2, and 3.5% (6/170) in group 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:22:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>172/431 (39.9%) withdrew from the study. However, ITT analyses were performed.</P>
<P>Quote: "An intention-to-treat analysis of the data (... including the patients lost to follow-up, who were considered to have had treatment failure) yielded similar results for the comparison of the odds of cure for the different treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-30 20:03:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>One patient withdrew in the placebo group. Reasons for withdrawal were reported. However, no ITT analyses were performed. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 12:54:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 12:38:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 13:36:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>There were losses to follow-up and no ITT analyses were performed. Also, the distribution of the lesions and the size was uneven between the 2 arms.</P>
<P>Quote: "More papules (57.7%) were treated by thermotherapy compared to (42.3%) those which were treated by Glucantime. Nodules were mostly treated by Glucantime (58.9%), whereas all ulcers were treated by Glucantime. The lesion size interval was [1&#8211;4 cm²] with median of 1 cm² for thermotherapy by radio frequency and 2 cm² for Glucantime."</P>
<P>This is important because the authors found out the following significant associations:</P>
<P>Quote: "Type and size of lesion, were significantly associated with the outcome variable (cure/failure). Type of lesion was significantly associated with treatment outcome in this sample, taking papules as reference (Table V). Those who had nodules were 41% less likely and those with ulcers were 80% less likely to be cured compared with those with papules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 15:28:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>Imbalance in numbers and reasons for missing data across intervention groups: 7/57, ketoconazole; 9/23, ILMA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 12:56:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>No explanation was provided for missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 13:53:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>There were 31 withdrawals (16/96 (16.7%) in the ILMA + cryotherapy and 15/95 (15.8%) in the CO&#8322; laser group)</P>
<P>Comment: no ITT analyses were performed. However, withdrawals accounted for &lt; 20% and were homogeneous among the treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-11-03 13:09:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:02:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>Of the 85 participants initially recruited, 63 participants were followed-up for the full observation period. Participants who did not show up after the first or second injection were excluded. We do not know numbers of missing data across intervention groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:12:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>Dropouts: 26/130 (25%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:19:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>
<I>Comment</I>: relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:37:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Quote: "The intention-to-treat analysis (ITT) is solely added as additional information. Patients that could not be evaluated were patients that were lost immediately after registration before treatment started. 81 out of 87 patients (93.1%) were suitable for the ITT and 69 (79.3%) for the PP analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-08 14:48:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>100 out of 115 participants completed the study. 6 participants who received systemic MA were excluded because of side effects that included severe muscular pain and topical reaction of inoculation site (severe erythema and pruritus)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-10-30 13:02:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-09 08:16:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>Quote: "No subjects withdrew because of this adverse effect"</P>
<P>Comment: no dropouts, so ITT analyses were performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-09 08:33:37 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 12:34:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Protocol not available; not registered in a prospective clinical trial registry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 10:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>Protocol not available. Not registered in a clinical trial registry. Pre-specified outcomes of the review were reported.</P>
<P>Tables were not available in the links of the journal, and .pdf does not work. No adverse effects reported in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:53:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 13:03:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>No information about adverse effects was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:54:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 16:55:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>Insufficient information to judge.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 12:43:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>Clinical Trial Registration: ClinicalTrials.gov NCT 00884377; all prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:33:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 08:19:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 10:00:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 10:13:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:33:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:30:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>Protocol not available; not registered; in clinical trial registry; adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:57:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:05:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>ClinicalTrials.gov NCT00703924. Pre-specified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:13:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>ClinicalTrials.gov number, NCT00606580. Pre-specified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 17:44:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>Outcomes of interest were reported in results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 19:17:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>The study published reported our outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-18 09:50:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>No protocol available. Not possible to allocate to high or low risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:45:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>Our primary outcomes (cure and adverse effects) were described in Methods and reported in Results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 09:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:00:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:00:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 17:11:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>All relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:08:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>Protocol not available. The trial was registered with <A HREF="http://www.anzctr.org.au">www.anzctr.org.au</A> and the registration number is ACTRN12607000295448. Some outcomes registered in the protocol were not reported: successful treatment; therapeutic failure; reactivation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 17:13:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 12:26:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>Our primary outcomes (Complete healing and adverse effects) were described in Methods and reported in Results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:56:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Comment: no reference to adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:02:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:13:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>The study published does not report 2 primary outcomes: adverse effects and recurrence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>One outcome of interest in the review is not reported: adverse effects, so that it cannot be entered in a meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:02:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>All relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:03:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>All relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:05:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>All relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 11:23:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>Comment: all relevant outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-19 09:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>The study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:06:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>Relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:29:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>No adverse effects data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:30:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>Our primary outcomes (cured and adverse effects) were described in the Methods and reported in the text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-30 17:49:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>Insufficient information to judge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>The study published reports our primary outcomes: cured and adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-18 13:03:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>Main outcomes were included. Trial was registered at clinicaltrial.gov: NCT00947362</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 14:10:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>Our primary outcomes (cure and adverse effects) were described in Methods and reported in Results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 14:29:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>Protocol not available; not registered in a trial registry; SD not provided for pain severity (VAS)</P>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>It is an abstract. At least they reported complete cure of cases and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 14:51:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>Comment: all relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:01:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>Comment: all relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>Comment: no adverse effects information reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 15:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>The study protocol is not available, but he published reports probably include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-26 07:53:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 08:17:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>Protocol not available; not registered; however, pre-specified outcomes of the review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 08:53:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>Number of lesions higher in the liposomal ampB group (P &lt; 0.05) whereas number of papule and plaque lesions where higher in the ILMA group (P = 0.011)</P>
<P>Outcomes described in the methods were reported in the results section. However, only one time point was reported</P>
<P>Protocol not available; not registered in a clinical trial registry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 12:25:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>The study protocol is not available but it is probably that the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:05:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>No baseline data. Side effects not clearly reported (no statistical analyses performed either)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:13:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>No protocol available. Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 14:50:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>The study protocol is not available but it is probably that the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-23 12:58:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>The study protocol is not available but it is probably that the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:33:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified. The study published reports our primary outcomes: 'cured' and adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:37:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:41:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>Protocol not available; not registered; in clinical trial registry; adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:33:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:59:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:03:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:06:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:10:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>Comment: relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:14:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:25:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Complete cure was described in Methods and Results, but partial cure and treatment failure was not reported in the Results section.</P>
<P>No adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 15:22:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-11-17 15:19:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>Protocol not available, not registered. Adverse effects not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:00:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>No protocol was available; not registered. Insufficient information to permit judgment</P>
<P>SD not provided for duration of treatment and number of injections</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-23 10:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>The study published reports our primary outcome and adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:22:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>Comment: relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 12:30:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>Comment: relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-03 12:03:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>
<I>Comment</I>: relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:14:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:37:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>Adverse effects were described in Methods but not in Results. They mention them vaguely in the Discussion section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:40:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:43:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports included all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>Protocol not available. Not registered. Some pre-specified outcomes were reported. Data on individuals not presented. Conflicting data is presented between the abstract and the tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:57:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>The study report fails to include results for a key outcome that would be expected to have been reported for such a study. The adverse effects are not properly described, although questionnaires regarding response to treatment and drug side effects were completed and in Table 2 there are data, numbers (%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:03:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:14:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:19:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>
<I>Comment</I>: relevant outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:37:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Clinicaltrials.gov ID: NCT00996463. Registered: 15 October 2009</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>Protocol not available. Not registered. Alhtough most pre-specified outcomes were reported, adverse effects were not clearly reported (only for those excluded from the analysis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>Insufficient information to permit judgment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:14:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-11-09 08:32:24 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:18:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adam-2009">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:31:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al-Hamdi-2010">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:18:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Al_x002d_Fouzan-1991">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:18:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alkhawajah-1997">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:54:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alrajhi-2002">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:18:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alsaleh-1995">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:55:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronson-2010">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:19:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-1995">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:55:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2003">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:19:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2004a">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:19:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asilian-2004b">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania</I> spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-05 17:12:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asilian-2006">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:19:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Asilian-2014">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:57:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-1995">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:57:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2009">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:58:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ben-Salah-2013">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:31:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bumb-2013">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 15:58:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daie-Parizi-2015">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-06 11:36:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dandashli-2005">
<DESCRIPTION>
<P>Sample size calculation and baseline comparability were not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:31:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dastgheib-2012">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dogra-1990">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:31:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dogra-1991">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dogra-1992">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dogra-1996">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:31:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejaz-2014">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Sayed-2010">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:31:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emad-2011">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Esfandiarpour-2002">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Faghihi-2003">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:02:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farajzadeh-2015">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fekri-2015">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Firooz-2005">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Firooz-2006">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gholami-2000">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harms-1991">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-07 12:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Iraji-2004">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Iraji-2005">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffar-2006">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffary-2010">
<DESCRIPTION>
<P>Sample size calculation, inclusion criteria, reporting of <I>Leishmania </I>spp involved and baseline comparability was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffary-2014a">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jaffary-2014b">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:07:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebran-2014">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jowkar-2012">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kashani-2010">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khatami-2012">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:08:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khatami-2013">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2000">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kochar-2006">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larbi-1995">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Layegh-2007">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:09:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Layegh-2009">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:09:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Layegh-2011">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 09:53:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lynen-1992">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:05:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maleki-2012">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:13:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mapar-2010">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mashood-2001">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mohebali-2007">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:10:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-1996">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Momeni-2002">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:11:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Momeni-2003">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:46:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mostafavi-2013">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 10:51:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mujtaba-1999">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:11:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nassiri_x002d_Kashani-2005">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2004">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability were not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:20:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2006">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:10:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2007">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2008">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:26:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2012">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2013">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nilforoushzadeh-2014a">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nilforoushzadeh-2014b">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ranawaka-2010">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:14:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranawaka-2015">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:15:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reithinger-2005">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghian-2006a">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sadeghian-2006b">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sadeghian-2007">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-20 16:15:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Safi-2012">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salmanpour-2001">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 13:43:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salmanpour-2006">
<DESCRIPTION>
<P>Sample size calculation, reporting of <I>Leishmania </I>spp involved and baseline comparability were not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shamsi-Meymandi-2011">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shanehsaz-2015">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 14:03:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharquie-1997">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharquie-2001">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shazad-2005">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-07-14 12:23:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stahl-2014">
<DESCRIPTION>
<P>Other items assessed correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-09 08:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yazdanpanah-2011">
<DESCRIPTION>
<P>There was not enough information in the publication to assess if there were other biases present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zerehsaz-1999">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-08 11:37:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997">
<DESCRIPTION>
<P>Sample size calculation and reporting of <I>Leishmania </I>spp involved was not correctly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2015-07-18 12:34:27 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Intention-to-treat/Drop-outs?</NAME>
<DESCRIPTION>
<P>Was ITT used? How many drop-outs in total?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-11-09 10:44:26 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-11-09 10:38:06 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-11-09 10:27:59 +0000" MODIFIED_BY="[Empty name]">Itraconazole (200 mg for 6 to 8 weeks) versus placebo for Old World cutaneous leishmaniasis</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Itraconazole (200 mg for 6-8 weeks) versus placebo for Old World cutaneous leishmaniasis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: patients with Old World cutaneous leishmaniasis<BR/>
<B>Settings</B>: Kuwait, India, and Iran<BR/>
<B>Intervention</B>: itraconazole (200 mg for 6-8 weeks)<BR/>
<B>Comparison</B>: placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Itraconazole (200 mg for 6-8 weeks)</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Percentage of lesions cured after the end of treatment</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Not measured in this comparison</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Percentage of participants with complete cure</B>
<BR/>Follow-up: mean 2.5 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.70 </B>
<BR/>(0.35 to 38.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>244<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>454 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(159 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>370 per 1000</B>
<BR/>(35 to 1000)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Adverse effects</I> </P>
<P>Mild abdominal pain and nausea</P>
<P/>
<P>
<I>Adverse effects</I> </P>
<P>Mild abnormal liver function</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>40 per 1000</B>
</P>
<P/>
<P/>
<P/>
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>95 per 1000</B>
<BR/>(30 to 302)</P>
<P/>
<P/>
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.36 </B>
<BR/>(0.74 to 7.47)</P>
<P/>
<P>
<B>RR 3.08 </B>
<BR/>(0.53 to 17.98)</P>
</TD>
<TD VALIGN="TOP">
<P>204<BR/>(3 studies)</P>
<P/>
<P/>
<P>84<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>b</SUP>
</P>
<P/>
<P/>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>c</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Speed of healing (time taken to be 'cured')</B>
</P>
</TD>
<TD COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>Neither of the studies reported speed of healing (time taken to be 'cured') in this comparison.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Microbiological or histopathological cure of skin lesions</B>
<BR/>Follow-up: mean 2.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 17.00 </B>
<BR/>(0.47 to 612.21)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>There were zero events in the placebo group</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality/certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality/certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality/certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality/certainty</B>: we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by 4 levels due to: risk of bias (2 RCTs have many uncertain items), inconsistency (there is considerable heterogeneity - I² = 73%), and imprecision (2 levels due to wide 95% confidence intervals, crossing the line of no effect).<BR/>
<SUP>b</SUP>Downgraded by 3 levels due to: risk of bias (many uncertain items in the risk of bias judgment), and imprecision (2 levels due to wide 95% confidence intervals, crossing the line of no effect).<BR/>
<SUP>c</SUP>Downgraded by 3 levels due to: risk of bias (many uncertain items in the risk of bias judgment), and imprecision (2 levels due to wide 95% confidence intervals, crossing the line of no effect).<BR/>
<SUP>d</SUP>Downgraded by 3 levels due to: risk of bias (many uncertain items in the risk of bias judgment), and imprecision (2 levels due to wide 95% confidence intervals; this outcome is only reported for one study involving 20 participants).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-11-09 10:44:26 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-11-09 10:40:34 +0000" MODIFIED_BY="[Empty name]">Paromomycin ointment versus vehicle for Old World cutaneous leishmaniasis</TITLE>
<TABLE COLS="6" ROWS="21">
<TR>
<TD COLSPAN="6">
<P>
<B>Paromomycin ointment versus matched vehicle for Old World cutaneous leishmaniasis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: patients with Old World cutaneous leishmaniasis<BR/>
<B>Settings</B>: primary health centres, Iran and Tunisia<BR/>
<B>Intervention</B>: paromomycin ointment (15% + 10% urea) twice daily for 14 days<BR/>
<B>Comparison</B>: vehicle</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Vehicle</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Paromomycin ointment (15% + 10% urea) twice daily for 14 days</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Percentage of lesions cured after the end of treatment</B>
</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Not measured in this comparison</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Percentage of participants with complete cure</B>
<BR/>Follow-up: mean 2.5 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.00 </B>
<BR/>(0.86 to 1.17)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>383<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>623 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>623 per 1000</B>
<BR/>(536 to 729)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>619 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>619 per 1000</B>
<BR/>(532 to 724)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<I>Adverse effects</I> Skin/local reactions</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.42 </B>
<BR/>(0.67 to 3.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>713<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>b</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>96 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>136 per 1000</B>
<BR/>(64 to 287)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>128 per 1000</B>
<BR/>(60 to 271)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Speed of healing (time taken to be 'cured')</B>
</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Not measured in this comparison</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Microbiological or histopathological cure of skin lesions</B>
<BR/>Follow-up: mean 2.5 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.88 to 1.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>383<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>c</SUP>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>859 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>884 per 1000</B>
<BR/>(756 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>792 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>816 per 1000</B>
<BR/>(697 to 950)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>N/A</B>: not applicable.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality/certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality/certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality/certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality/certainty</B>: we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by 4 levels due to risk of bias (1 RCT has many uncertain risks), indirectness (2 levels because one of the studies focused on young people), and imprecision (the confidence interval around the estimate risk ratio ranges from a 14% reduction to a 17% increase in the risk ratio for healing with paromomycin).<BR/>
<SUP>b</SUP>Downgraded by 4 levels due to risk of bias (2 RCTs have many uncertain risks), indirectness (2 levels because one of the studies focused on young people), and imprecision (the confidence interval crosses the line of no effect).<BR/>
<SUP>c</SUP>Downgraded by 5 levels due to risk of bias (1 RCT has many uncertain risks), inconsistency (there is considerable heterogeneity - I² = 84%), indirectness (2 levels because one of the studies focused on young people), and imprecision (the confidence interval around the estimate risk ratio ranges from a 12% reduction to a 20% increase in the risk ratio for healing with paromomycin).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-11-15 17:38:41 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-11-09 11:05:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-12-21 16:23:27 +0000" MODIFIED_BY="Laura E Prescott">Glossary</TITLE>
<TABLE COLS="2" ROWS="29">
<TR>
<TH VALIGN="BOTTOM">
<P>Term</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Definition</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Antimonials</P>
</TD>
<TD VALIGN="TOP">
<P>Pharmaceutical agents containing antimony. Antimony-containing compounds (meglumine antimoniate and sodium stibogluconate) are the principal medications used to treat leishmaniases, an infection caused by a protozoan parasite.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Arthralgia</P>
</TD>
<TD VALIGN="TOP">
<P>Pain in the joints. The causes of arthralgia are varied and range, from a joints perspective, from degenerative and destructive processes such as osteoarthritis and sports injuries to inflammation of tissues surrounding the joints, such as bursitis.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cardiac arrhythmia</P>
</TD>
<TD VALIGN="TOP">
<P>An arrhythmia is an abnormal heart rhythm. Many types of arrhythmia have no symptoms. When symptoms are present these may include palpitations or feeling a pause between heartbeats. More seriously there may be lightheadedness, passing out, shortness of breath, or chest pain.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cutaneous necrosis</P>
</TD>
<TD VALIGN="TOP">
<P>The death of living tissues in response to disease or injury.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cytolysis</P>
</TD>
<TD VALIGN="TOP">
<P>The degeneration or dissolution of cell caused by the disruption of cell membrane.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Exudate</P>
</TD>
<TD VALIGN="TOP">
<P>A fluid with a high content of protein and cellular debris that has escaped from blood vessels and has been deposited in tissues or on tissue surfaces, usually as a result of inflammation.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Human monocytes</P>
</TD>
<TD VALIGN="TOP">
<P>Monocytes are the biggest type of white blood cell in the immune system. Originally formed in the bone marrow, they are released into our blood and migrate into the connective tissue where they differentiate into macrophages. When certain germs enter the body, they quickly rush to the site of attack.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Hypotension</P>
</TD>
<TD VALIGN="TOP">
<P>A systolic blood pressure reading (the top number) of 90 millimetres of mercury (mmHg) or less a diastolic blood pressure reading (the bottom number) of 60 mmHg or less is generally considered low blood pressure. The causes of low blood pressure can range from dehydration to serious medical or surgical disorders.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Immune response modifier</P>
</TD>
<TD VALIGN="TOP">
<P>Any of a broad family of biomolecules that up- or down-regulate, or restore immune responsiveness, which are generated after T cells recognise an antigen present on the surface of a self-antigen-presenting cell, which, once activated, produce multiple cytokines.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Immunolabeling</P>
</TD>
<TD VALIGN="TOP">
<P>A biochemical process that enables the detection and localisation of an antigen to a particular site within a cell, tissue, or organ. Antigens are organic molecules, usually proteins, capable of binding to an antibody. These antigens can be visualised using a combination of antigen-specific antibodies as well as a means of detection, called a tag, that is covalently linked to the antibody. If the immunolabeling process is meant to reveal information about a cell or its substructures, the process is called immunocytochemistry. Immunolabeling of larger structures is called immunohistochemistry.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>In vitro</P>
</TD>
<TD VALIGN="TOP">
<P>Biological processes or reactions made to occur outside the living organism in an artificial environment, such as a culture medium.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intralesional meglumine antimoniate</P>
</TD>
<TD VALIGN="TOP">
<P>Meglumine antimoniate (or Glucantime) is a medicine used for treating leishmaniasis. It belongs to a group of compounds known as the pentavalent antimonials.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Lymphadenopathies</P>
</TD>
<TD VALIGN="TOP">
<P>Lymph nodes that have an abnormal in size, number or consistency; often used as a synonym for swollen or enlarged lymph nodes. Common causes of lymphadenopathy are infection, autoimmune disease, or malignancy.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Lymphatic channels</P>
</TD>
<TD VALIGN="TOP">
<P>The vessels that transport lymph throughout the body. Lymph is a clear fluid that contains cells important for forming antibodies that fight infection.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Lymphokine</P>
</TD>
<TD VALIGN="TOP">
<P>Any of various soluble protein mediators released by sensitised lymphocytes on contact with antigen, and believed to play a role in macrophage activation, lymphocyte transformation, and cell-mediated immunity. They regulate immune responses through differentiation, amplification, and inhibition of cell functions. Lymphokines may also have a cytotoxic effector function. Used as biologic response modifiers in the treatment of cancer.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Macrophages</P>
</TD>
<TD VALIGN="TOP">
<P>White blood cells (activated monocytes) that protect the body against infection and foreign substances by breaking them down into antigenic peptides recognised by circulating T cells.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Miltefosine</P>
</TD>
<TD VALIGN="TOP">
<P>An oral alkyl phosphocholine analogue used to treat cutaneous and visceral leishmaniasis. Interacts with lipids and sterols in the Leishmania membrane resulting in inhibition of mitochondria and apoptotic cell death.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Mucous membranes</P>
</TD>
<TD VALIGN="TOP">
<P>The mucous membranes (or mucosae or mucosas; singular mucosa) are linings of mostly endodermal origin, covered in epithelium, which are involved in absorption and secretion. They line cavities that are exposed to the external environment and internal organs.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Myalgia</P>
</TD>
<TD VALIGN="TOP">
<P>Myalgia, or muscle pain, is a symptom of many diseases and disorders. The most common causes are the overuse or over-stretching of a muscle or group of muscles. Myalgia without a traumatic history is often due to viral infections. Long-term myalgias may be indicative of a metabolic myopathy, some nutritional deficiencies or chronic fatigue syndrome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Nodular lymphangitis</P>
</TD>
<TD VALIGN="TOP">
<P>Nodular lymphangitis is a distinct clinical entity, separate from lymphangitis. This disorder is characterised by inflammatory nodules along the lymphatics draining a primary skin infection</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Papule</P>
</TD>
<TD VALIGN="TOP">
<P>A solid, rounded growth that is elevated from the skin, usually inflammatory but nonsuppurative. A papule is usually less than 1 cm across.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Parenteral</P>
</TD>
<TD VALIGN="TOP">
<P>Administration of a medicinal or therapeutic substance, other than through the gastrointestinal or respiratory tracts, e.g. by intravenous, intramuscular or subcuticular injection.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pentamidine</P>
</TD>
<TD VALIGN="TOP">
<P>Pentamidine (e.g. isethionate) is an antiprotozoal and antifungal agent of the class of aromatic diamidines, administered intravenously or intramuscularly in treatment of early African trypanosomiasis and leishmaniasis, and intravenously, intramuscularly, or by oral inhalation in treatment and prophylaxis of <I>Pneumocystis carinii</I> pneumonia.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pentavalent antimony</P>
</TD>
<TD VALIGN="TOP">
<P>Pentavalent antimonials are a group of compounds used for the treatment of leishmaniasis. The first pentavalent antimonial used was urea stibamine: first introduced in the 1930s, it fell out of favour in the 1950s due to higher toxicity compared to sodium stibogluconate. The compounds currently available for clinical use are: sodium stibogluconate (Pentostam; manufactured by GlaxoSmithKline; available in the USA and UK), which is administered by slow intravenous injection, intralesional or intramuscular injection, and meglumine antimoniate (Glucantime; manufactured by Aventis; available in Brazil, France and Italy), which is administered by intramuscular, intralesional, or intravenous injection.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Promastigotes</P>
</TD>
<TD VALIGN="TOP">
<P>Term now generally used instead of 'leptomonad' or 'leptomonad stage' to avoid confusion with the flagellate genus Leptomonas. It denotes the flagellate stage of a trypanosomatid protozoan in which the flagellum arises from a kinetoplast in front of the nucleus and emerges from the anterior end of the organism; usually an extracellular phase, as in the insect intermediate host (or in culture) of <I>Leishmania </I>parasites.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Protozoan</P>
</TD>
<TD VALIGN="TOP">
<P>Any of a group of single-celled, usually microscopic, eukaryotic organisms, such as amoebas, ciliates, flagellates, and sporozoans.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ThermoMed device</P>
</TD>
<TD VALIGN="TOP">
<P>The ThermoMed is a battery-operated device that delivers precisely controlled localised current field radiofrequency heat to selectively destroy certain diseased tissue and is recommended by the World Health Organization as an alternative therapy for cutaneus leishmaniasis.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Thermotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>The treatment of disease by the application of heat. Thermotherapy may be administered as dry heat with heat lamps, diathermy machines, electric pads, or hot water bottles or as moist heat with warm compresses or immersion in warm water. Warm soaks or compresses may be used to treat local infections, relax muscles and relieve pain in patients with motor problems, and promote circulation in peripheral vascular disorders such as thrombophlebitis.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-11-15 17:38:41 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2017-11-09 11:06:25 +0000" MODIFIED_BY="[Empty name]">Interventions for Old World cutaneous leishmaniasis</TITLE>
<TABLE COLS="2" ROWS="15">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Drug</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Doses</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Systemic antimonials</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sodium stibogluconate (Pentostam, Stibanate)</P>
<P>Meglumine antimonate (Glucantime)</P>
<P/>
<P>Combined with pentoxifylline</P>
</TD>
<TD VALIGN="TOP">
<P>20 mgSb <SUP>v+</SUP>/kg/d intramuscularly or intravenously for 20-30 days</P>
<P/>
<P>400 mg orally 3 times a day for 10&#8211;20 days</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="TOP">
<P>
<B>Intralesional antimonials</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sodium stibogluconate (Pentostam, Stibanate)</P>
<P>Meglumine antimonate (Glucantime)</P>
</TD>
<TD VALIGN="TOP">
<P>1&#8211;5 mL per session every 3&#8211;7 days. Up to 10 sessions depending on the clinical response, but most patients require &#8804; 5 sessions</P>
<P/>
</TD>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="TOP">
<P>Non-antimonial systemic treatments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fluconazole</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg orally daily for 6 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Miltefosine</P>
</TD>
<TD VALIGN="TOP">
<P>50 mg orally three times daily for 28 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Liposomal amphotericin B</P>
</TD>
<TD VALIGN="TOP">
<P>3 mg/kg/d IV on days 1-5 and 10 (18 mg/kg total dose)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="TOP">
<P>
<B>Non-antimonial topical or intralesional therapies</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15% paromomycin/12% methylbenzethonium chloride</P>
</TD>
<TD VALIGN="TOP">
<P>Ointment twice daily for 10-20 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15% paromomycin/0.5% gentamicin sulphate</P>
</TD>
<TD VALIGN="TOP">
<P>Twice a day for 20 days</P>
</TD>
</TR>
<TR>
<TH COLSPAN="2" VALIGN="TOP">
<P>Physical therapies</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cryotherapy with liquid nitrogen</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Frozen for 10-30 s and thaw applied locally 2-3 times in each session, repeated every 1-4 weeks to complete healing (usually 2-4 sessions)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Local heat therapy</P>
</TD>
<TD VALIGN="TOP">
<P>50°-55ºC for 30 s by:</P>
<P>Infrared light</P>
<P>Direct current electrical stimulation</P>
<P>Ultrasound</P>
<P>Laser</P>
<P>Radiofrequency waves</P>
<P>ThermoMed device</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2017-11-09 12:19:31 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2017-11-09 11:24:14 +0000" MODIFIED_BY="[Empty name]">Adverse effects of oral antibiotics</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kochar-2000" TYPE="STUDY">Kochar 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Biochemical tests were done to detect any toxic effects of the drug."</P>
</TD>
<TD VALIGN="TOP">
<P>Biochemical tests were done at the end of 1 week, 2 weeks and 4 weeks post- treatment.</P>
</TD>
<TD VALIGN="TOP">
<P>I1: oral rifampicin 1200 mg/d</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention</B>
</P>
<P>23 participants evaluated for AEs. Quote: "The drug was well-tolerated and no side-effects were seen in any participant."</P>
<P>
<B>Placebo</B>
</P>
<P>23 participants evaluated for AEs. Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jaffar-2006" TYPE="STUDY">Jaffar 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "clinical examination, liver function tests, renal function tests"</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Before, during, and after completion of treatment"</P>
</TD>
<TD VALIGN="TOP">
<P>I1: oral rifampicin 10 mg/kg/d</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention </B>
</P>
<P>46 participants evaluated for AEs. Elevation liver enzymes: 1 (2%)</P>
<P>
<B>Placebo</B>
</P>
<P>16 participants evaluated for AEs. Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kochar-2006" TYPE="STUDY">Kochar 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Haemoglobin, leukocyte count, and liver test</P>
</TD>
<TD VALIGN="TOP">
<P>Biochemical tests were done at the end of 2 week, 4 weeks and 6 weeks post-treatment</P>
</TD>
<TD VALIGN="TOP">
<P>I1: oral rifampicin + omeprazole</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>
</P>
<P>23 participants evaluated for AEs.</P>
<P>
<B>Intervention 2</B>
</P>
<P>21 participants evaluated for AEs.</P>
<P>Quote: "All participants tolerated the drug and placebo very well and no side effect was reported."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Layegh-2007" TYPE="STUDY">Layegh 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Azythromycin group: monthly up to 4 months</P>
</TD>
<TD VALIGN="TOP">
<P>I1: azithromycin 500 mg/d</P>
<P>I2: IMMA 60 mg/kg/d</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>
</P>
<P>22 participants evaluated for AEs (35 lesions). Nausea and vomiting: 2 (9%)</P>
<P>
<B>Intervention 2</B>
</P>
<P>27 participants evaluated for AEs (58 lesions). Myalgia: 3 (11%);</P>
<P>Erythema: 1 (3.7%).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Adam-2009" TYPE="STUDY">Adam 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Complete haemogram, including haemoglobin and liver and renal function tests Participants were questioned about expected adverse effects for 3 days (Days 5&#8211;7) following administration of the doses."</P>
</TD>
<TD VALIGN="TOP">
<P>Haemogram: 1 and 2 months</P>
<P>Clinical AEs: days 5-7; 19-21; 33-35; 47-19.</P>
</TD>
<TD VALIGN="TOP">
<P>I1: artesunate</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>
</P>
<P>20 participants evaluated for AEs.</P>
<P>
<B>Placebo</B>
</P>
<P>21 participants evaluated for AEs.</P>
<P>Skin rash with itching: 1 (4.7%)</P>
<P>Quote: "There was no significant difference in biological tests (liver and renal function tests) in all the participants before and after treatment."</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Interview, physical examination, laboratory test, evaluation for pain, standardised questionnaire for the occurrence of systemic side effects (e.g. vertigo, tinnitus). Diminished hearing was verified with audiometer.</P>
<P>Laboratory test.</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Investigators observed each participant each day that the topical creams were administered and at follow-up study visits (days 50-100-180). Clinical and laboratory evidence of side effects was determined on D10 and D20."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: WR 279,396</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention </B>
</P>
<P>50 participants evaluated for AEs. Erythema at the site of application: 15 (30%); mild pain within 30 minutes of application: 7 (14 %); mild increases and decreases in hearing acuity from baseline: 14 (28%); change hearing acuity: 14 (28%); vertigo: 0 (0%); Increase serum creatinine: 0 (0%); Death: 0 (0%)</P>
<P>
<B>Placebo </B>
</P>
<P>42 participants evaluated for AEs. Erythema at the site of application: 10 (24%); mild pain within 30 minutes of application: 6 (14 %); mild increases and decreases in hearing acuity from baseline: 9 (21%); change hearing acuity: 9 (21%); vertigo: 0 (0%); increase serum creatinine: 0 (0%); death: 0 (0%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dastgheib-2012" TYPE="STUDY">Dastgheib 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Participants were interviewed and underwent laboratory tests three times"</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "In Allopurinol group, the participants which were visited and received medication underwent laboratory tests three times (before, one month a2fter, and end of the treatment)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: azithromycin + allopurinol</P>
<P>I2: IMMA</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>
</P>
<P>36 participants evaluated for AEs.</P>
<P>Gastrointestinal complaints and headache severe: 1 (2.7%); slight gastrointestinal complications (nausea, heartburn, and epigastric pain): 3 (8.3%)</P>
<P>
<B>Intervention 2</B>
</P>
<P>35 participants evaluated for AEs.</P>
<P>Myalgia: 2 (5.7%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; <B>IMMA</B>: intramuscular meglumine antimoniate.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2017-11-14 15:23:59 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2017-11-09 12:02:39 +0000" MODIFIED_BY="[Empty name]">Adverse effects of topical paromomycin</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Asilian-1995" TYPE="STUDY">Asilian 1995</LINK>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Clinical evaluation and laboratory tests</P>
</TD>
<TD VALIGN="TOP">
<P>Days 15, 45 and 105</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>126 participants evaluated for AEs.</P>
<P>
<I>During treatment</I>: oedema, local pain, vesiculation: 1 (0.7%)</P>
<P>
<I>After treatment</I>: redness, pain, vesiculation, and inflammation: 8 (6.3%)</P>
<P>Quote: "There were no significant differences in four laboratory test results of safety (SGOT, BUN, Hb, and WBC) between the groups either before or after treatment."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ben-Salah-1995" TYPE="STUDY">Ben Salah 1995</LINK>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Clinical evaluation, physical examination, advice to participants, laboratory test: liver function, haemoglobin and white blood cell count</P>
</TD>
<TD VALIGN="TOP">
<P>Days 15, 45 and 105</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>57 participants evaluated for AEs.</P>
<P>Quote: "A local reaction (inflammation, vesication, pain and/or red ness) was recorded for 12 participants, with no significant difference between the 2 groups."</P>
<P>Laboratory test changes: 0 (0%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-_x00d6_zg_x00f6_ztasi-1997" TYPE="STUDY">Özgöztasi 1997</LINK>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>At the end of treatment (day 30) and 1 month post-treatment</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin + MBCL</P>
<P>I2: oral ketoconazole</P>
</TD>
<TD VALIGN="TOP">
<P>40 participants (62 lesions) evaluated for AEs</P>
<P>Quote: "Treatment-related adverse effects were only observed in the paromomycin group. The most common side-effect was the development of irritant contact dermatitis. No subjects withdrew because of this adverse effect."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Asilian-2003" TYPE="STUDY">Asilian 2003</LINK>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Clinical evaluation</P>
</TD>
<TD VALIGN="TOP">
<P>Days 15, 29, 45 and 105</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>108 participants evaluated for AEs.</P>
<P>Quote: "Treatment was well tolerated, and no adverse reactions to the ointment were observed or reported in either group."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Faghihi-2003" TYPE="STUDY">Faghihi 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Quote "Clinical evaluation and follow-up were performed fortnightly until 1 month post treatment and then monthly until 3 months post treatment, and finally every 3 months until 1 year post treatment"</P>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin + urea</P>
<P>I2: ILMA weekly</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shazad-2005" TYPE="STUDY">Shazad 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Week 1 and week 6 post-treatment and at 6 months after treatment was completed</P>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin + urea</P>
<P>I2: ILMA weekly</P>
</TD>
<TD VALIGN="TOP">
<P>30 participants evaluated for AEs.</P>
<P>Cutaneous reactions (erythematosus, urticaria or lymphadenitis with pain): 1 (3%)</P>
<P>Quote: "No systemic toxic reaction attributable to the drug was observed."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Iraji-2005" TYPE="STUDY">Iraji 2005</LINK>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Clinical evaluation</P>
</TD>
<TD VALIGN="TOP">
<P>Days 7, 14, 21 and 30</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: paromomycin</P>
<P>I2: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>30 participants evaluated for AEs.</P>
<P>Mild contact dermatitis: 3 (10%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Asilian-2006" TYPE="STUDY">Asilian 2006</LINK>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Weekly during treatment and monthly for up 2 months</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: photodynamic therapy</P>
<P>I2: paromomycin</P>
<P>I3: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>19 participants (34 lesions) evaluated for AEs.</P>
<P>Quote: "Adverse side-effects seen in some participants in all groups were pruritus, burning, redness, discharge, oedema, and pain, but all were generally mild and tolerable."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ben-Salah-2009" TYPE="STUDY">Ben Salah 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Renal toxic effects and ototoxic effects from aminoglycoside exposure were ascertained by means of serum creatinine measurements at the end of therapy (at 20 days) and participants' daily reports of tinnitus and vertigo."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Safety</P>
<P>end points were assessed daily during therapy (20 days)."</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1:Paromomycin -Gentamicin</P>
<P>I2: paromomycin Alone</P>
<P>I3: vehicle Control</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>:</P>
<P>125 participants evaluated for AEs.</P>
<P>Erythema: 6 (5%); local infection: 0 (0%); inflammation: 0 (0%); vesicles mild-moderate: 31 (25%); mild oedema: 2 (2%); pain: 2 (2%);</P>
<P>mild bronchitis: 5 (4%); paronychia: 2 (2%); superinfection: 3 (2%); upper respiratory tract infection: 0 (0%); oropharyngeal pain: 4 (3%); skin irritation: 3 (2%); tinnitus: 0 (0%); vertigo: 0 (0%); creatinine serum changes: 0 (0%)</P>
<P>
<B>Intervention 2</B>:</P>
<P>125 participants evaluated for AEs.</P>
<P>Erythema: 7 (6%); local infection: 0 (0%); inflammation: 0 (0%); vesicles mild-moderate: 32 (26%); mild-moderate oedema: 3 (3%); pain: 2 (2%); bronchitis mild-moderate: 3 (3%); paronychia: 0 (0%); superinfection: 0 (0%); upper respiratory tract infection: 2 (2%); oropharyngeal pain: 3 (2%); skin irritation: 9 (7%); tinnitus: 0 (0%); vertigo: 0 (0%); creatinine serum changes: 0 (0%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; <B>BUN</B>: blood urea nitrogen; <B>Hb</B>: haemoglobin; <B>ILMA</B>: intralesional meglumine antimoniate; <B>SGOT</B>: serum glutamic-oxaloacetic transaminase; <B>WBC</B>: white blood cells.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2017-11-09 12:23:58 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2017-11-09 11:44:47 +0000" MODIFIED_BY="[Empty name]">Adverse effects of intralesional zinc sulphate</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Participants were seen at 10-15 day intervals after injection, and at 6 weeks post treatment"</P>
</TD>
<TD VALIGN="TOP">
<P>I1: IL 2% zinc sulphate</P>
<P>I2: IL 7% sodium chloride</P>
<P>I3: ILSSG 2-5 mL per lesion</P>
</TD>
<TD VALIGN="TOP">
<P>19 participants evaluated for AEs.</P>
<P>Quote: "Apart from pain at the time of injection, no appreciable side-effect was noted."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Iraji-2004" TYPE="STUDY">Iraji 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>I1: IL zinc sulphate</P>
<P>I2: ILMA weekly</P>
</TD>
<TD VALIGN="TOP">
<P>31 participants evaluated for AEs.</P>
<P>Severe pain caused vasovagal shock: 2 (6.4%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Firooz-2005" TYPE="STUDY">Firooz 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>I1: IL zinc sulphate</P>
<P>I2: ILMA weekly</P>
</TD>
<TD VALIGN="TOP">
<P>36 participants evaluated for AEs.</P>
<P>Pain: 13 (36.1%); burning at site injection: 3 (8.4%); itching: 3 (8.4%); inflammation: 7 (19.4%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Maleki-2012" TYPE="STUDY">Maleki 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>14, 28, 42, and 56 days after starting the treatment</P>
</TD>
<TD VALIGN="TOP">
<P>I1: IL 2% zinc sulphate</P>
<P>I2: ILMA weekly</P>
</TD>
<TD VALIGN="TOP">
<P>24 participants evaluated for AEs.</P>
<P>Quote: "The side effects seen in both groups were pain after injection and hyperpigmentation."</P>
<P>Burning after injection and necrosis of the lesions: 24 (100%); inflammation and swelling: 3 (12.5%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; <B>IL</B>: intralesional; <B>ILMA</B>: intralesional meglumine antimoniate; <B>ILSSG</B>: intralesional sodium stibogluconate.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2017-11-09 12:26:18 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2017-11-09 12:24:12 +0000" MODIFIED_BY="[Empty name]">Adverse effects of intralesional hypertonic sodium chloride solution</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sharquie-1997" TYPE="STUDY">Sharquie 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Participants were seen at 10-15 day intervals after injection, and at 6 week post treatment"</P>
</TD>
<TD VALIGN="TOP">
<P>I1: IL 2% zinc sulphate</P>
<P>I2: IL 7% HSCS</P>
<P>I3: ILSSG 2-5 mL per lesion</P>
</TD>
<TD VALIGN="TOP">
<P>17 participants evaluated for AEs.</P>
<P>Quote: "No side-effect other than pain at the time of injection was noted."</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sadeghian-2006b" TYPE="STUDY">Sadeghian 2006b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>I1: IL 5% HSCS</P>
<P>I2: ILMA 0.5-1 mL/week</P>
</TD>
<TD VALIGN="TOP">
<P>36 participants evaluated for AEs. Allergic reaction (erythema, oedema, and pruritus): 0 (0%); sporotrichoid dissemination: 3 (8.3%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ranawaka-2010" TYPE="STUDY">Ranawaka 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Participants were seen weekly for the first three injections; fortnightly for the fourth and fifth injections; then monthly until cure. Participants were followed-up every 3 months after cure for 18 months to assess recurrences and evidence of visceralization."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: ILSSG</P>
<P>I2: IL 7% HSCS</P>
</TD>
<TD VALIGN="TOP">
<P>67 participants evaluated for AEs.</P>
<P>Leishmaniasis recidivans: 0 (0%)</P>
<P>Quote: "There were no systemic side effects with SSG or HS. Pain during injection was the only local side effect noted with both therapies. After healing, scarring was minimal, but postinflammatory hyperpigmentation</P>
<P>was observed in all participants for both treatments, which faded out over 6&#8211;8 months."</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; <B>IL</B>: intralesional; <B>ILSSG</B>: intralesional sodium stibogluconate; <B>HSCS</B>: hypertonic sodium chloride solution.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2017-11-09 12:35:25 +0000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2017-11-09 12:27:02 +0000" MODIFIED_BY="[Empty name]">Adverse effects of laser</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Asilian-2004b" TYPE="STUDY">Asilian 2004b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>1, 3, 4, 8, 12 and 24 weeks after treatment</P>
</TD>
<TD VALIGN="TOP">
<P>I1: CO&#8322;</P>
<P>I2: IMMA 50 mg/kg/d</P>
</TD>
<TD VALIGN="TOP">
<P>123 participants evaluated for AEs. Quote: "Complications were seen in (4) 4.5% of participants and included hyperpigmentation, persistent redness." Hypertonic scars: 5 (4%)</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shamsi-Meymandi-2011" TYPE="STUDY">Shamsi Meymandi 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Follow-up was performed and any side-effects were recorded."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Follow-up evaluation was performed by clinical assessment of treated lesions at weeks 2, 6, 12 and 16."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: CO&#8322;</P>
<P>I2: cryotherapy + MA</P>
</TD>
<TD VALIGN="TOP">
<P>80 participants (95 lesions) evaluated for AEs.</P>
<P>Hyperpigmentation + trivial scar: 20 (25%); atrophic scar: 7 (8.75%); hypertrophic scar: 1 (1.25%); sporotrichoid: 1 (1.25%); raised papular lesions: 1 (1.25%); persistent erythema: 3 (3.75%); hypopigmentation + trivial scar: 4 (5%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nilforoushzadeh-2014a" TYPE="STUDY">Nilforoushzadeh 2014a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Participants were followed in the first, third, and sixth months after treatment with the final evaluation in the sixth month."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: ablative CO&#8322; laser</P>
<P>I2: fractional CO&#8322; laser</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>: </P>
<P>30 participants evaluated for AEs.</P>
<P>Erythema: 2 (6.7%)</P>
<P>
<B>Intervention 2</B>: </P>
<P>30 participants evaluated for AEs.</P>
<P>Erythema: 4 (13.3%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; <B>IMMA</B>: intramuscular meglumine antimoniate; <B>MA</B>: meglumine antimoniate.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2017-11-09 12:35:47 +0000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2017-11-09 11:39:34 +0000" MODIFIED_BY="[Empty name]">Adverse effects of cryotherapy</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Asilian-2004a" TYPE="STUDY">Asilian 2004a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Fortnightly until 6 months post-treatment and 2 weeks and 4 weeks post-treatment</P>
</TD>
<TD VALIGN="TOP">
<P>I1: cryotherapy + ILMA</P>
<P>I2: cryotherapy alone</P>
<P>I3: ILMA alone</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>: </P>
<P>100 participants evaluated for AEs. Postinflammatory hypopigmentation: 5 (5%)</P>
<P>
<B>Intervention 2</B>: </P>
<P>200 participants evaluated for AEs. Postinflammatory hypopigmentation: 10 (5%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Salmanpour-2006" TYPE="STUDY">Salmanpour 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>I1: ILMA alone</P>
<P>I2: cryotherapy alone</P>
<P>I3: cryotherapy + ILMA</P>
</TD>
<TD VALIGN="TOP">
<P>
<U>I</U>
<B>ntervention 2</B>: </P>
<P>20 participants evaluated for AEs.</P>
<P>Erythema and oedema of the lesions and perilesional area: (28%)</P>
<P>
<B>Intervention 3</B>: </P>
<P>20 participants evaluated for AEs. </P>
<P>Erythema and oedema of the lesions and perilesional area: (33%)</P>
<P>Quote: "There were no serious side-effects in any of the treatment groups"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Layegh-2009" TYPE="STUDY">Layegh 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Weekly for up to six weeks of treatment and six months after."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: cryotherapy</P>
<P>I2: ILMA</P>
</TD>
<TD VALIGN="TOP">
<P>36 participants evaluated for AEs.</P>
<P>Hypopigmentation: 2 (5.5%); hyperpigmentation: 7 (19.4%). </P>
<P>Quote: "the most common adverse reactions were erythema and oedema of the treated site, which appeared during the initial hours of treatment, and blistering of the treatment site, which became evident 1&#8211;2 days after treatment and responded well to local treatment."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shamsi-Meymandi-2011" TYPE="STUDY">Shamsi Meymandi 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Follow-up was performed and any side-effects were recorded."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Follow-up evaluation was performed by clinical assessment of treated lesions at weeks 2, 6, 12 and 16."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: CO&#8322;</P>
<P>I2: cryotherapy + MA</P>
</TD>
<TD VALIGN="TOP">
<P>80 participants (95 lesions) evaluated for AEs.</P>
<P>Hyperpigmentation + trivial scar: 15 (18.7%);</P>
<P>atrophic scar: 6 (7.5%); hypertrophic scar: 0 (0%); sporotrichoid: 0 (0%); raised papular lesions: 0 (0%); persistent erythema: 0 (0%); hypopigmentation + trivial scar: 15 (18.8%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jowkar-2012" TYPE="STUDY">Jowkar 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "During these visits the healing process of the ulcer, change of diameter and induration of lesions and complications were assessed."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "The participants were evaluated every 2 weeks up to 12 weeks."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: cryotherapy + 3% salicylic + 3% sodium nitrite</P>
<P>I2: cryotherapy + 3% salicylic + placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>: </P>
<P>36 participants evaluated for AEs.</P>
<P>Erythema, a burning sensation and skin irritation: 7 (19.4%)</P>
<P>
<B>Intervention 2</B>: </P>
<P>27 participants evaluated for AEs.</P>
<P>Erythema, a burning sensation and skin irritation: 1 (3.7%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; <B>ILMA</B>: intralesional meglumine antimoniate; <B>MA</B>: meglumine antimoniate.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2017-11-09 12:41:23 +0000" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2017-11-09 12:36:00 +0000" MODIFIED_BY="[Empty name]">Adverse effects of thermotherapy</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Method of assessment</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Timing</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Interventions</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Adverse effects</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Reithinger-2005" TYPE="STUDY">Reithinger 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "The occurrence of adverse effects was evaluated blindly by means of participant interviews and physical examinations."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "The occurrence of adverse effects was evaluated &#8230; during follow-up visits."</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: ILSSG 2-5 mL per lesion</P>
<P>I2: IMSSG 20 mg/kg</P>
<P>I3: thermotherapy</P>
</TD>
<TD VALIGN="TOP">
<P>138-108 participants evaluated for AEs.</P>
<P>Secondary infections: 8 (5.7%).</P>
<P>Quote: "The original CL ulcer often increased in size immediately after and up to 2 weeks after treatment."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sadeghian-2007" TYPE="STUDY">Sadeghian 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Appearance of lesions at subsequent follow-up visits and occurrence of unwanted side-effects were also recorded on the form."</P>
</TD>
<TD VALIGN="TOP">
<P>Weekly 4 weeks and monthly up to 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>I1: thermotherapy</P>
<P>I2: ILMA weekly</P>
</TD>
<TD VALIGN="TOP">
<P>57 participants (83 lesions) evaluated for AEs.</P>
<P>Satellite lesions: 1 (1.7%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Aronson-2010" TYPE="STUDY">Aronson 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Interview, physical examination, laboratory testing (complete blood count, creatine phosphokinase, amylase, lipase, complete metabolic profile), and electrocardiograms."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Daily for the first 10 days and follow-up at 2, 6, and 12&#8211;24 months post treatment"</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>I1: thermotherapy</P>
<P>I2: ILSSG</P>
</TD>
<TD VALIGN="TOP">
<P>27 participants evaluated for AEs.</P>
<P>Serious AE: 4 (15%); ECG changes: 10 (37%); abdominal discomfort: 1 (4%); wound infection: 5 (19%); musculoskeletal: 5 (19%); headache: 3 (11%); fatigue: 5 (19%); rash: 1 (4%); blister reaction: 25 (93%); erythema: 7 (26%); oozing: 21 (78%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Safi-2012" TYPE="STUDY">Safi 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "The occurrences of adverse effects were evaluated by means of participant interviews and physical examinations during follow-up visits."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "During treatment, all participants were then followed for four visits at weekly intervals &#8230; After initial treatment, all participants were scheduled for four subsequent follow-up visits: 10 days after baseline and 1-month, 2 months and 6 months after treatment."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: thermotherapy</P>
<P>I2: ILMA weekly</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>189 participants evaluated for AEs</P>
<P>Not reported</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bumb-2013" TYPE="STUDY">Bumb 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>Not described</P>
</TD>
<TD VALIGN="TOP">
<P>I1: radiofrequency heat treatment</P>
<P>I2: ILSSG</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "RFHT was cosmetically acceptable because it was associated with less scarring and hyperpigmentation compared with intralesional SSG injections."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jebran-2014" TYPE="STUDY">Jebran 2014</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "In case of clinical signs for a superinfection, a smear was taken, Gram stained and microscopically evaluated for the presence of bacteria and/or fungi."</P>
</TD>
<TD VALIGN="TOP">
<P>Quote: "Adverse events such as bacterial or fungal superinfections of the wounds, the formation or scars and the rate of re-ulcerations were monitored during the treatment and follow-up period."</P>
</TD>
<TD VALIGN="TOP">
<P>I1: electrocauterisation + DAC N-055.</P>
<P>I2: electrocauterisation + placebo.</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Intervention 1</B>: </P>
<P>38 participants evaluated for AEs.</P>
<P>Bacterial and fungal superinfections: 3 (8.0%); Keloïd formation: 2 (5%)</P>
<P>
<B>Intervention 2</B>: </P>
<P>32 participants evaluated for AEs.</P>
<P>Bacterial and fungal superinfections: 3 (9.0%); Keloïd formation: 2 (6%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<B>AE</B>: adverse effect; CL: cutaneous leishmaniasis; <B>ILMA</B>: intralesional meglumine antimoniate; <B>ILSSG</B>: intralesional sodium stibogluconate; <B>IMSSG</B>: intramuscular sodium stibogluconate.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-11-15 14:53:11 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-10-19 12:36:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ILMA weekly versus ILMA fortnightly for up to 8 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="102" EVENTS_2="89" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:25:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="111" TOTAL_2="104" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILMA weekly</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA fortnightly</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA fortnightly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA weekly</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1823743712914891" CI_START="0.9751828246947564" EFFECT_SIZE="1.0737928940176131" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="89" LOG_CI_END="0.07275500754659542" LOG_CI_START="-0.010913956288339985" LOG_EFFECT_SIZE="0.030920525629127702" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.04914756352469165" STUDY_ID="STD-Mujtaba-1999" TOTAL_1="111" TOTAL_2="104" VAR="0.002415483000413601" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-10-19 12:36:49 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>ILMA (every other day) versus IMMA (6 d/week) for up to 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="48" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:26:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="70" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4627260649014615" CI_START="0.9007187042822513" EFFECT_SIZE="1.1478260869565218" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="46" LOG_CI_END="0.16516300032829262" LOG_CI_START="-0.04541081862381623" LOG_EFFECT_SIZE="0.0598760908522382" MODIFIED="2017-07-12 12:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.12369210360968345" STUDY_ID="STD-Alkhawajah-1997" TOTAL_1="70" TOTAL_2="77" VAR="0.015299736495388665" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-10-19 12:37:08 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>IMMA (30 mg/kg/d for 3 weeks) + cimetidine versus IMMA (30 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="127" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:27:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="150" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>IMMA30+Cimetidine</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA30+Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA30+Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA30+Cimetidine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.213981651568658" CI_START="0.9623201641247475" EFFECT_SIZE="1.0808510638297872" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="94" LOG_CI_END="0.08421212275019177" LOG_CI_START="-0.016680414053788145" LOG_EFFECT_SIZE="0.03376585434820179" MODIFIED="2016-12-22 08:44:46 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.05926477554476961" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="150" TOTAL_2="120" VAR="0.0035123136203719218" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-10-19 11:45:31 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>IMMA (30 mg/kg/d for 3 weeks) + cimetidine versus IMMA (60 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="127" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:27:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="150" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>IMMA30+Cimetidine</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA60</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA60</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA30+Cimetidine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0206728515919552" CI_START="0.8460493080020394" EFFECT_SIZE="0.9292682926829269" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="82" LOG_CI_END="0.008886563325256554" LOG_CI_START="-0.07260432541348885" LOG_EFFECT_SIZE="-0.03185888104411617" MODIFIED="2016-12-22 08:45:03 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.047868151431544013" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="150" TOTAL_2="90" VAR="0.002291359921473229" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-10-24 11:16:18 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>IMMA (60 mg/kg/d for 3 weeks) + placebo versus IMMA (30 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="82" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 10:15:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="90" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>IMMA 60</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA 30+placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA30+placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA60</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3036990646495632" CI_START="1.037700717087231" EFFECT_SIZE="1.1631205673758864" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="94" LOG_CI_END="0.1151773539379399" LOG_CI_START="0.01607211684669602" LOG_EFFECT_SIZE="0.06562473539231795" MODIFIED="2016-12-22 08:45:34 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.05821490684623219" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="90" TOTAL_2="120" VAR="0.0033889753791154914" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-11-09 12:56:48 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>IMMA (30 mg/kg/d for 3 weeks) + placebo versus IMMA (60 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="1.0059338474088462" CI_END="0.9642265065989866" CI_START="0.7135352386844935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8294634353194981" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="65" I2="0.5898844565307138" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.015820933928053872" LOG_CI_START="-0.1465845739322107" LOG_EFFECT_SIZE="-0.08120275393013231" METHOD="MH" MODIFIED="2017-07-05 15:50:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31587920225183996" P_Q="1.0" P_Z="0.014923455079453614" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.0736890563422562E-4" TOTALS="YES" TOTAL_1="75" TOTAL_2="73" WEIGHT="100.0" Z="2.4342313068597408">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>IMMA30+placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA60</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA60</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA30+placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0167726502921546" CI_START="0.7273995812018418" EFFECT_SIZE="0.86" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="40" LOG_CI_END="0.007223855812134242" LOG_CI_START="-0.13822695332499882" LOG_EFFECT_SIZE="-0.06550154875643228" MODIFIED="2016-06-21 11:16:32 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.0854385252802691" STUDY_ID="STD-Nilforoushzadeh-2008" TOTAL_1="45" TOTAL_2="43" VAR="0.007299741602067183" WEIGHT="79.65267816371603"/>
<DICH_DATA CI_END="1.004636468443366" CI_START="0.5160075472904491" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.0020089390596965077" LOG_CI_START="-0.2873439461971597" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2016-06-21 11:16:32 +0100" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.16996731711975951" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="30" TOTAL_2="30" VAR="0.028888888888888895" WEIGHT="20.34732183628397"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:56:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="90" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>IMMA30+placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA60</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA 30</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA 60</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="25" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-11-09 12:56:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse effects</NAME>
<DICH_DATA CI_END="1.004636468443366" CI_START="0.5160075472904491" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.0020089390596965077" LOG_CI_START="-0.2873439461971597" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2017-07-04 22:43:32 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.16996731711975951" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="30" TOTAL_2="30" VAR="0.028888888888888895" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 12:01:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Skin reaction</NAME>
<DICH_DATA CI_END="1.2761166235604249" CI_START="0.2666510031257073" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.10589036612048203" LOG_CI_START="-0.5740567781872179" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2017-07-04 22:41:56 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.3994043183589901" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="30" TOTAL_2="30" VAR="0.1595238095238095" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-10-23 10:47:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Cardiac toxicity 'QT prolongation'</NAME>
<DICH_DATA CI_END="2.288930488946035" CI_START="0.15727869489202628" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35963260406574094" LOG_CI_START="-0.8033301032984537" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2017-07-04 22:46:37 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Shanehsaz-2015" TOTAL_1="30" TOTAL_2="30" VAR="0.4666666666666667" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2017-10-19 14:05:06 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>IMMA (30 mg/kg/d for 3 weeks) + 40 mg omeprazole versus IMMA (60 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 11:38:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>IMMA30+Omeprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA60</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA60</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA30+omeprazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1008641364569542" CI_START="0.8294269833258301" EFFECT_SIZE="0.9555555555555556" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="0.04173372366935821" LOG_CI_START="-0.08122184006087246" LOG_EFFECT_SIZE="-0.01974405819575713" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.07222470677499393" STUDY_ID="STD-Nilforoushzadeh-2008" TOTAL_1="36" TOTAL_2="43" VAR="0.005216408268733853" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2017-10-19 11:46:49 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>IMMA (30 mg/kg/d for 3 weeks) + placebo versus IMMA (60 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 11:38:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="69.10545310798588" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="45" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>IMMA30+placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA60</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA60</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA30+placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0167726502921546" CI_START="0.7273995812018418" EFFECT_SIZE="0.86" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="40" LOG_CI_END="0.007223855812134242" LOG_CI_START="-0.13822695332499882" LOG_EFFECT_SIZE="-0.06550154875643228" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.0854385252802691" STUDY_ID="STD-Nilforoushzadeh-2008" TOTAL_1="45" TOTAL_2="43" VAR="0.007299741602067183" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2017-10-19 11:47:21 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>IMMA (30 mg/kg/d for 3 weeks) + 40 mg omeprazole versus IMMA (60 mg/kg/d for 3 weeks) + placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:29:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>IMMA30+Omeprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA30+Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA30+Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA30+omeprazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3385484043152687" CI_START="0.9223184587531658" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.12663408067567852" LOG_CI_START="-0.03511909955432825" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.09501461875826149" STUDY_ID="STD-Nilforoushzadeh-2008" TOTAL_1="36" TOTAL_2="45" VAR="0.009027777777777777" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2017-11-09 12:57:16 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>ILMA + non-silver polyester dressing versus ILMA (weekly injections for 6 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:39:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILMA+non-silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+non-silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7186479701051924" CI_START="0.5914984289961844" EFFECT_SIZE="1.008254716981132" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.23518692945182423" LOG_CI_START="-0.22804640450890662" LOG_EFFECT_SIZE="0.0035702624714587837" MODIFIED="2016-12-21 09:43:26 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.27210555341051806" STUDY_ID="STD-Khatami-2013" TOTAL_1="53" TOTAL_2="45" VAR="0.07404143219684431" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:57:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (itching and burning)</NAME>
<GROUP_LABEL_1>ILMA+non-silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+non-silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.030333834214632" CI_START="0.6383768844876899" EFFECT_SIZE="2.2641509433962264" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9047335999914662" LOG_CI_START="-0.19492284709779462" LOG_EFFECT_SIZE="0.3549053764468358" MODIFIED="2017-07-06 15:27:04 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.6459436404074347" STUDY_ID="STD-Khatami-2013" TOTAL_1="53" TOTAL_2="45" VAR="0.41724318658280923" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:57:16 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (oedema)</NAME>
<GROUP_LABEL_1>ILMA+non-silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+non-silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.86014819532594" CI_START="0.47808957703959315" EFFECT_SIZE="1.3584905660377358" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5866039780336333" LOG_CI_START="-0.32049072437267456" LOG_EFFECT_SIZE="0.1330566268304794" MODIFIED="2017-07-06 15:28:52 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.532831918384659" STUDY_ID="STD-Khatami-2013" TOTAL_1="53" TOTAL_2="45" VAR="0.28390985324947593" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2017-11-09 12:57:30 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>ILMA (weekly injections for 6 weeks) + silver polyester dressing versus ILMA (weekly injections for 6 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:44:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILMA+silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5955627790204399" CI_START="0.5508440417114674" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.20291389661838732" LOG_CI_START="-0.25897134381887443" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2016-12-21 09:43:05 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.2713136766016618" STUDY_ID="STD-Khatami-2013" TOTAL_1="60" TOTAL_2="45" VAR="0.07361111111111111" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:57:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (itching and burning)</NAME>
<GROUP_LABEL_1>ILMA+silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.6767667653060645" CI_START="0.396352376805583" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.7541010512411993" LOG_CI_START="-0.4019185331298369" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2017-07-06 15:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.6790516262487788" STUDY_ID="STD-Khatami-2013" TOTAL_1="60" TOTAL_2="45" VAR="0.46111111111111114" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:57:30 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="126.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (oedema)</NAME>
<GROUP_LABEL_1>ILMA+silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1082601682909066" CI_START="0.1707569138830904" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.32392420363781343" LOG_CI_START="-0.7676217028705262" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2017-07-06 15:31:36 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.6411794687223782" STUDY_ID="STD-Khatami-2013" TOTAL_1="60" TOTAL_2="45" VAR="0.41111111111111115" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2017-11-09 12:57:57 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>ILMA (weekly injections for 6 weeks) + silver polyester dressing versus ILMA (weekly injections for 6 weeks) + non-silver polyester dressing</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:46:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILMA+silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA+non-silver</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+non-silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5448577071806524" CI_START="0.559646180337906" EFFECT_SIZE="0.9298245614035088" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.18888848386949458" LOG_CI_START="-0.2520864560128993" LOG_EFFECT_SIZE="-0.03159898607170235" MODIFIED="2016-12-21 09:43:45 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.2590308625480753" STUDY_ID="STD-Khatami-2013" TOTAL_1="60" TOTAL_2="53" VAR="0.06709698775239988" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:57:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (itching and burning)</NAME>
<GROUP_LABEL_1>ILMA+silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA+non-silver</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+non-silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7863833645214342" CI_START="0.2456954418166458" EFFECT_SIZE="0.6625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2519746657674879" LOG_CI_START="-0.609602900549797" LOG_EFFECT_SIZE="-0.17881411739115455" MODIFIED="2017-07-06 15:32:33 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.5060949273325095" STUDY_ID="STD-Khatami-2013" TOTAL_1="60" TOTAL_2="53" VAR="0.2561320754716981" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:57:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (oedema)</NAME>
<GROUP_LABEL_1>ILMA+silver</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA+non-silver</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+silver</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+non-silver</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.024198519802188" CI_START="0.27609587645867456" EFFECT_SIZE="1.1777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7010667912290005" LOG_CI_START="-0.5589400795781098" LOG_EFFECT_SIZE="0.07106335582544537" MODIFIED="2017-07-06 15:33:20 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.7401342730466983" STUDY_ID="STD-Khatami-2013" TOTAL_1="60" TOTAL_2="53" VAR="0.5477987421383647" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2017-11-09 12:45:52 +0000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>ILMA (weekly injections for 6 weeks) + gel mask twice a day versus ILMA (weekly injections for 6 weeks) + vehicle</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:45:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>ILMA + gel mask</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA + vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>ILMA placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>ILMA gel mask</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.737253120922802" CI_START="0.766359795651634" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.23986310054911913" LOG_CI_START="-0.11556728705143024" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.2087815690853567" STUDY_ID="STD-Mostafavi-2013" TOTAL_1="20" TOTAL_2="20" VAR="0.043589743589743574" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2017-11-09 12:46:22 +0000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>ILSSG (20 mg/kg/d) + IMSSG (remaining total dose days 1, 3, 5) versus ILSSG (1000 mg/mL days 1, 3, 5)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:32:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILSSG+IMSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG-IMSSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.629898361013276" CI_START="0.9734216492737976" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.4199389644197792" LOG_CI_START="-0.01169899910792959" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.25354627641855493" STUDY_ID="STD-El_x002d_Sayed-2010" TOTAL_1="15" TOTAL_2="12" VAR="0.06428571428571427" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2017-10-19 11:49:58 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>ILSSG (5 injections of 2 mL to 5 mL every 5 to 7 d for 29 days) versus IMSSG (20 mg/kg/d for 3 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="70" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-20 16:09:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="148" TOTAL_2="144" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>IL SSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IM SSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM SSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IL SSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8585445742933016" CI_START="1.7783916716465547" EFFECT_SIZE="2.6195426195426195" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="26" LOG_CI_END="0.5864235216282947" LOG_CI_START="0.2500274158591675" LOG_EFFECT_SIZE="0.4182254687437311" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.1976007377163647" STUDY_ID="STD-Reithinger-2005" TOTAL_1="148" TOTAL_2="144" VAR="0.03904605154605155" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:48:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="148" TOTAL_2="144" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (mild heart symptoms)</NAME>
<GROUP_LABEL_1>IL SSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IM SSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL SSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM SSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.081763862673946" CI_START="0.034131838789608904" EFFECT_SIZE="0.32432432432432434" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48879935824138937" LOG_CI_START="-1.4668403142801296" LOG_EFFECT_SIZE="-0.48902047801937015" MODIFIED="2017-07-06 15:39:10 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.1487524242116454" STUDY_ID="STD-Reithinger-2005" TOTAL_1="148" TOTAL_2="144" VAR="1.319632132132132" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2017-10-19 11:50:34 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Ketoconazole 600 mg/d for 6 weeks versus ketoconazole 800 mg/d for 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Ketoconazole 600 mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Ketoconazole 800 mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ketoconazole 800</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ketoconazole 600</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8815294995760026" CI_START="0.6561512330860475" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.2745110317989303" LOG_CI_START="-0.18299605067758" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2017-07-03 08:10:14 +0100" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.26874192494328497" STUDY_ID="STD-Alsaleh-1995" TOTAL_1="18" TOTAL_2="15" VAR="0.0722222222222222" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (nausea and vomiting)</NAME>
<GROUP_LABEL_1>Ketoconazole 600 mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Ketoconazole 800 mg/day</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ketoconazole 600</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ketoconazole 800</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.42560553580117" CI_START="0.012262420168239335" EFFECT_SIZE="0.2807017543859649" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8079140609473425" LOG_CI_START="-1.9114238069804756" LOG_EFFECT_SIZE="-0.5517548730165667" MODIFIED="2017-07-06 15:45:04 +0100" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="1.597352524560342" STUDY_ID="STD-Alsaleh-1995" TOTAL_1="18" TOTAL_2="15" VAR="2.551535087719298" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2017-10-19 11:50:49 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Ketoconazole 600 mg/d for 30 d versus ILMA (6 to 8 biweekly injections)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="64" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Participants cured</NAME>
<GROUP_LABEL_1>Ketoconazole 600 mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA biweekly</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ketoconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.564445202544701" CI_START="0.9814624583251674" EFFECT_SIZE="1.2391304347826086" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="23" LOG_CI_END="0.1943603558176283" LOG_CI_START="-0.008126307835793682" LOG_EFFECT_SIZE="0.09311702399091731" MODIFIED="2017-07-03 08:23:47 +0100" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="0.11894166855517045" STUDY_ID="STD-Salmanpour-2001" TOTAL_1="64" TOTAL_2="32" VAR="0.014147120518688022" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="64" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect (liver enzymes increase)</NAME>
<GROUP_LABEL_1>Ketoconazole 600 mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA biweekly</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ketoconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="51.3611264729975" CI_START="0.1254603904693614" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7106345402874692" LOG_CI_START="-0.9014933651453678" LOG_EFFECT_SIZE="0.4045705875710507" MODIFIED="2017-07-06 15:44:20 +0100" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.5343768618929166" STUDY_ID="STD-Salmanpour-2001" TOTAL_1="64" TOTAL_2="32" VAR="2.3543123543123543" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2017-11-09 12:47:17 +0000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>ILSSG (100 mg/mL days 1, 3, 5) + oral ketoconazole (600 mg/d for 4 weeks) versus ILSSG (100 mg/mL days 1, 3, 5)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:53:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILSSG+ketoconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG-Ketoconazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6175168059038922" CI_START="0.9566492178756415" EFFECT_SIZE="1.5824175824175823" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.41788947877032323" LOG_CI_START="-0.019247279222011214" LOG_EFFECT_SIZE="0.19932109977415605" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.2567762955065477" STUDY_ID="STD-El_x002d_Sayed-2010" TOTAL_1="13" TOTAL_2="12" VAR="0.06593406593406591" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2017-11-09 12:48:02 +0000" MODIFIED_BY="[Empty name]" NO="19">
<NAME>ILSSG (100 mg/mL days 1, 3, 5) + ketoconazole (600 mg/d for 4 weeks) versus ILSSG (20 mg/kg/d) + IMSSG (remaining total dose days 1, 3, 5)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:54:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILSSG+Ketoconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG+IMSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG+IMSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursILSSG+Ketoconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.216667189044641" CI_START="0.8039525888361944" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.08517179620187228" LOG_CI_START="-0.09476956196540974" LOG_EFFECT_SIZE="-0.004798882881768708" MODIFIED="2017-07-03 08:40:49 +0100" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.1056984445115498" STUDY_ID="STD-El_x002d_Sayed-2010" TOTAL_1="13" TOTAL_2="15" VAR="0.011172161172161174" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2017-11-12 16:39:24 +0000" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Itraconazole (200 mg for 6 weeks) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 13:15:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="309.82" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1151.3303490188916" CI_START="0.834686587406402" EFFECT_SIZE="31.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="3.0611999527969767" LOG_CI_START="-0.07847656512843114" LOG_EFFECT_SIZE="1.4913616938342726" MODIFIED="2017-07-12 12:23:33 +0100" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="1.4033096713819666" STUDY_ID="STD-Dogra-1992" TOTAL_1="20" TOTAL_2="20" VAR="1.9692780337941629" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2017-10-19 11:52:20 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Itraconazole (200 mg for 3 weeks) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:08:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="309.82" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.17724566230272" CI_START="0.8165260395547402" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" LOG_CI_END="0.3379074339851744" LOG_CI_START="-0.08802996076857467" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2017-07-12 12:21:58 +0100" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.19037695827853288" STUDY_ID="STD-Momeni-1996" TOTAL_1="70" TOTAL_2="70" VAR="0.036243386243386244" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2017-11-14 15:27:40 +0000" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Itraconazole (200 mg for 6 to 8 weeks) versus placebo</NAME>
<DICH_OUTCOME CHI2="7.516724884047008" CI_END="38.990892845466604" CI_START="0.35174288896421557" CI_STUDY="99" CI_TOTAL="99" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7033456890707064" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="54" I2="73.39266727395243" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="1.5909631801333488" LOG_CI_START="-0.45377467375055525" LOG_EFFECT_SIZE="0.5685942531913968" METHOD="MH" MODIFIED="2017-07-18 11:55:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02332200144541885" P_Q="1.0" P_Z="0.15198448431179173" Q="0.0" RANDOM="YES" SCALE="309.82" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.775049274366734" TOTALS="YES" TOTAL_1="125" TOTAL_2="119" WEIGHT="100.0" Z="1.4325569768446806">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7107273747733671" CI_START="0.9341509531296759" EFFECT_SIZE="1.2641509433962264" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="53" LOG_CI_END="0.23318080494421875" LOG_CI_START="-0.02958293874414401" LOG_EFFECT_SIZE="0.10179893310003736" MODIFIED="2016-12-17 17:39:27 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.11744487073784976" STUDY_ID="STD-Nassiri_x002d_Kashani-2005" TOTAL_1="100" TOTAL_2="100" VAR="0.01379329766263024" WEIGHT="46.69177446933203"/>
<DICH_DATA CI_END="85.3757253811905" CI_START="0.573933630211889" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.9313344066188425" LOG_CI_START="-0.24113832659032894" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2016-07-12 08:45:04 +0100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Dogra-1996" TOTAL_1="10" TOTAL_2="10" VAR="0.9428571428571427" WEIGHT="30.73109265463534"/>
<DICH_DATA CI_END="512.2455909304425" CI_START="0.40340147120575126" EFFECT_SIZE="14.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.7094782289710952" LOG_CI_START="-0.39426252224775904" LOG_EFFECT_SIZE="1.157607853361668" MODIFIED="2016-12-17 17:39:37 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.3872478227552316" STUDY_ID="STD-Al_x002d_Fouzan-1991" TOTAL_1="15" TOTAL_2="9" VAR="1.9244565217391303" WEIGHT="22.57713287603262"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4138624487945903" CI_END="6.383371479859388" CI_START="1.0288723350611706" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5627474163572597" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-022.02" LOG_CI_END="0.8050501189024102" LOG_CI_START="0.012361489807965522" LOG_EFFECT_SIZE="0.4087058043551879" METHOD="MH" MODIFIED="2017-11-09 12:58:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8779805990974523" P_Q="0.969209864807724" P_Z="0.04327015527391051" Q="0.06254822408567756" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="165" TOTAL_2="143" WEIGHT="300.0" Z="2.0210928412679454">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Itraconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.16573782168269" CI_END="7.4692061476533675" CI_START="0.744615660689727" DF="2" EFFECT_SIZE="2.358323105611842" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="7.652718626574956" ID="CMP-022.02.01" LOG_CI_END="0.8732744459901822" LOG_CI_START="-0.1280678339790179" LOG_EFFECT_SIZE="0.37260330600558217" MODIFIED="2017-07-17 13:16:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3386228818159991" P_Z="0.14466965863884942" STUDIES="3" TAU2="0.11098422944534216" TOTAL_1="105" TOTAL_2="99" WEIGHT="100.0" Z="1.4586202438470104">
<NAME>Mild abdominal pain and nausea</NAME>
<DICH_DATA CI_END="58.627412036251464" CI_START="0.16657097185121464" EFFECT_SIZE="3.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.768100723739944" LOG_CI_START="-0.7784006803797558" LOG_EFFECT_SIZE="0.494850021680094" MODIFIED="2017-07-04 23:03:47 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="1.4958275301651591" STUDY_ID="STD-Al_x002d_Fouzan-1991" TOTAL_1="15" TOTAL_2="9" VAR="2.2375" WEIGHT="14.731693130261753"/>
<DICH_DATA CI_END="216.3886995962606" CI_START="0.7810019669017899" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3352345769930722" LOG_CI_START="-0.10734787237939857" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2017-07-04 23:04:11 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.4347850217395144" STUDY_ID="STD-Dogra-1992" TOTAL_1="20" TOTAL_2="20" VAR="2.058608058608059" WEIGHT="15.946382728198772"/>
<DICH_DATA CI_END="5.085887573602296" CI_START="0.44240065621551716" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7063667556226622" LOG_CI_START="-0.3541842375112997" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2017-07-05 15:09:09 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.622972903178973" STUDY_ID="STD-Momeni-1996" TOTAL_1="70" TOTAL_2="70" VAR="0.38809523809523805" WEIGHT="69.32192414153947"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20193584928238534" CI_END="17.980314099972237" CI_START="0.5288230022087825" DF="2" EFFECT_SIZE="3.0835699575336735" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-022.02.02" LOG_CI_END="1.2547972741988342" LOG_CI_START="-0.2766896626088741" LOG_EFFECT_SIZE="0.48905380579498003" MODIFIED="2017-07-17 13:16:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9039621077239954" P_Z="0.21065697226215008" STUDIES="3" TAU2="0.0" TOTAL_1="45" TOTAL_2="39" WEIGHT="100.0" Z="1.2517610471538205">
<NAME>Mild abnormal liver function</NAME>
<DICH_DATA CI_END="41.68599516816314" CI_START="0.08433587793257213" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6199901738523137" LOG_CI_START="-1.0739876297248385" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2017-07-04 23:05:50 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="1.5824558972264176" STUDY_ID="STD-Al_x002d_Fouzan-1991" TOTAL_1="15" TOTAL_2="9" VAR="2.5041666666666664" WEIGHT="32.317560255459206"/>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2017-07-04 23:05:54 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Dogra-1992" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="35.11363016392481"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2017-07-04 23:06:03 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Dogra-1996" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="32.56880958061598"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="43.63240889305693" CI_START="0.15792446887103861" DF="0" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-022.02.03" LOG_CI_END="1.639809190527107" LOG_CI_START="-0.8015505750431559" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2017-07-17 13:16:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5009677325361446" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="5" WEIGHT="100.0" Z="0.6729678760373875">
<NAME>Headache and dizziness</NAME>
<DICH_DATA CI_END="43.63240889305693" CI_START="0.15792446887103861" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.639809190527107" LOG_CI_START="-0.8015505750431559" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2017-07-06 15:59:24 +0100" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="1.4340668112217154" STUDY_ID="STD-Dogra-1990" TOTAL_1="15" TOTAL_2="5" VAR="2.056547619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-14 15:27:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="612.2063683182253" CI_START="0.47206304108515523" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.786897842920707" LOG_CI_START="-0.32600000016415914" LOG_EFFECT_SIZE="1.2304489213782739" MODIFIED="2016-07-12 08:51:18 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="1.3913406761125573" STUDY_ID="STD-Dogra-1996" TOTAL_1="10" TOTAL_2="10" VAR="1.9358288770053478" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2017-11-15 14:51:08 +0000" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Itraconazole (200 mg for 6 to 8 weeks) versus no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 10:57:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="309.82" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="265.7045140635738" CI_START="0.23340072041516713" EFFECT_SIZE="7.875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.4243989327175717" LOG_CI_START="-0.6318978077942952" LOG_EFFECT_SIZE="0.8962505624616381" MODIFIED="2017-07-06 16:03:08 +0100" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="1.3660422499218055" STUDY_ID="STD-Dogra-1990" TOTAL_1="15" TOTAL_2="5" VAR="1.8660714285714286" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:58:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (headache and dizziness)</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Itraconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="43.63240889305693" CI_START="0.15792446887103861" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.639809190527107" LOG_CI_START="-0.8015505750431559" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2017-07-06 16:02:37 +0100" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="1.4340668112217154" STUDY_ID="STD-Dogra-1990" TOTAL_1="15" TOTAL_2="5" VAR="2.056547619047619" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-023.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:51:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Itraconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Itraconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="114.55863590853946" CI_START="0.541343954632208" EFFECT_SIZE="7.875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.059027833691773" LOG_CI_START="-0.26652670876849655" LOG_EFFECT_SIZE="0.8962505624616381" MODIFIED="2017-07-06 16:07:08 +0100" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="1.3660422499218055" STUDY_ID="STD-Dogra-1990" TOTAL_1="15" TOTAL_2="5" VAR="1.8660714285714286" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2017-10-19 11:53:02 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Fluconazole (200 mg for 6 weeks) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:11:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="264" TOTAL_2="102" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.381247700414152" CI_START="1.560385957788415" EFFECT_SIZE="2.897727272727273" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="10" LOG_CI_END="0.730882983209315" LOG_CI_START="0.19323203335825823" LOG_EFFECT_SIZE="0.46205750828378656" MODIFIED="2017-07-03 09:00:39 +0100" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="0.3158188293576352" STUDY_ID="STD-Dandashli-2005" TOTAL_1="264" TOTAL_2="102" VAR="0.09974153297682711" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 13:21:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="106" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fluconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.161760821370388" CI_START="1.8604642906709246" EFFECT_SIZE="2.782590051457976" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="22" LOG_CI_END="0.6192771174556613" LOG_CI_START="0.2696213386878936" LOG_EFFECT_SIZE="0.44444922807177745" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.20538953527220594" STUDY_ID="STD-Alrajhi-2002" TOTAL_1="106" TOTAL_2="103" VAR="0.04218486119933272" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2017-11-09 12:48:55 +0000" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Fluconazole (400 mg/d for 6 weeks) versus fluconazole (200 mg/d for 6 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="47" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="58" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>400 mg Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>200 mg Fluconazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluconazole 200 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fluconazole 400 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.240006764056219" CI_START="1.2548647040923187" EFFECT_SIZE="1.676575505350773" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="29" LOG_CI_END="0.35024932975731277" LOG_CI_START="0.09859690395762268" LOG_EFFECT_SIZE="0.22442311685746774" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.14782188061433604" STUDY_ID="STD-Emad-2011" TOTAL_1="58" TOTAL_2="60" VAR="0.021851308388359015" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="57" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="174" TOTAL_2="180" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>400 mg Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>200 mg Fluconazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fluconazole 400 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fluconazole 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-025.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 10:58:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Rise creatinine and liver enzymes</NAME>
<DICH_DATA CI_END="105.42206909807734" CI_START="0.2534919192922115" EFFECT_SIZE="5.169491525423729" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.022931535774396" LOG_CI_START="-0.5960358803651128" LOG_EFFECT_SIZE="0.7134478277046417" MODIFIED="2017-07-06 16:17:00 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.5383944243381398" STUDY_ID="STD-Emad-2011" TOTAL_1="58" TOTAL_2="60" VAR="2.3666574048346765" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="0" I2="0.0" ID="CMP-025.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 10:58:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Cheilitis</NAME>
<DICH_DATA CI_END="1492.3647982366424" CI_START="5.931484979874522" EFFECT_SIZE="94.08474576271186" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="0" LOG_CI_END="3.1738749963913837" LOG_CI_START="0.7731634349880485" LOG_EFFECT_SIZE="1.9735192156897163" MODIFIED="2017-07-06 16:17:36 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4101898548822063" STUDY_ID="STD-Emad-2011" TOTAL_1="58" TOTAL_2="60" VAR="1.9886354268126982" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-025.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 10:58:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="362.2122288400327" CI_START="1.3014609074023749" EFFECT_SIZE="21.71186440677966" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.55896310867294" LOG_CI_START="0.11443112753214435" LOG_EFFECT_SIZE="1.3366971181025422" MODIFIED="2017-07-06 16:17:46 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4359301863505662" STUDY_ID="STD-Emad-2011" TOTAL_1="58" TOTAL_2="60" VAR="2.061895500072772" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2017-10-19 11:53:37 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Oral dapsone (200 mg/d for 6 weeks) versus placebo</NAME>
<DICH_OUTCOME CHI2="3.498813168358179" CI_END="403.4281886339121" CI_START="1.4370632089228499" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="24.07803578633819" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="2" I2="71.41887972059821" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="2.605766240283424" LOG_CI_START="0.15747587090574436" LOG_EFFECT_SIZE="1.381621055594584" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06141295210372344" P_Q="1.0" P_Z="0.02695998489543896" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.0522636656818216" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="2.212096688462581">
<NAME>Participants complete Cure</NAME>
<GROUP_LABEL_1>Dapsone 200 mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dapsone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1568.998866959755" CI_START="6.246658430666281" EFFECT_SIZE="99.0" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="0" LOG_CI_END="3.195622629964691" LOG_CI_START="0.795647759230409" LOG_EFFECT_SIZE="1.99563519459755" MODIFIED="2017-07-03 09:19:05 +0100" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="1.4097571191365266" STUDY_ID="STD-Dogra-1991" TOTAL_1="60" TOTAL_2="60" VAR="1.9874151349561189" WEIGHT="41.03913463635717"/>
<DICH_DATA CI_END="33.78778821751038" CI_START="2.3973158431844945" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.5287597633531889" LOG_CI_START="0.3797252555254611" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2017-07-03 09:13:28 +0100" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.6749485577105528" STUDY_ID="STD-Dogra-1992" TOTAL_1="20" TOTAL_2="20" VAR="0.45555555555555555" WEIGHT="58.96086536364283"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.018603898594821845" CI_END="157.2913588712881" CI_START="3.0378439687839927" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="21.85924531837687" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="2.196704864405875" LOG_CI_START="0.48256546365568864" LOG_EFFECT_SIZE="1.3396351640307818" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.891508155998389" P_Q="1.0" P_Z="0.002187610939879644" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="3.063504254991911">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Dapsone 200 mg/day</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dapsone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.018603898594821845" CI_END="157.2913588712881" CI_START="3.0378439687839927" DF="1" EFFECT_SIZE="21.85924531837687" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" I2="0.0" ID="CMP-026.02.01" LOG_CI_END="2.196704864405875" LOG_CI_START="0.48256546365568864" LOG_EFFECT_SIZE="1.3396351640307818" MODIFIED="2017-07-17 10:59:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.891508155998389" P_Z="0.002187610939879644" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="3.063504254991911">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="319.26525205943875" CI_START="1.1307212346829125" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.5041516537100184" LOG_CI_START="0.0533555481956394" LOG_EFFECT_SIZE="1.2787536009528289" MODIFIED="2017-07-06 16:25:42 +0100" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="1.439609764015525" STUDY_ID="STD-Dogra-1991" TOTAL_1="60" TOTAL_2="60" VAR="2.0724762726488355" WEIGHT="48.91903846839344"/>
<DICH_DATA CI_END="395.4815026007054" CI_START="1.5803520414734176" EFFECT_SIZE="25.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.5971261755547905" LOG_CI_START="0.19875384178928426" LOG_EFFECT_SIZE="1.3979400086720377" MODIFIED="2017-07-06 16:25:46 +0100" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="1.4088157809883821" STUDY_ID="STD-Dogra-1992" TOTAL_1="20" TOTAL_2="20" VAR="1.984761904761905" WEIGHT="51.08096153160657"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2017-11-09 12:49:51 +0000" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Allopurinol (15 mg/kg/d for 3 weeks) + IMMA (20 mg/kg/d for 2 weeks) versus allopurinol (15 mg/kg/d for 3 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.603705572166398" CI_START="1.7079204211708525" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.8333333333333335" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="0.9346855399567868" LOG_CI_START="0.23246763131111167" LOG_EFFECT_SIZE="0.5835765856339493" METHOD="MH" MODIFIED="2017-11-09 12:49:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0011233999066585143" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="3.257647166160577">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Allopurinol+ IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Allopurinol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Allopurinol+IMMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.603705572166398" CI_START="1.7079204211708525" EFFECT_SIZE="3.8333333333333335" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="6" LOG_CI_END="0.9346855399567868" LOG_CI_START="0.23246763131111167" LOG_EFFECT_SIZE="0.5835765856339493" MODIFIED="2017-07-03 09:40:01 +0100" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.4124862755731782" STUDY_ID="STD-Esfandiarpour-2002" TOTAL_1="50" TOTAL_2="50" VAR="0.1701449275362319" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2017-11-09 12:49:59 +0000" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Allopurinol (15mg/kg/d for 3 weeks)+ IMMA (20 mg/kg/d for 2 weeks) versus IMMA (20 mg/kg/d for 2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.414624661395232" CI_START="1.0758462423832131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="0.5333429726021686" LOG_CI_START="0.03175020733776761" LOG_EFFECT_SIZE="0.28254658996996806" METHOD="MH" MODIFIED="2017-11-09 12:49:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.027237956674745854" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="2.208090621099102">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Allopurinol +MMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Allopurinol +IMMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.414624661395232" CI_START="1.0758462423832131" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5333429726021686" LOG_CI_START="0.03175020733776761" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2017-07-03 09:39:32 +0100" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.29463807324054125" STUDY_ID="STD-Esfandiarpour-2002" TOTAL_1="50" TOTAL_2="50" VAR="0.08681159420289855" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2017-10-19 11:55:47 +0100" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Allopurinol (15 mg/kg/d for 3 weeks) versus IMMA (20 mg/kg/d for 2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6202369657280633" CI_START="0.3471714396710096" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="0.20957853638339138" LOG_CI_START="-0.45945600959999133" LOG_EFFECT_SIZE="-0.12493873660829995" METHOD="MH" MODIFIED="2017-07-18 12:15:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4641525531454237" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.7320262473629757">
<NAME>Lesions Cured</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Allopurinol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6202369657280633" CI_START="0.3471714396710096" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.20957853638339138" LOG_CI_START="-0.45945600959999133" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2017-07-03 09:34:06 +0100" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.3929942040850532" STUDY_ID="STD-Esfandiarpour-2002" TOTAL_1="50" TOTAL_2="50" VAR="0.15444444444444444" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2017-11-14 15:28:15 +0000" MODIFIED_BY="[Empty name]" NO="30">
<NAME>Allopurinol (20 mg/kg/d for 3 weeks) + IMMA (30 mg/kg/d for 20 days) versus IMMA (60 mg/kg/d for 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:50:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Allopurinol +IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Allopurinol +IMMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2935810751020824" CI_START="0.7147261434269132" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.11179365328141747" LOG_CI_START="-0.14586033187897815" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2017-07-12 12:32:46 +0100" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.1513472262910124" STUDY_ID="STD-Momeni-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.02290598290598292" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-030.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:17:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="108" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Allopurinol +IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Allopurinol +IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-030.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:01:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Mild abdominal pain</NAME>
<DICH_DATA CI_END="222.53099871746065" CI_START="0.7594447558947646" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3473905170437956" LOG_CI_START="-0.11950381243012181" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2017-07-12 12:32:09 +0100" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="1.4490659404568516" STUDY_ID="STD-Momeni-2002" TOTAL_1="36" TOTAL_2="36" VAR="2.0997920997920994" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-030.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Skin eruption</NAME>
<DICH_DATA CI_END="7.9199970308142" CI_START="0.014029185955349858" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.898725018773679" LOG_CI_START="-1.8529675282130038" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2017-07-12 12:32:12 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.6163578231977633" STUDY_ID="STD-Momeni-2002" TOTAL_1="36" TOTAL_2="36" VAR="2.612612612612612" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-030.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Muscle pain and weakness</NAME>
<DICH_DATA CI_END="1.9912523628464711" CI_START="0.006199956993245031" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29912630414908753" LOG_CI_START="-2.2076113230277374" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2017-07-12 12:32:18 +0100" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="1.472470090755044" STUDY_ID="STD-Momeni-2002" TOTAL_1="36" TOTAL_2="36" VAR="2.168168168168168" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4104654197034603" CI_START="0.8752911514088213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="0.14936244305000518" LOG_CI_START="-0.057847461928654836" LOG_EFFECT_SIZE="0.04575749056067514" METHOD="MH" MODIFIED="2017-11-14 15:28:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.38669586867743966" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="0.8656249664425164">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Allopurinol + IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Allopurinol +IMMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4104654197034603" CI_START="0.8752911514088213" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.14936244305000518" LOG_CI_START="-0.057847461928654836" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2017-11-13 15:58:30 +0000" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.12171612389003689" STUDY_ID="STD-Momeni-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.014814814814814808" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2017-10-19 11:56:51 +0100" MODIFIED_BY="[Empty name]" NO="31">
<NAME>Allopurinol (20 mg/kg/d for 3 weeks)+ IMMA (10 mg/kg/d for 20 d) versus IMMA (20 mg/kg/d for 28 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-031.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:18:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="1050" TOTAL_2="912" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Allopurinol + IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Allopurinol +IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>IMMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="19" I2="0.0" ID="CMP-031.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Secondary infection</NAME>
<DICH_DATA CI_END="1.7167904230311843" CI_START="0.5368156693073886" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.2347172819539408" LOG_CI_START="-0.270174815874804" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2017-07-07 11:43:37 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.29657611752079643" STUDY_ID="STD-Ejaz-2014" TOTAL_1="175" TOTAL_2="152" VAR="0.08795739348370926" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-031.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="1.6280047567543008" CI_START="0.3218050958289902" EFFECT_SIZE="0.7238095238095238" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.21165566948999237" LOG_CI_START="-0.4924070830682858" LOG_EFFECT_SIZE="-0.14037570678914674" MODIFIED="2017-07-07 11:44:25 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.4135699460195658" STUDY_ID="STD-Ejaz-2014" TOTAL_1="175" TOTAL_2="152" VAR="0.17104010025062658" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-031.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>ECG changes</NAME>
<DICH_DATA CI_END="2.754391181232694" CI_START="0.030432872735115545" EFFECT_SIZE="0.2895238095238095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.44002561921298755" LOG_CI_START="-1.516657050135356" LOG_EFFECT_SIZE="-0.5383157154611844" MODIFIED="2017-07-07 11:44:37 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="1.1493650857106399" STUDY_ID="STD-Ejaz-2014" TOTAL_1="175" TOTAL_2="152" VAR="1.3210401002506265" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-031.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Chest pain</NAME>
<DICH_DATA CI_END="7.061157235962991" CI_START="0.01189156828903597" EFFECT_SIZE="0.2897727272727273" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8488758823559581" LOG_CI_START="-1.924760865788385" LOG_EFFECT_SIZE="-0.5379424917162134" MODIFIED="2017-07-07 11:44:52 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="1.6292479555833206" STUDY_ID="STD-Ejaz-2014" TOTAL_1="175" TOTAL_2="152" VAR="2.65444890077243" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-031.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:33 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Pain injection site</NAME>
<DICH_DATA CI_END="3.5935502445800163" CI_START="0.00841189408584981" EFFECT_SIZE="0.17386363636363636" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.555523721487548" LOG_CI_START="-2.0751062041526875" LOG_EFFECT_SIZE="-0.7597912413325698" MODIFIED="2017-07-07 11:45:01 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="1.5452450401492197" STUDY_ID="STD-Ejaz-2014" TOTAL_1="175" TOTAL_2="152" VAR="2.3877822341057633" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-031.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:02:36 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Abscess</NAME>
<DICH_DATA CI_END="1.4176492682539479" CI_START="0.004405582695582912" EFFECT_SIZE="0.07902892561983471" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1515687980524347" LOG_CI_START="-2.3559966423619865" LOG_EFFECT_SIZE="-1.102213922154776" MODIFIED="2017-07-07 11:45:03 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="1.4729563523485498" STUDY_ID="STD-Ejaz-2014" TOTAL_1="175" TOTAL_2="152" VAR="2.169600415923945" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" MODIFIED="2017-10-19 11:57:13 +0100" MODIFIED_BY="[Empty name]" NO="32">
<NAME>Allopurinol (20 mg/kg/d for 3 weeks) versus IVSSG (20 mg/kg/d for 15 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-032.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:19:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cured</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>IVSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Allopurinol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7075423580094018" CI_START="0.8635157944996927" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.23237148577762765" LOG_CI_START="-0.06372971437755584" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2017-07-07 12:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.17393131069573445" STUDY_ID="STD-Mashood-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.03025210084033611" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-032.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:27:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="80" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>IVSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVSSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-032.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:03:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Abdominal symptoms</NAME>
<DICH_DATA CI_END="2.0452762263354756" CI_START="0.03055821956723241" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31075197027588036" LOG_CI_START="-1.514871952931805" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2017-07-07 11:59:09 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Mashood-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-032.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:03:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Liver abnormalities</NAME>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2017-07-07 12:04:04 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Mashood-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-032.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:03:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="2.5983769423254333" CI_START="0.007854196568971131" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4147021537028376" LOG_CI_START="-2.1048982337313515" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2017-07-07 12:00:12 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Mashood-2001" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-032.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:03:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2017-07-07 12:04:13 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Mashood-2001" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" MODIFIED="2017-11-15 14:51:20 +0000" MODIFIED_BY="[Empty name]" NO="33">
<NAME>Oral rifampicin (10 mg/kg/d for 4 to 6 weeks) versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:19:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="39.67" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="71" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Oral rifampicin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oral rifampicin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="3" I2="0.0" ID="CMP-033.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:04:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Evaluated 3 months after treatment</NAME>
<DICH_DATA CI_END="7.08143897750181" CI_START="0.8371414864183644" EFFECT_SIZE="2.4347826086956523" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="3" LOG_CI_END="0.8501215170808891" LOG_CI_START="-0.07720113510367393" LOG_EFFECT_SIZE="0.38646019098860757" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5447139162143724" STUDY_ID="STD-Jaffar-2006" TOTAL_1="46" TOTAL_2="16" VAR="0.29671325051759834" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-033.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:04:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Evaluated after treatment</NAME>
<DICH_DATA CI_END="118.19239033677077" CI_START="2.445165878924519" EFFECT_SIZE="17.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="2.0725895159603294" LOG_CI_START="0.38830832679621863" LOG_EFFECT_SIZE="1.2304489213782739" MODIFIED="2017-07-07 12:33:04 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.9893551078413476" STUDY_ID="STD-Kochar-2000" TOTAL_1="25" TOTAL_2="25" VAR="0.9788235294117646" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-033.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:51:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Oral rifampicin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rifampicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0625075319530595" CI_START="0.05882311242077971" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.026332017380285656" LOG_CI_START="-1.2304520000362105" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2017-11-13 16:11:06 +0000" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.7382411530116699" STUDY_ID="STD-Kochar-2000" TOTAL_1="25" TOTAL_2="25" VAR="0.5449999999999999" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" MODIFIED="2017-11-09 13:27:58 +0000" MODIFIED_BY="[Empty name]" NO="34">
<NAME>Oral rifampicin (10 mg/kg/d) + omeprazole (20 mg/d) for 6 weeks versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-034.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 13:44:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="39.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Rifampicin +Omeprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Rifampicin+Omepra</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.045967835812593" CI_START="1.7726848723303554" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.205365917322845" LOG_CI_START="0.24863153854967954" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2017-07-07 12:43:05 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.5619905100029122" STUDY_ID="STD-Kochar-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.31583333333333335" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-035" MODIFIED="2017-11-09 12:51:40 +0000" MODIFIED_BY="[Empty name]" NO="35">
<NAME>Azythromicin (500 mg/d for 5 d/month up to 4 months) versus IMMA (60 mg/kg/d for 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-035.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:51:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Azithromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.013617428594552" CI_START="0.1787827195413529" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.30397696153399134" LOG_CI_START="-0.7476744607667041" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2016-07-12 08:02:59 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.6177452512179263" STUDY_ID="STD-Layegh-2007" TOTAL_1="29" TOTAL_2="58" VAR="0.3816091954022989" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-035.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:20:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-035.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:05:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="198.3762100027426" CI_START="0.48742963908377746" EFFECT_SIZE="9.833333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.2974895887656093" LOG_CI_START="-0.31208806624860813" LOG_EFFECT_SIZE="0.9927007612585006" MODIFIED="2017-07-07 12:55:41 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.5328788321730762" STUDY_ID="STD-Layegh-2007" TOTAL_1="29" TOTAL_2="58" VAR="2.349717514124294" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-036" MODIFIED="2017-10-19 11:59:34 +0100" MODIFIED_BY="[Empty name]" NO="36">
<NAME>Azythromicin (10 mg/kg/d) + allopurinol (10 mg/kg/d) for 1 month versus IMMA (20 mg/kg/d for 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-036.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:32:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>azithromycin+allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Azithromycin+allo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.730305994966666" CI_START="0.5462710365289613" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.23812291247805695" LOG_CI_START="-0.26259182531208014" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.29412231555585255" STUDY_ID="STD-Dastgheib-2012" TOTAL_1="36" TOTAL_2="35" VAR="0.0865079365079365" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-036.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 12:21:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="108" TOTAL_2="105" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>azithromycin+allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azithromycin+allo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-036.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:16:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal complaints and headache</NAME>
<DICH_DATA CI_END="69.32192460389543" CI_START="0.12290610371691862" EFFECT_SIZE="2.918918918918919" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408706116478897" LOG_CI_START="-0.9104265488079806" LOG_EFFECT_SIZE="0.4652220314199547" MODIFIED="2017-07-07 12:54:02 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.6161255711923692" STUDY_ID="STD-Dastgheib-2012" TOTAL_1="36" TOTAL_2="35" VAR="2.6118618618618616" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-036.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:16:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal complications</NAME>
<DICH_DATA CI_END="127.22514851599533" CI_START="0.36460671841798176" EFFECT_SIZE="6.8108108108108105" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.10457296651833" LOG_CI_START="-0.43817533308923146" LOG_EFFECT_SIZE="0.8331988167145491" MODIFIED="2017-07-07 12:54:09 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.4936229379965618" STUDY_ID="STD-Dastgheib-2012" TOTAL_1="36" TOTAL_2="35" VAR="2.2309094809094807" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-036.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:16:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="3.9143835914223986" CI_START="0.009673823569159861" EFFECT_SIZE="0.1945945945945946" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5926633822507466" LOG_CI_START="-2.0144018375221995" LOG_EFFECT_SIZE="-0.7108692276357265" MODIFIED="2017-07-07 12:56:21 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.5314030152755984" STUDY_ID="STD-Dastgheib-2012" TOTAL_1="36" TOTAL_2="35" VAR="2.345195195195195" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-037" MODIFIED="2017-10-19 12:00:13 +0100" MODIFIED_BY="[Empty name]" NO="37">
<NAME>Oral pentoxifylline (400 mg 3 times daily) + IMMA (20 mg/kg/d) for 20 d versus placebo + IMMA (20 mg/kg/d) for 20 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-037.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 11:17:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Oral pentoxyfilline+IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo+IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo + IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Pentoxy+ IMMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3866444352930936" CI_START="1.106417428985695" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="16" LOG_CI_END="0.3777877221938487" LOG_CI_START="0.04391900843593772" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.19611613513818404" STUDY_ID="STD-Sadeghian-2006a" TOTAL_1="32" TOTAL_2="32" VAR="0.038461538461538464" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-037.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:29:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Oral pentoxyfilline+IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo+IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Pentoxy + IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo + IMMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-037.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-07 12:58:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Allergic macule-papular</NAME>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2017-07-07 12:58:55 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Sadeghian-2006a" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-038" MODIFIED="2017-10-24 11:17:12 +0100" MODIFIED_BY="[Empty name]" NO="38">
<NAME>Oral miltefosine (2.5 mg/kg/d for 4 weeks) versus IMMA (60 mg/kg/d for 2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-038.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:32:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Oral miltefosine</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oral miltefosine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2803647911295526" CI_START="0.7927867565809161" EFFECT_SIZE="1.0075" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.10733372293195727" LOG_CI_START="-0.10084361330566309" LOG_EFFECT_SIZE="0.003245054813147085" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.12228439780041213" STUDY_ID="STD-Mohebali-2007" TOTAL_1="32" TOTAL_2="31" VAR="0.01495347394540944" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-039" MODIFIED="2017-10-19 12:00:51 +0100" MODIFIED_BY="[Empty name]" NO="39">
<NAME>Oral miltefosine (2.5 mg/kg/d for 4 weeks) versus IMMA (60 mg/kg/d for 2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-039.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:30:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Miltefosine</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Miltefosine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7333076975023176" CI_START="0.4706705327713896" EFFECT_SIZE="0.9032258064516129" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.23887566569458962" LOG_CI_START="-0.3272829906786966" LOG_EFFECT_SIZE="-0.04420366249205347" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.332564397284216" STUDY_ID="STD-Khatami-2013" TOTAL_1="31" TOTAL_2="42" VAR="0.11059907834101385" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-040" MODIFIED="2017-10-19 12:01:26 +0100" MODIFIED_BY="[Empty name]" NO="40">
<NAME>Oral zinc sulphate 2.5 mg/kg/d for 45 days versus oral zinc sulphate 5 mg/kg/d for 45 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-040.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 13:50:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="39" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Zn Sulphate 2.5</GROUP_LABEL_1>
<GROUP_LABEL_2>Zn Sulphate 5</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulphate 5</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulphate 2.5</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2284608444483258" CI_START="0.679410232180002" EFFECT_SIZE="0.9135802469135802" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.08936131847907766" LOG_CI_START="-0.16786791677442475" LOG_EFFECT_SIZE="-0.03925329914767358" MODIFIED="2017-07-09 05:51:57 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.15109772609315744" STUDY_ID="STD-Sharquie-2001" TOTAL_1="39" TOTAL_2="37" VAR="0.02283052283052283" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-040.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:30:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="274.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="78" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Zn Sulphate 2.5</GROUP_LABEL_1>
<GROUP_LABEL_2>Zn Sulphate 5</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulphate 2.5</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulphate 5</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-040.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-09 05:55:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="14.620490390302137" CI_START="0.06156193959243745" EFFECT_SIZE="0.9487179487179487" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1649619396690678" LOG_CI_START="-1.2106877055880763" LOG_EFFECT_SIZE="-0.022862882959504227" MODIFIED="2017-07-09 05:55:47 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.3954683612794478" STUDY_ID="STD-Sharquie-2001" TOTAL_1="39" TOTAL_2="37" VAR="1.9473319473319475" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-040.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 09:46:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Oedema</NAME>
<DICH_DATA CI_END="95.76250783640066" CI_START="0.235608909058078" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9811955108867518" LOG_CI_START="-0.6278082916370187" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2017-07-09 05:57:02 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.5325417483795722" STUDY_ID="STD-Sharquie-2001" TOTAL_1="39" TOTAL_2="37" VAR="2.348684210526316" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-041" MODIFIED="2017-10-19 12:01:58 +0100" MODIFIED_BY="[Empty name]" NO="41">
<NAME>Oral zinc sulphate 2.5 mg/kg/d for 45 d versus oral zinc sulphate 10 mg/kg/d for 45 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-041.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:31:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.8714156776962692" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Zn Sulphate 2.5</GROUP_LABEL_1>
<GROUP_LABEL_2>Zn Sulphate 10</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulphate 10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulphate 2.5</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1022624146100175" CI_START="0.6381728286052052" EFFECT_SIZE="0.8387096774193549" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" LOG_CI_END="0.04228499891706113" LOG_CI_START="-0.19506169064397053" LOG_EFFECT_SIZE="-0.07638834586345469" MODIFIED="2017-07-09 05:53:33 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13941862033321165" STUDY_ID="STD-Sharquie-2001" TOTAL_1="39" TOTAL_2="39" VAR="0.019437551695616215" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-041.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:31:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="78" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Zn Sulphate 2.5</GROUP_LABEL_1>
<GROUP_LABEL_2>Zn Sulphate 10</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulphate 2.5</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulphate 10</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-041.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-09 05:58:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="15.425791638464126" CI_START="0.06482649470685871" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1882474608994193" LOG_CI_START="-1.1882474608994193" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-07-09 05:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.3959648809042255" STUDY_ID="STD-Sharquie-2001" TOTAL_1="39" TOTAL_2="39" VAR="1.948717948717949" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-041.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 09:01:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Oedema</NAME>
<DICH_DATA CI_END="21.16211905093586" CI_START="0.18901698787216242" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3255591532521103" LOG_CI_START="-0.7234991619241479" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2017-07-09 05:58:13 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.2036269973367784" STUDY_ID="STD-Sharquie-2001" TOTAL_1="39" TOTAL_2="39" VAR="1.448717948717949" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-042" MODIFIED="2017-10-19 12:02:58 +0100" MODIFIED_BY="[Empty name]" NO="42">
<NAME>Oral zinc sulphate 5 mg/kg/d for 45 d versus oral zinc sulphate 10 mg/kg/d for 45 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-042.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 13:51:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Zn Sulphate 5</GROUP_LABEL_1>
<GROUP_LABEL_2>Zn Sulphate 10</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulphate 10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulphate 5</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1820175227334517" CI_START="0.7130270268167505" EFFECT_SIZE="0.9180470793374019" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.07262391476015917" LOG_CI_START="-0.14689400819172155" LOG_EFFECT_SIZE="-0.037135046715781155" MODIFIED="2017-07-09 05:54:34 +0100" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.1289459145731783" STUDY_ID="STD-Sharquie-2001" TOTAL_1="37" TOTAL_2="39" VAR="0.016627048885113398" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-042.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:32:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="226.15877507657314" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="74" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Zn Sulphate 5</GROUP_LABEL_1>
<GROUP_LABEL_2>Zn Sulphate 10</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulphate 5</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulphate 10</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-042.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-09 05:59:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="16.24380269075935" CI_START="0.06839715859758755" EFFECT_SIZE="1.054054054054054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2106877055880763" LOG_CI_START="-1.1649619396690678" LOG_EFFECT_SIZE="0.022862882959504165" MODIFIED="2017-07-09 05:59:12 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.3954683612794478" STUDY_ID="STD-Sharquie-2001" TOTAL_1="37" TOTAL_2="39" VAR="1.9473319473319475" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-042.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 09:46:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Oedema</NAME>
<DICH_DATA CI_END="8.350687523862646" CI_START="0.014743074052697943" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9217222330318426" LOG_CI_START="-1.8314119530488628" LOG_EFFECT_SIZE="-0.4548448600085102" MODIFIED="2017-07-09 05:59:18 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="1.617204649137821" STUDY_ID="STD-Sharquie-2001" TOTAL_1="37" TOTAL_2="39" VAR="2.6153508771929825" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-043" MODIFIED="2017-10-19 12:03:45 +0100" MODIFIED_BY="[Empty name]" NO="43">
<NAME>Oral zinc sulphate (10 mg/kg/d for 45 d) versus IMMA (20 mg/kg/d for 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-043.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:32:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Oral Zn</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oral Zn</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6849527802755586" CI_START="0.4551581116994178" EFFECT_SIZE="0.8757396449704142" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="26" LOG_CI_END="0.22658773455269232" LOG_CI_START="-0.34183771299012455" LOG_EFFECT_SIZE="-0.05762498921871614" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.3338959216379956" STUDY_ID="STD-Yazdanpanah-2011" TOTAL_1="26" TOTAL_2="74" VAR="0.11148648648648649" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-044" MODIFIED="2017-11-09 12:53:06 +0000" MODIFIED_BY="[Empty name]" NO="44">
<NAME>Artesunate 400 mg + sulphamethoxypyrazine/pyrimethamine 1000 mg/50 mg 4 times daily for 4 d versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-044.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:33:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Artesunato+sulfa/pyri</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artesunato+sulfa/pyri</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.318441623957192" CI_START="0.8362144974541525" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.12006090549500736" LOG_CI_START="-0.07768230735513115" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.11615534207286157" STUDY_ID="STD-Adam-2009" TOTAL_1="20" TOTAL_2="21" VAR="0.013492063492063486" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-045" MODIFIED="2017-10-19 12:04:54 +0100" MODIFIED_BY="[Empty name]" NO="45">
<NAME>Topical 2% miconazole (twice a day) versus topical 1% clotrimazole (twice a day) for 30 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-045.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 13:54:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="62" TOTAL_2="89" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>2% Miconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>1% Clotrimazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>1% Clotrimazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>2% Miconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8106870088650441" CI_START="0.002993330773876775" EFFECT_SIZE="0.04926108374384237" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="-0.09114678642941239" LOG_CI_START="-2.5238452893970136" LOG_EFFECT_SIZE="-1.307496037913213" MODIFIED="2017-07-09 06:21:12 +0100" MODIFIED_BY="[Empty name]" ORDER="310" O_E="0.0" SE="1.4289791426949703" STUDY_ID="STD-Larbi-1995" TOTAL_1="62" TOTAL_2="89" VAR="2.0419813902572526" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-046" MODIFIED="2017-11-09 13:00:40 +0000" MODIFIED_BY="[Empty name]" NO="46">
<NAME>Topical ketoconazole (twice a day) versus vehicle (twice a day) for 30 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-046.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:00:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Ketoconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ketoconazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.531149492222868" CI_START="0.7417789055249719" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6562083907107423" LOG_CI_START="-0.12972552116157954" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2017-07-09 06:26:00 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.4616614702694098" STUDY_ID="STD-Momeni-2003" TOTAL_1="45" TOTAL_2="45" VAR="0.21313131313131312" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-047" MODIFIED="2017-10-19 12:08:55 +0100" MODIFIED_BY="[Empty name]" NO="47">
<NAME>Topical amphotericin B (3 to 7 drops twice daily for 8 weeks) versus ILMA (max 2 mL) once a week for 8 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-047.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 11:48:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure (ITT)</NAME>
<GROUP_LABEL_1>Aphotericin B</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anphotericin B</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3685776099496596" CI_START="0.6055394294689973" EFFECT_SIZE="0.9103448275862069" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.1362694306224041" LOG_CI_START="-0.21785757268065412" LOG_EFFECT_SIZE="-0.040794071029125" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.20801595469715403" STUDY_ID="STD-Layegh-2011" TOTAL_1="50" TOTAL_2="60" VAR="0.043270637408568444" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-047.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:33:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="150" TOTAL_2="180" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Aphotericin B</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Anphotericin B</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-047.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:22:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Hypersensitivity</NAME>
<DICH_DATA CI_END="86.19309023234527" CI_START="0.14937894083207914" EFFECT_SIZE="3.588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9354724515063286" LOG_CI_START="-0.8257106242413422" LOG_EFFECT_SIZE="0.5548809136324931" MODIFIED="2017-07-12 12:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.6219326067708426" STUDY_ID="STD-Layegh-2011" TOTAL_1="50" TOTAL_2="60" VAR="2.630665380906461" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-047.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:22:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Mild pruritus</NAME>
<DICH_DATA CI_END="232.29723471752288" CI_START="0.7451790698406064" EFFECT_SIZE="13.156862745098039" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3660440399592164" LOG_CI_START="-0.12773935181710477" LOG_EFFECT_SIZE="1.1191523440710558" MODIFIED="2017-07-12 12:57:04 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.4648607087562886" STUDY_ID="STD-Layegh-2011" TOTAL_1="50" TOTAL_2="60" VAR="2.145816896057976" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-047.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:22:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Erithema and oedema</NAME>
<DICH_DATA CI_END="1.3626766631077225" CI_START="0.00466599190883618" EFFECT_SIZE="0.07973856209150326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.13439281835361705" LOG_CI_START="-2.3310560186393183" LOG_EFFECT_SIZE="-1.0983316001428507" MODIFIED="2017-07-12 12:57:11 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.4482168510182196" STUDY_ID="STD-Layegh-2011" TOTAL_1="50" TOTAL_2="60" VAR="2.097332047573128" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-048" MODIFIED="2017-11-15 14:51:36 +0000" MODIFIED_BY="[Empty name]" NO="48">
<NAME>Paromomycin 15% + 12% MBCL (twice daily for 28 d) versus vehicle (twice daily for 28 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-048.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:01:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours paromomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.368342519302118" CI_START="1.1396757732891254" EFFECT_SIZE="3.088235294117647" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9226394477180522" LOG_CI_START="0.056781316337313696" LOG_EFFECT_SIZE="0.48971038202768297" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.5086093524399209" STUDY_ID="STD-Asilian-2006" TOTAL_1="34" TOTAL_2="30" VAR="0.2586834733893557" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-048.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 12:29:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Scarring</NAME>
<GROUP_LABEL_1>Favours paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paromomycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.071999702384618" CI_START="0.685868729442007" EFFECT_SIZE="2.3529411764705883" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9069811372163763" LOG_CI_START="-0.16375899731699933" LOG_EFFECT_SIZE="0.37161106994968846" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.6289580552740521" STUDY_ID="STD-Asilian-2006" TOTAL_1="34" TOTAL_2="30" VAR="0.39558823529411763" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-048.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:51:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.9007518072666585" CI_START="1.5168098085573112" EFFECT_SIZE="3.235294117647059" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" LOG_CI_END="0.8388964078330552" LOG_CI_START="0.18093112839888456" LOG_EFFECT_SIZE="0.5099137681159699" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="800" O_E="0.0" SE="0.38649206212029297" STUDY_ID="STD-Asilian-2006" TOTAL_1="34" TOTAL_2="30" VAR="0.14937611408199641" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-049" MODIFIED="2017-11-09 13:02:04 +0000" MODIFIED_BY="[Empty name]" NO="49">
<NAME>Paromomycin (twice daily for 30 d) versus vehicle (twice daily for 30 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0630537766262145" CI_START="0.24730527503117636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-049.01" LOG_CI_END="0.31451054866516676" LOG_CI_START="-0.6067666200216428" LOG_EFFECT_SIZE="-0.146128035678238" METHOD="MH" MODIFIED="2017-11-09 13:02:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5341010648282306" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6217579178026823">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours paromomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0630537766262145" CI_START="0.24730527503117636" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.31451054866516676" LOG_CI_START="-0.6067666200216428" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2017-07-12 13:04:35 +0100" MODIFIED_BY="[Empty name]" ORDER="403" O_E="0.0" SE="0.541162769282166" STUDY_ID="STD-Iraji-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.2928571428571428" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-050" MODIFIED="2017-11-15 14:51:45 +0000" MODIFIED_BY="[Empty name]" NO="50">
<NAME>Paromomycin 15% + 10% urea (twice daily for 14 d) versus vehicle (twice daily for 14 d)</NAME>
<DICH_OUTCOME CHI2="7.359370654840352E-4" CI_END="1.171721014313897" CI_START="0.8588225975024996" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0031452960869252" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-050.01" LOG_CI_END="0.06882421887735078" LOG_CI_START="-0.06609653684696068" LOG_EFFECT_SIZE="0.0013638410151951101" METHOD="MH" MODIFIED="2017-11-09 13:02:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.978357515364102" P_Q="1.0" P_Z="0.9683925474501285" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="192" TOTAL_2="191" WEIGHT="100.0" Z="0.03962443370659548">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2126712072385484" CI_START="0.8322650571488475" EFFECT_SIZE="1.0046212577858147" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="79" LOG_CI_END="0.08374306612788575" LOG_CI_START="-0.07973833894389445" LOG_EFFECT_SIZE="0.0020023635919956427" ORDER="1" O_E="0.0" SE="0.09602978658517018" STUDY_ID="STD-Asilian-1995" TOTAL_1="126" TOTAL_2="125" VAR="0.009221719911593332" WEIGHT="68.11155679452808"/>
<DICH_DATA CI_END="1.3166266478734743" CI_START="0.7595167556536486" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" LOG_CI_END="0.11946264075096157" LOG_CI_START="-0.11946264075096155" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.1403458930534474" STUDY_ID="STD-Ben-Salah-1995" TOTAL_1="66" TOTAL_2="66" VAR="0.0196969696969697" WEIGHT="31.88844320547192"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2191477347092965" CI_END="1.9347916186832388" CI_START="0.45496870443957527" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9382268574885617" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" I2="9.875310745726642" I2_Q="0.0" ID="CMP-050.02" LOG_CI_END="0.2866341974018092" LOG_CI_START="-0.34201847577507033" LOG_EFFECT_SIZE="-0.02769213918663057" METHOD="MH" MODIFIED="2017-11-11 18:30:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32969971236589535" P_Q="1.0" P_Z="0.8629086581243178" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04742106280162763" TOTALS="SUB" TOTAL_1="232" TOTAL_2="231" WEIGHT="100.0" Z="0.1726727580315086">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Paramomycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2191477347092965" CI_END="1.9347916186832388" CI_START="0.45496870443957527" DF="2" EFFECT_SIZE="0.9382268574885617" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" I2="9.875310745726642" ID="CMP-050.02.01" LOG_CI_END="0.2866341974018092" LOG_CI_START="-0.34201847577507033" LOG_EFFECT_SIZE="-0.02769213918663057" MODIFIED="2017-11-11 18:30:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32969971236589535" P_Z="0.8629086581243178" STUDIES="3" TAU2="0.04742106280162763" TOTAL_1="232" TOTAL_2="231" WEIGHT="100.0" Z="0.1726727580315086">
<NAME>Skin/local reaction</NAME>
<DICH_DATA CI_END="1.733323317684134" CI_START="0.3003267110152179" EFFECT_SIZE="0.7215007215007215" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.23887957944182117" LOG_CI_START="-0.5224060399933971" LOG_EFFECT_SIZE="-0.1417632302757879" MODIFIED="2017-07-04 23:31:55 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.44718294128083974" STUDY_ID="STD-Asilian-1995" TOTAL_1="126" TOTAL_2="125" VAR="0.19997258297258297" WEIGHT="55.119871512515395"/>
<DICH_DATA CI_END="2.9415147329610676" CI_START="0.33996090136640345" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4685710279495982" LOG_CI_START="-0.4685710279495982" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-07-04 23:32:02 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.5504818825631803" STUDY_ID="STD-Ben-Salah-1995" TOTAL_1="66" TOTAL_2="66" VAR="0.30303030303030304" WEIGHT="38.91069431479098"/>
<DICH_DATA CI_END="131.2766945785389" CI_START="0.3732574175280195" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1181876330635214" LOG_CI_START="-0.42799155303500774" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2017-07-04 23:32:14 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="1.4956382577045184" STUDY_ID="STD-Iraji-2005" TOTAL_1="40" TOTAL_2="40" VAR="2.2369337979094075" WEIGHT="5.9694341726936235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.27265504794843" CI_END="1.2047374314486732" CI_START="0.8831417366132102" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0314814139733781" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="164" I2="84.05778745434017" I2_Q="0.0" ID="CMP-050.03" LOG_CI_END="0.08089240417352862" LOG_CI_START="-0.053969590319170396" LOG_EFFECT_SIZE="0.013461406927179106" METHOD="MH" MODIFIED="2017-11-15 14:51:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.01226162341475523" P_Q="1.0" P_Z="0.6955960669409447" Q="0.0" RANDOM="YES" SCALE="1.55" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.010664997184432423" TOTALS="YES" TOTAL_1="192" TOTAL_2="191" WEIGHT="100.0" Z="0.39127217208607096">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paramomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2232502148842508" CI_START="0.9753180052196536" EFFECT_SIZE="1.0922719256052589" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="99" LOG_CI_END="0.08751530072303342" LOG_CI_START="-0.010853758255899022" LOG_EFFECT_SIZE="0.03833077123356721" MODIFIED="2016-12-17 18:30:20 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.057782472178920075" STUDY_ID="STD-Asilian-1995" TOTAL_1="126" TOTAL_2="125" VAR="0.0033388140911076725" WEIGHT="44.81342229193066"/>
<DICH_DATA CI_END="1.0372727631722314" CI_START="0.9346311693911981" EFFECT_SIZE="0.9846153846153847" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="65" LOG_CI_END="0.015892974290709926" LOG_CI_START="-0.029359739608646695" LOG_EFFECT_SIZE="-0.0067333826589683786" MODIFIED="2016-12-27 10:22:04 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.0265816681490286" STUDY_ID="STD-Ben-Salah-1995" TOTAL_1="66" TOTAL_2="66" VAR="7.065850815850816E-4" WEIGHT="55.18657770806935"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-051" MODIFIED="2017-11-09 13:03:17 +0000" MODIFIED_BY="[Empty name]" NO="51">
<NAME>Paromomycin 15% (daily for 20 d) versus vehicle</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="102" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-051.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:03:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="125" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paramomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paramomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.65579309335115" CI_START="1.1790943452183815" EFFECT_SIZE="1.3972602739726028" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="73" LOG_CI_END="0.21900606673029216" LOG_CI_START="0.0715485565526311" LOG_EFFECT_SIZE="0.14527731164146168" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.08661727140480559" STUDY_ID="STD-Ben-Salah-2013" TOTAL_1="125" TOTAL_2="125" VAR="0.007502551705613751" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-052" MODIFIED="2017-11-09 13:03:50 +0000" MODIFIED_BY="[Empty name]" NO="52">
<NAME>Paromomycin 15% + gentamicin 0.5% (daily for 20 d) versus vehicle</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="101" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-052.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:03:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="125" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paramomycin+Gentamicin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paramomycin-Genta</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6413556323565581" CI_START="1.166257198962275" EFFECT_SIZE="1.3835616438356164" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="73" LOG_CI_END="0.21520268978958798" LOG_CI_START="0.06679433753478534" LOG_EFFECT_SIZE="0.14099851366218666" MODIFIED="2016-07-20 16:16:54 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.08717580074766278" STUDY_ID="STD-Ben-Salah-2013" TOTAL_1="125" TOTAL_2="125" VAR="0.007599620235996203" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-053" MODIFIED="2017-10-19 12:40:51 +0100" MODIFIED_BY="[Empty name]" NO="53">
<NAME>Paromomycin 15% + gentamicin 0.5% (daily for 20 d) versus paromomycin 15% alone (daily for 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="101" EVENTS_2="102" I2="0.0" I2_Q="0.0" ID="CMP-053.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-13 16:35:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="125" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paramomycin+Gentamicin</GROUP_LABEL_1>
<GROUP_LABEL_2>Paramomycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paramomycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paramomycin-Genta</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1156606750275477" CI_START="0.8788409376503826" EFFECT_SIZE="0.9901960784313726" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="102" LOG_CI_END="0.047532125272299705" LOG_CI_START="-0.056089721230849696" LOG_EFFECT_SIZE="-0.004278797979274972" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.0608679855723627" STUDY_ID="STD-Ben-Salah-2013" TOTAL_1="125" TOTAL_2="125" VAR="0.0037049116676373534" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-054" MODIFIED="2017-11-14 15:29:50 +0000" MODIFIED_BY="[Empty name]" NO="54">
<NAME>Paromomycin 15% + 10% urea (twice daily for 45 d) versus ILMA (weekly for up to 3 months)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-054.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 14:03:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paromomycin+urea</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin+urea</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8182289640558968" CI_START="0.19554428775888424" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.08712515120404757" LOG_CI_START="-0.7087548661400276" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2017-07-09 06:38:32 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.3651483716701107" STUDY_ID="STD-Faghihi-2003" TOTAL_1="48" TOTAL_2="48" VAR="0.1333333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-054.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-14 15:29:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>Paromomycin+urea</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin+urea</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.709056553075023" CI_START="0.21235676164198924" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.672933906102297" LOG_CI_START="-0.672933906102297" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-11-13 08:50:39 +0000" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.7905694150420948" STUDY_ID="STD-Faghihi-2003" TOTAL_1="48" TOTAL_2="48" VAR="0.6249999999999999" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-054.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-14 15:29:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Scarring</NAME>
<GROUP_LABEL_1>Paromomycin+urea</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin+urea</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6023329066622156" CI_START="0.09606764736363155" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4153628534393404" LOG_CI_START="-1.0174228447673028" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2017-11-13 08:49:52 +0000" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.8416254115301731" STUDY_ID="STD-Faghihi-2003" TOTAL_1="48" TOTAL_2="48" VAR="0.7083333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-055" MODIFIED="2017-10-19 12:12:18 +0100" MODIFIED_BY="[Empty name]" NO="55">
<NAME>Paromomycin 15% + 10% urea (twice daily for 20 d) versus ILMA (weekly for up to 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-055.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 14:04:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paromomycin+urea</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin+urea</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6353725305206617" CI_START="0.754915395846543" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.21361669859922858" LOG_CI_START="-0.12210171747787829" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2017-07-09 06:50:09 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.19720265943665385" STUDY_ID="STD-Shazad-2005" TOTAL_1="30" TOTAL_2="30" VAR="0.03888888888888888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-055.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:37:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paramomycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-055.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:25:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Cutaneous reaction</NAME>
<DICH_DATA CI_END="3.0260386806300987" CI_START="0.036718338011454264" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48087447513357967" LOG_CI_START="-1.4351169845729046" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2017-07-09 06:51:49 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Shazad-2005" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-056" MODIFIED="2017-11-15 14:52:00 +0000" MODIFIED_BY="[Empty name]" NO="56">
<NAME>Paromomycin + MBCL (twice daily for 15 d) versus ketoconazole (weekly for up to 30 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-056.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-19 10:46:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paromomycin+MBCL</GROUP_LABEL_1>
<GROUP_LABEL_2>Ketoconazole 600 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ketoconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin+MBCL</GRAPH_LABEL_2>
<DICH_DATA CI_END="401.6289999129296" CI_START="1.5500956237739658" EFFECT_SIZE="24.951219512195124" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="2.6038250638168745" LOG_CI_START="0.19035849016797493" LOG_EFFECT_SIZE="1.3970917769924247" MODIFIED="2017-07-09 06:56:43 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="1.4176822122135795" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997" TOTAL_1="40" TOTAL_2="32" VAR="2.0098228548267887" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-056.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:52:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Paromomycin+MBCL</GROUP_LABEL_1>
<GROUP_LABEL_2>Ketoconazole 600 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ketoconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin+MBCL</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.252377874296225" CI_START="0.37112705504982313" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3526412525003271" LOG_CI_START="-0.4304773845610665" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2017-07-12 13:07:48 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.4600077639096354" STUDY_ID="STD-_x00d6_zg_x00f6_ztasi-1997" TOTAL_1="40" TOTAL_2="32" VAR="0.21160714285714285" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-057" MODIFIED="2017-11-15 14:52:25 +0000" MODIFIED_BY="[Empty name]" NO="57">
<NAME>Paromomycin (15% + 12% MBCL twice daily for 28 days) versus PDT (weekly for 4 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-057.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-20 16:18:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours paromomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6647398036990714" CI_START="0.2914566337725842" EFFECT_SIZE="0.44016227180527384" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="-0.1773483154949896" LOG_CI_START="-0.5354260553624114" LOG_EFFECT_SIZE="-0.3563871854287005" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="804" O_E="0.0" SE="0.21033663691152263" STUDY_ID="STD-Asilian-2006" TOTAL_1="34" TOTAL_2="31" VAR="0.0442415008272497" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-057.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 09:26:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Scarring</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paromomycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="625.5680306781082" CI_START="0.38617767583390544" EFFECT_SIZE="15.542857142857143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.796274546230098" LOG_CI_START="-0.41321283553428984" LOG_EFFECT_SIZE="1.1915308553479043" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="805" O_E="0.0" SE="1.4345123318577992" STUDY_ID="STD-Asilian-2006" TOTAL_1="34" TOTAL_2="31" VAR="2.057825630252101" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-057.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:52:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Paromomycin</GROUP_LABEL_1>
<GROUP_LABEL_2>PDT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paromomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8391854932247033" CI_START="0.508217749681611" EFFECT_SIZE="0.6530612244897959" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="31" LOG_CI_END="-0.07614203228222534" LOG_CI_START="-0.2939501711349901" LOG_EFFECT_SIZE="-0.18504610170860772" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="806" O_E="0.0" SE="0.1279415789297898" STUDY_ID="STD-Asilian-2006" TOTAL_1="34" TOTAL_2="31" VAR="0.01636904761904763" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-058" MODIFIED="2017-11-15 14:52:35 +0000" MODIFIED_BY="[Empty name]" NO="58">
<NAME>Paromomycin (4 weeks) versus paromomycin (2 weeks) + vehicle (2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="58" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-058.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:05:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="117" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Paromomycin (4 weeks)</GROUP_LABEL_1>
<GROUP_LABEL_2>Paromomycin (2 weeks)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Parom (2wks)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Parom (4wks)</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.804031657002271" CI_START="0.9913321172051969" EFFECT_SIZE="1.3373086861458954" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="43" LOG_CI_END="0.2562441542373923" LOG_CI_START="-0.0037808233091771773" LOG_EFFECT_SIZE="0.12623166546410758" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.15273995895525255" STUDY_ID="STD-Asilian-2003" TOTAL_1="117" TOTAL_2="116" VAR="0.023329495061652234" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-058.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:52:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="117" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>Paromomycin (4 weeks)</GROUP_LABEL_1>
<GROUP_LABEL_2>Paromomycin (2 weeks)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Parom (2wks)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Parom (4wks)</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1079040472187107" CI_START="1.0281528828072934" EFFECT_SIZE="1.4721574721574722" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="33" LOG_CI_END="0.32385083770185535" LOG_CI_START="0.012057697560910744" LOG_EFFECT_SIZE="0.16795426763138302" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="808" O_E="0.0" SE="0.18314883391972622" STUDY_ID="STD-Asilian-2003" TOTAL_1="117" TOTAL_2="116" VAR="0.03354349536615546" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-059" MODIFIED="2017-10-19 12:13:51 +0100" MODIFIED_BY="[Empty name]" NO="59">
<NAME>IL zinc 2% (twice a week for 2 weeks) versus ILSSG (100 mg/mL) for 2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-059.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 09:09:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="38" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulfate</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2311254166536278" CI_START="0.929283469708356" EFFECT_SIZE="1.069609507640068" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" LOG_CI_END="0.09030229743672455" LOG_CI_START="-0.03185178810376436" LOG_EFFECT_SIZE="0.029225254666480106" MODIFIED="2017-07-11 07:34:48 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.07175391451895867" STUDY_ID="STD-Sharquie-1997" TOTAL_1="38" TOTAL_2="35" VAR="0.005148624248794028" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-060" MODIFIED="2017-10-19 12:43:25 +0100" MODIFIED_BY="[Empty name]" NO="60">
<NAME>IL zinc 2% (twice a week for 2 weeks) versus IL 7% HSCS for 2 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-060.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 09:09:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="38" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILHSC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILHSC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulfate</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2951987506911051" CI_START="0.9590992249427143" EFFECT_SIZE="1.1145510835913313" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.11233641683841421" LOG_CI_START="-0.018136459966045453" LOG_EFFECT_SIZE="0.047099978436184374" MODIFIED="2017-07-11 07:35:06 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.07664041368609592" STUDY_ID="STD-Sharquie-1997" TOTAL_1="38" TOTAL_2="40" VAR="0.005873753009975918" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-061" MODIFIED="2017-10-19 12:43:16 +0100" MODIFIED_BY="[Empty name]" NO="61">
<NAME>ILSSG (100 mg/mL) for 2 weeks versus IL 7% HSCS for 2 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-061.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 09:10:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>ILHSC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILHSC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2430119364566936" CI_START="0.8735226055734496" EFFECT_SIZE="1.0420168067226891" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="34" LOG_CI_END="0.09447529912626676" LOG_CI_START="-0.058725851586858044" LOG_EFFECT_SIZE="0.01787472376970434" MODIFIED="2017-07-11 07:35:34 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.08999111428681617" STUDY_ID="STD-Sharquie-1997" TOTAL_1="35" TOTAL_2="40" VAR="0.008098400650582809" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-062" MODIFIED="2017-11-09 13:06:02 +0000" MODIFIED_BY="[Empty name]" NO="62">
<NAME>IL zinc 2% (weekly for up to 6 weeks) versus ILMA (max 2 mL weekly for up to 6 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-062.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 09:12:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulfate</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7807387902065612" CI_START="0.25300505966312986" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.10749424262307061" LOG_CI_START="-0.5968707935996543" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2017-07-11 07:45:35 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.2874622084966415" STUDY_ID="STD-Firooz-2005" TOTAL_1="53" TOTAL_2="53" VAR="0.0826345213137666" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-062.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 09:15:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cured</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulfate</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.130185332429045" CI_START="0.906617161056913" EFFECT_SIZE="1.3896987366375122" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" LOG_CI_END="0.3284173899879238" LOG_CI_START="-0.04257606458266601" LOG_EFFECT_SIZE="0.1429206627026289" MODIFIED="2017-07-11 07:51:53 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.2179233916619824" STUDY_ID="STD-Iraji-2004" TOTAL_1="49" TOTAL_2="55" VAR="0.04749060463346178" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-062.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:06:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="242" TOTAL_2="254" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulfate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-062.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-11 08:10:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<DICH_DATA CI_END="6.538245232528445" CI_START="1.033916557055447" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8154612058033185" LOG_CI_START="0.01448549013831748" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2017-07-11 07:56:48 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.4704971002753591" STUDY_ID="STD-Firooz-2005" TOTAL_1="36" TOTAL_2="36" VAR="0.22136752136752136" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-062.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-11 07:57:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Burning</NAME>
<DICH_DATA CI_END="130.82359964630137" CI_START="0.3745501586294664" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.116686094689066" LOG_CI_START="-0.42649001466055253" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2017-07-11 07:57:06 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.493874235556739" STUDY_ID="STD-Firooz-2005" TOTAL_1="36" TOTAL_2="36" VAR="2.231660231660231" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-062.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-11 07:57:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Itching</NAME>
<DICH_DATA CI_END="130.82359964630137" CI_START="0.3745501586294664" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.116686094689066" LOG_CI_START="-0.42649001466055253" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2017-07-11 07:57:18 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.493874235556739" STUDY_ID="STD-Firooz-2005" TOTAL_1="36" TOTAL_2="36" VAR="2.231660231660231" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-062.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-11 07:57:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Inflammation</NAME>
<DICH_DATA CI_END="2.1587847808217293" CI_START="0.3546555482518128" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.334209347679057" LOG_CI_START="-0.4501932416344306" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2017-07-11 07:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.4607619638181816" STUDY_ID="STD-Firooz-2005" TOTAL_1="36" TOTAL_2="36" VAR="0.21230158730158727" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-062.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 09:19:47 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Pruritus and erythema</NAME>
<DICH_DATA CI_END="148.08471422352545" CI_START="0.415070524478449" EFFECT_SIZE="7.84" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.170510231573283" LOG_CI_START="-0.3818781062044066" LOG_EFFECT_SIZE="0.8943160626844384" MODIFIED="2017-07-11 08:12:02 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="1.499285544136654" STUDY_ID="STD-Iraji-2004" TOTAL_1="49" TOTAL_2="55" VAR="2.2478571428571428" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-062.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-11-09 13:06:02 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Severe pain</NAME>
<DICH_DATA CI_END="113.87337110006591" CI_START="0.27539362097607945" EFFECT_SIZE="5.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0564221776665645" LOG_CI_START="-0.5600461236541637" LOG_EFFECT_SIZE="0.7481880270062004" MODIFIED="2017-07-11 08:12:25 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="1.53692643192277" STUDY_ID="STD-Iraji-2004" TOTAL_1="49" TOTAL_2="55" VAR="2.362142857142857" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-063" MODIFIED="2017-11-09 13:06:17 +0000" MODIFIED_BY="[Empty name]" NO="63">
<NAME>IL zinc 2% (twice a week for 2 weeks) versus ILMA (60 mg/kg/d for 2 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-063.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:34:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Zn Sulfate</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7942431624676507" CI_START="0.2185868501174315" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="-0.1000465152673886" LOG_CI_START="-0.6603759681558233" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Maleki-2012" TOTAL_1="24" TOTAL_2="10" VAR="0.10833333333333334" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-063.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:06:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Zinc Sulfate</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Zn Sulfate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-063.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-11-09 13:06:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Inflammation</NAME>
<DICH_DATA CI_END="54.7080385901726" CI_START="0.1734004772326837" EFFECT_SIZE="3.08" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.7380511445940543" LOG_CI_START="-0.7609497115931655" LOG_EFFECT_SIZE="0.4885507165004443" MODIFIED="2017-07-11 08:08:01 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="1.4679254731781157" STUDY_ID="STD-Maleki-2012" TOTAL_1="24" TOTAL_2="10" VAR="2.1548051948051947" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-064" MODIFIED="2017-11-09 13:06:48 +0000" MODIFIED_BY="[Empty name]" NO="64">
<NAME>Imiquimod (5% 3 times/week for 28 d) + IMMA (20 mg/kg/d for 14 d) versus vehicle + IMMA</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-064.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-20 16:20:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Imiquimod + IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Imiq+IM MA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6812708638887885" CI_START="0.7219132338317414" EFFECT_SIZE="1.1016949152542372" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.2256376867981112" LOG_CI_START="-0.14151499679668847" LOG_EFFECT_SIZE="0.04206134500071136" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="817" O_E="0.0" SE="0.21566730377868032" STUDY_ID="STD-Firooz-2006" TOTAL_1="59" TOTAL_2="60" VAR="0.04651238591916558" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-064.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-17 11:29:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Participants with treated lesions that recur</NAME>
<GROUP_LABEL_1>Imiquimod + IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Imiq+IM MA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.524468060000667" CI_START="0.04214707139221921" EFFECT_SIZE="0.3854166666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5470935791886671" LOG_CI_START="-1.375232597133814" LOG_EFFECT_SIZE="-0.4140695089725734" MODIFIED="2017-07-11 08:19:53 +0100" MODIFIED_BY="[Empty name]" ORDER="817" O_E="0.0" SE="1.129183911639865" STUDY_ID="STD-Firooz-2006" TOTAL_1="32" TOTAL_2="37" VAR="1.2750563063063063" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-064.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:41:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Imiquimod + IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Imiq+IM MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM MA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-064.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:29:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Itch and burning</NAME>
<DICH_DATA CI_END="134.84405287113384" CI_START="0.3755964268802131" EFFECT_SIZE="7.116666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1298317971945115" LOG_CI_START="-0.42527854791175157" LOG_EFFECT_SIZE="0.8522766246413802" MODIFIED="2017-07-12 13:11:24 +0100" MODIFIED_BY="[Empty name]" ORDER="817" O_E="0.0" SE="1.5008844647156117" STUDY_ID="STD-Firooz-2006" TOTAL_1="59" TOTAL_2="60" VAR="2.2526541764246684" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-065" MODIFIED="2017-10-19 12:43:51 +0100" MODIFIED_BY="[Empty name]" NO="65">
<NAME>IL 7% HSCS (0.2 mL to 7 mL per lesion) versus ILSSG (max 2 mL) max 5 injections</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="56" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-065.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:34:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="64" TOTAL_2="83" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Hypertonic Saline</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hypertonic Saline</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9622865589881529" CI_START="0.7946051652310379" EFFECT_SIZE="0.8744357438968218" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="83" LOG_CI_END="-0.01669558029550692" LOG_CI_START="-0.09984861619476801" LOG_EFFECT_SIZE="-0.05827209824513746" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.04884450490139208" STUDY_ID="STD-Ranawaka-2010" TOTAL_1="64" TOTAL_2="83" VAR="0.0023857856590621153" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-066" MODIFIED="2017-10-19 12:44:23 +0100" MODIFIED_BY="[Empty name]" NO="66">
<NAME>IL 5% HSCS (0.5 mL to 1 mL per lesion) versus ILMA (0.5 mL to 1 mL per lesion) weekly for 6 to 10 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-066.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-12 10:44:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>IL 5% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IL 5% HSCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5569882994643076" CI_START="0.3612743912035382" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.19228534892189053" LOG_CI_START="-0.44216282213849045" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2017-07-11 08:26:18 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.3726779962499649" STUDY_ID="STD-Sadeghian-2006b" TOTAL_1="36" TOTAL_2="36" VAR="0.13888888888888884" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-066.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:41:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>IL 5% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL 5% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-066.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-11 08:28:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Sporotrichotic dissemination</NAME>
<DICH_DATA CI_END="4.628229173269056" CI_START="0.2160653594631033" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6654148555134973" LOG_CI_START="-0.6654148555134973" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-07-11 08:28:34 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.7817359599705715" STUDY_ID="STD-Sadeghian-2006b" TOTAL_1="36" TOTAL_2="36" VAR="0.611111111111111" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-066.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-11 08:28:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="4.025049578857407" CI_START="0.009937765788056413" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6047712341924788" LOG_CI_START="-2.002711242864516" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2017-07-11 08:28:41 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="1.5316481142697058" STUDY_ID="STD-Sadeghian-2006b" TOTAL_1="36" TOTAL_2="36" VAR="2.3459459459459455" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-067" MODIFIED="2017-10-19 12:45:03 +0100" MODIFIED_BY="[Empty name]" NO="67">
<NAME>IL 7% HSCS (0.1 mL to 0.5 mL per lesion) versus IL 2% ciprofloxacin solution (0.1 mL to 0.5 mL per lesion)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-067.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:34:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>Hypertonic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Hypertonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ciprofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4423950178097087" CI_START="0.7929252428296818" EFFECT_SIZE="1.0694444444444444" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.15908421361625333" LOG_CI_START="-0.1007677561338265" LOG_EFFECT_SIZE="0.0291582287412134" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.15263833331919216" STUDY_ID="STD-Al-Hamdi-2010" TOTAL_1="27" TOTAL_2="21" VAR="0.023298460798460804" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-068" MODIFIED="2017-11-14 15:47:11 +0000" MODIFIED_BY="[Empty name]" NO="68">
<NAME>IL 15% HSCS (0.2 mL to 4 mL per lesion) maximum 5 injections versus IL 10% HSCS (0.2 mL to 4 mL per lesion)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="92" EVENTS_2="268" I2="0.0" I2_Q="0.0" ID="CMP-068.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:42:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="98" TOTAL_2="290" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>IL 15% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 10% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 15% HSCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0790479234058543" CI_START="0.9563330784005633" EFFECT_SIZE="1.0158391714894912" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="268" LOG_CI_END="0.033040733291374115" LOG_CI_START="-0.019390822244918893" LOG_EFFECT_SIZE="0.006824955523227629" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.030798555262404242" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="98" TOTAL_2="290" VAR="9.485510062513681E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-068.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:24:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="92" TOTAL_2="270" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>IL 15% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>15% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>10% HSCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.498202321764644" CI_START="0.7490691778835057" EFFECT_SIZE="2.9347826086956523" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="1.0606299462001019" LOG_CI_START="-0.12547807257323768" LOG_EFFECT_SIZE="0.46757593681343207" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.6967257215568441" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="92" TOTAL_2="270" VAR="0.485426731078905" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-068.03" MODIFIED="2017-11-14 15:47:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="8.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="290" TOTAL_2="98" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>IL 15% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 15% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10% HSCS</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.441202419359577" CI_START="-4.341202419359579" EFFECT_SIZE="-1.450000000000001" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="12.65" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="8.65" SD_2="13.71" SE="1.475130381050373" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="290" TOTAL_2="98" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-068.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:44:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="41.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="98" TOTAL_2="290" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>IL 15% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 15% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10% HSCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="9" I2="0.0" ID="CMP-068.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:30:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="290" WEIGHT="0.0" Z="0.0">
<NAME>Ulceration and necrosis</NAME>
<DICH_DATA CI_END="20.039612124334045" CI_START="4.8552547707328495" EFFECT_SIZE="9.863945578231293" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="9" LOG_CI_END="1.301889311312393" LOG_CI_START="0.6862120236612047" LOG_EFFECT_SIZE="0.9940506674867988" MODIFIED="2017-07-11 08:34:21 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.36165188641803375" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="98" TOTAL_2="290" VAR="0.13079208694972239" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-069" MODIFIED="2017-11-14 15:30:29 +0000" MODIFIED_BY="[Empty name]" NO="69">
<NAME>ILSSG (0.2 mL to 4 mL per lesion) max 5 injections versus IL 10% HSCS (0.2 mL to 4 mL per lesion)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="226" EVENTS_2="268" I2="0.0" I2_Q="0.0" ID="CMP-069.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:44:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="235" TOTAL_2="290" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 10% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0849534900348405" CI_START="0.9981514461334987" EFFECT_SIZE="1.040647824706256" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="268" LOG_CI_END="0.03541112117610263" LOG_CI_START="-8.035596844387504E-4" LOG_EFFECT_SIZE="0.017303780745831953" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.021272682803043463" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="235" TOTAL_2="290" VAR="4.52527033638901E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-069.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:24:57 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="226" TOTAL_2="270" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10% HSCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.96175013981765" CI_START="0.20264976053345235" EFFECT_SIZE="0.8960176991150443" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5978870819243296" LOG_CI_START="-0.6932539051177566" LOG_EFFECT_SIZE="-0.047683411596713556" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.758422607039484" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="226" TOTAL_2="270" VAR="0.5752048508685677" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-069.03" MODIFIED="2017-11-14 15:30:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="16.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="235" TOTAL_2="290" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10% HSCS</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.087126071285308" CI_START="-6.312873928714691" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="11.2" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="3.89" SD_2="8.65" SE="0.5678032542908434" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="235" TOTAL_2="290" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-069.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:47:09 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="130.0894472369696" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="235" TOTAL_2="290" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 10% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10% HSCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="9" I2="0.0" ID="CMP-069.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 13:47:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="235" TOTAL_2="290" WEIGHT="0.0" Z="0.0">
<NAME>Ulceration and necrosis</NAME>
<DICH_DATA CI_END="1.109244910101885" CI_START="0.0037968839693228013" EFFECT_SIZE="0.06489741302408564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="0.045027444582880216" LOG_CI_START="-2.420572674456937" LOG_EFFECT_SIZE="-1.1877726149370282" MODIFIED="2017-07-11 08:35:48 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.448305714841416" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="235" TOTAL_2="290" VAR="2.097589443642305" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-070" MODIFIED="2017-11-14 15:30:36 +0000" MODIFIED_BY="[Empty name]" NO="70">
<NAME>ILSSG (0.2 mL to 4 mL per lesion) maximum 5 injections versus IL 15% HSCS (0.2 mL to 4 mL per lesion)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="226" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-070.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:47:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="235" TOTAL_2="98" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 15% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 15% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.084113170114689" CI_START="0.9680171019638555" EFFECT_SIZE="1.0244218316373728" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="92" LOG_CI_END="0.03507462038586144" LOG_CI_START="-0.014116969940653043" LOG_EFFECT_SIZE="0.010478825222604222" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.028895383660093893" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="235" TOTAL_2="98" VAR="8.349431968640211E-4" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-070.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:25:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="226" TOTAL_2="92" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 15% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 15% HSCS</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.127466516141682" CI_START="0.04381457159552227" EFFECT_SIZE="0.3053097345132743" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3278627335183948" LOG_CI_START="-1.358381430338686" LOG_EFFECT_SIZE="-0.5152593484101456" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.753683613563994" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="226" TOTAL_2="92" VAR="0.56803898935488" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-070.03" MODIFIED="2017-11-14 15:30:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="16.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="235" TOTAL_2="98" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>ILSSG</GROUP_LABEL_1>
<GROUP_LABEL_2>IL 15% HSCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 15% HSCS</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.890420171947051" CI_START="-9.40957982805295" EFFECT_SIZE="-6.65" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="12.65" MODIFIED="2016-07-12 07:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="3.89" SD_2="13.71" SE="1.4079747637304372" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="235" TOTAL_2="98" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-070.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:49:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="410.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="98" TOTAL_2="235" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>IL 15% HSCS</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL 15% HSCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="0" I2="0.0" ID="CMP-070.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 09:42:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="235" WEIGHT="0.0" Z="0.0">
<NAME>Ulceration and necrosis</NAME>
<DICH_DATA CI_END="2354.651719713063" CI_START="8.980212379684183" EFFECT_SIZE="145.41414141414143" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="0" LOG_CI_END="3.3719266790264886" LOG_CI_START="0.9532866077401584" LOG_EFFECT_SIZE="2.1626066433833238" MODIFIED="2017-07-11 08:37:30 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4207211503350325" STUDY_ID="STD-Ranawaka-2015" TOTAL_1="98" TOTAL_2="235" VAR="2.0184485870092983" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-071" MODIFIED="2017-11-15 14:52:49 +0000" MODIFIED_BY="[Empty name]" NO="71">
<NAME>IL IFN-&#947; (weekly for 5 weeks) versus ILMA (0.5 mL to 1 mL per lesion) weekly for 5 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-071.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-12 10:43:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>IL IFN -&#947;</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IL IFN -&#947;</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.28380702855240136" CI_START="0.005791031447326375" EFFECT_SIZE="0.04054054054054054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="26" LOG_CI_END="-0.5469768533333514" LOG_CI_START="-2.2372440766892763" LOG_EFFECT_SIZE="-1.3921104650113136" MODIFIED="2017-07-11 08:47:43 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="0.9928713339569664" STUDY_ID="STD-Harms-1991" TOTAL_1="37" TOTAL_2="39" VAR="0.9857934857934859" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-071.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:52:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>IL IFN -&#947;</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IL IFN -&#947;</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8291951700027189" CI_START="0.5144177752472537" EFFECT_SIZE="0.65311004784689" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="-0.0813432363023399" LOG_CI_START="-0.28868403316621827" LOG_EFFECT_SIZE="-0.18501363473427915" MODIFIED="2017-07-11 08:49:43 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="0.12179301043133949" STUDY_ID="STD-Harms-1991" TOTAL_1="37" TOTAL_2="38" VAR="0.014833537389928368" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-072" MODIFIED="2017-11-09 13:09:05 +0000" MODIFIED_BY="[Empty name]" NO="72">
<NAME>WR279,396 (twice a day for 20 d) versus vehicle (twice a day for 20 d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="43" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-072.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:09:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>WR279,396</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WR279,396</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7205509567756043" CI_START="1.0401606390489817" EFFECT_SIZE="1.3377777777777777" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="27" LOG_CI_END="0.2356675394496816" LOG_CI_START="0.017100415515280173" LOG_EFFECT_SIZE="0.12638397748248087" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.12838741052377992" STUDY_ID="STD-Ben-Salah-2009" TOTAL_1="50" TOTAL_2="42" VAR="0.016483327181001595" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-072.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:09:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="150" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>WR279,396</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WR279,396</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-072.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:34:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Erythema</NAME>
<DICH_DATA CI_END="2.5045231806888184" CI_START="0.6338931147618136" EFFECT_SIZE="1.26" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.3987250556696344" LOG_CI_START="-0.19798396543450866" LOG_EFFECT_SIZE="0.10037054511756291" MODIFIED="2017-07-12 10:38:11 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.35050983275386566" STUDY_ID="STD-Ben-Salah-2009" TOTAL_1="50" TOTAL_2="42" VAR="0.12285714285714289" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-072.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:34:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Mild pain</NAME>
<DICH_DATA CI_END="2.6915288195263893" CI_START="0.35682322739126204" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.42999903438179155" LOG_CI_START="-0.44754688299680184" LOG_EFFECT_SIZE="-0.00877392430750515" MODIFIED="2017-07-12 10:38:19 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.5154748157905347" STUDY_ID="STD-Ben-Salah-2009" TOTAL_1="50" TOTAL_2="42" VAR="0.2657142857142857" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-072.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:34:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Hearing acuity problems</NAME>
<DICH_DATA CI_END="2.7114873029071633" CI_START="0.6296831174341794" EFFECT_SIZE="1.3066666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.43320757510366414" LOG_CI_START="-0.20087795050207458" LOG_EFFECT_SIZE="0.1161648123007948" MODIFIED="2017-07-12 10:38:24 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.37246497651478416" STUDY_ID="STD-Ben-Salah-2009" TOTAL_1="50" TOTAL_2="42" VAR="0.13873015873015873" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-073" MODIFIED="2017-10-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" NO="73">
<NAME>IL metronidazole (2.5 mg to 10 mg each lesion) versus ILMA (150 mg to 600 mg each lesion) for up to 8 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-073.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:36:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>IL metronidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>IL metronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6741174675387331" CI_START="0.0789987508620115" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.17126441940118858" LOG_CI_START="-1.10237977577316" LOG_EFFECT_SIZE="-0.6368220975871743" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.5469417694282446" STUDY_ID="STD-Mapar-2010" TOTAL_1="18" TOTAL_2="18" VAR="0.2991452991452991" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-073.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:55:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>IL metronidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL metronidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-073.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:35:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Local inflammatory reactions</NAME>
<DICH_DATA CI_END="3.894602970670363" CI_START="0.010270623296195696" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5904631907799177" LOG_CI_START="-1.9884031994519553" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2017-07-12 10:42:23 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="1.5148388832167146" STUDY_ID="STD-Mapar-2010" TOTAL_1="18" TOTAL_2="18" VAR="2.2947368421052627" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-074" MODIFIED="2017-11-09 13:09:32 +0000" MODIFIED_BY="[Empty name]" NO="74">
<NAME>Topical miltefosine 6% (once daily) versus ILMA (twice a week) for up to 28 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-074.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:09:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Miltefosine</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucantime (ILMA)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Miltefosine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3866444352930936" CI_START="1.106417428985695" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="16" LOG_CI_END="0.3777877221938487" LOG_CI_START="0.04391900843593772" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.19611613513818404" STUDY_ID="STD-Asilian-2014" TOTAL_1="32" TOTAL_2="32" VAR="0.038461538461538464" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-075" MODIFIED="2017-11-10 10:06:15 +0000" MODIFIED_BY="[Empty name]" NO="75">
<NAME>Dapsone gel 5% (twice a day) + ILMA (weekly) versus cryotherapy (every 2 weeks) + IMMA (weekly) for up to 16 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-075.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:56:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Dapsone gel +IMMA</GROUP_LABEL_1>
<GROUP_LABEL_2>CryoT + IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryot + IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dapsone + IMMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1595433278782643" CI_START="0.7850769730018691" EFFECT_SIZE="0.9541125541125541" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" LOG_CI_END="0.06428698126799165" LOG_CI_START="-0.10508776069278537" LOG_EFFECT_SIZE="-0.020400389712396858" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.09949156184625499" STUDY_ID="STD-Fekri-2015" TOTAL_1="35" TOTAL_2="38" VAR="0.009898570878607182" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-076" MODIFIED="2017-10-19 12:50:13 +0100" MODIFIED_BY="[Empty name]" NO="76">
<NAME>DAC-055 + MWT (for 15 min) versus DAC-055 alone for up to 75 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-076.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:56:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>DAC-055 + Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>DAC-055 alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAC-055 alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAC-055 + Heat</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3659960009905125" CI_START="0.9620077582882557" EFFECT_SIZE="1.146341463414634" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.13544942793241296" LOG_CI_START="-0.016821425500449072" LOG_EFFECT_SIZE="0.05931400121598193" MODIFIED="2017-07-14 12:43:45 +0100" MODIFIED_BY="[Empty name]" ORDER="830" O_E="0.0" SE="0.089444653059344" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="0.008000345960906416" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-076.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:56:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="12.022909119827393" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>DAC-055 + Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>DAC-055 alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>DAC-055 + Heat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>DAC-055 alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-076.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 12:45:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Reulceration</NAME>
<DICH_DATA CI_END="5.304499254107467" CI_START="0.3351452592629133" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7246443926780186" LOG_CI_START="-0.47476691946141886" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2017-07-14 12:45:53 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="0.7045401419324543" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="0.4963768115942029" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-076.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 12:50:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Keloïd scars</NAME>
<DICH_DATA CI_END="98.75289399148167" CI_START="0.25315713787746275" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9945498316515593" LOG_CI_START="-0.596609822979522" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2017-07-14 12:50:25 +0100" MODIFIED_BY="[Empty name]" ORDER="831" O_E="0.0" SE="1.52206000757745" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="2.316666666666667" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-077" MODIFIED="2017-10-19 12:50:05 +0100" MODIFIED_BY="[Empty name]" NO="77">
<NAME>DAC-055 + heat (for 15 min) versus ILSSG (0.6 mL) for up to 75 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-077.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-14 13:14:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>DAC-055 + Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>DAC-055 + Heat</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0505786321718027" CI_START="1.120974931851913" EFFECT_SIZE="1.5161290322580645" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.31187642754379186" LOG_CI_START="0.049595900659097816" LOG_EFFECT_SIZE="0.18073616410144477" MODIFIED="2017-07-14 12:46:19 +0100" MODIFIED_BY="[Empty name]" ORDER="832" O_E="0.0" SE="0.1540648798016162" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="0.02373598718828645" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-077.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>DAC-055 + Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAC-055 + Heat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-077.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 12:49:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Reulceration</NAME>
<DICH_DATA CI_END="1.689456106918272" CI_START="0.19327558195076205" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2277469130266808" LOG_CI_START="-0.7138230103992698" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2017-07-14 12:49:33 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.5530828338666934" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="0.3059006211180124" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-077.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 12:49:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Keloïd scars</NAME>
<DICH_DATA CI_END="98.75289399148167" CI_START="0.25315713787746275" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9945498316515593" LOG_CI_START="-0.596609822979522" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2017-07-14 12:49:53 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="1.52206000757745" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="2.316666666666667" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-078" MODIFIED="2017-10-19 12:50:32 +0100" MODIFIED_BY="[Empty name]" NO="78">
<NAME>DAC-055 alone (for 15 min) versus ILSSG (0.6 mL) for up to 75 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-078.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:57:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>DAC-055 alone</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAC-055 Alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8692061701458456" CI_START="0.9510870476310624" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.27165720593662757" LOG_CI_START="-0.021779732720027725" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2017-07-14 12:51:14 +0100" MODIFIED_BY="[Empty name]" ORDER="838" O_E="0.0" SE="0.17236631030319188" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="0.029710144927536236" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-078.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:58:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="43.10153720355221" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="46" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>DAC-055 alone</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DAC-055 Alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-078.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 12:48:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Reulceration</NAME>
<DICH_DATA CI_END="1.4557140923687122" CI_START="0.1261741370442357" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.16307608630988804" LOG_CI_START="-0.8990296568990769" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2017-07-14 12:47:48 +0100" MODIFIED_BY="[Empty name]" ORDER="834" O_E="0.0" SE="0.6238861710691669" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="0.3892339544513458" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-078.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-14 12:49:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Keloïd scars</NAME>
<DICH_DATA CI_END="98.75289399148167" CI_START="0.25315713787746275" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9945498316515593" LOG_CI_START="-0.596609822979522" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2017-07-14 12:49:13 +0100" MODIFIED_BY="[Empty name]" ORDER="835" O_E="0.0" SE="1.52206000757745" STUDY_ID="STD-Stahl-2014" TOTAL_1="23" TOTAL_2="23" VAR="2.316666666666667" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-079" MODIFIED="2017-11-09 14:58:30 +0000" MODIFIED_BY="[Empty name]" NO="79">
<NAME>Thio-Ben (1 mL to 2 mL daily) + cryotherapy (fortnightly) versus ILMA (0.5 mL to 2 mL per lesions) weekly + cryotherapy (fortnightly) for up to 12 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-079.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:37:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Thio Ben+ Cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryo+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Thio Ben+Cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.177785032773121" CI_START="0.829035149061635" EFFECT_SIZE="0.9881422924901185" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.07106603102852607" LOG_CI_START="-0.08142705603608671" LOG_EFFECT_SIZE="-0.005180512503780329" MODIFIED="2016-07-12 09:10:51 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.08957519419470863" STUDY_ID="STD-Daie-Parizi-2015" TOTAL_1="22" TOTAL_2="25" VAR="0.008023715415019762" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-079.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:10:30 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>Thio Ben+ Cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryo+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Thio Ben+Cryo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.040436923893542" CI_START="0.3800526589037173" EFFECT_SIZE="1.5151515151515151" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.781068353649786" LOG_CI_START="-0.42015622473352343" LOG_EFFECT_SIZE="0.1804560644581313" MODIFIED="2017-07-12 10:46:59 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.7056052634999174" STUDY_ID="STD-Daie-Parizi-2015" TOTAL_1="22" TOTAL_2="25" VAR="0.49787878787878787" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-079.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 13:59:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Thio Ben+ Cryo</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Thio Ben+Cryo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryo+ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-079.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:37:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Dizziness and nausea</NAME>
<DICH_DATA CI_END="2.963234205692798" CI_START="0.008800938083101919" EFFECT_SIZE="0.16149068322981366" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4717659782503187" LOG_CI_START="-2.0554710343723825" LOG_EFFECT_SIZE="-0.7918525280610318" MODIFIED="2017-07-12 10:50:48 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.484511531239546" STUDY_ID="STD-Daie-Parizi-2015" TOTAL_1="22" TOTAL_2="25" VAR="2.203774486383182" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-079.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:37:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Hypersensitive reaction</NAME>
<DICH_DATA CI_END="8.802545501889" CI_START="0.01613021795743741" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9446082786917515" LOG_CI_START="-1.7923597642246263" LOG_EFFECT_SIZE="-0.42387574276643736" MODIFIED="2017-07-12 10:50:52 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Daie-Parizi-2015" TOTAL_1="22" TOTAL_2="25" VAR="2.584726867335563" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-080" MODIFIED="2017-10-23 09:55:01 +0100" MODIFIED_BY="[Empty name]" NO="80">
<NAME>CO&#8322; laser (30 W continuous) versus IMMA (50 mg/kg/d) for up to 15 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5514730538763497" CI_START="0.5346272397056094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9107468123861566" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-080.01" LOG_CI_END="0.19074423712003313" LOG_CI_START="-0.2719489173481794" LOG_EFFECT_SIZE="-0.04060234011407311" METHOD="MH" MODIFIED="2017-07-09 00:02:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7308596090722828" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="183" TOTAL_2="250" WEIGHT="100.0" Z="0.3439822852062377">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>CO2</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CO2</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5514730538763497" CI_START="0.5346272397056094" EFFECT_SIZE="0.9107468123861566" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" LOG_CI_END="0.19074423712003313" LOG_CI_START="-0.2719489173481794" LOG_EFFECT_SIZE="-0.04060234011407311" MODIFIED="2017-07-09 00:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.2717882493026812" STUDY_ID="STD-Asilian-2004b" TOTAL_1="183" TOTAL_2="250" VAR="0.0738688524590164" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-080.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:00:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="549" TOTAL_2="750" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>CO2</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CO2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-080.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 10:08:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Hyperpigmentation and redness</NAME>
<DICH_DATA CI_END="226.62238099589342" CI_START="0.6651108272216351" EFFECT_SIZE="12.277173913043478" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.355302798126824" LOG_CI_START="-0.1771059823051712" LOG_EFFECT_SIZE="1.0890984079108266" MODIFIED="2017-07-12 13:21:30 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="1.487549453251389" STUDY_ID="STD-Asilian-2004b" TOTAL_1="183" TOTAL_2="250" VAR="2.2128033758685066" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-080.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 10:08:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Hypertrophic scarring</NAME>
<DICH_DATA CI_END="269.67443160547793" CI_START="0.8349440904524713" EFFECT_SIZE="15.005434782608695" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.4308397720404247" LOG_CI_START="-0.07834260478097121" LOG_EFFECT_SIZE="1.1762485836297267" MODIFIED="2017-07-12 13:21:50 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="1.4739061487979708" STUDY_ID="STD-Asilian-2004b" TOTAL_1="183" TOTAL_2="250" VAR="2.172399335464466" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="22" I2="0.0" ID="CMP-080.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 10:09:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="250" WEIGHT="0.0" Z="0.0">
<NAME>Systemic symptoms</NAME>
<DICH_DATA CI_END="0.4964999245406092" CI_START="0.0018508344842713257" EFFECT_SIZE="0.03031400966183575" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="22" LOG_CI_END="-0.30408081317383573" LOG_CI_START="-2.7326324174338485" LOG_EFFECT_SIZE="-1.518356615303842" MODIFIED="2017-07-12 13:21:55 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="1.426543233866653" STUDY_ID="STD-Asilian-2004b" TOTAL_1="183" TOTAL_2="250" VAR="2.0350255980907286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-081" MODIFIED="2017-11-13 10:42:41 +0000" MODIFIED_BY="[Empty name]" NO="81">
<NAME>CO&#8322; laser (30 W continuous) versus cryotherapy (fortnightly) + ILMA (weekly) for up to 12 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="90" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-081.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 10:42:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="95" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>CO2</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryo+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CO2</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.367363023301536" CI_START="1.0817770112107934" EFFECT_SIZE="1.2162162162162162" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="74" LOG_CI_END="0.13588383138292118" LOG_CI_START="0.034137748033776186" LOG_EFFECT_SIZE="0.08501078970834869" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.0597661530105231" STUDY_ID="STD-Shamsi-Meymandi-2011" TOTAL_1="95" TOTAL_2="95" VAR="0.0035719930456772596" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-081.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 10:42:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="285" TOTAL_2="285" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>CO2</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CO2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryo+ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="15" I2="0.0" ID="CMP-081.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:38:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Hyperpigmentation</NAME>
<DICH_DATA CI_END="2.4442362761471017" CI_START="0.7273346669169497" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.38814318539501885" LOG_CI_START="-0.13826571217841893" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2017-07-08 01:19:16 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.3092151922007056" STUDY_ID="STD-Shamsi-Meymandi-2011" TOTAL_1="95" TOTAL_2="95" VAR="0.09561403508771929" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="15" I2="0.0" ID="CMP-081.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-11-09 13:10:57 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Atrophic scar</NAME>
<DICH_DATA CI_END="1.0928012481032072" CI_START="0.19928397607138368" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.03854118235139055" LOG_CI_START="-0.7005276204342394" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2017-07-08 01:19:26 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.4341326732058555" STUDY_ID="STD-Shamsi-Meymandi-2011" TOTAL_1="95" TOTAL_2="95" VAR="0.18847117794486212" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-081.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:38:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Hypopigmentation</NAME>
<DICH_DATA CI_END="164.88338459455917" CI_START="0.4912562912216742" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2171768937132588" LOG_CI_START="-0.30869187483460875" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2017-07-08 01:19:31 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="1.4837078178970715" STUDY_ID="STD-Shamsi-Meymandi-2011" TOTAL_1="95" TOTAL_2="95" VAR="2.2013888888888893" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-082" MODIFIED="2017-11-10 12:43:26 +0000" MODIFIED_BY="[Empty name]" NO="82">
<NAME>Ablative CO&#8322; laser (25 kW for 1 session) versus 3 weeks fractional CO&#8322; laser</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-082.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:01:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Partcipants complete cure</NAME>
<GROUP_LABEL_1>Ablative CO2</GROUP_LABEL_1>
<GROUP_LABEL_2>Fractional CO2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fractional CO2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ablative CO2</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8252722850563651" CI_START="0.4489553371468424" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="46" LOG_CI_END="-0.0834027394649826" LOG_CI_START="-0.34779686121372705" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.15530641588722274" STUDY_ID="STD-Nilforoushzadeh-2014a" TOTAL_1="60" TOTAL_2="60" VAR="0.02412008281573499" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-082.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 12:43:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Ablative CO2</GROUP_LABEL_1>
<GROUP_LABEL_2>Fractional CO2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ablative CO2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fractional CO2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-082.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-11-10 12:43:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Erythema</NAME>
<DICH_DATA CI_END="2.6276323925290224" CI_START="0.09514268461250855" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41956460705852205" LOG_CI_START="-1.0216245983864845" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2017-07-08 01:22:51 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.8465616732800195" STUDY_ID="STD-Nilforoushzadeh-2014a" TOTAL_1="60" TOTAL_2="60" VAR="0.7166666666666666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-083" MODIFIED="2017-11-14 15:31:04 +0000" MODIFIED_BY="[Empty name]" NO="83">
<NAME>TCA (50% wt/vol) fortnightly up to 3 times versus ILMA alone (weekly for up to 6 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-083.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:13:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>TCA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6046110452389395" CI_START="0.7963816536868484" EFFECT_SIZE="1.1304347826086956" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="23" LOG_CI_END="0.20536977731544365" LOG_CI_START="-0.09887875340899348" LOG_EFFECT_SIZE="0.05324551195322505" MODIFIED="2017-07-08 01:35:11 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.1787170930020508" STUDY_ID="STD-Nilforoushzadeh-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.03193979933110368" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-083.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 10:39:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>TCA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.317746471024236" CI_START="0.36187858886243285" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6352571378898941" LOG_CI_START="-0.4414371118737813" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2017-07-08 01:36:18 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Nilforoushzadeh-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.39999999999999997" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-083.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 10:39:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>TCA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TCA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour sILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-083.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-08 01:46:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Mild erythema and itch</NAME>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2017-07-08 01:46:17 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Nilforoushzadeh-2006" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2557191445999822" CI_START="0.7441508305920732" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-083.04" LOG_CI_END="0.09889251552392295" LOG_CI_START="-0.12833902916533563" LOG_EFFECT_SIZE="-0.014723256820706347" METHOD="MH" MODIFIED="2017-11-14 15:31:04 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7995047588901898" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.253988090810019">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>TCA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2557191445999822" CI_START="0.7441508305920732" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="30" LOG_CI_END="0.09889251552392295" LOG_CI_START="-0.12833902916533563" LOG_EFFECT_SIZE="-0.014723256820706347" MODIFIED="2017-11-13 16:22:48 +0000" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Nilforoushzadeh-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-084" MODIFIED="2017-11-10 10:47:43 +0000" MODIFIED_BY="[Empty name]" NO="84">
<NAME>Topical TCA 50% + local heat versus ILMA twice a week for up to 8 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-084.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 10:47:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>TCA+Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA+Heat</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9744133176862869" CI_START="0.4561149117909877" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="-0.011256788998821744" LOG_CI_START="-0.34092572911254077" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.19364916731037085" STUDY_ID="STD-Nilforoushzadeh-2012" TOTAL_1="30" TOTAL_2="30" VAR="0.0375" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-084.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:11:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>TCA+Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA+Heat</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-084.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-12-23 08:56:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Males</NAME>
<DICH_DATA CI_END="1.7744056755351945" CI_START="0.26198971264991905" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.24905291792234974" LOG_CI_START="-0.5817157614553998" LOG_EFFECT_SIZE="-0.16633142176652502" MODIFIED="2016-12-23 08:56:32 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.3713203305486893" STUDY_ID="STD-Nilforoushzadeh-2012" TOTAL_1="22" TOTAL_2="15" VAR="0.13787878787878788" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="16" I2="0.0" ID="CMP-084.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-11-09 13:11:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Females</NAME>
<DICH_DATA CI_END="1.4996164957298772" CI_START="0.3444891170315949" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.17598020900015232" LOG_CI_START="-0.46282449360477856" LOG_EFFECT_SIZE="-0.1434221423023131" MODIFIED="2016-12-23 08:56:32 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.2855201203600804" STUDY_ID="STD-Nilforoushzadeh-2012" TOTAL_1="16" TOTAL_2="23" VAR="0.08152173913043478" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-085" MODIFIED="2017-11-14 15:31:17 +0000" MODIFIED_BY="[Empty name]" NO="85">
<NAME>TCA + ILMA (weekly for up to 8 weeks) versus ILMA alone (twice a week for up to 8 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-085.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:04:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>TCA+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8604186273174794" CI_START="1.4183953940261849" EFFECT_SIZE="2.34" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" LOG_CI_END="0.5866344025152553" LOG_CI_START="0.15179731230503032" LOG_EFFECT_SIZE="0.3692158574101428" MODIFIED="2016-07-12 09:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.2554254592677974" STUDY_ID="STD-Nilforoushzadeh-2013" TOTAL_1="30" TOTAL_2="26" VAR="0.06524216524216525" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-085.02" MODIFIED="2017-11-14 15:31:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="9.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>TCA+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TCA+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8549888926208942" CI_START="-2.345011107379105" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="6.8" MODIFIED="2016-07-12 09:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="1.0" SD_2="1.7" SE="0.38011469254315794" STUDY_ID="STD-Nilforoushzadeh-2013" TOTAL_1="30" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-086" MODIFIED="2017-10-19 13:09:04 +0100" MODIFIED_BY="[Empty name]" NO="86">
<NAME>Fractional laser + ILMA (fortnightly 2 sessions) versus ILMA alone (twice a week for up to 8 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-086.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:05:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Fracional+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>ILMA alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fractional Laser+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.769987806769624" CI_START="1.355848202412669" EFFECT_SIZE="2.260869565217391" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5763399455741662" LOG_CI_START="0.13221106966024626" LOG_EFFECT_SIZE="0.3542755076172062" MODIFIED="2016-07-12 09:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.26088350018522893" STUDY_ID="STD-Nilforoushzadeh-2013" TOTAL_1="23" TOTAL_2="26" VAR="0.06806020066889634" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-087" MODIFIED="2017-11-14 15:31:25 +0000" MODIFIED_BY="[Empty name]" NO="87">
<NAME>TCA + ILMA (weekly for up to 8 weeks) versus fractional laser + ILMA (fortnightly 2 sessions)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-087.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:05:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>TCA+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Laser-ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2618700798431175" CI_START="0.848918614611403" EFFECT_SIZE="1.035" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="20" LOG_CI_END="0.10101464293365807" LOG_CI_START="-0.07113394334778501" LOG_EFFECT_SIZE="0.014940349792936524" MODIFIED="2016-07-12 09:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.10112093173096502" STUDY_ID="STD-Nilforoushzadeh-2013" TOTAL_1="30" TOTAL_2="23" VAR="0.010225442834138489" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-087.02" MODIFIED="2017-11-14 15:31:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>TCA+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser+ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TCA+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Laser+ILMA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.17719542979489078" CI_START="-2.37719542979489" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="6.3" MODIFIED="2016-07-12 09:16:21 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="1.0" SD_2="3.0" SE="0.6516422954040202" STUDY_ID="STD-Nilforoushzadeh-2013" TOTAL_1="30" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-088" MODIFIED="2017-11-13 11:14:35 +0000" MODIFIED_BY="[Empty name]" NO="88">
<NAME>TCA fortnightly up to 8 weeks + ILMA (twice a week) versus ILMA alone (weekly for up to 8 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="78" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-088.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 11:14:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="91" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>TCA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TCA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2213182395574296" CI_START="0.9399345285217853" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="76" LOG_CI_END="0.08682884304026707" LOG_CI_START="-0.026902396285380645" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2017-11-13 11:14:35 +0000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.06680629295859972" STUDY_ID="STD-Nilforoushzadeh-2014b" TOTAL_1="91" TOTAL_2="95" VAR="0.004463080778870251" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-089" MODIFIED="2017-11-09 13:28:31 +0000" MODIFIED_BY="[Empty name]" NO="89">
<NAME>Cryotherapy + ILMA (weekly) versus cryotherapy (weekly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-089.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:06:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Cryotherapy + ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7740670761874286" CI_START="0.9317918395973612" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.24897003616501587" LOG_CI_START="-0.030681097314879727" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2017-07-08 01:10:30 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.16426846010152701" STUDY_ID="STD-Salmanpour-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.02698412698412697" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-089.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:06:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryotherapy + ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-089.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:42:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Erythema and oedema</NAME>
<DICH_DATA CI_END="2.8613687729925816" CI_START="0.47568531674705605" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.45657383325260914" LOG_CI_START="-0.32268025399138267" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2017-07-08 22:34:14 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.4577377082170635" STUDY_ID="STD-Salmanpour-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.20952380952380956" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-090" MODIFIED="2017-11-09 13:28:46 +0000" MODIFIED_BY="[Empty name]" NO="90">
<NAME>Cryotherapy + ILMA (weekly) versus ILMA (weekly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-090.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:26:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Cryotherapy+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.607203539809762" CI_START="0.8959661700163047" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.206070880259701" LOG_CI_START="-0.04770838816445134" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2017-07-08 01:08:36 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.14907119849998596" STUDY_ID="STD-Salmanpour-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.022222222222222213" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-090.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:07:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryotherapy+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-090.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:42:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Erythema and oedema</NAME>
<DICH_DATA CI_END="5.054481752734225" CI_START="0.6058979238263821" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7036766330296992" LOG_CI_START="-0.21760053565711035" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2017-07-08 22:34:06 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.541162769282166" STUDY_ID="STD-Salmanpour-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.29285714285714287" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-091" MODIFIED="2017-11-14 15:33:21 +0000" MODIFIED_BY="[Empty name]" NO="91">
<NAME>Cryotherapy + ILMA (weekly) versus ILMA alone (weekly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-091.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:26:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3682778805245681" CI_START="0.636647806348478" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.1361743062460132" LOG_CI_START="-0.19610075300089963" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2017-07-08 01:11:38 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Salmanpour-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.0380952380952381" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-091.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:07:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-091.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:45:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Erythema and oedema</NAME>
<DICH_DATA CI_END="4.5194868175771" CI_START="0.49784413381832293" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6550891239823025" LOG_CI_START="-0.3029066058709399" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2017-07-08 22:34:31 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Salmanpour-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-092" MODIFIED="2017-11-14 15:33:34 +0000" MODIFIED_BY="[Empty name]" NO="92">
<NAME>Cryotherapy (weekly) versus ILMA (weekly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-092.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:37:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8061910206289102" CI_START="1.1586386432258782" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.5804905803575443" LOG_CI_START="0.06394800911029437" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.30341966327759984" STUDY_ID="STD-Layegh-2009" TOTAL_1="36" TOTAL_2="36" VAR="0.09206349206349207" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-093" MODIFIED="2017-11-09 13:29:12 +0000" MODIFIED_BY="[Empty name]" NO="93">
<NAME>Cryotherapy + ILMA (weekly) versus cryotherapy alone (weekly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="120" EVENTS_2="120" I2="0.0" I2_Q="0.0" ID="CMP-093.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:28:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="149" TOTAL_2="230" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Cryotherapy+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.78764759112717" CI_START="1.3329112306461106" EFFECT_SIZE="1.5436241610738255" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="120" LOG_CI_END="0.25228190802053996" LOG_CI_START="0.1248012271900977" LOG_EFFECT_SIZE="0.18854156760531884" MODIFIED="2017-07-08 22:59:51 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.07488278295934914" STUDY_ID="STD-Asilian-2004a" TOTAL_1="149" TOTAL_2="230" VAR="0.0056074311837369896" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-093.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:08:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100" TOTAL_2="230" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryotherapy+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-093.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-08 23:03:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="230" WEIGHT="0.0" Z="0.0">
<NAME>Hypopigmentation</NAME>
<DICH_DATA CI_END="3.278194714560689" CI_START="0.40342326040789434" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.5156347457408258" LOG_CI_START="-0.3942390650336025" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2017-07-08 23:03:07 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.5344643803969013" STUDY_ID="STD-Asilian-2004a" TOTAL_1="100" TOTAL_2="230" VAR="0.28565217391304354" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-094" MODIFIED="2017-11-09 13:29:36 +0000" MODIFIED_BY="[Empty name]" NO="94">
<NAME>Cryotherapy + ILMA (weekly) versus ILMA (fortnightly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="120" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-094.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:28:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="149" TOTAL_2="160" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Cryotherapy+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8132017883714584" CI_START="1.297852116617265" EFFECT_SIZE="1.5340364333652925" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="84" LOG_CI_END="0.25844613873403216" LOG_CI_START="0.11322520972475571" LOG_EFFECT_SIZE="0.18583567422939393" MODIFIED="2017-07-08 23:00:14 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.08530349255524114" STUDY_ID="STD-Asilian-2004a" TOTAL_1="149" TOTAL_2="160" VAR="0.00727668584212208" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-094.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:09:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100" TOTAL_2="160" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryotherapy+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-094.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-08 23:02:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="160" WEIGHT="0.0" Z="0.0">
<NAME>Hypopigmentation</NAME>
<DICH_DATA CI_END="313.72862090759213" CI_START="0.9800319500985273" EFFECT_SIZE="17.534653465346533" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.4965541404230818" LOG_CI_START="-0.008759765608217415" LOG_EFFECT_SIZE="1.243897187407432" MODIFIED="2017-07-08 23:02:14 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="1.471633789906629" STUDY_ID="STD-Asilian-2004a" TOTAL_1="100" TOTAL_2="160" VAR="2.1657060115949482" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-095" MODIFIED="2017-11-09 13:13:35 +0000" MODIFIED_BY="[Empty name]" NO="95">
<NAME>Cryotherapy alone (weekly) versus ILMA (fortnightly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="120" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-095.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:28:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="230" TOTAL_2="160" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2046731240680628" CI_START="0.8198209113979444" EFFECT_SIZE="0.9937888198757764" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="84" LOG_CI_END="0.08086922145733488" LOG_CI_START="-0.08628100820918479" LOG_EFFECT_SIZE="-0.002705893375924934" MODIFIED="2017-07-08 23:00:59 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.09818487231309472" STUDY_ID="STD-Asilian-2004a" TOTAL_1="230" TOTAL_2="160" VAR="0.009640269151138714" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="247.99281092564223" CI_START="0.8638280266926778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="14.636363636363637" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-095.02" LOG_CI_END="2.394439091227113" LOG_CI_START="-0.06357270947986361" LOG_EFFECT_SIZE="1.1654331908736246" METHOD="MH" MODIFIED="2017-11-09 13:13:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.06308654477702162" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="230" TOTAL_2="160" WEIGHT="100.0" Z="1.8585810530632214">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="247.99281092564223" CI_START="0.8638280266926778" DF="0" EFFECT_SIZE="14.636363636363637" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-095.02.01" LOG_CI_END="2.394439091227113" LOG_CI_START="-0.06357270947986361" LOG_EFFECT_SIZE="1.1654331908736246" MODIFIED="2017-11-09 13:13:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06308654477702162" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="160" WEIGHT="100.0" Z="1.8585810530632214">
<NAME>Hypopigmentation</NAME>
<DICH_DATA CI_END="247.99281092564223" CI_START="0.8638280266926778" EFFECT_SIZE="14.636363636363637" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.394439091227113" LOG_CI_START="-0.06357270947986361" LOG_EFFECT_SIZE="1.1654331908736246" MODIFIED="2017-07-08 23:04:13 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="1.4438482990899242" STUDY_ID="STD-Asilian-2004a" TOTAL_1="230" TOTAL_2="160" VAR="2.0846979107848673" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-096" MODIFIED="2017-11-10 12:09:04 +0000" MODIFIED_BY="[Empty name]" NO="96">
<NAME>Cryotherapy (fortnightly) + 15% paromomycin + 10% urea cream (twice a day) + ILMA (twice a day for 4 weeks) versus ILMA (twice a week) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="68" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-096.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:14:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="81" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Cryo+paramomycin+ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cryo+Cream+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3148497288640297" CI_START="0.9529039774768611" EFFECT_SIZE="1.1193415637860082" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="57" LOG_CI_END="0.11887612114949041" LOG_CI_START="-0.02095086027771739" LOG_EFFECT_SIZE="0.04896263043588653" MODIFIED="2017-07-08 00:54:05 +0100" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.08213506104506287" STUDY_ID="STD-Nilforoushzadeh-2004" TOTAL_1="81" TOTAL_2="76" VAR="0.006746168252876203" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-097" MODIFIED="2017-10-19 13:57:25 +0100" MODIFIED_BY="[Empty name]" NO="97">
<NAME>Cryotherapy (weekly) + 3% salicylic + 3% sodium nitrite cream (twice a day) for up to 12 weeks versus cryotherapy (weekly) + 3% salicylic cream (twice a day)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-097.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:11:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Cryo+salicylic+nitro</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+salicylic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours salycilic alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salycilic+nitro</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4688802135423553" CI_START="0.8616257393431799" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" LOG_CI_END="0.16698638073327027" LOG_CI_START="-0.06468133583850774" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.1360827634879544" STUDY_ID="STD-Jowkar-2012" TOTAL_1="36" TOTAL_2="27" VAR="0.01851851851851853" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-097.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 10:49:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Cryo+salicylic+nitro</GROUP_LABEL_1>
<GROUP_LABEL_2>Cryo+salicylic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours salycilic+nitro</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salycilic alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-097.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:48:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Mild skin symptoms</NAME>
<DICH_DATA CI_END="40.17462185881844" CI_START="0.6860674407057288" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.603951797684258" LOG_CI_START="-0.16363319087234446" LOG_EFFECT_SIZE="0.7201593034059569" MODIFIED="2017-07-08 00:44:20 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="1.038288171964955" STUDY_ID="STD-Jowkar-2012" TOTAL_1="36" TOTAL_2="27" VAR="1.0780423280423281" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-098" MODIFIED="2017-11-09 12:59:01 +0000" MODIFIED_BY="[Empty name]" NO="98">
<NAME>Radiofrequency waves versus ILMA (1 mL to 7 mL per lesion) weekly for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-098.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-20 16:30:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="83" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heat</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.800038906778582" CI_START="1.182934092202554" EFFECT_SIZE="1.4592215013901761" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="52" LOG_CI_END="0.2552818922236595" LOG_CI_START="0.07296054835564456" LOG_EFFECT_SIZE="0.16412122028965204" MODIFIED="2016-06-21 13:08:01 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.10709645989327951" STUDY_ID="STD-Sadeghian-2007" TOTAL_1="83" TOTAL_2="94" VAR="0.011469651721672828" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.128956199388419" CI_END="1.554524619500251" CI_START="0.9656212459174557" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2251865163685043" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="177" I2="68.0404602597039" I2_Q="0.0" ID="CMP-098.02" LOG_CI_END="0.1915976044933557" LOG_CI_START="-0.015193187315009552" LOG_EFFECT_SIZE="0.08820220858917312" METHOD="MH" MODIFIED="2017-07-18 14:11:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07691327081827071" P_Q="1.0" P_Z="0.09453185510796568" Q="0.0" RANDOM="YES" SCALE="2.76" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.021152542146024144" TOTALS="YES" TOTAL_1="246" TOTAL_2="253" WEIGHT="100.0" Z="1.6719617994583789">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Heat</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.837991898202682" CI_START="1.1034865040838553" EFFECT_SIZE="1.4241486068111455" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" LOG_CI_END="0.26434359270100455" LOG_CI_START="0.04276702599993781" LOG_EFFECT_SIZE="0.15355530935047118" MODIFIED="2016-12-05 13:00:00 +0000" MODIFIED_BY="Ana Royuela " ORDER="111" O_E="0.0" SE="0.13015517210190108" STUDY_ID="STD-Sadeghian-2007" TOTAL_1="57" TOTAL_2="60" VAR="0.016940368824875488" WEIGHT="38.73409689484761"/>
<DICH_DATA CI_END="1.238700519942766" CI_START="1.0018479446922641" EFFECT_SIZE="1.113997113997114" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="143" LOG_CI_END="0.09296631988888852" LOG_CI_START="8.0181155897033E-4" LOG_EFFECT_SIZE="0.04688406572392945" MODIFIED="2016-12-05 13:00:12 +0000" MODIFIED_BY="Ana Royuela " ORDER="112" O_E="0.0" SE="0.05413788841466802" STUDY_ID="STD-Safi-2012" TOTAL_1="189" TOTAL_2="193" VAR="0.0029309109619990456" WEIGHT="61.26590310515239"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-098.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 12:59:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="57" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Heat</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Heat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="11" I2="0.0" ID="CMP-098.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 10:53:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="0.7583961641019975" CI_START="0.002757095968077418" EFFECT_SIZE="0.04572713643178411" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.12010387228595618" LOG_CI_START="-2.5595481168535703" LOG_EFFECT_SIZE="-1.339825994569763" MODIFIED="2017-07-05 00:05:30 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="1.4329416247027773" STUDY_ID="STD-Sadeghian-2007" TOTAL_1="57" TOTAL_2="60" VAR="2.053321699805835" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-099" MODIFIED="2017-11-13 11:33:31 +0000" MODIFIED_BY="[Empty name]" NO="99">
<NAME>Radiofrequency waves (50 uCTM applied for 30 s) versus ILSSG (10 days of 20 mg/kg/d)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-099.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 11:33:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="86" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>Thermotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>SSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Thermotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5300615555409673" CI_START="0.9899057723098303" EFFECT_SIZE="1.2306976744186047" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="50" LOG_CI_END="0.1847089031666291" LOG_CI_START="-0.004406143294875466" LOG_EFFECT_SIZE="0.09015137993587684" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.11108711442606557" STUDY_ID="STD-Aronson-2010" TOTAL_1="86" TOTAL_2="84" VAR="0.012340346991509786" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-099.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 11:35:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="86" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects (serious)</NAME>
<GROUP_LABEL_1>Thermotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Thermotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.644001246549217" CI_START="0.30050523482674846" EFFECT_SIZE="1.302325581395349" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7515871010017621" LOG_CI_START="-0.5221479581485343" LOG_EFFECT_SIZE="0.11471957142661392" MODIFIED="2017-07-08 22:20:45 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.7481982788351141" STUDY_ID="STD-Aronson-2010" TOTAL_1="86" TOTAL_2="84" VAR="0.5598006644518272" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-100" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="100">
<NAME>Radiofrequency waves (1 treatment of &gt; 1 consecutive application at 50ºC for 30 s) versus IMSSG (20 mg/kg/d for 3 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-100.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 09:03:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="139" TOTAL_2="144" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Thermotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>IMSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IMSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Thermotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.371323805270187" CI_START="2.042952346730109" EFFECT_SIZE="2.9883785279468733" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="26" LOG_CI_END="0.6406129779912464" LOG_CI_START="0.31025823653282675" LOG_EFFECT_SIZE="0.47543560726203665" MODIFIED="2017-11-13 09:03:09 +0000" MODIFIED_BY="[Empty name]" ORDER="807" O_E="0.0" SE="0.19405201041501943" STUDY_ID="STD-Reithinger-2005" TOTAL_1="139" TOTAL_2="144" VAR="0.03765618274611081" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-100.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 09:05:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="139" TOTAL_2="144" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event (secondary infection)</NAME>
<GROUP_LABEL_1>Thermotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>IMSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursThermotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IMSSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="31.026464429697775" CI_START="0.5534559710395147" EFFECT_SIZE="4.143884892086331" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.4917322890822062" LOG_CI_START="-0.25691692274397226" LOG_EFFECT_SIZE="0.617407683169117" MODIFIED="2017-11-13 09:05:18 +0000" MODIFIED_BY="[Empty name]" ORDER="808" O_E="0.0" SE="0.7815761709208124" STUDY_ID="STD-Reithinger-2005" TOTAL_1="139" TOTAL_2="144" VAR="0.6108613109512391" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-101" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="101">
<NAME>Radiofrequency waves (1 treatment of &gt; 1 consecutive application at 50ºC for 30 s) versus ILSSG (5 injections of 2 mL to 5 mL every 5 to 7 days)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-101.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 09:10:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="139" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Thermotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILSSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Thermotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4345789970889784" CI_START="0.9071848915282916" EFFECT_SIZE="1.1408016443987667" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="70" LOG_CI_END="0.15672446827055225" LOG_CI_START="-0.04230419123394117" LOG_EFFECT_SIZE="0.05721013851830554" MODIFIED="2017-11-13 09:10:55 +0000" MODIFIED_BY="[Empty name]" ORDER="809" O_E="0.0" SE="0.1169104198006932" STUDY_ID="STD-Reithinger-2005" TOTAL_1="139" TOTAL_2="148" VAR="0.013668046257974315" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="99" CI_TOTAL="99" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-101.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-13 09:10:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="139" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event (secondary infection)</NAME>
<GROUP_LABEL_1>Thermotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>iLSSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursThermotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILSSG</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.1658557259529045" CI_START="0.40500998988927567" EFFECT_SIZE="1.7035971223021582" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.8552680600325354" LOG_CI_START="-0.39253426443896133" LOG_EFFECT_SIZE="0.23136689779678707" MODIFIED="2017-11-13 09:10:55 +0000" MODIFIED_BY="[Empty name]" ORDER="810" O_E="0.0" SE="0.557717669290589" STUDY_ID="STD-Reithinger-2005" TOTAL_1="139" TOTAL_2="148" VAR="0.3110489986389267" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-102" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="102">
<NAME>Radiofrequency waves versus ILSSG</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-102.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:16:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>RFHT</GROUP_LABEL_1>
<GROUP_LABEL_2>IL SSG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL SSG</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFHT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1298908300138282" CI_START="0.9619665265106643" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="47" LOG_CI_END="0.053036484002907586" LOG_CI_START="-0.01684003981731519" LOG_EFFECT_SIZE="0.018098222092796223" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.04104581598637028" STUDY_ID="STD-Bumb-2013" TOTAL_1="50" TOTAL_2="50" VAR="0.0016847590099869705" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-103" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="103">
<NAME>Electrocauterisation + DAC n-055 (daily) versus electrocauterisation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-103.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 11:37:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="146" TOTAL_2="124" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Electrocauterizat plus DAC n-055</GROUP_LABEL_1>
<GROUP_LABEL_2>Electrocauterizat</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EC plus DAC n-055</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Electrocauterizat</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-103.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:51:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Superinfection</NAME>
<DICH_DATA CI_END="2.5003870462754305" CI_START="0.28848977067131476" EFFECT_SIZE="0.8493150684931506" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3980072402924865" LOG_CI_START="-0.5398695815368907" LOG_EFFECT_SIZE="-0.07093117062220206" MODIFIED="2017-07-12 13:43:11 +0100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.5509134877077185" STUDY_ID="STD-Jebran-2014" TOTAL_1="73" TOTAL_2="62" VAR="0.3035056709382825" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-103.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:51:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Keloid formation</NAME>
<DICH_DATA CI_END="2.2407516705105137" CI_START="0.0804792533530927" EFFECT_SIZE="0.4246575342465753" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3503937288675701" LOG_CI_START="-1.0943160614399365" LOG_EFFECT_SIZE="-0.37196116628618325" MODIFIED="2017-07-12 13:43:21 +0100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.8486296822554282" STUDY_ID="STD-Jebran-2014" TOTAL_1="73" TOTAL_2="62" VAR="0.7201723376049491" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-104" MODIFIED="2017-11-15 14:53:03 +0000" MODIFIED_BY="[Empty name]" NO="104">
<NAME>PDT (weekly for 4 weeks) versus placebo (twice a day for 4 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-104.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-20 16:31:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Lesions cured</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.552510797033847" CI_START="2.8045028524131763" EFFECT_SIZE="7.016129032258065" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="4" LOG_CI_END="1.2443392488533171" LOG_CI_START="0.4478558860594498" LOG_EFFECT_SIZE="0.8460975674563834" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.4678582699613498" STUDY_ID="STD-Asilian-2006" TOTAL_1="31" TOTAL_2="30" VAR="0.21889136077122728" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-104.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-10 11:45:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Scarring</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5704280349142326" CI_START="0.00745112590121681" EFFECT_SIZE="0.13839285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41000544929344407" LOG_CI_START="-2.1277780982932244" LOG_EFFECT_SIZE="-0.8588863244998901" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="1.4907066180835706" STUDY_ID="STD-Asilian-2006" TOTAL_1="31" TOTAL_2="30" VAR="2.2222062211981566" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-104.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:53:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.3115785916853" CI_START="2.3669795848627238" EFFECT_SIZE="4.694711538461538" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.969023313155583" LOG_CI_START="0.3741945121666402" LOG_EFFECT_SIZE="0.6716089126611117" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.3494053821509574" STUDY_ID="STD-Asilian-2006" TOTAL_1="31" TOTAL_2="30" VAR="0.12208412107605657" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-105" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="105">
<NAME>Mesotherapy gun (0.5 mL of MA weekly) versus ILMA (0.1 mL weekly) for up to 6 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-105.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-20 10:38:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Mesotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mesotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1896267509275025" CI_START="0.7771817608312132" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.07541072152732722" LOG_CI_START="-0.10947740012488798" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.10860419786947374" STUDY_ID="STD-Kashani-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.011794871794871806" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-105.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:19:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Mesotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mesotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-105.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-18 11:02:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2017-07-07 20:31:29 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Kashani-2010" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-105.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-31 09:04:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Development of cell-mediated immunity</NAME>
<GROUP_LABEL_1>Mesotherapy</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mesotherapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.3444766693104" CI_START="0.26963943805788637" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9213991047351494" LOG_CI_START="-0.569216586623787" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2017-07-31 09:04:53 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Kashani-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-106" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="106">
<NAME>Diminazene aceturate solution (weekly) versus cetrimide + chlorhexidine solution for 50 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-106.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:04:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Aceturate</GROUP_LABEL_1>
<GROUP_LABEL_2>Cetrimide+Clorhexidine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Cetrimide+Clorhexidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aceturate</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9498776299815794" CI_START="1.0051912847569393" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.290007356854141" LOG_CI_START="0.0022487145023350305" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2017-07-07 20:41:21 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.16903085094570333" STUDY_ID="STD-Lynen-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.028571428571428577" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-107" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="107">
<NAME>Topical garlic (twice a day) versus vehicle for 3 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-107.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:18:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="96" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Garlic</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours garlic</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7341263518544112" CI_START="0.5068294182025028" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2390807378426078" LOG_CI_START="-0.2951381850430949" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2017-07-07 20:47:23 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.31380283972937884" STUDY_ID="STD-Gholami-2000" TOTAL_1="96" TOTAL_2="75" VAR="0.09847222222222221" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-108" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="108">
<NAME>Topical herbal extract + placebo (5 d) versus IMMA (15-20/mg/kg/d) + vehicle for 20 d</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="64" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-108.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 11:07:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="86" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Topical Herb</GROUP_LABEL_1>
<GROUP_LABEL_2>IMMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Topical Herb</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.98314751974881" CI_START="1.8989731913319918" EFFECT_SIZE="2.750252780586451" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="23" LOG_CI_END="0.600226391226419" LOG_CI_START="0.2785188336476197" LOG_EFFECT_SIZE="0.43937261243701936" MODIFIED="2017-07-07 20:56:52 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.18897261179987984" STUDY_ID="STD-Zerehsaz-1999" TOTAL_1="86" TOTAL_2="85" VAR="0.03571064801046809" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-109" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="109">
<NAME>Topical honey (twice a day) + ILMA (weekly) versus ILMA (weekly) for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-109.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-20 16:32:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>Honey + ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IL MA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Honey + IL MA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.035627781540636" CI_START="0.49882937838099073" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="32" LOG_CI_END="0.015203692214711578" LOG_CI_START="-0.3020479768193378" LOG_EFFECT_SIZE="-0.1434221423023131" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.18635520081168974" STUDY_ID="STD-Nilforoushzadeh-2007" TOTAL_1="50" TOTAL_2="50" VAR="0.03472826086956521" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-110" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="110">
<NAME>
<I>Cassia fistula </I>(topical gel) <I>+ </I>ILMA (0.5 mL to 2 mL), twice a week versus ILMA (0.5 mL to 2 mL), twice a week + vehicle</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="47" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-110.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:20:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>
<I>Cassi fistula </I>+ ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cassi fistula+ILMA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.238991541684986" CI_START="1.1731330420329165" EFFECT_SIZE="1.6206896551724137" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="29" LOG_CI_END="0.350052452932994" LOG_CI_START="0.06934726714052875" LOG_EFFECT_SIZE="0.20969986003676136" MODIFIED="2016-06-20 12:12:47 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.16488761564757354" STUDY_ID="STD-Jaffary-2010" TOTAL_1="70" TOTAL_2="70" VAR="0.02718792579394194" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-110.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:20:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>
<I>Cassi fistula </I>+ ILMA</GROUP_LABEL_1>
<GROUP_LABEL_2>Vehicle + ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>FavoursCassi fistula+ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-110.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:55:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Itching</NAME>
<DICH_DATA CI_END="2.369069530781858" CI_START="0.42210664862587316" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.37457780719458844" LOG_CI_START="-0.37457780719458844" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-07-07 21:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.4400577162723017" STUDY_ID="STD-Jaffary-2010" TOTAL_1="70" TOTAL_2="70" VAR="0.19365079365079363" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-111" MODIFIED="2017-11-14 15:34:11 +0000" MODIFIED_BY="[Empty name]" NO="111">
<NAME>
<I>Cassia fistula</I> boiled (topical) versus ILMA (0.5 mL to 2 mL), twice a week for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-111.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:28:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>C. fistula Boiled</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours C. fistula boiled</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.890351029626031" CI_START="0.4194489338438995" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="36" LOG_CI_END="-0.05043873473360361" LOG_CI_START="-0.37732090515655836" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.1920122049992835" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" VAR="0.03686868686868687" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-111.02" MODIFIED="2017-11-14 15:34:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>C. fistula Boiled</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours C. fistula boiled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.11335395874280274" CI_START="-3.486646041257199" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="6.4" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="3.7" SD_2="5.2" SE="0.8605495073181174" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-111.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:29:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>C. fistula Boiled</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours C. fistula boiled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-111.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:56:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="8.629502693031073" CI_START="0.2607334489642182" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9359857686125963" LOG_CI_START="-0.5838032505012336" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2017-07-07 21:07:59 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.8927315929044389" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" VAR="0.7969696969696969" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-112" MODIFIED="2017-11-14 15:34:24 +0000" MODIFIED_BY="[Empty name]" NO="112">
<NAME>
<I>Cassia fistula </I>hydroalcoholic (topical) versus ILMA (0.5 mL to 2 mL), twice a week for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-112.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:29:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>C. fistula Hydroalcoholic</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours C. fistula</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8278486875598923" CI_START="0.37282414038533185" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="36" LOG_CI_END="-0.08204903539261255" LOG_CI_START="-0.4284959748139996" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.2035046471561311" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" VAR="0.04141414141414142" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-112.02" MODIFIED="2017-11-14 15:34:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.05" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (weeks)</NAME>
<GROUP_LABEL_1>C. fistula Hydroalcoholic</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours C. fistula</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.20210410899617992" CI_START="-3.20210410899618" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="6.4" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="3.8" SD_2="5.2" SE="0.8684364214965988" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-112.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:30:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Adverse reaction</NAME>
<GROUP_LABEL_1>C. fistula Hydroalcoholic</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours C. fistula</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-112.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:56:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="6.848285213705944" CI_START="0.14602195568587464" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8355818393091744" LOG_CI_START="-0.8355818393091744" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-07-07 21:09:23 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.9816498172140428" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" VAR="0.9636363636363636" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-113" MODIFIED="2017-11-13 09:12:56 +0000" MODIFIED_BY="[Empty name]" NO="113">
<NAME>
<I>Cassia fistula</I> boiled (topical) versus<I> C fistula</I> hydroalcoholic (topical) for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-113.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:31:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>C. fistula Boiled</GROUP_LABEL_1>
<GROUP_LABEL_2>C. fistula Hydroalcoholic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydroalcoholic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours boiled</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.771364956133496" CI_START="0.6830890471273444" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.2483080485452387" LOG_CI_START="-0.16552267822878858" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.24308621740219885" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" VAR="0.05909090909090909" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-113.02" MODIFIED="2017-11-10 12:42:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="3.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Speed of healing (days)</NAME>
<GROUP_LABEL_1>C. fistula Boiled</GROUP_LABEL_1>
<GROUP_LABEL_2>C. fistula Hydroalcoholic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours boiled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hydroalcoholic</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1016888295982339" CI_START="-1.7016888295982353" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.9" MODIFIED="2016-06-21 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="3.7" SD_2="3.8" SE="0.7151605032819874" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-113.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-18 14:32:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>C. fistula Boiled</GROUP_LABEL_1>
<GROUP_LABEL_2>C. fistula Hydroalcoholic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours boiled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hydroalcoholic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-113.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:57:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reaction</NAME>
<DICH_DATA CI_END="8.629502693031073" CI_START="0.2607334489642182" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9359857686125963" LOG_CI_START="-0.5838032505012336" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2017-07-07 21:11:34 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.8927315929044389" STUDY_ID="STD-Jaffary-2014b" TOTAL_1="55" TOTAL_2="55" VAR="0.7969696969696969" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-114" MODIFIED="2017-11-15 14:53:11 +0000" MODIFIED_BY="[Empty name]" NO="114">
<NAME>Topical gel <I>Achilles millefollium</I> (twice daily) + ILMA (weekly 20 mg/kg/d) versus ILMA (weekly 20 mg/kg/d) + vehicle (twice daily) for 4 weeks</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-114.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:23:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Participants complete cure</NAME>
<GROUP_LABEL_1>ILMA+Achilles</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA+vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+Achilles</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3143959948185437" CI_START="0.7681389795686892" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3644376690716105" LOG_CI_START="-0.11456019585501069" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2016-07-13 09:28:34 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.2813657169355689" STUDY_ID="STD-Jaffary-2014a" TOTAL_1="30" TOTAL_2="30" VAR="0.07916666666666666" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-114.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-09 13:23:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>ILMA+Achilles</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA+vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+Achilles</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-114.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-07-17 11:57:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Itching</NAME>
<DICH_DATA CI_END="10.006924413115998" CI_START="0.8993772340484326" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.000300619372041" LOG_CI_START="-0.04605810993271604" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2017-07-08 00:32:36 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.6146362971528592" STUDY_ID="STD-Jaffary-2014a" TOTAL_1="30" TOTAL_2="30" VAR="0.37777777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-114.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-11-15 14:53:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological cure of skin lesions</NAME>
<GROUP_LABEL_1>ILMA+Achilles</GROUP_LABEL_1>
<GROUP_LABEL_2>ILMA+vehicle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ILMA+placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ILMA+Achilles</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.627644034470314" CI_START="0.42665621581713864" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.21155943079342393" LOG_CI_START="-0.36992192288867354" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2016-07-13 09:29:11 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.34156502553198664" STUDY_ID="STD-Jaffary-2014a" TOTAL_1="30" TOTAL_2="30" VAR="0.1166666666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-11-15 12:18:31 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-11-15 12:18:31 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAQKCAYAAABqsBTuAACAAElEQVR42uy9D2RWb/z//2GSzExk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-14 15:07:48 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgments about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXAAAAvDCAIAAAAWVYn9AACAAElEQVR42uydv04jydqHW0JCBAQE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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-14 15:07:48 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAdQklEQVR42u1da3Ab13U+fOwLgEjskqxFqfGYopp2Rv2ROpViyaJi
g1YStUmcZJqZjOO8PFPZidNkOsk0iTvjOv0RW07k1PXYSWTPKH6lzdjjqZ2HZUuCY0PKg+qo02mU
ZhxSUuSIoCtyl5QILoAFwd7XPvAiQRAAQfp8egB795x77i4+3Ht3cb89AAhEw9AGOp4ERINgteM5
QDQOSC8E0guB9EIgkF4IpBcC6YVAIL0Qq4ZOPAX1hYWnIHCnHum1fsaDVhmJcjg4InDuhUB6IRBI
LwTSC4H0WjMwm+6IaBC9YgRyKFl212od2+YKsfXIEi2s4Bgrb71gII0a3nvF4/EJabCljm0naVW5
vsn+fW2O7pEWbeds7O2aMTga53IAfZqskK9zLKrK5GUkpNBbuE5YDju0UJEP26qUYOa2pKgJuk+K
ONRS1WO8ayD/zJASNpmDYpN9Kq1SlAGrNUqMnAivtXufbHv1xLpV0YYY+0PLuZUb9xm7B2xZ0Vhs
mfqAV5ejDvuOISXkt4HF1VhNAL2arJLjSsiy2gvS3CDyqBlzry0SwJVwNpwi7/PjEfISU5PzZKPn
+azcQwuTxz/XP355mFl3RTJHbyL7Rh26L/bSeKATuHomc0RnDtPdADdq522/DGC7nMzTWq2sQmuF
p493efVAxzjMhrPTKdLLsH6m53leDm7cvz/BYr9MY0/zdrG66Luo9t9zrqOuZNSrvTawuBdHuXXK
zIbmAIYj2aOzACeyyKNG04vOvXLTAOlJMK8n2+cN+pIbNabIRuZaGEuT1yljaOdZQ9vNPBQnsS1D
9vWDSV6cbUbgx4ScBEMaq4Ua58b6bb8MQDvLa5WYJ5wzhoa8emDUAHsStOvdqj4mYp9z485vI7Gz
PLaogb2zMjTSZNprwxiM5rw2UFhGP7e2NXaQUqZ3GzHflkMeVUC9lEKxONjGZdJ7TW3J5XfG6Tb9
J2fZC90ib0Uh+0cIFf34412X2HBIvv+S41nSF17obsXdKTXvKPYf8ozkI2VcprbMz/M2CGclE4hL
20Rjb5gM+AS8IeAYaDQEajIH5nO74jB1tdN2vp+3x4WFvznm9EacDE35Evn/Vpi8HGCvCXRuc9Is
c7Evpe4LXSEfKrkoIB/4Hm4pbguc5IUCJ5mzX/YEt6WeRzyjE77LrXDJvzg8QWIvBOMOmTz2bLBK
4d0WaCZt9FBBix0wPyUuLeXX6IiamtBuJQ1+HLupJjB++jEyWz5+1O7xi9KD0EvHwa0wqBabqwnj
BTIxU/tADwOc0pjlSduk3Cd92WHNs+zcmtRYmc0rsbdAD5lAqQ4cC/nV8Xoojk/aGY+VanHsX54h
hTaLrSRdH1KXTur65WCfyhhJ26DB1l8VtLgbtH9nb/K/Hb2JH8GPyCGfwWUnTelQZ/aaMLOnP1Dn
qazaRudcGTk7VWy9Ya/MRjJbThPynO9VqOV098bv04v/bvmzfic4PTdAPvB4VNav8D43o9AYU1Hp
YNgzEvWwdmxgbejcCOViy2QmtcHgsf/E9SF1XUfqesW+TEgmX8VuQPTIduFNiBm1j9cUuo0FiOxV
hmcAdsvIowbPveo1gav6Joht1xrF/PhTPfVstfPBpw2ce5Wfe3WA1jr0Gp+vzu7L/9kx/+qjtUY5
MJX6eT1b3Z38emAr3baKXUVrIK8FTgY+Y6KuwMXQgcXQFs5KG3VqEYALchBILwTSC4FAeiGaCZza
45VjAy9vkF6rMB6s8yEDZbQInHshkF4IBNILgfRCIL0aDXP1q0Zh2dqllxGjK7ViFeW1m1cmvF3M
927+Yj+4hM/dy5LRRmykUevQKzvSu+j+xTWsK8JveN+k71zabhky2gs69nYtQy/TsXLex2Fypaqj
UR1sUpPVY66G1QzJmumpcYHJc21fj9utyQnXT5T1aYrCTWO6st+2VckOKG2pfYx3PKeVHWAosmYz
PW6IN8YMy/RdUlNsX38rC12uzPW30BdibfJi2bKkJcCQUUZbCU1frXpPZF79RwkGztG/DyuzG76V
hW55ujsHvzndvuGJ3LmBON1z34ZUF9kzcPGN76bYGtZ2ZqNLqbCWgYHkhX2xvPDTLdjwhZ9DPnJl
tn2eVXzxD5/rjF74qx/Ow1eOQoTs4/a0aoLnfnoY8qFU195R+LdXvnv5YBuLNwfxP22Db0VCbfOi
CSRWiMV6g8YiGHjjwqG7mbWIFQ7NXXkmB8ced/zjq2a1atv65lRgtWrTe69DMsieLNAZhVHy0WTP
SmmAFzWwdrl71DG2R6hxCW5hNpkxOOsrZ7kf1cI+xPS7rtx1ypjcedYYIlsPSWA95Nlz3LINoNO0
R18k8XeAxlVEGtfo3n72Usa1K4wF7N0lbi1ifTNn21RG62A3VfGL1NzlleZHFwBOJo0SpSrZdc2n
D+2KL6ZhhaLiAnmt05vbk4kHpLiV5LhURmv+8fxC96UiGW3CWVpGywtErJEbchDfzbS1Hiz8zbEx
MtqqoP0iHo93nBFbVKna5goSN7c/dcWzE3sgWABcE1tSxhWw3TD5Qkm4EwVyXP++gzGXjFwOymjp
O8dVOArfEu1vr9smEWvH3ER4GO9jtNAXiapUQT0ttu4/A1slAGmLQ4rz0ihdv5EYoXuohlUKOnIb
dStsUYvLuJo2V6DfdcdYx9PWUsKwUUwmg+A+g10FSCNgiOGO63blQUdx7b5QEIvd0YC38ydQiFia
YYyTzljDZSetQq/cKPlv9CviC/+J9yrpCwC/y0SOAoRnv0o/c4VNoC70sD0+uM25zH5nqqhsKip9
gFBo5on+50rCTUX3p30ht8QeDfAfVwGcsqXUNIlyo3KLUOZ2K1S3a9l3Trt292Ykp1D7O6rZfDmX
iPWyLUeJ6VXPI49aZO7VAjD7EzvqWZ8TSS5TRvvWmXu9FXWORiZVz+oe/Hpw8oX0eqvTq6HAxdAo
o23GqUUALshBIL0QSC8EAumFaCZwao9Xjg28vEF6tdZ40ODRZL4ZZ2ABB0cEzr0QSC8EAumFQHoh
kF7VwqyTDWJ90IsmNVP7ykhcY4uqU235y2XLg3rYSu6bF2/dCvS0wlVfKLMvIXetoMoSGS3+il1d
7xWPT2h88WaJinQRWWnXzLfKlgf1sJXcdzb48Mx0uWR4w8cvr6DO4mOx0tgHVzk4Glbe6690pmA1
NZZPNublc3XCLBUsuHleY0N/zTwMpkhNaBLN00psXTEqyyRL3RNM0dqrKjxbrSIEq0LRCkFfHkcI
aCFmM8+RsBwaYe1yfcyCfLGuH1fOcgxKEm2ZNhLMXRvb/U+BHLXMXeTITYRkNcrz2yaYcvdwQX2O
KrLRCruEpGi9IEkoo6127mX4qlqeT/aHWtK91bvA8rn2SMl7+TbP8ypyt8JUUv0hwHtMh+ZphY5x
Uf6Idn6Om++eeL4HYPZoZvpvgOV4jTLf2VDW5MOL68vjdMoT7kr3vgmaKXb7dHaK5iGDcUhxn6uV
jPqkW5fnZ2Vf9DQdWZpNKpdUt/vlHU/TqG6O2o5x6n5M5Mh9z0tZTvWnj5N67R91f7agvsfGNf5O
2D0Zybz8EQD5HuRRNfQik6933O9tnWMK1md5PlkKnpY1c9Z4J99OizyvHDlj9FkvTyvNCcvxwli/
sDlldGWI0xBoo7wyro+VHKZFBd+Xx1HHjFPucGTQOKoEGhUUjhnQyX3eNQajL/h1CT8J9ni6w+te
p8Q3xlS/nLfMbTvd8nPk2kNgXc8OfYi0MXvtpXRBfe80RK5aYfcDx952COD1f0AeVUBwMTSVifZd
zgRUpAX5ZEUB1YwWZ2cFT2NqDkxru+IB3WpQmEoNnL6vf3Vn0GDkhnmYZZqzQt/SOOApXUfenac+
paLa4ryyIsctfS1V1AZy1Ip/I3vdNLblkuD6PsLOiWbbN0xyYa43E8PfHBcqy2gvFV9ptZeISb2C
whyzDtOYbm7rea3A+qRnMsIMuvPXFs6rd8wlQ3fyy8hCX79208tQKyZBO+xkKFJGa0tRoJxtN7l7
R7Gi9mRxjlqGPW1yoHEnzKL6+twWCTsp9SbNaWu2YTdV5bdF7yi+7TAI1xQUKFtAP8EHx1/DoOKV
98JWMnLk/5flafU/nc7B5D6+fROcJta3Tm3rKfgENdto+z6f7Pm+NM5pL7DO4qQdb2ZIfcjL/cVa
WwrVgdc8aWMn1YMPwKBcVM7arpZ+77iSV0A+3acW+KXgjBK0ozltPwlw5n7kUXVzLzn9apHBqaxS
qE6dctxHkOT2BfO8tskZMlcK3+Ylo72DJYN9xb5GZAz+pvwhYr1zQzBbLbEJf0RKzbCN8G0bA7um
blbcx7wZLI7VrcyJvoX6TJO6euR0yS2Pqah0ryfMfoBqctuU7Pmi8qK2uwj/5cZA1nXt4GWrwO9n
6vumgnYbdHn4E+SaBaf21cy9qoaeLRUKLplJNlbzQ+Fq9wRz82UpFm/sKXS6LtYvG+06m3stn14R
Z6EzfKmkWM4u4SfV/JiiJate7JvgzAafX9OQs9mzXBkt0gtRI3AxNMpom3FqEYALchBILwTSC4FA
eiGaCZza45VjAy9vkF4tNB6staGkwl00lNEicO6FQHohEEgvBNILgfRqAMxVjmOuUnuQXpVBRbeh
5LJFt4byYEnZpiYdrIhjhN12Voi/aVnZaB80kEYN6L3i8Qn5Nv6uZFdlr9nwF0vKdjXpYHkcc+6N
JeLvWlY22p1z2Ns1ZHA0po97/dUxlrPVCe93RbdRpp81NeUY/7pzzWts9zvoBrETilSR+5Wrbc0w
18XqivJagsltzQflMP/0ejWF1m3ITEGb2C+rvWT3l1g9tvy+zyfAVdfGjimKbbP2iP2x6L79tpeN
VjbcdvJ4tFzEcbT9hpuNdkq0MaruF9myk1qIZ6N128Li7ZBPI48aMvfSfW3EkfEZpn29z72Vmx8P
p4jFvyQ/ImyVjKq7otvO5w/JnX53EIeo1jVHbOTMw/Rjn09O3/v+JPPfmZ3kvzHMvpzZSUxS4axJ
ahzemT06S3bfd2iyB6A7fOSde4Gpa2m0I8ljRj9rj9gP+ad3druxb37Ta6c+nXn4GlYu4kSVh+dc
O0PibVwY/0Q3b+jBi6GrvbakvHhvfgh5VH96kcnXX/j3/+9iOtTbx4zzooDnkdU+6qpwtTEY9bQ5
t18LY0qwstwYlawSm5s15qtluIpX3QEalwelh+Az19M8sob9IoD8d73biMPtEmgfA5DuSdyc9vaR
tri6WLGfVPiZ3W4ox/baqUnwGb7SWsRxWH5b0cazvI3nWF5binuNScdry24vno3ZaCuh9sXQVCGR
2Jsuq7EtUeGCr2YtVuAWqW1dm0JRLGVFX45KV0UeWaFgpbtPZsDRs21ky9ych65Lxe4nM4W6WNpG
t53gKnMLxLd+kwJK24JstH253K64G69uMtr18ptjvbLRDuVLr/EL57ntBaJbLxrd+FTwJgBX2xbY
8HJPxNq18OJZYHlkwx9mClZtlu8mTJFmJ35Ctgw7GfpwiXuxkuNTJpQqc0WcrYW5bkUbXSTd1nUt
XDoHXjyc2VdEB2g1eg6QExxdcOgr/0v/hf81/Z1NwQLn0fR3xhgJtbukR6+0sXIyFj5mHzrRBhdn
r3wjeQ7G0x3qI5F8Lmgj/uVOPWoAe4hS+8y37ye2+/7ngdCpeVBf+TNLzkN4tkNvd0C98sDfPj7v
7gu4i/1ii8QhFf32EdttZy7XcfjlHC0Xca6/7UqYbdPQvI1ubeT/rzjvP8QK2mdSgbY8CoHeK922
kqFkbWGhQrlHqfSK5l6yM1ZUNpVTCpf4WBnlOR7jgqGkT3lTrYycJaQ53tX/GLDsr9NzV0LcpnDB
lHWDLLSzxzcw27sMpqCN7JW7LlONq5weo3pWZfg43xcubA/fL8CzzD6f89p5iuegJeUiztdYfltu
R9roFD4dLKS91ypuC4mXk7Cbqvvcq2ocvnOupQ7Z3HSlrnwY2TNeJxnt+pt7NZpeXR97vGOmxb7d
9qEv1rO6yKXg/ALphTLaBgIXQ6OMthmnFgG4IAeB9EIgvRAIpBeimcCpPV45NvDyBum19seDukSs
44PlUEaLwLkXAumFQCC9EEgvBNKr2TBr2rVcFzO4C5ef1gtNXjFRdQoD31BNVzQSeSCXU1uhi+6l
AyLloTnXlmyUa6goK95V1+far1oXUc8bE/oqnozlYhGNbQ25bAtcArlqSfl1/F28MI9uKYp35Wzs
7VpncBS5Y0eYbtYR+WS/Jw8bCZ5T1h6mOWeB6W7DXOMq8tCCbw+u/LZvn2yzzLVc8arIhxNcz+vl
kCX7DgNLLatwhSzNh8u/XzRXrVfO6osqol4SYaQg1y3FiCa0v72aPKzTnNxUyyvNYTbaFpp75ZPT
3QA3audtrq2lytT9Ez/OvJ+Vw1XPKNuZ3dUzmSNcd7v9DZGH1rMX3Ugc7F+kojQvbpblls0nj3/u
A+PHac5cK6vwzGs98sSngT58IDud4ulvj2ameU4kmqvWK2fi2WeTol7KXxGLt5di+8VJXmfKzP4X
af1whGl5+7LIo9ahF08amxvrt+n/MEo7mVOG9q5zrFzkjgWmkBjiy4xVAzT+Ebr2HpyzUsbPLcvz
ylLVa0YCkyvQMmMG/R3QngSR/pbmw+W62NzrwXKKawOr5t1YvL1sKmFovE6aN5cM2lImQbW8r+eQ
RxVQuxCtJlCF2h3s5d130O09d8CBjnkYuAvc8oELcKA9T9/tGRgY+D2Tlb2bvDufD9pzcZhXDfn/
QOc89fWqJy4X2HS18xtwgBRMfa+z823Mxek58OrbmLKs/V4IlPtt43/dWHd4QjTyrpMFN78rtROn
iW8fPviHg6y9HtLNV5PVJeJCHRtUFyHayuDrZocKdzgsdywEFbRtvtrVs+dzMTdjbElu2UAOWZPZ
vg0mI3y7K98l0kLSXLV+eZkWFrXNcW9ZbAaZ5s3tSU1ot0Kx8hfRAve9OrcmCcklDbb+qnBHD8sd
C+xpAIeJyQkHjo24eWiF/QnDvImzSt7iKGT03FqcW1YlXvz5KsppoLa5STvDOTM/dbPIh0tz1frl
Ce8CkHP2/pK2dYPGH4yR/+0onR9qCeNH5DLiDC47aTl6Tc8NkA8x3iPbRRf67Sx3LJ1hd8uffVVo
XBWbdzjCPpLqpz2cvBGsdOQYGeEyxbllp6LSQa6onfqQQm1neBZcaSPVwIqjlncHy5WNrrPM3pXm
up1R+3jTwrf102vP8F5leAZgt4w8qjhut5i0pdG5Ywvue2262LPyWqY2j9cvG+2qdRGNua3acvRq
dO7YAhjZ2ZVXEpGCK1SRXkF6tdy0oZnsqs+Pi0UMzTf9lOWhZYGz0joDZbQtMbVHIL0QCKQXAumF
eAsCp/Z1BspoUUb7Fh0PVti0am+NoYwWgXMvBNILgUB6IZBeCKTXqsFsgsfK/BCtTC8npOzv8oUa
xVlfNy2a5bYc7q7goUdq8quQjTZiI43WAr26lOR98LWKuxfPEVsOvynvYV5n1eQnULzrgo693Vqg
V37MMC4/RHPEyiH+iVEl7QiTwNpC3Ko54GhuOe1KulXXPmYz5SzNejvC1K9CDhuLqrJBNbBKlHc8
gyelmvygL6RxDW+fxlLlGrKkJcBQtiCP1gC9OgeOOXQ5oT6dfYn/rnD1zzKT2wFsJeXmsZX+CJ6S
3HKKjnHPvm9C6iE+akZhdEgKOSzkxyMpgO1qUqy7y/6kNj/I/CHC23UlnJmeBZgNOeZegB9jutC1
QK83/vmDYS3JcsQK/ayzAzSV8MHPEfuTe+DziltOMWp49heMs4ScziiM0c/7rLcAnufFVceMc3w7
t602PzhnXOJR05NMifvNnG2Thm1DelVCi621Nwd2vbhojlhzU1pNB3LUslyxnr1IFuu+VMiLKzm1
+QWy0fbm9mTiMHJDDuK7C/UBFv7m2KJPyFFMMGaOl8kRe9KfOxsd0QNBha1r5bD7Ceanufq1nG7Z
z4vbbtbmB32uRTdMvkBedsxNhIfxPsYaGRzTA47ZLZFXrp+l/QzXz0pbHNUlmXxtl1fu+gn7a2AL
3XcGtooMfyeCo5Y9CNck+BzvTG1+MAdv5zLa3FGbKtg0wxhfIC+47GQt0Mu6L7Ixd4G88hyxdFZ0
o3JLBOB3LEfs/f206P9O3OyVu37CvmN/7i6y771K+gLfIQXvb/l5ceVf1+YHo5p9nr2ZeaL/OTpN
s+UoMb3qeeTR2ph7rQRLC3BFXlzz4y9ItfhVQP2y0a6/uVeTn5DTSFxc/PC7Fjp/+uqj9N2BqUxb
LX4V8OfPPBAc4dtauS9ZEap+iI4WOBkozKvvCI+nALPRNuHUIgAX5CCQXgikFwKB9EI0Ezi1xyvH
Bl7eIL1aaDyo+1AyvypnAGW0CJx7IZBeCATSC4H0QiC93hrAFahIrwbA2CezhLWVNLsVpLQIpFcV
SM7dlTX13kVz4FLE8VQhvZaPjdoQaFqa62h1RfLz2sa69zELRxUZaRMhWYkC2JKiJfDEIb2qgTpG
/hvLcs1uPnmZ57V9keo2Op5mFo+NH+F5iN7zUjZEhtEvRjIvP4knrgJwtWrh1IqNekqG6RyfNegL
FTHSgmfZgvrYfTtcNSQ3j8AlO7DUfkVr7dfLj0KtqXNsAbBMju5VI2fN9bFYbMHbgh3uknWzO0LX
lFsLXf29eOJwcKwGmUHy36BUwLgCyS6V0vI3m9pkqmKTUm+GZvHEIb2qwYSdgIT9O4CTnpI248Br
Id8iBWe4lHZBGqXLTVTbeOGTeOIqYB0J0eqBg1cmLzxtPUhY0zkv8sHnom0XJ+dEtnYYeOrJH1gd
dGt2+M7vnDkHenv7EwcP+zWsRIhWdw3bwuqcRRSiNQw4tcepPaJJwNWq9UZ+VVyRXm8N4FwDrxwR
SC8E0guBQHohkF4IpBcCgfRCIL0QSC/EsmCtsn9rVYD0QmDvhUB6IRBFwPVeLTb3Wg/AB4834dzW
SM+Vft1boAIcHBE490IgvRAInNojVuM6B6f2jbh21NmLXv002fNhr8ty9afTem2x/em4XnUL+C6/
1ZWCIr3qzi5+ktnfqtnlfjC62KreteCCtZbYvrsF1bbAKjrSikFx7tVCNzNqvyVg6XX7XtQ1GvZe
De7IahlXa3C1im+4LT+2XnUL9KoPGOnVqA7Jon+tqq+c3LGRvC7XFTzPGmOX1FNTC8r5IL0aOeCJ
mckyx8gaXPUVx15pC8r74NyrNcZGa4VD28rHZX3ls7lSH6RXCzGx9p/D6/VDer1/kMfbqvWnSvAu
QXWnN3DXabmuhUFXUIG+nMaXu+9VxsdCeiEa+E3DwRHRQCC9EEgvBNILgUB6IZBeiHWBwI9CqHFB
1Al6GXrhHTBEfWDh4IjAuRcC6YVAIL0QSC/E+kLn4jP/tXdNiW1veXoV92n5NXxEubXU9qKMewtr
nV04OCKQXoh1Ty+ryr0ldpbll67SD09W2eDWmjger+2VmtTKp75eQrSlHkew1uaqLXg8+ho89csf
HC1LfJO8b4bF/og9wW8ct7SKvknCzLduajfmBg8ejftitfTx8FhQ0P5WP/XL7r3KPYnA0gv3BLfd
p1p4AsvCB180nV+6/7e0MX5bW/N4aJyC4K1+6mscHHVL/Cnqd/WSPrmkb9ZXtb/Wy8bWC19b63is
ojNf2sDWPfV1fAiAHnhI1dKnS7daYia2yLy3VY6nCoVty576zvqeB/rtWeLRBFbgIWWrzy+9oE1r
9nhatam13vfS2XNU9FruXAQuCpp29q2SgcNa4q5Fqx6PtZKbRk0/9Z3LPDC9cs/q7+G8K7TULW8n
39PUwbEoWrAx9J1oU8sfT9l2tvKpDzwEwP92F2u382vpZ+Hi3xzXUtuLf3PUl7qZ1aLHoVf4MBCt
/bnBGltFgfRaS1hzC3TK0yu/hj+C3Bpu+8J6+z50rosvCba9RYELchBILwTSC4FAeiGQXgikFwKx
OII3JvAJTIjG0Qufv4TAwRGB9EIgkF4IpBcC6YVAIL0QSC8EAoFYGv8PJakdRkB24LcAAAAASUVO
RK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot 1_1bueno.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-07-14 13:39:27 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Forest Plot of Primary Outcome: Lesions Cured (Various comparisons)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABZMAAAngCAMAAADUQk3ZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot2.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-07-18 14:41:52 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Forest plot of primary outcome: 1.2 Participants cured (Various comparisons)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABc8AAA2wCAMAAACPqwf7AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-11-09 13:33:39 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-09-29 14:03:13 +0100" MODIFIED_BY="[Empty name]">Cochrane Skin Specialised Register/CRS</TITLE>
<APPENDIX_BODY MODIFIED="2017-10-19 10:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>(solitary or limited or "old world" or localised or diffuse or cutaneous) AND (leishmania*))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-09-18 11:52:50 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-09-18 11:30:17 +0100" MODIFIED_BY="[Empty name]">CENTRAL (Cochrane Library) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-18 11:30:32 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Leishmaniasis, Cutaneous] this term only<BR/>#2 (solitary or limited or localised or old world or diffuse or cutaneous):ti,ab,kw<BR/>#3 leishmania*:ti,ab,kw<BR/>#4 #2 and #3<BR/>#5 #1 or #4</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-09-29 14:04:19 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-09-29 14:03:22 +0100" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-29 14:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. leishmania$.mp.<BR/>2. (solitary or limited or old world or localised or diffuse or cutaneous).mp.<BR/>3. 1 and 2<BR/>4. Leishmaniasis, Cutaneous/<BR/>5. 3 or 4<BR/>6. randomised controlled trial.pt.<BR/>7. controlled clinical trial.pt.<BR/>8. randomized.ab.<BR/>9. placebo.ab.<BR/>10. clinical trials as topic.sh.<BR/>11. randomly.ab.<BR/>12. trial.ti.<BR/>13. 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. exp animals/ not humans.sh.<BR/>15. 13 not 14<BR/>16. 5 and 15</P>
<P>[Lines 6-15: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision)]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-09-29 14:03:29 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-09-29 14:03:29 +0100" MODIFIED_BY="[Empty name]">Embase (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-11-30 20:09:27 +0000" MODIFIED_BY="[Empty name]">
<P>1. skin leishmaniasis/<BR/>2. leishmania$.mp.<BR/>3. (solitary or limited or old world or localised or diffuse or cutaneous).mp.<BR/>4. 2 and 3<BR/>5. 1 or 4<BR/>6. crossover procedure.sh.<BR/>7. double-blind procedure.sh.<BR/>8. single-blind procedure.sh.<BR/>9. (crossover$ or cross over$).tw.<BR/>10. placebo$.tw.<BR/>11. (doubl$ adj blind$).tw.<BR/>12. allocat$.tw.<BR/>13. trial.ti.<BR/>14. randomised controlled trial.sh.<BR/>15. random$.tw.<BR/>16. or/6-15<BR/>17. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/<BR/>18. human/ or normal human/<BR/>19. 17 and 18<BR/>20. 17 not 19<BR/>21. 16 not 20<BR/>22. 5 and 21</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-09-29 14:04:42 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-09-18 11:32:38 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-29 14:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>(cutaneous and leishmaniasis) or (cutanea and leishmaniosis) or (old and world and leishman$) or ((solitar$ or locali$ or limited) and leishman$)</P>
<P>In LILACS we searched using the above terms and the Controlled clinical trials topic-specific query filter.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-11-09 13:33:39 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2017-11-09 13:33:39 +0000" MODIFIED_BY="[Empty name]">Adverse effects search strategy in MEDLINE (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-30 14:52:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. exp product surveillance, postmarketing/ or exp adverse drug reaction reporting systems/ or exp clinical trials, phase iv/<BR/>2. adverse event$.mp.<BR/>3. adverse effect$.mp.<BR/>4. exp hypersensitivity/ or exp drug hypersensitivity/ or exp drug eruptions/ or exp hypersensitivity, delayed/ or exp hypersensitivity, immediate/<BR/>5. exp hypersensitivity, immediate/ or exp anaphylaxis/ or exp conjunctivitis, allergic/ or exp dermatitis, atopic/ or exp food hypersensitivity/ or exp respiratory hypersensitivity/ or exp urticaria/<BR/>6. side effect$.mp.<BR/>7. exp Poisoning/<BR/>8. exp Substance-Related Disorders/<BR/>9. exp Drug Toxicity/<BR/>10. exp Abnormalities, Drug-Induced/<BR/>11. exp Teratogens/<BR/>12. exp Mutagens/<BR/>13. exp Carcinogens/<BR/>14. exp dermatitis, contact/ or exp dermatitis, allergic contact/ or exp dermatitis, irritant/ or exp dermatitis, phototoxic/<BR/>15. photoallergic reaction$.mp.<BR/>16. exp dermatitis, allergic contact/ or exp dermatitis, photoallergic/<BR/>17. sensiti?ation.mp.<BR/>18. fetal abnormalit$.mp.<BR/>19. exp Drug Monitoring/<BR/>20. harm$ effect$.mp.<BR/>21. (toxic effect$ or drug effect$).mp.<BR/>22. undesirable effect$.mp.<BR/>23. (safe or safety).mp.<BR/>24. toxicity.mp.<BR/>25. noxious.mp.<BR/>26. serious reaction$.mp.<BR/>27. complication$.mp.<BR/>28. tolerability.mp.<BR/>29. (adverse adj3 (effect$ or reaction$ or event$ or outcome$)).mp.<BR/>30. Tachyphylaxis/ci, de [Chemically Induced, Drug Effects]<BR/>31. *Itraconazole/<BR/>32. *Ketoconazole/<BR/>33. *Paromomycin/<BR/>34. *Allopurinol/<BR/>35. *Amphotericin B/<BR/>36. aminosidine sulphate.mp.<BR/>37. pentamidine isethionate.mp. or *Pentamidine/<BR/>38. *Aminoglycosides/<BR/>39. miltefosine.mp.<BR/>40. thermotherapy.mp.<BR/>41. *Granulocyte-Macrophage Colony-Stimulating Factor/<BR/>42. *Mefloquine/<BR/>43. *Immunotherapy/<BR/>44. *BCG Vaccine/ or bacillus calmette guerin.mp.<BR/>45. *Meglumine/<BR/>46. sodium stibogluconate.mp.<BR/>47. or/1-30<BR/>48. or/31-46<BR/>49. 47 and 48<BR/>50. (solitary or limited or old world or localised or diffuse or cutaneous).mp.<BR/>51. leishmania$.mp.<BR/>52. 50 and 51<BR/>53. exp Leishmaniasis, Cutaneous/<BR/>54. 52 or 53<BR/>55. 49 and 54</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;40 new studies and 49 studies from the previous review = 89 studies included in qualitative synthesis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;49 studies included in the previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;40 new studies included&lt;/p&gt;" WIDTH="121">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;69 record&lt;/span&gt;s assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;521 records screened after 2 duplicates removed&lt;/p&gt;" WIDTH="106">
<FLOWCHARTBOX TEXT="&lt;p&gt;Our database searches for this update identified 517 records (Skin Group Specialised Register, CENTRAL, MEDLINE, Embase and LILACS)&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;6 ongoing studies were identified through trials registry searches&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;452 records excluded based on titles and abstracts&lt;/p&gt;" WIDTH="116"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;15 studies excluded for the following reasons:&lt;/p&gt;&lt;p&gt;6 - participants were randomly selected but not randomly assigned to the treatment groups&lt;br&gt;2 - cross-over studies&lt;br&gt;2 - no assessment of primary clinical outcomes&lt;br&gt;3 - review articles&lt;br&gt;2 - participants included in the study were immunocompromised and chronically ill patients&lt;/p&gt;&lt;p&gt;6 Ongoing studies; see &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_ONGOING_STUDIES&quot;&gt;Characteristics of ongoing studies&lt;/a&gt;&lt;/p&gt;&lt;p&gt;8 Awaiting classification; see &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_AWAITING_STUDIES&quot;&gt;Characteristics of studies awaiting classification&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="228"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1504131145345024920315694334049_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="z1504131145345024920315694334049"><ADDRESS><DEPARTMENT>Department of Preventive Medicine and Public Health</DEPARTMENT><ORGANISATION>Ramón y Cajal University Hospital</ORGANISATION><CITY>Madrid</CITY><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>